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The world has opened its eyes to the threat posed by cancer and other noncommunicable diseases (NCDs). 
Realization is growing, in global political circles and in civil society, that these diseases constitute a major 
obstacle to human development and well-being.
The United Nations General Assembly High-Level Meeting on the Prevention and Control of Noncommunicable 
Diseases, held in September 2011, marked a turning point in the awareness of political leaders and the 
international community of the need for urgent action to avert a worldwide crisis.
The new figures and projections of the global cancer burden presented in this edition of World Cancer Report 
starkly highlight the problem: the incidence of cancer has increased from 12.7 million in 2008 to 14.1 million in 
2012, and this trend is projected to continue, with the number of new cases expected to rise a further 75%. This 
will bring the number of cancer cases close to 25 million over the next two decades. The greatest impact will 
unquestionably be in low- and middle-income countries, many of which are ill-equipped to cope with this 
escalation in the number of people with cancer.
Many developing countries find themselves in the grip of cancers from two vastly different worlds. Those associ-
ated with the world of poverty, including infection-related cancers, are still common, while those associated with 
the world of plenty are increasingly prevalent, owing to the adoption of industrialized lifestyles, with increasing 
use of tobacco, consumption of alcohol and highly processed foods, and lack of physical activity.
This rising burden of cancer and other NCDs places enormous strains on the health-care systems of developing 
countries. Coupled with ageing populations and the spiralling costs of cancer treatment, increasing demands are 
placed on the health-care budgets of even the wealthiest nations. As a result, prevention is central to reducing or 
reversing the rise in cancer burden. The central role of prevention was acknowledged in the Political Declaration 
adopted at the United Nations meeting, which described it as the cornerstone of the global response.
The United Nations Political Declaration gave WHO a clear mandate to coordinate the global response to this 
threat along with some important time-bound responsibilities captured within the Global Action Plan for the 
Prevention and Control of NCDs 2013–2020. IARC’s contribution has been and will continue to be instrumen-
tal in this process. Independent, robust scientific evidence is the foundation of the formulation of sound public 
health policies. The high-quality research produced by IARC is essential for the development of evidence-based 
guidelines and policy by WHO, and for the adoption of regulatory decisions by national institutions to protect the 
health of their populations.
This new edition of World Cancer Report represents a timely update on the state of knowledge on cancer 
statistics, causes, and mechanisms, and on how this knowledge can be applied for the implementation of 
effective, resource-appropriate strategies for cancer prevention and early detection. I am confident that 
World Cancer Report 2014, like the previous editions, will constitute a key reference tool that will find extensive 
use among scientists, public health workers, and governments in supporting the implementation of national and 
regional plans for cancer prevention and control.
Dr Margaret Chan
Director-General
World Health Organization
Foreword
xCancer is costly. First and foremost there is the human cost, comprising the uncertainty and suffering that a 
diagnosis of cancer brings in its wake. Behind each statistic of a new cancer case is an individual face, accom-
panied by the faces of family and friends drawn into this singular event. The harrowing experience of a cancer 
diagnosis is a truly universal one, played out in every community worldwide, every day.
In contrast, as a cancer patient moves beyond diagnosis, individual experiences diversify across the world. 
In fact, the future of a cancer patient depends in large part on where the person lives. In less economically 
developed countries, cancer is typically diagnosed at more advanced stages of disease, while access to effec-
tive treatment is limited or unavailable, as is palliative care. Even within more economically developed coun-
tries, there are disparities in access to care among different communities. The experiences of individual cancer 
patients all too frequently reflect the worst of global inequalities.
Cancer also has a societal cost; enormous human potential is lost, and treating and caring for an increasing 
number of cancer patients has an escalating economic impact. This too is a universal experience, but again 
the details differ greatly between countries. World Cancer Report 2014 reveals a cancer burden that is pro-
jected to increase by about 70% worldwide in just two decades, but it is in the lowest-income countries with 
the least-developed cancer services that the impact will be greatest. Already, the early onset of some com-
mon cancers (e.g. cervix, liver) and generally poorer survival in low- and middle-income countries mean that 
the burden of years of life lost to cancer in these countries is similar to that in higher-income countries. Given 
population growth, ageing, and the spread of risk factors, such as tobacco use, the situation will worsen in the 
next decades, posing a major challenge to health systems in low- and middle-income countries, so that this 
divide between the experiences of individual cancer patients will only broaden. Taken in isolation, this is a dark 
prediction.
It is time to take up the challenges posed by the markedly increasing number of cancer cases globally. The 
particularly heavy burden projected to fall on low- and middle-income countries makes it implausible to treat 
our way out of cancer; even the highest-income countries will struggle to cope with the spiralling costs of treat-
ment and care. Therefore, elucidating the causes and devising effective prevention strategies are essential 
components of cancer control, as is the gathering of accurate data on cancer occurrence from population-
based cancer registries. These approaches will complement the benefits in improved access to affordable and 
effective cancer treatment.
In parallel to work carried out on causes and prevention, remarkable progress has been made in understand-
ing the molecular and cellular events that transform a normal functioning cell into part of a malignant growth 
that can kill its host. These exciting advances in basic science have ramifications that are evident throughout 
this edition of World Cancer Report, notably in classifying cancers, in providing new avenues for clues about 
their causes, in highlighting opportunities for early detection and prevention, and in laying a foundation for the 
development of new, targeted treatments in the clinic. As never before, there is an opportunity to bring together 
interdisciplinary cancer expertise so that the advances of basic science are translated into both improved 
treatment and more widespread prevention and early detection. This integrated and complementary approach 
reflects not only the duty of care to today’s cancer patients but also the duty of care to the next generation, to 
free as many people as possible from the threat of this disease.
Preface
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In the highlands of Kenya among the Kalenji people, who incidentally 
have provided some of the greatest middle- and long-distance runners 
in the world, there is a saying: “We should put out the fire while it is 
still small.” It is this saying that greets patients arriving at the Tenwek 
Mission Hospital in the Western Highlands (see photo). We might adopt 
it as an idiom for cancer prevention. Since the middle of the last century, 
enormous progress has been made in identifying the causes of cancer, 
so that more than 50% of cases could be prevented based on current 
knowledge. These successes in identifying cancer causes must be com-
plemented by an evaluation of the most effective interventions and an 
understanding of how best to support their implementation into specific 
health-care settings. Collectively, this knowledge provides huge potential 
for reducing the cancer burden; one can only imagine the interest that 
would follow an announcement of the availability of new cancer treat-
ments able to cure 50% of all patients. Therefore, prevention must be 
writ large in cancer control plans if we are to defy the dark prediction of 
the statistics.
The International Agency for Research on Cancer (IARC) will play its part 
as it works for cancer prevention and control, with a particular commit-
ment to low- and middle-income countries. IARC has a primary role in promoting international collaboration, 
and this role, acting as a catalyst for research, is increasingly proving to be vital because national questions 
can only be answered by international studies. Furthermore, the interdisciplinary approach taken by IARC is 
bearing fruit as knowledge about mechanisms of carcinogenesis casts new light on the causes and prevention 
of the disease.
The personal impact of cancer should never be far from the minds of all whose careers lead them to join in 
efforts to reduce the burden of suffering due to cancer. At the same time, cancer professionals from all disci-
plines need reliable knowledge on which to act, and the general public has the same need in order to make 
informed decisions. It is in this context that World Cancer Report 2014 provides its up-to-date description of 
the occurrence, causes, underlying mechanisms, and prevention of cancer. My hope is that it will be a catalyst 
for collectively meeting the challenges of cancer in a way that benefits people in an inclusive way worldwide.
Dr Christopher P. Wild
Director 
International Agency for Research on Cancer
xii
Research underpins the development and implementation of all measures calculated to reduce the cancer bur-
den. In addressing cancer research developed over the five-year period since the previous edition of World 
Cancer Report was published, all the contributors to this volume faced the challenge of identifying the most 
pertinent developments. At the same time, an interval of five years represents a suitable time frame to reappraise 
the descriptive epidemiology of cancer occurrence worldwide – with this edition of World Cancer Report incor-
porating GLOBOCAN 2012 data as they became available in the weeks immediately before publication – and to 
assess cancer occurrence in relation to the broad and rapidly expanding knowledge available for cancer control.
Cancer etiology and biology
Specification of cancer incidence and mortality data with varying degrees of confidence for virtually all countries 
is fundamental to cancer control. These data – particularly as they relate to specific tumour types – not only 
establish the burden of disease as it may impinge upon public health and clinical services planning; they also 
indicate, in many instances, causative relationships, the impact of socioeconomic differences, and priorities that 
may be accorded to particular cancer control options.
In many cases, differences in cancer incidence between countries reflect the decades-old perception that cancer 
is a disease of affluence. But this perception is inadequate, having been displaced initially by the level of tobacco-
induced lung cancer in China and some other Asian countries, and more recently as cancer rates are expected 
to grow due to the impact of rapid increases in the prevalence of obesity, which is not confined to high-income 
countries. Cancers associated with chronic infections remain a particularly important challenge in low- and mid-
dle-income countries. These differing and evolving profiles of risk factors are occurring against the background 
of marked demographic changes, characterized in many countries by an ageing and growing population, which 
will see the greatest proportional increases in cancer burden falling on some of the economically poorest regions 
of the world. World Cancer Report illustrates that cancer is truly a global problem.
The impacts of tobacco, obesity, and infections are just part of a broad spectrum of other agents and risk factors 
that contribute to cancer development and that, together, influence the striking geographical heterogeneity in 
incidence rates. Certain of these risk factors are non-modifiable, for example race, familial genetic background, 
and reproductive and hormonal history. Exposure to carcinogens may result from what are often characterized 
as lifestyle choices, which include alcohol consumption and behaviour in relation to avoidable sun exposure. 
Finally, people may be exposed to carcinogens in circumstances over which they have little or no control, which 
is the case in relation to occupational exposures, the effects of pollution (e.g. of ambient air or water), and ex-
posures resulting from the use of particular foods, drugs, or consumer products. Priorities accorded to avoiding 
the impact of various causative agents may be influenced by attributable risk: the proportion of total cancers for 
which a particular agent or circumstance played a causal role in the development. Such quantitative determina-
tions may vary markedly depending on which community or country is under consideration. The overarching 
principle, however, is that people should not be knowingly exposed to circumstances likely to increase their risk 
of developing cancer.
Analytical epidemiological studies, often incorporating molecular and biological measurements made possible 
through the availability of, for example, archived blood and/or tissue samples, increasingly identify key biologi-
cal processes whose relevance is initially indicated through experimental studies. The past five years has wit-
nessed the identity of many cancer pathways being derived from whole-genome sequencing for multiple cases 
of each major tumour type, and from analogous comprehensive data of the “–omics” sciences, which encompass 
genomics, transcriptomics, proteomics, metabolomics, and the like. These data have been generated through 
international collaboration. Genomic and similar data provide singular insight into the nature of cancer cell devel-
opment within the context of normal tissue. These data offer, for example, the prospect of improved detection of 
early-stage disease, but also more refined molecular classification of malignancy with relevance to descriptive 
and etiological epidemiology. They also reveal perturbed signalling and other alterations in cancer cells, which, 
Introduction
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by definition, establish at least a basis for what is termed targeted therapy. Such opportunities are already being 
translated into clinical practice. The elucidation of biological changes that characterize cancer cells has been 
paralleled by observations at the cellular level to the effect that malignant tumours are inadequately understood 
as simply a mass of cancer cells: malignant tumours are also made up of fibrous, inflammatory, vascular, and im-
munological cell populations. Any one or more of these populations may be, at particular times, critical to tumour 
development and hence may offer an approach to prevention or therapy.
Reducing cancer incidence and mortality
Community awareness of the burden of cancer is inevitably focused on the development of improved therapies 
to the benefit of cancer patients, and media reports of “breakthroughs” are often the vehicle for reporting novel 
developments. The challenge posed by agent-specific resistance largely accounts for the reality of persistent 
disease despite incremental progress. This challenge highlights the certain benefits accruing from the adoption 
of measures to prevent cancer – benefits that accrue, however, in the longer term. For example, the impact of 
reduced cigarette consumption at the population level on lung cancer incidence came with a lag of some two 
to three decades. While smoking cessation is the most effective cancer preventive measure involving reduced 
exposure to proven carcinogens, cancer prevention involves a broad spectrum of initiatives, extending from vac-
cination – to ameliorate or prevent entirely the impact of relevant infections – through to screening tests aimed at 
detection, and consequently treatment, of early-stage disease.
National planning and international collaboration have emerged as critical to effective cancer control. Along with 
GLOBOCAN 2012 and the availability of genomic and related data, this edition of World Cancer Report highlights 
the WHO Framework Convention on Tobacco Control, the first international treaty negotiated under the auspices 
of WHO. As a response to the major recognized cause of cancer, tobacco control measures are almost univer-
sally applicable: what is effective in one country has been established as likely to be effective in most, if not all, 
countries. Although priorities must be accorded on a national basis, options for cancer control are increasingly 
available to countries and communities based on what has succeeded elsewhere. The inherent worth and benefit 
of collaboration across national boundaries is established for cancer control. Without doubt, national govern-
ments are seeking this internationally established evidence base, developed free from vested interests, for im-
plementation at the local level.
The scope and design of World Cancer Report
Comprehensive texts on clinical oncology, often including sections on epidemiology, cancer biology, and public 
health matters, are published regularly and typically extend to thousands of pages. Likewise, annual reviews pro-
vide both researchers and clinicians with comprehensive coverage of recent publications in particular disciplines 
or concerning specified types of cancer or advances in therapies. World Cancer Report is readily distinguished 
from both these types of publication with reference to its scope and design. Concerning scope, emphasis on the 
global burden of cancer, and the environmental, lifestyle, and biological factors that might account for that bur-
den, elevates the means of cancer prevention and their implementation to singular prominence. World Cancer 
Report does not address clinical care and the determination of optimal therapies, notwithstanding the exciting 
promise of these areas. Concerning design, World Cancer Report seeks to provide authoritative assessments 
through several different presentational approaches, while maintaining a publication of manageable length.
We, as editors, are grateful to the contributors to World Cancer Report, who, without exception, are aware of 
literally hundreds of publications that could be reasonably cited in the respective chapters were it not for length 
constraints that the present publication imposes. Because of these limitations, and the possibility that inevitable 
generalizations may preclude an appreciation of complexity, World Cancer Report features “boxes” in which a 
further group of investigators outline how certain precise issues are being elucidated with relevance to particular 
chapters.
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The structure of World Cancer Report 2014 is essentially in line with that adopted for earlier editions. However, 
World Cancer Report 2014 is distinguished from its predecessors by the inclusion of a series of “Perspectives”. 
Several prominent investigators have been invited to provide a personal viewpoint without the boundaries implicit 
in the headings of particular chapters. The perspectives offered are both distinctive and challenging, and serve 
to indicate the variety of issues immediately relevant to cancer control that either remain as challenges for further 
research or have yet to achieve their full potential by comprehensive implementation.
Cancer continues as a scourge of humankind. Increasingly, cancer is a particular burden on the populations of 
low- and middle-income countries. Cancer control may be achieved in large part through the insight gained from 
research, through detailed knowledge of how individuals and communities are affected, and through implementa-
tion of policies whose efficacy is often proven by the experience of other countries or groups of countries. The 
inclusion in this volume of several examples of national cancer control planning further demonstrates both the 
specific and general experiences from which lessons can be drawn in translating research-derived evidence into 
practice. World Cancer Report 2014 therefore captures the dynamic state of both cancer research and cancer 
control worldwide with respect to what has been achieved, and what remains to be accomplished, to the benefit 
of the global community.
          
Bernard W. Stewart and Christopher P. Wild (Editors)
Lyon, December 2013
Cancer affects all of humankind, but there are marked 
differences across local, national, and regional bound- 
aries, particularly when considering specific tumour types 
rather than cancer as a whole. Epidemiological data on 
incidence of cancer and deaths caused by cancer vary 
enormously in coverage and quality between countries 
and regions worldwide, ranging from complete coverage 
by national cancer registries to population-based regis-
tries covering a part of the country, hospital-based reg-
istries, or no available data at all on cancer occurrence. 
In the absence of data, inferences must be drawn from 
surrounding countries to provide the best estimate pos-
sible. This edition of World Cancer Report provides data 
from GLOBOCAN 2012, the most current appraisal of the 
distribution of cancer worldwide. The findings show that 
high-resource countries have the highest incidence of 
cancer and also provide the best services for detection, 
diagnosis, and treatment, as may be inferred from mortal-
ity and survival data. The highest prevalence proportions 
of cancer also occur in these populations. The most com-
mon cancers include lung, breast, prostate, and colorectal 
cancers. In countries in epidemiological transition, these 
cancers are increasingly common but incidence of stom-
ach, oesophageal, and liver cancers remains high. Data 
from low-resource countries show that cervical cancer 
is still often the most common cancer among women. In 
low- and middle-resource countries, incidence of particu-
lar tumours may be relatively low, but corresponding mor-
tality data often reflect late-stage diagnosis as the norm 
and consequently poor clinical outcomes. Worldwide, dif-
ferences in cancer incidence have been recognized for 
more than half a century as indicating different causes 
and, by inference, different opportunities for prevention. 
These lines of investigation have been greatly refined in 
recent years. Accordingly, cancer epidemiological data 
as now presented not only establish the burden of cancer 
but also underpin and very often confirm determinations 
of causation and opportunities for prevention, as elabo-
rated in subsequent sections of this Report.
Cancer 
worldwide
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Summary
• Cancer is a major cause of 
morbidity and mortality, with 
approximately 14 million new 
cases and 8 million cancer-re-
lated deaths in 2012, affecting 
populations in all countries and 
all regions. These estimates 
correspond to age-standard-
ized incidence and mortal-
ity rates of 182 and 102 per 
100 000, respectively.
• Among men, the five most com-
mon sites of cancer diagnosed 
in 2012 were the lung (16.7% 
of the total), prostate (15.0%), 
colorectum (10.0%), stomach 
(8.5%), and liver (7.5%). Among 
women, the five most common 
incident sites of cancer were 
the breast (25.2% of the total), 
colorectum (9.2%), lung (8.7%), 
cervix (7.9%), and stomach 
(4.8%).
• Among men, lung cancer had 
the highest incidence (34.2 per 
100 000) and prostate cancer 
had the second highest in-
cidence (31.1 per 100 000). 
Among women, breast cancer 
had a substantially higher inci-
dence (43.3 per 100 000) than 
any other cancer; the next high-
est incidence was of colorectal 
cancer (14.3 per 100 000).
• Prevalence estimates for 2012 
indicate that there were 8.7 mil-
lion people (older than 15 years) 
alive who had had a cancer di-
agnosed in the previous year, 
22.0 million with a diagnosis 
in the previous 3 years, and 
32.6 million with a diagnosis in 
the previous 5 years.
• The worldwide estimate for the 
number of cancers diagnosed 
in childhood (ages 0–14 years) 
in 2012 is 165 000 (95 000 in 
boys and 70 000 in girls).
• For all cancers combined (ex-
cluding non-melanoma skin 
cancer) the highest incidence 
rates are associated with the 
high-income countries of North 
America and western Europe 
(together with Japan, the Re- 
public of Korea, Australia, and 
New Zealand).
• More than 60% of the world’s 
cancer cases occur in Africa, 
Asia, and Central and South 
America, and these regions 
account for about 70% of the 
cancer deaths.
• The distribution of cancer in 
world regions indicates marked, 
and sometimes extreme, differ-
ences with respect to particu-
lar tumour types. Such data 
are key to any understanding 
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of causation, and hence the 
development of preventive 
measures.
Robust statistics on cancer occur-
rence and outcome are an essential 
prerequisite for national and region-
al programmes of cancer control 
and for informing the cancer re-
search agenda. Since 1984, IARC 
has regularly published estimates 
of the global and regional burden 
of cancer in terms of both incidence 
and mortality [1]. Since 2001, such 
estimates have also been made 
available for all major countries of 
the world through the GLOBOCAN 
project [2,3]. These estimates are 
based on all sources of informa-
tion available for any given country 
Fig. 1.1.1. Fishermen in Bahia de Kino, 
Mexico. On a world scale, intermediate 
cancer incidence rates occur in Central 
and South America.
Chapter 1.1 • The global and regional burden of cancer 17
1 
W
O
R
LD
W
ID
E
C
H
A
P
TE
R
 1
.1
[4] and, where possible, make use 
of incidence data published in the 
IARC series Cancer Incidence in 
Five Continents [5–7] and mortal-
ity data made available by WHO [8]. 
For more details about the graphics 
presented in this chapter, see “A 
guide to the epidemiology data in 
World Cancer Report”.
Global burden of cancer
Incidence and mortality
Results from GLOBOCAN [3] show 
that in 2012 there were an estimated 
14.1 million new cases of cancer di-
agnosed worldwide (excluding non-
melanoma skin cancer) and 8.2 mil-
lion estimated deaths from cancer. 
These estimates correspond to 
age-standardized incidence and 
mortality rates of 182 and 102 per 
100 000, respectively. There were 
slightly more incident cases (53% of 
the total) and deaths (57%) among 
men than among women. The es-
timated global annual numbers of 
new cases and cancer deaths for 
the most important types of cancer 
are shown in Figs 1.1.4 and 1.1.5, 
for both sexes combined and for 
men and women separately.
Among men, the five most com-
mon sites of cancer diagnosed in 
2012 were the lung (16.7% of the 
total), prostate (15.0%), colorec-
tum (10.0%), stomach (8.5%), and 
liver (7.5%). These sites also rep-
resented the most common causes 
of cancer death in men; the rela-
tive importance of lung cancer in-
creased to 23.6% of the total, fol-
lowed by liver cancer (11.2%) and 
stomach cancer (10.1%) as the sec-
ond and third most common causes 
of cancer death.
Among women, the five most 
common incident sites of cancer 
were the breast (25.2% of the to-
tal), colorectum (9.2%), lung (8.7%), 
cervix (7.9%), and stomach (4.8%). 
These sites also represented the 
most common causes of cancer 
death in women; the relative impor-
tance of breast cancer decreased 
to 14.7% of the total, followed by 
lung cancer (13.8%) as the sec-
ond most common cause of cancer 
death. In both sexes combined, the 
five most common incident sites of 
cancers were the lung (13.0% of the 
total), breast (11.9%), colorectum 
(9.7%), prostate (7.9%), and stom-
ach (6.8%); together, cancers of 
these five sites constitute half of the 
overall global cancer burden.
Estimated age-standardized in-
cidence and mortality rates for the 
15 most common cancers world-
wide for men and women in 2012 
are shown in Fig. 1.1.6. Among 
men, lung cancer has the highest 
incidence and mortality rates (34.2 
and 30.0 per 100 000, respective-
ly). Prostate cancer has the sec-
ond highest incidence rate (31.1 
per 100 000), not far below that for 
lung cancer. However, the mortal-
ity rate for prostate cancer (7.8 per 
100 000) is considerably lower than 
that for lung cancer. The differential 
between mortality and incidence for 
these two cancers reflects the much 
lower fatality rate (or improved sur-
vival) of prostate cancer compared 
with lung cancer. Stomach, liver, 
and oesophageal cancers are three 
of the other major cancers in men 
that, like lung cancer, have relative-
ly poor survival and hence mortality 
rates that are close to the incidence 
rates (incidence and mortality of 
17.4 and 12.7 per 100 000, respec-
tively, for stomach cancer, 15.3 and 
14.3 per 100 000 for liver cancer, 
and 9.0 and 7.7 per 100 000 for 
oesophageal cancer). The other 
major cancer in men is colorectal 
cancer, which has an incidence rate 
of 20.6 per 100 000 but a substan-
tially lower mortality rate of 10.0 per 
100 000.
Among women, breast cancer 
has a considerably higher inci-
dence rate (43.3 per 100 000) than 
any other cancer. The next highest 
is cancer of the colorectum (14.3 
per 100 000), and then cancers of 
the cervix (14.0), lung (13.6), cor-
pus uteri (8.2), and stomach (7.5). 
Fig. 1.1.3. Times Square, New York. The 
four major cancers that affect populations 
in North America are the same as those in 
Europe: cancers of the prostate, breast, 
lung, and colorectum.
Fig. 1.1.2. A view of Paris. High-income countries, exemplified by countries in western 
Europe and North America, have the highest overall cancer rates in both sexes.
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Fig. 1.1.4. Estimated world cancer incidence proportions by major sites, in both sexes combined, in men, and in women, 2012.
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Fig. 1.1.5. Estimated world cancer mortality proportions by major sites, in both sexes combined, in men, and in women, 2012.
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However, breast cancer has a rela-
tively low fatality rate, and thus al-
though it has the highest mortality 
rate of any cancer in women (12.9 
per 100 000), this is less than one 
third of the incidence rate and not 
much higher than the lung cancer 
mortality rate (11.1 per 100 000), 
which is the next highest. As in men, 
the stomach cancer mortality rate 
(5.7 per 100 000) is not far below 
the incidence rate, but the mortality 
rates for the other major cancers in 
women – cancers of the colorectum 
(6.9 per 100 000), cervix (6.8) and, 
especially, corpus uteri (1.8) – are 
substantially lower than the corre-
sponding incidence rates.
Prevalence
A further measure of cancer bur-
den is prevalence: the number of 
people who have been diagnosed 
with cancer and are still alive at a 
specific time [9]. Prevalence es-
timates for 2012 show that there 
were 8.7 million people (older than 
15 years) alive who had had a can-
cer diagnosed in the previous year, 
22.0 million with a diagnosis in the 
previous 3 years, and 32.6 million 
with a diagnosis in the previous 
5 years [3]. Estimates of 5-year 
prevalence for the nine most com-
mon cancer sites worldwide are 
shown in Fig. 1.1.7, for both sexes 
combined and for men and women 
separately. With 6.3 million survi-
vors diagnosed within the previous 
5 years, breast cancer is by far the 
most prevalent cancer, even when 
results for both sexes are com-
bined. The second most prevalent 
is prostate cancer, with 3.9 million, 
and then colorectal cancer, with 
3.5 million (1.9 million men and 
1.6 million women), and lung can-
cer, with 1.9 million (1.3 million men 
and 0.6 million women). Prevalence 
reflects the integration of incidence 
and extent of survival, and for lung 
cancer, because of its very poor 
survival, the 5-year prevalence is 
very close to the annual mortality 
(1.6 million).
Incidence by age group
Cancer has a strong relationship 
with age, and Fig. 1.1.8 shows 
the GLOBOCAN estimated inci-
dence rates for all cancers com-
bined (excluding non-melanoma 
skin cancer) by age group for men 
and women. Rates in the youngest 
age group (0–14 years) are about 
10 per 100 000, increasing to 150 
per 100 000 by 40–44 years and to 
more than 500 per 100 000 by 60–
64 years. Only in the youngest age 
group (0–14 years) are rates similar 
between the sexes. After childhood, 
rates are higher in women than in 
men until about the age of 50 years, 
when rates in men overtake those 
in women and then become sub-
stantially higher from the age of 
60 years. The excess in women 
before the age of 50 years is due 
Fig. 1.1.6. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by major sites, in men and 
women, 2012.
Chapter 1.1 • The global and regional burden of cancer 21
1 
W
O
R
LD
W
ID
E
C
H
A
P
TE
R
 1
.1
Fig. 1.1.7. Estimated world cancer 5-year prevalence proportions by major sites, in both sexes combined, in men, and in women, 
2012.
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to the relatively earlier age at onset 
of cervical cancer and, especially, 
breast cancer compared with other 
major cancers. Above the age of 
60 years, prostate cancer and lung 
cancer in men become more com-
mon. The worldwide estimate for 
the number of cancers diagnosed 
in childhood (0–14 years) in 2012 is 
165 000 (95 000 in boys and 70 000 
in girls), and in teenagers and young 
adults (15–39 years), the estimate 
is just more than 1 million (380 000 
in men and 670 000 in women). For 
more information on the descriptive 
epidemiology of cancer in these 
age groups, see Chapter 1.3.
Global distribution
Incidence
World maps of estimated age-
standardized incidence rates for 
all cancers combined (exclud-
ing non-melanoma skin cancer) 
in 2012 are shown in Fig. 1.1.9 
for men (Fig. 1.1.9A) and women 
(Fig. 1.1.9B). In general, and with 
some exceptions, the highest in-
cidence rates are associated with 
the high-income countries of North 
America and western Europe (to-
gether with Japan, the Republic 
of Korea, Australia, and New 
Zealand). This is the case for both 
sexes, although the absolute level 
of the upper rate category is higher 
in men than in women. Intermediate 
rates are seen in Central and South 
America, eastern Europe, and 
much of South-East Asia (includ-
ing China), and the lowest rates are 
seen in much of Africa and West 
and South Asia (including India). 
There are some interesting excep-
tions to this pattern. For example, 
Uruguay and Mongolia fall into the 
high-incidence category, Uruguay 
partly because of particularly high 
rates for lung cancer (and other 
smoking-related cancers), which 
are now being brought under con-
trol [10], and Mongolia because of 
the extraordinary high rate of liver 
cancer resulting from the particular-
ly high prevalence of infection with 
hepatitis B and C viruses [11].
Mortality
Similar world maps are shown in 
Fig. 1.1.10 for age-standardized 
mortality rates. These also show ex-
tensive international variation, but 
the contrasts are less marked than 
those for incidence. For example, 
there is less variation between 
North and South America and be-
tween western and eastern Europe. 
In both cases, this is a result of the 
impact of clinical care and generally 
improved cancer survival in North 
America and western Europe, lead-
ing to lower mortality rates (relative 
to the incidence rates) than is ob-
served in South America and east-
ern Europe [12]. In addition, and 
as described in the discussion of 
regional patterns of cancer below, 
cancers associated with a lifestyle 
typical of industrialized countries, 
including cancers of the breast, 
colorectum, and prostate, have a 
relatively good prognosis, whereas 
cancers of the liver, stomach, and 
oesophagus, which are more com-
mon in low-income countries, have 
a significantly poorer prognosis. In 
general, therefore, relatively more 
cancer deaths are seen for a given 
number of incident cases in the less 
economically developed countries, 
and cancer mortality rates are not 
very different from those in more 
developed countries.
Fig. 1.1.8. Estimated world cancer incidence rates per 100 000 by 5-year age group, 
for all sites combined (excluding non-melanoma skin cancer), in men and women, 
2012.
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Fig. 1.1.9. Global distribution of estimated age-standardized (World) cancer incidence rates (ASR) per 100 000, for all sites 
combined (excluding non-melanoma skin cancer), in (A) men and (B) women, 2012.
A
B
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Fig. 1.1.10. Global distribution of estimated age-standardized (World) cancer mortality rates (ASR) per 100 000, for all sites 
combined (excluding non-melanoma skin cancer), in (A) men and (B) women, 2012.
A
B
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Regional patterns of cancer
A regional breakdown of the global 
cancer incidence and mortality bur-
den by continental region is provid-
ed in Fig. 1.1.11. About half of the in-
cidence burden occurs in Asia, and 
almost a half of this, or 22% of the 
global total, arises in China, and 7% 
in India. A quarter of the incidence 
burden occurs in Europe, and the 
remainder is divided between the 
Americas and Africa (with 1% in 
Oceania). The mortality proportion-
al distribution shows an increase 
in the proportion of cancer-related 
deaths occurring in Asia and Africa, 
together with a decrease in the pro-
portions occurring in the economi-
cally more developed regions of 
Europe and North America.
Further analyses of the regional 
patterns are shown in Figs 1.1.12 
to 1.1.39, in which, for each world 
region, a proportional breakdown 
is provided of the estimated 2012 
numbers of cancer cases and 
deaths by sex, together with histo-
grams showing the age-standard-
ized incidence and mortality rates 
by cancer site and a chart showing 
the major 5-year prevalent cancers.
Europe
In Europe, the incidence pattern is 
dominated by prostate and breast 
cancers, which are the most com-
mon sites in men and women, re-
spectively, together with lung and 
colorectal cancers (Fig. 1.1.12). 
In terms of mortality, lung cancer, 
because of its poor survival, is the 
most important cause of cancer 
death in men (Fig. 1.1.13). Bladder, 
stomach, and kidney cancers also 
contribute significantly to the bur-
den in men, with incidence rates 
of more than 10 per 100 000, 
whereas in women, cancers of the 
corpus uteri and cervix also have 
incidence rates of more than 10 per 
100 000 (Fig. 1.1.14). Breast, pros-
tate, and colorectal cancers are the 
most prevalent; together, cancers 
of these three sites represent half 
of all the 5-year prevalent cases in 
Europe (Fig. 1.1.15).
North America
In North America, patterns of the 
four major cancers are very similar 
to those in Europe. Prostate and 
breast cancer are the most common 
incident sites in men and women, 
respectively, and lung cancer is 
the most common cause of cancer 
death in both sexes (Figs 1.1.16, 
1.1.17). However, unlike in Europe, 
lung cancer is also relatively more 
important than colorectal cancer in 
women in terms of incidence. Also, 
alongside bladder and kidney can-
cers, malignant melanoma, non-
Hodgkin lymphoma, and leukaemia 
contribute significantly to the can-
cer burden in men, with incidence 
rates of more than 10 per 100 000 
(Fig. 1.1.18). This is also evident for 
malignant melanoma, non-Hodgkin 
lymphoma, corpus uteri, and thy-
roid cancers in women. Compared 
with the European pattern, stom-
ach cancer in men and cervical 
cancer in women are much less 
common, at least partially reflecting 
the greater heterogeneity in rates 
across Europe for these cancer 
sites. The prevalence pattern in 
North America is very similar to that 
in Europe, with prostate, breast, 
and colorectal cancers together 
accounting for half of all the 5-year 
prevalent cases (Fig. 1.1.19).
Fig. 1.1.11. Estimated world cancer incidence and mortality proportions by major world regions, in both sexes combined, 2012.
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Oceania
In Oceania, one again sees the 
European and North American pat-
terns in relation to prostate and 
breast cancers as the most com-
mon sites in men and women, re-
spectively, and lung cancer as the 
most common cause of cancer 
death in men (Figs 1.1.20, 1.1.21). 
However, after colorectal cancer, 
malignant melanoma is the third 
most important incident cancer 
in both sexes, although it ranks 
relatively low in terms of mortality. 
Lung, kidney, and bladder cancers 
as well as non-Hodgkin lymphoma 
and leukaemia in men and can-
cers of the lung, corpus uteri, cer-
vix, and thyroid in women are the 
other cancers with rates of more 
than 10 per 100 000 (Fig. 1.1.22). 
Malignant melanoma makes an 
important contribution to cancer 
prevalence in Oceania, as the third 
most prevalent type. Otherwise, the 
pattern of prevalence is similar to 
that in Europe and North America 
(Fig. 1.1.23).
Latin America and the 
Caribbean
For the region Latin America and 
the Caribbean, in common with 
Europe and North America, pros-
tate and breast cancers are the 
most common incident sites in 
men and women, respectively 
(Fig. 1.1.24). Breast cancer is the 
most common cause of cancer 
death in women, whereas prostate 
and lung cancers make similar con-
tributions to cancer mortality in men 
(Figs 1.1.25, 1.1.26). However, and 
unlike the situation in the more eco-
nomically developed regions, cervi-
cal cancer makes a major contribu-
tion to the cancer burden in women, 
as the second most common inci-
dent cancer and cause of cancer 
death in women. The incidence 
rate for cervical cancer (21.2 per 
100 000) is substantially larger than 
that estimated for Europe or North 
America (11.4 and 6.6 per 100 000, 
respectively) (Fig. 1.1.26). Stomach 
cancer is also important, especially 
in men, where it is the fourth most 
common incident cancer (with lung 
and colorectal cancers as second 
and third, respectively). Whereas 
the incidence rates for stomach 
cancer (12.8 and 7.1 per 100 000 
in men and women, respectively) 
are of similar magnitude to those in 
Europe (13.2 and 6.4 per 100 000), 
these are much higher than those 
in North America (5.5 and 2.8 per 
100 000). Cervical cancer also 
contributes to the pattern of cancer 
prevalence in the region, repre-
senting 8.6% of all 5-year preva-
lent cancers, third in importance 
after breast and prostate cancers 
(Fig. 1.1.27).
Middle East and North Africa
In the Middle East and North Africa 
region (Figs 1.1.28, 1.1.29), breast 
cancer again dominates the pattern 
of cancer in women, representing 
30% of the cancer cases. Colorectal 
cancer is the next most common 
cancer in women, but breast cancer 
is the only type for which the inci-
dence or mortality rates (43.0 and 
16.2 per 100 000, respectively) ex-
ceed 10 per 100 000 (Fig. 1.1.30). 
Among men, lung cancer is the 
most important incident cancer 
and cause of cancer death, with 
incidence and mortality rates of 
27.1 and 24.5 per 100 000, respec-
tively (Fig. 1.1.30). Prostate, blad-
der, colorectal, and liver cancers 
are the next most common, all with 
incidence rates of more than 10 
per 100 000. In this region, breast 
cancer represents a quarter of 
all 5-year prevalent cancers, and 
whereas prostate cancer is rela-
tively less prevalent compared with 
other world regions, bladder and 
thyroid cancers make important 
contributions to the overall pattern 
(Fig. 1.1.31).
Sub-Saharan Africa
Sub-Saharan Africa provides sev-
eral contrasts with other world re-
gions. Among women, this is the 
only region where cervical cancer 
is equivalent to breast cancer in 
terms of incidence (each consti-
tutes approximately a quarter of 
the total burden) and is the most 
common cause of cancer death 
in women (23.2% of the total) 
(Figs 1.1.32, 1.1.33). The incidence 
and mortality rates for cervical can-
cer are 34.8 and 22.5 per 100 000, 
respectively (Fig. 1.1.34), the high-
est of any world region. Among 
men, prostate and liver cancers are 
the most common forms of incident 
cancer and causes of cancer death. 
Although the leading role of pros-
tate cancer in the cancer incidence 
pattern in men is shared with most 
other world regions, this region also 
has mortality rates comparable to 
incidence rates. The rates of 27.9 
and 20.9 per 100 000 for prostate 
cancer incidence and mortality, re-
spectively, stand in marked contrast 
to those in Europe (64.0 and 11.3 
per 100 000, respectively) or North 
America (97.2 and 9.8 per 100 000, 
respectively), where incidence is 
much higher but mortality is much 
lower. The importance of liver can-
cer in this region should be empha-
sized; it is the second most com-
mon cancer in men and the third 
most common in women. Cervical 
and breast cancers in women and 
prostate and liver cancers in men 
are the only cancers with sex-spe-
cific incidence or mortality rates 
of more than 10 per 100 000, but 
the high rates of Kaposi sarcoma in 
sub-Saharan Africa, especially in 
men, should also be noted. Kaposi 
sarcoma is the third most common 
cancer in men and represents 9.2% 
of all cancer diagnoses, with an 
incidence rate of 7.2 per 100 000. 
This reflects the very high regional 
level of HIV infection and associ-
ated cancer sequelae before the 
advent of highly active antiretroviral 
therapy [13]. Cervical cancer and 
Kaposi sarcoma also make impor-
tant contributions to the pattern 
of 5-year prevalence in the region 
(Fig. 1.1.35).
East and Central Asia
East and Central Asia is by far the 
most populous world region, con-
taining 57% of the global popu-
lation (19% in China and 18% in 
India). Among men, the most com-
mon cancers and causes of cancer 
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death are cancers of the lung, 
stomach, liver, colorectum, and 
oesophagus (Figs 1.1.36, 1.1.37), 
sites with incidence rates of more 
than 10 per 100 000 (Fig. 1.1.38). 
Although relatively high, the inci-
dence and mortality rates for lung 
cancer in men (35.1 and 31.5 per 
100 000, respectively) are still sub-
stantively below those in Europe 
and North America. However, the 
corresponding rates for stomach 
cancer (23.3 and 16.9 per 100 000, 
respectively) and liver cancer (20.7 
and 19.5 per 100 000, respectively) 
are the highest of any world region. 
Among women, breast cancer is the 
most common incident cancer, fol-
lowed by cancers of the lung, cer-
vix, colorectum, and stomach. Due 
to the varying fatality rates of these 
cancers, the mortality patterns are 
a little different in the region, and 
lung cancer is the leading cause of 
cancer death. As in other regions, 
breast cancer makes a substantial 
contribution to 5-year prevalence in 
East and Central Asia, but in con-
trast to elsewhere, cancers of the 
stomach and lung are also impor-
tant contributors to the pattern of 
prevalence (Fig. 1.1.39).
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Fig. 1.1.12. Europe. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, and in women, 2012.
Chapter 1.1 • The global and regional burden of cancer 29
1 
W
O
R
LD
W
ID
E
C
H
A
P
TE
R
 1
.1
Fig. 1.1.13. Europe. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, and in women, 2012.
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Fig. 1.1.14. Europe. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by major sites, 
in men and women, 2012.
Fig. 1.1.15. Europe. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 2012. 
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Fig. 1.1.16. North America. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, and in women, 
2012.
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Fig. 1.1.17. North America. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, and in women, 
2012.
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Fig. 1.1.18. North America. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by major 
sites, in men and women, 2012.
Fig. 1.1.19. North America. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 2012.
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Fig. 1.1.20. Oceania. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, and in women, 2012.
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Fig. 1.1.21. Oceania. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, and in women, 2012.
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Fig. 1.1.22. Oceania. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by major sites, 
in men and women, 2012.
Fig. 1.1.23. Oceania. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 2012.
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Fig. 1.1.24. Latin America and the Caribbean. Estimated cancer incidence proportions by major sites, in both sexes combined, in 
men, and in women, 2012.
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Fig. 1.1.25. Latin America and the Caribbean. Estimated cancer mortality proportions by major sites, in both sexes combined, in 
men, and in women, 2012.
Chapter 1.1 • The global and regional burden of cancer 39
1 
W
O
R
LD
W
ID
E
C
H
A
P
TE
R
 1
.1
Fig. 1.1.26. Latin America and the Caribbean. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 
100 000, by major sites, in men and women, 2012.
Fig. 1.1.27. Latin America and the Caribbean. Estimated cancer 5-year prevalence proportions by major sites, in both sexes 
combined, 2012.
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Fig. 1.1.28. Middle East and North Africa. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, 
and in women, 2012.
Chapter 1.1 • The global and regional burden of cancer 41
1 
W
O
R
LD
W
ID
E
C
H
A
P
TE
R
 1
.1
Fig. 1.1.29. Middle East and North Africa. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, 
and in women, 2012.
42
Fig. 1.1.30. Middle East and North Africa. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 
100 000, by major sites, in men and women, 2012.
Fig. 1.1.31. Middle East and North Africa. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 
2012.
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Fig. 1.1.32. Sub-Saharan Africa. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, and in 
women, 2012.
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Fig. 1.1.33. Sub-Saharan Africa. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, and in 
women, 2012.
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Fig. 1.1.34. Sub-Saharan Africa. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by 
major sites, in men and women, 2012.
Fig. 1.1.35. Sub-Saharan Africa. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 2012.
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Fig. 1.1.36. East and Central Asia. Estimated cancer incidence proportions by major sites, in both sexes combined, in men, and in 
women, 2012.
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Fig. 1.1.37. East and Central Asia. Estimated cancer mortality proportions by major sites, in both sexes combined, in men, and in 
women, 2012.
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Fig. 1.1.38. East and Central Asia. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, 
by major sites, in men and women, 2012.
Fig. 1.1.39. East and Central Asia. Estimated cancer 5-year prevalence proportions by major sites, in both sexes combined, 2012.
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Country-specific patterns of 
cancer
The consideration of incidence and 
mortality rates in specific countries 
selected to be representative of the 
world regions provides a further de-
gree of focus on the international 
variation in the cancer burden. 
Figs 1.1.40 and 1.1.41 show age-
standardized incidence rates in men 
and women, respectively, in about 
2005 for all cancers combined (ex-
cluding non-melanoma skin cancer) 
for a range of countries representa-
tive of different world regions and 
selected because of the high qual-
ity of their cancer incidence data. 
These data are derived from cancer 
registry data sets, and all of the reg-
istries have met the quality criteria 
for publication in Cancer Incidence 
in Five Continents, Volume X [7].
Comparable mortality data, where 
available from the WHO Mortality 
Database [8] or elsewhere [14], for 
the same countries are shown in 
Figs 1.1.42 and 1.1.43. Cancer in-
cidence and mortality information 
for the same set of countries is pre-
sented in the site-specific chapters 
later in this Report. It should be not-
ed that cause-specific death certifi-
cation is available for only a limited 
sample of the Chinese population 
and is not routinely undertaken in 
India and Uganda, and thus rele-
vant mortality data are not available 
for India and Uganda.
Among men, incidence (Fig. 1.1.40) 
varies by approximately 4-fold, from 
100 per 100 000 in Indian registries 
to more than 400 per 100 000 in the 
USA Surveillance, Epidemiology 
and End Results (SEER) Black pop-
ulation. Among women (Fig. 1.1.41), 
incidence varies by approximately 
3-fold, from just more than 100 per 
100 000 in Indian registries to about 
300 per 100 000 in the USA SEER 
White population and in Denmark. 
For both sexes there is, within this 
group of countries, a gradation in 
all-cancer incidence rates between 
the extremes and, especially in 
men, the higher rates are in eco-
nomically more developed popu-
lations. Among women, while the 
association with economic devel-
opment is also apparent, the rates 
in Japanese registries are at the 
lower end of the spectrum (170 per 
100 000), whereas those in Uganda 
(212 per 100 000) are relatively high. 
As observed in the world maps, the 
between-country variation in mortal-
ity (Figs 1.1.42, 1.1.43) is less pro-
nounced than that for incidence and, 
in both sexes, is less than 2-fold. 
Thus, in men (Fig. 1.1.42) the vari-
ation extends from 99 per 100 000 
in Costa Rica to 203 per 100 000 
in Slovakia, whereas in women 
(Fig. 1.1.43) it extends from 69 per 
100 000 in Japan to 121 per 100 000 
in Denmark.
Fig. 1.1.40. Age-standardized (World) cancer incidence rates 
per 100 000 in selected cancer registry populations, for all 
cancers combined (excluding non-melanoma skin cancer) in 
men, 2003–2007.
Fig. 1.1.41. Age-standardized (World) cancer incidence rates 
per 100 000 in selected cancer registry populations, for all 
cancers combined (excluding non-melanoma skin cancer) in 
women, 2003–2007.
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Data from the same populations 
and the same sources as used in 
Figs 1.1.40 to 1.1.43 are present-
ed in terms of trends over time in 
Figs 1.1.44 and 1.1.45 (incidence) 
and Figs 1.1.46 and 1.1.47 (mortali-
ty) for all cancers combined (exclud-
ing non-melanoma skin cancer). It 
is difficult to discern any general 
consistent trends in incidence from 
country to country, although, with 
few exceptions (e.g. the decline in 
incidence among men in Chinese 
registries), rates have tended to in-
crease from the 1980s to the pres-
ent. In some cases, for example in 
Slovakia, Colombia, and Denmark, 
this has been a fairly constant in-
crease over the entire time period, 
whereas elsewhere, for example in 
Japan and the USA, an initial period 
of increase has been followed by a 
drop in rates. Some of the observed 
effects can be readily explained. 
For example, the peak in the ear-
ly 1990s among men in the USA 
(Black and White) and Australia is 
explained by the rapid increase in 
the number of prostate cancer di-
agnoses after the introduction of 
testing for prostate-specific antigen 
[15]. Changes in the prevalence of 
smoking and hence, after a suit-
able lag period, in the incidence 
of lung cancer and other smoking-
associated cancers, will also be 
important determinants of all-can-
cer incidence and mortality rates 
[16]. However, other trends require 
detailed consideration of country-
specific patterns by type of cancer.
The mortality trends (Figs 1.1.46, 
1.1.47) are more consistent in that, 
in both sexes, most populations 
have shown a substantive decline 
in age-standardized mortality, with 
the exception of China (although 
the Chinese data are for a much 
shorter time series). The mortality 
decline is evident in countries such 
as Denmark and Costa Rica, which 
have, respectively, relatively high 
and low absolute levels of mortality. 
Such mortality decreases against a 
background of increase in incidence 
are indications of improved survival 
as a result of improved therapy and/
or earlier detection (including as a 
consequence of screening).
Nearly all cancer types show 
important variations between re-
gions, subregions, and countries 
in terms of both contemporary in-
cidence rates and their trends over 
time. The broad overview present-
ed in this chapter inevitably masks 
some of these geographical asso-
ciations. For example, the consid-
eration given above, at the regional 
level, to East and Central Asia 
does not identify the extraordinarily 
high rates of thyroid cancer among 
women in the Republic of Korea, 
estimated as 89 per 100 000 – the 
most common cancer among wom-
en in the country, and the highest 
rate of any country in the world. It is 
currently unclear to what extent this 
Fig. 1.1.42. Age-standardized (World) cancer mortality rates per 
100 000 by year in selected countries, for all cancers combined 
(excluding non-melanoma skin cancer) in men, 2003–2007.
Fig. 1.1.43. Age-standardized (World) cancer mortality rates per 
100 000 by year in selected countries, for all cancers combined 
(excluding non-melanoma skin cancer) in women, 2003–2007.
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epidemic is driven by improved di-
agnostic technology [17]. Similarly, 
the estimated European incidence 
rate of cervical cancer (11.4 per 
100 000) obscures the internal vari-
ation, ranging from 29 per 100 000 
in Romania to 4 per 100 000 in 
Switzerland, due primarily to the 
impact of cytological screening 
programmes [18]. Likewise, in sub-
Saharan Africa, the average inci-
dence rate for oesophageal cancer 
in men is 6 per 100 000, ranging 
from 25 per 100 000 in Uganda and 
Malawi to less than 1 per 100 000 
in Guinea and Nigeria. The reason 
for the variation in this case is little 
understood, which should act as a 
stimulus for research [19].
Conclusions
Monitoring geographical variation 
in disease prevalence and search-
ing for an understanding of the 
underlying reasons is frequently 
an important starting point for 
cancer epidemiology [20]. The un-
derstanding of the causes of any 
specific cancer is not complete 
without an explanation of the geo-
graphical distribution, and cancer 
is especially complex, given the 
diversity in cancer types, with 
each type often having its own set 
of risk factors and giving rise to a 
unique geographical pattern. Such 
variations have significant implica-
tions for tailoring cancer control to 
region- or country-specific priori-
ties [21]. This chapter has focused 
primarily on the current overall bur-
den of cancer globally and in ma-
jor world regions and serves as a 
backdrop to the consideration of 
specific types in later chapters of 
this Report. However, with approxi-
mately 14 million new cases and 
8 million cancer-related deaths per 
year, cancer must be viewed as a 
major cause of morbidity and mor-
tality that affects populations in all 
countries and all regions.
While there are some common-
alities, such as breast cancer being 
the major type of cancer among 
women in all world regions, there 
are also important differences, and 
the variation in the relative impor-
tance of cervical cancer across dif-
ferent regions is one such example. 
Some of these differences relate to 
the level of economic development, 
for example the higher incidence of 
cancers associated with infections 
in less-developed economies [22], 
and the associations with develop-
ment are considered in more detail 
in Chapter 1.2. The importance of 
genetic variation as a cause of 
between-population differences in 
risk, such as for prostate cancer, is 
also recognized.
At a more general level, under-
standing the pattern of cancer in a 
Fig. 1.1.44. Age-standardized (World) cancer incidence rates 
per 100 000 by year in selected populations, for all cancers 
combined (excluding non-melanoma skin cancer) in men, circa 
1975–2012.
Fig. 1.1.45. Age-standardized (World) cancer incidence rates 
per 100 000 by year in selected populations, for all cancers 
combined (excluding non-melanoma skin cancer) in women, 
circa 1975–2012.
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Fig. 1.1.46. Age-standardized (World) cancer mortality rates 
per 100 000 by year in selected countries, for all cancers 
combined (excluding non-melanoma skin cancer) in men, circa 
1975–2012.
Fig. 1.1.47. Age–standardized (World) cancer mortality rates 
per 100 000 by year in selected countries, for all cancers 
combined (excluding non-melanoma skin cancer) in women, 
circa 1975–2012.
population is an essential prereq-
uisite for planning any programme 
for cancer control. It is impossi-
ble to develop such plans without 
knowing which types of cancer are 
common and whether cancers are 
changing in incidence. Likewise, 
the impact of any control mea-
sures cannot be evaluated without 
monitoring the effect on cancer in-
cidence or mortality in the years, or 
sometimes decades, after an inter-
vention. To generate the relevant 
incidence data, as used extensively 
in this chapter, the work of cancer 
registries throughout the world is vi-
tal [23] and needs to be supported 
as part of any cancer control plans, 
especially in less-developed re-
gions, where cancer registries are 
often absent or under-resourced 
[24].
The authors thank Joannie Lortet-Tieulent 
and Mathieu Laversanne for their assistance 
in producing the figures.
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Summary
• From a global perspective, the 
cancer burden for each coun-
try, and the most common tu-
mour types, are associated 
with the value of the Human 
Development Index (HDI) for 
that country. Transitions to-
wards higher levels of human 
development have the effect of 
increasing the burden of cancer 
overall, and of specific types.
• Cancers of the lung, breast, 
prostate, and colorectum are 
the major incident cancers in 
countries with high or very high 
HDI. In countries with low or 
medium HDI, cancers of the 
colorectum, breast, and lung 
have become rather more fre-
quent, although there remains 
an excess of poverty- and 
infection-related cancers, no-
tably cancers of the stomach, 
liver, cervix, and oesophagus.
• In countries in transition, de-
clines in the incidence of cer-
vical cancer tend to be offset 
by concomitant increases in 
the incidence of female breast 
cancer. In countries with low or 
medium HDI, incidence rates 
of colorectal cancer increase 
markedly as HDI rises in a giv-
en country.
• The predicted global cancer 
burden is expected to exceed 
20 million new cancer cases 
annually by 2025, compared 
with the estimated 14.1 million 
new cases worldwide in 2012.
This chapter reviews the evolution 
of the cancer burden worldwide 
in relation to transitions in human 
development. Societal, economic, 
and lifestyle changes in a rapidly 
1.2
1 WORLDWIDE
Transitions in human 
development and the 
global cancer burden
Freddie Bray Bernard W. Stewart (reviewer)
Christopher P. Wild (reviewer)
globalizing world continue to have 
profound effects on the scale and 
profile of the cancer burden and the 
need for tailored and effective strat-
egies for cancer control and pre-
vention. The increasing magnitude 
of the cancer problem is partly the 
consequence of population growth 
and ageing. Such demographic tran-
sitions mean that by 2030, well over 
20 million new cancer cases will be 
diagnosed every year. The great-
est impact will unquestionably be in 
countries presently in the midst of 
Fig. 1.2.1. In India, an information technology business park stands where agricultural 
fields previously existed, indicative of the transition towards a higher Human 
Development Index rating.
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this developmental transition, many 
of which are ill-equipped to deal with 
the escalating numbers of cancer 
patients expected over the next 
decades.
As countries transition to higher 
levels of human development, the 
underlying populations tend to in-
creasingly adopt behavioural and 
lifestyle habits that have become 
conventional in prosperous and in-
dustrialized countries. A changing 
prevalence and distribution of sev-
eral reproductive, dietary, and hor-
monal risk factors has the effect of 
increasing the risk at the population 
level of certain cancers associated 
with affluence; these include female 
breast cancer, prostate cancer, and 
colorectal cancer in both sexes. 
The net effect of this shift to life-
styles typical of industrialized coun-
tries – occurring largely in countries 
traditionally classified as “develop-
ing” – is a steady increase in the 
overall incidence rates of cancer, 
as well as a change in the spec-
trum of the most common cancers 
towards those observed in most of 
the highly developed industrialized 
countries.
This chapter explores the link 
between developmental trends and 
these dual aspects of cancer transi-
tion using the Human Development 
Index, an indicator introduced 
through the United Nations Devel- 
opment Programme [1]. The geo-
graphical and temporal patterns of 
cancer-specific incidence, mortal-
ity, and prevalence are examined 
at the national, regional, and global 
level. The combined demographic 
and epidemiological impact of a 
rising and transforming cancer bur-
den in the many countries undergo-
ing transition has, of course, major 
implications for public health and 
clinical services planning. Some 
of the main characteristics of this 
global phenomenon emphasize the 
need for an increasing focus on 
the cancers associated with afflu-
ence, which invariably rank within 
the “top five” most frequent cancers 
presently observed in high-income 
countries.
Epidemiological transitions, 
noncommunicable diseases, 
and cancer
Omran’s theory of epidemiological 
transition focused on how changing 
health and disease patterns interact 
with complex demographic, social, 
and economic determinants [2]. 
Omran described how, in the third 
stage of transition, “pandemics of in-
fection” are superseded by “degen-
erative and man-made diseases” as 
the major causes of morbidity and 
mortality. Thus, there is some anal-
ogy with the rather recent documen-
tation of the increasing burden of 
noncommunicable diseases, which 
are displacing infection-related dis-
eases as major causes of morbidity 
and mortality in many parts of the 
world. Noncommunicable diseases 
are the foremost cause of total mor-
tality in the world today, responsi-
ble for two thirds of the estimated 
57 million deaths worldwide in 2008 
[3]. This shift in disease burden 
has been gaining political momen-
tum and, subsequent to the United 
Nations Resolution on noncommu-
nicable diseases in 2011, govern-
ments have approved a global mon-
itoring framework and an updated 
Global Action Plan 2013–2020 
for the prevention and control of 
noncommunicable diseases, aimed 
at tackling the four major diseases – 
cardiovascular disease, diabetes, 
chronic respiratory disease, and 
cancer – at the national, regional, 
and global level.
That cancer has emerged as 
such an important cause of death in 
human populations is, and remains, 
striking [4]. Yet in compilations of 
global mortality by cause, the com-
mon practice of distinguishing be-
tween neoplasms according to the 
major anatomical sites has tended 
to obscure cancer’s importance as 
a leading cause of death, in some 
instances almost to the point of its 
exclusion. As an example, WHO 
statistics for 2011 place ischaemic 
heart disease, stroke, lower respi-
ratory infections, chronic obstruc-
tive pulmonary disease, diarrhoea, 
and HIV/AIDS above lung cancer as 
leading causes of death worldwide 
[5]. However, when presented as a 
single entity, the 7.9 million deaths 
due to cancer outrank deaths from 
every other major cause of death, as 
estimated, in that year (Fig. 1.2.2).
Countries in rapid societal, eco-
nomic, and lifestyle transition are 
journeying towards an ever-greater 
impact of cancer. A global view 
of cancer patterns and trends in 
Fig. 1.2.2. The 10 leading causes of death worldwide in 2011. COPD, chronic obstruc-
tive pulmonary disease.
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relation to national level of develop-
ment becomes a vital consideration 
as a matter subject to understand-
ing, prediction, and planning in re-
lation to anticipated changes in the 
cancer burden and the spectrum of 
major cancer causes.
The Human Development 
Index: a marker of growth and 
development
Before studying cancer patterns 
and trends against socioeconomic 
markers, it is important to consider 
what constitutes human develop-
ment, how it may be measured, and 
how it is changing with time. There 
is no automatic link between eco-
nomic growth and human progress; 
thus, policy issues concern the ex-
act process through which growth 
translates, or fails to translate, into 
human development under differ-
ent developmental conditions. The 
Human Development Index (HDI) 
is a summary measure developed 
by the United Nations Development 
Programme and first published in 
1990 [1]. For the 2012 estimates, 
the HDI is a composite index of 
three basic dimensions of human 
development – a long and healthy 
life, education, and a decent stan-
dard of living – combined into a 
unit-free index with a value between 
0 and 1. The first dimension is mea-
sured by life expectancy at birth. 
This component is calculated using 
a minimum value of 20 years and 
a maximum value of 83.57 years; 
these are the observed extremes 
of this determination for countries 
over the period 1980–2012. Access 
to knowledge, the educational com-
ponent, is indicated by the average 
duration of schooling that has been 
provided to adults aged 25 years 
and the expected years of school-
ing for children of school-entry age. 
The third component, a decent 
standard of living, is measured by 
gross national income per capita (in 
purchasing power parity in United 
States dollars).
Using country-specific HDI val-
ues, one can go beyond the histori-
cal construct of characterizing the 
dichotomy between a “developed” 
and a “developing” country or area 
(Fig. 1.2.3A). A two-level construct 
based on HDI estimates for 2012 is 
shown in Fig. 1.2.3B. This still rep-
resents a rather crude dichotomy; 
therefore, to provide greater dis-
crimination, four levels of HDI are 
used. The 2012 HDI is divided into 
quartiles, indicating “very high”, 
“high”, “medium”, and “low” levels 
of human development. The global 
breakdown of countries according 
to the HDI quartiles is shown in 
Fig. 1.2.3C. The low HDI category 
is concentrated within sub-Saharan 
Africa, although several African 
countries have transitioned to the 
medium HDI category, as have 
many Asian countries, including the 
Fig. 1.2.3. Global map of development level of individual countries. (A) Historical 
approach: developing and developed countries. (B) Two levels of Human Development 
Index (HDI): countries with high or very high HDI versus those with low or medium 
HDI, 2012. (C) Four levels of HDI: countries with low, medium, high, and very high 
HDI, 2012.
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very densely populated countries of 
India and China. Many countries in 
Latin America and Central Asia now 
lie within the high HDI band.
Without exception, all coun-
tries worldwide have a higher HDI 
in 2012 than they had in 2000 
(Fig. 1.2.4). Most countries experi-
enced steady rises in the HDI deter-
mination over time. Highlighted are 
temporal patterns in eight countries 
that represent a broad spectrum of 
HDI values. The rates of change are 
such that a HDI of 0.4 was reached 
in Uganda 24 years after China, a 
value of 0.7 was attained in China 
22 years after Argentina, and a val-
ue of 0.8 was reached in Argentina 
30 years after Norway. In these ex-
amples, two to three decades were 
required to transition from one HDI 
category to the next.
Global cancer statistics 
by human development 
level in 2012
To examine cancer patterns in 
2012 by levels of socioeconomic 
development, the country-specific 
GLOBOCAN estimates from IARC 
[6] were linked to the correspond-
ing HDI, as estimated for 2012 by 
the United Nations Development 
Programme [7]. Methodological 
details of the data sources and 
methods of estimation used to com-
pile global estimates of incidence, 
mortality, and prevalence are well 
documented, alongside more de-
tailed presentation of these results 
[6,8–10]; the methods are largely 
dependent on the availability and 
the accuracy of the data sources 
locally. Generally, there is a pauci-
ty of high-quality cancer incidence 
and mortality data in areas with 
low and medium HDI. For exam-
ple, there are national or regional 
population-based cancer registries 
in slightly more than one third of 
the 184 countries examined here; 
less than 20 of these systems are 
in countries with low or medium 
HDI, whereas there are no vital 
statistics available in more than 
80 countries, predominantly those 
with low or medium HDI.
Cancer burden by two-level 
Human Development Index
The most common cancers in terms 
of new cases and deaths accord-
ing to two levels of HDI – high and 
very high HDI versus low and me-
dium HDI – are shown in Fig. 1.2.5 
for 2012. After lung cancer, breast, 
prostate, and colorectal cancers 
are the most frequent cancers in 
countries with high or very high 
HDI. Whereas colorectal, breast, 
and lung cancers have also be-
come rather more frequent in coun-
tries with low or medium HDI, there 
remains a large excess of poverty- 
and infection-related cancers in 
these countries, notably cancers 
of the stomach, liver, cervix, and 
oesophagus.
Lung cancer is the major cause 
of cancer death in both HDI areas, 
and colorectal cancer ranks a clear 
second in countries with high or very 
high HDI. Liver and stomach can-
cers remain as major causes of can-
cer death in areas with low or medi-
um HDI, a result of a high incidence 
of these cancers in these areas as 
well as an extremely poor prognosis 
for patients after diagnosis.
The extent to which cancers 
more strongly associated with life-
styles typical of industrialized coun-
tries (colorectal, breast, and pros-
tate cancers combined) dominate 
the distribution of tumour types 
compared with those cancers wholly 
or partly related to infectious causes 
(cervical, liver, and stomach cancers 
Fig. 1.2.4. Trends in Human Development Index (HDI) in 1980–2012, colour-coded by 
HDI category: red, low; orange, medium; turquoise, high; blue, very high.
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and Kaposi sarcoma combined) is 
captured in Fig. 1.2.6. Colorectal, 
breast, and prostate cancers con-
stitute more than one third of the 
7.9 million new cancers annually in 
countries with high or very high HDI, 
whereas cervical, liver, and stom-
ach cancers and Kaposi sarcoma 
in combination constitute less than 
10% of the total cancer burden in 
these areas. Conversely, in coun-
tries with low or medium HDI, infec-
tion-related cancers form a greater 
proportion of the 6.2 million esti-
mated new cases annually, with one 
quarter due to infection – a higher 
relative proportion than the one fifth 
due to cancers of the colorectum, 
breast, and prostate.
Cancer burden by four-level 
Human Development Index
A closer examination of the five 
most common cancers contributing 
to incidence, mortality, and 5-year 
prevalence by sex and by four lev-
els of HDI is depicted in Fig. 1.2.7. 
Overall, in countries with high or 
very high HDI, the same five neo-
plasms rank as the five most fre-
quently diagnosed cancers: lung 
and stomach cancers and the so-
called cancers of affluence, breast, 
prostate, and colorectal cancers. 
Lung cancer occupies a high rank 
in terms of incidence and is the 
most frequent cause of cancer 
death in all HDI categories except 
low HDI. The disease has a lesser 
rank in terms of prevalence, how-
ever, because of poor survival after 
diagnosis.
Incidence rates of breast, pros-
tate, and colorectal cancers in 2012 
are a function of level of develop-
ment, and risk of developing these 
cancers increases as countries 
transition to higher HDI levels, while 
risk of mortality varies consider-
ably less, because of proportion-
ately higher case fatality in coun-
tries with lower HDI (Fig. 1.2.8). 
For female breast cancer, there 
is a gradient in the magnitude of 
the cumulative incidence with HDI 
level (Fig. 1.2.8A), with cumulative 
risks of 2.7%, 4.9%, and 8.4% es-
timated in 2012 in countries with 
medium, high, and very high HDI, 
respectively; cumulative risk is also 
relatively high in areas with low 
HDI (3.4%). However, this gradient 
is much less consistent for corre-
sponding mortality; the estimates of 
1.6% and 1.5% in areas with high 
and very high HDI, respectively, are 
elevated compared with those for 
countries with medium HDI. Risk 
of breast cancer death is highest in 
countries with low HDI (1.8%), due 
to incidence combined with a pre-
dominantly poorer survival prospect 
Fig. 1.2.5. Total burden of the 27 most common cancers in 2012: (A) incidence and (B) mortality according to two-level Human 
Development Index (HDI).
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after diagnosis in these areas. 
Despite affecting women almost 
exclusively, breast cancer (close to 
1.7 million new cases worldwide in 
2012) is among the five most com-
mon incident and prevalent cancers 
in each of the four HDI categories, 
and it is also the leading cause of 
cancer death in women in countries 
with low HDI (Fig. 1.2.7).
Similarly, prostate cancer also 
shows rapidly diverging incidence 
rates at medium to very high HDI, 
with lifetime risk of diagnosis rang-
ing from 0.7% to 9.3% in coun-
tries with medium to very high HDI 
(Fig. 1.2.8B). As with breast cancer, 
the cumulative incidence of prostate 
cancer is higher in countries with 
low HDI than in those with medium 
HDI, while the corresponding risk of 
death in areas with low HDI (1.1%) 
is comparable to the risk estimated 
in countries with high HDI (1.3%), 
which is elevated relative to coun-
tries with medium or very high HDI.
Perhaps the clearest gradient of 
increasing risk of cancer with hu-
man development is for colorectal 
cancer, with almost a 2-fold incre-
ment in cumulative incidence in 
both sexes combined: from 0.6% 
in countries with low HDI to 1.3%, 
2.1%, and 3.6% in countries with 
medium, high, and very high HDI, 
respectively. A similar gradient 
emerges for mortality, although 
the estimated risk of death from 
colorectal cancer is close to equal 
in countries with high and very 
high HDI. Colorectal cancer now 
ranks within the five most frequent 
cancers in countries with medium, 
high, or very high HDI, is the sec-
ond most common cause of cancer 
death in countries with high and 
very high HDI, and ranks among the 
top five prevalent cancers in all four 
HDI areas (Fig. 1.2.7).
Stomach cancer appears with-
in the top five cancers in term of 
both incidence and mortality in all 
four HDI categories (Fig. 1.2.7). 
Whereas stomach cancer is the 
fifth most frequent cancer in coun-
tries with high or very high HDI, it 
is the third most common cancer in 
countries with medium HDI. Liver 
cancer ranks above stomach can-
cer in countries with medium HDI, 
surpassed only by lung cancer, with 
the impact of cancers common in 
China influencing the cancer pro-
file in this HDI category. Cervical 
cancer is the second most common 
cause of cancer incidence and mor-
tality burden in countries with low 
HDI, where it is the cause of almost 
one in five of the cancer deaths es-
timated among women.
Evidence of cancer 
transitions: some temporal 
examples
Colorectal cancer as a marker 
of development
Fig. 1.2.9 shows trends in colo-
rectal cancer incidence rates plot-
ted concomitantly with HDI levels 
for men in selected countries with 
high-quality population-based can-
cer registries. Across most coun-
tries, increasing incidence rates 
have paralleled increases in HDI. 
However, the magnitude of the 
rates does not necessarily corre-
spond with HDI levels attained by a 
given year: for example, rates are 
much lower in Colombia than in 
China in recent years, when their 
respective HDI levels were broadly 
similar. HDI has also increased in 
some countries where increases in 
colorectal cancer incidence are not 
evident, as is the case in Uganda. 
Finally, it is notable that rates tend 
to eventually stabilize and decline 
in countries that have attained very 
high HDI, as can be observed in 
the USA from 1985, Japan from 
the early 1990s, and Australia from 
1995.
Fig. 1.2.6. Percentage of cancers related to industrialized lifestyles (colorectal cancer, 
female breast cancer, and prostate cancer), infection-related cancers (cervical, liver, 
and stomach cancers and Kaposi sarcoma), and all other cancers (A) in countries with 
high or very high Human Development Index (HDI) and (B) in countries with low or 
medium HDI, 2012.
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Fig. 1.2.7. The five most frequent cancers in terms of incident cases, cancer deaths, and 5-year cancer prevalence in 2012 
(ages 15 years and older), according to four-level Human Development Index (HDI).
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The rise of cancer in women: 
breast cancer compared with 
cervical cancer
The evolution of cancers in women 
shows a consistent and very striking 
pattern during the epidemiological 
transition, with rapid declines in the 
incidence of cervical cancer offset 
by concomitant increases in the inci-
dence of breast cancer (Fig. 1.2.10). 
The year in which the two cancers 
are equally common, with one 
trending up and the other down, is 
a marker of the extent of transition 
in a given country; this time is in the 
distant past for Australia, Spain, and 
the USA and is much more recent 
for Colombia, Costa Rica, and India. 
However, the picture in Uganda 
is markedly different, with rates of 
both cancers still rising, and cervical 
cancer incidence rates twice those 
of breast cancer. This is in major 
contrast to the 10–20-fold variations 
in breast and cervical cancer inci-
dence rates in countries with very 
high HDI across Europe, Oceania, 
and North America.
Regional cancer profiles and 
human development
Chapter 1.1 includes a regional and 
inter-regional analysis of the geo-
graphical variations in the cancer 
burden according to continent. To 
link such variations to level of hu-
man development, the ecological 
comparisons of the levels of HDI 
in the countries of Africa and Latin 
America and the corresponding 
age-standardized rates of cervical, 
breast, and prostate cancer are pre-
sented in Fig. 1.2.11.
In Africa, the HDI varies from 
about 0.3 in the Democratic Re- 
public of the Congo, Niger, and 
Mozambique to about 0.7 in 
Botswana and Gabon, with the 
highest values in the North African 
countries of Algeria, the Libyan 
Arab Jamahiriya, and Tunisia. Rates 
of cervical cancer tend to be very 
high in countries with the lowest 
HDI (< 0.4), including Mali, Malawi, 
Mozambique, and Zimbabwe, yet 
rates are low in Niger, the country 
with the lowest HDI ranking world-
wide in 2012, as well as among the 
highest HDI ranked countries on the 
continent, in North Africa.
For breast cancer, the situa-
tion tends to be reversed, with the 
highest rates observed where HDI 
is high and cervical cancer rates 
are low, as in Algeria and Egypt, 
or intermediate, as in Ethiopia and 
Nigeria. Yet breast cancer incidence 
rates are relatively low in countries 
with elevated cervical cancer rates, 
such as Malawi and Mozambique, 
whereas in Botswana breast cancer 
rates are low and cervical cancer 
rates intermediate, contrasting with 
the country’s relatively high HDI. Of 
course, this observation may partly 
relate to heterogeneity in the preva-
lence and distribution of risk factors 
for breast cancer within these coun-
tries, as well as the considerable lag 
between average changes in human 
development in the national popu-
lation and anticipated increases in 
breast cancer incidence, linked to 
the etiological factors and the natu-
ral history of the disease.
For prostate cancer, rates tend 
to be less driven by HDI levels, 
with rates elevated in countries with 
low to intermediate HDI, such as 
the United Republic of Tanzania, 
Uganda, Zimbabwe, Guinea, and 
the Republic of the Congo, but also 
in countries with higher HDI, such as 
South Africa; rates are consistently 
low in North Africa.
In Latin America, the HDI does 
not vary as much as on the African 
continent, from about 0.6, as in 
Guatemala and Nicaragua, to just 
over 0.8, as in Chile and Argentina. 
However, some of the disparities in 
burden are in line with cancer tran-
sitions, with relatively low rates of 
cervical cancer, and relatively high 
Fig. 1.2.8. Cumulative risk of (A) female breast cancer, (B) prostate cancer, and 
(C) colorectal cancer incidence and mortality (ages 0–74 years) in 2012, according to 
four-level Human Development Index (HDI).
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Fig. 1.2.9. Trends in age-standardized (World) incidence rates (ASR) for colon cancer in men in 1978–2010 in 12 countries versus 
concomitant trends in Human Development Index (HDI) in 1980–2012. Incidence is smoothed using Loess regression.
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Fig. 1.2.10. Trends in age-standardized (World) incidence rates (ASR) for breast cancer versus cervical cancer in 1978–2010 in 12 
countries. Incidence is smoothed using Loess regression.
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rates of breast cancer, in countries 
with high HDI, such as Argentina, 
Uruguay, and Brazil, and the oppo-
site situation in countries with lower 
HDI, such as Nicaragua and Bolivia. 
Yet for other Latin American coun-
tries such simple relations appear 
not to hold: the rates of both cancers 
are relatively low in Chile, while for 
cervical cancer, rates in Peru are 
twice those of neighbouring Brazil, 
despite approximately similar HDI 
levels in 2012. Prostate cancer inci-
dence is high in countries with higher 
HDI such as Brazil and Costa Rica, 
but in countries with analogous de-
velopment levels such as Argentina 
and Peru, rates are intermediate to 
low in relative terms, respectively.
This description of the cancer 
burden for the three cancers by re-
gion and level of human develop-
ment provides some evidence of 
cancer transition at the continental 
level but reveals the complexity lim-
iting a broad interpretation, given the 
counter-intuitive examples provided 
above, and indeed the possible lag 
between HDI transitions and cancer 
risk. Certainly, the extent and modal-
ities of early detection and screening 
vary from country to country and be-
tween and within the two regions ex-
amined. Increasing levels of screen-
ing at the population level are linked 
to human development, and where 
precursor lesions are not the target 
of the intervention, such interven-
tions have the potential to artificially 
increase the incidence burden of fe-
male breast cancer due to mammo-
graphic screening programmes and, 
particularly, prostate cancer due to 
prostate-specific antigen testing of 
asymptomatic individuals.
The extent to which cytological 
screening of the cervix has been 
introduced is partly linked to devel-
opment levels and national cancer 
control policies and will have had 
an impact on the rates of cervical 
cancer in some countries, while 
other factors may explain some 
of the variation, including rates of 
high-risk human papillomavirus in-
fection at the population level, as 
influenced by religious and cultural 
practices in given countries.
Fig. 1.2.11. Regional maps of Human Development Index (HDI) value versus age-
standardized (World) incidence rates (ASR) of cervical, breast, and prostate cancer, 
(A) in Africa and (B) in Latin America, 2012.
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There are regional determinants 
for prostate cancer. Incidence rates 
are influenced by the diagnosis of 
latent cancers mainly in countries 
with higher HDI, while the distri-
bution of mortality rates is less 
affected by the effects of early di-
agnosis. Evidently the elevated 
mortality rates in several sub-Saha-
ran countries, such as Uganda and 
Zimbabwe, suggest that prostate 
cancers commonly diagnosed in 
these populations are developed as 
a result of largely unknown inherited 
or environmental factors linked to 
the underlying risk of invasive dis-
ease, rather than being determined 
by interventions aimed at revealing 
evidence of asymptomatic cancers.
As with breast cancer, differenc-
es within countries in the unknown 
determinants and the extensive de-
lay between developmental chang-
es and an increasing risk of pros-
tate cancer may help to illuminate 
the apparent paradoxes. The inher-
ent lack of high-quality registry data 
underpinning national incidence 
estimation, most notably in Africa, 
is likely to have hampered the infer-
ence attempted here.
Cancer incidence by 2025: 
demographic and trend-based 
predictions
The global population, 7 billion in 
2012, will reach 8.3 billion by 2025 
[11]. Slow changes in fertility and 
increasing life expectancy are hav-
ing a major impact on population 
growth and ageing in countries in 
developmental transition, with the 
greatest increases in cancer burden 
in the very same countries where 
trends in overall cancer rates are 
also rising. Updating an exercise 
based on the observed time trends 
in cancer-specific incidence by HDI 
level [9], with annual increases in 
rates of colorectal cancer, female 
breast cancer, and prostate cancer 
worldwide – and, in areas with high 
to very high HDI, for lung cancer 
in women – alongside annual de-
creases in rates of stomach cancer 
and cervical cancer worldwide – 
and, in areas with high to very high 
HDI, for lung cancer in men – a pre-
dicted global burden of more than 
20 million new cancer cases can 
be anticipated by 2025. Countries 
with medium HDI and, particularly, 
those with low HDI will experience 
the greatest proportional popula-
tion growth during this time, and 
thus the greatest increases in the 
future cancer burden (Fig. 1.2.14). 
Notably, this scenario predicts an 
excess of almost 2 million cancers 
in men over cancers in women.
Fig. 1.2.12. A woman in China tends a farm with her child at her side. Generally, 
there is a relative paucity of cancer incidence and mortality data in areas with low and 
medium Human Development Index.
Fig. 1.2.13. Children look out at Kampala’s skyline during a celebration of Uganda’s 
50th anniversary of independence. Currently, all countries worldwide have a higher 
Human Development Index (HDI) than they had in 2000, but countries differ in the rate 
of transition to a higher HDI level.
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Overview
The predicted global burden is ex-
pected to surpass 20 million new 
cancer cases by 2025, compared 
with an estimated 14.1 million new 
cases in 2012. Demographic chang-
es are the key drivers of the unprec-
edented growth in the cancer bur-
den, but the profiles of cancer are 
changing as populations increas-
ingly adopt behavioural and lifestyle 
habits that are common in affluent, 
industrialized countries. Elevated 
rates of female breast cancer, pros-
tate cancer, and colorectal cancer 
incidence are linked to an attain-
ment of higher levels of human de-
velopment, with colorectal cancer 
the most markedly associated with 
HDI. A close to 2-fold increase in 
cumulative incidence of colorectal 
cancer is estimated as countries 
transition from low to higher cat-
egories of HDI. This, coupled with 
the increases in incidence rates 
of colorectal cancer in countries 
where HDI is rapidly rising, may be 
related to the increasing prevalence 
of unhealthy dietary habits and de-
creased levels of physical activity 
in populations undergoing develop-
mental transition.
Lung cancer is the leading 
cause of cancer death in countries 
with medium, high, and very high 
HDI and is determined very largely 
by tobacco smoking, with risk be-
ing influenced by the number of 
cigarettes smoked, the duration of 
the habit, and the composition of 
the tobacco used. Given the limited 
nature of long-term data accumula-
tion on tobacco-related cancer in-
cidence and mortality in countries 
with low and medium HDI, along-
side the relatively recent smoking 
histories in these populations, cur-
rent lung cancer rates are often 
low and not indicative of impending 
epidemics in either sex. The extent 
of the projected increases in lung 
cancer and other tobacco-related 
diseases is, however, inextricably 
linked to the global tactics of to-
bacco companies aiming to expand 
their sales [12]. A smoking epidemic 
is unfolding in many countries with 
lower HDI that are in transition, 
potentially impeding human devel-
opment by consuming scarce re-
sources, increasing pressures on 
already weak health-care systems, 
and inhibiting national productivity. 
Discernible increases in smoking-
attributable risks have recently been 
reported in Bangladesh [13], China 
[14], India [15], and South Africa 
[16]. In many countries, in keeping 
with the tobacco epidemic model, 
the habit has been acquired rela-
tively recently in women; in some 
countries, in a departure from this 
model, women have not acquired 
the habit at all. Perhaps there is 
more encouraging evidence of the 
latter scenario, at least in China 
where a recent epidemiological 
study of asbestos workers reported 
Fig. 1.2.14. Population estimates for 2012 and predictions for 2025: (A) changes 
in total population size by four-level Human Development Index (HDI); (B) incident 
cancer burden based on demographic changes and demographic + incidence rate 
changes, by sex and four-level HDI.
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Fig. 1.2.15. Ranking of premature mortality from cancer compared with cardiovascular disease and diabetes (combined) and 
chronic obstructive pulmonary disease (ages 30–69 years, both sexes), estimated for 2011.
that of the relevant workforce, 79% 
of men smoked compared with less 
than 1% of women [17].
Cancer is becoming the major 
cause of premature deaths among 
noncommunicable diseases. A rap-
id assessment of the ranking of pre-
mature mortality (ages 30–69) from 
major noncommunicable diseases 
(Fig. 1.2.15) reveals how cancer has 
surpassed cardiovascular disease 
(here combined with diabetes) and 
chronic obstructive pulmonary dis-
ease in countries with very high 
HDI. It can therefore be expected 
that cancer will become a leading 
cause of premature death not only 
compared with other noncommuni-
cable diseases but across the spec-
trum of causes, as countries head 
towards the higher human develop-
ment threshold. In turn, therefore, 
noncommunicable diseases are 
recognized as a barrier to human 
development and as such should 
be a central part of the post-2015 
agenda, after the target date for the 
Millennium Development Goals.
The author thanks Mathieu Laversanne for 
statistical analysis and generation of the 
graphics.
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Summary
• Childhood cancers are distinct 
entities from cancers occurring 
in adults. Overall annual inci-
dence rates vary between 50 
and 200 per million in children 
and between 90 and 300 per 
million in adolescents. Reliable 
data on cancer in children and 
adolescents are available for 
only a small fraction of the 
world’s population.
• Over the past 50 years, 5-year 
survival has improved in high-
income countries from less 
than 30% to more than 80%, al-
though this trend may have pla-
teaued recently. Treatment and 
follow-up must be adapted to 
the age of the patient and must 
embrace the patient’s family 
and its circumstances.
• The growing population of 
survivors requires specialized 
follow-up and care. Innovation 
in clinical research is required 
to ensure continued improve-
ment of prognosis and reduced 
occurrence and severity of the 
late effects of treatment.
• The mortality-to-incidence ratio 
remains high in countries with 
low human development in-
dex, although some diagnoses 
are highly curable at low cost. 
National investment and inter-
national collaboration are re-
quired to improve outcomes.
Incidence rates
The term “childhood cancer” is most 
commonly used to designate cancers 
1.3
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Fig. 1.3.1. Cancer cases and deaths in children (aged < 15 years) as a proportion of 
the total numbers in the population, in 2012. HDI, Human Development Index.
that arise before the age of 15 years. 
Cancer in childhood represents be-
tween 0.5% and 4.6% of the total 
number of cancer cases in a popu-
lation (Fig. 1.3.1) [1]. The proportion 
of cancers that occur in children is 
higher in countries with low Human 
Development Index (HDI) than in 
countries with high HDI. This is 
70
because children make up a larger 
percentage of the overall population 
(up to 50%) and concomitantly the 
elderly population, which exhibits 
the highest risk of cancer, is quite 
small in countries with low HDI.
Population-based cancer reg-
istries around the world report 
overall incidence rates that vary 
between 50 and 200 per million 
children per year. The spectrum of 
tumour types differs across popu-
lations (Fig. 1.3.2) [2–12]. Acute 
lymphoblastic leukaemia is the 
most common diagnosis, except 
in sub-Saharan Africa, where chil-
dren are more prone to develop 
non-Hodgkin lymphomas (most 
commonly Burkitt lymphoma) and 
Kaposi sarcoma, due to the specific 
infectious exposures in that region 
(notably Plasmodium, Epstein–Barr 
virus, and HIV) [11]. Brain tumours 
are the second most common ma-
lignancy in regions that can afford 
to implement non-invasive diag-
nostic technologies [13]. Improved 
diagnostics may also influence the 
incidence of neuroblastoma; inci-
dental findings of indolent tumours 
discovered in the countries with 
highly developed medical surveil-
lance may account for observed 
increases in incidence.
All childhood cancers are indi-
vidually rare, with incidence rates 
varying from 1 per million for a very 
rare cancer such as hepatoblastoma 
to 50 per million for the most com-
mon subgroup, lymphoid leukaemia. 
Haematological malignancies repre-
sent 40–60% of tumours in the first 
15 years of life. Embryonal tumours 
(e.g. retinoblastoma, neuroblastoma, 
nephroblastoma) constitute about 
20% of childhood malignancies and 
virtually never occur except in chil-
dren. Carcinomas represent less 
than 5% of childhood tumours, while 
these are the most frequent histolo-
gies in adults. The characteristic 
morphological appearances imply 
a distinct developmental origin and 
etiology for tumours in childhood. 
Because of the age-specific histol-
ogy, the International Classification 
of Childhood Cancer [14] is used to 
describe the occurrence and out-
comes of cancer in childhood.
Increasingly, adolescents (aged 
15–19 years) and young adults 
(aged 20–24 years) with cancer are 
being considered as a group re-
quiring special consideration, simi-
lar to childhood cancer, due to the 
unique composition of cancer types 
(Fig. 1.3.3) [15] and their health-care 
requirements. Although embryonal 
neoplasms in adolescents are rare, 
haematological neoplasms continue 
to be common, and most are lym-
phomas. Central nervous system tu-
mours still represent a large propor-
tion of cancers, and bone tumours 
peak in the adolescent age group 
in many populations. Malignant 
melanoma is more common than in 
children, particularly in female ado-
lescents. The leading cancer site in 
male adolescents is the testis, with 
age-specific rates rising until ages 
in the early forties. The prominent 
types in female adolescents are 
thyroid cancer, ovarian germ cell 
tumours, and cervical cancer. The 
worldwide incidence rates vary ap-
proximately 3-fold in male (9–30 per 
100 000) and in female (9–27 per 
100 000) adolescents [16].
Fig. 1.3.2. Incidence rates of cancer in children (aged 0–14 years) in the 1990s and 
2000s. CNS, central nervous system; PNET, primitive neuroectodermal tumours; 
SEER, Surveillance, Epidemiology and End Results national statistics; SNS, sympa-
thetic nervous system.
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The overall incidence of child-
hood cancer increased by about 1% 
per year over the last three decades 
of the 20th century in Europe, North 
America, Australia, and elsewhere, 
although the rate of increase seems 
to have levelled off over the most 
recent decade [10,17–19]. Among 
adolescents, incidence has also 
increased (Fig. 1.3.4), at a similar 
rate [17,20]. The observed temporal 
trends might partly reflect improved 
diagnosis and reporting of cancers 
[13], but the impact of changes in ex-
posures and lifestyles over the same 
period may have also contributed to 
the changes in incidence. For exam-
ple, the recent study that showed 
a reduction of incidence rates of 
Wilms tumour and some other rare 
childhood tumours in the USA after 
supplementation of the food supply 
with folic acid [21] provides hope 
that the predisposing environmental 
factors will be identified and child-
hood cancers prevented.
It is estimated that by 2035 
the annual number of new can-
cers across all ages will grow by 
70% compared with 2012 esti-
mates [1] (see also Chapter 1.2). In 
comparison, the annual numbers 
of cancer cases and deaths among 
children are expected to increase 
by only 7%, based on the assump-
tion of a medium fertility variant of 
the population growth [22] and sta-
ble incidence and mortality rates. 
However, from the international data 
it appears that the rate of childhood 
leukaemia, the most common can-
cer in many childhood populations, 
is positively correlated with socio-
economic status [23], and several 
hypotheses suggest that the risk 
factors associated with a high level 
of development, such as delayed 
exposure to common infections, 
population mixing, and changes in 
reproductive behaviour, influence 
the incidence of acute lymphoblastic 
leukaemia. In sub-Saharan African 
countries, where childhood leukae-
mia is reported relatively rarely, sig-
nificant increases in rates of child-
hood leukaemia may be expected in 
the near future, both due to improv-
ing diagnostic facilities and due to 
adoption of industrialized lifestyles.
Outcomes
Over the past 40 years, outcomes 
of cancer in children have im-
proved dramatically. In the United 
Kingdom, the 5-year survival rate 
increased from less than 30% to al-
most 80% on average, thus reduc-
ing the risk of death by 68% overall 
(Fig. 1.3.5) [24], and similar chang-
es were observed in other high-in-
come countries. These spectacular 
Fig. 1.3.3. Cancer incidence rates in (A) male and (B) female adolescents (aged 15–
19 years) and young adults (aged 20–24 years) in Europe, in 2003–2007. Data from 
84 cancer registries contributing data for the selected calendar years were retrieved 
from the European Cancer Observatory on 18 November 2013. CNS, central nervous 
system.
Fig. 1.3.4. Cancer trends in adolescents and young adults (aged 15–24 years) in 
Europe. Pooled data from the European Cancer Observatory from all cancer registries 
with data covering the period shown: Finland, Germany (Saarland), Iceland, Italy 
(Varese), Norway, Slovakia, Sweden, Switzerland (Geneva, St Gallen-Appenzell) and 
the United Kingdom (Scotland).
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improvements are the results of 
therapeutic advances, fostered 
through worldwide collaboration 
of childhood cancer study groups 
and the International Society of 
Paediatric Oncology (www.siop-
online.org).
Because of the age proxim-
ity, the overlapping spectrum of tu-
mours, and the need for a very sen-
sitive approach, adolescent patients 
Fig. 1.3.5. Five-year survival rates of children diagnosed before the age of 15 years in 
Britain during the indicated periods.
with selected malignancies are man-
aged within a paediatric oncology 
practice. Indeed, adolescents may 
benefit from inclusion in paediatric 
therapeutic protocols compared with 
those developed for adults, at least 
for “paediatric-like” cancers such as 
acute lymphoblastic leukaemia [25]. 
The overall 5-year survival of ado-
lescents is similar to that of children, 
reaching 84% [4,26].
Table 1.3.1. Five-year survival rates (%) in children (aged 0–14 years) with cancer diagnosed during the indicated periods
Cancer type
Location (period) [source of data]
Australia
(1997–2006)
[18]
Shanghai, China
(2002–2005)
[27]
Chennai, India
(1990–2001)
[9]
Thailand
(2003–2004)
[7]
All cancers 79.6 55.7 40.0 54.9
Leukaemias 80.6 52.2 36.3 57.4
Lymphomas 89.9 58.8 55.3 59.5
Central nervous system tumours 71.0 41.2 26.8 41.7
Neuroblastoma 67.8 — 36.9 33.6
Retinoblastoma 98.4 75.0 48.1 73.1
Renal cancers 88.6 86.7 58.0 70.4
Liver cancers 76.0 33.3 10.5 44.5
Malignant bone tumours 68.9 52.6 30.6 33.7
Soft tissue sarcomas 72.1 54.1 36.3 50.1
Germ cell tumours 89.4 78.4 38.0 70.6
Carcinomas and melanoma 93.3 88.9 35.1 —
Other 72.2 — — —
The spectacular improvement in 
outcomes is, however, limited to high-
income countries. The results from 
rare reports of childhood cancer sur-
vival in middle-income countries are 
compared with data from Australia in 
Table 1.3.1 [7,9,18,27]. Despite the dif-
ferent reporting periods, it is evident 
that the proportion of 5-year survivors 
in India is much lower than that seen 
in high-income countries. The low 
survival figures may be explained by 
late presentation at diagnosis, treat-
ment abandonment, and the absence 
of sophisticated multidisciplinary care 
and adequate resources.
In the absence of globally compa-
rable data on cancer patient survival, 
estimates are used to describe the 
ultimate cancer burden in terms of 
mortality. Compared with the estimat-
ed 163 000 new cancers in children 
worldwide in 2012, the 80 000 deaths 
represented about a half of the new 
cases. In 2012, 82% of the new cases 
and 93% of the deaths occurred in the 
less developed countries [1]. In Africa, 
the mortality represents 60% of the 
incidence, while in North America 
this ratio is less than 15% (Fig. 1.3.6) 
[1,16]. National investment and inter-
national collaborations are required to 
improve this situation.
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Whereas low- and middle-income 
countries need to build capacity to 
reach the 80% 5-year survival cur-
rently achievable in the countries with 
the most resources, the reduction in 
mortality observed in Europe and the 
USA has plateaued over the most 
recent period (Fig. 1.3.7) [28,29]. 
There remains, therefore, an urgent 
need for new major breakthroughs in 
therapies to re-accelerate the current 
rate of improvement in survival [30].
The greatly improved survival 
in high-income countries has given 
rise to a growing population of sur-
vivors of cancer in childhood or 
adolescence, a large proportion of 
whom face significant late effects 
of their primary disease and cancer 
treatment. Survivors experience an 
excess risk of death and second 
primary cancer long past their diag-
nosis. In a Nordic study of 21 984 
5-year survivors of childhood cancer, 
the overall standardized mortality 
ratio was 8.3 and the absolute ex-
cess risk was 6.2 per 1000 person-
years. The causes of death included 
primary cancer (60%), subsequent 
malignant neoplasms (12%), and 
non-cancer causes (27%) [31]. 
Other sequelae of cancer treatment 
include neurocognitive impairment, 
cardiovascular disease, and other 
organ dysfunction, but also the psy-
chosocial impact of the disease and 
its treatment on patients, their family 
members, and their future lives. It is 
clear that the usual 5-year survival 
statistics reflect a short-term, rather 
than a long-term, prognosis for chil-
dren with cancer. Lifelong follow-up 
is important and has to take into ac-
count the inevitable transition into 
the non-specialized, and often un-
aware, primary health-care system.
Data sources
Worldwide, there are approximately 
50 countries with established na-
tional population-based cancer reg-
istries, which provide their data for 
comparative international studies. 
Most of these registries collect data 
on cancers occurring in individuals of 
all ages (a general cancer registry), 
but some countries are also covered 
by a separate, national paediatric 
cancer registry. Paediatric cancer 
registries often collect more details 
on the patient, diagnosis, treatment, 
and outcome. Regional population-
based cancer registries operate in 
other countries and provide valuable 
information on cancer burden, in-
cluding that in children. Comparative 
incidence data on childhood cancer 
were reported in the two volumes 
of the IARC Scientific Publications 
series International Incidence of 
Childhood Cancer; a third volume 
of the series, describing incidence 
in children and adolescents over the 
past two decades, is in preparation 
(http://iicc.iarc.fr/).
Childhood cancer is a rare dis-
ease, requiring that large populations 
are covered to collect sufficient num-
bers of cases for meaningful analy-
ses. National cancer registration is 
the ideal option for rare cancers such 
Fig. 1.3.6. Estimated mortality-to-incidence ratio for cancer in children (aged 
0–14 years) in 2012, and percentage of population coverage by cancer registration 
(all ages).
Fig. 1.3.7. Cancer mortality in children (aged 0–14 years) in three European countries 
(Ireland, the Netherlands, and the United Kingdom combined) for 1950–2009 and in 
the USA for 1950–2007.
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as those occurring in childhood and 
possibly also in adolescence, and is 
a workable model, as shown by the 
examples of Argentina, South Africa, 
and the Islamic Republic of Iran. In 
low-income settings, however, a 
more appropriate strategy would be 
to start a regional population-based 
cancer registry. In this respect, exist-
ing hospital-based cancer registries 
may aim to become population-
based if they succeed in determining 
the relevant geographically defined 
population at risk. It is no coinci-
dence that population coverage by 
cancer registration is correlated with 
high incidence rates and low mortal-
ity rates (Fig. 1.3.6). Although found-
ing a cancer registry will not auto-
matically reduce the mortality rates 
in a population, cancer registration 
is an essential element of a cancer 
control plan, and is bound to serve 
as the evidence base that will inform 
other services to cancer patients and 
eventually lead to improvements in 
survival.
The value of the statistics pro-
duced by cancer registries depends 
on the quality, accuracy, and com-
pleteness of the data generated 
in clinical practice. The better the 
cooperation between the partners, 
the more useful the produced out-
put will be. For optimal functioning 
of cancer registries, it is essential to 
ensure access to the relevant data. 
Regulations imposing requirements 
of informed consent, trusted third 
parties, or various encryption tech-
niques would make it virtually im-
possible to use data from a cancer 
registry and thus hinder the achieve-
ment of better outcomes for current 
survivors and future patients.
Several initiatives have been un-
dertaken in Europe recently to en-
large the information base available 
within population-based cancer reg-
istries and allow a more specific inter-
pretation of the outcome in addition 
to a description of the geographical 
and temporal patterns. This work is 
funded by the European Union within 
the Seventh Framework Programme 
of the European Commission. The 
European Network for Cancer Re- 
search in Children and Adolescents 
is a Network of Excellence with the 
overall aims to improve survival and 
quality of life for children and ado-
lescents with cancer, to facilitate ac-
cess to the best therapies, to develop 
biology-guided therapies, and to ef-
ficiently structure and enhance col-
laboration within the field of paediat-
ric oncology in Europe (http://www.
encca.eu/). PanCare Childhood and 
Adolescent Cancer Survivor Care 
and Follow-up is a research proj- 
ect of the PanCare Network with a 
mission to provide every childhood 
and adolescent cancer survivor with 
better access to care and better long-
term health (http://www.pancare 
surfup.eu/). The member registries 
of the European Network of Cancer 
Registries (http://www.encr.com.fr/) 
are involved in the European 
Network for Cancer Research in 
Children and Adolescents and in 
PanCare Childhood and Adolescent 
Cancer Survivor Care and Follow-
up to investigate the feasibility of 
collecting additional clinically rel-
evant information on children and 
adolescents with cancer to facilitate 
routine short-term clinical follow-up 
and long-term follow-up for selected 
late effects. The additional variables 
of interest may include pre-existing 
patient conditions (e.g. genetic syn-
drome), diagnostic data (e.g. biologi-
cal markers or stage), information on 
treatment received (e.g. inclusion in 
clinical trials), referral and follow-up 
(e.g. date of relapse), and possible 
late effects in long-term survivors 
(e.g. cause of death, cardiac con-
dition). Sharing expertise between 
clinical and population-based re-
search will simultaneously enhance 
the potential of data collected in 
both types of resources and provide 
a cost-effective solution to advance 
research in paediatric oncology.
Fig. 1.3.8. A young patient is treated at 
the 57357 Children’s Cancer Hospital in 
Cairo, Egypt.
Fig. 1.3.9. A child receiving chemotherapy at the Uganda Cancer Institute (Lymphoma 
Treatment Centre). Burkitt lymphoma is common in Uganda.
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Summary
Various conditions throughout geo-
graphically and societally diverse 
parts of the world share in common 
the potential to inflict severe, often 
prolonged, psychological stresses 
on human populations. Telomere 
maintenance, which is emerging 
as a central biological process that 
plays roles in both prevention and 
progression of human cancers and 
other ageing-related diseases, is 
adversely affected by psychological 
stress. Telomeres are the dynamic 
structures that cap and protect 
chromosome ends. Telomeric DNA 
attrition commonly occurs in hu-
man cells during ageing or because 
of inherited “telomere syndromes”. 
If unchecked, such attrition can 
eventually lead to cellular malfunc-
tioning. This in turn contributes to 
multiple, often co-morbid, diseases 
of ageing, including a spectrum of 
cancers. Clear links already are 
known to exist between stress, 
telomere attrition, and several other 
common diseases of ageing be-
sides cancers. Therefore, the les-
sons already learned from such 
studies should inform strategies 
and policies in efforts to intercept 
human cancers and reduce their 
worldwide burden.
Telomeres, the protective terminal 
regions of our chromosomes, are 
dynamic structures that play multi-
ple roles to ensure correct cellular 
functions and prevent genomic in-
stability. Both biologically internal 
and external factors that influence 
human conditions can compromise 
telomere maintenance, and as I dis-
cuss in this Perspective, this knowl-
edge has implications for reducing 
cancer risks.
First, a short background on telo-
meres and telomerase. Telomeres, 
found at every end of every sta-
ble eukaryotic chromosome, form 
“caps” made up of elaborately con-
trolled DNA–protein complexes. 
The telomere structure consists of 
a scaffold of a thousands-of-base-
pairs-long stretch of a simple re-
peated DNA sequence at the ex-
treme end of the chromosome that 
directly binds a suite of telomeric, 
DNA sequence-specific, protective 
proteins. These proteins in turn in-
teract with several other proteins 
that, through multiple mechanisms 
(collectively called capping), aid in 
protecting the telomeres (reviewed 
in [1]).
Crucially, a minimum length of 
telomeric DNA is required to sus-
tain chromosome stability and cel-
lular functions. However, net telo-
mere erosion commonly occurs in 
humans over the lifespan [2]. Action 
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of the cellular enzyme telomerase 
(a specialized ribonucleoprotein re-
verse transcriptase) can elongate 
telomeric DNA and thus counteract 
telomere erosion, replenishing telo-
mere length and functional integrity. 
The telomeric complex is a dynamic 
entity, with the capacity to be con-
stantly shortened, built, shortened, 
and rebuilt. Yet the general rule 
in humans as they age appears 
to be that telomerase action over-
all in somatic cells is insufficient 
to guarantee continued telomere 
maintenance in the face of attrition 
throughout the human lifetime.
If the telomeric repeat DNA tract 
becomes too short, the chromo-
some end behaves as though it is 
a broken DNA end and becomes 
subject to inappropriate responses 
in the cell. These responses include 
premature cessation of cell divi-
sion as well as reprogramming of 
transcriptional and other pathways 
to produce pro-inflammatory and 
tumour-promoting factors (reviewed 
in [3]). Furthermore, deleterious at-
tempts by the cell to repair the telo-
mere lead to genomic instabilities 
of various kinds that can promote 
cancers [4]. In humans the net re-
sult is to cause or spur various dis-
ease processes, including cancer 
progression [3,5].
Telomere maintenance and 
telomerase
Clinical, genetic, cellular, and mo-
lecular research of the past sev-
eral years has recently converged 
to show that either too much or too 
little telomerase, even over quite a 
narrow range, can greatly increase 
lifetime risks of a range of different 
cancers, including many common 
cancers. Such findings indicate that 
humans appear to live on a knife-
edge with respect to the telomere 
maintenance machinery and can-
cer risks. Therefore, external fac-
tors that influence telomere main-
tenance and telomerase constitute 
potentially significant contributors 
to cancer risks. Importantly, these 
factors include psychosocial inputs 
that bear on chronic psychological 
stress. In this Perspective, I briefly 
discuss current understanding of 
these issues, and their implications.
Can telomere shortening con-
tribute to diseases of ageing, in-
cluding cancers? The answer is 
yes. Inherited disorders that com-
promise telomere maintenance 
establish a causal relationship be-
tween functional compromise of 
telomeres (usually caused by their 
over-shortening to below-functional 
lengths) and a wide range of dis-
eases, collectively dubbed “telo-
mere syndromes” [3]. These inher-
ited syndromes include pulmonary 
fibrosis, diabetes, compromised 
cardiovascular function, and im-
mune system disorders such as 
aplastic anaemia. They also include 
high risks for various haematologi-
cal malignancies and gastrointes-
tinal tract and squamous cell can-
cers, which can account for about 
10% of the overall mortality in indi-
viduals with such syndromes. Such 
telomere maintenance mutations 
have cropped up sporadically in in-
dividual families from different parts 
of the world and are often well stud-
ied, as are mouse genetic models 
of telomere deficiency. Therefore, 
the causal link between this large 
inherited risk of cancers and very 
short, and hence non-functional, 
telomeres (caused by inadequate 
telomerase action) is compelling.
Can there be too much telome-
rase? Again the answer is yes, in 
abnormal situations. In addition to 
the cancer-causing mutations that 
diminish telomerase and cause 
overly short telomeres, even small 
changes in telomerase activity in 
the upward as well as the down-
ward direction can greatly augment 
risks for some cancers and appear 
to act early in cancer progression. 
Point mutations (somatic or inher-
ited) that increase expression of 
a telomerase component by only 
about 2-fold were recently shown 
to be associated with dramatically 
increased risks of melanoma in hu-
mans and are highly recurrent in 
sporadic melanomas [6,7]. Similar 
mutations were found also in liver 
and bladder cancers. It has been 
known for many years that highly 
upregulated telomerase is a hall-
mark of many advanced (especially 
highly malignant) human cancers. 
This upregulation can be rational-
ized primarily as the need for can-
cer cells to maintain their telomeres 
to sustain their continued prolifera-
tion, a central property of cancer 
cells. However, interestingly, the 
melanoma-causing mutations de-
scribed above bear the hallmarks 
of sunlight-induced mutations. This 
suggests that small but abnormal 
increases in telomerase may drive 
melanoma at even early stages 
[6,7].
Risks of age-related diseases
In human populations as well as pa-
tients with inherited telomere mainte-
nance diseases, telomere shortness 
is linked to risks of some cancers. 
Indeed, in multiple population and 
cohort studies, the degree of telo-
mere shortness is quantitatively 
linked to future risks of acquiring 
many age-related diseases, includ-
ing some (but not all) cancers [8]. 
Impaired telomere maintenance 
leading to eventual over-shortening 
of telomeres has defined cellular 
and pathogenic consequences, as 
shown by laboratory research and 
the inherited telomere syndromes 
described above. Strikingly, these 
early-onset telomere syndrome dis-
eases echo the diseases that become 
common with ageing in general hu-
man populations. After correcting for 
age and many other factors, links 
repeatedly have been found be-
tween shortness of telomeres in 
normal cells and the most common 
diseases of ageing – poor immune 
function, various forms of cardio-
vascular disease, diabetes, pul-
monary disease, certain cancers, 
dementia, depression, and some 
other mental disorders. Such con-
ditions are often co-morbid. Thus, 
it is plausible and indeed likely that 
in general populations, telomere 
shortening can contribute a caus-
al role (but obviously not the sole 
role) in the development and patho-
genesis of these diseases. Being 
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systemic, and hence common 
across all organs and tissues, telo-
mere shortening (with eventual loss 
of telomere function) begins to pro-
vide a compelling explanation for the 
co-morbidity of many age-related 
diseases and conditions.
Since most cancers in general 
populations are not obviously inher-
ited, and since compromised telo-
mere maintenance can increase 
cancer risks, factors that can affect 
telomere maintenance are of great 
interest. Although telomeres gen-
erally shorten with age in humans, 
chronological age can account 
for only 10% or less of the total 
variance in telomere length in the 
general population [9]. While telo-
mere length shows some degree of 
heritability, common genetic varia-
tions in populations (as opposed to 
rare mutations) account for only a 
very limited portion of variability in 
telomere length. Furthermore, the 
heritability of telomere length dimin-
ishes with age. In a telling example, 
an interaction between smoking 
history and a common single-nucle-
otide polymorphism associated with 
telomere length has been reported 
for risk of bladder cancer (reviewed 
in [10]). Hence, it is important to un-
derstand other influences on telo-
mere maintenance, and eventually 
to understand how genetic and non-
genetic influences interact to affect 
cancer risks.
Effects of psychological 
stress
One important factor is severe psy-
chological stress. This can have 
many inputs, including societal con-
ditions of poverty, war, and social 
strife, and childhood abuse, trau-
ma, and neglect [11]. Psychological 
stress has long been established 
as an important risk factor for some 
common diseases of ageing – prom-
inently including cardiovascular dis-
ease, diabetes, and depression – 
but its relationship to cancers is 
less well understood. Chronic psy-
chological stress is also associated 
with telomere shortness. A growing 
body of studies links various types 
of chronic psychological stress, dis-
tress, and poor lifestyle (e.g. smok-
ing and lack of exercise) to shorter 
telomeres [12,13]. In addition, social 
factors that cause chronic psycho-
logical stress are also established 
as risk factors for at least some 
chronic diseases of ageing and are 
also linked to telomere shortness in 
both adults and children. Some of 
these studies indicate that the psy-
chological stress causes the telo-
mere shortening, but this does not 
exclude two-way effects. Hence, 
stress, telomere shortness, and dis-
ease risks are quantifiably related 
through three pairwise links: stress 
with telomere shortness, stress with 
disease risks, and telomere short-
ness with risks of these same dis-
eases (reviewed in [14]). The fact 
that telomere compromise is linked 
to (and in some situations is known 
to cause) diseases similar to those 
linked to (and in some cases caused 
by) stress leads directly to the hy-
pothesis that telomere shortness 
at least partly explains how stress 
causes many common, often co-
morbid, diseases of ageing.
Effects of severe stress on telo-
mere shortness can begin even 
early in life, as shown in direct stud-
ies of children exposed to adverse 
socioeconomic situations and vio-
lence. Significantly, the effects can 
be lasting: past histories of child-
hood adversity, and even exposure 
of developing fetuses to maternal 
stress, have been quantitatively re-
lated to telomere shortness in hu-
man adults (reviewed in [14]). It is 
also well established that adverse 
events that occurred in childhood 
predict early onset of chronic dis-
eases, including mental disorders, 
in adults. Thus, it will be important 
to understand how much telomere 
compromise underlies or contributes 
to the effects of childhood stressors 
on risks of diseases that continue 
to reverberate throughout life. An 
important unanswered question 
is whether such diseases include 
cancers. While compromised telo-
mere maintenance has been linked 
to cancer risks, less is known about 
the impact of chronic psychological 
stress on cancer. Nonetheless, be-
cause both telomere shortness and 
chronic stress have independently 
been linked to several other chronic 
diseases of ageing, it will be impor-
tant to extend the lessons learned 
from these other chronic diseases 
into a fuller understanding of can-
cer risks and cancer progression. 
Going forward, policies aimed at 
lessening the burden of cancer and 
other diseases throughout the world 
[15] cannot afford to ignore these 
connections.
Conclusions
A tsunami of overwhelming health 
and social issues is looming for 
the world’s ageing population, can-
cers being prominent among them. 
We need to know how stress af-
fects cancers. Basic biomedical 
research has identified telomeres, 
and correctly controlled telomere 
maintenance mechanisms, as cru-
cial for replenishment of cells and 
tissues and prevention of cancers. 
Compromised telomere mainte-
nance is emerging as a potential 
root factor underlying and interact-
ing with mechanisms and etiolo-
gies of multiple co-morbid diseases 
of ageing. Psychological stress, 
including that related to societal 
and life factors, has independently 
been linked to these same chronic 
diseases and to telomere compro-
mise. What we have learned about 
this underlying disease process 
should be applied to strategies 
to mitigate cancer risks, intercept 
cancer progression, and improve 
cancer survival.
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Most cancers are associated with risks from en-
vironmental, lifestyle, or behavioural exposures. 
Comparing the highest with the lowest incidence 
recorded for different communities or examining 
changes over time provides clues as to which factors 
determine the distribution of cancer globally and how 
they differ in their impact. For the most important fac-
tor – tobacco smoking – differences worldwide reflect 
timing. The epidemic of lung cancer has peaked in 
high-income countries, whereas in China, for exam-
ple, the epidemic is starting. Chronic infections con-
tinue to play a major role in common cancers in parts 
of Africa and Asia but are far less common in Europe 
and North America. Diet exerts an influence on can-
cer development; in parts of Africa and Asia, this is 
sometimes related to the impact of potent carcino-
gens such as aflatoxins, but in high-income countries 
this is primarily because of energy-rich food intake 
and associated overweight or obesity, linked in part 
to low levels of physical activity. Personal choices 
about alcohol intake and deliberate sun exposure are 
reflected in the incidence of particular cancer types. 
Worldwide, exposure to hazardous workplaces and 
environmental pollution causes cancer in low- and 
middle-income countries despite experience that 
may have been gained from other communities.
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Summary
• Worldwide, tobacco use kills 
approximately 6 million people 
annually, from cancer and other 
diseases.
• Consumption of manufactured 
cigarettes has peaked and is 
declining in most high-income 
countries but is increasing 
or persisting at high levels in 
many low- and middle-income 
countries.
• The historical progression of the 
cigarette epidemic that unfolded 
first in high-income countries is 
now occurring worldwide, espe-
cially in men.
• The application of effective to-
bacco control measures such 
as large periodic increases in 
excise taxes and the elimination 
of advertising can provide un-
paralleled opportunities for the 
prevention of cancer and other 
diseases worldwide.
At least 1.3 billion people world-
wide use some form of tobacco 
[1]. In 2000, 4.83 million (uncer-
tainty range, 3.94–5.93 million) 
premature deaths globally were 
attributable to smoking, 2.41 mil-
lion (1.80–3.15 million) in low- 
and middle-income countries and 
2.43 million (2.13–2.78 million) in 
high-income countries. Of these 
deaths, 3.84 million were in men. 
The leading causes of death from 
smoking were cardiovascular dis-
eases (1.69 million deaths), chronic 
obstructive pulmonary disease 
(0.97 million deaths), and lung 
cancer (0.85 million deaths) [2]. By 
2013, the total number of deaths 
worldwide attributable to tobacco 
use was approximately 6 million [3].
Manufactured cigarettes are the 
predominant tobacco product used 
globally; nearly 20% of the world’s 
adult population (about 800 million 
men and 200 million women) smoke 
cigarettes [4]. Other smoked prod-
ucts (cigars, pipes, bidis, kreteks, 
and water pipes) and smokeless 
forms of tobacco (snuff, chewing 
tobacco, betel quid, and paan) are 
also commonly used regionally 
[5]. Reliable nationally representa-
tive data on smoking prevalence 
have been available for certain 
high-income countries since the 
mid-20th century, but coverage of 
low- and middle-income countries 
has expanded only during the past 
decade. The Global Adult Tobacco 
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Survey has now surveyed 19 coun-
tries that include half of the world’s 
adult population [6]; the Global 
Youth Tobacco Survey has studied 
students aged 13–15 years in more 
than 160 countries [7]. Whereas 
in most high-income countries 
cigarette smoking has now peaked 
and is declining, in many low- and 
middle-income countries it has 
become entrenched, especially in 
men. More than 80% of all smokers 
reside in low- and middle-income 
countries; more than 60% live in 
just 10 countries (in decreasing 
order): China, India, Indonesia, 
the Russian Federation, the USA, 
Japan, Brazil, Bangladesh, Ger-
many, and Turkey [8].
Historical progression
The large geographical and tem-
poral variations in tobacco use 
observed currently are best un-
derstood in terms of the historical 
progression that unfolded first in 
high-income countries such as the 
United Kingdom and the USA [9,10] 
and that is now occurring worldwide, 
especially in men. Manufactured 
cigarettes were introduced early in 
the 20th century in the USA and the 
United Kingdom. They rapidly dis-
placed traditional tobacco products 
such as cigars, pipes, hand-rolled 
cigarettes, and snuff and by 1920 
were the product of choice among 
new users. The distribution of free 
cigarettes to soldiers in the First 
and Second World Wars, combined 
with mass advertising, greatly in-
creased cigarette sales. Women 
did not begin smoking regularly un-
til the Second World War, when ad-
vertising targeted to women and the 
entry of women into the workforce 
overcame social and cultural norms 
against female smoking.
Successive birth cohorts of 
men, and later women, smoked 
more cigarettes per day and initi-
ated smoking at progressively ear-
lier ages. Cigarette sales continued 
to increase sharply in the United 
Kingdom until the 1950s and in the 
USA until the early 1960s, when 
studies of smoking and mortality 
and authoritative government re-
ports increased concern about the 
health hazards of smoking, causing 
a decline in consumption and smok-
ing prevalence [10,11]. Continuing 
publicity about the harmful effects 
of smoking and the introduction of 
effective tobacco control policies 
such as smoke-free laws and in-
creased taxes on cigarettes further 
discouraged smoking. However, 
the number of deaths caused by 
smoking continued to increase for 
several decades after the decline in 
cigarette sales, due to the ageing of 
continuing smokers with the great-
est lifetime exposure to actively in-
haled tobacco smoke.
Stages of the epidemic
The progression of the cigarette ep-
idemic, first observed in developed 
countries, has been conceptual-
ized as a sequence of four stages 
that apply more broadly worldwide. 
These stages (Fig. 2.1.2) are con-
ventionally defined by increasing 
or decreasing trends in smoking 
prevalence, and then in smoking-
attributable deaths, in a given 
country. However, most low- and 
middle-income countries have only 
cross-sectional data on smoking 
prevalence and no formal estimates 
of smoking-attributable deaths. In 
these countries, the stages can be 
approximated using cross-sectional 
measures of adult prevalence in re-
lation to longitudinal trends in per 
capita cigarette sales. The staging 
of countries discussed below refers 
only to cigarettes or cigarette-like 
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Fig. 2.1.2. Stages of the tobacco epidemic in (A) men and (B) women. For details, see text.
Fig. 2.1.3. Smoking home-grown tobacco 
wrapped in green leaves or stuffed in a 
pipe is a tribal tradition in Phak Nam in 
north-eastern Cambodia, among mem-
bers of the Kreung ethnic minority.
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products such as bidis, although 
other tobacco products are also dis-
cussed. The stages typically differ 
for men and women in their severity 
and timing.
Stage 1 represents the begin-
ning of the epidemic. At this stage, 
the prevalence of cigarette smok-
ing in adult men or women is low 
(< 20%), and as yet few deaths can 
be attributed to smoking. Per capita 
consumption is flat or only begin-
ning to increase, and there is no 
history of greater smoking in the 
past. In stage 2, the prevalence of 
cigarette smoking in adults rises 
above 20% and may increase to 
a peak of between 40% and 80%. 
Per capita cigarette consump-
tion also rises. In countries where 
estimates of tobacco-attributable 
deaths are available, this percent-
age begins to rise as a fraction of all 
deaths. Stage 3 is characterized by 
a flattening or downturn in smoking 
prevalence (and usually in per cap-
ita consumption), coinciding with a 
continuing steep increase in smok-
ing-attributable deaths. Stage 4 is 
characterized by a decline in both 
smoking prevalence and smoking-
attributable deaths [11].
Several factors influence the 
stage of the epidemic within a given 
country or region. These include 
the affordability and availability of 
cigarettes and the intensity of to-
bacco industry marketing efforts. 
The uptake of smoking among 
women may be deterred, possibly 
indefinitely, by religious and so-
cial norms that discourage female 
smoking, hence limiting the appli-
cability of the stages of the epidem-
ic model to countries that observe 
a significant increase in female 
smoking prevalence. Public edu-
cation about the harmful effects of 
smoking and second-hand smoke 
and implementation of effective to-
bacco control policies also curtail 
tobacco use. Even within a given 
region there may be considerable 
variation in tobacco use because of 
these factors.
Geographical variations
Most of the stages of the cigarette 
epidemic can be observed in Africa. 
Women in all countries are in stage 
1, as are men in many countries 
in sub-Saharan Africa [12]. Men in 
several sub-Saharan African coun-
tries, such as Namibia, Botswana, 
and Sierra Leone, are in stage 2 
(adult prevalence > 20%), as are 
men in all countries in North Africa 
[4]. The prevalence of cigarette 
smoking among adult men in North 
Africa ranges from 28% in Morocco 
to 53% in Tunisia (stage 2 or 3), 
not counting the use of water pipes 
(shisha and hookah) [4]. In Egypt, 
38% of adult men smoke cigarettes, 
and per capita consumption has 
nearly doubled over the past 20 
years [13,14]. Most sub-Saharan 
African countries, with the excep-
tion of South Africa, are positioned 
on the upslope rather than the 
downslope of the epidemic curve 
and remain especially vulnerable to 
industry marketing [12,15].
In Central and South America, 
the prevalence of cigarette smok-
ing in men generally increases 
from north to south, ranging from 
3% in Suriname and Belize to 30% 
in Chile [4]. The smoking preva-
lence in individual countries does 
Fig. 2.1.4. Tobacco advertising has always been common in Formula One racing. 
However, as tobacco advertising bans take effect, teams have started using an 
alternative livery that alludes to the tobacco sponsor or eliminates its name entirely.
Fig. 2.1.5. Preparation of paan in Varanasi, India. Paan is a stimulating, psychoactive 
preparation of betel leaf combined with areca nut and/or cured tobacco. It is chewed 
and then spat out or swallowed.
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not necessarily follow this gen-
eral pattern. Male smoking preva-
lence exceeds 40% in Cuba, Peru, 
and Bolivia and exceeds 30% in 
Venezuela, Uruguay, and Argentina 
[4]. Brazil is the only country in 
South America that may be in stage 
4 for men, with decreases in per 
capita consumption and smoking 
prevalence in men (22%) and wom-
en (13%) due to rigorous tobacco 
control efforts [13,16]. Cuba has the 
highest female smoking prevalence 
in the Caribbean (29%) [4] and also 
has higher lung cancer death rates 
in women than those in most of 
Europe [17].
In North America, northern 
Europe, Australia, and New Zea-
land, men are in stage 4 of the epi-
demic, whereas women are gener-
ally transitioning from stage 3 to 
stage 4. In all of these countries, 
male cigarette smoking prevalence 
exceeded 50% in past decades 
[16]. Currently, Sweden has the 
lowest smoking prevalence in men 
(13%) and is the only country in 
Europe where prevalence is higher 
in women (16%) than in men [4]. The 
use of smokeless tobacco (snus) is 
most common in Sweden but is also 
seen in other Scandinavian coun-
tries [4]. Greece has the highest 
smoking prevalence in men (63%), 
and Austria has the highest preva-
lence in women (45%) [4].
Countries in the former Soviet 
Union have some of the highest 
male cigarette smoking preva-
lence rates in the world, whereas 
smoking prevalence in men has 
decreased substantially in some 
countries in eastern Europe. Male 
smoking prevalence exceeds 50% 
in the Russian Federation (59%) 
and Georgia (57%) and remains at 
50% in Latvia [4]. Smoking preva-
lence among men has decreased in 
Poland and Ukraine [13]. Although 
female prevalence does not gen-
erally exceed 25% in these coun-
tries, it is increasing rapidly in the 
Russian Federation and to a lesser 
extent in Ukraine [4]. Per capita con-
sumption in the Russian Federation 
has almost doubled in the past 
20 years [14].
Tobacco smoking is uncom-
mon among women in the Middle 
East, except in Lebanon [4]. Men 
are in stage 1 in Qatar, Oman, 
Saudi Arabia, and the United 
Arab Emirates and in stage 3 or 
late stage 2 in Turkey (48%) [14], 
Jordan (42%) [4], and the Syrian 
Arab Republic (36%) [4]. Use of 
water pipes (shisha, hookah, and 
narghile) is common throughout 
the region.
Smoking is uncommon (< 10%) 
among women in nearly all coun-
tries in East and South-East Asia 
[4]. Among men the highest smok-
ing prevalence estimates are in 
Indonesia (57%) [4] and China 
(53%) [13]. Per capita cigarette con-
sumption is still increasing in many 
countries (China, Bangladesh, Ne-
pal, Viet Nam, Indonesia, and the 
Philippines) where men account for 
most of the smoking [14]. Smoking 
prevalence is decreasing among 
older women in China. A concern, 
based on limited anecdotal infor-
mation, is that smoking prevalence 
may be beginning to increase 
Fig. 2.1.6. Cigarette consumption and prices in (A) France (1980–2011), (B) Thailand (1990–2011), and (C) South Africa (1961–
2009). THB, Thai baht; ZAR, South African rand.
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Figure 2b: Cigarette Consumption and Prices in Thailand 
(1990-2011) 
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Figure 2c: Cigarette Consumption and Real Price in South 
Africa (1961-2009) 
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among young urban Chinese wom-
en [18]. Smoking typically begins at 
young ages, and Chinese women 
represent a vast untapped market 
for the tobacco companies.
Tobacco smoking is rare among 
women in India, Pakistan, and 
Bangladesh, but the use of smoke-
less tobacco by women in these 
countries is the highest in the world 
[4]. Nearly half of adult men in 
Bangladesh (45%) smoke either cig-
arettes or bidis [13]. The prevalence 
of male tobacco smoking is lower in 
India (24%) and Pakistan (28%) [4], 
but the use of smokeless products 
(paan, gutkha, and betel quid) ex-
ceeds 30% [13]. Per capita consump-
tion of manufactured cigarettes is low 
in all three countries [14].
Strategies to curtail the 
epidemic
Education about the harms of to-
bacco use and policy interventions 
advocated by the WHO Framework 
Convention on Tobacco Control 
have reduced tobacco use in many 
countries. For example, increases 
in excise taxes on cigarettes con-
sistently decrease cigarette sales 
[19,20]. This is exemplified by the 
decrease in per capita cigarette 
consumption in Thailand, South 
Africa, and France, which coincided 
with large increases in the real price 
of cigarettes (Fig. 2.1.6) [14,21–26]. 
Other important strategies that 
promote cessation and decrease 
initiation include smoke-free laws, 
public service counter-advertising, 
and restrictions on or banning of 
tobacco industry advertising [27]. 
Many countries have implemented 
graphic health warnings on ciga-
rette packs. Australia is leading the 
way on plain packaging (removal 
of all graphic branding from ciga-
rette packs). The widespread ap-
plication of a few powerful tobacco 
control interventions could prevent 
a large proportion of the anticipated 
450 million deaths from tobacco 
over the next few decades by en-
abling those who are current smok-
ers to quit and by persuading youth 
to never start smoking in the first 
place [28].
In conclusion, tobacco use re-
mains an enormous health prob-
lem worldwide. Use is currently 
decreasing in most high-income 
countries but increasing or persist-
ing at high levels in many low- and 
middle-income countries. Effective 
tobacco control strategies such as 
large periodic increases in excise 
taxes and the elimination of ad-
vertising provide unparalleled op-
portunities for cancer prevention 
worldwide.
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Summary
• Tobacco smoke contains more 
than 7000 chemical compounds, 
of which many are known carcin-
ogens. Components of tobacco 
smoke contribute to carcinogen-
esis through multiple pathways, 
including DNA binding and mu-
tations, inflammation, oxidative 
stress, and epigenetic changes.
• Smokeless tobacco products 
contain more than 3000 chemi-
cals and numerous carcinogens. 
DNA binding and mutations are 
among the mechanisms clearly 
implicated in carcinogenesis 
due to smokeless tobacco use.
• Epidemiological studies have 
shown causal associations be-
tween tobacco smoking and 
at least 14 different types of 
cancer to date. Accumulated 
evidence from epidemiological 
studies so far has been suf-
ficient to show that smokeless 
tobacco causes cancers of the 
oral cavity and pancreas.
• Comprehensive tobacco con-
trol strategies are in place at 
the global level through provi-
sions in the WHO Framework 
Convention for Tobacco Control 
to combat the epidemic of to-
bacco use.
Worldwide, tobacco is used in di-
verse smoked or smokeless prod-
ucts, all delivering nicotine to their 
users. The worldwide epidemic of 
tobacco-caused diseases comes 
largely from widespread smoking 
of manufactured cigarettes, now 
mostly manufactured and distrib-
uted by a small number of multi-
national corporations and, in the 
case of China, the China National 
Tobacco Corporation. In some 
countries, particularly India and 
Bangladesh, smokeless tobacco 
use is prominent, especially among 
women, even though smoking is 
rare among them. The potency of 
tobacco products, particularly cig-
arettes, as a cause of cancer and 
their role in causing cardiovascular 
and lung diseases make tobacco 
use the leading cause of avoidable 
premature mortality worldwide, 
causing an estimated 6 million 
deaths annually [1].
Tobacco smoking
Manufactured cigarettes are highly 
engineered for the purpose of deliv-
ering nicotine-containing smoke to 
their users. They burn at high tem-
perature, generating thousands of 
chemicals, and consequently smok-
ers inhale a highly toxic mixture con-
taining many known carcinogens 
and toxins, such as benzo[a]pyr-
ene and other polycyclic aromatic 
hydrocarbons, tobacco-specific ni-
trosamines (N-nitroso derivatives 
of nicotine and its metabolites), 
benzene (a cause of leukaemia), 
formaldehyde (an irritant and car-
cinogen), carbon monoxide and cy-
anide (asphyxiants), acrolein (an ir-
ritant), and polonium (a radioactive 
carcinogen) [2]. The smoke inhaled 
by the smoker is referred to as 
mainstream smoke, and that emit-
ted from the smouldering cigarette 
is called sidestream smoke. In the 
presence of smoking, nonsmokers 
inhale second-hand smoke, made 
up largely of sidestream smoke 
and also some exhaled mainstream 
smoke. Pipes, cigars, and water 
pipes deliver smoke with mixtures 
of components comparable to those 
from cigarettes, although there are 
differences in smoke characteris-
tics across products.
Smokeless tobacco
Smokeless tobacco is consumed in 
ways apart from the tobacco being 
burnt; relevant products are most 
commonly used orally and some-
times nasally. Oral smokeless tobac-
co use delivers nicotine more slowly 
than cigarette smoking does – the 
peak increase in plasma levels of 
nicotine in smokeless tobacco users 
is 30 minutes after intake – but the 
level remains higher longer because 
it declines slowly while the product is 
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held in the mouth. Over the course 
of a day, a smokeless tobacco user 
may ingest twice as much nicotine 
as a smoker. Smokeless tobacco 
comes in many forms, with names 
specific to the countries of origin, 
but the products may be generally 
classified as loose leaf for chew-
ing or twist (sweetened, flavoured 
strands), flakes, shredded or fine-
cut tobacco for chewing or holding in 
the mouth, solid compressed tobac-
co products in the form of chunks or 
sticks, viscous pastes, dry or moist 
ground tobacco (snuff) for oral or 
nasal use, liquid snuff (an extract) 
for nasal use in Eastern Africa, and 
tobacco-smoke water for gargling in 
South Asia. Newer products include 
fine-cut or powdered tobacco (i.e. 
snuff) in teabag-like pouches, dis-
solvable tobacco lozenges, and to-
bacco toothpicks. 
Some smokeless tobacco prod-
ucts are plain tobacco leaf. Most 
products are flavoured: sweetened 
with sugar, molasses, or artificial 
sweeteners, salted, and/or aro-
matized with substances like es-
sences, spices, and perfumes. 
Menthol is often used to prevent 
irritation. Smokeless tobacco is 
used along with areca nut by many 
people of South-East Asia, both in 
their countries of origin and wher-
ever they have migrated. The user 
may mix tobacco with areca nut or 
may purchase a pre-mixed product. 
Areca nut contributes its own set of 
carcinogens, mainly through areca 
nut-specific nitrosamines [3].
Tobacco-specific nitrosamines 
are relevant to both smoking and 
smokeless tobacco use but are of 
particular prominence in the use of 
smokeless tobacco because poly-
cyclic aromatic hydrocarbons are 
generated by combustion and are 
therefore not implicated in smoke-
less tobacco carcinogenesis. These 
compounds are formed by the nitro-
sation of nicotine and its metabolites. 
The nature and amount of these 
compounds depends on the tobacco 
species, the growing conditions, the 
amount of fermentation and ageing, 
and how finely the tobacco is cut 
or powdered. Smokeless tobacco 
products, as with many cigarette 
brands, usually have an ingredient 
that increases the pH, to promote the 
availability of nicotine for absorption. 
Such agents include ammonia, am-
monium carbonate, calcium hydrox-
ide, potassium hydroxide, potassium 
carbonate, and sodium carbonate. 
Nicotine availability also increases 
with finer powdering of the tobacco 
[3]. Products with different levels of 
free nicotine are marketed to differ-
ent types of users; novices usually 
start with low-nicotine products and 
may graduate to brands with higher 
levels [4].
Patterns of use
Cigarettes
The Global Adult Tobacco Survey 
and the Global Youth Tobacco 
Survey, both implemented by WHO 
and the United States Centers for 
Disease Control and Prevention 
in collaboration with participating 
countries, track the use of tobacco 
worldwide. The first global report 
based on the Global Adult Tobacco 
Survey was published in 2012, 
drawing on findings from 14 low- and 
middle-income countries and from 
the USA and the United Kingdom [5]. 
The findings showed a wide range 
of smoking prevalence among the 
19 countries and far higher rates of 
smoking among men than women, 
although in several countries the 
prevalence of smoking among 
women approached that among 
men (Fig. 2.2.1). In some countries, 
exemplified by China and India, 
only a small percentage of ever-
smokers had stopped smoking. This 
survey, which covered most of the 
high-burden countries, documented 
tobacco use by about 850 million 
people. Among those aged 24–
35 years who were interviewed for 
this survey, the mean age of smoking 
initiation was 17.7 years in men and 
18.0 years in women [5]. For those 
aged 35 years or older, the average 
age of initiation was generally older 
in women than men.
The Global Youth Tobacco 
Survey data collected from adoles-
cents aged 13–15 years in schools in 
most countries show that youth con-
tinue to smoke worldwide [6]. In some 
countries more than 30% of boys and 
girls in this age range have smoked 
in the past month and the prevalence 
of smoking among girls is approach-
ing that among boys. Countries with 
the highest rate of smoking among 
boys include Papua New Guinea 
(50.6% prevalence), Timor-Leste 
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Fig. 2.2.1. Prevalence of current tobacco smoking among male and female adults 
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and the USA.
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(50.6%), and Tonga (37.5%), whereas 
the highest rates of smoking among 
girls were reported in Chile (39.9%), 
Papua New Guinea (35.8%), and the 
Czech Republic (32.7%) [6].
Smokeless tobacco
Smokeless tobacco is used orally in 
all regions of the world, but its use is 
most prevalent in the Pacific Islands, 
South and South-East Asia, Africa, 
and Europe [6]. Countries with the 
highest known prevalence of smoke-
less tobacco use include Marshall 
Islands, Myanmar, Bangladesh, 
India, and Madagascar (prevalence 
20% and above). These are fol-
lowed by Bhutan, Nepal, Sweden, 
Sri Lanka, Sudan, Turkmenistan, 
Federated States of Micronesia, 
Uzbekistan, Yemen, and Norway 
(prevalence 10–19%). Fig. 2.2.2 
shows the relative position of coun-
tries according to national prevalence 
of adult smokeless tobacco use. 
Such data are not yet available for 
many countries, especially in Africa. 
Products are exported from the USA, 
Sweden, and India to many destina-
tions around the world. Several of the 
largest cigarette manufacturers are 
now marketing smokeless tobacco 
products to smokers as extensions of 
their cigarette brands, pitching them 
as products to be used in smoke-
free environments [6]. Prevalence 
figures for youth who use smokeless 
tobacco are not available from most 
countries at present. However, the 
Global Youth Tobacco Survey shows 
a high proportion of non-cigarette 
tobacco use among youth in many 
countries, and a large part of this use 
is believed to be smokeless tobacco 
[7]. In Congo in 2006, 18.0% of youth 
aged 13–15 years had used smoke-
less tobacco in the previous 30 days 
[8]. In India in 2006, the correspond-
ing prevalence was 8.1% [9].
Tobacco as a cause of cancer
Mechanisms of cancer 
causation
Tobacco smoking
Tobacco smoke is a mixture of gas-
es and particles sufficiently small to 
reach and deposit in the bronchioles 
and alveoli. Tobacco smoke compo-
nents, including nicotine, move from 
the lungs into the circulation and 
reach throughout the body, resulting 
in various tissues being exposed to 
differing levels of carcinogens, not 
simply in organs where primary ab-
sorption occurs but throughout most 
of the body.
Tobacco smoke contains more 
than 7000 chemical compounds, 
including numerous known car-
cinogens, as evaluated for carcino-
genicity by IARC [10]. Broad classes 
of carcinogens in tobacco smoke 
include polycyclic aromatic hydro-
carbons, N-nitrosamines, and aro-
matic amines, together with a range 
of tobacco-specific toxins, includ-
ing volatile aldehydes and phenolic 
amines.
Fig. 2.2.3 provides a general 
schema for the causation of can-
cer by the carcinogens in tobacco 
smoke. There are both specific 
and nonspecific pathways by which 
smoking causes cancer, and there 
is very extensive experimental evi-
dence documenting these pathways 
[2,10]. The figure begins with initia-
tion of cigarette smoking and addic-
tion; it is the maintained contact with 
tobacco smoke carcinogens result-
ing from addiction that leads to the 
very high risk of cancer in those 
who smoke daily throughout their 
lives, the general pattern of the ad-
dicted smoker. It is not necessary 
to smoke across the full lifetime to 
have excess risk of cancer from 
smoking. Even a decade or two of 
smoking increases risk, and cancer 
risk for former smokers, although re-
duced, does not drop to that of nev-
er-smokers. The figure highlights the 
multiple processes that lead to un-
controlled cell growth and malignan-
cy and the multiple points in these 
processes at which tobacco smoke 
components contribute to carcino-
genesis. The major pathway to can-
cer is considered to be DNA binding 
and consequent mutations (central 
pathway), but tobacco smoke also 
contributes to increased cancer risk 
through inflammation (top pathway) 
and epigenetic mechanisms (bottom 
pathway) [10].
Smokeless tobacco
Smokeless tobacco contains more 
than 3000 chemicals and at least 
28 carcinogens, many the same 
as those contained in cigarette 
smoke, and the general scheme of 
Fig. 2.2.3 is applicable. Smokeless 
tobacco use results in exposure to 
tobacco-specific nitrosamines, vol-
atile N-nitrosamines, N-nitrosamino 
acids, and volatile aldehydes such 
as formaldehyde and acetalde-
hyde, as well as metals including 
cadmium, lead, arsenic, nickel, 
and chromium, and radioactive 
elements. Certain tobacco-relat-
ed nitrosamines (e.g. nicotine-
derived nitrosamine ketone and 
N ′-nitrosonornicotine), their me-
tabolites, and benzo[a]pyrene are 
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Genetic susceptibility to tobacco-related cancers
James D. McKay
The first-degree relatives of pa-
tients with tobacco-related cancers 
have an excess risk of developing 
the same type of cancer. While a 
shared environmental exposure 
such as tobacco could influence 
such observations, this finding also 
suggests a role for genetic suscep-
tibility [1]. Susceptibility genes have 
indeed been identified and encom-
pass both rare and common genet-
ic variants.
Several rare cancer syndromes, 
such as Li–Fraumeni syndrome 
(OMIM 151623) and dyskeratosis 
congenita (OMIM 127550), linked 
with mutations in the TP53 and 
TERT genes, respectively, include 
tobacco-related cancers in their 
disease spectrum, which implicates 
such genes in genetic susceptibil-
ity. Similarly, a rare familial form of 
lung adenocarcinoma appears to 
be linked with germline mutations 
in EGFR [2].
Genome-wide assoc iat ion 
study (GWAS) approaches have 
identified several other intriguing 
loci with much more common popu-
lation frequencies (Fig. B2.2.1). At 
chromosome 15q25, a locus that 
contains several nicotinic acetyl-
choline receptors, the same vari-
ants linked with lung cancer are also 
linked with propensity to smoke, 
leading to the debated suggestion 
that this association could be medi-
ated by behavioural changes [3,4]. 
Two independent common variants 
at 5p15.33, a region containing the 
TERT gene, have been linked with 
lung cancer [5]. These variants, al-
though in close proximity, appear 
to differ in their effects in terms of 
histology, with one being more rel-
evant to adenocarcinoma [6]. This 
same locus has been subsequently 
linked with genetic susceptibility to 
many other cancer types [7].
GWAS and other approaches 
have identified genetic variants at 
several other lung cancer suscepti-
bility loci; the chromosome 6 major 
histocompatibility complex (MHC) 
region [3], which is critical to im-
mune response; and several genes 
involved in DNA repair and cell-cy-
cle regulation, notably CHEK2 [8], 
RAD52 [9], and CDNK2A [9], all of 
which appear particularly relevant 
to lung squamous cell carcinoma 
(Fig. B2.2.1). Several additional 
lung cancer susceptibility loci have 
been identified in Asian populations 
[10], although their involvement in 
lung cancer in other populations re-
mains unclear. Within cancers of the 
head and neck, the genes involved 
in alcohol metabolism (ADH and 
ALDH2) appear particularly relevant 
[11].
It is also notable that the ge-
netic studies carried out so far have 
identified fewer susceptibility loci in 
tobacco-related cancers compared 
with other common cancers, de-
spite the comparably sized genetic 
studies and similar estimations of 
hereditary components. The reason 
for this remains unclear, but some 
of the unexplained risk may be ex-
plained by components of genetic 
variation not tested extensively to 
date, such as rare population fre-
quencies and copy number repeats, 
with the latter potentially important 
particularly for metabolism genes. 
Further studies are also required on 
gene–environment interactions.
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known to attach to cellular DNA, 
leading to certain mutations in on-
cogenes and tumour suppressor 
genes, which are found in oral pre-
malignant lesions associated with 
smokeless tobacco use. Smokeless 
tobacco also generates reactive 
oxygen species, oxidative stress, 
and associated DNA fragmenta-
tion in laboratory experiments. 
Inflammation of the oral mucosa at 
the site of tobacco quid placement 
may begin as early as 2–7 days after 
the initial application by regular us-
ers on a new site. A precise role for 
inflammation caused by smokeless 
tobacco use is not clear at present.
Epidemiological evidence
Tobacco smoking
The epidemiological evidence on 
smoking and cancer comes from 
numerous case–control and cohort 
studies carried out since the mid-
20th century. The epidemiological 
evidence on smoking and cancer 
is consistent in identifying cigarette 
smoking as a cause of many types of 
cancer [11,12]. Fig 2.2.4 identifies the 
cancer sites and types for which IARC 
[12] and/or the United States Surgeon 
General [11] have concluded that the 
relationship is causal. The affected 
sites include those where smoke is 
directly deposited (e.g. the orophar-
ynx and lung) and distal sites that are 
reached by circulating tobacco smoke 
components (e.g. the pancreas and 
urinary bladder). Overall, risks of can-
cers caused by smoking increase 
with duration of smoking and with 
number of cigarettes smoked daily; 
cancer risk falls after successful ces-
sation of smoking, but for longer-term 
smokers, the risks do not completely 
drop to those of never-smokers [11]. 
Associations between active smok-
ing and breast cancer continue to be 
investigated [13].
Table 2.2.1 provides estimates of 
relative risks of death from smoking-re-
lated cancers for major sites in two co-
hort studies carried out in the USA by 
the American Cancer Society: Cancer 
Prevention Study I (CPS-I) (enrolment 
in 1959, follow-up through 1965) and 
CPS-II (enrolment in 1982, follow-up 
through 1988) [14]. Questionnaires 
administered at enrolment provided 
the data on participants’ smoking sta-
tus. Several general findings are no-
table: (i) the relative risks for current 
and former smokers compared with 
never-smokers are remarkably high 
for some sites (e.g. lung and laryngeal 
cancer), (ii) former smokers uniformly 
have decreased relative risks com-
pared with current smokers, (iii) rela-
tive risks have tended to be lower in 
women than in men, and (iv) relative 
risks tended to increase for women 
over the two decades between the 
two studies [14]. Findings of more 
recent studies suggest that relative 
risks have continued to rise as more 
recent cohorts of women have started 
to smoke at a similarly young age as 
men and have smoked at comparable 
rates for similar periods [15]. The rela-
tive risks in Table 2.2.1 reflect those 
in high-income countries. In low- and 
middle-income countries, the relative 
risks tend to be lower because heavy 
smoking beginning at a young age – 
the pattern in high-income countries – 
has not been typical of smokers to 
date.
Epidemiological evidence also 
shows that involuntary smoking, the 
inhalation of second-hand smoke by 
nonsmokers, causes cancer. The 
first epidemiological studies on in-
voluntary smoking and lung cancer 
risk in nonsmokers were published 
in 1981; by 1986, there was sufficient 
evidence, particularly in the context 
of the already extensive literature on 
active smoking, to conclude that invol-
untary smoking causes lung cancer 
in nonsmokers [16,17]. Exposure to 
involuntary smoking increases lung 
cancer risk by about 25%, a finding 
replicated worldwide [10].
Smokeless tobacco
Numerous epidemiological studies, 
including cohort and case–control 
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Fig. 2.2.3. Pathway for causation of cancer by carcinogens in tobacco smoke.
Fig. 2.2.4. Cancer sites and types for 
which IARC [12] and/or the United States 
Surgeon General [11] have concluded 
that the relationship with tobacco smoking 
is causal. Note: For cancers of the liver, 
colon, rectum, ovary (mucinous), and 
paranasal sinuses, causal conclusions 
reached by IARC only.
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studies adjusted or stratified for 
smoking and alcohol intake, have 
also shown a causal relationship of 
smokeless tobacco use with can-
cer [3]. At this time, the evidence 
is strongest for cancers of the oral 
cavity and pancreas. Traditional 
products from the USA, South 
Asia, and Sudan have been found 
to contain very high amounts of 
tobacco-specific nitrosamines, and 
users have high risk of oral cancer, 
as shown in several studies. The 
level of risk experienced by us-
ers depends largely on the type of 
product they are using. Risk esti-
mates for cancer associated with 
smokeless tobacco use in case–
control studies increase with fre-
quency of use per day and with du-
ration of use in years, and women 
smokeless tobacco users tend to 
have higher risks, compared with 
non-users, than men. Smokeless 
tobacco users often have pre-
cancerous oral mucosal lesions, 
such as leukoplakia. These white 
lesions tend to disappear within 
1–2 months after discontinuation 
of tobacco use. These lesions are 
more common in smokers who 
also use smokeless tobacco, and 
such individuals also have a higher 
risk of cancer.
Prevention
Tobacco smoking
Tobacco control has had a lengthy 
evolution that has been closely 
linked to the increasing evidence 
on the health effects of active and 
involuntary smoking and on which 
tobacco control modalities are ef-
ficacious [4,18]. Historically, the 
initial findings on lung cancer and 
smoking were followed by efforts to 
educate the public about the risks 
of smoking, with the expectation 
that they would stop. Since then, 
we have learned that tobacco con-
trol requires far more complex ap-
proaches that acknowledge the hi-
erarchy of factors that determine the 
use of tobacco and the interplay of 
these factors across the life-course, 
as health is damaged by smoking 
from conception onward. At each 
age, the emphasis of tobacco con-
trol shifts, moving from preventing 
initiation to promoting successful 
cessation. Particular issues include 
avoiding exposure to second-hand 
smoke and discouraging pregnant 
women from smoking. In addition, 
tobacco control efforts need to be 
dynamic in time, changing as the to-
bacco industry attempts to counter 
control measures.
Many nations have now imple-
mented tobacco control programmes. 
Most importantly, there is now the 
WHO Framework Convention on 
Tobacco Control (FCTC), the first trea-
ty negotiated under the auspices of 
WHO, which brings a global approach 
to the global epidemic of tobacco use. 
The WHO FCTC has been in force 
since 2005, and most nations of the 
world have become Parties. Key ele-
ments of most national tobacco con-
trol policies coincide with core WHO 
FCTC provisions, including a com-
prehensive ban on tobacco advertis-
ing, promotion, and sponsorship; a 
ban on misleading descriptors such 
as “light”; and a mandate to place 
rotating warnings that cover at least 
30% of tobacco packaging and en-
couragement for even larger, graphic 
Table 2.2.1. Age-adjusted relative risks of death from smoking-related cancers from the Cancer Prevention Study I (CPS-I) and 
CPS-II, adults aged ≥ 35 years
Disease category (ICD-9 code)
CPS-I (1959–1965) CPS-II (1982–1988)
Men Women Men Women
CS FS CS FS CS FS CS FS
Lip, oral cavity, pharynx (140–149) 6.3 2.7 2.0 1.9 10.9 3.4 5.1 2.3
Oesophagus (150) 3.6 1.3 1.9 2.2 6.8 4.5 7.8 2.8
Stomach (151) 1.8 1.7 1.0 1.0 2.0 1.5 1.4 1.3
Pancreas (157) 2.3 1.3 1.4 1.4 2.3 1.2 2.3 1.6
Larynx (161) 10.0 8.6 3.8 3.1 14.6 6.3 13.0 5.2
Trachea, bronchus, lung (162) 11.4 5.0 2.7 2.6 23.3 8.7 12.7 4.5
Cervix uteri (180) NA NA 1.1 1.3 NA NA 1.6 1.1
Urinary bladder (188) 2.9 1.8 2.9 2.3 3.3 2.1 2.2 1.9
Kidney, other urinary (189) 1.8 1.8 1.4 1.5 2.7 1.7 1.3 1.1
Acute myeloid leukaemia (204–208) 1.6 1.6 1.0 1.0 1.9 1.3 1.1 1.4
CS, current smokers; FS, former smokers; ICD-9, International Classification of Diseases, 9th Revision; NA, not applicable.
Fig. 2.2.5. Chewing tobacco has been 
proven to cause oesophageal, oral, blad-
der, and pancreatic cancers.
94
warnings. The WHO FCTC also has 
provisions requiring Parties to imple-
ment smoke-free workplace laws, 
address tobacco smuggling, and in-
crease tobacco taxes.
In 2008, WHO identified six ev-
idence-based tobacco control mea-
sures that are the most effective in 
reducing tobacco use [19]. Known 
as “MPOWER”, these measures 
correspond to one or more of the de-
mand reduction provisions included 
in the WHO FCTC: Monitor tobacco 
use and prevention policies, Protect 
people from tobacco smoke, Offer 
help to quit tobacco use, Warn peo-
ple about the dangers of tobacco, 
Enforce bans on tobacco advertis-
ing, promotion, and sponsorship, 
and Raise taxes on tobacco. WHO 
is tracking in-country implementa-
tion of MPOWER and coverage of 
the world’s population by its provi-
sions. To date, its reach is still lim-
ited, although increasing coverage 
of the world’s population by its ele-
ments can be anticipated [1]. Global 
tobacco control has been supported 
by governments as well as from 
nongovernment sources, including 
funding from the Bloomberg Family 
Foundation and the Bill & Melinda 
Gates Foundation, first made avail-
able in 2007 and now slated to con-
tinue through 2016.
Information about the impact of 
initiatives designed to encourage 
individuals to cease smoking is pre-
sented in Chapter 4.1.
Smokeless tobacco
Tobacco control needs to include 
smokeless tobacco in its purview. 
Each aspect of tobacco control 
has to take into consideration both 
smoking and smokeless tobacco 
use. Hence, taxation needs to cover 
both forms equally so that people do 
not simply switch over to cheaper 
smokeless forms after an increase in 
cigarette taxation, as has happened 
in some countries. Information cam-
paigns need to explicitly address the 
dangers of both types of tobacco, so 
that smokeless tobacco is not seen 
as risk-free. The risk of oral cancer 
is very high for smokeless tobacco 
users, especially if use is initiated at 
an early age or if the same individu-
als are also smokers. The impact 
of unbranded products has been 
recognized in several countries and 
warrants action. Prohibition of spit-
ting in public places, prohibition 
of smokeless tobacco use at the 
workplace, and bans on the sale of 
all tobacco products in and around 
educational institutions are options 
to control smokeless tobacco use. 
The same stringent requirements 
on health warnings and prohibition 
of advertisements, including use of 
tobacco-related imagery and ex-
tending the tobacco brand to other 
products (i.e. brand stretching), are 
appropriate for smokeless tobacco 
as for smoked products. Health-care 
providers may be informed on how 
to encourage and support smoke-
less tobacco users to quit. Bans on 
import of smokeless tobacco and 
control of smuggling are also ap-
propriate and required to control 
smokeless tobacco use.
In areas where smokeless to-
bacco is widely used, such as 
South-East Asia, the acceptance 
of tobacco use as “normal” needs 
to be addressed along with rais-
ing public awareness of the health 
hazards and offering help for quit-
ting [20]. For example, successful 
interventions with student youth in 
India have been formulated based 
on a study of the characteristics and 
needs of target groups. These tar-
geted interventions have been able 
to engage the students’ interest. The 
interventions have involved the stu-
dents in interactive classroom and 
home-based activities (with parents) 
as well as in activism for tobacco 
control. Significantly reduced indica-
tors of tobacco use compared with 
non-intervention schools have been 
achieved [21,22]. Researchers have 
been sharing their systematically 
tested and well-documented con-
cepts and materials with the gov-
ernment for application across the 
country in government schools [21]. 
In community interventions, use of 
multiple types of media with pretest-
ed messages to diffuse information 
at mass level and in small groups as 
well as by one-to-one interaction with 
health educators has been found to 
be reinforcing and effective [23,24]. 
Inclusion of oral examination in com-
munity and worksite interventions 
has also been found to be effective 
for promoting cessation and reduc-
tion of tobacco use among adults, 
as well as for implementing interven-
tions that lead to regression of leuko-
plakia in tobacco users [25,26].
Conclusion
Tobacco use in both smoked and 
smokeless forms remains the world’s 
leading cause of cancer morbidity 
and mortality. Numerous mechanis-
tic pathways have been implicated 
in tobacco-induced carcinogenesis. 
For multiple sites, including lung 
cancer in smokers and oral cancer in 
smokeless tobacco users, risks are 
remarkably high compared with other 
circumstances involving cancer de-
velopment, and causality is proven. 
Thus, tobacco control provides a 
tremendous opportunity for cancer 
prevention. A global public health 
treaty, the WHO FCTC, calls for the 
ratifying nations to implement a set of 
effective tobacco control policies. In 
force since 2005 and ratified by 176 
nations to date, the FCTC has cre-
ated a global tobacco control move-
ment that continues to work towards 
preventing initiation and promoting 
successful cessation of tobacco use.
Fig. 2.2.6. Areca nut chewing is popular 
in Papua New Guinea. When the nut’s 
fibrous inner core is chewed, a red colour 
is produced that stains the teeth.
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Summary
• The relationship between al-
cohol consumption and cancer 
risk has been known since the 
beginning of the 20th century. 
Epidemiological and biological 
research on the association 
has established that alcohol 
consumption causes cancers 
of the mouth, pharynx, larynx, 
oesophagus, liver, colorectum, 
and female breast.
• Typically, for cancer types 
caused by alcohol consumption, 
a dose–response association 
has been established.
• For 2010, alcohol-attributable 
cancers were estimated to be 
responsible for 337 400 deaths 
wor ldwide, predominant ly 
among men, with liver cancer 
accounting for the largest pro-
portion of deaths among the 
different tumour types.
• Alcoholic beverages are com-
plex mixtures, but ethanol, me-
diating a genotoxic effect upon 
metabolism to acetaldehyde, 
is recognized as the agent 
predominantly accounting for 
carcinogenesis.
• The burden of alcohol-attrib-
utable cancer can be reduced 
through alcohol policy measures 
such as reduction of availability, 
increases in price, and marketing 
bans.
The association between alcohol 
consumption and risk of cancer was 
known as early as the beginning of 
the 20th century, when Lamy ob-
served that approximately 8 out of 
10 patients with either cancer of the 
oesophagus or cancer of the cardiac 
region of the stomach were alcohol 
misusers [1]. This observation was 
followed by an ecological study in-
dicating that people who were more 
likely to consume alcohol (such as 
people involved in the production 
and distribution of alcoholic bev-
erages) had a higher risk of head 
and neck cancers compared with 
people who abstained from drink-
ing for religious reasons, and that 
such abstainers had a markedly 
lower risk of these forms of cancers 
compared with the population as 
a whole [2]. After these early ob-
servations, several thousand more 
analytical studies followed to ex-
plore the biology and epidemiology 
of the relationship between alcohol 
consumption and risk of cancer. As 
a result, alcoholic beverages were 
declared “carcinogenic to humans” 
(Group 1) by the IARC Monographs 
Programme, first in 1988 [2] and 
then again in 2007 and in 2010 
[3–5]. Tumour types caused by 
drinking alcoholic beverages include 
cancers of the oral cavity, pharynx, 
larynx, oesophagus, liver, colorec-
tum, and female breast. For renal 
cell carcinoma and non-Hodgkin 
lymphoma, there is “evidence sug-
gesting lack of carcinogenicity” for 
alcohol consumption [4,5].
Most cultures throughout the 
world have traditionally consumed 
some form of alcoholic beverages, 
and local specialty alcoholic bever-
ages still account for the majority. 
Only a small number have evolved 
into commodities that are produced 
commercially on a large scale, such 
as beer from barley, wine from 
grapes, and certain distilled bever-
ages. Further known beverages are 
other fruit wines, cider, and a broad 
range of very diverse spirits, includ-
ing shochu, sake, lotus- or agave-
based spirits, and various types 
of country-made liquor in India. In 
many developing countries, vari-
ous types of home-made or locally 
produced alcoholic beverages, 
such as sorghum beer, palm wine, 
or sugar-cane spirits, continue to 
be the main available beverage 
types. Alcopops – flavoured, often 
sweet, alcoholic beverages – have 
received special attention mainly in 
a European context.
A large variety of substances 
that are not intended for human 
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consumption are nevertheless be-
ing consumed as alcohol (surrogate 
alcohol such as hairspray, after-
shaves, lighter fluid, medicines, or al-
cohol-containing mouthwash). They 
often contain very high concentra-
tions of ethanol and may also con-
tain higher alcohols and toxic con-
centrations of methanol and other 
chemicals [5].
Epidemiological evidence
Since the association between alco-
hol and various forms of cancer is 
relatively modest at lower levels of 
consumption, there have been mul-
tiple individual observational studies, 
where the majority of participants 
consume low to moderate amounts of 
alcohol, that have found a significant 
positive association, an absence of 
a significant association, or a signifi-
cant negative association between 
alcohol consumption and the risk of 
mortality and morbidity from certain 
cancers. To determine whether an 
association exists between alcohol 
consumption and various forms of 
cancer, the results of numerous 
case–control and cohort studies 
have been combined using meta-
analytical techniques. These meta-
analyses establish that a significant 
positive dose–response association 
exists between alcohol consumption 
and cancers of the mouth, pharynx, 
oesophagus, colorectum, liver, lar-
ynx, pancreas, female breast, and 
prostate, while a significant negative 
association or no association have 
been observed for each of Hodgkin 
lymphoma [4,6], non-Hodgkin lym-
phoma [4,7,8], and renal cell carcino-
ma [4,9–11]. When epidemiological 
criteria were examined for causal-
ity [12], the association between al-
cohol consumption and cancers of 
the mouth, pharynx, oesophagus, 
colorectum, liver, larynx, and fe-
male breast was found to be causal 
[4,5,13]. Table 2.3.1 provides a list of 
cancers that have been found to be 
associated with alcohol consumption 
through at least one meta-analysis 
and shows the level of evidence sup-
porting these associations.
The relationship between aver-
age daily alcohol consumption and 
the risk of mortality from cancers of 
the upper digestive tract (except can-
cers of the mouth and oral cavity) and 
from cancer of the female breast is ex-
ponential. The relationship between 
alcohol consumption and the risk of 
mortality from cancers of the lower 
digestive tract and from cancers of 
the mouth and oral cavity is linear. 
For cancers of the upper digestive 
tract, lower digestive tract, mouth, 
oral cavity, and female breast, former 
drinkers (people who have not con-
sumed alcohol within the past year 
but who have consumed it before in 
their lifetime) were found to have a 
higher risk of cancer compared with 
lifetime abstainers. It should be noted 
that there is evidence that the risk of 
head and neck cancers decreases 
with time since cessation of drinking 
[14]; however, more data are need-
ed to explore the effect of drinking 
Table 2.3.1. Cancers where alcohol consumption may be a component cause
Disease ICD-10 code Effecta Epidemiological evidencea
Malignant neoplasms
Cancers of the upper aerodigestive tract
Cancer of the oral cavity and pharynx C00–C13 Detrimental Causally related
Cancer of the larynx C32 Detrimental Causally related
Cancer of the oesophagus C15 Detrimental Causally related
Cancer of the colorectum C18–C21 Detrimental Causally related
Cancer of the liver and hepatobiliary tract C22 Detrimental Causally related
Cancer of the stomach C16 Detrimental Insufficient causal evidence
Cancer of the pancreas C25 Detrimental Causality may need to be re-evaluated
Cancer of the lung C33–C34 Detrimental Insufficient causal evidence
Cancer of the female breast C50 Detrimental Causally related
Cancer of the prostate C61 Detrimental Insufficient causal evidence
Cancer of the kidney and cancer of the 
urinary bladder
C64–C66, C68 (except 
C68.9)
Beneficialb/no associationa 
(renal cell carcinoma only)
Insufficient causal evidence
Cancers of the lymphatic and haematopoietic system
Hodgkin lymphoma C81 Beneficialc/no associationa Insufficient causal evidence
Non-Hodgkin lymphoma C82–C85, C96 Beneficiald/no associationa Insufficient causal evidence
ICD-10, International Classification of Diseases, 10th Revision.
a For more information, see [4].
b For more information, see [4,9–11].
c For more information, see [4,6].
d For more information, see [4,7,8].
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cessation on risk over time for 
other alcohol-related cancer sites. 
Box 2.3.1 provides plots of the rela-
tive risk functions for all cancers 
that are currently determined to be 
causally associated with alcohol 
consumption [13]. The relative risk 
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Box 2.3.1. The relationship between average daily alcohol consumption and relative risk of cancer.
functions presented in Box 2.3.1 are 
not separated by cancer mortality 
and incidence. However, the rela-
tive risk functions for alcohol-related 
cancers may be different for mortal-
ity and incidence (as a difference 
between relative risks of mortality 
and incidence has been observed 
for other alcohol-related diseases, 
such as liver cirrhosis [15]). Thus, 
more research is needed to system-
atically determine whether there is a 
difference between the relative risks 
of incidence and mortality for alco-
hol-related cancers.
Evidence suggests a synergistic 
effect of tobacco smoking and con-
sumption of alcoholic beverages on 
the risk of cancer of the oral cavity, 
pharynx, larynx, and oesophagus, 
with very high risks observed in 
individuals who are both heavy 
drinkers and heavy smokers [4].
Observational research has 
suggested that there is a significant 
positive dose–response association 
between alcohol consumption and 
risk of prostate cancer, with multiple 
meta-analyses confirming this rela-
tionship. Biological pathways indicat-
ing how alcohol consumption may in-
crease the risk of prostate cancer are 
currently unknown (see below), and 
thus additional research is needed to 
clarify a possible causal association.
Conflicting epidemiological evi-
dence exists for the association be-
tween alcohol consumption and 
cancers of the bladder, lung, and 
stomach. A nonsignificant positive 
association has been observed 
between alcohol consumption and 
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cancers of the endometrium and 
ovary [13].
One pooled analysis and one 
meta-analysis found that in cohort 
and case–control studies, heavy al-
cohol consumption – drinking more 
than 30 g of pure alcohol per day – 
has been consistently related to an 
increase in the risk of pancreatic can-
cer (cited in [4]); however, as men-
tioned in [4], confounding of smoking 
could not be excluded as a possible 
explanation of these results.
Meta-analyses have found no 
association or a significant negative 
association between alcohol con-
sumption and the risk of renal cell 
carcinoma, Hodgkin lymphoma, and 
non-Hodgkin lymphoma [5,6]. These 
apparently protective observed ef-
fects should be interpreted with cau-
tion since the biological mechanisms 
are not understood and confounding 
and/or misclassification of abstainers 
may be responsible for the observa-
tions that have been made.
Associations have been reported 
between alcohol consumption and 
cancer of the cervix, endometrium, 
ovary, vulva and vagina, testis, brain, 
thyroid, and skin (malignant mela-
noma, basal cell carcinoma, and 
squamous cell carcinoma) as well as 
leukaemia and multiple myeloma [5]; 
however, few studies have examined 
these associations. Epidemiological 
research is required to support pre-
vious study results, and biological 
studies are needed to determine the 
mechanisms by which alcohol intake 
affects the risk of developing these 
cancers.
Global rates of alcohol-
attributable cancers
The number of deaths and number 
of disability-adjusted life years 
(DALYs) lost (a measure that 
combines years of life lost due to pre-
mature mortality and years of healthy 
life lost due to disability) from can-
cers that are currently determined to 
be causally associated with alcohol 
consumption and from other disease 
conditions and injuries, in each case 
for 2010, can be calculated using 
mortality and morbidity data (see the 
WHO Global Information System on 
Alcohol and Health for global alcohol 
exposure estimates since 1960), with 
reference to the alcohol-attributable 
fraction methodology of the 2010 
Global Burden of Disease study (see 
[16]).
In 2010, 337 400 deaths (91 500 
of women and 245 900 of men) and 
8 670 000 DALYs lost (2 252 000 for 
women and 6 418 000 for men) were 
caused by malignant neoplasms at-
tributable to alcohol consumption. 
This burden represents 0.6% of all 
deaths (0.4% of all deaths of women 
and 0.8% of all deaths of men) and 
0.3% of all DALYs lost (0.2% of all 
DALYs lost for women and 0.5% of 
all DALYs lost for men) in 2010. It 
should be noted that alcohol-attrib-
utable cancer data for 2010 reflect 
the level of drinking in the early 
1990s, due to the long time it takes 
for cancer to develop [17].
The rates of alcohol-attribut-
able cancer deaths and of alcohol- 
Mouth cancer Cancer of thenasopharynx
Cancer of
other part of
pharynx and
oropharynx
Oesophageal
cancer
Cancers of
the colon and
rectum
Liver cancer Laryngealcancer
Cancer of the
female breast
All cancer
deaths
Total 27,8% 29,3% 26,7% 19,4% 5,5% 10,7% 21,5% 8,8% 4,2%
Women 11,6% 12,6% 9,3% 8,3% 5,2% 6,4% 7,9% 8,8% 2,7%
Men 37,0% 36,3% 32,5% 23,8% 5,8% 12,7% 23,5% 5,4%
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
30,0%
35,0%
40,0%
Pe
rc
en
ta
ge
 o
f d
ea
th
s 
at
tr
ib
ut
ab
le
 t
o 
al
co
ho
l c
on
su
m
pt
io
n
Fig. 2.3.1. Percentage of deaths from various forms of cancer attributable to alcohol consumption, in 2010.
100
attributable DALYs lost varied glob-
ally with reference to regions de-
fined by WHO as Global Burden 
of Disease regions (see [23]). The 
number of deaths and the number 
of DALYs lost per 100 000 people 
are shown in Tables 2.3.2 and 2.3.3, 
respectively, by Global Burden 
of Disease region for 2010. The 
Eastern Europe region experienced 
the highest alcohol-attributable can-
cer burden, with 8.7 cancer deaths 
per 100 000 people (5.7 per 100 000 
women and 12.9 per 100 000 men) 
and 242.5 DALYs lost per 100 000 
people (153.9 per 100 000 women 
and 357.4 per 100 000 men), while 
the North Africa/Middle East region 
experienced the lowest alcohol-
attributable cancer burden, with 0.6 
cancer deaths per 100 000 peo-
ple (0.5 per 100 000 women and 
0.8 per 100 000 men) and 18.5 
DALYs lost per 100 000 people (14.8 
per 100 000 women and 22.0 per 
100 000 men).
In 2010, the largest contributors 
to the burden of alcohol-attributable 
cancer deaths were: overall, liver 
cancer (responsible for 23.9% of 
all such deaths); for women, breast 
cancer (responsible for 42.0% of 
these deaths); and for men, oesoph-
ageal cancer (responsible for 27.4% 
of these deaths). In 2010, the largest 
contributors to DALYs lost caused 
by alcohol-attributable cancer were: 
overall, liver cancer (responsible for 
24.7% of all such DALYs lost); for 
women, breast cancer (responsible 
for 48.1% of these DALYs lost); and 
for men, liver cancer (responsible for 
28.2% of these DALYs lost).
The percentage of cancer deaths 
and the percentage of cancer DALYs 
lost attributable to alcohol consump-
tion are shown in Figs 2.3.1 and 
2.3.2, respectively, by cause. In 
2010, 4.2% of all deaths caused by 
cancer were attributable to alcohol 
consumption (2.7% for women and 
5.4% for men) and 4.6% of all DALYs 
lost caused by cancer were attribut-
able to alcohol consumption (2.8% 
for women and 6.0% for men). In 
2010, alcohol consumption was re-
sponsible for the largest percentage 
of the total deaths and DALYs lost 
from nasopharyngeal cancer com-
pared with other cancer types; was 
responsible for 29.3% of all deaths 
from cancers of the mouth and 
oropharynx (12.6% for women and 
36.3% for men); and was responsi-
ble for 29.3% of all DALYs lost from 
cancers of the mouth and orophar-
ynx (12.7% for women and 36.1% 
for men).
Contribution of cancer to 
the total alcohol-attributable 
burden of disease
Alcohol consumption is related to 
more than 200 three-digit ICD-10 
(International Classification of 
Diseases, 10th Revision) code dis-
eases, conditions, and injuries, such 
as infectious diseases, malignant 
neoplasms, diabetes, neuropsy-
chiatric conditions, cardiovascular 
disease, digestive diseases, condi-
tions arising during the prenatal pe-
riod, and injuries (for an overview 
of the conditions related to alcohol 
consumption, see [16]). In 2010, al-
cohol consumption was responsible 
for 2 734 200 deaths (910 800 of 
Fig. 2.3.2. Percentage of disability-adjusted life years (DALYs) lost from various forms of cancer attributable to alcohol consumption, 
in 2010.
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women and 1 823 400 of men) and 
97 118 000 DALYs lost (22 523 000 
for women and 74 595 000 for men). 
Of the total deaths and DALYs lost 
attributable to alcohol consumption 
in 2010, alcohol-attributable cancers 
were responsible for 12.3% of all 
alcohol-attributable deaths (10.0% 
for women and 13.5% for men) 
and 8.9% of all alcohol-attributable 
DALYs lost (10.0% for women and 
8.6% for men).
Possible biological 
mechanisms
As indicated above, alcohol con-
sumption is carcinogenic and caus-
es a variety of human cancers, and 
there may be different biological 
pathways depending on the anatom-
ical site. Alcoholic beverages are 
multicomponent mixtures containing 
several carcinogenic compounds, 
such as ethanol, acetaldehyde, afla-
toxins, and ethyl carbamate (see 
[18]), and all of these compounds 
may contribute to increase the risk 
of cancer due to alcohol consump-
tion reported in observational stud-
ies. A recent chemical risk analysis 
concluded that ethanol is the most 
important carcinogen in alcoholic 
beverages, with all other carcino-
genic compounds contained in al-
coholic beverages increasing the 
risk of cancer below the threshold 
normally acceptable for food con-
taminants [18].
The biological mechanisms by 
which alcohol intake increases the 
risk of cancer are not fully understood, 
but the main mechanisms are likely to 
include a genotoxic effect of acetal-
dehyde, the induction of cytochrome 
P450 2E1 and associated oxidative 
stress, increased estrogen concen-
tration, a role as a solvent for tobacco 
carcinogens, changes in folate me-
tabolism, and changes in DNA repair 
[4,5].
For cancers of the digestive tract, 
especially those of the upper diges-
tive tract, acetaldehyde from alcohol 
metabolism in the body and from 
Table 2.3.2. Cancer deaths attributable to alcohol consumption, by sex and by Global Burden of Disease region, for 2010a
Global Burden  
of Disease regionb
Sex
Female Male Total
Deaths Deaths per 100 000 people Deaths
Deaths per 
100 000 people Deaths
Deaths per 
100 000 people
Asia Pacific, high-income 4 000 2.4 13 400 8.1 17 400 5.2
Asia, Central 1 200 3.3 2 000 6.2 3 300 4.6
Asia, East 20 300 2.7 99 800 11.8 120 100 7.5
Asia, South 6 300 1.1 27 200 4.2 33 400 2.7
Asia, South-East 4 700 1.9 12 200 4.7 16 900 3.3
Australasia 800 4.1 1 200 5.6 2 000 4.9
Caribbean 400 2.0 1 000 4.4 1 400 3.2
Europe, Central 3 600 3.7 9 900 11.2 13 500 7.2
Europe, Eastern 10 400 5.7 17 300 12.9 27 700 8.7
Europe, Western 18 300 4.8 29 700 8.2 48 000 6.5
Latin America, Andean 400 2.0 300 1.4 700 1.7
Latin America, Central 1 800 1.8 2 800 3.0 4 600 2.4
Latin America, Southern 1 700 4.4 2 200 6.3 3 900 5.3
Latin America, Tropical 2 800 2.8 5 900 6.2 8 600 4.4
North Africa/Middle East 800 0.5 1 300 0.8 2 100 0.6
North America, high-income 8 500 3.4 11 300 4.4 19 800 3.9
Oceania 100 4.6 200 5.6 300 5.1
Sub-Saharan Africa, Central 400 1.8 700 2.9 1 100 2.3
Sub-Saharan Africa, Eastern 2 500 2.8 3 300 3.7 5 900 3.3
Sub-Saharan Africa, Southern 600 2.1 1 600 6.8 2 200 4.3
Sub-Saharan Africa, Western 1 700 2.0 2 700 2.9 4 400 2.4
World 91 500 2.7 245 900 7.1 337 400 4.9
a Numbers have been rounded.  
b For definitions of regions, see [23].
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Table 2.3.3. Cancer disability-adjusted life years (DALYs) lost attributable to alcohol consumption, by sex and by Global Burden 
of Disease region, for 2010a
Global Burden  
of Disease regionb
Sex
Female Male Total
DALYs  
lost
DALYs lost per 
100 000 people
DALYs  
lost
DALYs lost per 
100 000 people
DALYs  
lost
DALYs lost per 
100 000 people
Asia Pacific, high-income 81 000 60.8 284 000 196.5 365 000 128.5
Asia, Central 38 000 98.5 58 000 170.9 95 000 132.1
Asia, East 530 000 69.3 2 690 000 318.9 3 221 000 200.0
Asia, South 182 000 28.8 782 000 115.3 964 000 73.9
Asia, South-East 113 000 41.8 342 000 124.7 455 000 82.7
Australasia 17 000 101.3 24 000 129.6 42 000 115.9
Caribbean 12 000 53.6 25 000 113.2 36 000 83.5
Europe, Central 90 000 103.8 253 000 302.9 342 000 199.6
Europe, Eastern 250 000 153.9 461 000 357.4 711 000 242.5
Europe, Western 374 000 121.5 649 000 206.5 1 023 000 163.9
Latin America, Andean 11 000 48.9 9 000 38.0 20 000 43.4
Latin America, Central 47 000 45.9 66 000 67.1 112 000 56.6
Latin America, Southern 38 000 106.8 49 000 144.4 86 000 124.4
Latin America, Tropical 76 000 75.4 167 000 172.7 243 000 122.7
North Africa/Middle East 28 000 14.8 42 000 22.0 70 000 18.5
North America, high-income 205 000 90.0 263 000 112.0 468 000 100.8
Oceania 4 000 124.0 5 000 153.4 9 000 138.7
Sub-Saharan Africa, Central 13 000 47.6 21 000 81.9 34 000 64.4
Sub-Saharan Africa, Eastern 72 000 71.3 98 000 97.9 170 000 84.3
Sub-Saharan Africa, Southern 17 000 56.6 47 000 182.8 63 000 114.9
Sub-Saharan Africa, Western 54 000 53.0 85 000 80.7 139 000 66.9
World 2 252 000 66.0 6 418 000 184.8 8 670 000 125.9
a Numbers have been rounded.  
b For definitions of regions, see [23].
ingestion as a component of alco-
holic beverages [19] has been high-
lighted as a likely and important 
causal pathway [4,5]. For colorectal 
cancer, in addition to the genotoxic 
effect of acetaldehyde, there may 
be the involvement of folate: alcohol 
may act through folate metabolism or 
synergistically with low folate intake 
(see [5]). The biological mechanisms 
accounting for how alcohol intake 
may cause pancreatic cancer are 
currently unclear; however, potential 
mechanisms include pancreatitis and 
the accumulation of fatty acid esters 
in the pancreas, which may induce 
inflammatory responses and fibrosis 
[4].
The biological effects of alco-
hol intake on the risk of digestive 
tract cancers are also dependent 
on the genotype of the consumer; 
individuals with the ALDH2 Lys487 
allele (and therefore a deficiency of 
ALDH2) experience a higher risk of 
oesophageal cancer for the same 
amount of alcohol consumed. The 
ALDH2 Lys487 allele is thought to 
modify the risk of all cancers that are 
caused by the metabolites of alcohol 
[4,5].
In relation to breast cancer, al-
cohol intake has been shown to 
increase levels of estrogen and 
plasma insulin-like growth factor 
produced by the liver, to enhance 
mammary gland susceptibility to car-
cinogenesis (by altering mammary 
gland structural development and 
by stimulating cell proliferation), to 
increase mammary DNA damage, 
and to facilitate the ability of breast 
cancer cells to migrate [20].
Implications for prevention
The relationship between alco-
hol consumption and cancer has 
been observed as monotonic and 
without threshold (see above and 
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[3,4]). Thus, as the amount of alco-
hol consumed increases, the risk of 
developing cancer increases. This 
means that any reduction in alco-
hol consumption will be beneficial 
for health through the reduction of 
cancer risk. There are cost-effective 
ways to reduce alcohol consump-
tion: most notably, restrictions in 
availability; increases in price for 
alcoholic beverages, which could 
be achieved by increasing taxation 
or increasing minimum prices; and 
marketing bans [21]. In addition, the 
risk of cancer for high-risk heavy 
alcohol consumers can be reduced 
by providing more opportunities for 
brief interventions and treatment for 
alcohol use disorders [22].
Fig. 2.3.3. Female drinking has risen steadily for the past 20 years, with more women 
than men drinking heavily on single occasions.
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Summary
• Infections with viruses, bacteria, 
and macroparasites have been 
identified as strong risk factors 
for specific cancers.
• Overall, about 2 million (16%) 
of the total of 12.7 million new 
cancer cases in 2008 are attrib-
utable to infections. This fraction 
varies 10-fold by region; it is low-
est in North America, Australia, 
and New Zealand (≤ 4%) and 
highest in sub-Saharan Africa 
(33%).
• Helicobacter pylori, hepatitis 
B and C viruses, and human 
papillomaviruses are responsi-
ble for 1.9 million cancer cases 
globally, including mainly gas-
tric, liver, and cervical cancer, 
respectively.
• Infection with HIV substantially 
increases the risk of virus-
associated cancers, through 
immunosuppression.
• Application of existing methods 
for infection prevention, such as 
vaccination, safe injection prac-
tices, and safe sexual behaviour, 
or antimicrobial and antiparasite 
treatments could have a major 
impact on the future burden of 
cancer worldwide.
2.4
2 ETIOLOGY
Infections
Silvia Franceschi
Rolando Herrero
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Few aspects of cancer etiology have 
undergone as much progress in the 
past three decades as the relationship 
between a selected number of chronic 
infections and the risk of cancer. When 
Doll and Peto [1] estimated in 1981 the 
proportion of cancer cases attributable 
to different causes, only the relation-
ships of hepatitis B virus (HBV) with 
liver cancer and of Epstein–Barr vi-
rus (EBV) with Burkitt lymphoma were 
relatively well understood, and the at-
tribution to infections was very uncer-
tain (> 1%, but the upper confidence 
interval limit was not reported). About 
30 years later, the IARC Monographs 
Volume 100B Working Group [2] de-
clared 11 infectious agents as well-es-
tablished human carcinogenic agents 
(Table 2.4.1). In addition, de Martel et 
al. [3] considered infectious agents 
classified by IARC as carcinogenic to 
humans and calculated correspond-
ing population attributable fractions 
(PAFs) worldwide and in eight geo-
graphical regions, using statistics on 
estimated cancer incidence from 2008 
[4] (Fig. 2.4.1). In this chapter, we use 
the term “developed regions” to in-
clude Japan, North America, Europe, 
Australia, and New Zealand, i.e. high-
income countries, and the term “de-
veloping regions” to include all other 
countries, i.e. low- and middle-income 
countries. In this context, the PAF is 
an estimate of the proportion of cases 
of a cancer that could theoretically be 
avoided if exposure to a specific infec-
tion were avoided or if the infection 
were detected early and treated be-
fore the development of cancer.
The associations of infections with 
cancer are nearly always very strong 
(relative risk > 10), and therefore 
calculations can often be based on 
the prevalence of infection in cancer 
cases (e.g. DNA of human papil-
lomavirus [HPV] or EBV in cancer 
tissue biopsies) rather than on the 
less-often-available prevalence in 
the general population [3]. Estimates 
of prevalence of infection and relative 
risks are extracted from published 
data, and a short description of the 
rationale for each cancer site is pre-
sented here for each infectious agent 
in relation to its associated cancer. 
HIV infection greatly increases the risk 
of some infection-associated cancer 
types, especially Kaposi sarcoma and 
lymphomas, through immunosuppres-
sion [2]. To avoid double attribution, 
the fraction of cancer due to HIV will 
not be reported separately, but HIV 
will be mentioned when the infection 
is strongly implicated in the increase 
of certain cancer types.
Helicobacter pylori
Non-cardia gastric 
adenocarcinoma
A causal association between chron-
ic gastric infection with Helicobacter 
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make-up of both the host and the 
bacterium can modulate the strength 
of the causal relation between the 
bacterium and the cancer, no risk 
factors for non-cardia gastric adeno-
carcinoma as strong as H. pylori have 
been recognized.
A well-known difficulty in esti-
mating the prevalence of H. pylori 
infection is the gradual decline in 
bacterial load with increasing gas-
tric atrophy – a precursor lesion of 
gastric adenocarcinoma – and the 
consequent lack of sensitivity of 
serological markers at the time of 
cancer diagnosis. Studies in which 
H. pylori antibodies were measured 
well before the onset of cancer are 
considered the most reliable for cal-
culating the true prevalence in cases 
and controls and therefore for esti-
mating the relative risk. A review of 
such studies in 2001 reported that the 
average prevalence of H. pylori infec-
tion in cases is 90%, a figure that was 
quite homogeneous across studies in 
various continents despite a highly 
variable background rate in popu-
lation-based controls [5]. A pooled 
analysis of 11 of these studies yielded 
a common relative risk of 5.9 (95% 
confidence interval [CI], 3.4–10.3) 
for patients who developed cancer 
more than 10 years after blood draw 
[5]. This yields a PAF of 75% for H. 
pylori in non-cardia gastric adenocar-
cinoma [3] (Table 2.4.2).
Table 2.4.1. Major cancer sites related to infectious agents classified as carcinogenic to humans
Cancer site Well-established human carcinogenic agents
Stomach Helicobacter pylori
Liver Hepatitis B virus
Hepatitis C virus
Opisthorchis viverrini
Clonorchis sinensis
Cervix Human papillomavirus, with or without HIV
Anogenital (penis, vulva, vagina, anus) Human papillomavirus, with or without HIV
Nasopharynx Epstein–Barr virus
Oropharynx Human papillomavirus, with or without tobacco use/alcohol consumption
Non-Hodgkin lymphoma Helicobacter pylori
Epstein–Barr virus, with or without HIV
Hepatitis C virus
Human T-cell lymphotropic virus type 1
Kaposi sarcoma Kaposi sarcoma herpesvirus, with or without HIV
Hodgkin lymphoma Epstein–Barr virus, with or without HIV
Bladder Schistosoma haematobium
Fig. 2.4.1. Number of new cancer cases in 2008 attributable to infection, by infectious 
agent and development status.
pylori and development of gastric 
adenocarcinoma is well established 
[2]. The risk is restricted to the non-
cardia part (i.e. body) of the stom-
ach; adenocarcinoma of the gastric 
cardia shares risk factors with oe-
sophageal cancer and is not asso-
ciated with H. pylori [2,5]. Although 
environmental factors such as the di-
etary habits of the host or the genetic 
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Inflammation and cancer
Curtis C. Harris
Inflammation has long been associ-
ated with cancer, and it is one of the 
hallmarks of cancer [1]. Whereas 
acute inflammation protects against 
infectious pathogens, chronic in-
flammation is associated with DNA 
and tissue damage, including ge-
netic and epigenetic changes lead-
ing to cancer [2]. This association 
can be both inherited and acquired 
(Table B2.4.1). Both single-gene 
inheritance (e.g. haemochromato-
sis) and complex multiple-gene in-
heritance (e.g. inflammatory bowel 
disease) have been defined by 
genetic analysis. Infections by vi-
ruses, bacteria, and parasites are 
well-known examples of acquired 
etiology. Tobacco smoke contains 
more than 60 chemical carcinogens 
and also induces an inflammatory 
response that may facilitate lung 
carcinogenesis [3]. The inflamma-
tory response to gastric acid reflux 
in Barrett disease may be respon-
sible for the increased incidence 
of oesophageal cancer. Obesity 
has been recognized as a chronic 
inflammatory condition predispos-
ing to cardiovascular disease and 
cancer [4]. The cellular and mo-
lecular basis of this predisposition 
involves the accumulation of mac-
rophages in the adipose tissue, 
with the establishment of pro-in-
flammatory feedback loops among 
macrophages, pre-adipocytes, and 
adipocytes to generate inflamma-
tory cytokines and free radicals [5]. 
The prevention of colon polyps and 
cancer by aspirin and other anti-in-
flammatory agents strengthens the 
Table B2.4.1. Chronic inflammation or infection increases cancer risk
Disease Type of cancer
Auto-inflammatory/non-infectious
Crohn disease Colon cancer
Ulcerative colitis Colon cancer
Chronic pancreatitis Pancreatic cancer
Endometriosis Endometrial cancer
Haemochromatosis Liver cancer
Thyroiditis Thyroid cancer
α-1-Anti-trypsin deficiency Liver cancer
Acquired
Viral
Hepatitis B virus Liver cancer
Hepatitis C virus Liver cancer
Epstein–Barr virus Hodgkin lymphoma and Burkitt lymphoma
Bacterial
Helicobacter pylori Gastric cancer
Pelvic inflammatory disease Ovarian cancer
Chronic prostatitis Prostate cancer
Parasitic
Schistosoma haematobium Bladder cancer
Schistosoma japonicum Colon cancer
Liver fluke Cholangiocarcinoma and liver cancer
Chemical/physical/metabolic
Alcohol Multiple cancers (including cancers of the liver, pancreas, and 
head and neck)
Asbestos Mesothelioma
Obesity Multiple cancers
Tobacco smoke and inhalation of other noxious chemicals Lung cancer (and multiple other cancers)
Gastric reflux, Barrett oesophagus Oesophageal cancer
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causal link between inflammation 
and cancer in humans [6].
The Human Microbiome Project 
is defining the microbes on the ex-
ternal and internal epithelial surfac-
es of the host in health and disease 
[7]. The gut microbiota is clearly 
implicated in intestinal inflammation 
and possibly human colon cancer 
[8]. Loss of the epithelial barrier 
integrity, due to mutations or other 
factors, allows translocation of the 
microbiota into the mucosa to elicit a 
cellular inflammatory response and 
release of cytokines. For example, 
microbes can elicit a TH17 response 
promoting IL-17 expression [9] and 
increase STAT3, which transcribes 
both coding and non-coding genes 
to signal proliferation of epithelial 
cells and their acquisition of epi-
genetic and genetic changes [10]. 
Current research focuses on the 
mechanistic connections among 
obesity, the microbiome, chronic in-
flammation, and cancer risk.
The molecular mechanisms of 
chronic inflammation driving can-
cer are being discovered [11]. The 
tumour microenvironment, includ-
ing macrophages and senescent 
stromal cells, can facilitate tumour 
progression and metastasis [12]. 
Significant advances include iden-
tifying pro- and anti-inflammatory 
cytokines and their cellular signal 
transduction pathways, such as the 
NF-κB pathway [11]. Discoveries in 
the chemistry of free radicals gener-
ated by inflammation provide insight 
into their contribution to carcino-
genesis. Mutations to DNA by both 
direct and indirect damage lead to 
activation of oncogenes and inacti-
vation of tumour suppressor genes 
[13,14]. Animal models are helping 
to identify the oncogenic function of 
specific cytokines and free radicals 
[11,12]. Future research on inflam-
mation will continue to improve pre-
vention and treatment of cancer.
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Gastric lymphoma
Non-Hodgkin lymphoma (NHL) in 
the stomach represents approxi-
mately 5% of all NHL and less than 
2% of all gastric cancers. Nearly all 
mucosa-associated lymphoid tis-
sues and an unknown proportion of 
diffuse large B-cell lymphomas in 
the stomach are related to H. pylori 
infection [6]. Based on these limited 
data, the pooled prevalence of H. 
pylori in gastric lymphoma is 86% 
and the pooled relative risk esti-
mate is 7.2, giving a PAF of 74% [3] 
(Table 2.4.2).
Hepatitis B and C viruses
Hepatocellular carcinoma
Chronic infection with HBV and/or 
HCV is the most common risk factor 
for hepatocellular carcinoma world-
wide. Some non-viral exposures 
are also important risk factors for 
hepatocellular carcinoma, including 
heavy alcohol consumption and di-
etary aflatoxin contamination. The 
contribution of viral and non-viral 
risk factors, alone or in association, 
varies greatly in different geographi-
cal regions. For hepatitis viruses, 
HBV infection is found in the general 
population substantially more often 
than HCV in most Asian and African 
countries, while the opposite is true 
in Europe and the USA but also in 
Japan, Pakistan, and Mongolia [7]. 
In HBV-endemic areas, HBV is typi-
cally acquired in early life, and the 
prevalence of chronic HBV carriage 
tends to plateau after adolescence. 
In contrast, HCV infection can be ac-
quired at any age through contami-
nated needles and blood, and HCV 
prevalence increases steadily with 
age due to the accumulating risk of 
exposure.
Estimates of HBV and HCV prev-
alence in hepatocellular carcinoma 
cases were derived from a 2007 re-
view [7], which was updated using 
more recent papers [2]. However, 
there are few data on HBV and HCV 
Fig. 2.4.2. Helicobacter pylori bacterium. 
H. pylori infection plays a key role in the 
genesis of gastric cancer.
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Table 2.4.2. Number of new cancer cases in 2008 attributable to infectious agents, by anatomical site
Cancer site Number of new cases in 2008a PAF (%)
Number attributable to infection
By sex By development statusb
Male Female Developing regions
Developed 
regions
Carcinoma
Non-cardia gastric 870 000 74.7 410 000 240 000 470 000 180 000
Liverc 750 000 76.9 400 000 170 000 510 000 69 000
Cervix 530 000 100.0 0 530 000 450 000 77 000
Vulva 27 000 43.0 0 12 000 4 100 7 500
Anus 27 000 88.0 11 000 13 000 12 000 12 000
Penis 22 000 50.0 11 000 0 7 600 3 200
Vagina 13 000 70.0 0 9 000 5 700 3 400
Oropharynx 85 000 25.6 17 000 4 400 6 400 15 000
Nasopharynx 84 000 85.5 49 000 23 000 66 000 5 900
Bladder 260 000 2.3 4 600 1 400 6 000 0
Lymphoma/leukaemia
Hodgkin lymphoma 68 000 49.1 20 000 13 000 23 000 10 000
Non-Hodgkin gastric lymphoma 18 000 74.1 7 400 5 800 6 500 6 700
Burkitt lymphoma 11 000 62.5 4 000 2 800 6 300 530
HCV-associated non-Hodgkin 
lymphoma
360 000 8.2 17 000 13 000 18 000 11 000
Adult T-cell leukaemia/lymphoma 2 100 100.0 1 200 900 660 1 500
Sarcoma
Kaposi sarcoma 43 000 100.0 29 000 14 000 39 000 4 100
Total from infections 3 200 000 64.4 990 000 1 100 000 1 600 000 410 000
HCV, hepatitis C virus; PAF, population attributable fraction.
a Numbers are rounded to two significant digits.
b Developed regions include Japan, North America, Europe, Australia, and New Zealand, i.e. high-income countries. Developing regions include all other 
countries, i.e. low- and middle-income countries.
c Including cholangiocarcinoma.
prevalence in large parts of eastern 
Europe and Central Asia. In HBV-
endemic areas, almost all hepato-
cellular carcinomas in individuals 
younger than 50 years are due to 
HBV. The PAF for HCV is especially 
challenging as the infection does not 
show geographical clustering; high-
prevalence countries may thus be 
geographically close to low-preva-
lence countries. For these reasons, 
regional prevalence estimates were 
derived by statistical modelling [3].
A meta-analysis of 32 case–con-
trol studies published in 1992–1997 
yielded a summary relative risk of 
22.5 (95% CI, 19.5–26.0) for HBV 
alone and of 17.3 (95% CI, 13.9–
21.6) for HCV alone [8]. The dual 
impact of HBV and HCV infection 
on risk is not well quantified. Recent 
prospective and retrospective stud-
ies are consistent with previous stud-
ies in that they yield relative risks 
for hepatocellular carcinoma of a 
similar magnitude [2]. The estimated 
prevalence of either HBV or HCV in 
hepatocellular carcinoma cases var-
ied from 42% in North America to 
87% in Japan. Worldwide, the PAF 
for hepatocellular carcinoma is 77% 
(Table 2.4.2).
Non-Hodgkin lymphoma
HCV infection is a well-established 
cause of essential mixed cryoglob-
ulinemia, a lymphoproliferative 
disease that can evolve into B-cell 
NHL. Several studies found a high 
prevalence of HCV seropositivity 
in patients with B-cell lymphoprolif-
erative disorders, particularly B-cell 
NHL, including cases where essen-
tial mixed cryoglobulinemia was ab-
sent. A meta-analysis of studies of 
NHL and HCV seropositivity showed 
a pooled relative risk for NHL of 2.5 
(95% CI, 2.1–3.1) based on 15 case–
control studies and of 2.0 (95% CI, 
1.8–2.2) in three cohort investiga-
tions [9]. The number of new cases 
of NHL attributable to HCV varies 
by country and therefore can be es-
timated very approximately. Based 
on a summary relative risk of 2.5 
and the prevalence of HCV in cases 
from different regions [9], the HCV-
associated PAF for NHL would be 
8% (Table 2.4.2).
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Human papillomaviruses
Cervical cancer and other 
anogenital cancers
HPV infection is a necessary cause 
of cervical cancer; its genome can 
be found in nearly all cervical can-
cers with the most sensitive detec-
tion methods [2]. Comprehensive 
mechanistic and epidemiological 
data have firmly established the 
chain of causality, with relative risks 
of more than 100 in many case–
control studies [2]. It is generally 
acknowledged that 100% of cervical 
cancers are attributable to 13 high-
risk HPV types classified as carcino-
genic or probably carcinogenic (i.e. 
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, and 68) [2]. HPV16 and 
18 are the most frequently involved 
types and together account for about 
70% of cervical cancer in all world 
regions [10].
In contrast to the universal pres-
ence of HPV in cervical cancers, 
other anogenital cancer sites show a 
varying prevalence of HPV infection, 
depending on the cancer subtype, 
the age distribution, and the geo-
graphical region of the population 
studied [11]. High-risk HPVs were 
found in approximately 88% of anal 
cancers, 70% of vaginal cancers, 
50% of penile cancers, and 43% of 
vulvar cancers [11]. Compared with 
cervical cancers, a stronger predom-
inance of HPV16 is reported. PAFs 
for each anogenital site are reported 
in Table 2.4.2.
Head and neck cancers
Head and neck cancers represent 
a large and heterogeneous group of 
malignancies, for which tobacco use 
and alcohol consumption are consid-
ered the major causes. Over the past 
decade, HPV DNA has been reported 
to be present in a variable fraction of 
head and neck cancers (0–60%). 
Among HPV-positive cancers, HPV16 
predominates (90% of HPV-positive 
carcinomas). HPV prevalence is no-
tably high in oropharyngeal cancer 
[12], in which HPV16 is present at 
high copy number, localized to cell 
nuclei, frequently integrated into the 
cell genome, and actively transcrib-
ing viral oncoproteins E6 and E7 [13]. 
Survival differences by HPV DNA 
presence have also been consis-
tently reported exclusively for oro-
pharyngeal cancers. These features 
support, for the moment, a causal role 
of HPV infection in some oropharyn-
geal cancers, whose incidence is cur-
rently increasing in some developed 
Fig. 2.4.3. Human papillomavirus (HPV)-mediated progression to cervical cancer. HPV is thought to access the basal cells through 
microabrasions in the cervical epithelium. After infection, the early HPV genes E1, E2, E4, E5, E6, and E7 are expressed and the 
viral DNA replicates from episomal DNA. In the upper layers of epithelium (the midzone and superficial zone) the viral genome is 
replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 encapsidate the viral genomes to form progeny 
virions in the nucleus. LCR, long control region.
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countries [14]. The HPV-related PAF 
was, therefore, estimated only for 
cancers of the oropharynx including 
the tonsils and the base of the tongue 
(ICD-10 [International Classification of 
Diseases, 10th Revision] codes C01 
and C09–C10) [3].
High-risk HPVs were found in 
approximately half of oropharyngeal 
cancers in developed countries, but 
this weighted average prevalence var-
ied in different areas; it was generally 
higher in North America and northern 
Europe than in southern Europe. In the 
few developing countries with avail-
able data, high-risk HPVs were found 
in 0–30% of oropharyngeal cancers 
[3]. The global PAF for oropharyngeal 
cancer is 26% (Table 2.4.2).
Epstein–Barr virus
Hodgkin lymphoma
EBV is more commonly associated 
with two Hodgkin lymphoma sub-
types: nodular sclerosis and mixed 
cellular [2]. The EBV-related global 
PAF for Hodgkin lymphoma is 49% 
(Table 2.4.2); however, the PAF is 
about 40% in adults in developed 
countries, whereas it is closer to 
90% in children, and about 60% in 
adults in developing countries [3].
Burkitt lymphoma
In endemic areas of sub-Saharan 
Africa where malaria burden is very 
high, the EBV-related PAF for Burkitt 
lymphoma is more than 95% [2]. 
Outside endemic areas, EBV tran-
scriptional gene products are detect-
ed much less frequently in Burkitt 
lymphoma. Sporadic forms of Burkitt 
lymphoma have been described 
elsewhere, but EBV was detected 
in only 20–30% of cases [3]. The 
EBV-related global PAF for Burkitt 
lymphoma is 63% (Table 2.4.2).
Nasopharyngeal carcinoma
Nasopharyngeal carcinoma is a rare 
cancer worldwide but has an excep-
tionally high incidence (10–30 per 
Fig. 2.4.4. Precancerous changes caused 
by human papillomavirus infection can be 
detected in cervical tissue. Micrograph 
(400×) of a Pap test showing a low-grade 
squamous intraepithelial lesion with effects 
of human papillomavirus.
Do infections play a role in breast cancer?
James F. Holland
Human breast cancer has many 
phenotypes and, often modulated 
by estrogens, probably results from 
many different etiologies. Wide 
variation in the incidence of breast 
cancer globally is often ascribed to 
reproductive patterns, ethnicity, and 
diet. Breast cancer in feral and labo-
ratory mice is caused by the mouse 
mammary tumour virus (MMTV), 
discovered in 1936. In the 1990s, 
molecular techniques not previ-
ously available were used to find a 
unique 660 bp sequence of MMTV 
that does not occur in the human ge-
nome or in any other organism. After 
this sequence was detected using 
polymerase chain reaction, the en-
tire 9.9 kb viral structure of human 
mammary tumour virus (HMTV), 
which is 90–95% homologous to 
MMTV, was isolated [1].
The distribution of HMTV is 
similar to that of indigenous mouse 
species. Mus domesticus, the com-
mon house mouse, is dominant in 
countries in western Europe and in 
all of their former colonies, presum-
ably distributed on sailing ships. M. 
domesticus has abundant MMTV in 
its genome. In eastern Europe and 
Asia, different mouse species, with 
less MMTV in their genome, are in-
digenous. In six countries of west-
ern Europe and North and South 
America as well as in Australia, 
where breast cancer incidence 
is high, 30–40% of human breast 
cancer specimens contain HMTV 
sequences, but in four countries 
of Asia where breast cancer inci-
dence is low, only 0–12% of speci-
mens contain these sequences [2]. 
Normal tissues from the affected 
breast do not contain virus, thereby 
establishing that HMTV is acquired 
after conception and is not geneti-
cally inherited [3,4]. The possibility 
of MMTV contamination has been 
excluded in these analyses.
HMTV can be seen budding 
from breast cancer cells by electron 
microscopy, and can infect human 
mammary epithelial cells in vitro, 
causing changes in gene expression, 
morphology, and migration, suggest-
ing malignant transformation. It also 
can infect B and T lymphocytes. In 
mice, MMTV in breast milk infects 
lymphocytes, which transfer virus to 
the breast. HMTV has been detected 
in the breast milk of 8% of healthy 
American women; the virus has been 
passed from mother to daughter via 
breast milk perhaps for eons, extend-
ing the parallelism with mouse biol-
ogy. These data raise the possibility 
that some breast cancers may have 
an infectious etiology, which would in 
turn open new perspectives on ther-
apy and prophylaxis and raise ques-
tions about other “portable DNA” in 
the etiology of human cancer.
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100 000 person-years in men) in 
southern China, Singapore, and 
Malaysia [2]. For the non-keratinizing 
subtype, EBV genome or gene prod-
ucts have been detected in virtually 
all cases, irrespective of geographical 
origin, and thus EBV appears to be a 
necessary step in the malignant pro-
cess [2]. The EBV-associated PAF for 
nasopharyngeal carcinoma in areas of 
high or intermediate incidence is near-
ly 100%. This figure is probably less 
(possibly about 80%) in areas of low 
incidence [3], but the lack of published 
data does not allow a precise estimate 
(the global PAF is 86%) (Table 2.4.2).
Other non-Hodgkin 
lymphomas
Due to the heterogeneity of this 
group of tumours, even a crude es-
timation of the PAF is not possible 
from the published data, although 
most NHLs arising in HIV-positive 
individuals and organ transplant 
recipients are causally related to 
EBV [15].
Gastric carcinoma
Although EBV DNA has been found 
in 5–10% of gastric carcinomas, the 
IARC Monographs Volume 100B 
Working Group [2] concluded that 
there is insufficient epidemiological 
evidence for the involvement of the 
virus. Therefore, we have not calcu-
lated the PAF for EBV and gastric 
cancer.
Kaposi sarcoma herpesvirus
Kaposi sarcoma
Kaposi sarcoma herpesvirus is a 
causal factor for the development 
of Kaposi sarcoma and a few rare 
lymphoproliferative disorders, in-
cluding primary effusion lymphoma 
and multicentric Castleman disease 
[2]. Although virtually all cases of 
Kaposi sarcoma are attributable to 
Kaposi sarcoma herpesvirus [3], var-
ious forms of the disease have been 
described and suggest that other 
factors, notably immunosuppres-
sion associated with HIV or organ 
transplantation, have an important 
contributory role in cancer develop-
ment. In some regions of Europe and 
North America, after years of dra-
matically increasing Kaposi sarcoma 
incidence, a rapid decline of inci-
dence has followed the introduction 
of highly active antiretroviral therapy 
in 1996 [16]. Conversely, with the 
large number of people with HIV/
AIDS in sub-Saharan Africa and the 
still-limited access to treatment, the 
estimated incidence of Kaposi sar-
coma is, for example, about 40 per 
100 000 person-years in Zimbabwe, 
and it is the most common cancer in 
men in a few sub-Saharan African 
countries.
Human T-cell lymphotropic 
virus type 1
Adult T-cell leukaemia
A causal association between hu-
man T-cell lymphotropic virus type 1 
(HTLV-1) and adult T-cell leukaemia, 
found nearly exclusively in Japan, 
has been firmly established. Thus, 
100% of adult T-cell leukaemia cases 
in Japan are attributable to HTLV-1 
[3] (Table 2.4.2), although the global 
PAF is unclear [3]. Restriction of the 
duration of breastfeeding has dimin-
ished the circulation of HTLV-1 and 
the corresponding cancer burden in 
Japan [2].
Macroparasite infections
Chronic infections with the liver 
flukes Opisthorchis viverrini and 
Clonorchis sinensis have long been 
associated with cholangiocarcinoma 
(cancer of the bile ducts). Human 
liver fluke infection is endemic in ar-
eas of China, the Republic of Korea, 
the Democratic People’s Republic 
of Korea, Thailand, Lao People’s 
Democratic Republic, Viet Nam, 
and Cambodia, where it is estimat-
ed that a total of 24.4 million people 
are infected [2]. Flukes are acquired 
from eating contaminated raw fish, 
either fresh or fermented. A total of 
Fig. 2.4.5. An HIV-infected H9 T cell. The 
image has been coloured to highlight HIV 
budding (yellow) against the T cell (blue).
Fig. 2.4.6. Unsafe needle use during an immunization day in rural Sylhet, Bangladesh. 
Contaminated needles have been implicated in the spread of infections such as HIV/
AIDS.
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2000 cases of cholangiocarcinoma 
were attributable to liver flukes [3] (in-
cluded in liver cancer in Table 2.4.2).
The causal association between 
the macroparasite Schistosoma 
haematobium and bladder cancer is 
strong and consistent [2]. Endemic 
areas are found in sub-Saharan 
Africa, Sudan, Egypt, and Yemen, 
where the snail that transmits the 
macroparasite is present. The num-
ber of people infected with S. hae-
matobium in sub-Saharan Africa is 
estimated to be 112 million, and the 
number of bladder cancers per year 
attributable to S. haematobium was 
estimated to be about 6000 [3]. The 
global PAF for bladder cancer is 2% 
(Table 2.4.2).
HIV
HIV-positive individuals have an in-
creased cancer risk. Advanced HIV 
infection is characterized by immu-
nosuppression, which is a risk factor 
for many malignancies [16]. There 
are three AIDS-defining cancers: 
Kaposi sarcoma, NHL, and cervi-
cal cancer. In contrast to the gen-
eral population, almost all NHLs in 
HIV-infected people are caused by 
EBV. HIV-infected people also have 
elevated risks of other virus-related 
cancers, notably anal cancer, hepa-
tocellular carcinoma, and Hodgkin 
lymphoma. As HIV typically coexists 
with oncogenic viruses, the inclusion 
of HIV-associated malignancies in 
the computation of global PAF would 
mean that some infection-associat-
ed cancers would be counted twice. 
However, HIV-infected people also 
have a higher prevalence of lifestyle-
associated risk factors, including 
smoking and alcohol consumption, 
leading to increased risks of can-
cers of the head and neck and lung. 
Overall, in HIV-infected people the 
risk of non-AIDS-defining cancers 
is double that in the general popula-
tion [16]. The advent of antiretroviral 
therapy led to a striking increase in 
the life expectancy of HIV-infected 
people. The cancer burden is set to 
increase as they age, and cancer pre-
vention strategies need to be put in 
place in parallel with efforts to detect 
and treat HIV infection early enough 
to prevent immunosuppression.
Conclusions
Conservative estimates indicate that 
about 2 million of the new cancer 
cases per year (16% of the global 
cancer burden) are attributable to 
a few chronic infections [3]. This 
fraction is substantially larger in de-
veloping countries (26%) than in de-
veloped countries (8%) (Fig. 2.4.1). 
Large variations are also seen by 
Table 2.4.3. Number of new cancer cases in 2008 attributable to infectious agents, by geographical region
Region Number of new cases in 2008a
Number attributable
to infection
PAF
(%)
Africa
Sub-Saharan Africa 550 000 180 000 32.7
North Africa and West Asia 390 000 49 000 12.7
Asia
India 950 000 200 000 20.8
Other Central Asia 470 000 81 000 17.0
China 2 800 000 740 000 26.1
Japan 620 000 120 000 19.2
Other East Asia 1 000 000 230 000 22.5
Americas
South America 910 000 150 000 17.0
North America 1 600 000 63 000 4.0
Europe
Europe 3 200 000 220 000 7.0
Oceania
Australia and New Zealand 130 000 4 200 3.3
Other Oceania 8 800 1 600 18.2
Developing regionsb 7 100 000 1 600 000 22.9
Developed regionsb 5 600 000 410 000 7.4
World 12 700 000 2 000 000 16.1
PAF, population attributable fraction.
a Numbers are rounded to two significant digits.
b Developed regions include Japan, North America, Europe, Australia, and New Zealand, i.e. high-income countries. Developing regions include all other 
countries, i.e. low- and middle-income countries.
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continent and country (Table 2.4.3). 
The fraction of cancer attributable 
to infections is largest in sub-Sa-
haran Africa (33%) and smallest in 
Australia, New Zealand, and North 
America (≤ 4%). A better under-
standing of the association between 
NHL and infectious agents would 
lead to a substantial increase in the 
infection-associated PAF, especially 
in developed countries.
Prevention or eradication of 
these infections is a key tool to 
overcome inequalities in cancer 
incidence between populations in 
high-income countries and those in 
low- and middle-income countries. 
Of note, substantial reductions in the 
occurrence of many cancer-associ-
ated infections are now achievable 
and, in many instances, affordable. 
Control measures include avoid-
ance of contaminated blood and 
needles (HBV, HCV, HIV), safe sex 
practices (HBV and HIV), and early 
detection and treatment of the infec-
tion (e.g. detection and treatment of 
HPV-related precancerous cervical 
lesions in screening programmes, 
antibiotic treatment of H. pylori, and 
praziquantel against liver flukes). 
Very efficacious vaccines against 
HBV and HPV are currently avail-
able (see Chapter 4.6). Historically, 
only clean water has performed bet-
ter than vaccination to reduce dis-
ease burden. If high coverage can 
be achieved, vaccines can reduce 
inequalities in health more than 
other medical interventions can. 
Clinicians and public health profes-
sionals should better appreciate the 
importance of infections that cause 
cancer and support the implementa-
tion of currently available prevention 
strategies, especially in developing 
countries.
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Summary
• Reproductive and menstrual 
factors are relevant to the etiol-
ogy of breast, endometrial, and 
ovarian cancers.
• Obesity is a risk factor for these 
cancers in women as well as for 
some cancers in men; its influ-
ence is most likely mediated 
through hormonal mechanisms, 
as further supported by the influ-
ence of obesity on the effects 
of exogenous and endogenous 
hormones.
• Use of oral contraceptives sub-
stantially reduces the risk of en-
dometrial and ovarian cancers 
but appears to increase the 
risk of breast and of cervical 
cancers, consistent with grow-
ing evidence for a possible role 
of hormonal factors in cervical 
carcinogenesis.
• Reproductive and hormonal 
factors appear to have particu-
lar associations for different 
subtypes of cancers in women, 
including those defined by either 
histology or hormone receptor 
status.
• The role of hormonal factors in 
the etiology of some cancers in 
men is being revealed, although 
2.5
2 ETIOLOGY
Reproductive and 
hormonal factors
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risk relationships remain to be 
clarified.
Reproductive and hormonal factors 
are well recognized to play a major 
role in the etiology of many cancers 
in women. This is particularly true 
for breast, endometrial, and ovarian 
cancers, where such factors likely 
explain large proportions of disease 
occurrence. A few cancers in men 
may also be influenced by hormonal 
factors, although the relationships 
are less well defined.
Female breast cancer
The role of reproductive factors in the 
etiology of breast cancer has been 
recognized for more than 100 years, 
beginning with the observation by 
Ramazzini of a high incidence of 
the disease in nuns. It is now well 
established that nulliparous women 
have approximately twice the risk of 
parous women, and that multipar-
ity may be associated with further 
decreases in risk. Women with early 
age at first childbirth are at lowest 
risk, and risk rises steadily with later 
ages at first birth [1]. Interestingly, 
women with a first birth at age 30 
or later are generally at higher risk 
than nulliparous women, presum-
ably because of promotional effects 
of pregnancy on previously initiated 
cells in older mothers. The effect 
of pregnancy on breast cancer risk 
is dependent on it being a full-term 
pregnancy; there is little evidence for 
relationships with short-term preg-
nancies, including miscarriages and 
abortions.
The reduced risk associated 
with parity may be further enhanced 
if a woman decides to breastfeed. 
However, protection is likely depen-
dent on longer periods of breastfeed-
ing; thus, in most developed coun-
tries, where numbers of births are 
limited and each child is breastfed for 
a relatively short period of time, there 
is little evidence of a relationship with 
breastfeeding. The most conclusive 
findings about the protective effects 
of breastfeeding derive from stud-
ies where women have given birth 
to multiple children who have been 
breastfed for long periods of time, 
leading to long durations of cumula-
tive breastfeeding.
Menstrual factors are also predic-
tive of risk; early age at menarche 
and later age at natural menopause 
are associated with the highest risks, 
presumably reflecting in part an influ-
ence of ovulatory activity (Fig. 2.5.1) 
[2]. Women who have an early surgi-
cal menopause involving removal of 
both ovaries are at low risk, and those 
who undergo this operation before 
the age of 40 have approximately half 
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in endogenous hormonal profiles are 
involved, but additional research is 
needed to clarify effects. It is also 
unclear how hormonally induced 
changes in breast tissue are in-
volved. Recent attention has focused 
on the effects of parity on involution 
of lobules, the structures from which 
the majority of breast cancers are 
thought to arise (Fig. 2.5.2) [3].
The relationship of obesity with 
breast cancer risk is complex; obe-
sity is inversely related to risk of 
premenopausal-onset breast cancer 
and is directly associated with risk 
of postmenopausal breast cancer. 
Obesity-associated anovulation has 
been hypothesized as responsible 
for the decreased risk, while conver-
sion of androgens to estrogens in 
adipose tissue appears to influence 
the increased risk. Menopausal hor-
mone use has been associated with 
increased breast cancer risk among 
postmenopausal women, and the 
highest risks have been observed 
among thin women. The type of hor-
mones used is also a major risk pre-
dictor, with higher risks observed for 
the risk of those who have a natural 
menopause after the age of 55.
Menstrual and reproductive fac-
tors are major risk factors and can 
be used to estimate individual risks 
via the Gail Model Breast Cancer 
Risk Assessment Tool (http://www.
cancer.gov/bcrisktool/) and other risk 
prediction models. Despite the well-
recognized role of these factors in 
breast cancer etiology, studies have 
been unable to relate them to specific 
underlying biological mechanisms. It 
is generally assumed that changes 
Fig. 2.5.1. Relative risk of breast cancer by (A) age at menarche and (B) age at meno-
pause, based on multiple studies. Calculated stratifying by study, age, year of birth, 
parity, age at first birth, smoking, alcohol consumption, height, and current body mass 
index. CI, confidence interval; g-s, group-specific; RR, relative risk.
Fig. 2.5.2. Terminal ductal lobular unit 
(TDLU) involution. (A) Minimal or no TDLU 
involution. (B) Marked involution demon-
strating TDLUs containing few acini sur-
rounded by dense collagen.
A
B
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use of estrogen plus estrogen than 
for unopposed estrogen therapy. This 
has been hypothesized as being due 
to mitotic influences of progestins on 
breast tissues.
Combined estrogen–progesto-
gen oral contraceptives are associ-
ated with an increased risk of breast 
cancer, notably among young wom-
en (see Chapter 2.10). Endogenous 
Fig. 2.5.4. Endogenous estrogen metabolism in women.
hormones clearly are important 
predictors of breast cancer risk, 
although it has been difficult for 
studies to fully define relationships 
with either breast cancer risk or 
patterns of risk factors. This most 
likely reflects difficulties in measur-
ing hormones or the complexity of 
patterns of many interrelated mark-
ers, including not only estrogens 
but also androgens, progesterone, 
prolactin, and insulin-like growth 
factors. In addition, the importance 
of large inter-individual differences 
in metabolism, which may have 
etiological implications, is being in-
creasingly recognized. Recent pool-
ing efforts have provided evidence 
that estrogens and androgens are 
directly related to both hormone- 
receptor-positive and -negative 
breast cancers (Fig. 2.5.3) [4], but 
Fig. 2.5.3. Sex steroid hormones and sex hormone-binding globulin (SHBG) levels in relation to estrogen recep-
tor (ER) breast cancer subtypes, from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. 
CI, confidence interval; OR, odds ratio. * Test for heterogeneity between ER-positive and ER-negative breast cancer 
was assessed using a log likelihood ratio test with and without an interaction term for breast cancer subtype outcome. 
** Log2 continuous increase in circulating hormone level.
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Fig. 2.5.5. Age-standardized incidence of endometrial cancer by menopausal hormone 
therapy use and body mass index, from the United States National Institutes of Health-
American Association of Retired Persons (NIH-AARP) Diet and Health Study. EPT, 
estrogen plus progestin therapy; ET, unopposed estrogen therapy; MHT, menopausal 
hormone therapy.
further clarity about relationships 
may derive from additional analyses 
that use more precise hormone mea-
surement techniques. Recently de-
veloped liquid chromatography-mass 
spectrometry assays are now allow-
ing measurements of 15 individual 
estrogen metabolites (Fig. 2.5.4) 
[5], which are showing different ef-
fects on breast cancer risk. A recent 
analysis within the Prostate, Lung, 
Colorectal, and Ovarian Cancer 
Screening Trial indicated that al-
though total estrogens were predic-
tive of risk, further risk discrimina-
tion was dependent on hydroxylation 
pathways [6].
Endometrial cancer
Endometrial tissue is extremely hor-
monally responsive, and endometrial 
cancer is believed to arise as a result 
of estrogen stimulation that is unop-
posed by progestins. Both obesity 
and menopausal hormone therapy 
are strong risk predictors. Particularly 
high risks have been noted for unop-
posed estrogen use, which has been 
associated with 2–10-fold increases 
in risk, depending on the duration of 
use and the woman’s body size (with 
higher relative risks observed among 
thin women).
Much lower risks have been 
noted for estrogen plus progestin 
hormone use; in fact, some stud-
ies suggest that relative risks may 
actually be lower among users than 
among non-users. These risks also 
appear to be modified by body mass, 
although in contrast to unopposed 
estrogens the greatest reductions 
in relative risks are seen among 
heavier women. Because of these 
complexities, more meaningful in-
sights can be derived by a focus on 
absolute risks. The lowest risks are 
seen among thin women (either non-
hormone users or users of continu-
ous estrogen plus progestin therapy; 
these two groups are at similar risk), 
while the highest risks are observed 
among obese non-hormone users 
(who are at higher risk than obese 
users of continuous estrogen plus 
progestin therapy) (Fig. 2.5.5) [7]. 
Combination therapy may also be 
influenced by how it is prescribed 
(estrogens given sequentially vs 
Table 2.5.1. Associations between history of endometriosis and the histological subtypes of ovarian cancer
Histological subtype Stratified and adjusted ORa (95% CI) P value
Invasive 1.46 (1.31–1.63) < 0.0001
Clear cell 3.05 (2.43–3.84) < 0.0001
Endometrioid 2.04 (1.67–2.48) < 0.0001
Mucinous 1.02 (0.69–1.50) 0.93
High-grade serous 1.13 (0.97–1.32) 0.13
Low-grade serous 2.11 (1.39–3.20) < 0.0001
Borderline 1.12 (0.93–1.35) 0.24
Mucinous 1.12 (0.84–1.48) 0.45
Serous 1.20 (0.95–1.52) 0.12
CI, confidence interval; OR, odds ratio.
a Stratified by age (5-year categories) and ethnic origin (non-Hispanic White, Hispanic White, Black, Asian, other) and adjusted for duration of oral 
contraceptive use (never, < 2 years, 2–4.99 years, 5–9.99 years, ≥ 10 years) and parity (0, 1, 2, 3, ≥ 4). Pooled analysis of 13 ovarian cancer case–control 
studies: 1 in Australia, 3 in Europe, and 9 in the USA.
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to elevated risks of endometrial 
cancer in premenopausal women, 
for the more commonly used oral 
contraceptives, a combination of 
estrogen and progestin, use has 
been related to substantial risk 
reductions. Long-term users have the 
lowest risk, and reduced risk persists 
for some time after discontinuation 
of use. Although the progesterone 
content of the pills used might affect 
risk, studies have not been able to 
definitely confirm this hypothesis.
Despite the recognition of a 
strong role for hormonal factors in 
the etiology of endometrial cancers, 
relatively few studies have under-
taken the assessment of the role 
of endogenous hormones. There 
is suggestive evidence that both 
estrogens and androgens deserve 
specific further attention. In such 
studies, it will be important to distin-
guish patterns of risk according to 
specific tumour subtypes (e.g. type 
1 vs type 2 endometrial cancers), 
which have been shown to be etio-
logically heterogeneous.
Ovarian cancer
Nulliparity is a well-recognized risk 
factor for ovarian cancers, as is 
infertility. Although there has been 
extensive controversy about poten-
tial effects of fertility drugs, the lat-
est studies show that the indications 
for use are more important than the 
drugs themselves. Endometriosis is 
a well-established predictor of cer-
tain types of ovarian cancers, in-
cluding clear cell and endometrioid 
cancers (Table 2.5.1) [8].
Some studies suggest elevated 
risks with early age at menarche 
and late age at menopause, but the 
results are not entirely consistent. 
Substantially reduced risks have 
been observed among women who 
have had a simple hysterectomy or 
tubal ligation. Although this finding 
might reflect detection of abnormali-
ties and removal of ovaries during 
either of these procedures, more 
recent attention has focused on the 
effects of partial devascularization 
or partial removal of tubes, given in-
creasing evidence of the tubal origin 
of many serous cancers.
Use of oral contraceptives is 
related to substantial reductions 
in the risk of ovarian cancer, par-
ticularly when long-term use is in-
volved. However, use of menopausal 
hormones has been linked with in-
creases in risk. This has been most 
clearly demonstrated for unopposed 
continuously), although studies are 
only beginning to pursue this issue.
Whereas nulliparous women 
have high risks and multiparous 
women the lowest risks of develop-
ing endometrial cancer, no effect on 
risk has been demonstrated accord-
ing to age at first birth. Instead, age 
at or interval since last birth may be 
an important contributor to risk, al-
though studies are still attempting 
to understand these relationships. 
Early age at menarche and late age 
at menopause are even stronger risk 
factors for endometrial cancer than 
for breast cancer, presumably be-
cause these parameters indicate an 
enhanced opportunity for circulating 
estrogens to influence risk. Despite 
these patterns of risk, current un-
derstanding of the effects of endog-
enous hormones on endometrial 
cancer is still imprecise. Studies are 
needed to assess the independence 
of endogenous hormones from the 
strong effects on risk of obesity and 
of exogenous hormone use. Further 
study of estrogen metabolism pat-
terns may also provide some clarity.
Whereas use of sequential oral 
contraceptives (estrogen-only pills 
followed by a limited number of days 
of progestin pills) has been related 
Table 2.5.2. Associations between menopausal hormone therapy and ovarian cancer risk in the United States National Institutes of 
Health-American Association of Retired Persons (NIH-AARP) Diet and Health Study cohort, 1995–2006
Number of cancers Person-years RRa (95% CI)
Use of ET only, among 23 584 women with a hysterectomy at baseline
No MHT use 23 55 868 1.00 (reference)
ET only 76 116 139 1.69 (1.05–2.71)
Duration of use of ET only (years)
< 10 27 58 393 1.25 (0.71–2.20)
≥ 10 49 55 878 2.15 (1.30–3.57)
Use of EPT only, among 68 596 women with an intact uterus at baseline
No MHT use 150 316 239 1.00 (reference)
ET only 98 170 556 1.43 (1.09–1.86)
Duration of use of EPT only (years)
< 10 67 126 465 1.33 (0.98–1.79)
≥ 10 31 43 752 1.68 (1.13–2.49)
CI, confidence interval; EPT, estrogen plus progestin therapy; ET, unopposed estrogen therapy; MHT, menopausal hormone therapy; RR, hazard rate 
ratio.
a RR adjusted for continuous age (years), race (White, other/unknown), parity (nulliparous, 1, 2, ≥ 3, unknown), duration of oral contraceptive use (none, 
< 10 years, ≥ 10 years, unknown), and body mass index (< 25 kg/m2, 25–29 kg/m2, ≥ 30 kg/m2, unknown); models included terms for use of other MHT 
formulations.
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estrogen therapy, but there is grow-
ing evidence that combination es-
trogen plus progestin therapy may 
also be linked with elevated risk 
(Table 2.5.2) [9].
Although many of the identified 
risk factors for ovarian cancer are 
consistent with a protective effect 
of reduced ovulation, this does not 
appear to entirely explain all of the 
identified risk factors. Recent atten-
tion has focused on the possible 
role of hormonal and immunological 
factors [10]. Conflicting results have 
emerged about the respective role of 
estrogens, androgens, follicle-stimu-
lating hormone, sex hormone-bind-
ing globulin, and insulin-like growth 
factor. Further investigation appears 
warranted, especially with respect to 
specific ovarian cancer subtypes, for 
which there is growing evidence of 
etiological heterogeneity.
Cervical cancer
Although infection with the human 
papillomaviruses is recognized as a 
necessary cause of cervical cancer, 
other co-factors are clearly impor-
tant. Epidemiological studies have 
for some time implicated a variety 
of factors that could increase risk 
through hormonal mechanisms, 
Fig. 2.5.6. Estrogen signalling pathways (A) and process of cervical carcinogenesis (B). 
(A) Estrogen-bound receptors dimerize and translocate to the nucleus, where they 
activate or repress target genes by binding to estrogen response elements (ERE) or to 
AP1 or Sp1 transcription factors. Estrogen also binds to the membrane receptor GPR30 
and transduces various signalling pathways, including phosphatidylinositol 3-kinase 
(PI3K), mitogen-activated protein kinase (MAPK), and Ca2+ signalling. (B) High-risk 
human papillomaviruses (HR-HPVs), such as HPV16, infect and persist in multipotent 
reserve cells, resulting in atypical squamous metaplasia (ASM), which gives rise to 
cervical intraepithelial neoplasia (CIN) grades 1–3 and eventually cervical cancer. This 
progressive neoplastic disease process usually takes more than a decade after initial 
HPV infection.
Fig. 2.5.7. Risk factors for male breast cancer, from the United States National Institutes 
of Health-American Association of Retired Persons (NIH-AARP) Diet and Health Study. 
RR, relative risk.
such as oral contraceptive use and 
multiparity, but the role of hormonal 
factors in the etiology of cervi-
cal cancer is not well understood. 
Transgenic mice models have re-
cently provided evidence that estro-
gen and its nuclear receptor promote 
cervical cancer in combination with 
human papillomavirus oncogenes 
(Fig. 2.5.6) [11]. If future studies can 
demonstrate that human cervical 
cancers are dependent on estro-
gens, it may be possible to develop 
hormonal agents to prevent or treat 
cervical cancers.
Testicular cancer
Hormonal factors clearly play a role 
in the etiology of testicular cancer, 
as evidenced by the rise in incidence 
starting at adolescence and a vari-
ety of risk factors including height, 
subfertility, and possibly exposure 
to endocrine disrupters. Several risk 
factors also support an influence of 
exposures received in utero, includ-
ing cryptorchidism, hypospadias, in-
guinal hernia, low birth weight, short 
gestational age, and being a twin, 
some of which may reflect the influ-
ence of endogenous hormones [12]. 
Recent studies have attempted to 
assess the role of endogenous hor-
mones in the etiology of testicular 
cancer, but further studies are need-
ed to fully understand relationships.
Male breast cancer
The incidence of breast cancers in 
men is only about 1% of the rate in 
women, complicating the evalua-
tion of etiological factors. The few 
available studies, however, appear 
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Fig. 2.5.8. Association between risk of prostate cancer and increasing fifths of hormone concentrations. The position of each square 
indicates the magnitude of the relative risk (RR), and the area of the square is proportional to the amount of statistical information 
available. The length of the horizontal line through the square indicates the 95% confidence interval (CI). The chi-square 1 degree 
of freedom statistic for linear trend is calculated by replacing the categorical variables with a continuous variable scored as 0, 0.25, 
0.5, 0.75, and 1. The P value was two-sided for statistical significance of the chi-square linear trend statistic. DHEA-S, dehydroepi-
androsterone sulfate; DHT, dihydrotestosterone; SHBG, sex hormone-binding globulin.
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to implicate several hormonally 
related risk factors, with sugges-
tions of increased risks related 
to gynaecomastia and Klinefelter 
syndrome and, in the most recent 
prospective study [13], to obesity, 
lack of physical activity, prior bone 
fractures, and current cigarette 
smoking (Fig. 2.5.7). Studies have 
not been undertaken to assess 
relationships with endogenous 
hormones.
Prostate cancer
Prostate cancers respond well to an-
ti-androgen therapies, and both sur-
gical and medical castration results 
in substantial reductions in risk of 
metastatic disease. Although it has 
also been assumed that androgens 
would play a role in the etiology of 
the disease, studies to date have not 
provided evidence of a role for any 
hormones as risk predictors. This 
includes an absence of association 
in a large pooling project (Fig. 2.5.8) 
[14] of testosterone, calculated free 
testosterone, and conversion prod-
ucts; the major conversion product 
is dihydrotestosterone, to which 
testosterone is converted within the 
prostate by 5α-reductase. The only 
evidence of association observed 
was an inverse relationship with sex 
hormone-binding globulin.
Finasteride use reduces pros-
tate cancer risk by blocking the 
conversion of testosterone to dihy-
drotestosterone; use has also been 
associated with increases in estra-
diol levels. The Prostate Cancer 
Prevention Trial has shown substan-
tial reductions in prostate cancer in-
cidence associated with exposure to 
finasteride (http://www.cancer.gov/
clinicaltrials/noteworthy-trials/pcpt/
Page1). This has raised concern as 
to whether estrogen levels might 
play a role in prostate cancer etiol-
ogy. As with androgens, however, 
no relationships of prostate cancer 
risk with estrogen levels have been 
observed. Data from the trial, how-
ever, have shown that participants 
who developed prostate cancer 
while taking finasteride experienced 
higher-grade tumours. Thus, it may 
be worthwhile for future studies to 
consider effects of estrogens and 
androgens on subgroups of prostate 
cancers as well as to consider ef-
fects on risk of combined measures 
or estrogens and androgens as well 
as hormone metabolites.
Other cancers
Although colorectal cancer is not 
classically considered as a hormon-
ally related cancer, there is evidence 
supporting the possibility of inverse 
associations of colorectal cancer risk 
with use of both oral contraceptives 
and menopausal hormones. Oral 
contraceptives have also been noted 
to be a risk factor for liver cancer in 
the absence of infection with hepa-
titis B virus, an important cause of 
this disease.
Fig. 2.5.9. One mother helps another to breastfeed her baby in Kolkata, India. Generally, 
reduced risk of breast cancer is associated with prolonged rather than short-term 
breastfeeding.
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Summary
• Excess body fat increases risk 
of cancers of the oesophagus, 
colon, pancreas, endometrium, 
and kidney, as well as postmen-
opausal breast cancer.
• Regular physical activity re-
duces risks of multiple can-
cers by contributing to weight 
control, and risks of colorectal 
and breast cancer by additional 
mechanisms.
• Among dietary factors related 
to excess body weight, reduc-
tion of consumption of sugar-
sweetened beverages should 
be a high priority.
• High consumption of red meat, 
especially processed meat, is 
associated with risk of colorec-
tal cancer.
• A diet high in fruits and vegeta-
bles and whole grains does not 
appear to be as strongly protec-
tive against cancer as initially 
believed. However, this dietary 
pattern is still advisable because 
of the benefits for diabetes and 
cardiovascular diseases, and 
some possible reductions in 
cancer incidence.
• Additional research is needed 
on many aspects of diet and 
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2 ETIOLOGY
Diet, obesity, and 
physical activity
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physical activity in relation to 
cancer, including the effects of 
these behaviours during child-
hood and in early adult life.
Interest in diet as contributing to 
the cause and prevention of cancer 
emerged from observations that 
cancer rates vary greatly between 
countries and are correlated with 
dietary factors, and that nutrition 
can modify cancer incidence in ani-
mals. To provide more specific in-
formation for human cancer, many 
retrospective case–control studies, 
some prospective cohort studies, 
and a few randomized trials have 
been conducted. These studies 
have limitations: measurement of 
diet and physical activity is always 
imperfect, the diagnosis of cancer 
can distort the recall of diet in the ret-
rospective studies, and adherence 
to the assigned diet is often poor in 
randomized trials (see “Challenges 
of measuring diet in cancer epide-
miological studies and new perspec-
tives”). In addition, initial nutritional 
status may affect response to chang-
es in dietary intake. Despite the 
many methodological challenges, 
much has been learned during the 
past 30 years about the relation of 
diet, obesity, and physical activity to 
cancer; major findings are briefly de-
scribed here. Because prospective 
cohort studies are least susceptible 
to biases, findings from these stud-
ies are emphasized, together with 
the findings from the small number 
of randomized trials.
Diet
Fat
Among dietary factors, fat has re-
ceived the greatest attention due to 
strong international correlations with 
rates of several cancers common in 
developed countries. However, pro-
spective studies have consistently 
shown little relationship of fat intake 
with breast cancer risk [1], even with 
up to 20 years of follow-up. In two 
large randomized trials of low-fat 
Fig. 2.6.1. A man eats a hamburger and 
fried potato chips and drinks a pint of beer. 
Drinking alcohol, consumption of red and 
processed meats, and a high caloric di-
etary intake are variously associated with 
increased risk of cancer at several ana-
tomical sites.
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Challenges of measuring diet in cancer epidemiological studies and new 
perspectives
Nadia Slimani
Among the different environmental 
and lifestyle risk factors, diet is one 
of the most complex exposures to 
investigate in relation to diseases, 
particularly cancer. Indeed, diet is 
a universal exposure, and foods 
are consumed in combinations and 
with preparation methods that vary 
greatly between individuals and over 
the whole lifespan. In addition, the 
several thousand chemicals (includ-
ing contaminants) present in foods 
may have complex synergistic or an-
tagonistic bioactive effects, making 
it difficult to disentangle individual 
chemical effects and remove con-
founding completely when investi-
gating diet–disease relationships 
and underlying biological mecha-
nisms [1]. Finally, diet has strong 
social, religious, and psychological 
aspects that affect study designs 
and the dietary outcomes of indi-
viduals [2].
In addition, the nutrition transi-
tion, a phenomenon occurring with 
an accelerated pace worldwide [3,4], 
is another under-evaluated chal-
lenge to measuring diet–cancer as-
sociations. The nutrition transition 
is the shift in dietary patterns from 
traditional diets (high in cereal and 
fibre) to diets more typical of devel-
oped countries and characterized by 
an increased contribution of (highly) 
industrially processed foods (high in 
sugars, fats, and animal sources) [4].
Cancer is a multiphase and mul-
tifactorial disease that essentially 
occurs late in life but that might be 
affected by different (early) expo-
sure windows, which are difficult 
to evaluate. Most cancer epide-
miological studies involve middle-
aged populations and use single or 
limited repeated dietary measure-
ments, which are not able to ap-
proximate lifelong dietary exposure 
[5]. Furthermore, the food frequency 
questionnaire (FFQ) assessment 
method predominantly used in epi-
demiology has been challenged with 
respect to its validity and reliability 
[6,7]. The FFQ is a retrospective 
method that asks respondents to 
report their usual frequency of con-
sumption of each food from a list 
of foods for a specific period (sev-
eral months or a year). In contrast, 
repeated 24-hour dietary recalls 
Fig. B2.6.1. Integrative approaches for measuring diet in large-scale epidemiological studies. 24-HDRs, 24-hour dietary recalls; 
DQ, dietary questionnaire; FFQ, food frequency questionnaire; FPQ, food propensity questionnaire (non-quantitative FFQ).
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diets, there was no significant effect 
on risk of breast cancer. Prospective 
studies of colorectal cancer have 
also not supported the positive rela-
tionship with fat intake suggested by 
international comparisons of cancer 
rates [1,2]. Prospective studies of 
dietary fat and prostate cancer are 
fewer but do not generally support a 
relation with total or specific types of 
dietary fat [1,3].
For patients with cancer, the effect 
of diet after diagnosis on survival is of 
great interest. Two randomized trials 
of low-fat diets have been conducted 
among women with breast cancer. In 
one study, a marginally significantly 
lower risk of breast cancer was seen, 
but this might have been explained by 
a greater weight loss compared with 
the control group. In the other trial, no 
effect of the dietary intervention was 
observed [4].
Meat and dairy products
Higher intake of red meat, especial-
ly processed meat, has been asso-
ciated with greater risk of colorectal 
cancer in many prospective stud-
ies and in a meta-analysis of these 
studies [1] (see “Single-nucleotide 
polymorphisms relevant to meat 
consumption and cancer risk”). 
Although consumption of meat dur-
ing midlife or later has generally not 
been associated with risk of breast 
cancer, a positive relation has been 
seen with intake in adolescence and 
early adult life [5]. Studies of red 
meat and risk of prostate cancer 
have been limited and results in-
consistent [1].
Higher consumption of milk or 
dairy products has been associated 
with lower risk of colorectal cancer 
[1]. In contrast, higher consump-
tion of dairy products has been 
associated with increased risks 
of total or fatal prostate cancer in 
many studies [1]; the fat component 
of milk does not appear to account 
for these associations.
Fruits, vegetables, and 
phytochemicals
Higher intakes of essential nutrients 
and other biologically active constit-
uents of plants have reduced cancer 
incidence in laboratory animals and 
appear to have benefits in isolated 
cells. Although higher intakes of 
fruits and vegetables were associ-
ated with lower risks of many can-
cers in retrospective studies, these 
findings have generally not been 
strongly supported by prospective 
studies [1].
A large protective role for total in-
take of fruits and vegetables against 
overall cancer risk now appears 
unlikely, but specific phytochemical 
(24-HDRs) or food records (FRs), 
considered to be more precise and 
reliable than FFQs, are increasingly 
used or recommended in nutritional 
cancer research [8]. The 24-HDR is 
a retrospective assessment method 
in which an interviewer prompts a 
respondent to recall and describe 
all foods and beverages consumed 
during the preceding 24 hours or 
the preceding day. The FR is used 
to record food intake at the time of 
consumption, over a number of days 
that are not necessarily sequential.
Based on decades of methodo-
logical research [9], front-line nutri-
tional research increasingly favours 
approaches that integrate traditional 
and more innovative measurements 
of dietary exposure: (i) repeated 
24-HDRs or FRs benefiting from 
cost-effective new innovative (web) 
technologies [10,11]; (ii) the FFQ or 
food propensity questionnaire (FPQ) 
approach, designed to rank individu-
als and/or identify foods infrequently 
consumed, to complement 24-HDRs 
and other open-ended methods; and 
(iii) the use of recovery and/or con-
centration nutritional biomarkers 
as independent observations or as 
substitute estimates of dietary expo-
sure [12,13] (Fig. B2.6.1). In addition, 
the rapid development of metabo-
lomic research opens a promising 
perspective for a more holistic ap-
proach to measure dietary exposure 
through individual and population-
specific metabolomic profiles (or 
phenotypes) [14]. These approaches 
will be maximized when applied in 
large studies with wide variations 
in dietary exposures and disease 
outcomes.
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or botanical subgroups may reduce 
risks of some cancers. Promising 
leads include carotenoid-containing 
vegetables and estrogen-receptor-
negative breast cancer, cruciferous 
vegetables and several cancer sites 
including prostate, bladder, and 
lung; allium vegetables and stom-
ach cancer; and folate-rich fruits 
and vegetables and colon cancer. 
High consumption of soy products, 
rich in anti-estrogenic compounds, 
during adolescence, but not during 
midlife or later, has been associated 
with lower risk of breast cancer [6]. 
More research is needed on these 
associations, and currently none of 
them is firmly established.
Dietary fibre
Fibre has long been hypothesized 
to reduce risk of colorectal cancer 
by providing bulk to dilute potential 
carcinogens and speed their transit 
through the colon, by binding and 
thus inactivating carcinogens, or 
by altering the flora and biochemi-
cal environment of the colon (see 
“Diet and the gut microbiome”). 
Several large prospective cohort 
studies of dietary fibre and colon 
cancer risk have not supported 
an association [7], although an in-
verse relation was seen in the large 
European Prospective Investigation 
into Cancer and Nutrition (EPIC) 
study and a recent meta-analysis 
[8]. The variation in findings from 
prospective studies needs to be 
better understood; dietary fibre is 
complex and heterogeneous, and 
the relation with colorectal cancer 
could differ by dietary source [9].
Higher intake of fibre has also 
been hypothesized to reduce risk 
of breast cancer by interrupting 
the enterohepatic circulation of 
estrogens. Although no relation 
with breast cancer has been seen 
in most prospective studies, a 
weak inverse relation was seen in 
a recent meta-analysis [10] and a 
new analysis from the large EPIC 
study [11].
Vitamins and minerals
Calcium
In a pooled analysis of large cohort 
studies, persons with the highest 
calcium intake had a 22% lower risk 
of colorectal cancer [12]; most of 
the benefit was achieved with about 
800 mg/day. This benefit is sup-
ported by reductions in recurrence 
of colorectal adenomas with calci-
um supplementation in some ran-
domized trials [1], but not all [13]. 
However, higher calcium intake has 
also been associated with a greater 
risk of total or advanced prostate 
cancer in several studies [1]. The 
possibility of competing risks and 
benefits associated with higher in-
take of dairy products and calcium 
has made recommendations about 
consumption difficult in relation to 
cancer, but adequate intakes of cal-
cium are essential for bone growth 
and other aspects of health.
Vitamin D
Higher blood levels of vitamin D, 
which reflect both intakes and sun-
light exposure, have been consis-
tently associated with lower risk of 
colorectal cancer [14], and recently 
with survival [15], but more research 
is needed to determine whether 
this reflects a true protective 
effect. Inconsistent associations 
have been seen with other specific 
cancers.
Folate
Folate is important for DNA meth-
ylation, repair, and synthesis, and 
in some prospective studies, higher 
intakes have been associated with 
lower risk of colorectal and several 
other cancers [16]. In a recent analy-
sis, a lag of at least 12–14 years was 
seen between low folate intake and 
increased risk of colorectal cancer 
[4]. A role of folate in colorectal car-
cinogenesis is supported by the con-
firmed association between a genetic 
polymorphism in MTHFR, an enzyme 
involved in folate metabolism, and risk 
of colorectal cancer [17].
In randomized trials among pa-
tients with a history of colorectal ade-
nomas, supplements of folic acid have 
not reduced recurrent adenomas, and 
in one trial an increased risk of recur-
rent advanced adenoma or multiple 
adenomas was seen [18]. These 
studies suggest that supplemental 
folic acid is unlikely to be beneficial 
for those with existing colonic neopla-
sia and adequate folate intake, and 
might even be harmful. This concern 
was heightened by a report suggest-
ing a small and transient increase in 
incidence of colorectal cancer in the 
USA almost immediately after the ini-
tiation of folic acid fortification of grain 
products, but this transient increase 
was likely to have been an artefact 
Fig. 2.6.2. In a remote semi-arid region of Laikipia North in Kenya, Masai warriors have 
exchanged their spears for cricket bats. Physical activity is associated with reduced risk 
of colorectal and other cancers.
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Single-nucleotide polymorphisms relevant to meat consumption and cancer 
risk
Rashmi Sinha
Meat is a source of a variety of car-
cinogens, including heterocyclic a- 
mines (HCAs) and polycyclic aro-
matic hydrocarbons (PAHs), which 
are formed in meats cooked at 
high temperatures, and N-nitroso 
compounds (NOCs), which are 
found in processed meats as a re-
sult of nitrate or nitrite added during 
processing, and are formed endog-
enously from haem iron. HCAs, 
PAHs, and NOCs undergo extensive 
metabolism by phase I (cytochrome 
P450s) and phase II (sulfotrans-
ferases, glucuronosyltransferases, 
N-acetyltransferases) xenobiotic 
metabolizing enzymes (XMEs). 
Single-nucleotide polymorphisms 
(SNPs) in the genes encoding 
these XMEs can modify the abil-
ity of these enzymes to activate or 
detoxify these meat carcinogens 
(Fig. B2.6.2).
While many studies have ob-
served modifying effects of SNPs 
in XME genes on the association be-
tween meat carcinogen intake and 
colorectal cancer, the evidence for 
primary associations and interac-
tions between XME polymorphisms, 
meat consumption, and the risk of 
colorectal adenomas or carcinomas 
has been mixed. One of the largest 
analyses to investigate these associ-
ations conducted to date, a study of 
1205 advanced colorectal adenoma 
cases and 1387 controls, revealed 
only one statistically significant in-
teraction. The study reported an in-
teraction between intake of the HCA 
2-amino-3,8-dimethylimidazo[4,5-
f ]quinoxaline (MeIQx) and the 
NAT1 polymorphism rs6586714 
(Pinteraction = 0.001); among indi-
viduals carrying a GG genotype, 
high MeIQx intake was positively 
associated with colorectal ade-
noma (odds ratio [OR], 1.43; 95% 
confidence interval [CI], 1.11–1.85; 
Ptrend = 0.07), whereas those with 
the A variant had a decreased risk 
(OR, 0.50; 95% CI, 0.30–0.84; 
Ptrend = 0.01) [1]. The study also 
investigated substrate-oriented 
pathway-based approaches, in-
corporating a range of XME genes 
involved in both the activation and 
detoxification of xenobiotics, but 
there was no strong evidence for 
associations.
Two SNPs related to the xenobi-
otic MDRI, thought to restrict intesti-
nal absorption of HCAs and PAHs, 
were associated with colorectal 
cancer in one study [2]. In contrast, 
8 genes involved in uptake, absorp-
tion, and metabolism of dietary iron 
(TF, TFRC, HMOX1, SLC40A1, 
SLC11A2, HAMP, ACO1, HP01) 
were not associated with colorec-
tal adenoma despite a statistically 
significant association between 
several SNPs and serum iron indi-
ces [3]. The PARP gene in the base 
excision repair pathway appeared 
to modify the association between 
intake of red meat cooked at high 
temperatures and risk of colorectal 
cancer as meat carcinogens may 
induce oxidative DNA damage [4].
Fig. B2.6.2. Simplified schematic of polymorphic genes coding for enzymes involved in metabolism of heterocyclic amines (HCAs), 
polycyclic aromatic hydrocarbons (PAHs), nitrate/nitrate, and iron. AHR, aryl hydrocarbon receptor.
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because it corresponded with a large 
increase in screening colonoscopy 
and an accelerated decline in colo-
rectal cancer mortality rates [1,4].
Vitamin and mineral 
supplementation
The role of vitamin and mineral sup-
plements in cancer prevention has 
been examined in both prospective 
cohort studies and randomized tri-
als. Trials of β-carotene and other 
single supplements, including vita-
min E and selenium, have not shown 
benefits [1]. In trials using combina-
tions of multiple vitamins or minerals 
at lower doses than those in single 
supplements, reductions in cancer 
rates have been seen in a Chinese 
population with multiple nutrient 
deficiencies [19,20], in French men 
but not women, and in physicians in 
the USA [21].The study of physicians 
in the USA was notable because this 
population was well nourished, and 
the modest benefit was detectable 
only after 10 years, which is a period 
longer than that used in virtually all 
other studies. Overall, supplements 
with multivitamins and minerals are 
likely to be beneficial in populations 
with multiple nutrient deficiencies, 
although improvements in general 
nutrition should be the long-term 
goal in such populations.
Diet and excess adiposity
Because excess adiposity is as-
sociated with risk of many cancers 
[1], the relationship of diet to weight 
gain and obesity is important for 
cancer prevention. In trials with 
similar intensity of intervention and 
that have lasted at least 1 year, low-
fat diets have not been effective in 
weight loss [22]. A diet low in rap-
idly absorbed carbohydrates (such 
as sugar, jam, and refined cere-
als) may facilitate weight loss [23]. 
A Mediterranean-style, restricted-
calorie dietary pattern, which is high 
in cereals, fruits, and vegetables and 
low in animal products, has been ef-
fective in sustaining weight loss for 
as long as 6 years [24]. Reduced 
consumption of soda and other 
sugar-sweetened beverages has 
reduced weight among children and 
adults who were initially overweight 
[25].
In an analysis of long-term weight 
gain in three large cohort studies, 
foods associated with greater weight 
gain included potato chips, sugar-
sweetened beverages, red meat, 
and processed meat, whereas fruits, 
vegetables, whole grains, nuts, and 
yogurt were associated with less 
weight gain [26]. Among bever-
ages, sugar-sweetened beverages 
and fruit juices were associated 
with greater weight gain. Because 
they lack any nutritional value and 
are directly related to adiposity, dia-
betes, and cardiovascular disease, 
sugar-sweetened beverages are a 
high-priority focus area for weight 
control efforts in populations with 
substantial intakes.
Fig. 2.6.3. Relation of body mass index with risk of developing cancers of the oesopha-
gus, colon, pancreas, breast, endometrium, and kidney.
Overall, the inconsistent findings 
reflect several limitations of existing 
studies, including the inability to ac-
curately estimate the intake of spe-
cific meat carcinogens, the limited 
number of well-characterized cases 
to ensure sufficient power by geno-
type, and our current limited under-
standing of the precise genetic vari-
ants that account for XME function. 
Very large studies that include both 
comprehensive meat intake informa-
tion and numerous markers across 
multiple XME genes are essential for 
studying this complex association.
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Overweight and obesity
Overweight and obesity are important 
causes of several types of cancer. 
Body fatness is usually assessed 
using body mass index (BMI), which 
is calculated as the weight in kilo-
grams divided by the square of the 
height in metres and thus provides 
a simple index of weight relative to 
height that can be measured eas-
ily in population studies. A BMI of 
20–24.9 kg/m2 is considered normal, 
whereas a BMI of 25–29.9 kg/m2 
is classed as overweight and a BMI 
of 30 kg/m2 or more as obese. Waist 
circumference is another simple mea-
sure of adiposity, and shows associa-
tions with cancer risk similar to those 
for BMI.
Epidemiological studies have 
provided convincing evidence that 
obesity increases the risk of can-
cers of the oesophagus (adeno-
carcinoma), colon (in men), pan-
creas, breast (postmenopausal), 
endometrium, and kidney [27] 
(Fig. 2.6.3); these associations of 
BMI with cancer risk generally fol-
low a dose–response relationship, 
so that as well as the increased 
risk with obesity, there is also a 
smaller increase in risk for people 
who are overweight but not obese. 
The magnitude of the increase in risk 
varies between cancer sites. For an 
increase in BMI of 10 kg/m2, rela-
tive risks are approximately 2.3 for 
adenocarcinoma of the oesophagus, 
1.5 for colon cancer in men, 1.3 for 
pancreatic cancer in women, 1.4 for 
postmenopausal breast cancer, 2.9 
for endometrial cancer, and more 
than 1.5 for kidney cancer.
There is also substantial evidence 
that obesity increases the risks of 
cancer of the gall bladder (in wom-
en), malignant melanoma, ovarian 
cancer, thyroid cancer, non-Hodgkin 
lymphoma, multiple myeloma, and 
leukaemia [1,28]. Cancer mortality 
(all sites combined) increases in a 
linear fashion with increasing BMI 
and is about 70% higher in people 
who are extremely obese than in 
people of normal weight (Fig. 2.6.4) 
[28].
Estimates of the percentage of 
cancers that can be attributed to 
excess body weight suggest that 
overweight and obesity are sub-
stantial causes of cancer in many 
developed countries [29], but the 
magnitude of attributable risk has 
varied depending on the prevalence 
of obesity and on other underlying 
assumptions. For example, esti-
mates for the United Kingdom for 
2007 suggested that 5% and 6% 
of all incident cancers in men and 
women, respectively, were attribut-
able to overweight and obesity, with 
attributable risks of about 40% for 
cancers of the oesophagus (adeno-
carcinoma), gall bladder (in women), 
and endometrium [30], whereas es-
timates for the USA for 1999–2000 
suggested that overweight and obe-
sity were responsible for 4.2% and 
Fig. 2.6.4. Relation of body mass index with risk of death from cancer of any type in 
men and women who had never smoked.
Fig. 2.6.5. Children compete in a sack race in Banda Aceh, Indonesia. Such encourage-
ment of physical activity may reduce the likelihood of overweight and obesity in childhood.
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14.3% of cancer mortality in men 
and women, respectively, rising to 
14.2% and 19.8%, respectively, in 
men and women who had never 
smoked [31]. These proportions are 
predicted to grow in most countries 
due to the increasing prevalence of 
overweight and obesity.
Additional research is required 
on the possible associations of 
overweight and obesity with the 
risk of less common types of can-
cer. There is also a need to explore 
further the importance of obesity 
at different ages with lifetime risk 
of cancer, and to better understand 
whether the distribution of body fat 
is important.
Mechanisms
The mechanisms through which 
obesity increases cancer risk are 
only partially understood but ap-
pear to vary between different 
cancer sites. For adenocarcinoma 
of the oesophagus, the increase in 
cancer risk probably involves an in-
crease in the prevalence of chronic 
acid reflux from the stomach into 
the oesophagus, which damages 
the oesophageal epithelium. For 
breast and endometrial cancers, 
the increased risk with obesity in 
postmenopausal women is prob-
ably caused by the increase in cir-
culating estradiol, due to increased 
formation of estrogens from precur-
sor hormones in the adipose tissue; 
obesity also increases the risk of en-
dometrial cancer in premenopausal 
women, and this may be due to 
anovulation and therefore reduced 
production of progesterone in obese 
premenopausal women. For colon 
cancer in men, kidney cancer, and 
other cancers, the mechanisms by 
which obesity increases risk are less 
clear but may involve increases in 
insulin and other hormonal changes 
in obesity.
Diet and the gut microbiome
Johanna W. Lampe
The human gut is host to a large 
and diverse community of microbes 
that have physiological effects and 
carry out metabolic functions that 
can influence host health. Diet af-
fects the amount and types of mi-
crobes present in the gut, and, in 
turn, actions of the gut microbiota 
on dietary constituents may shape 
cancer susceptibility. Bacteria me-
tabolize xenobiotics, both potentially 
beneficial (e.g. phytochemicals) and 
detrimental (e.g. carcinogens), and 
harvest otherwise inaccessible nutri-
ents and/or sources of energy from 
the diet.
Gut microbes carry out unique 
metabolic reactions that the host 
cannot. Metagenomic studies of 
the gut microbiome (i.e. the collec-
tive genomic content of a microbial 
community) have revealed the var-
ied anaerobic reactions involved in 
fermentation and other processes. 
Enzymes specific to bacteria, and 
in some cases specific classes of 
bacteria, catalyse a range of meta-
bolic reactions, such as hydrolysis 
of glycosides, amides, and esters, 
as well as reduction, ring cleavage, 
demethylation, and dehydroxylation. 
Plant polysaccharides (e.g. dietary 
fibre and resistant starch) are ma-
jor dietary factors that mould the 
structure of the human gut microbial 
community [1]. Gut bacterial metabo-
lism of non-digestible carbohydrates 
produces fermentation end-prod-
ucts, such as short-chain fatty ac-
ids, that act as signalling molecules, 
serve as fuel to gut epithelial cells 
(butyrate) and peripheral tissues (ac-
etate and propionate), and modulate 
inflammation. Hydrolysis of plant gly-
cosides typically results in metabo-
lites that are more biologically active 
than the parent compounds. Further 
bacterial transformation of aglycones 
can produce lower-molecular-weight 
compounds that systemically may be 
more or less active. High inter-indi-
vidual variation in circulating concen-
trations of phytochemicals and their 
metabolites is, in part, a reflection 
of variation in gut microbial activity 
[2]. Some microbial metabolites of 
dietary constituents are associated 
with increased risk of tumorigenesis. 
Ingested nitrate can be reduced to 
nitrite by bacterial nitrate reductase 
and produce N-nitroso compounds, 
which can form DNA adducts. 
Hydrogen sulfide, produced from 
sulfur-containing amino acids and 
inorganic sulfur sources by sulfate-
reducing bacteria, has cytotoxic and 
genotoxic effects.
Gut microbes also promote the 
harvest of energy from the diet and 
contribute to fat deposition [3]. Thus, 
the gut microbiome may influence 
adiposity and adiposity-associated 
inflammation, and therefore, indi-
rectly, cancers for which excess 
body fat is a risk factor. Studies 
in animal models suggest that gut 
microbes play an important role in 
energy regulation and adiposity. In 
humans, the gut microbial commu-
nity is altered in obese individuals 
and can change with weight loss; 
however, whether the structure and 
function of the gut microbial com-
munity causes obesity in humans is 
unclear.
Understanding the complex 
and dynamic interaction between 
the gut microbiome and host diet 
may help elucidate mechanisms of 
carcinogenesis and guide future 
cancer prevention strategies.
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Reversing the effect of 
obesity on cancer risk
The clear evidence that overweight 
and obesity increase the risk of 
several types of cancer implies that 
weight loss should, to some extent, 
reverse this effect, and there is some 
direct evidence to support this un-
derstanding. Observational cohort 
studies and randomized controlled 
trials of both dietary interventions 
and bariatric surgery have shown 
reductions in cancer incidence oc-
curring within a few years after in-
tentional weight loss [32].
Obesity and cancer survival
Obesity may affect survival in can-
cer patients [33]. Several studies of 
breast cancer patients have shown 
that obesity is correlated with a 
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poorer prognosis; this relationship 
is not well understood but may in-
volve later diagnosis and also higher 
endogenous hormone levels in 
obese patients. Further research 
is needed on the effects of obesity 
on survival for breast cancer and 
for other types of cancer, including 
careful examination of relationships 
with stage at diagnosis and details 
of treatment.
Physical activity
Physical activity is difficult to measure 
in epidemiological studies, and under-
standing its relationship with cancer 
risk is complicated because it is gener-
ally inversely related to obesity and is 
also correlated with other factors that 
can affect cancer risk. Considering all 
the available evidence, it is likely that 
the most important impact of physical 
activity in relation to cancer preven-
tion is through its contribution to 
protecting against weight gain and 
obesity. Thus, physical activity can 
contribute to reduction of risk of all 
types of cancer for which obesity in-
creases risk. There is also evidence 
that physical activity reduces the risk 
of colon cancer and breast cancer 
and improves survival [34] indepen-
dently of its effects on BMI, perhaps 
by acting through hormonal changes 
[1,27]. The type and amount of physi-
cal activity required to reduce cancer 
risk remains uncertain, but the gen-
eral consensus among researchers 
is that activity should be of at least 
moderate intensity and should aver-
age at least 1 hour per day.
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After the discovery that ciga-
rette smoking is a major cause of 
cancer, and the development of 
modern epidemiological and toxi-
cological methods, much more 
systematic and widespread efforts 
were undertaken to determine the 
causes of cancer, and many more 
causes were identified, in both 
Summary
• To date, 32 occupational agents 
as well as 11 exposure circum-
stances are identified as car-
cinogenic to humans, and an 
additional 27 agents and 6 ex-
posure circumstances primarily 
relevant to occupational expo-
sure are probably carcinogenic 
to humans.
• Workplace exposure to several 
well-recognized carcinogens, 
such as asbestos, polycyclic aro-
matic hydrocarbons, heavy met-
als, diesel engine emissions, and 
silica, is still widespread.
• The burden of occupational can-
cer among exposed groups may 
be substantial.
• Prevention of occupational can-
cer is feasible and has taken 
place in industrialized countries 
during recent decades.
• Little information is available on 
occupational cancer risk in low-
income countries, but it can be 
reasonably expected to become 
a large problem.
From the late 18th century until the 
early 20th century, remarkable num-
bers of cases of scrotal cancer were 
2.7
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Lesley Rushton (reviewer)
Fig. 2.7.1. A head nurse at a clinic out-
side Accra, Ghana, withdraws blood from 
a woman for an HIV test. In discharging 
their duties, nurses in a variety of clini-
cal circumstances may be exposed to 
biological and chemical agents identified 
as, or suspected to be, carcinogenic.
reported among chimney sweeps, 
coal tar and paraffin workers, shale 
oil workers, and mule spinners in the 
cotton textile industry. Remarkable 
numbers of lung cancer cases were 
reported among metal miners, and 
of bladder cancer cases among 
workers in a plant that produced 
dyestuffs from coal tar. During the 
first half of the 20th century, there 
were additional reports of cancer 
clusters among other identifiable 
occupational groups. Unexpectedly 
high numbers of occurrences of 
respiratory cancer were evident in 
such diverse occupational settings 
as nickel refineries, coal carboni-
zation processes, chromate manu-
facture, manufacture of sheep dip 
containing inorganic arsenicals, and 
manufacture of asbestos products 
[1]. Each of these discoveries was 
typically based on astute observa-
tion of particular cases by a clinician, 
followed up with rather primitive ret-
rospective cohort studies. In most 
of such instances of increased risk, 
the relevant information concerned 
a particular occupation or industry, 
with little or no information allow-
ing risk to be attributed to particular 
chemicals. These high-risk occupa-
tions constituted virtually the only 
known causes of human cancer 
until the discovery in the 1950s of 
the cancer-causing effects of ciga-
rette smoking.
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occupational and non-occupational 
settings. Even today, however, oc-
cupational carcinogens represent a 
large fraction of all known human car-
cinogens. Although the discovery of 
occupational carcinogens provides an 
immediate means for preventing occu-
pational cancer, the potential benefit 
of such discoveries goes beyond the 
factory walls since most occupation-
al carcinogens are also found in the 
general environment and in consumer 
products, sometimes at concentra-
tions as high as those encountered 
in the workplace. Examples include 
polycyclic aromatic hydrocarbons in 
charcoal-broiled foods, 2-naphthyl-
amine in tobacco smoke, asbestos 
fibres in poorly maintained buildings, 
and atmospheric pollution by diesel 
engine emissions, benzene, and poly-
chlorinated biphenyls. Furthermore, 
research on occupational carcino-
gens can sometimes provide useful 
information for assessing risks in-
curred at levels found in the general 
environment.
Specifying occupational 
carcinogens
A large volume of epidemiologi-
cal and experimental data concern 
cancer risks in different workplaces. 
This chapter includes a tabular sum-
mary of current knowledge on oc-
cupational carcinogens, the occupa-
tions and industries in which they are 
found, and their target organs [2].
Although seemingly simple, 
drawing up an unambiguous list of 
occupational carcinogens is difficult. 
The first source of ambiguity is the 
definition of an “occupational carcin-
ogen”. Exposures to most occupa-
tional carcinogens also occur in the 
general environment and/or in the 
course of using consumer products, 
and reciprocally, most environmen-
tal exposures and those associated 
with using certain consumer prod-
ucts, including medications, foods, 
and others, also occur in some occu-
pational context. The distinction be-
tween occupational and non-occu-
pational exposures can be arbitrary. 
For instance, whereas exposures to 
tobacco smoke, sunlight, and immu-
nosuppressive medications are gen-
erally not identified as occupational 
exposures, there are people whose 
occupation results in them being in 
contact with these agents to a degree 
that would not otherwise occur. Also, 
whereas asbestos, benzene, diesel 
engine emissions, and radon gas are 
considered to be occupational car-
cinogens, exposure to these agents 
is also experienced by the general 
population, and indeed many more 
people are probably exposed to 
these substances in the course of 
day-to-day life than are exposed at 
work. There is no simple criterion to 
distinguish “occupational” carcino-
gens from “non-occupational” car-
cinogens. Given this complexity, the 
following operational procedure is 
adopted: a carcinogen is considered 
to be “occupational” if the primary 
human exposure circumstance to 
the agent is in the workplace and/or 
if the main epidemiological studies 
that led to the identification of an ele-
vated risk of cancer were undertaken 
among workers, and if notable num-
bers of workers are exposed to the 
agent. Even this operational defini-
tion is somewhat vague and requires 
judgement in its implementation.
Another source of ambiguity de-
rives from the nature of the occupa-
tional circumstances that have been 
investigated. For instance, there is 
evidence that exposure to soot may 
cause skin tumours and that expo-
sure to 2-naphthylamine may cause 
bladder tumours, and it is likely that 
the historical observations of excess 
risks of scrotal cancer in chimney 
sweeps and of bladder cancer in dye 
factory workers were respectively 
related to these two carcinogens. If 
there is persuasive evidence that a 
given chemical or mixture is carcino-
genic – soot and 2-naphthylamine, in 
the current example – then this may 
be considered a relatively estab-
lished proposition, requiring consid-
eration of the level of exposure but 
little else. However, the knowledge 
that an occupation or industry is as-
sociated with excess cancer risk is 
rooted in the specific time and place 
at which the research took place. In 
some instances, an occupationally 
characterized group may be shown 
to experience excess cancer risk but 
the causative agent is unknown, or 
at least unproven; examples are lung 
cancer among painters and bladder 
cancer among workers in the alumin-
ium industry. An occupation does not 
in itself confer a carcinogenic risk; 
it is the exposures or conditions of 
work that may confer a risk. Thus, 
the statement that a given occupa-
tion involves a carcinogenic risk is 
potentially misleading and should be 
considered in light of the different 
exposure circumstances that may be 
associated with a given occupation 
in different times or places.
IARC Monographs
IARC Monographs provide authori-
tative information for compiling a 
list of occupational carcinogens [3]. 
The objective of the Monographs 
Programme, which has been operating 
Fig. 2.7.2. A mine worker in Burdwan, 
India. Workers engaged in mining a 
range of products experience increased 
risk of lung cancer.
Fig. 2.7.3. A man in Uruguay wears a 
protective mask while spray-painting 
a car. Work as a painter is linked to in-
creased risk of lung cancer and bladder 
cancer.
136
Evaluating carcinogens: dioxins and dioxin-like substances
Kurt Straif
Since 1997 [1], 2,3,7,8-tetrachlo-
rodibenzo-para-dioxin (TCDD) has 
been classified by IARC as Group 1, 
carcinogenic to humans, based on 
limited evidence of carcinogenicity 
in humans, sufficient evidence in 
rodents, and strong evidence in hu-
mans and animals for a mechanism 
via initial binding to the aryl hydro-
carbon receptor (AhR), which leads 
to changes in gene expression, cell 
replication, and apoptosis. Thus, 
TCDD was one of the first agents 
to be upgraded to Group 1 on the 
basis of mechanistic evidence 
(Table B2.7.1).
There is now sufficient evidence 
from epidemiological studies for all 
cancers combined, making TCDD 
the first agent to be classified as 
Group 1 initially based on strong 
mechanistic data and later con-
firmed by increased cancer risk 
in humans [2]. This highlights the 
ability of mechanistic information to 
provide robust evidence of carcino-
genicity. Sufficient evidence for an 
increased risk for all cancers com-
bined is mainly derived from heavily 
exposed occupational cohorts. In 
addition, there is limited evidence 
for an increased risk of lung cancer, 
soft-tissue sarcoma, and non-Hodg-
kin lymphoma.
Like TCDD, 2,3,4,7,8-penta-
chlorodibenzofuran and 3,3′,4,4′,5- 
pentachlorobiphenyl (PCB 126) are 
complete carcinogens in experi-
mental animals, and there is strong 
evidence that they act through the 
same AhR-mediated mechanism. 
Therefore, in the context of the 
re-evaluation of TCDD, these two 
chemicals were classified as Group 
1. Recognizing the complexity of 
the mechanistic evaluation, the 
IARC Monographs Volume 100F 
Working Group decided to make 
evaluations only for these two in-
dicator chemicals, and suggested 
that future Monographs meetings 
be focused on other dioxin-like 
compounds.
PCB congeners can be catego-
rized by their degree of chlorination, 
substitution pattern, and binding 
affinity to receptors. Twelve con-
geners with high affinity for AhR 
are referred to as dioxin-like PCBs. 
PCBs are readily absorbed and dis-
tributed in the body, and accumulate 
in adipose tissue. On the basis of 
sufficient evidence of carcinogenic-
ity in experimental animals and hu-
mans (based on an increased risk of 
melanoma), PCBs were classified as 
Group 1 [3]. In addition, dioxin-like 
PCBs were also classified as Group 
1 on the basis of extensive evidence 
of an AhR-mediated mechanism of 
carcinogenesis that is identical to that 
of TCDD, and sufficient evidence 
of carcinogenicity in experimental 
animals. It was noted that the 
carcinogenicity of PCBs cannot 
Table B2.7.1. Evolution of evaluations of 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) and other dioxin-like compounds
IARC Monographs volume (V) 
or supplement (S)
(year)
Agent
Degree of evidence of carcinogenicity Overall evaluation 
of carcinogenicity 
to humansaIn humans In animals
V7 (1974), V18 (1978), 
S1 (1979), S4 (1982)
Polychlorinated biphenyls Inadequate Sufficient Group 2B
V15 (1977), S1 (1979) TCDD No overall evaluation
V18 (1978) Polybrominated biphenyls No overall evaluation
S4 (1982), S7 (1987) TCDD Inadequate Sufficient Group 2B
V41 (1986), S7 (1987) Polybrominated biphenyls Inadequate Sufficient Group 2B
S7 (1987) Chlorinated dibenzodioxins 
(other than TCDD)
Inadequate Inadequate Group 3
S7 (1987) Polychlorinated biphenyls Limited Sufficient Group 2A
V69 (1997) TCDD Limited Sufficient Group 1b
V69 (1997) Polychlorinated dibenzo-para-
dioxins (other than TCDD)
No data Inadequate or 
limited
Group 3
V69 (1997) Polychlorinated dibenzofurans Inadequate Inadequate or 
limited
Group 3
V100F (2012) TCDD Sufficient Sufficient Group 1
V100F (2012) 3,3′,4,4′,5-Pentachlorobiphenyl 
(PCB 126)
Sufficient Group 1b
V107 (2014) Polychlorinated biphenyls Sufficient Sufficient Group 1
V107 (2014) Dioxin-like polychlorinated 
biphenylsc
Sufficient Group 1b
V107 (2014) Polybrominated biphenyls Inadequate Sufficient Group 2Ab
a Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable 
as to its carcinogenicity to humans; Group 4, probably not carcinogenic to humans.
b Upgraded on the basis of mechanistic evidence.
c With a toxic equivalency factor (TEF) according to WHO (PCBs 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 169, 189).
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.7since 1971, is to publish critical 
reviews of epidemiological and ex-
perimental data on carcinogenicity 
for chemicals, groups of chemicals, 
industrial processes, other complex 
mixtures, physical agents, and bio-
logical agents to which humans are 
known to be exposed, and to evaluate 
data indicative of carcinogenicity.
Agents are selected for evalua-
tion on the basis of two criteria: hu-
mans are exposed to the agent, and 
there is reason to suspect that the 
agent may be carcinogenic. Direct 
evidence of carcinogenicity of an 
agent can be derived from epidemio-
logical studies or from experimental 
studies of animals (usually rodents). 
Account may also be taken of chem-
ical structure–activity relationships 
and data indicative of mechanism, 
including absorption and metabo-
lism of the agent and physiological 
change induced, together with mu-
tagenic, toxic, and other effects ex-
hibited by the agent. Expert Working 
Groups are convened to evaluate all 
relevant data.
Over the past 40 years, more 
than 100 meetings have been con-
vened by the IARC Monographs 
Programme and almost 1000 agents 
have been evaluated. Exposure to 
many such chemicals or mixtures 
occurs occupationally.
Occupational agents or 
exposure circumstances 
evaluated as carcinogenic 
or probably carcinogenic
Table 2.7.1 lists occupational agents, 
occupations, and industries that have 
been classified as Group 1, carcino-
genic to humans. The table explicitly 
distinguishes 32 chemical or physi-
cal agents from 11 occupations and 
industries that involve an increased 
risk of cancer but for which the re-
sponsible agent has not been speci-
fied. The overall burden of cancer 
caused by a given agent is a func-
tion of several factors, including the 
prevalence of the exposure, the type 
or types of cancer involved, and the 
relative risk of cancer induced as de-
termined by each known exposure 
circumstance. Among the carcino-
gens listed in Table 2.7.1 that may 
induce the largest excess numbers 
of cases are asbestos, diesel engine 
emissions, silica, solar radiation, 
and second-hand tobacco smoke 
[4]. Some of the carcinogens listed 
occur naturally, such as wood dust 
or solar radiation, whereas some are 
man-made, such as 1,3-butadiene 
or vinyl chloride. Some are single 
chemical compounds, such as ben-
zene or trichloroethylene; others are 
families of compounds that include 
some carcinogens, and still others 
are mixtures of varying chemical 
composition, of which diesel engine 
emissions and mineral oils are ex-
amples. Most known human carcino-
gens have been established to induce 
only one or a few different types of 
cancer.
Among the occupations and in-
dustries shown in Table 2.7.1, most 
are industries in which the number of 
workers is relatively small, and so the 
population burden of any risk attribut-
able to these industries would be lim-
ited, at least in developed countries. 
But one occupational group – paint-
ers – stands out as an occupation that 
is widespread on a population basis, 
and for which the agent or agents re-
sponsible for the excess risk of lung 
and bladder cancer have not been 
identified. Aromatic amines such 
as benzidine and 2-naphthylamine 
may be responsible for some of the 
excess bladder cancer risk, but the 
cause of excess lung cancer risk is 
not so readily suggested.
be solely attributed to the carcino-
genicity of the dioxin-like PCBs. 
Interestingly, particularly low-chlori-
nated PCBs also seem to act via a gen-
otoxic mechanism. Polybrominated 
biphenyls (PBBs) were classified as 
Group 2A, probably carcinogenic 
to humans, taking into account 
evidence of an AhR-mediated 
mechanism of carcinogenicity.
These evaluations refer to can-
cer hazard identification; the burden 
of cancer attributable to environ-
mental exposures, for example via 
TCDD-contaminated food, is still 
controversial.
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Fig. 2.7.4. A man works in a toxic environment at a tannery in the densely populated 
area of Hazaribagh in Dhaka, Bangladesh. Occupational exposure to chromium 
compounds, specifically including work in chromate production, causes increased 
lung cancer risk.
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Table 2.7.1. Occupational exposures, occupations, industries, and occupational circumstances classified as definite carcino- 
genic exposures (Group 1) by the IARC Monographs, Volumes 1–106
Agent, occupation, or industry Cancer site/Cancer Main industry or use
Chemical or physical agent
Acid mists, strong inorganic Larynx Chemical
4-Aminobiphenyl Bladder Rubber
Arsenic and inorganic arsenic 
compounds
Lung, skin, bladder Glass, metals, pesticides
Asbestos (all forms) Larynx, lung, mesothelioma, ovary Insulation, construction, renovation
Benzene Leukaemia Starter and intermediate in chemical 
production, solvent
Benzidine Bladder Pigments
Benzo[a]pyrene Lung, skin (suspected) Coal liquefaction and gasification, coke 
production, coke ovens, coal-tar distillation, 
roofing, paving, aluminium production
Beryllium and beryllium compounds Lung Aerospace, metals
Bis(chloromethyl)ether; chloromethyl 
methyl ether
Lung Chemical
1,3-Butadiene Leukaemia and/or lymphoma Plastics, rubber
Cadmium and cadmium compounds Lung Pigments, batteries
Chromium (VI) compounds Lung Metal plating, pigments
Coal-tar pitch Lung, skin Construction, electrodes
Diesel engine exhaust Lung Transportation, mining
Ethylene oxide – Chemical, sterilizing agent
Formaldehyde Nasopharynx, leukaemia Plastics, textiles
Ionizing radiation (including radon-222 
progeny)
Thyroid, leukaemia, salivary gland, lung, 
bone, oesophagus, stomach, colon, 
rectum, skin, breast, kidney, bladder, brain
Radiology, nuclear industry, underground 
mining
Leather dust Nasal cavity Shoe manufacture and repair
4,4′-Methylenebis(2-chloroaniline) 
(MOCA)
– Rubber
Mineral oils, untreated or mildly treated Skin Lubricant
2-Naphthylamine Bladder Pigments
Nickel compounds Nasal cavity, lung Metal alloy
Shale oils Skin Lubricant, fuel
Silica dust, crystalline, in the form of 
quartz or cristobalite
Lung Construction, mining
Solar radiation Skin Outdoor work
Soot Lung, skin Chimney sweeps, masons, firefighters
2,3,7,8-Tetrachlorodibenzo-para-dioxin 
(TCDD)
– Chemical
Tobacco smoke, second-hand Lung Bars, restaurants, offices
ortho-Toluidine Bladder Pigments
Trichloroethylene Kidney Solvent, dry cleaning
Vinyl chloride Liver Plastics
Wood dust Nasal cavity Wood
Occupation or industry, without specification of the responsible agent
Aluminium production Lung, bladder –
Auramine production Bladder –
Coal gasification Lung –
Coal-tar distillation Skin –
Coke production Lung –
Haematite mining (underground) Lung –
Iron and steel founding Lung –
Isopropyl alcohol manufacture using 
strong acids
Nasal cavity –
Magenta production Bladder –
Painter Bladder, lung, mesothelioma –
Rubber manufacture Stomach, lung, bladder, leukaemia –
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Table 2.7.2. Occupational exposures, occupations, industries, and occupational circumstances classified as probable carcino- 
genic exposures (Group 2A) by the IARC Monographs, Volumes 1–106
Agent, occupation, or industry Suspected target organ Main industry or use
Chemical or physical agent
Acrylamide – Plastics
Bitumens (combustion products during 
roofing)
Lung Roofing
Captafol – Pesticide
α-Chlorinated toluenes (benzal 
chloride, benzotrichloride, benzyl 
chloride) and benzoyl chloride 
(combined exposures)
– Pigments, chemicals
4-Chloro-ortho-toluidine Bladder Pigments, textiles
Cobalt metal with tungsten carbide Lung Hard-metal production
Creosotes Skin Wood
Diethyl sulfate – Chemical
Dimethylcarbamoyl chloride – Chemical
1,2-Dimethylhydrazine – Research
Dimethyl sulfate – Chemical
Epichlorohydrin – Plastics
Ethylene dibromide – Fumigant
Glycidol – Pharmaceutical industry
Indium phosphide – Semiconductors
Lead compounds, inorganic Lung, stomach Metals, pigments
Methyl methanesulfonate – Chemical
2-Nitrotoluene – Production of dyes
Non-arsenical insecticides – Agriculture
Polychlorinated biphenyls – Electrical components
Polycyclic aromatic hydrocarbons 
(several apart from benzo[a]pyrene)
Lung, skin Coal liquefaction and gasification, coke 
production, coke ovens, coal-tar distillation, 
roofing, paving, aluminium production
Styrene-7,8-oxide – Plastics
Tetrachloroethylene 
(perchloroethylene)
– Solvent
1,2,3-Trichloropropane – Solvent
Tris(2,3-dibromopropyl) phosphate – Plastics, textiles
Vinyl bromide – Plastics, textiles
Vinyl fluoride – Chemical
Occupation or industry, without specification of the responsible agent
Art glass, glass containers, and 
pressed ware (manufacture of)
Lung, stomach –
Carbon electrode manufacture Lung –
Food frying at high temperature – –
Hairdressers or barbers Bladder, lung –
Petroleum refining – –
Occupational circumstance, without specification of the responsible agent
Shiftwork that involves circadian 
disruption
Breast Nursing, several others
Table 2.7.2 lists occupational 
agents, occupations, and indus-
tries that have been classified 
as Group 2A, probably carcino-
genic to humans. The table explicitly 
distinguishes 27 chemical or 
physical agents from 5 occupations 
and industries that have been found 
to present a probable risk but for 
which a causative agent has not 
been identified, and the other sin-
gular occupational circumstance – 
shiftwork. Most agents in Table 2.7.2 
are unequivocally carcinogenic in 
experimental animals, with little 
or no epidemiological evidence to 
confirm or contradict the evidence 
in animals. For a few of the agents, 
including lead compounds and creo-
sotes, there is a reasonable body of 
epidemiological evidence. However, 
the evidence taken together provides 
limited evidence of carcinogenicity to 
humans by IARC Monographs cri-
teria, i.e. because bias, confound-
ing, or chance cannot be excluded 
as contributing to the association 
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evident in epidemiological studies, 
or because different studies provide 
conflicting results.
Polycyclic aromatic hydrocar-
bons pose a particular challenge 
in the identification of occupational 
carcinogens. This class of chemicals 
includes several potent experimen-
tal carcinogens, such as benzo[a]
pyrene, benz[a]anthracene, and 
dibenz[a,h]anthracene. However, hu-
mans are always exposed to mixtures 
of polycyclic aromatic hydrocarbons; 
several such mixtures are indicated 
in Tables 2.7.1 and 2.7.2, including 
coal tars, soots, and creosotes. 
Because of the difficulty of isolat-
ing the impact of specific polycyclic 
aromatic hydrocarbons in exposure 
assessment, it is difficult to evaluate 
human cancer risks associated with 
individual members of this class of 
chemicals. Only for benzo[a]pyrene 
has the evidence warranted a Group 
1 evaluation, based on mechanis-
tic data taken together with other 
available evidence, but there are 
probably many more individual poly-
cyclic aromatic hydrocarbons that 
are carcinogenic to humans.
In the past, epidemiological re-
search of occupational risk factors 
has largely focused on occupational 
exposures associated with “dirty” 
industrial environments. In recent 
decades, however, occupational 
hygiene in many industries has im-
proved or different technology has 
been adopted such that the histori-
cal circumstances no longer apply, 
at least in developed countries. 
Increasing attention is now being paid 
to nonchemical agents in the work 
environment. Physical agents such 
as solar radiation and electromag-
netic fields have been investigated, 
but behavioural and ergonomic char-
acteristics of particular occupations, 
such as physical activity (or seden-
tary behaviour) are now also recog-
nized as occupational cancer risk fac-
tors. Together with such factors may 
be included exposure to second-hand 
tobacco smoke at work. For almost 
all these risk factors, the distinction 
between occupational and non-occu-
pational exposure is becoming more 
blurred. Although it is not of critical 
importance to maintain a clear dis-
tinction between occupational and 
non-occupational factors, it does fa-
cilitate communication and regulation 
to make this distinction, and the dis-
tinction may be critically relevant to 
controlling the exposure in question.
Industries and occupations are 
constantly evolving. Even if we knew 
all there was to know about the 
cancer risks in today’s occupational 
environments – which we do not – 
continuing to monitor cancer risks in 
occupational settings would remain 
an important activity because oc-
cupational exposure circumstances 
change over time and novel expo-
sures may be introduced; a recent ex-
ample is exposure to nanoparticles.
Although the lists of occupa-
tional carcinogens and associated 
exposures shown in Tables 2.7.1 and 
2.7.2 are long, they are not complete. 
There are likely many more occu-
pational carcinogens that have not 
been discovered or properly docu-
mented. For many, if not most, occu-
pational circumstances, there is no 
relevant epidemiological evidence 
about carcinogenic risk. One of the 
foremost problems in occupational 
epidemiology is to reveal as-yet-
unrecognized carcinogens and car-
cinogenic risks.
Since the revolution in genetic 
research methods, there has been 
a shift in research resources on oc-
cupational cancer, from an attempt 
to assess the main effects of occu-
pations and occupational exposures 
to an attempt to assess genetic risk 
factors or, at best, gene–environ-
ment interactions. This is an inter-
esting and worthwhile pursuit, but 
it has not yet led to a proportionate 
increase in knowledge of new car-
cinogens. It remains the case that 
almost all the knowledge that has 
accrued about occupational risk 
factors has been gained without re-
course to genetic data.
Estimates of the burden of 
occupational carcinogens
Over the years, there have been mul-
tiple attempts, sometimes accompa-
nied by controversy, to estimate what 
proportion of cancer cases are at-
tributable to occupation. Estimating 
attributable fractions is feasible when 
the exposure factor is well defined 
and there is a body of evidence to 
support estimates of the magnitude 
of risk associated with the risk factor 
and the prevalence of exposure to the 
risk factor in the population, such as 
is the case for cigarette smoking. 
Fig. 2.7.5. Asbestos fibres are the fine, 
elongated crystals that bind together to 
give asbestos its strength and durabil-
ity. These fibres are naturally resistant 
to heat and electricity – the primary rea-
son why asbestos was incorporated into 
thousands of commercial products like 
insulation and roofing materials. Among 
asbestos workers there is increased inci-
dence of lung, larynx, and ovarian cancer 
and mesothelioma.
Fig. 2.7.6. An asbestos abatement work-
er uses appropriate personal protective 
clothing and equipment in the course of 
removing asbestos. Despite bans on the 
use of asbestos, the material may often 
be encountered in the course of demoli-
tion or rebuilding.
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None of these conditions exist for 
the generic class of occupational 
exposures. Apart from the difficulty 
of establishing an unequivocal list of 
occupational carcinogens, there are 
many obstacles to deriving reliable 
estimates of attributable fractions 
for this class of carcinogens. These 
include the incompleteness of lists 
of occupational carcinogens, mea-
gre information on quantitative rela-
tive risks associated with exposure 
to known carcinogens, and scant 
information on the prevalence of 
exposure, both historically and 
quantitatively, among workers. 
Furthermore, as with any estimates 
of attributable fractions, the results 
are rooted in the time and place at 
which estimates of exposure preva-
lence are estimated. Still, by way of 
Preventing occupational cancer: successes and failures
Lesley Rushton
Approaches to preventing workplace 
exposures to occupational carcino-
gens and reduction of occupational 
cancer include eliminating the pro-
duction or use of carcinogens and 
controlling exposure to below a mini-
mal risk exposure level, for exam-
ple an occupational exposure limit 
(OEL). Examples of potential control 
measures are given in Table B2.7.2. 
All routes of exposure need to be 
considered, and control measures 
should not themselves cause addi-
tional hazards.
Current occupational cancer is 
due to past exposures, sometimes 
over many years, and because of the 
long latency of many cancers, these 
(often high) exposures will contrib-
ute to substantial occupational can-
cers 20–30 years in the future [1]. 
Exposure to many established occu-
pational carcinogens has gradually 
decreased over time in high-income 
countries due to an overall decline in 
heavy manufacturing industry and to 
regulatory activity and resulting risk 
reduction controls [2,3]. Some ex-
posures will rapidly disappear in the 
future – for example, second-hand 
smoke, as the willingness of society 
to accept a ban on workplace smok-
ing increases.
There has been mixed success 
in reducing other important expo-
sures, such as asbestos, a major 
contributor to the total occupational 
cancer burden. Increasing calls for 
a total ban on asbestos production 
and use contrast with continuing 
mining and widespread use of prod-
ucts containing chrysotile asbestos 
(an IARC Group 1 carcinogen), par-
ticularly in developing countries.
In some circumstances, it can 
be demonstrated that certain risk re-
duction strategies, such as improve-
ment of compliance with a current 
OEL (e.g. for silica exposure) and 
targeting small- and medium-sized 
industries, would be more effective 
than other measures, such as OEL 
reduction [1]. Similar strategies may 
be relevant in many rapidly industri-
alizing countries.
Reduction of high levels of expo-
sure to occupational carcinogens re-
mains an urgent priority in low- and 
middle-income countries, where 
the newest technology may be un-
available, there is little or no regula-
tion, and many may be employed in 
small workplaces, including children. 
Appropriate adaptation of effective 
regulation and control measures to 
different circumstances is required. 
However, the large numbers of 
workers who continue to be exposed 
to low levels of occupational carcino-
gens and who will contribute to the 
total occupational cancer burden 
must not be forgotten. Female work-
ers are particularly affected; many 
are employed in service industries 
where low levels of many carcino-
gens, including asbestos, occur. 
Concurrent exposure to multiple car-
cinogens is of concern. Protection 
measures for one carcinogen may 
also simultaneously reduce others – 
for example, measures to reduce 
general dust; these will also poten-
tially reduce non-malignant occupa-
tional disease, such as respiratory 
ill health. A concerted international 
effort is required to prioritize strate-
gies to reduce occupational cancer 
in all workplaces where exposure to 
known carcinogens is still occurring.
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Table B2.7.2. Measures to control workplace exposures to occupational carcinogens
Reduction method Examples of good practice
Worker education Provide information and training on all workplace carcinogens and the use of appropriate control 
methods.
Use information media (e.g. posters, leaflets, data sheets) imaginatively and strategically.
Safer occupational practices Design and operate effective and reliable processes and activities to minimize exposure.
Provide safe storage, handling, transportation, and disposal facilities.
Use suitable personal protective equipment.
Surveillance Design and use procedures for regular measuring and monitoring of carcinogens in the workplace, 
including accidental high exposures.
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illustration, recent estimates have 
been in the range of 4–8% of all 
cancers attributable to occupation-
al cancer risk factors in developed 
countries [5,6,7], with higher fractions 
for lung cancer than for other cancers 
[6]. Estimates for other areas of the 
world are more speculative [8].
In developed countries, the hey-
day of dirty, smoky industrial work-
places was the first half of the 20th 
century. As a result of many social, 
economic, and technological forces 
in the past 50 years, in developed 
countries there have been declines 
both in the numbers of workers in-
volved in “dirty” blue-collar work 
and in the concentration levels of 
pollutants in typical workplaces. In 
developing countries, however, the 
picture is reversed. There, indus-
trial activities have undergone rapid 
growth, often in the absence of mean-
ingful occupational hygiene control 
measures. Nor is there an infrastruc-
ture to conduct research into possi-
ble hazards in those environments. 
If the occupational environment in 
developing countries continues to 
be poorly regulated, a significant 
increase in occupational cancer 
there may be expected in the com-
ing decades.
Prevention
The designation of an agent as carci-
nogenic is an important public health 
statement, as well as a scientific one. 
Such a designation usually has im-
plications for engineering and/or in-
dustrial hygiene measures to reduce 
or eliminate occupational exposure 
to the agent. There are many pos-
sible ways in which exposure to an 
agent may be prevented or at least 
reduced, depending on the agent and 
the nature of the industrial or occu-
pational process in which the agent 
is used or produced (see “Preventing 
occupational cancer: successes and 
failures”). Sometimes one or another 
of the following classes of measures 
can be adopted: substitution of one 
type of raw material for another, 
modification or mechanization of an 
industrial process, and/or improved 
ventilation and/or the use of personal 
protective equipment. In addition to 
protecting workers, the designation of 
a carcinogen may trigger the need to 
exercise better control of emissions 
of that carcinogen into the atmo-
sphere, water, or soil, or changes to 
policies for marketing consumer and 
other products.
All of these policies and proce-
dures would be facilitated through 
precise and reliable data on the 
magnitude of risks associated with 
different agents, and on the nature 
of dose–response relationships. 
Unfortunately, such information is 
not always available, or not in a form 
that facilitates intervention. Even the 
qualitative assessment of carcino-
genicity is often rendered difficult 
by the fragility of data on exposure 
histories of workers. For quantitative 
risk estimation, the data sources are 
even more fragile, especially as the 
statistical modelling often requires an 
estimate of the exposure situation in 
the remote past. Thus, even if certain 
workers are known to have experi-
enced an excess risk of cancer in the 
past, it is challenging to derive reli-
able estimates as to whether current 
workers, known to be exposed to dif-
ferent, often lower, levels of specified 
agents, would also be at risk. Equally 
challenging is the goal of determining 
a level of exposure such that carcino-
genic risk is virtually eliminated.
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Summary
• Exposure to all types of ionizing 
radiation, from both natural and 
man-made sources, increases 
the risk of various types of ma-
lignancy; the risk is higher if the 
exposure occurs early in life.
• Cancer incidence rates among 
irradiated patients, workers in 
nuclear plants, and others un-
derpin current consensus on the 
absence of a threshold for the 
induction of cancers by radia-
tion and presumption of a linear 
dose–response relationship.
2.8
2 ETIOLOGY
Radiation:
ionizing, ultraviolet, 
and electromagnetic
Ausrele Kesminiene
Joachim Schüz
Bruce K. Armstrong (reviewer)
Sarah C. Darby (reviewer)
Fig. 2.8.1. The electromagnetic spectrum. The diagram shows several important divisions based on the properties and applica-
tions of the different frequencies: pale blue, extremely low-frequency; orange, radiofrequency; green, microwave; red, infrared; 
dark blue, ultraviolet; yellow, X-ray.
• Exposure to ultraviolet radiation – 
both from the sun and from 
tanning devices – is established 
to cause all types of skin can-
cers, including melanoma. Public 
health campaigns discourage de-
liberate sun exposure and speci-
fy options for sun protection.
• Associations between extremely 
low-frequency magnetic fields 
and cancer are restricted to in-
creased risk of childhood leukae-
mia, where a causal relationship 
has not been recognized.
• Associations between heavy 
use of mobile phones and cer-
tain brain cancers have been 
observed, but causal interpreta-
tion is controversial; more data 
are needed, particularly on long-
er-term use of mobile phones.
Natural and man-made sources gen-
erate radiant energy in the form of 
electromagnetic waves. These are 
characterized by their wavelength, 
frequency, or photon energy. The 
electromagnetic spectrum extends 
from static (non-alternating) electric 
and magnetic fields to low-frequency 
electric and magnetic fields (low en-
ergy; long wavelength), intermediate 
and radiofrequency electromagnetic 
fields, microwaves, optical radiation 
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(infrared, visible light, ultraviolet ra-
diation), and ionizing radiation (high 
energy; very short wavelength) 
(Fig. 2.8.1). The interaction of vari-
ous types of radiation with biological 
systems is generally well understood 
on a cellular level and, when estab-
lished, is determined by the intensity 
of the radiation, the related energy, 
and the energy absorbed by the ex-
posed tissue. Ionizing radiation and 
ultraviolet radiation are known to 
cause cancer, but questions remain 
about dose-related effects, suscep-
tibility, and mechanisms.
Ionizing radiation
By definition, ionizing radiation is 
sufficiently energetic to remove oth-
erwise tightly bound electrons from 
atoms. Such radiation can be in the 
form of electromagnetic rays, such 
as X-rays or γ-rays, or in the form of 
subatomic or related particles, such 
as protons or neutrons, as well as 
α-particles and β-particles. Human 
exposure to environmental ionizing 
radiation is unavoidable [1].
Sources and exposures
Natural radiation
For the vast majority of people, expo-
sure from natural sources accounts 
for most of the total annual dose 
of ionizing radiation (Fig. 2.8.2). 
The two major sources of natural 
radiation are cosmic rays and ra-
dionuclides originating from the 
Earth’s crust, radiation from which 
is referred to as terrestrial radiation. 
Radionuclides are everywhere – in 
the ground, rocks, building materials, 
and drinking-water, as well as in the 
human body itself (sometimes desig-
nated as internal sources). Inhalation 
of radon gas, which arises from the 
decay of radium-226, is the leading 
source of natural ionizing radiation 
exposure in humans, and this source 
is responsible for nearly half of the 
average annual dose.
Man-made sources
The greatest contribution to ionizing 
radiation exposure from man-made 
sources is medical radiation. Other 
man-made sources of exposure 
include consumer products, fall-
out from weapons testing, nuclear 
accidents (as exemplified by the 
Chernobyl disaster), routine releas-
es from nuclear installations, and 
occupational exposure. Exposures 
in the course of medical care arise 
from certain diagnostic procedures, 
such as radiography and computed 
tomography (CT), or as a conse-
quence of treatment, most common-
ly during radiotherapy for cancer. In 
high-income countries, medical radi-
ation exposure is increasing rapidly 
due to expansion in use of CT, angi-
ography, and radiographically con-
trolled interventional procedures. In 
some countries, average exposure 
from medical radiation now exceeds 
that from natural sources.
Cancer causation
Ionizing radiation is one of the 
most intensely studied carcinogens 
[1]. Evidence that ionizing radia-
tion can cause human cancer has 
come from the follow-up of patients 
therapeutically irradiated for cancer 
and for non-malignant conditions 
including ankylosing spondylitis 
and tinea capitis. This evidence is 
complemented by epidemiological 
studies involving people exposed 
to ionizing radiation as a result of 
nuclear accidents and atmospheric 
nuclear test sites and, most nota-
bly, thermonuclear warfare in the 
Japanese cities of Hiroshima and 
Nagasaki. Lately, evidence on the 
carcinogenic effects of ionizing ra-
diation has emerged from studies 
on populations with protracted low-
dose radiation exposures in occu-
pational settings and also from pa-
tients who have undergone medical 
diagnostic procedures. These data 
are matched by tumorigenesis evi-
dent in animal bioassays.
A variety of mechanistic investi-
gations have been made to evaluate 
the effects of different types of ion-
izing radiation, centred on the effects 
of variation in dose and exposure 
pattern, and with reference to cel-
lular and molecular end-points. The 
energy-deposition characteristics of 
all sources of ionizing radiation cover 
Fig. 2.8.2. Annual per capita effective dose of ionizing radiation to the global population 
(1997–2007) due to all sources, in millisievert (mSv). Per caput, per unit of population.
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a wide variety of molecular damage, 
specifically indicating DNA damage 
as the biological determinant of out-
come from exposure [2,3]. However, 
only a small fraction of such changes 
result in malignant transformation. 
The processes through which cells 
harbouring DNA damage may give 
rise to neoplasia are not fully under-
stood, although a basis for mutation 
is evident. However, demonstration 
of epigenetic effects and the role 
played by genomic instability and 
effects evident in surrounding cells 
not subject to radiation damage, so-
called bystander effects, all attest 
to biological complexity. In addition, 
host factors such as age, sex, im-
mune status, and genetic variations 
in specific genes may determine 
susceptibility.
X-radiation and γ-radiation
The study of the survivors of the ther-
monuclear bombings in Hiroshima 
and Nagasaki holds an important 
place in radiation epidemiology. The 
survivors were exposed primarily to 
γ-radiation, although there was also 
a neutron contribution. Leukaemia 
was the first cancer consequent 
upon the radiation exposure in this 
cohort [4] and exhibited the highest 
relative risk – more than 5-fold – of 
any cancer. Analyses of leukaemia 
mortality during 1950–2000 estab-
lished that the excess risk was larg-
est among those exposed at younger 
ages, but the risk decreased more 
rapidly than for those exposed later 
in life [5]. Approximately 11% of the 
solid cancer cases among survivors 
of detonations who were exposed 
to 0.005 Gy or more are thought to 
have been caused by the radiation. 
Significant radiation-associated in-
creases in incidence occurred for 
multiple cancers, including those of 
the oral cavity, oesophagus, stom-
ach, colon, lung, breast, bladder, 
nervous system, and thyroid, as well 
as non-melanoma skin cancer [6].
In a large IARC study of nuclear 
industry workers from 15 countries 
exposed to protracted low-dose 
radiation, a statistically significant 
positive dose–response associa-
tion was evident for lung cancer 
mortality; no other specific cancer 
category demonstrated a statistical-
ly significant dose–response trend 
[7]. A study of the United Kingdom 
National Registry for Radiation 
Workers, which included many 
workers from the 15-country study 
but with a longer period of obser-
vation, found a positive association 
between radiation dose and mortali-
ty due to leukaemia excluding chron-
ic lymphocytic leukaemia, and also 
between radiation dose and mortal-
ity due to all malignant neoplasms 
excluding leukaemia. Similar results 
were recorded in analyses of inci-
dence of leukaemia and all malig-
nant neoplasms [8].
Excesses of childhood leukae-
mia incidence in populations near 
nuclear installations in the United 
Kingdom, Germany, France, and 
other countries have been recorded 
[9], but in the absence of information 
on other major causes of childhood 
leukaemia, which might confound 
possible exposure to ionizing radia-
tion in these environments, the cor-
rect interpretation of these findings 
is problematic [10].
Recent increases in the rates 
of CT use, which account for rela-
tively high radiation doses in a broad 
cross-section of the community 
compared with doses attributable 
to conventional radiography, have 
raised health concerns despite the 
substantial immediate benefit of 
such scans to the individual patient 
when clinically indicated. In 2012, 
the first results were published from 
a historical cohort study of more than 
175 000 patients without previous 
cancer diagnoses who were exam-
ined with CT scans in Great Britain 
[11]. The study reported a positive 
association between radiation dose 
from CT scans and leukaemia and 
brain tumours. Potential increases 
in future cancer risk, attributable to 
the rapid expansion in CT use, have 
encouraged the design of new CT 
scanners with dose-reduction op-
tions, as well as increased aware-
ness among medical practitioners 
of the need to limit use of CT scans 
to situations involving a clear medi-
cal benefit and to optimize CT radia-
tion doses, particularly for paediat-
ric patients. Optimization involves 
keeping radiation exposure as low 
as reasonably achievable for every 
examination. Various modality- and 
procedure-specific techniques are 
available, although they are not al-
ways used.
Fig. 2.8.3. A technician at the University of Washington Medical Center, in Seattle, 
prepares a patient for a positron emission tomography-computed tomography 
(PET-CT) scan.
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An IARC announcement that made waves
Robert A. Baan
In the early evening of Tuesday 
31 May 2011, a Working Group 
of experts invited by the IARC 
Monographs Programme concluded 
what had become widely known as 
the “mobile phone radiation meeting”. 
Although the Working Group decid-
ed on a broad evaluation of “radio-
frequency electromagnetic fields” – 
placing this agent in Group 2B, 
possibly carcinogenic to humans – 
the post-meeting media attention 
was focused almost exclusively on 
two sets of epidemiological data 
that showed a slight increase in the 
risk for glioma – a malignant type of 
brain cancer – among heavy users 
of wireless and cordless telephones. 
With 6 billion such users across the 
globe, never in the history of the 
IARC Monographs had an evalua-
tion touched so many.
Indeed, the highest human ex-
posure to radiofrequency radiation 
comes from a functioning mobile 
phone held against the ear during a 
voice call. Holding a mobile phone 
against the head can result in rela-
tively high exposures in the brain, de-
pending on the position of the phone 
and its antenna, and the quality of the 
link with the base station: the better 
the connection, the lower the energy 
output from the phone. It is of interest 
to note that modern, third-generation 
(3G) phones emit, on average, about 
1% of the energy emitted by the GSM 
(2G) phones that were in use when 
the above-mentioned epidemiological 
studies were conducted.
Also considered by the Working 
Group – but not mentioned in the 
media – were single-study findings 
of leukaemia or lymphoma among 
workers in plastic sealing and in ra-
dar maintenance, where exposures 
to radiofrequency fields are relatively 
high as well. In addition, studies in 
experimental animals showed ef-
fects with a variety of exposure sce-
narios and frequency ranges, which 
led the Working Group to decide not 
to limit the evaluation to the two nar-
row frequency bands used for wire-
less communication, but to define the 
agent as “radiofrequency electromag-
netic fields”. This being so, the hazard 
evaluation also encompasses expo-
sures associated with, for example, 
base-station antennae, local area 
networks (Wi-Fi), radio or television 
broadcast antennae, and smart me-
ters. Because exposures in these 
cases are 3–4 orders of magnitude 
lower than those from mobile phones, 
the ensuing risk from these sources is 
likely to be much less. Nonetheless, 
this latter point has remained a major 
issue in the continuing debate since 
the IARC evaluation was announced.
Prospective epidemiological stud-
ies – with accurate exposure assess-
ment – still in progress now focus 
on possible effects of mobile phone 
use, also among youngsters. A large 
cancer bioassay in rodents is be-
ing conducted by the United States 
National Toxicology Program. Also, 
the search for a plausible mechanism 
continues, seeking complementary in-
formation to that from the epidemio-
logical findings.
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Internalized radionuclides
Internalized radionuclides that emit 
α-particles and β-particles are also 
carcinogenic to humans. For most 
people, exposure to ionizing radia-
tion from inhaled and tissue-depos-
ited radionuclides is mainly from 
naturally occurring radon-222. The 
epidemiological evidence that radon 
is a cause of lung cancer in humans 
is derived largely from cohort stud-
ies of underground miners who were 
exposed to high levels of radon in the 
past [12]. Evidence has subsequently 
emerged from case–control studies 
in North America, Europe [13], and 
China [14] that environmental radon 
exposure in buildings, and especially 
in homes, acts as a cause of lung 
cancer in the general population. 
Until recently, naturally occurring ra-
diation was perceived as unalterable. 
However, it has now been shown that 
low radon concentrations can usually 
be achieved very cheaply if appro-
priate radon control measures are 
installed in new buildings. Several 
national programmes and interna-
tional recommendations, including 
a WHO Handbook [15], were de-
signed to provide recommendations 
on reducing cancer risk from radon, 
together with policy options.
Another source of exposure to 
internalized radionuclides for rel-
evant workers and for the general 
community has been the occurrence 
of accidents and other releases from 
nuclear power plants. The largest 
nuclear accident in history occurred 
on 26 April 1986 at the Chernobyl 
nuclear plant in northern Ukraine. 
The Chernobyl accident resulted in 
a large release of radionuclides – 
of which the most important were 
iodine-131 and caesium-137 – 
that were deposited over a very 
wide area, particularly in Belarus, 
the western part of the Russian 
Federation, and Ukraine. In a large 
case–control study [16], exposure 
to iodine-131 in childhood was as-
sociated with an increased risk of 
thyroid cancer: for a dose of 1 Gy, 
the estimated odds ratio of thyroid 
cancer varied from 5.5 (95% confi-
dence interval [CI], 3.1–9.5) to 8.4 
(95% CI, 4.1–17.3), depending on the 
risk model.
Ultraviolet radiation
Sources and exposures
Solar radiation is the main source of 
human exposure to ultraviolet radia-
tion. In addition to this natural source, 
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tanning lamps and beds are a com-
mon source of exposure. Ultraviolet 
radiation is conventionally classified 
into three types: UVA (wavelengths 
of 315–400 nm), UVB (280–315 nm), 
and UVC (100–280 nm). An intact 
ozone layer in the atmosphere ab-
sorbs almost all UVC, as well as ap-
proximately 90% of UVB. Because 
UVA radiation is less blocked by the 
ozone layer, the radiation reaching 
the Earth’s surface is largely com-
posed of UVA (95%), with just 5% 
UVB. The level of solar ultraviolet 
radiation exposure at the Earth’s sur-
face varies with latitude, altitude, time 
of day, time of year, cloud cover, other 
atmospheric factors (specifically in-
cluding air pollution), and reflection 
from nearby surfaces (e.g. snow, 
water). Tanning lamps and beds emit 
mainly UVA, with less than 5% UVB. 
Powerful tanning equipment may be 
a source 10–15 times as intense as 
midday sunlight on the Mediterranean 
Sea [17].
The most common acute skin 
reaction induced by exposure to ul-
traviolet radiation is erythema (skin 
reddening), an inflammatory process 
in the skin, commonly called sun-
burn; tanning is another response. 
Tanning of the skin is predominantly 
triggered by DNA damage induced 
by ultraviolet radiation. UVB is far 
more efficient than UVA in inducing 
a deep, persistent tan and is 1000 
times as potent as UVA in induc-
ing sunburn. Individual reactions to 
ultraviolet radiation depend highly 
on skin type, as classified by indi-
viduals’ susceptibility to sunburn and 
tanning. Generally, people with fair 
skin are more susceptible to sun-
burn and are less likely to develop a 
tan than people with olive or darker 
skin. A tan provides some protection 
against acute effects, and probably 
chronic effects, of sun exposure. 
Exposure to ultraviolet radiation 
also involves beneficial health ef-
fects. Photosynthesis mediated by 
sunlight is the most common source 
of vitamin D; however, it appears that 
rather modest amounts of sun expo-
sure are needed to increase vitamin 
D levels sufficiently [18].
Cancer causation
Exposure to sunlight has been 
shown to be the main cause of skin 
cancer, including cutaneous malig-
nant melanoma, basal cell carcino-
ma, and squamous cell carcinoma 
[19]. Epidemiological evidence has 
established that sunbed use also 
increases skin cancer risk [17]. In 
2009, radiation from tanning devices 
was classified as carcinogenic to hu-
mans (Group 1) [1], the same as the 
earlier evaluation of solar radiation.
Although basal cell carcinoma 
and squamous cell carcinoma rep-
resent the most frequent types of 
skin cancer and contribute to the ris-
ing morbidity, cutaneous melanoma 
causes most skin cancer deaths 
because of its greater tendency to 
metastasize. Over the past 50 years, 
the incidence of all skin cancer types 
has steeply increased in Caucasian 
populations worldwide, with highest 
incidence rates where fair-skinned 
populations are exposed to intense 
ultraviolet radiation in countries 
such as Australia [20]. Individual 
risk varies widely, depending on en-
vironment, behaviour, and genetic 
constitution. In addition to ultraviolet 
radiation, a sun-sensitive phenotype 
and other genetically determined 
characteristics influence risk of skin 
cancer. Melanoma at younger ages 
occurs mainly at body sites with in-
termittent sun exposure, whereas in 
older people, who experience mela-
noma more frequently on the head 
and neck, risk is thought be more 
closely related to chronic exposure 
[21]. Findings from seminal migrant 
studies indicate that childhood is 
a susceptible period for ultraviolet 
carcinogenesis. Risk of squamous 
cell carcinoma occurrence is related 
to the total cumulative lifetime solar 
exposure, whereas that for basal cell 
carcinoma is more complicated and 
is suggested to be more strongly as-
sociated with intermittent exposure 
to ultraviolet radiation.
Prevention
The first sun protection activities 
were initiated in Australia in the 
1960s. In the early 1980s, the prima-
ry prevention campaign “Slip! Slop! 
Slap!” was introduced, advising peo-
ple to slip on a shirt, slop on the sun-
screen, and slap on a hat. In 1988, 
the more comprehensive and broad-
based skin cancer prevention pro-
gramme SunSmart was implement-
ed. Comparable activities, including 
education programmes and public 
awareness campaigns, were imple-
mented starting in the mid-1980s in 
the USA and in several European 
countries (Fig. 2.8.4). Several or-
ganizations, including WHO, have 
developed recommendations about 
indoor tanning. Some jurisdictions 
have established laws banning provi-
sion of commercial sunbed services 
to those under 18 years old.
Electric, magnetic, and 
electromagnetic fields
Sources and exposures
Ubiquitous exposure occurs to ex-
tremely low-frequency electromag-
netic fields due to power transmission 
and the use of electrical appliances, 
and to fields in the radiofrequen-
cy range due to communication 
Fig. 2.8.4. Danish Cancer Society and 
TrygFonden campaign for the preven-
tion of skin cancer (2013): “A little shade 
does not hurt. Reduce your sun between 
12 and 3 pm. Sunscreen is not always 
enough. Use the shade and reduce your 
risk of skin cancer.”
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and broadcasting. Normal residential 
background exposure to extremely 
low-frequency magnetic fields is 
usually below 0.1 µT. A small frac-
tion of households located very close 
to high-voltage power lines or other 
sources can have appreciably higher 
background exposures. Higher but 
short-term exposures occur when 
electrical devices are used and may 
also be experienced in particular cat-
egories of work, such as by electri-
cians and electrical engineers. For 
most people, the highest exposure 
to radiofrequency electromagnetic 
fields occurs when using mobile 
(cell) phones because the source of 
emission is held close to the head. 
Much lower levels of exposure arise 
from transmitters, but field strength 
may exceed 1 V/m even at points 
several kilometres from high-output 
television or radio broadcast trans-
mitters. The number of sources con-
tinues to increase with further use of 
the whole electromagnetic frequency 
spectrum.
Cancer risk
Studies have been conducted in 
residential settings by investigating 
cancer risk in relation to the near-
est overhead high-voltage power 
lines and the resulting magnetic 
fields, as well as in occupational 
settings that involve electrical 
work. Epidemiological studies have 
consistently recorded a positive 
association of extremely low-fre-
quency magnetic fields with child-
hood leukaemia, with an appar-
ently 2-fold higher risk at average 
24-hour exposure levels exceeding 
0.3–0.4 µT (Fig. 2.8.5) [22–25]. 
However, a causal relationship has 
not been established due to the po-
tential for bias and confounding in 
the observational studies and be-
cause supporting evidence from 
experimental studies and mecha-
nistic data are lacking [26]. If a 
causal association did exist, it is 
estimated that < 1–4% of childhood 
leukaemia cases could be attribut-
able to exposure to extremely low-
frequency magnetic fields [27]. The 
2001 IARC Monograph on extremely 
low-frequency magnetic fields clas-
sified them as possibly carcinogenic 
to humans (Group 2B); the evidence 
for other types of malignancy was 
evaluated to be inadequate. Other 
reviews came to similar conclusions 
later [22,28]. Recent studies have 
not shown an effect of exposure to 
extremely low-frequency magnetic 
fields on survival after childhood 
leukaemia [29].
In the 2001 IARC Monograph 
evaluation, extremely low-frequen-
cy electric fields and static electric 
and magnetic fields were consid-
ered not classifiable as to their car-
cinogenicity to humans (Group 3). 
Since 2001, there have been few 
studies relevant to these evalua-
tions and none suggest a basis for 
re-evaluation, as recently reflected 
by an expert panel of the European 
Commission [28].
Radiofrequency electromag-
netic fields have been classified 
as possibly carcinogenic to hu-
mans (Group 2B) (see “An IARC 
announcement that made waves”) 
(Fig. 2.8.6). Case–control studies 
on mobile phone use and cancer 
have reported increased risks of gli-
oma and acoustic neuroma in heavy 
users of mobile phones [30]. A large 
Danish nationwide cohort study of 
mobile phone subscribers did not 
reveal any association with brain tu-
mour risk. Such an increased risk 
was suggested from a series of in-
terrelated case–control studies in 
13 countries, Interphone, in which 
a 40% increased risk for glioma 
and also for acoustic neuroma was 
observed, restricted to the 10% of 
people who were the heaviest users 
of mobile phones. Several factors, 
including inaccuracy and evidence 
of bias in self-reported use, pre-
vented causality being established 
by these studies [31]. Time trends in 
glioma incidence based on Nordic 
countries and the USA exclude any 
large increase in incidence attribut-
able to mobile phone use, albeit with 
reference to a relatively short time 
from initiation of exposure. No asso-
ciation was observed between mo-
bile phone use and other cancers. 
Several studies on occupational 
Fig. 2.8.5. Comparison of results from pooled analyses of epidemiological studies of 
residential exposure to extremely low-frequency magnetic fields and the risk of child-
hood cancer: (A) childhood leukaemia [23]; (B,C) childhood leukaemia [24], excluding 
(B) and including (C) a study from Brazil; and (D) childhood brain tumours [25]. Pooled 
odds ratios and their 95% confidence intervals (vertical axis) are shown by increas-
ing levels of exposure to extremely low-frequency magnetic fields (reference category, 
< 0.1 μT).
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exposure to radiofrequency elec-
tromagnetic fields provide no con-
sistent associations. With regard to 
environmental exposures from trans-
mitters, including television, radio, 
and military transmissions as well as 
mobile phone networks, the evi-
dence is inadequate due to lack of 
high-quality studies with accurate 
individual exposure assessment. 
Some large studies on childhood 
cancer and fields generated by 
high-output television and/or radio 
transmitters reported inconsistent 
or no associations [22]. Few data 
are available for electromagnetic 
fields in the intermediate frequency 
range [28].
Fig. 2.8.6. Mobile phone use has become very popular over the past few decades. 
Studies have been done mainly in relation to mobile phone use causing radiofrequency 
electromagnetic field exposure to the head.
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Summary
• Many known, probable, and 
possible carcinogens can be 
found in the environment, and 
all people carry traces of these 
pollutants in their bodies.
• Air pollution from vehicle 
emissions, power generation, 
household combustion of solid 
fuels, and a range of industries 
includes known carcinogens 
such as diesel emissions, poly-
cyclic aromatic hydrocarbons, 
benzene, and 1,3-butadiene, 
together with inorganic carcin-
ogens such as asbestos, arse-
nic, and chromium compounds. 
Exposure to outdoor air pollu-
tion in general, and specifically 
to particulate matter, causes 
lung cancer. Household com-
bustion of solid fuels causes 
lung cancer and is associated 
with other cancers in many low- 
and middle-income countries.
• In drinking-water, inorganic ar-
senic is a recognized carcino-
gen. Other contaminants, such 
as disinfection by-products, or-
ganic solvents, nitrates, nitrites, 
and some pesticides, may also 
contribute to an increased can-
cer burden.
2.9
2 ETIOLOGY
Pollution of air, 
water, and soil
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• There are wide disparities in ex-
posure, and pollution levels can 
be particularly high in newly and 
rapidly industrializing countries 
where environmental monitoring 
and regulation are less exten-
sive and rigorous.
• Pollution of air, water, and soil 
contributes to the world’s can-
cer burden to differing degrees 
depending on the geographical 
setting.
• Exposure to important sources 
of environmental pollution in 
water and air can be reduced 
by regulatory action and techno-
logical improvements, offering 
considerable promise for reduc-
tion of the burden of cancer and 
other adverse health outcomes.
The impact of pollution on cancer 
development is often described with 
reference to “environmental factors”, 
which may lead to ambiguity. In a 
broad sense, environmental factors 
are implicated in the majority of hu-
man cancers. Environmental factors 
may be understood to encompass 
everything that is not specifically ge-
netic in origin. The term therefore 
includes many significant causes of 
cancer – such as tobacco smoking, 
alcohol consumption, and diet – that 
are also considered lifestyle or 
behavioural factors. Evidence for the 
broad role of environmental factors 
comes from a variety of sources: 
from geographical variations in 
the distribution of the world cancer 
burden, from time trends showing 
increases or decreases in differ-
ent forms of cancer, from studies of 
people migrating from one country 
to another, and from analytical stud-
ies within populations that have both 
high and low exposure to selected 
environmental factors.
However, the term “environment” 
may also identify a prominent sub-
set of factors that are distinguished 
from lifestyle factors because the 
individual has little, if any, control 
over exposure to these factors. As 
affecting all in the community, ex-
posure to pollution occurs because 
of the chemical contamination of 
the air breathed, the water and food 
consumed, and the soil, sediment, 
surface waters, and groundwater 
that surround living space. Some, 
such as polycyclic aromatic hydro-
carbons generated by the combus-
tion of fossil and biomass fuels, are 
the direct result of human activity, 
while others, such as aflatoxins that 
contaminate foods, are generated 
by natural processes involving little 
or no human activity (see Chapter 
2.11). Regardless, many carcinogens 
occur in the environment, and all 
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people carry traces of environmental 
pollutants in their bodies.
The cancer risks from environ-
mental pollution are challenging to 
study. People are exposed to hun-
dreds, if not thousands, of chemi-
cals and other agents through their 
environment, and environmental 
exposure assessment, a neces-
sary component of such studies, 
can be exceedingly complex. Some 
environmental pollutants are widely 
dispersed across the globe, while 
others are concentrated in small 
geographical areas near specific 
industrial sources. This results in 
wide disparities in the level of ex-
posure to environmental pollutants. 
Some population groups may face 
high risks that do not have a no-
ticeable impact on national cancer 
incidence statistics. IARC has 
identified environmental pollutants 
that are known to cause cancer in 
humans (Table 2.9.1) (http://mono 
graphs.iarc.fr/ENG/Classification/
index.php).
Asbestos
Asbestos is one of the best charac-
terized causes of human cancer in 
the workplace (see Chapter 2.7). The 
carcinogenic hazard associated with 
asbestos fibres has been recognized 
since the 1950s. Non-occupational 
exposure to asbestos may occur do-
mestically and as a consequence of 
localized pollution. People who live 
with asbestos workers may be ex-
posed to asbestos dust on clothes. 
The installation, degradation, remov-
al, and repair of asbestos-containing 
products in the context of household 
maintenance represents another 
mode of residential exposure. Whole 
neighbourhoods may be exposed to 
asbestos as a result of local asbes-
tos mining or manufacturing. Some 
parts of the world also experience 
asbestos exposure as a result of the 
erosion of asbestos or asbestiform 
rocks.
In common with occupational ex-
posure, exposure to asbestos due to 
residential circumstances results in 
an increased risk of mesothelioma 
[1]. Likewise, non-occupational ex-
posure to asbestos may cause lung 
cancer, particularly among smokers 
[2]. A high incidence of mesothelio-
ma as a consequence of neighbour-
hood exposure is evident among 
inhabitants of villages in Turkey 
where houses and natural surround-
ings contain the mineral erionite. All 
forms of asbestos are carcinogenic 
to humans [3], and stopping the use 
of all forms of asbestos is the most 
efficient way to eliminate asbestos-
related diseases.
Outdoor air pollution
Emissions from multiple sources, 
including motor vehicles, industrial 
processes, power generation, and 
the combustion of household solid 
fuel, pollute the ambient and indoor 
air in all populated regions of the 
globe [4]. The precise chemical and 
physical features of air pollution, 
which comprises hundreds of indi-
vidual chemical constituents, vary 
around the world, reflecting differ-
ences in the sources of pollution and 
Table 2.9.1. Environmental pollutants classified by IARC as Group 1, carcinogenic to humans
Agent Cancer site/Cancer Main context of pollution for general population
Arsenic and inorganic arsenic compounds Lung, skin, bladder Water
Asbestos (all forms) Larynx, lung, mesothelioma, ovary Atmosphere
Benzene Acute non-lymphocytic leukaemia Atmosphere (engine emissions)
1,3-Butadiene Leukaemia, lymphoma Atmosphere
Chromium (VI) compounds Lung Water, soil
Diesel engine exhaust Lung Atmosphere (engine emissions)
Erionite Mesothelioma Atmosphere (particular regions only)
Ethylene oxidea Breast, lymphoid tumours Atmosphere (indoor)
Formaldehyde Nasopharynx, leukaemia Atmosphere (indoor, outdoor)
Household coal combustion (indoor emissions) Lung Atmosphere (indoor)
Outdoor air pollution Lung Atmosphere
Particulate matter in outdoor air pollution Lung Atmosphere
Polychlorinated biphenyls Skin Food, atmosphere (indoor)
Radon and its decay products Lung Atmosphere (indoor)
Silica dust, crystalline Lung Atmosphere
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD) All cancers combined Food, soil
Tobacco smoke, second-hand Lung Atmosphere (indoor)
Trichloroethylene Kidney Water, food
a Upgraded to Group 1 based on mechanistic data; limited evidence of carcinogenicity in humans.
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in meteorology, but these polluting 
mixtures contain specific chemicals 
or mixtures known to be carcinogen-
ic to humans (Table 2.9.1) [5].
People are exposed to air pol-
lution mixtures containing carcino-
gens that may cause lung cancer or 
cancers at other sites in a variety 
of settings, or micro-environments, 
both indoor and outdoor. A given 
individual’s total personal exposure 
to such mixtures or to specific car-
cinogens is a function of the time 
spent in different micro-environments 
characterized by a relatively homo-
geneous concentration of the air pol-
lution mixture or specific carcinogen. 
The actual dose of pollutants to the 
lung or other organs depends further 
on physiological characteristics such 
as pulmonary minute ventilation, 
metabolism, and rate of elimination. 
Typically, epidemiological studies rely 
solely on estimates of exposure to air 
pollution mixtures or specific carcino-
gens in single micro-environments, 
such as place of residence, to esti-
mate the risk of cancer [5].
Ambient air contains a variety of 
known human carcinogens, including 
polycyclic aromatic hydrocarbons, 
1,3-butadiene, benzene, inorganic 
compounds such as arsenic and 
chromium, and radionuclides. Some, 
such as polycyclic aromatic hydrocar-
bons, are present as part of complex 
mixtures such as diesel emissions, 
which are themselves carcinogenic 
[6]. Such mixtures often comprise 
carbon-based particles to which the 
organic compounds are adsorbed, 
sulfuric acid in particle form, and 
photochemical oxidants. Complex 
air pollution mixtures are character-
ized for purposes of both regulatory 
policy and scientific research in terms 
of indicators, for example, the mass 
Fig. 2.9.1. A traffic police officer observes exhaust pouring from an automobile in Salem, 
Tamil Nadu, India. Motor vehicles are a recognized source of air pollution worldwide.
Fig. 2.9.2. Estimated annual average atmospheric PM2.5 (particulate matter < 2.5 μm in diameter) concentrations (μg/m3), for 2005. 
An estimated 89% of the world’s population live in areas where the WHO air quality guideline (10 μg/m3 PM2.5 annual average) is 
exceeded.
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Bisphenol A and cancer
David Melzer and Tamara S. Galloway
The rising incidence of certain re-
productive cancers since the 1970s 
has been attributed to multiple pos-
sible factors, including exposure to 
endocrine disrupting agents in the 
environment. One widely studied 
compound is bisphenol A. This com-
pound was first synthesized in the 
1930s as an estrogen and is used 
as a loosely bound monomer in the 
production of polycarbonate plastic 
and in the epoxy resins lining food 
and beverage cans. More than 90% 
of people in the USA, Europe, and 
Asia are exposed to bisphenol A [1], 
probably through ingestion of bis-
phenol A-contaminated food and liq-
uids. There is growing evidence from 
epidemiological and laboratory stud-
ies that exposure to this compound 
at levels found in the general popula-
tion, about 0.2–20 ng/ml, may be as-
sociated with adverse human health 
effects. Exposure to bisphenol A in 
utero or during childhood has also 
been associated with reproductive 
and developmental abnormalities 
[2], whereas in adults there is pro-
spective evidence of its association 
with cardiovascular disease [3].
Whether exposure to bisphenol A 
is linked to cancer incidence is far from 
clear. Work in the 1980s by the United 
States National Toxicology Program 
based on laboratory studies with ro-
dents found that the compound was 
not a robust carcinogen in the con-
text of adult exposure and supported 
a recommended maximum daily dose 
of 50 µg/kg/day as safe for humans 
(www.epa.gov/iris/subst/0356.htm). 
Since then, hundreds of studies have 
shown that bisphenol A disrupts the 
hormone system and causes changes 
that mirror properties of cancer cells 
at concentrations within current limits 
of exposure, although this evidence 
is contested [4,5]. Potential modes of 
action proposed for a carcinogenic 
effect include estrogenic endocrine 
disruption, promotion of tumorigenic 
progression, genotoxicity, and de-
velopmental reprogramming that 
increases susceptibility to other car-
cinogenic events [6].
Bisphenol A binds to and activates 
both types of estrogen receptor (ERα 
and ERβ), albeit with weaker affinity 
than estradiol itself [7]. Additional cel-
lular targets have emerged that may 
shed further light on the potential link 
between this pollutant and cancer 
induction. For example, binding of 
bisphenol A to G protein-coupled 
receptors has been implicated in the 
proliferation of breast cancer cells and 
recruitment of cancer-associated fi-
broblasts [8]. Recent epidemiological 
studies have shown that exposure 
to bisphenol A is associated with 
enhanced expression of the orphan 
nuclear receptor estrogen-related re-
ceptor α (ERRα) in white blood cells 
in vivo [9]. ERRα is upregulated in ad-
vanced breast cancer cells and has 
been correlated with poor prognosis 
and the promotion of tumour growth 
[10]. 
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concentration of fine particles (par-
ticulate matter < 2.5 µm in diameter 
[PM2.5]) and ozone. The combustion 
of fossil fuels and biomass for power 
generation, cooking, and transpor-
tation is the source of most of the 
organic and inorganic compounds, 
acids, and oxidants, and contributes 
heavily to particulate air pollution in 
most populated areas [4,7].
Levels of ambient air pollutants, 
including PM2.5, have been declining 
steadily in high-income countries 
over the past 20 years, although 
air pollution levels remain elevated 
in many urban areas and current 
levels are associated with a range 
of adverse health outcomes [4,7]. 
Fig. B2.9.1. Many food and liquid con-
tainers, including baby bottles, are made 
of polycarbonate or have a lining that con-
tains bisphenol A. Studies have shown 
that bisphenol A may increase cancer 
risk.
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Air quality has deteriorated, how-
ever, in some middle-income coun-
tries, including China and India, as 
a consequence of industrialization 
and an increased number of motor 
vehicles. The uncontrolled burning 
of low-quality biomass fuels and coal 
contributes to poor air quality in low- 
and middle-income countries [8]. 
In 2005, estimated population-
weighted average annual levels of 
PM2.5 in East Asia were 4 times those 
in high-income North America, and 
89% of the world’s population lived 
in areas where the WHO air quality 
guideline for exposure to PM2.5 was 
exceeded (Fig. 2.9.2) [7]. In the USA, 
hazardous air pollutants, or air tox-
ics, are reported to exceed applicable 
reference concentrations, and have 
been estimated to increase cancer 
risk [9].
Exposure to air pollution mixtures 
has effects at the genetic and cellu-
lar level that are considered likely to 
increase cancer risk. Urban air pollu-
tion mixtures are mutagenic in in vivo 
assays and carcinogenic in rodents, 
these effects being largely mediated 
by combustion products [10]. Studies 
in human populations have identified 
markers of genetic damage and cell 
mutation associated with exposure to 
combustion emissions [11].
Long-term exposure to ambi-
ent air pollution is associated with 
an increased risk of lung cancer. 
Populations in urban areas with el-
evated ambient levels of polycyclic 
aromatic hydrocarbons and other 
Fig. 2.9.3. The Niederaussem brown-coal power plant near Cologne, Germany. Coal-
burning plants release carbon dioxide, fine particles, nitrogen oxide, and mercury, which 
can have a serious impact on public health. The coal ash produced by these plants 
contains contaminants such as arsenic, a known carcinogen.
Fig. 2.9.4. Proportion of the national population (%) estimated by WHO to use solid fuels for cooking, for 2010. Common solid fuels 
include wood, charcoal, dung, and crop residues, which are not only environmentally unsustainable but also harmful to the local 
communities. In homes without proper ventilation, exposure to indoor smoke poses serious health threats.
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pollutants experience higher rates 
of lung cancer than rural popula-
tions, independent of tobacco smok-
ing. Higher rates of lung cancer 
are also associated with long-term 
residence near stationary air pollu-
tion sources such as smelters, incin-
erators, and power plants, and with 
residential proximity to busy roads 
[5,12]. Increased risk has been re-
ported in studies of populations 
both in Europe and the USA and in 
countries in Asia [5,8,13]. Large co-
hort studies of long-term exposure 
to PM2.5 in the USA and Europe 
that controlled for tobacco smok-
ing report 6–36% increases in lung 
cancer associated with each 10 µg/m3 
increase in PM2.5, an increment well 
within the range of exposure in North 
America and Europe, although the 
highest recorded levels occur in 
Saharan Africa, the Middle East, and 
Central Asia (Fig. 2.9.2). These stud-
ies also report an increased risk of 
lung cancer in never-smokers [14,15]. 
Biomarkers of air pollution exposure 
and genetic effects have been used 
in some epidemiological studies to 
link ambient exposure with lung can-
cer occurrence [16].
IARC recently reviewed the 
evidence summarized above and 
concluded that long-term exposure 
to outdoor air pollution, and specifi-
cally particulate matter in outdoor 
air, causes lung cancer. Exposure to 
outdoor air pollution is also associ-
ated with an increased risk of blad-
der cancer [17]. Exposure to ambient 
PM2.5 has recently been estimated to 
have contributed to 3.2 million prema-
ture deaths worldwide in 2010, due 
largely to cardiovascular disease, and 
223 000 deaths from lung cancer. 
More than half of the lung cancer 
deaths attributable to ambient PM2.5 
occurred in China and other countries 
in East Asia [18].
Comprehensive air quality man-
agement programmes, using regu-
latory approaches and adoption of 
cleaner technologies for transpor-
tation, power generation, industrial 
production, and waste management 
have led to improvements in popula-
tion health [19,20].
Air pollution by chlorofluoro-
carbons is believed to be indirectly 
responsible for increases in skin 
cancer rates around the globe [21]. 
These chemicals, including carbon 
tetrachloride and methyl chloroform 
and other halons, are emitted from 
home air conditioners, foam cush-
ions, and many other products. 
Chlorofluorocarbons are carried by 
winds into the stratosphere, where 
the action of strong solar radiation 
releases chlorine and bromine atoms 
that react with, and thereby eliminate, 
molecules of ozone. Depletion of the 
ozone layer is believed to be respon-
sible for global increases in ultraviolet 
B (UVB) radiation (see Chapter 2.8).
Indoor air pollution
Household air pollution
Despite declines over the past 
30 years in the percentage of the 
global population that burn solid 
fuels, either coal or biomass, for 
household cooking or heating, 
the number of people exposed 
has remained largely unchanged 
at 2.8 billion, due to population 
growth [22]. The proportion of the 
population estimated by WHO to 
have been cooking with solid fuels in 
2010 is highest in sub-Saharan Africa 
and South and East Asia (Fig. 2.9.4). 
Indoor burning of solid fuels in un-
ventilated homes results in exposures 
to levels of fine particles (PM2.5) and 
other health-damaging air pollutants, 
such as carbon monoxide, that are 
many times ambient levels, and the 
components of this indoor smoke 
include known human carcinogens 
such as polycyclic aromatic hydrocar-
bons, formaldehyde, and benzene. 
Household combustion of solid fuels 
also contributes to outdoor air pollu-
tion in settings where solid fuels are 
widely used [18].
Exposure to household air pollu-
tion from solid fuel use has recently 
been estimated to have contributed 
to 3.5 million premature deaths 
worldwide in 2010, due largely to 
cardiovascular disease and acute 
and chronic respiratory disease, and 
126 000 deaths from lung cancer due 
to household coal burning [18]. Indoor 
burning of coal causes lung cancer in 
humans, and indoor burning of bio-
mass may as well [23]. Exposure to 
emissions from indoor coal burning is 
Fig. 2.9.5. On a cold day, a mother in Gatlang, a village in the Rasuwa district, Nepal, 
keeps her baby warm in front of a traditional wood stove. Indoor burning of solid fuels 
in unventilated homes results in exposures to levels of fine particles and other health-
damaging air pollutants such as carbon monoxide.
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Pesticides and cancer
Laura E. Beane Freeman
Pesticides encompass a large 
and diverse number of chemicals 
designed to kill pests, including 
weeds, insects, rodents, algae, and 
moulds, for agricultural, residential, 
and public health purposes. These 
chemicals make important contribu-
tions to production and protection of 
agricultural commodities and control 
of insect disease vectors. They also 
present potential hazards to human 
health.
Unlike many other chemical 
agents, pesticides are designed for 
release into the environment, and 
exposure can occur occupationally, 
through environmental bystander 
exposure, and through ingestion 
of foods containing pesticides or 
pesticide residues. In 2007, the lat-
est year for which estimates are 
available, 5.2 billion pounds (2.4 
million tonnes) of pesticide active 
ingredient were applied in the world 
(http://www.epa.gov/opp00001/
pestsales/07pestsales/usage2007.
htm#3_1). Despite widespread po-
tential exposure, cancer risks as-
sociated with long-term exposure to 
specific pesticides are generally not 
well characterized. Only one group 
of pesticides, inorganic arsenic com-
pounds, and one pesticide contami-
nant, the dioxin TCDD, are classified 
by IARC as Group 1, carcinogenic to 
humans. The fungicide captafol and 
the fumigant ethylene dibromide are 
classified as Group 2A, probably car-
cinogenic to humans, as is occupa-
tional exposure in the application of 
non-arsenical insecticides. However, 
there are several pesticides that are 
listed as Group 3, not classifiable as 
to their carcinogenicity to humans, 
largely due to inadequate evidence 
in humans, and many more that have 
been linked with cancer that require 
further investigation (http://mono 
graphs.iarc.fr/ENG/Classification/
ClassificationsAlphaOrder.pdf).
A few areas where the evidence 
seems to be the strongest at this 
time are highlighted. Several or-
ganochlorine and organophosphate 
insecticides have been linked with 
an increased risk of prostate cancer. 
This is notable since farmers, an oc-
cupationally exposed group, have 
long been reported to have increased 
rates of prostate cancer [1]. Farmers 
also experience increased rates of 
lymphoma, and several reports have 
linked multiple pesticides to increased 
risk at this site, although confirmation 
is required [1]. Finally, a growing body 
of evidence suggests that parental 
exposure to pesticides, particularly 
of the mother during pregnancy, may 
increase the risk of leukaemia in chil-
dren, although data on specific chemi-
cals are largely lacking [2].
Developing accurate assessment 
of pesticide exposure is a major chal-
lenge in epidemiological studies but 
is essential for identifying hazards 
associated with these chemicals. 
Many studies of pesticides and can-
cer have focused on occupational 
exposures, where levels are likely to 
be highest, but it is also important for 
future research to assess effects of 
environmental exposures because of 
the widespread use of these chemi-
cals. Future studies need to evaluate 
specific chemicals and to consider 
potential mechanisms of action to 
support the biological plausibility of 
the epidemiological observations.
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B2.9.2. A crop duster spraying pesti-
cide in California.
associated with a 2-fold increase in 
lung cancer risk [24]. Women are the 
most heavily exposed, and nonsmok-
ing women in some parts of China ex-
perience very high lung cancer rates 
due to indoor coal burning. Indoor ex-
posure to cooking-oil emissions from 
high-temperature frying may cause 
lung cancer. Indoor burning of solid 
fuels has also been associated with 
increased rates of cancer of the up-
per airways.
Improved ventilation of coal com-
bustion emissions and the use of al-
ternative types of stoves with lower 
emissions have been shown to re-
duce lung cancer rates in exposed 
women [24,25]. The use of cleaner 
fuels, such as compressed natural 
gas, is associated with reduced rates 
of lung cancer and other adverse 
health outcomes relative to the use 
of coal and biomass.
Involuntary smoking
Tobacco smoke is an impor-
tant source of indoor air pollution 
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worldwide, and involuntary smok-
ing (exposure to second-hand or 
“environmental” tobacco smoke) 
is carcinogenic to humans (see 
Chapter 2.2).
Water pollution
Disinfection by-products
Access to clean water is one of the 
basic requirements of human health. 
Water quality is influenced by climate 
and weather, the geology of the soil, 
land use patterns, and discharges 
from agriculture and industry. The 
greatest and most immediate con-
cern relates to infectious disease. 
Microbiological contamination of wa-
ter is controlled by disinfection meth-
ods based on chlorine, chloramine, 
or ozone. As a result of the interac-
tion of chlorine with organic chemi-
cals already present, drinking-water 
typically contains chlorination by-
products, some of which may present 
a carcinogenic risk. Chloroform and 
other trihalomethanes are among 
the by-products most commonly 
detected, but not necessarily the 
most threatening to health. Studies 
of bladder cancer and some other 
cancers have suggested increased 
risk associated with consumption 
of chlorinated drinking-water [26]. 
Given the large number of people 
exposed to chlorination by-products, 
however, even a small increase in 
risk would implicate a substantial 
number of cases. It is desirable to 
reduce such by-products without 
reducing the effectiveness of disin-
fection procedures.
Arsenic
Arsenic causes cancers of the skin, 
lung, bladder, and possibly other 
organs [27]. The main source of en-
vironmental exposure to arsenic for 
the general population is contami-
nated drinking-water. High exposure 
to arsenic from drinking-water is 
found around the world, including ar-
eas of Bangladesh, India, Mongolia, 
China, Argentina, Chile, Mexico, and 
the USA. In areas of high arsenic 
content, with concentrations typi-
cally above 100 µg/l, there is strong 
evidence of an increased risk of 
cancers of the bladder, skin, and lung 
after consumption of water with high 
arsenic contamination [27]. The data 
for other cancers, such as those of 
the liver and kidney, are more limited 
but are consistent and suggestive of 
a systemic effect. Given the many 
difficulties of conducting studies in 
areas with arsenic concentrations 
below 100 µg/l, the risks at these 
markedly lower levels are not clear. 
However, given the demonstrated 
risk at higher levels, the possibility 
of increased risk of different types of 
cancer at low exposures is plausible.
Estimates of the cancer burden 
associated with arsenic in drinking-
water have been made for some 
regions of the world. In northern 
Chile, where most of the population 
was exposed to very high levels of 
arsenic in drinking-water from 1955 
to 1970, arsenic might still account 
for 7% of all deaths among those 
aged 30 years and older, given 
the long latency of the effect [27]. 
In Bangladesh, tens of millions of 
people have been exposed to el-
evated levels of arsenic in water, 
and an estimated 6% of all deaths, 
including cancer deaths, are due to 
these exposures [28]. West Bengal, 
India, which has a similar exposure 
profile, may experience a similar 
burden of disease and death [29]. 
About 14 million people in Latin 
America are exposed to arsenic in 
drinking-water above the limit es-
tablished by several national and 
international agencies [30].
Other drinking-water 
contaminants
Several other groups of pollutants of 
drinking-water have been investigat-
ed as possible sources of cancer risk 
in humans. These include organic 
compounds such as chlorinated sol-
vents and pesticides from industrial, 
commercial, and agricultural activi-
ties, and chemicals leached from 
waste sites. Organic pollutants that 
persist in the environment and accu-
mulate in fish, such as polychlorinat-
ed dibenzo-para-dioxin, polychlori-
nated biphenyls, and organochlorine 
pesticides, are of particular concern, 
as is contamination by nitrates and 
nitrites, radionuclides, hormonally 
active compounds, and asbestos. 
For most pollutants, the epidemio-
logical studies are inconclusive; 
however, an increased risk of stom-
ach cancer has been repeatedly 
reported in areas with high nitrate 
Fig. 2.9.6. Water pollution is usually identified with contaminants in water for domestic 
and agricultural use, but marine water may also be at risk. This oil spill occurred in 
the Gulf of Mexico in 2010 after an explosion on Deepwater Horizon, an offshore oil 
drilling unit.
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levels in drinking-water, and there 
is evidence of excess thyroid cancer 
[31].
Soil pollution
A variety of toxic agents, including 
heavy metals, solvents, and persis-
tent organic pollutants such as di-
oxins, contaminate soil, sometimes 
at high concentrations [32]. In local 
regions, such pollution occurs by 
substances produced as waste or 
as other consequences of a particu-
lar mining or industrial process. The 
ranges of concentrations detected 
are specified for particular com-
pounds in the corresponding IARC 
Monograph.
Soil contaminants present a car-
cinogenic risk as a result of being 
vaporized and consequently inhaled, 
or being leached from the soil to con-
taminate water supplies. Accordingly, 
risk of cancer has generally been 
studied in relation to consequential 
air or water pollution, rather than with 
primary reference to particular levels 
of contaminants in soil. However, ac-
cumulation of a variety of pollutants 
via the food-chain, and an estimate 
of any associated burden of disease, 
is being investigated through the 
WHO Foodborne Disease Burden 
Epidemiology Reference Group. 
References
1. Boffetta P (2006). Human cancer from en-
vironmental pollutants: the epidemiological 
evidence. Mutat Res, 608:157–162. http://
dx.doi.org/10.1016/j.mrgentox.2006.02.015 
PMID:16843042
2. HEI Asbestos Literature Review Panel 
(1991). Asbestos in Public and Commercial 
Buildings: A Literature Review and 
Synthesis of Current Knowledge. 
Cambridge, MA: Health Effects Institute-
Asbestos Research.
3. IARC (2012). Arsenic, metals, fibres, and 
dusts. IARC Monogr Eval Carcinog Risks 
Hum, 100C:1–499. PMID:23189751
4. WHO (2006). Air Quality Guidelines. Global 
Update 2005. Geneva: WHO. Available at 
http://www.euro.who.int/__data/assets/
pdf_file/0005/78638/E90038.pdf.
5. Samet JM, Cohen AJ (2006). Air pollu-
tion. In: Schottenfeld D, Fraumeni JF, eds. 
Cancer Epidemiology and Prevention. New 
York: Oxford University Press, pp. 355–381.
6. IARC (2013). Diesel and gasoline engine 
exhausts and some nitroarenes. IARC 
Monogr Eval Carcinog Risks Hum, 105.
7. Brauer M, Amann M, Burnett RT et 
al. (2012). Exposure assessment for 
estimation of the global burden of dis-
ease attributable to outdoor air pollu-
tion. Environ Sci Technol, 46:652–660. 
ht tp://dx.doi.org/10.1021/es2025752 
PMID:22148428
8. HEI International Scientific Oversight 
Committee (2010). Outdoor Air Pollution 
and Health in the Developing Countries 
of Asia: A Comprehensive Review. HEI 
Special Report 18. Boston, MA: Health 
Effects Institute.
9. HEI Air Toxics Review Panel (2007). Mobile-
Source Air Toxics: A Critical Review of the 
Literature on Exposure and Health Effects. 
HEI Special Report 16. Boston, MA: Health 
Effects Institute.
10. Claxton LD, Woodall GM Jr (2007). A review 
of the mutagenicity and rodent carcinogenic-
ity of ambient air. Mutat Res, 636:36–94. 
http://dx.doi.org/10.1016/j.mrrev.2007.01.001 
PMID:17451995
11. Lewtas J (2007). Air pollution combustion 
emissions: characterization of causative 
agents and mechanisms associated with 
cancer, reproductive, and cardiovascular 
effects. Mutat Res, 636:95–133. http://
dx.doi.org/10.1016/j.mrrev.2007.08.003 
PMID:17951105
12. HEI Panel on the Health Effects of Traffic-
Related Air Pollution (2010). Traffic-
Related Air Pollution: A Critical Review 
of the Literature on Emissions, Exposure, 
and Health Effects. HEI Special Report 17. 
Boston, MA: Health Effects Institute.
13. Cao J, Yang C, Li J et al. (2011). Association 
between long-term exposure to outdoor air 
pollution and mortality in China: a cohort 
study. J Hazard Mater, 186:1594–1600. http://
dx.doi.org/10.1016/j.jhazmat.2010.12.036 
PMID:21194838
14. Brunekreef B, Beelen R, Hoek G et al. (2009). 
Effects of Long-Term Exposure to Traffic-
Related Air Pollution on Respiratory and 
Cardiovascular Mortality in the Netherlands: 
The NLCS-AIR Study. HEI Research Report 
139. Boston, MA: Health Effects Institute.
15. Turner MC, Krewski D, Pope CA 3rd et al. 
(2011). Long-term ambient fine particu-
late matter air pollution and lung cancer 
in a large cohort of never-smokers. Am J 
Respir Crit Care Med, 184:1374–1381. http://
dx.doi.org/10.1164/rccm.201106-1011OC 
PMID:21980033
16. Demetriou CA, Raaschou-Nielsen O, Loft S 
et al. (2012). Biomarkers of ambient air pol-
lution and lung cancer: a systematic review. 
Occup Environ Med, 69:619–627. http://
dx.doi.org/10.1136/oemed-2011-100566 
PMID:22773658
17. Loomis D, Grosse Y, Lauby-Secretan B 
et al. (2013). The carcinogenicity of 
outdoor air pollution. Lancet Oncol, 14:1262– 
1263. http://dx.doi.org/10.1016/S1470-2045 
(13)70487-X
18. Lim SS, Vos T, Flaxman AD et al. (2012). 
A comparative risk assessment of burden 
of disease and injury attributable to 67 
risk factors and risk factor clusters in 21 
regions, 1990–2010: a systematic analy-
sis for the Global Burden of Disease Study 
2010. Lancet 380:2224–2260. http://dx.doi.
org/10.1016/S0140-6736(12)61766-8 
PMID:23245609
160
19. Pope CA 3rd, Ezzati M, Dockery DW (2009). 
Fine-particulate air pollution and life expec-
tancy in the United States. N Engl J Med, 
360:376–386. http://dx.doi.org/10.1056/
NEJMsa0805646 PMID:19164188
20. HEI Accountability Working Group 
(2003). Assessing Health Impact of 
Air Quality Regulations: Concepts and 
Methods for Accountability Research. HEI 
Communication 11. Boston, MA: Health 
Effects Institute. Available at http://pubs.
healtheffects.org/view.php?id=153
21. IARC (2012). Radiation. IARC Monogr 
Eval Carcinog Risks Hum, 100D:1–437. 
PMID:23189752
22. Bonjour S, Adair-Rohani H, Wolf J et al. 
(2013). Solid fuel use for household cook-
ing: country and regional estimates for 
1980–2010. Environ Health Perspect, 
121:784–790. http://dx.doi.org/10.1289/ehp. 
1205987 PMID:23674502
23. Hosgood HD 3rd, Boffetta P, Greenland S 
et al. (2010). In-home coal and wood use 
and lung cancer risk: a pooled analysis of 
the International Lung Cancer Consortium. 
Environ Health Perspect, 118:1743–1747. 
http://dx.doi.org/10.1289/ehp.1002217 
PMID:20846923
24. Hosgood HD 3rd, Wei H, Sapkota A et al. 
(2011). Household coal use and lung can-
cer: systematic review and meta-analysis 
of case-control studies, with an emphasis 
on geographic variation. Int J Epidemiol, 
40:719–728. http://dx.doi.org/10.1093/ije/
dyq259 PMID:21278196
25. Lan Q, Chapman RS, Schreinemachers DM 
et al. (2002). Household stove improvement 
and risk of lung cancer in Xuanwei, China. J 
Natl Cancer Inst, 94:826–835. http://dx.doi.
org/10.1093/jnci/94.11.826 PMID:12048270
26. Richardson SD, Plewa MJ, Wagner ED 
et al. (2007). Occurrence, genotoxic-
ity, and carcinogenicity of regulated and 
emerging disinfection by-products in 
drinking water: a review and roadmap for 
research. Mutat Res, 636:178–242. http://
dx.doi.org/10.1016/j.mrrev.2007.09.001 
PMID:17980649
27. IARC (2004). Some drinking-water disinfect-
ants and contaminants, including arsenic. 
IARC Monogr Eval Carcinog Risks Hum, 
84:1–477. PMID:15645577
28. Flanagan SV, Johnston RB, Zheng Y 
(2012). Arsenic in tube well water in 
Bangladesh: health and economic impacts 
and implications for arsenic mitigation. 
Bull World Health Organ, 90:839–846. 
http://dx.doi.org/10.2471/BLT.11.101253 
PMID:23226896
29. Chatterjee D, Halder D, Majumder S et al. 
(2010). Assessment of arsenic exposure 
from groundwater and rice in Bengal Delta 
Region, West Bengal, India. Water Res, 
44:5803–5812. http://dx.doi.org/10.1016/j.
watres.2010.04.007 PMID:20638702
30. Bundschuh J, Litter MI, Parvez F et al. 
(2012). One century of arsenic expo-
sure in Latin America: a review of history 
and occurrence from 14 countries. Sci 
Total Environ, 429:2–35. http://dx.doi.
org/10.1016/j.scitotenv.2011.06.024 PMID: 
21959248
31. Ritter L, Solomon K, Sibley P et al. (2002). 
Sources, pathways, and relative risks of con-
taminants in surface water and groundwater: a 
perspective prepared for the Walkerton inquiry. 
J Toxicol Environ Health A, 65:1–142. http://
dx.doi.org/10.1080/152873902753338572 
PMID:11809004
32. Porta D, Milani S, Lassarino A et al. (2009). 
Systematic review of epidemiological studies 
on health effects associated with manage-
ment of solid waste. Environ Health, 8:60. 
http://dx.doi.org/10.1186/1476-069X-8-60 
PMID:20030820
Chapter 2.10 • Pharmaceutical drugs 161
2 
E
TI
O
LO
G
Y
C
H
A
P
TE
R
 2
.1
0
Summary
• Pharmaceutical drugs may have 
the potential to induce or prevent 
cancer development.
• Antineoplastic agents used in 
cancer therapy can induce sec-
ond cancers in patients who are 
apparently cured; this is most 
readily attributable to the geno-
toxicity of these agents.
• Apart from antineoplastic 
agents, drugs carcinogenic to 
humans include immunosup-
pressants, hormonal agents, 
and phenacetin.
• Some drugs are implicated, but 
not established, as carcinogenic 
to humans by limited epidemio-
logical data or by data restrict-
ed to the results of bioassay in 
animals.
• Monitoring of possible carcino-
genic risks associated with the 
use of pharmaceutical drugs is 
imperative.
• A few drugs have been ap-
proved for cancer preventive 
therapy, and several others are 
being evaluated as preventive 
agents, including aromatase 
inhibitors, aspirin, statins, and 
metformin.
2.10
2 ETIOLOGY
Pharmaceutical drugs
Søren Friis
Jørgen H. Olsen
Margaret R. Karagas (reviewer)
Pharmaceutical drugs are chemi-
cals that are developed and applied 
in medicine and dentistry for their 
ability to treat, prevent, or mitigate 
disease. Pharmaceutical drugs are 
invariably administered at levels that 
are biologically active, and thus may 
have side-effects in addition to their 
intended effects. A possible side-ef-
fect is modification of the likelihood 
of malignant transformation, which 
may involve either a risk-enhancing 
or a risk-reducing effect.
Hormonal agents are well estab-
lished as drugs with carcinogenic 
potential. These agents include oral 
contraceptives, hormone replace-
ment therapy, and anti-estrogens, 
such as tamoxifen. Other carcino-
genic drugs include antineoplastic 
agents that – particularly among 
those that are genotoxic – cause 
second cancers. For many such 
agents the benefit–risk ratio, de-
termined by reference to patients 
achieving increased survival or re-
lated outcome compared with those 
developing second cancers, is high 
and the continued use of these drugs 
is endorsed, although with intensive 
research to reduce dosage or de-
velop safer and more effective re-
placement products. In contrast, a 
decision to prescribe and use drugs 
that are established, or considered 
likely, to be carcinogenic is more 
problematic in circumstances involv-
ing non-life-threatening conditions.
In the most recent review involv-
ing pharmaceuticals [1], the IARC 
Monographs Programme re-evaluat-
ed 23 agents or combination thera-
pies categorized as carcinogenic to 
humans (Group 1). These predomi-
nantly include antineoplastic agents 
as well as a diverse range of drugs 
not used as cancer therapy.
Only a few drugs have been ap-
proved for cancer preventive thera-
py, including tamoxifen for women at 
risk of contralateral breast cancer.
Antineoplastic agents
Antineoplastic agents include mul-
tiple drugs that can induce second 
cancers in cancer patients who are 
apparently cured. Twelve such agents 
or combination therapies have been 
classified as carcinogenic to humans 
(Table 2.10.1) [1,2]. Of these, the ma-
jority, including busulfan, chlorambu-
cil, cyclophosphamide, melphalan, 
semustine (methyl-CCNU), thiotepa, 
and treosulfan, are alkylating agents 
that exhibit genotoxic activity, com-
monly through alkylation of purine 
bases in DNA. Typically these agents 
cause acute myeloid leukaemia that 
often exhibits clonal loss of either 
chromosome 5 or 7, as distinct from 
acute myeloid leukaemia induced 
by topoisomerase II inhibitors, such 
as etoposide. Several such agents 
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Table 2.10.1. Antineoplastic drugs and other drugs evaluated by the IARC Monographs Programme
Group 1 agent Cancer on which sufficient evidence in humans is based Established mechanistic events
Antineoplastic agents
Busulfan Acute myeloid leukaemia Genotoxicity (alkylating agent)
Chlorambucil Acute myeloid leukaemia Genotoxicity (alkylating agent)
Chlornaphazine Bladder Genotoxicity (alkylating agent, metabolism 
to 2-naphthylamine derivatives)
Cyclophosphamide Acute myeloid leukaemia, bladder Genotoxicity (metabolism to alkylating 
agents)
Etoposide (Group 2A in 2000) – Genotoxicity, translocations involving 
MLL gene
Etoposide in combination with cisplatin 
and bleomycin
Acute myeloid leukaemia Genotoxicity, translocations involving 
MLL gene (etoposide)
Melphalan Acute myeloid leukaemia Genotoxicity (alkylating agent)
MOPPa combined chemotherapy Acute myeloid leukaemia, lung Genotoxicity
Semustine (methyl-CCNU) Acute myeloid leukaemia Genotoxicity (alkylating agent)
Thiotepa Leukaemia Genotoxicity (alkylating agent)
Treosulfan Acute myeloid leukaemia Genotoxicity (alkylating agent)
Immunosuppressive agents
Azathioprine Non-Hodgkin lymphoma, skin Genotoxicity, immunosuppression
Ciclosporin Non-Hodgkin lymphoma, skin, multiple 
other sites
Immunosuppression
Other carcinogenic agents
Analgesic mixtures containing phenacetin Renal pelvis, ureter (See phenacetin)
Aristolochic acid (Group 2A in 2002) – Genotoxicity, DNA adducts in animals 
are the same as those found in humans 
exposed to plants, A:T → T:A transversions 
in TP53, RAS activation
Methoxsalen plus ultraviolet A radiation Skin Genotoxicity after photo-activation
Phenacetin (Group 2A in 1987) Renal pelvis, ureter Genotoxicity, cell proliferation
Plants containing aristolochic acid Renal pelvis, ureter Genotoxicity, DNA adducts in humans, 
A:T → T:A transversions in TP53 in human 
tumours
a Chlormethine (mechlorethamine), vincristine (Oncovin), procarbazine, and prednisone.
have since been supplemented 
or superseded by newer drugs [3]. 
It is therefore imperative that these 
new drugs and combinations thereof 
are monitored for possible carcino-
genic effects. Typically, the antineo-
plastic mechanisms of the replace-
ment drugs are similar to those of 
the traditional drugs, and much in-
sight can be gained from focusing 
on relevant mechanisms rather than 
the specific drugs. Since individual 
susceptibility is often a factor that 
emerges from relevant mechanistic 
analysis, this knowledge contributes 
to improved identification of patients 
who may be susceptible to drug- 
induced cancer [1].
Immunosuppressive agents
Immunosuppressive agents, such as 
azathioprine and ciclosporin (also 
known as cyclosporin, cyclosporine, 
or cyclosporin A), are carcinogenic 
to humans because of immuno-
suppressive rather than genotoxic 
effects. Use of these agents may 
cause skin cancer and non-Hodgkin 
lymphoma; relevant evidence comes 
primarily from studies of patients who 
have undergone organ transplanta-
tion (Table 2.10.1) [1].
Hormone therapy
Female sex hormones, including 
estrogen-only and estrogen–pro-
gestogen agents, are used widely to 
achieve various outcomes, including 
contraception and the amelioration 
of menopausal symptoms, uterine 
bleeding, and endometriosis [1]. In 
addition, these agents have been 
used widely for prevention of osteo-
porosis and coronary heart disease 
among postmenopausal women, 
although the latter indication was 
Fig. 2.10.1. A middle-aged woman sticks 
a hormone replacement therapy patch to 
her thigh. Hormonal agents are well estab-
lished as drugs with carcinogenic potential.
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Table 2.10.2. Hormonal agents assessed by the IARC Monographs Programme
Group 1 agent
Cancer on which 
sufficient evidence in 
humans is based
Sites where cancer 
risk is reduced
Established 
mechanistic events
Other likely 
mechanistic events
Combined estrogen–
progestogen meno-
pausal therapy
Endometrium (risk 
decreases with number 
of days per month of 
progestogen use), 
breast
– Receptor-mediated 
events
Estrogen genotoxicity
Combined estrogen–
progestogen oral 
contraceptives
Breast, cervix, liver Endometrium, ovary Receptor-mediated 
events
Estrogen genotoxicity, 
hormone-stimulated 
expression of human 
papillomavirus genes
Diethylstilbestrol Breast (exposure during 
pregnancy), vagina 
and cervix (exposure in 
utero)
Limited evidence: testis 
(exposure in utero), 
endometrium
– Estrogen-receptor-
mediated events 
(vagina, cervix), 
genotoxicity
Epigenetic programming
Estrogen-only meno-
pausal therapy
Endometrium, ovary
Limited evidence: breast
– Estrogen-receptor-
mediated events
Genotoxicity
Tamoxifen Endometrium Breast Estrogen-receptor-
mediated events, 
genotoxicity
–
abandoned in 2003 after publication 
of the Women’s Health Initiative trial, 
which could not replicate the risk re-
duction for coronary heart disease 
reported in many observational stud-
ies [4]. There is consistent evidence 
that female sex hormones may influ-
ence the risk of cancers of the fe-
male reproductive organs and breast 
(Table 2.10.2) [1]. The mechanisms 
of carcinogenesis of female sex hor-
mones include estrogen-receptor-
mediated responses and potentially 
direct genotoxic effects of the estro-
genic hormones or their associated 
by-products (Table 2.10.2) [1].
Estrogen-only menopausal 
therapy
Estrogen-only menopausal therapy 
refers to the use of estrogen without 
progestogen by perimenopausal and 
postmenopausal women, primar-
ily for the treatment of menopausal 
symptoms [1]. After a substantial 
increase in the use of this regimen 
in the 1960s and early 1970s, the 
use declined after reports of a strong 
association between estrogen-only 
therapy and risk of endometrial 
cancer. Since then, estrogen-only 
menopausal agents have been pre-
scribed predominantly to hysterec-
tomized women. In the recent re-
evaluation [1], IARC concluded that 
estrogen-only menopausal therapy 
causes cancers of the endometrium 
and ovary (Table 2.10.2). Moreover, 
an increased risk of breast cancer 
was also noted.
Combined estrogen–
progestogen menopausal 
therapy
Combined estrogen–progestogen 
menopausal therapy was initially 
developed to avoid the excess oc-
currence of endometrial cancer as-
sociated with estrogen-only therapy 
[1]. Estrogen–progestogen agents 
were used heavily in the 1990s and 
the beginning of the 2000s. However, 
in 2003 the Women’s Health Initiative 
trial reported that use of combined es-
trogen–progestogen agents among 
women aged 50–79 years at baseline 
was associated with a hazard ratio 
for coronary heart disease of 1.24 
(95% confidence interval, 1.00–1.54) 
after a mean follow-up of 5.2 years 
[4]. This study has affected the 
prescribing of combined estrogen–
progestogen menopausal therapy 
substantially, resulting in rapidly de-
clining use of these agents, restricted 
indications, and reduced duration of 
therapy. Based on a comprehen-
sive amount of evidence, IARC has 
concluded that long-term combined 
estrogen–progestogen menopausal 
therapy causes cancers of the breast 
and endometrium (Table 2.10.2) [1]. 
The increased risk of endometrial 
cancer decreases with the number 
of days per month that progestogens 
are added to the regimen. IARC has 
also noted an inverse association be-
tween the use of these agents and 
risk of colorectal cancer; however, 
this evidence is not conclusive. For 
several other sites, including cancers 
of the thyroid, lung, stomach, liver, 
urinary tract, pancreas, ovary, and 
cervix, as well as lymphoma, leu-
kaemia, cutaneous melanoma, and 
central nervous system tumours, the 
current evidence does not point to an 
association with combined estrogen–
progestogen menopausal therapy [1].
Fig. 2.10.2. Oral contraceptives are avail-
able in estrogen–progestogen combina-
tions as well as in progestogen-only pills.
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Combined estrogen–
progestogen contraceptives
Numerous types of combined hor-
monal contraceptives have been mar-
keted since these agents first became 
available in the late 1950s [1]. With 
reference to the IARC Monographs 
Programme evaluation, there is 
sufficient evidence that combined 
estrogen–progestogen oral contra-
ceptives cause cancers of the breast 
(notably among young women), 
cervix, and liver (Table 2.10.2) [1]. 
IARC has also concluded that these 
agents are protective against can-
cers of the endometrium and ovary 
(Table 2.10.2), and possibly also colo-
rectal cancer, although the evidence 
is not conclusive for colorectal cancer 
[1]. For other sites, including cancers 
of the thyroid, lung, stomach, urinary 
tract, gall bladder, and pancreas, as 
well as lymphoma, cutaneous mela-
noma, and central nervous system 
tumours, the available literature does 
not support an association with com-
bined estrogen–progestogen contra-
ceptives [1].
Diethylstilbestrol
This synthetic estrogen was first man-
ufactured in 1938 [1]. Diethylstilbestrol 
was widely used, especially from the 
1940s to the 1970s, to prevent po-
tential miscarriages by stimulating 
Breast implants and cancer
Eric Lavigne
The demand for breast implants 
among women has been rapidly 
increasing since the first mammary 
prosthesis was inserted into a wom-
an’s breast in the early 1960s [1]. 
Although breast implants are very 
popular for cosmetic purposes, con-
siderable controversy remains about 
their long-term effects on cancer 
incidence. Concerns were initially 
raised about the possible carcino-
genic effect of cosmetic breast im-
plants, specifically for breast cancer 
[2]. However, the weight of epide-
miological evidence based on large 
cohort studies with long follow-up 
periods showed no carcinogenic 
effect of breast augmentation on 
breast cancer [3–5].
Concerns about the carcino-
genic effect of breast implants have 
also been characterized according 
to specific implant characteristics, 
such as the type of implant (saline-
filled or silicone-gel-filled), implant 
placement (submuscular or subglan-
dular), and implant envelope (with or 
without polyurethane coating). For 
the implant envelope, available labo-
ratory studies show that 2,4-toluene- 
diamine, a biodegradation prod-
uct of polyurethane, may promote 
the progression of already present 
mutated cells [6,7]. In addition, one 
epidemiological study showed an el-
evation in breast cancer incidence 
for women with polyurethane-coated 
subglandular implants compared 
with women with subglandular im-
plants without polyurethane coating 
[3]. However, this finding is based on 
only one study with a small number 
of cases, and further investigations 
are required before this interpreta-
tion can be used in clinical practice. 
No differences in breast cancer inci-
dence have been reported between 
saline-filled and silicone-gel-filled 
implants [3,8]. In addition, one study 
found that women with subglandular 
implants had a reduced risk of breast 
cancer compared with women with 
submuscular implants [3].
Some studies have evaluated 
the relationship between breast 
implants and the incidence of can-
cers at sites other than the breast. 
No conclusive findings can be re-
ported about risk of other types of 
cancers [3,5]. Although there is con-
cern about a possible link between 
breast implants and anaplastic large 
T-cell lymphomas of the breast [9], 
no epidemiological cohort studies 
have reported any evidence for an 
association [3,5,10].
Another concern is that breast 
implants may obscure the visuali-
zation of breast tissue with mam-
mography, which may impair the 
ability to identify breast cancer at 
an early stage, for which survival is 
generally more favourable. In fact, 
recent epidemiological evidence 
has suggested that breast cancers 
are diagnosed at more advanced 
stages among women with cosmet-
ic breast implants and that breast 
cancer-specific survival is lower 
in these women [11]. However, 
further studies are warranted 
about breast cancer diagnosis and 
prognosis among women with 
breast augmentation.
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the synthesis of estrogen and pro-
gesterone in the placenta. In the USA 
alone, an estimated 5–10 million peo-
ple received diethylstilbestrol during 
pregnancy or were exposed to the 
drug during fetal life. Subsequently, 
several adverse effects emerged 
(Table 2.10.2) [1]. First, slightly in-
creased risks of breast cancer and 
possibly of endometrial cancer were 
observed among women exposed to 
diethylstilbestrol during pregnancy. 
Second, among female children of 
women who used diethylstilbestrol 
during pregnancy, a markedly in-
creased risk of adenocarcinoma of 
the vagina or cervix was recorded, 
typically occurring during adoles-
cence. Third, fetal exposure to di-
ethylstilbestrol was associated with 
increased risks of squamous cell car-
cinoma of the cervix among female 
offspring and testicular cancer among 
male offspring. Currently, evidence is 
accumulating of an increased risk of 
cancers of the female reproductive 
organs among third-generation off-
spring of women who used diethyl-
stilbestrol [1].
Tamoxifen
Tamoxifen is indicated as adjuvant 
therapy for treatment of postmen-
opausal estrogen-receptor-positive 
or progesterone-receptor-positive 
breast cancer among both women 
and men, as well as ductal carci-
noma in situ after breast surgery 
and radiotherapy among women 
[1]. Furthermore, tamoxifen has 
been approved as a breast cancer 
preventive agent among women at 
high risk of developing breast cancer 
(see below). Observational epide-
miological studies and randomized 
trials have consistently shown that 
use of tamoxifen increases the risk 
of endometrial cancer whether given 
as adjuvant therapy among women 
with breast cancer or as preventive 
therapy among women at high risk 
of breast cancer (Table 2.10.2) [1]. 
There is also some indication that 
tamoxifen may be associated with an 
increased risk of some types of gas-
trointestinal cancer; however, these 
results are not conclusive.
Phenacetin
The analgesic phenacetin and mix-
tures containing phenacetin were 
until recently classified by IARC as 
probably carcinogenic to humans 
(Group 2A), since the available 
evidence had not been able to dis-
criminate between potential carci-
nogenic effects of phenacetin and 
those attributable to other analge-
sics or components of analgesics 
used by the same patients. In the 
recent IARC re-evaluation [1], how-
ever, phenacetin and phenacetin-
containing mixtures were both clas-
sified as carcinogenic to humans 
(Group 1), causing cancers of the 
renal pelvis and ureter (Table 2.10.1). 
Since phenacetin was withdrawn 
from the market in most countries in 
about 1980, the pool of patients with 
excess risk of cancers of the renal 
pelvis or ureter due to phenacetin 
therapy is probably limited now, 
although a long latency period for 
development of these cancer types 
cannot be excluded and relevant 
cancers may yet be diagnosed.
Miscellaneous agents
Use of Aristolochia plants contain-
ing aristolochic acid has mainly 
been limited to traditional Chinese 
drugs, weight-loss pills in Belgium, 
and cereals from Balkan fields [1]. 
Aristolochic acid induces DNA dam-
age similar to that seen for antineo-
plastic agents and is associated with 
nephropathy and an increased risk 
of cancers of the renal pelvis and 
ureter (Table 2.10.1). Genome-wide 
sequencing has established the 
mutational signature of aristolochic 
acid [5].
Methoxsalen, which is a pso-
ralen produced naturally by vari-
ous plants, is a photosensitizer: the 
agent increases skin reactivity to ul-
traviolet radiation [1]. Methoxsalen 
is nowadays typically taken orally in 
conjunction with ultraviolet radiation 
as phototherapy for various condi-
tions, notably psoriasis. The drug 
has been suspected to cause vari-
ous types of skin cancer, but there is 
convincing evidence only for causa-
tion of squamous cell carcinoma [1]. 
Some common vegetables naturally 
contain methoxsalen, and there have 
been reports of photosensitivity and 
skin lesions among grocery or farm 
workers.
Photosensitivity is also induced 
by frequently used drugs such as 
certain types of antihypertensives, 
Fig. 2.10.3. A patient receives chemotherapy through a port located on his chest.
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for example hydrochlorothiazide and 
nifedipine. There is increasing evi-
dence that these drugs increase the 
risk of lip and skin cancers [6].
Many of the drugs evaluated by 
IARC have been categorized as 
probably carcinogenic to humans 
(Group 2A) or possibly carcinogenic 
to humans (Group 2B) because the 
epidemiological evidence has not 
been definitive and is hence cat-
egorized as limited or because car-
cinogenicity has been demonstrated 
only in experimental animals. These 
agents include, for example, gris-
eofulvin, metronidazole, phenytoin, 
chloramphenicol, iron-dextran com-
plexes, phenoxybenzamine, pheno-
barbital, oxazepam, propylthiouracil, 
and anti-retroviral agents (e.g. zido-
vudine) [7].
Cancer preventive drugs
Hormone antagonists
Several drugs within the therapeutic 
groups of selective estrogen-receptor 
modulators and aromatase inhibi-
tors have been approved for endo-
crine therapy among women with 
hormone-receptor-positive breast 
cancer. However, so far, only the two 
selective estrogen-receptor modula-
tors tamoxifen and raloxifene have 
been approved for preventive therapy 
against breast cancer [8]. Tamoxifen 
reduces the risk of contralateral 
breast cancer and, when given as 
preventive therapy, reduces the risk 
of estrogen-receptor-positive breast 
cancers. Tamoxifen has greater effi-
cacy than raloxifene and can be used 
in premenopausal women, but ralox-
ifene has fewer side-effects and is 
not classified as carcinogenic to hu-
mans. Newer drugs within the class of 
selective estrogen-receptor modula-
tors, for example lasofoxifene, also 
show efficacy, and possibly a better 
overall benefit–risk profile, but need 
further assessment. Aromatase in-
hibitors may be more efficacious, and 
drugs within this class, for example 
anastrozole and exemestane, are 
currently being evaluated as preven-
tive agents among women with a his-
tory of carcinoma in situ of the breast 
or other women considered to be at 
high risk of developing breast cancer.
Aspirin and other non-
steroidal anti-inflammatory 
drugs
Several observational epidemio-
logical studies, randomized trials 
of colon adenoma recurrence, and 
randomized trials in patients with 
hereditary colorectal cancer syn-
dromes have consistently shown 
that aspirin and other non-steroidal 
anti-inflammatory drugs (NSAIDs) 
reduce the risk of colorectal neo-
plasia and cancer [9,10]. A cancer 
preventive effect of aspirin or non-
aspirin NSAIDs against other cancer 
types is less certain [9,10]. Despite 
the cancer preventive effect of non-
aspirin NSAIDs, the use of these 
agents for prevention of colorectal 
cancer is hampered by their recently 
established association with cardio-
vascular events [10]. The evaluation 
of NSAIDs as a potential cancer pre-
ventive measure is thus focused on 
aspirin [10]. However, although the 
preventive effect of aspirin against 
colorectal neoplasia has been practi-
cally proven, aspirin cannot be rec-
ommended for cancer prevention 
in the general population of healthy 
individuals due to the risk of serious 
adverse events, notably upper gas-
trointestinal bleeding [10]. Moreover, 
uncertainty still remains as to the 
optimal dose and duration of aspi-
rin therapy for cancer prevention 
[9]. The results of several current 
randomized trials will hopefully 
provide more confirmatory data on 
these issues.
Statins
HMG-CoA reductase inhibitors 
(statins) reduce serum levels of 
cholesterol and are widely used to 
manage and prevent cardiovascu-
lar and coronary heart disease. In 
addition, a growing body of experi-
mental evidence has suggested that 
statins have cancer preventive prop-
erties [11]. To date, however, sev-
eral randomized trials with cancer 
as secondary end-point have failed 
to demonstrate a reduced risk of 
cancer, overall or at specific sites, 
within statin treatment periods of 
5–10 years. Likewise, observational 
epidemiological studies with longer 
follow-up have generally produced 
null results, with the exception of an 
inverse association between statin 
use and aggressive prostate cancer 
[12]. Statins have also been evalu-
ated as adjuvant therapy to standard 
cancer therapy; however, to date 
this has yielded primarily null results 
[11]. Several current trials will hope-
fully clarify whether statins have 
a future role in cancer prevention 
or therapy.
Recent research issues
There is substantial evidence that fe-
male sex hormones are associated 
with a decreased risk of colorectal 
cancer and thus represent further 
hormonal agents associated with 
both carcinogenic and cancer pre-
ventive properties. Meta-analysis 
indicates significant duration-de-
pendent reductions in ovarian cancer 
incidence associated with oral con-
traceptive use [13]. Observational 
epidemiological studies also indicate 
that metformin, a widely used oral an-
tidiabetic drug, may reduce the risk of 
several cancer types; however, these 
associations require further assess-
ment [14]. Several trials of metformin 
have recently been launched to as-
sess whether this old drug may have 
a cancer preventive potential.
Fig. 2.10.4. Today, the evaluation of non-
steroidal anti-inflammatory drugs as a 
potential cancer preventive measure is 
focused on aspirin.
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Some epidemiological studies in-
dicate that insulin treatment is asso-
ciated with increased risk of several 
cancer types; however, the results 
are equivocal [15]. Moreover, it has 
been suggested that insulin ana-
logues are more prone to induce can-
cer, but this hypothesis also remains 
to be clarified. Several international 
research initiatives have recently 
been launched to clarify these issues. 
A recent single study indicated that 
long-term current use of calcium-
channel blockers is associated with 
increased breast cancer risk among 
women aged 55–74 years [16].
Two large randomized trials 
have demonstrated that the two 
5α-reductase inhibitors, finasteride 
and dutasteride, indicated for treat-
ment of benign prostatic hyperplasia, 
reduce the risk of prostate cancer 
among men by 25%; however, both 
studies also revealed an increased 
risk of aggressive prostate cancer 
[17]. Whether the increased risk of 
aggressive prostate cancer is due 
to detection bias or a true biologi-
cal association remains unclear [17]. 
Until this spurious phenomenon is 
resolved, these agents should not be 
recommended as cancer preventive 
agents.
Concerns have been raised about 
the new biological response modifiers 
for treatment of rheumatoid arthri-
tis, which include tumour necrosis 
factor inhibitors. Tumour necrosis 
factor inhibitors have been sug-
gested to increase the risk of cer-
tain cancers, including lymphoma 
in children and adolescents, and 
these agents currently carry a label 
warning against a possible risk of 
malignancy. A large meta-analysis 
of 61 randomized trials of tumour 
necrosis factor inhibitors, including 
a total of 29 423 patients, concluded 
that use of these drugs was not as-
sociated with an increased risk of 
cancer overall or at specific sites 
[18]. However, follow-up was short 
(24–156 weeks) in this analysis, and 
continued monitoring is warranted.
The carcinogenicity of some 
drugs was recently evaluated for 
Volume 108 of the IARC Monographs 
[19], and two drugs attracted 
particular attention. Pioglitazone, 
used for treatment of type 2 diabe-
tes, was classified as probably car-
cinogenic to humans (Group 2A), 
with limited evidence that it causes 
bladder cancer in humans and evi-
dent carcinogenicity in experimen-
tal animals. Use of digoxin, which is 
widely prescribed for chronic heart 
failure and related conditions, is as-
sociated with an increased risk of 
breast cancer; causal interpretation 
of these data is precluded because 
of possible confounding, particularly 
in relation to obesity and alcohol 
consumption. In the absence of ani-
mal bioassay data, digoxin was cat-
egorized as possibly carcinogenic to 
humans (Group 2B).
Fig. 2.10.5. A patient with diabetes uses 
an “insulin pen” to inject insulin. Drugs that 
increase circulating insulin, including ex-
ogenous insulin, insulin analogues, and 
insulin secretagogues, may be associated 
with an increased cancer risk [15].
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Summary
• Natural products are chemicals 
from plants, fungi, lichens, and 
bacteria, some of which have 
unique pharmacological effects. 
Humans are primarily exposed 
to many of these bioactive 
naturally occurring chemicals 
through food and water; natural 
products are used as pharma-
ceuticals and herbal remedies.
• Natural products of bacteria that 
are possibly or probably carcino-
genic to humans include antibi-
otics, chemotherapeutic agents, 
and the water contaminant mi-
crocystin-LR. Environmental ex-
posure to cyanobacterial toxins 
is well documented.
• Mycotoxins are secondary me-
tabolites of fungi that are known 
to cause sickness or death in 
humans or animals. Exposure 
to carcinogenic mycotoxins can 
be high in areas where a single 
commodity is consumed as a 
dietary staple.
• Several chemicals found in par-
ticular plants used as food, food 
additives, or herbal medicines 
have been classified as human 
or animal carcinogens. Some of 
these plants are weeds and are 
sometimes harvested with crop 
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plants or are deliberately used 
as herbal medicines.
Information about possible, prob-
able, and known carcinogens that 
are naturally occurring chemicals of 
microbial or plant origin is summa-
rized in this chapter. Natural prod-
ucts are chemicals found in nature, 
which often have unique pharmaco-
logical effects. In the 2011 edition of 
the Dictionary of Natural Products, 
more than 230 000 natural products 
were described [1]. Cancer-causing 
chemicals produced by bacteria, 
fungi, and plants are discussed 
here. Compounds that are semi-
synthetic, such as etoposide and 
teniposide from podophyllotoxin, 
or are produced by a genetically 
modified organism, as illustrated by 
doxorubicin obtained from a geneti-
cally altered strain of Streptomyces, 
are not included. That said, these 
three agents do provide important 
insights into the potential of natu-
rally occurring chemicals to be 
carcinogenic. “Natural products” 
from tobacco, betel quid, or areca 
nut (see Chapter 2.2), ethanol (see 
Chapter 2.3), or naturally occurring 
chemicals produced by anaerobic 
bacteria such as methylated arse-
nic species, which are environmen-
tal pollutants (see Chapter 2.9), are 
discussed elsewhere.
One of the striking attributes of 
nature is biodiversity. As might be 
expected, there are a large number 
of biologically active organic chemi-
cals produced in nature by microbes 
and plants. Biologically produced 
naturally occurring organic com-
pounds are structurally diverse. Not 
surprisingly, humans are exposed 
to many of these chemicals primar-
ily through food and drinking-water. 
In addition, exposure to naturally 
occurring chemicals occurs because 
they are used as pharmaceuticals 
and herbal remedies useful in the 
treatment and/or prevention of 
diseases.
The discovery of naturally occur-
ring chemicals with potentially useful 
or dangerous biological activity is still 
in progress and is often proprietary. 
The current edition of the Dictionary 
of Natural Products [1] is a compre-
hensive survey of the literature on 
natural product discovery. For exam-
ple, from 1995 to 1997 more than 
6000 new compounds were added 
to the dictionary. Making informed 
decisions about the carcinogenic 
risk to humans posed by exposure 
to each of these 230 000 (and grow-
ing) biologically active natural prod-
ucts is a daunting, if not impossible, 
task. However, considering bacteria, 
including actinomycetes, and fungi, 
there are only 45 000 compounds 
with known biological activity [2]. 
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The proportion of biologically active 
chemicals derived from plants that 
are used as therapeutic agents is 
quite low, despite some important 
examples [3].
Since 1971, the IARC Monographs 
Programme has evaluated more 
than 900 agents. More than 400 
have been identified as carcinogen-
ic, probably carcinogenic, or pos-
sibly carcinogenic to humans. The 
information gained from assess-
ments of representative carcinogenic 
chemicals by IARC and the United 
States National Toxicology Program 
provides critical data for identifying 
which known or newly discovered 
chemicals may be carcinogenic 
hazards. For example, quantitative 
structure–activity relationships ob-
tained from long-term feeding stud-
ies can be used to develop predic-
tive models. These can be used for 
screening and prioritizing the carci-
nogenic hazards posed by naturally 
occurring chemicals when the data 
from animal studies are inadequate 
[4]. Accurate predictive modelling is 
dependent on the quality of the toxi-
cology data rather than on the quan-
tity of chemicals tested in long-term 
rodent carcinogenicity studies. Thus, 
it may be possible to predict which 
natural products are potential carci-
nogenic hazards without conducting 
long-term feeding studies on newly 
discovered natural products. This 
approach can be used effectively 
only if the toxicology database from 
long-term feeding studies represents 
all the relevant structures that have 
a high probability of contributing to 
cancer induction in humans. This 
task is also daunting, but not im-
possible, as would be testing every 
naturally occurring biologically ac-
tive chemical.
Naturally occurring 
carcinogens produced by 
bacteria
Table 2.11.1 summarizes naturally 
occurring chemicals produced by 
bacteria evaluated by IARC as 
possibly or probably carcinogenic 
to humans. With the exception of 
microcystin-LR, human exposure 
to these agents occurs from treat-
ment in a clinical setting. These six 
agents are produced by bacteria 
of the order Actinomycetales. The 
actinomycete genus Streptomyces 
produces a wide spectrum of natu-
ral products [5]. Actinomycetes are 
commonly found in soil and water 
and contribute to the decomposition 
of organic material [6]. The charac-
teristic smell of wet soil is due in part 
to geosmin (meaning “earth smell”), 
a secondary metabolite produced 
by Streptomyces. Streptomyces-
produced secondary metabolites 
Fig. 2.11.1. Streptomyces, or soil bacteria, 
are commonly found in soil and water and 
are necessary for the decomposition of 
organic material.
Table 2.11.1. Naturally occurring organic chemical carcinogens produced by bacteria
Agent 
(bacterial genera)a
Primary 
source of 
exposureb
Proposed mechanism of carcinogenicityc
Primary target 
or tumour 
sitesd
IARC 
evaluation of 
carcinogenicity 
to humanse
Azacitidine
(Streptoverticillium)
Chemotherapy Cytidine analogue/DNA methylation inhibitor Multiple sites Group 2A
Chloramphenicol
(Streptomyces)
Antibiotic Inhibits mitochondrial protein synthesis 
→ aplastic anaemia/bone-marrow depression
Blood Group 2A
Azaserine
(Glycomyces)
Antibiotic, 
chemotherapy
Glutamine/purine antagonist → inhibition of 
purine biosynthesis and glutamine-dependent 
enzymes
Pancreas, 
kidney
Group 2B
Daunomycin
(Streptomyces)
Antibiotic, 
chemotherapy
DNA intercalation → inhibition of macromolecu-
lar biosynthesis → topoisomerase II inhibition
Mammary, 
kidney, local 
sarcomas
Group 2B
Microcystin-LR
(Microcystis)
Water 
contaminant
Inhibition of protein phosphatases 1 and 2A → 
tumour promotion
Liver, colon Group 2B
Mitomycin C
(Streptomyces)
Antibiotic, 
chemotherapy
DNA/RNA alkylating agent → DNA/RNA 
damage
Dithiol cross-linking agent → protein damage
Multiple sites Group 2B
Streptozotocin
(Streptomyces)
Antibiotic, 
chemotherapy
DNA alkylating agent → DNA damage
Oxidative stress → diabetes
Liver, lung, 
kidney
Group 2B
a For all bacteria the most likely producing genera are given; the listing is not exhaustive.
b All of the agents listed can be produced by biosynthesis in situ, but for the antibiotics and chemotherapeutic agents exposure is in a controlled clinical setting.
c Where possible, the mechanism described is taken from the most recent IARC Monograph or IARC Scientific Publication.
d Includes reference to animal bioassay data. For some studies the route of exposure is oral, but in some studies exposure was intravenous, subcutaneous, 
or other.
e Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable as to 
its carcinogenicity to humans; Group 4, probably not carcinogenic to humans. Only agents in Groups 1, 2A, and 2B are listed here. There are several naturally 
occurring agents classified by IARC as Group 3, but they are not included in this table.
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may play important roles in bacte-
rial–fungal, bacterial–plant, and bac-
terial–animal interactions in nature 
[6]. For example, Streptomyces are 
endosymbionts in wasps, and in the 
process of building cocoons the lar-
vae incorporate nine different antibi-
otics on the surface of the cocoon for 
protection from microbial pathogens 
[7]. There are many other exam-
ples of actinomycetales secondary 
metabolites playing roles in sym-
biotic relationships with eukaryotic 
organisms [6]. Thus, environmental 
exposure to naturally produced an-
tibiotics, including the six listed in 
Table 2.11.1, is possible, but the lev-
els of human exposure would likely 
be quite low, given the nature of the 
environment where the producing 
organisms thrive (soil, compost, 
manure, fermenting hay).
In contrast, human environmental 
exposure to the cyanobacterial toxin 
microcystin-LR is well documented 
[8]. Exposure occurs most frequently 
through drinking-water or ingestion of 
water during recreational activities. 
Microcystin-LR contamination of di-
etary supplements produced using 
cyanobacteria has been demonstrat-
ed. In one documented case, expo-
sure resulting from contamination 
of water used for renal dialysis has 
resulted in acute toxicity in humans 
[8]. Many countries have guidelines 
to minimize exposure from drinking-
water and recreational exposure. In 
rodent studies, microcystin-LR was 
a promoter of preneoplastic lesions 
and persistent neoplastic nodules in 
the liver. Co-exposure to aflatoxin is a 
concern since in rats microcystin-LR 
promotes the formation of aflatoxin-
induced glutathione S-transferase 
placental form-positive foci, which 
are considered preneoplastic le-
sions [8]. The inhibition of protein 
phosphatases 1 and 2A in vivo is 
consistent with microcystin promotion 
of liver tumours in animals. Inhibition 
of phosphatases causes hyperphos-
phorylation of intracellular proteins, 
disruption of intermediate filament 
assembly, altered expression of on-
cogenes and early response genes, 
and expression of tumour necrosis 
factor α, leading to altered cell divi-
sion, survival, and apoptosis [8].
Naturally occurring 
carcinogens produced by 
fungi
As with bacteria, the total number of 
naturally occurring fungal metabo-
lites cannot be quantified; however, 
an estimate may be made. For exam-
ple, all fungi produce secondary me-
tabolites and there are approximate-
ly two unique secondary metabolites 
per fungal species [9]. Thus, the total 
number of unique fungal secondary 
metabolites can be estimated based 
on the estimated number of fungal 
species. In 2001, Hawksworth esti-
mated that there were about 100 000 
formally described fungal species, 
and that number was considered to 
represent 5% of the total worldwide 
[10]. However, this number is likely 
to be conservative since there are 
estimated to be 200 000 fungal spe-
cies at the tip of Africa alone [11]. 
The recent completion of an online 
world catalogue of fungal names 
(http://www.indexfungorum.org/) has 
produced a more accurate figure of 
about 300 000 for the number of spe-
cies names of fungi. Assuming two 
unique secondary metabolites per 
fungal species produces an estimate 
of about 600 000 secondary fungal 
metabolites. Some of these metabo-
lites may be carcinogens. Currently, 
there are eight fungal compounds 
(excluding alcoholic beverages) 
that have been evaluated as hav-
ing sufficient evidence of carcino-
genicity in humans and/or animals 
(Table 2.11.2).
Human exposure to ciclosporin 
(also known as cyclosporin, cy-
closporine, or cyclosporin A) and 
griseofulvin occurs exclusively in 
clinical settings. Nonetheless, en-
vironmental exposure is possible 
since the fungi that produce these 
agents are common in soil and other 
matrices [12]. The fungus most used 
for producing ciclosporin commer-
cially, Tolypocladium inflatum, also 
produces fumonisins B2 and B4 [13]. 
Dietary exposure to griseofulvin is 
also possible since both Penicillium 
griseofulvum and griseofulvin have 
been isolated or detected in honey, 
service tree fruits, and cured meats. 
That said, it is unlikely that exposure 
outside clinical settings is of great 
significance.
Mycotoxins are secondary metab-
olites of microfungi that are known to 
cause sickness or death in humans 
or animals [14]. Of the toxins listed 
in Table 2.11.2, six are almost exclu-
sively encountered as contaminants 
of food, although occupational ex-
posure also occurs [14]. The foods 
most likely to be contaminated with 
high concentrations of mycotoxins are 
cereal grains and groundnuts, which 
are dietary staples in many developing 
countries [14]. The only fungal toxin 
for which there is sufficient evidence 
of carcinogenicity in humans is the 
group referred to as aflatoxins [14,15]. 
Aflatoxins include aflatoxins B1, B2, G1, 
G2, and M1. In naturally contaminated 
food, aflatoxins B1 and B2 or aflatox-
ins G1 and G2 usually occur together; 
however, aflatoxins B2 and G2 are less 
biologically active and there is limited 
or inadequate evidence, respectively, 
of their carcinogenicity in experimen-
tal animals. Aflatoxin G1 is less mu-
tagenic than aflatoxin B1, and forms 
fewer DNA adducts. Aflatoxin M1 
Fig. 2.11.2. A woman in sub-Saharan Mali 
sifts newly harvested grain. Cereal crops 
subject to storage under tropical condi-
tions are susceptible to contamination by 
mycotoxins.
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occurs almost exclusively in milk and 
milk products and is less carcinogenic 
than aflatoxin B1. The mechanisms of 
action of aflatoxins B1, G1, and M1 are 
similar in that they can be metabolized 
to exo-epoxides that can react with 
DNA, form chemical adducts, and 
modify genes. Less is known about 
the metabolism of sterigmatocystin to 
the exo-epoxide. For aflatoxins, one 
affected gene in humans is the tumour 
suppressor gene TP53, and there is 
a mechanistic link between levels of 
genetic biomarkers for aflatoxin expo-
sure (codon 249-specific TP53 muta-
tions) and hepatocellular carcinoma.
Epidemiological studies of afla-
toxin have provided strong evidence 
of a greater than multiplicative 
interaction between aflatoxin expo-
sure and chronic infection with hepa-
titis B virus in relation to increased 
risk of hepatocellular carcinoma 
[14,15]. Other factors may potentiate 
the risk of aflatoxin-induced hepa-
tocellular carcinoma. For example, 
many of the populations at high risk 
for hepatocellular carcinoma are also 
consumers of large amounts of maize 
that is frequently co-contaminated 
with both aflatoxins and Fusarium 
verticillioides toxins, in particular 
fumonisin B1 [14,16]. For example, 
fumonisin B1 treatment was shown 
to synergistically increase the num-
ber of preneoplastic liver lesions in 
aflatoxin B1-initiated rats and signifi-
cantly increased liver tumours in a 
dose-dependent manner in aflatoxin 
B1-initiated trout in a long-term fu-
monisin feeding study [14,16]. The 
mechanistic basis for fumonisin pro-
motion of aflatoxin B1 carcinogenicity 
in trout and preneoplastic lesions in 
rats is likely a result of inhibited bio-
synthesis of ceramide (a lipid media-
tor of cell death) and elevation in lev-
els of the mitogenic sphingoid base 
metabolite sphinganine-1-phosphate, 
a ligand for the G protein-coupled ex-
tracellular receptors S1P1–S1P5 [16].
Ochratoxin A is a liver and kidney 
carcinogen in animals and is found 
in maize, many small grain cereals, 
and other commodities such as 
grapes, coffee, and even some meat 
products [14]. The mechanistic basis 
for the carcinogenicity of ochratoxin 
A in animals is unclear. Ochratoxin 
A is a phenylalanine analogue that 
accumulates in the kidney via an 
organic anion transporter. Some of 
its biological effects are due to phe-
nylalanine mimicry [14]. Like fumoni-
sin, ochratoxin A causes changes 
in regulatory processes that affect 
cell survival and proliferation. There 
is also evidence for DNA adduct 
formation by ochratoxin A via both 
direct and indirect processes [14]. 
Ochratoxin A has, for many decades, 
been suspected as the cause of 
the high incidence of urinary tract 
tumours in the Balkans referred to 
as Balkan endemic nephropathy. 
However, epidemiological support 
for this is not clear. More recently, 
natural products and food contami-
nants derived from plants have also 
been implicated in the genesis of this 
disease [17].
Table 2.11.2. Naturally occurring organic chemical carcinogens produced by fungi
Agent
(fungal genera)a
Primary 
source of 
exposureb
Proposed mechanism of carcinogenicityc
Primary target 
or tumour 
sitesd
IARC 
evaluation of 
carcinogenicity 
to humans 
(NTP class)e
Aflatoxins
(Aspergillus sp.)
Food 
contaminant
Metabolism to DNA/protein-reactive epoxide 
→ TP53 mutations
Liver Group 1 (K)
Ciclosporin
(Tolypocladium and 
some Fusarium species)
Pharmaceutical Binds cyclophilin, blocks calcineurin and inhibits 
its phosphatase activity → immune suppression
Skin, 
lymphoma, 
other sites
Group 1 (K)
Aflatoxin M1
(Aspergillus)
Food 
contaminant
DNA-reactive epoxide → mutations Liver Group 2B
Fumonisin B1
(Fusarium sp.)
Food 
contaminant
Inhibition of ceramide synthase → disruption 
of lipid metabolism and signalling pathways 
regulating cell growth/tumour promoter
Liver, kidney Group 2B
Fusarium moniliforme 
toxins
(Fusarium sp.)
Food 
contaminant
Inhibition of ceramide synthase → disruption 
of lipid metabolism and signalling pathways 
regulating cell growth/tumour promoter
Liver, kidney Group 2B
Griseofulvin
(Penicillium sp.)
Antifungal 
agent
Disruption of microtubule formation via tubulin 
binding/mitotic inhibitor
Liver, thyroid Group 2B
Ochratoxin A
(Aspergillus and 
Penicillium species)
Food 
contaminant
Phenylalanine analogue/disruption of signalling 
pathways regulating cell growth/DNA adducts?
Kidney, liver Group 2B (R)
Sterigmatocystin
(Aspergillus sp.)
Food 
contaminant
Metabolism to DNA-reactive epoxide 
→ mutations
Liver, lung Group 2B
a For all fungi the most likely producing genera are given; the listing is not exhaustive.
b All of the agents listed can be produced by biosynthesis in situ, but for ciclosporin and griseofulvin exposure is in a controlled clinical setting.
c Where possible, the mechanism described is taken from the most recent IARC Monograph or IARC Scientific Publication.
d For cancer studies, the route of exposure was usually oral.
e Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable as to 
its carcinogenicity to humans; Group 4, probably not carcinogenic to humans. Only agents in Groups 1, 2A, and 2B are listed here. There are several naturally 
occurring agents classified by IARC as Group 3, but they are not included in this table. NTP, United States National Toxicology Program: K, known be a human 
carcinogen; R, reasonably anticipated to be a human carcinogen.
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Naturally occurring 
carcinogens produced by 
plants
A large number of compounds pro-
duced by plants have been charac-
terized as being dietary pesticides 
[18]. The number of so-called natural 
pesticides consumed (5000–10 000) 
and the amount (1.5 g/person/day) 
were also estimated, and it was 
speculated that many such biologi-
cally active compounds may exhibit 
carcinogenic activity in animal bio-
assays. Whether or not these esti-
mates are correct, a large number of 
biologically active organic chemicals 
are biosynthesized by plants to deter 
a range of threats to their survival, 
and to promote successful competi-
tion with other plants and response 
to injury. Many may be carcinogenic 
in rodent bioassays if administered 
at high levels.
Table 2.11.3 lists agents classi-
fied as human or animal carcinogens 
by IARC and produced by plants that 
have been used as food, food addi-
tives, or herbal medicines. A study 
conducted by the United States 
Centers for Disease Control and 
Prevention found that 10% of adults 
in the USA consumed herbal medi-
cines in 1999 [19].
Herbal medicines containing 
extracts or preparations from plants 
producing aristolochic acid have 
been used since ancient times. 
Some herbal medicines and foods 
continue to be a source of inten-
tional or inadvertent exposure to 
aristolochic acid. Contamination of 
wheat with seeds from Aristolochia 
species has been suggested as 
contributing to Balkan endemic ne-
phropathy [19,20]. This suggestion 
is supported by mechanistic data 
involving aristolochic acid-derived 
DNA adducts detected in tumour 
tissue from people with Balkan en-
demic nephropathy. These same ad-
ducts are found in animals treated 
with aristolochic acid, and the same 
mutation in the TP53 gene was seen 
in tumour tissues from patients with 
Balkan endemic nephropathy and in 
human TP53 knock-in mouse fibro-
blasts treated with aristolochic acid 
[20]. More recently, whole-exome 
sequencing, based on urothelial 
carcinoma from 19 individuals with 
documented exposure to aristolochic 
acid, has established a mutational 
signature involving A:T → T:A trans-
versions, indicating the power of this 
technique to reveal individual expo-
sure to particular carcinogens [20].
Lasiocarpine, monocrotaline, 
and riddelliine (Table 2.11.3) are 
examples of pyrrolizidine alkaloids 
produced by plants growing in arid 
regions. For example, riddelliine-
producing plants grow in desert 
areas of North America and are 
occasional contaminants of herbal 
products and food, but are most 
notable for poisoning of grazing 
Fig. 2.11.3. Aspergillus flavus (A) grown as colonies on Czapek yeast extract agar (left) 
and malt extract agar (right) at 25 °C for 7 days; (B,C) heads, bars = 20 μm; (D) conidia, 
bar = 5 μm. This organism produces aflatoxins.
Fig. 2.11.4. Aristolochia manshuriensis: 
(A) fruit twig, (B) flower, and (C) transverse 
section. Aristolochia species have been 
linked to endemic diseases of the kidney 
in the general population and in research.
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Table 2.11.3. Naturally occurring organic chemical carcinogens produced by plants that are used as herbal medicines, food, or 
food additives or contaminants
Agent/plantsa
Primary 
source of 
exposureb
Proposed mechanism of carcinogenicityc
Primary target 
or tumour 
sitesd
IARC 
evaluation of 
carcinogenicity 
to humanse
Aristolochic acid
(Aristolochia/Asarum 
species)
Herbal 
medicine, food 
contaminant
Metabolism to DNA-reactive nitrenium ion 
→ TP53 mutations
Urothelium Group 1
Plants containing 
aristolochic acid
(Aristolochiaceae family)
Herbal 
medicine, food 
contaminant
Metabolism to DNA-reactive nitrenium ion 
→ TP53 mutations
Urothelium Group 1
Bracken fern
(Pteridium sp.)
Food, food 
contaminant
DNA alkylating activity (ptaquiloside?) Bladder, 
gastrointestinal 
tract
Group 2B
Caffeic acid
(Coffee, fruits, 
vegetables, grains, 
argan oil)
Herbal 
medicine, food 
component
Antioxidant/increased cell proliferation/
lipoxygenase inhibitor
Kidney, 
gastrointestinal 
tract
Group 2B
Carrageenan, degraded Food additive Oxidative stress/inflammation Colorectum Group 2B
Dihydrosafrole and 
safrole
(Sassafras, essential 
oils, spices)
Food 
additive, food 
contaminant
Metabolism to DNA-reactive sulfo-oxy 
metabolites → mutations
Liver, lung, 
oesophagus
Group 2B
1-Hydroxyanthraquinone
(Tabebuia avellanedae, 
Morinda officinalis, and 
many other plants)
Herbal 
medicine
Induces inflammation in the colon/oxidative 
stress/mutagen?
Large intestine Group 2B
Lasiocarpine
(Boraginaceae family)
Food 
contaminant
Metabolism to DNA-reactive dehydronecine 
→ mutations
Liver, 
lymphoma, 
leukaemia
Group 2B
Methyleugenol
(Essential oils, basil, 
tarragon, nutmeg, and 
others)
Food 
additive, food 
contaminant
Metabolism to DNA-reactive sulfo-oxy 
metabolites → mutations
Liver, stomach, 
kidney
Group 2B
Monocrotaline
(Fabaceae family)
Food 
contaminant
Metabolism to DNA-reactive dehydronecine 
→ mutations
Liver, multiple 
sites 
Group 2B
Riddelliine
(Senecio sp., 
Leguminosae family)
Herbal 
medicine
Metabolism to DNA-reactive dehydronecine 
→ mutations
Liver, lung, 
leukaemia
Group 2B
a For all agents examples of natural sources of exposure are given; the listing is not exhaustive.
b All of the agents listed can be produced by biosynthesis in situ.
c Where possible, the mechanism described is taken from the most recent IARC Monograph or IARC Scientific Publication.
d For all cancer studies, including animal bioassays where relevant, the route of exposure was usually oral.
e Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable as to 
its carcinogenicity to humans; Group 4, probably not carcinogenic to humans. Only agents in Groups 1, 2A, and 2B are listed here. There are several naturally 
occurring agents classified by IARC as Group 3, but they are not included in this table.
animals that consume the producing 
plants. Consumption of herbal teas 
prepared from plants that produce 
pyrrolizidine alkaloids has poisoned 
humans and caused death; however, 
there are no available human car-
cinogenicity data for riddelliine or 
any of the other pyrrolizidine alka-
loids [21]. The mechanism of toxicity 
and carcinogenicity of pyrrolizidine 
alkaloids in animals involves their 
metabolism to DNA-reactive me-
tabolites that bind DNA and cause 
mutations in specific genes, most 
notably TP53 and the K-ras onco-
gene [21].
There are numerous other plant 
natural products classified by the IARC 
Monographs as being carcinogenic. 
However, exposure or production at 
levels sufficient to pose appreciable 
risk of biological effects is primarily 
through exposure in industrial/ 
occupational or clinical settings or by 
intake of the agent produced syntheti-
cally (Table 2.11.4). Examples are the 
pharmaceutical methoxsalen [17] and 
chemicals produced in an industrial 
setting that are also natural products 
of plant origin. Examples of agents that 
are natural products produced synthet-
ically for industrial uses are listed in 
Table 2.11.4 [22].
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Table 2.11.4. Naturally occurring organic chemical carcinogens derived from plants that are produced for industrial or medical uses 
but also can occur naturally in foods
Agent/plantsa Primary source of exposureb Proposed mechanism of carcinogenicity
c
Primary target 
or tumour 
sitesd
IARC 
evaluation of 
carcinogenicity 
to humanse
Methoxsalen (plus 
ultraviolet A radiation)
(Parsnip, parsley, other 
vegetables)
Pharmaceutical Photo-activation, DNA reactivity → mutations Skin Group 1
5-Methoxypsoralen
(Parsnip, parsley, other 
vegetables, bergamot 
and lime oils)
Pharmaceutical, 
cosmetic 
additive
Photo-activation, DNA reactivity → mutations Skin Group 2A
Acetaldehyde
(Many fruits, vegetables, 
essential oils)
Industrial 
chemical
Irritant/DNA damage/protein binding Upper 
respiratory tract
Group 2Bf
Benzophenone
(Grapes, black tea, 
papaya)
Industrial 
chemical
Endocrine disruption/oxidative stress Liver, kidney, 
histiocytic 
sarcoma in 
multiple sites
Group 2B
Catechol
(Fruits, vegetables, 
argan oil)
Industrial 
chemical
Metabolism to benzo-1,2-quinone, which 
binds to protein?
Stomach Group 2B
Cumene
(Zingiber officinale, 
fruits, vegetables, 
meat, many foods and 
beverages)
Industrial 
chemical
Metabolism to DNA-reactive α-methylstyrene 
oxide → mutations
Respiratory 
tract, spleen, 
liver, kidney 
Group 2B
Dantron (danthron)
(Xyris semifuscata, 
Rheum palmatum, some 
insects)
Industrial 
chemical
DNA damage? Tumour promoter Liver, 
gastrointestinal 
tract
Group 2B
2,4-Hexadienal
(Fruits, vegetables, 
meat, many foods and 
beverages)
Industrial 
chemical
Direct-acting DNA alkylating agent → 
mutations?
Forestomach, 
tongue, adrenal 
glands
Group 2B
Methyl isobutyl ketone
(Fruits, vegetables, 
meat, beverages)
Industrial 
chemical
Cytotoxicity, regenerative cell proliferation Liver, kidney 
(inhalation)
Group 2B
a For all agents examples of natural sources of exposure are given; the listing is not exhaustive.
b All of the agents listed can be produced by biosynthesis in situ.
c Where possible, the mechanism described is taken from the most recent IARC Monograph or IARC Scientific Publication.
d For cancer studies the route of exposure was most likely oral.
e Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable as to 
its carcinogenicity to humans; Group 4, probably not carcinogenic to humans. Only agents in Groups 1, 2A, and 2B are listed here. There are several naturally 
occurring agents classified by IARC as Group 3, but they are not included in this table.
f Acetaldehyde associated with consumption of alcoholic beverages is classified as Group 1.
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Summary
There is strong evidence that several 
early-life factors influence the occur-
rence of different types of cancer as 
well as other noncommunicable dis-
eases. Although stand-alone cohorts 
seldom have the statistical power to 
study cancer incidence directly, they 
can provide important information on 
how early-life exposures affect risk 
factors for common adult cancers, 
and thus contribute to their preven-
tion. A potential solution is to pool 
several cohorts to increase sample 
size; such efforts have been limited 
by different definitions of exposures, 
outcomes, and confounders, as well 
as variable ages at ascertainment. 
Greater efforts should be made to 
coordinate data collection in cohorts 
that are still in early life so that, sev-
eral decades from now, the problems 
that we are currently facing will have 
been overcome.
Why birth cohorts are 
important
The role of early influences in shap-
ing adult life has long been recog-
nized. Reviews of this topic often 
cite John Milton (“The childhood 
shows the man”; 1671) and William 
Wordsworth (“The Child is father of 
the Man”; 1802) as examples of the 
long-standing awareness of the im-
portance of early factors.
In the 1960s the field was sub-
stantially advanced by René Dubos, 
who proposed the idea of “biologi-
cal Freudianism” [1]. He built upon 
Sigmund Freud’s work on the last-
ing effect of early behaviours, and 
expanded it to study the role of early 
stimuli in general, with special em-
phasis on nutritional and infectious 
exposures. Among many remark-
able insights, Dubos highlighted the 
importance of the gut microbiota, a 
topic that is currently high on our re-
search agenda. The work of Dubos, 
however, relied heavily on animal 
models instead of epidemiological 
studies.
Current interest in early expo-
sures was boosted by the work of 
David Barker since the late 1970s. 
This evolved into the field of research 
that is currently known as develop-
mental origins of health and disease 
[2,3], focusing on how several non-
communicable diseases (NCDs) – 
particularly cardiovascular disease 
(CVD) and metabolic diseases – may 
be programmed by early events. So 
far, research on developmental ori-
gins of health and disease has main-
ly addressed exposures related to 
nutrition and growth patterns, both 
in utero and during the first years of 
life, but the concept applies to many 
different types of risk factors.
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Experimental studies on the 
long-term consequences of early-
life exposures on NCDs are most 
often unethical, impracticable, or 
both. There are some remarkable 
exceptions, such as the nutrition 
supplementation trials carried out in 
Guatemala in the 1960s [4]. Other 
trials, such as the Belarus breast-
feeding promotion trial [5] and the 
Hyderabad nutrition trial [6], are 
likely to eventually produce results, 
but their subjects are still too young.
As a result of the dearth of ex-
perimental studies, birth cohorts 
provide by far the largest amount of 
epidemiological evidence on early-
life exposures. For most risk factors, 
prospective cohorts with primary 
data collection by trained and stan-
dardized field workers offer more re-
liable and complete information on 
exposures and confounders than do 
retrospective cohorts or case–con-
trol studies.
There are many more studies 
about early-life influences on CVD 
and related metabolic diseases than 
is the case for cancer. Two main rea-
sons seem to explain this differen-
tial. First, incidence rates for CVD 
and metabolic conditions tend to be 
higher than those of most, if not all, 
cancers. Second, there are many 
well-established, easily measurable 
risk factors and biomarkers that may 
be used as surrogates for the risk of 
CVD and metabolic conditions, even 
among young adults. For example, 
studies of the associations between 
early growth patterns and adult body 
mass index, blood pressure, serum 
lipids, C-reactive protein, and so on 
are plentiful in the literature. The 
relatively high incidence of these 
diseases and the substantial preva-
lence of reliable risk markers mean 
that a relatively small sample size 
is adequate, and such associations 
may be investigated within cohorts 
with a few thousand participants, 
even if the subjects are still young 
adults.
The situation for cancer studies 
is more complex. Incidence rates are 
low compared with those for CVD 
or metabolic diseases, particularly 
among young adults. As a conse-
quence, large numbers of subjects 
must be followed up for several de-
cades to study disease incidence. 
And while early determinants as-
sociated with common risk factors 
for cancer (e.g. smoking and high 
body mass index) may be studied in 
individual cohorts, there is a sharp 
contrast between the large number 
of easily measureable CVD biomark-
ers and the few that are currently 
available for cancer.
Research on the early determi-
nants of cancer is therefore harder 
to carry out, as well as costlier, than 
similar studies for other NCDs, and 
will entail special requirements, 
which are addressed below.
Birth cohorts for studying 
NCDs: high-income countries
Existing prospective birth cohorts 
may be classified according to their 
sample size and duration of follow-
up, as well as the level of economic 
development of the country where 
they take place.
A recent PubMed search for birth 
cohort studies produced about 6900 
references. Of the 20 countries from 
which the largest number of articles 
originated, only Brazil (234 refer-
ences) and India (47 references) do 
not fall into the high-income country 
category. (As far as I know, there is 
no comprehensive roster of birth 
cohorts, but there are ongoing at-
tempts to register such studies on 
web sites – see http://www.birthco 
horts.net and http://www.chicospro 
ject.eu – as well as in the Cohort 
Profiles section in the International 
Journal of Epidemiology.)
Cohorts from high-income coun-
tries may be divided into two groups, 
according to duration of follow-up to 
the present time. The first group is 
made up of prospective cohorts with 
several decades of follow-up. The 
best-known examples include British 
and Scandinavian cohorts [7–12]. 
Typically, these studies have sam-
ple sizes of about 10 000 or fewer 
participants. While such numbers 
are sufficient for studying several 
CVDs, metabolic conditions, or men-
tal illnesses, they are seldom large 
enough for cancer outcomes. Few 
such analyses are therefore avail-
able in the literature – one example 
is a report on leukaemia [13] from 
the Jerusalem birth cohort, which 
started with more than 90 000 new-
borns recruited in the 1960s and 
1970s [14].
A limitation of long-running co-
horts is that – by definition – expo-
sure information was collected many 
years ago. Few cohort studies col-
lected biological samples, question-
naires were often very short and not 
standardized, and information on 
important exposures and confound-
ers was not collected. An example is 
the Aberdeen Children of the 1950s 
Study, which failed to collect what is 
today regarded as essential informa-
tion, such as parental smoking sta-
tus [15]. This limitation restricts the 
ability of such studies to answer im-
portant questions on consequences 
of early risk factors.
The second group of cohorts from 
high-income settings includes young 
cohorts. Some of these cohorts have 
very large sample sizes, such as those 
launched in the past decade or two 
in Denmark, Norway, and the USA, 
among other countries [16]. Most in-
clude state-of-the-art exposure mea-
surement tools, as well as collection 
and storage of biological samples. 
In terms of cancer epidemiology, 
early results from several of the new 
cohorts are already being pooled in 
the International Childhood Cancer 
Cohort Consortium [16], but unfortu-
nately it will take many years before 
these can provide information on how 
early exposures affect risk factors for 
common adult cancers. A limitation 
of very large cohorts is that there is a 
trade-off between sample sizes and 
the frequency and intensity of mea-
surements on individual participants. 
The most informative cohorts tend to 
be those with smaller sample sizes 
and more detailed measurements.
Birth cohorts for studying 
NCDs: low- and middle-
income countries
As discussed above, most publi-
cations about birth cohort studies 
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originate in high-income countries. 
Yet these countries account for only 
11 million births a year, compared 
with 121 million births in low- and 
middle-income countries (LMICs) 
(http://www.unicef.org/sowc2012/
statistics.php). Findings from high-
income countries tend to influence 
global policies, and yet these may 
not be applicable to LMIC popula-
tions. As an example, concerns 
raised about the long-term con-
sequences of higher birth weight 
or rapid weight gains in infancy, 
derived from cohorts where infant 
undernutrition is rare, do not apply 
to populations where poor nutrition 
and growth faltering are still highly 
prevalent [17]. In LMICs, rapid catch-
up growth may be essential, not only 
for short-term survival but also for 
long-term health and human capital 
[18,19].
There are other reasons why 
more cohorts from LMICs are need-
ed [20]. Risk factors may operate 
differently in each setting, as is the 
case for asthma [21]. The frequency 
of some exposures, including ma-
ternal and fetal undernutrition and 
infectious diseases, are markedly 
higher in LMICs. Even if exposures 
appear to have similar prevalence, 
their nature may vary; for example, in 
LMICs physical activity is mostly due 
to commuting and manual domes-
tic labour, whereas in high-income 
countries leisure-time activities are 
the prevailing types of physical ac-
tivity [22]. Last, confounders may 
operate in different directions in 
high-income countries and in LMICs, 
as was recently shown for the con-
founding effect of socioeconomic 
status on the association between 
breastfeeding duration and precur-
sors for chronic diseases [23].
For these reasons there is a 
third relevant group of birth cohorts, 
comprising those from LMICs with 
long follow-up times [24]. The best-
known of these studies are part of 
the Consortium of Health-Orientated 
Research in Transitioning Societies 
collaboration [25]. These five cohorts 
are providing important information 
on precursors for NCDs, particu-
larly CVD and diabetes, sometimes 
with conflicting results from those 
reported from high-income settings 
[26–30]. The Consortium of Health-
Orientated Research in Transitioning 
Societies collaboration, however, is 
unlikely to provide direct evidence 
on cancer incidence. First, the total 
number of subjects under follow-up 
is close to 10 000, resulting in low 
statistical power for rare outcomes. 
Second, linkage studies are not 
possible because of inadequate 
sources of secondary data such as 
cancer registration and vital statis-
tics. Another limitation is that none 
of these cohort studies collected 
biological samples in early life that 
could be analysed for biomarkers.
Other types of birth cohorts
The three categories of birth cohort 
studies discussed so far are not 
exhaustive. There are also several 
new, relatively small cohorts both in 
high-income countries and in LMICs. 
In LMICs, as far as I am aware, there 
is only one new cohort with more 
than a few thousand subjects: the 
China Children and Families Cohort 
Study, which started in 2006–2007 
and plans to enrol 300 000 births [16].
There are also several retrospec-
tive cohorts, as well as cohorts that 
are fully based on record linkage, 
particularly in European countries. 
Most of these include subjects born 
in the 1970s or later, so that follow-
up to the present time is about four 
decades. Also, because informa-
tion on exposures is derived from 
routine records, available data are 
relatively restricted and their quality 
is variable. This is not to say that 
these cohorts cannot make impor-
tant contributions to answering spe-
cific questions – for example, on the 
importance of birth weight – but their 
ability to address multiple risk factors 
and to control for confounding may 
be limited.
Famine studies, a special type 
of retrospective cohort, have led to 
important insights into the timing of 
nutritional insults and their effect on 
adult outcomes, including cancer 
[31–35]. However, these populations 
faced unusual hardship conditions 
during relatively short time periods, 
and as such may not reflect the na-
ture of exposures usually faced by 
populations, which tend to be less 
acute but have a longer duration.
Implications for future studies 
and collaborations
Birth cohorts have thus far provided 
invaluable amounts of evidence on 
the role of early-life exposures in 
adult diseases, but there is undoubt-
edly much more to be learned from 
existing and new cohorts.
A critical issue is that birth co-
horts take a long time to produce 
results. Those launched several 
decades ago, whose members are 
now at the age of highest incidence 
for most NCDs, including cancers, 
tend to have limited information on 
most early-life exposures. Cohorts 
launched in the past two decades 
tend to have much better exposure 
data as well as larger sample sizes, 
but will take a long time to produce 
results. A second trade-off is that 
large cohorts have greater statistical 
power but tend to have less frequent 
and less detailed assessments of 
early-life exposures than do smaller 
cohorts.
An obvious solution, therefore, is 
to pool cohorts to increase sample 
size and enhance external validity. 
An excellent example is the Emerging 
Risk Factors Collaboration, with 
data from more than 100 prospec-
tive studies with more than 2 million 
participants (http://www.phpc.cam.
ac.uk/ceu/research/erfc/). However, 
these cohorts recruited adults rather 
than pregnant women or newborns, 
and were assembled relatively re-
cently, so that better and more stand-
ardized information on exposures is 
available, compared with what may 
be obtained from older birth cohorts. 
There are also several new initiatives 
for pooling birth cohorts to address 
specific health conditions, but these 
tend to be restricted to relatively 
young cohorts [16,36,37].
I am unaware of any successful 
initiatives in pooling several long-
term birth cohorts from high-income 
countries, to study cancer outcomes 
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or other NCDs. Even with large sam-
ple sizes, however, long-running co-
horts are unlikely to have collected 
much information that is now consid-
ered as essential. For example, few 
if any cohorts have stored biological 
samples collected in childhood.
My own experience, and certain-
ly that of others involved in such ex-
ercises, is that there are major gains 
from pooling cohorts, but there are 
also important difficulties. Pooling is 
easier said than done. We recently 
summarized the barriers we had to 
face in the Consortium of Health-
Orientated Research in Transitioning 
Societies network [25]:
Some of the weaknesses include: (i) 
differences in variable definitions, or 
in measurement techniques across 
sites (this affects exposures, out-
comes and confounding variables), 
which means that major effort has 
gone into producing a common data 
set; (ii) the different ages of individu-
als across the five cohorts and the 
different time periods they reflect; 
(iii) the different ages for which data 
are available throughout infancy 
and childhood; (iv) heterogeneity in 
the results for some of the analy-
ses, for example, those on body 
composition. In order to overcome 
these limitations, we have restricted 
potential analyses to those includ-
ing variables collected consistently 
across the cohorts; likewise, we 
have limited the analyses to ages 
with data available for all (or most) 
cohorts. In some analyses, different 
outcome variables have been used 
(e.g. pre-hypertension for adoles-
cents and hypertension for adults) 
because of the different ages of the 
individuals across cohorts.
Similar difficulties have been re-
ported by investigators involved in 
pooling younger birth cohorts from 
high-income countries [16].
Stand-alone, long-term birth 
cohorts also face important chal-
lenges. Attrition is possibly the most 
important issue. In the 1982 Pelotas 
(Brazil) birth cohort study, which I 
coordinate, we achieved relatively 
high follow-up rates (68% at the re-
cently completed 30-year visit), but 
even so individuals who were lost 
to follow-up differ in many ways 
from those who came to the clinic. 
Ensuring consistency and standardi-
zation of exposure measures over 
time – when methods are constantly 
evolving – is another major chal-
lenge. Obtaining continued funding 
is also problematic, because donor 
fatigue affects even the most suc-
cessful studies.
How can these challenges be 
overcome? Ideally, one would like 
to design an international birth co-
hort, involving multiple countries at 
different stages of development, with 
large sample sizes in each country. 
Measurements would take advan-
tage of the variety of new tools that 
are now available, including genetic, 
epigenetic, microbiome, and expo-
some assessments [38], among 
others. This design would allow 
analyses not only at an individual 
level but also at an ecological level, 
because some exposures may affect 
most, if not all, subjects from a given 
site [39]. Information on exposures 
would be collected at similar ages 
at all sites, using similar methods, 
including questionnaires, biological 
samples, and environmental mea-
surements. Obviously, this would be 
a massive undertaking with major 
practical difficulties, as has been 
shown by the long inception period 
that has been required for the United 
States National Children’s Study 
(http://www.nationalchildrensstudy.
gov/Pages/default.aspx). In addition 
to the major scientific challenges to 
be faced, finding sufficient finan-
cial resources for such a large co-
hort would require pooling funding 
agencies over an extended period of 
time – possibly an even harder task 
than pooling research teams.
A special plea must be made 
for multipurpose birth cohorts, ad-
dressing several different outcomes, 
related not only to health but also to 
human capital. This will allow us to 
investigate the full impact of early-life 
factors, because some exposures 
may positively affect some adult 
outcomes and have a detrimental 
effect on others. For example, adult 
height is largely determined by the 
linear growth velocity up to the age 
of 2 years [40]. Taller adults have 
greater incidence of several types of 
cancer [41] but also tend to be more 
intelligent, have higher schooling, 
and earn higher wages [19], as well 
as having lower all-cause mortal-
ity, largely due to protection against 
deaths due to CVD [42]. Only studies 
that capture multiple dimensions of 
human health and development can 
assess the overall effect of early-life 
exposures and growth patterns over 
the life-course.
In conclusion, there is strong 
evidence that several early-life fac-
tors influence the occurrence of 
different types of cancer as well as 
other NCDs. Whereas stand-alone 
cohorts seldom have the statistical 
power to study cancer incidence di-
rectly, they may provide important 
data on how early-life exposures af-
fect the adult prevalence of risk fac-
tors for cancer, and thus contribute 
to their prevention. Pooling several 
cohorts to increase sample size is 
a potential solution, but so far such 
efforts have been limited by different 
definitions of exposures, outcomes, 
and confounders, as well as variable 
ages at ascertainment. Greater ef-
forts should be made to coordinate 
data collection efforts in cohorts that 
are still in early life so that, several 
decades from now, the problems 
that we are currently facing will have 
been overcome.
I would like to thank Ezra Susser and Jørn 
Olsen for useful inputs to this Perspective.
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An understanding of cancer biology is critical to de-
velop rationally designed therapy and offer preven-
tive options. For decades, relevant knowledge has 
been sought by describing how cancer cells differ 
from normal cells – something being elucidated far 
more rapidly in the post-genomic era. Specification of 
the human genome has enabled the identification of 
how various types of tumour cells differ from normal 
cells in multiple parameters, including relevant so-
matic mutations and altered gene expression, which 
is often determined through epigenetic change such 
as alterations in DNA methylation patterns. Mutation 
or epigenetic change may mediate, amongst other 
effects, altered metabolism or modified intracellular 
signalling in response to growth-altering stimuli. In 
parallel, the roles of cancer stem cells and the tumour 
microenvironment have been recognized. Accordingly, 
description of how inflammation, growth of new blood 
vessels, and modification of the immune response 
mediate tumour growth now also enables options for 
cancer prevention and treatment to be identified.
Cancer 
biology
3
184
Summary
• All cancers harbour mutations 
in their genome, some of which 
have profound effects on the bi-
ology of the cancer cell by driv-
ing tumour growth that subse-
quently leads to cancer-related 
death.
• The types and subtypes of can-
cer, as well as the spectrum of 
cancer-causing mutations, dif-
fer considerably across world 
populations because of genetic 
diversity within communities 
and between individuals as well 
as diverse chemical exposures, 
infections, dietary components, 
and other factors that give rise 
to mutations.
• The International Cancer Ge-
nome Consortium was estab-
lished to generate a catalogue 
of cancer mutations for more 
than 25 000 tumours represent-
ing 50 types of cancer that are 
variously of clinical and societal 
importance across the globe.
• The Consortium is making the 
data available to the research 
community as rapidly as pos-
sible to accelerate research 
into the etiology of cancer and 
development of tailored cancer 
treatment based on unique 
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mutation profiles that are spe-
cific to individual tumours.
From the perspective of genome sci-
entists, cancer is a disease of the 
genome. All cancers harbour muta-
tions in their genome. Some of these 
mutations have profound effects on 
the biology of the cancer cell by driv-
ing tumour growth. Some mutations 
can inactivate genes that usually 
protect cells from abnormal prolifera-
tion; these are classically referred to 
as tumour suppressor genes. Other 
mutations can result in proteins with 
oncogenic functions that stimulate 
cell growth or provide other advan-
tages to cancer cells, thus affecting 
biological pathways involved in the 
transformation of normal cells into 
cancer cells [1,2].
As the new millennium dawned, 
scientists working on the Human 
Genome Project revealed the first 
comprehensive view of the sequence 
of a “normal” human genome and its 
constituents: protein-coding genes, 
non-coding RNAs, and non-coding 
sequences conserved across spe-
cies, providing clues to regulatory el-
ements required for gene expression 
as well as catalogues of genetic vari-
ants (or polymorphisms) representing 
genomic diversity among individuals 
within and across populations [3]. 
When the first draft of the human 
genome sequence was released, it 
was estimated that more than 100 on-
cogenes and 30 tumour suppressor 
genes had been identified [4].
The types and subtypes of cancer, 
as well as the spectrum of cancer-
causing mutations, vary considerably 
across world populations as a result 
of environmental differences, such 
as chemical exposures, infections, 
diet, and other factors, and popula-
tion diversity in the genes encod-
ing molecules that interact with the 
exogenous factors. In a new era of 
genome sciences and technologies 
[5,6], it became possible to conceive 
of systematic genome-wide searches 
of mutations in tumour genomes from 
a diversity of cancers originating in 
various organs of the body and affect-
ing individuals in different parts of the 
world. This concept became a reality 
relatively quickly as it became clear 
that cancer-causing mutations could 
be used as biomarkers to inform clini-
cal decisions. Thus, KRAS mutations 
may indicate non-responsiveness 
to drugs that inhibit a growth factor 
(EGFR) often found in colon cancer. 
Biomarkers may inform application 
of new targeted drugs such as tras-
tuzumab, for breast cancers over-
expressing the HER2 protein, and 
imatinib, a tyrosine kinase inhibitor 
effective in chronic myeloid leukae-
mia harbouring a specific mutation 
called the Philadelphia translocation 
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[7]. Understanding the mutational 
profiles of tumours in patients in dif-
ferent regions of the world is funda-
mental to translating genomic knowl-
edge into diagnostic and treatment 
strategies, and for developing new 
targeted solutions for cancer control.
An international network was 
established to generate a catalogue 
of cancer mutations for more than 
25 000 tumours representing 50 
types of cancer [8]. This monumen-
tal effort came together in 2007 as 
the result of advances in genome 
sequencing technologies [6] and ex-
perience gained in pilot projects in 
the United Kingdom and the USA. 
International leaders in cancer 
and genome research convened in 
Toronto to establish a framework for 
an internationally coordinated effort 
that would generate comprehensive 
catalogues of cancer mutations [9]. 
With support from governmental 
and philanthropic granting agen-
cies, teams of clinicians, scientists, 
ethicists, and computer scientists 
assumed responsibility for the com-
prehensive study of cancer genomes 
from one or more types of cancer un-
der the auspices of the International 
Cancer Genome Consortium. This 
decade-long project will ultimately 
engage more than 1000 clinicians 
and scientists, who will be involved 
in generating data and analysing 
more than 25 000 cancer samples. 
Following the principles adopted by 
the Human Genome Project, the 
Consortium is making the data avail-
able to the research community as 
rapidly as possible, and with minimal 
restrictions, to accelerate research 
into the causes and control of cancer.
Between October 2008 and 
January 2013, there has been a 
steady increase in the number of tu-
mour genome analyses undertaken 
by the International Cancer Genome 
Consortium, and the initial goal of 
25 000 has now been surpassed 
(Fig. 3.1.1). As of January 2013, the 
halfway stage of the International 
Cancer Genome Consortium effort, 
55 projects were under way in Asia, 
Australia, Europe, North America, 
and South America (Fig. 3.1.2). 
These projects will cover most of the 
common tumour types in participat-
ing countries (Fig. 3.1.3). At the half-
way point in a decade-long initiative, 
the Consortium is providing cancer 
genome data sets from 7358 tumours 
(Fig. 3.1.4) to the international com-
munity via an Internet portal. To en-
able users to access the data and 
perform queries that will enable fur-
ther cancer research, several data 
portals and search tools have been 
created by the Consortium and other 
organizations (Table 3.1.1). Despite 
this rapid growth of information, the 
task of completing the project and ac-
celerating the translation of cancer 
genome information into clinically 
useful data will face several chal-
lenges, which are summarized below.
Biological challenges
Biological complexity results from 
many factors. One is that there are 
numerous types of cancer-causing 
mutations. The simplest mutations 
affect single DNA bases, such as 
the substitution of one nucleotide 
for another or the insertion or dele-
tion of a nucleotide. Some mutations 
involve segments of a chromosome 
that are increased in number, typi-
fied by copy number gains and am-
plifications; others involve deletions 
of one or both copies of a gene, or 
sequences that are aligned in a di-
rection opposite to their original ori-
entations on normal chromosomes, 
referred to as inversions. Some 
mutations involve translocations 
between chromosomes. For exam-
ple, the Philadelphia translocation 
mentioned previously results from 
the joining of chromosomes 9 and 
22 and is observed in approximately 
95% of patients with chronic myeloid 
leukaemia. In 2–3% of all cancers 
and more frequently in bone cancers 
and medulloblastomas, rearrange-
ments are widespread and complex, 
a phenomenon called chromothrip-
sis (or chromosome shattering) [10]. 
Cancer cells may also acquire DNA 
from viruses such as Epstein–Barr 
virus, hepatitis B virus, and hu-
man papillomavirus. In defining its 
guidelines, the International Cancer 
Genome Consortium established 
recommendations that will lead to 
all forms of mutations affecting DNA, 
RNA, and methylation being de-
tected and catalogued. In practice, 
this usually requires the generation 
of different laboratory protocols for 
each mutation category, followed 
by parallel detection of normal and 
mutated constituents using high-
throughput detection technologies 
[5–7].
A second reason for the biologi-
cal complexity is the large number of 
mutations observed in every tumour. 
This is not unexpected given the fre-
quent observations of chromosome 
anomalies revealed by cytogenetic 
Fig. 3.1.1. Growth in the number of tumour genome analyses undertaken by International 
Cancer Genome Consortium members.
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studies over many decades. The mu-
tation spectra in cancer cells were 
further elucidated by whole cancer 
genome sequencing, which revealed 
an extensive number of putative so-
matic mutations in every cancer ge-
nome; for example, 33 345 somatic 
base substitutions were observed 
in the first melanoma genome and 
22 910 in the first small cell lung 
cancer genome [11,12]. These large 
numbers of somatic mutations usu-
ally result from repeated exposure 
to carcinogens (e.g. tobacco smoke 
or ultraviolet radiation) and defec-
tive DNA repair pathways found in 
cancer cells [1], and thus occur ran-
domly across the genome.
Some mutations occur in se-
quences that are functional and af-
fect cellular mechanisms that pro-
vide growth advantages to cells, 
such as oncogenic mutations or 
inactivating mutations involving 
tumour suppressors. These are of-
ten referred to as driver mutations, 
while the remaining majority of so-
matic mutations with no biological 
consequence are called passenger 
mutations [5]. The large numbers 
of mutations also indicate the long 
history between initiation of cancer 
and clinical manifestations for most 
cancers. There are exceptions to 
this, as some cancer types (usually 
paediatric) have low mutation rates. 
For example, rhabdoid tumours 
are highly aggressive cancers of 
early childhood with extremely low 
numbers of mutations, including a 
characteristic driver mutation in the 
SMARCB1 gene that is observed in 
all cases [13].
Heterogeneity of driver mutations 
among patients with similar forms 
Fig. 3.1.2. National locations of International Cancer Genome Consortium projects as of January 2013.
Fig. 3.1.3. Numbers of tumours, as indicated by numbers of donors, for each tumour 
type to undergo comprehensive genome analyses by International Cancer Genome 
Consortium members.
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Fig. B3.1.1. Frequency of TP53 mutations in various cancer types (histogram) and 
localization of mutation hotspots in the DNA-binding domain of the p53 protein 
(three-dimensional structure).
TP53 mutations and human cancer
Magali Olivier
The tumour suppressor gene TP53 
has been recognized as an impor-
tant anticancer gene for more than 
20 years because of its frequent 
alteration in most human cancers. 
TP53 encodes a protein of 393 
amino acids, p53, which plays an 
important role in the maintenance 
of cell integrity by responding to vari-
ous forms of cellular stresses and 
acting as a multifunctional protein 
through the control of various cel-
lular pathways. p53 has been shown 
to repress proliferative signalling, 
enhance the effects of growth sup-
pressors, sensitize cells to apoptosis 
and autophagy, suppress replicative 
immortality through senescence, 
promote genetic and genomic sta-
bility, control inflammation, exert 
anti-angiogenic effects, and repress 
metastasis, thus counteracting a 
large panel of tumour-promoting 
cellular activities [1]. Because of 
this large spectrum of anti-tumour 
functions, inactivating p53 function 
is an essential step during cancer 
development, and this is most fre-
quently achieved by mutating the 
TP53 gene. TP53 mutations are 
found in all cancer types with vari-
ous frequencies, ranging from 5% 
to 90% (Fig. B3.1.1). Recent whole-
genome and exome sequencing 
studies have confirmed that TP53 
is the most frequently mutated gene 
in most cancers.
IARC maintains a database that 
documents all TP53 gene variations 
reported in the scientific literature 
(http://p53.iarc.fr). More than 30 000 
somatic mutations are compiled, 
with annotations on tumour phe-
notype, patient characteristics, and 
structural and functional impacts of 
mutations [2]. Most TP53 mutations 
are single-amino-acid substitutions 
that are located in the DNA-binding 
domain of p53 and disrupt the tran-
scriptional activities of p53. Due to 
the three-dimensional structure of 
the p53 DNA-binding domain and its 
crucial function, most single-amino-
acid substitutions would disrupt p53 
function. As a result, mutations ob-
served in cancers are very diverse 
and are scattered along the entire 
coding sequence, although some 
mutation hotspots are observed. 
Some hotspots, such as codons 175, 
248, 273, 220, and 245, are found 
in all cancer types, while others are 
cancer-specific (such as codon 249 
in liver cancer, or codons 280 and 
285 in bladder cancer) (Fig. B3.1.1).
TP53 mutations may be used as 
diagnostic and prognostic markers 
in the clinic, and several drugs that 
target the p53 pathway are being de-
veloped [1]. TP53 mutations are also 
informative markers for carcinogen 
exposure. Indeed, specific TP53 mu-
tation patterns have been described 
in relation with exposure to ultravio-
let radiation in skin cancer, tobacco 
smoke in lung cancer, aflatoxins in 
liver cancer, or aristolochic acid in 
upper urinary tract cancers [3]. TP53 
mutations can thus be useful mark-
ers in molecular epidemiology stud-
ies to investigate tumour etiology.
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of cancer is an important source of 
complexity. In a survey of 100 breast 
tumours analysed for somatic muta-
tions and copy number alterations, 
both gains and deletions, in approxi-
mately 21 500 protein-coding genes, 
also called an exome, 40 genes 
were implicated as driver mutations 
across the set, of which 7 were seen 
in more than 10% of cases and 33 
were infrequent [14]. While some 
cells had more than one recognized 
driver mutation (the maximum seen 
in this study was six), 28 cases had 
only one. This study illustrates that 
most breast cancers differ from one 
another in the number of mutations 
and the set of driver mutations.
Another source of complexity is 
due to tumour masses usually be-
ing composed of different cancer 
cell subpopulations carrying related 
but distinct mutation profiles [15]. 
Over time and across metastatic 
lesions of a single patient, muta-
tion spectra evolve. Although not 
surprising given the high mutation 
rates in patients, this evolution has 
many consequences, of which the 
most serious is the acquisition of 
drug resistance, either through new 
mutations in genes that alter critical 
drug receptors or pharmacogenomic 
pathways or through the ability of 
subclones that are insensitive to 
drugs to outcompete other clones 
that are not, after therapy. Thus, 
the dynamic evolution of cancer 
genomes is emerging as a critical 
factor in explaining disease relapse 
and, ultimately, cancer deaths.
Opportunities for research on 
etiology
The first melanoma and small cell 
lung cancer genomes [11,12] have 
revealed that genome-wide mutation 
patterns, or “mutation signatures”, 
reflect exposure to environmental 
carcinogens (ultraviolet radiation, 
tobacco smoke). The mutation sig-
natures found genome-wide in a sin-
gle tumour were amazingly similar 
to those described in a single gene, 
TP53 (see “TP53 mutations and hu-
man cancer”). Similar striking muta-
tion signatures have been reported 
in upper urinary tract cancers linked 
to exposure to aristolochic acid 
[16]. More systematic research on 
mutation signatures across cancer 
types has revealed recurrent muta-
tion signatures in cancer genomes 
[17]. Through correlation of muta-
tion signatures and exposures, the 
underlying mutagenic mechanisms 
causing some of these signatures 
could be deduced from previous 
knowledge (smoking, ultraviolet ra-
diation, age, BRCA1/2 germline mu-
tations). However, many signatures 
remain unexplained and have led to 
new hypotheses about mutagenic 
mechanisms. For example, some 
signatures have been attributed 
to the APOBEC family of cytidine 
deaminases. As these enzymes 
are involved in the innate immune 
response to viruses and retrotrans-
posons, the presence of these sig-
natures might reflect an enhanced 
activity of APOBEC family members 
caused by a viral infection. These 
results may thus stimulate research 
on the potential role of viral infection 
in the development of new cancer 
types [18].
Research into associations be-
tween mutation signatures and ex-
posures, through genomic epidemi-
ology studies and model systems 
of induced mutagenesis, has great 
potential to uncover new causal links 
between the mutagenic processes 
and the influence of environmental 
exposures. For these new research 
opportunities to have worldwide 
benefits, it is important for such 
genomic epidemiology studies to 
consider geographical heterogeneity 
in etiologies and to focus on expo-
sures and cancer types relevant to 
low- and middle-income countries.
Technological challenges
Although genomic technologies 
are not discussed in detail in this 
Report, this topic is relevant to data 
generators, users of data available 
in International Cancer Genome 
Consortium and other databases, 
and future adoptees of genomic 
technologies for clinical applica-
tions. Given the recent development 
of most of these technologies, as 
well as the associated computa-
tional challenges, it is recognized 
that each data set contains false-
positive results and is incomplete 
(i.e. contains false negatives). To 
facilitate the task of future users of 
Consortium data sets, various quali-
ty control metrics, including second-
ary validation of potentially deleteri-
ous mutations, are conducted and 
reported. It is thus essential for ex-
perts and non-experts to be aware 
that the technology has limitations 
and that potentially important muta-
tions of clinical relevance require 
independent validation.
Fig. 3.1.4. Growth in the number of cancer genome data sets available via the 
International Cancer Genome Consortium Data Portal (http://dcc.icgc.org). Each colour 
represents a different tumour subtype.
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The rapid expansion of cancer 
genome data sets being generated 
is creating formidable challenges 
[19]. For each tumour, numerous 
types of primary data are collect-
ed, including clinical information, 
pathological data, DNA sequences 
(from normal and tumour tissues for 
the detection of several mutation 
categories, including simple base 
substitutions, copy number chang-
es, and other structural alterations), 
methylation, and RNA expression. 
In addition, interpreted data such 
as functional consequences of 
mutations to protein structure and 
potential clinical correlates also 
need to be recorded in robust and 
user-friendly databases. As these 
individual-specific data sets be-
come integrated at the project level 
and ultimately analysed across all 
tumour types, the computational 
challenges are daunting. Similarly, 
how this information is effectively 
disseminated to the wider scien-
tific community (via descriptive 
databases or through transfer and 
analysis of the large amounts of 
Table 3.1.1. Internet resources for cancer genomics data
Resource Website Description
International Cancer Genome Consortium 
(ICGC)
http://dcc.icgc.org/ The ICGC Data Portal provides access to 
cancer genome data and project data from 
ICGC members.
The Cancer Genome Atlas (TCGA) https://tcga-data.nci.nih.gov/tcga/
tcgaHome2.jsp
The TCGA Data Portal provides a platform 
for researchers to search, download, 
and analyse cancer genome data sets 
generated by institutions in the USA 
contributing to TCGA.
Catalogue of Somatic Mutations in Cancer 
(COSMIC)
http://www.sanger.ac.uk/genetics/CGP/
cosmic
COSMIC stores and displays curated 
somatic mutation data and other 
information related to human cancers.
Broad Institute Integrative Genomics 
Viewer (IGV)
http://www.broadinstitute.org/igv/ IGV is a high-performance visualization 
tool for interactive exploration of large, 
integrated genomic data sets.
University of California Santa Cruz (USCS) 
Cancer Genomics Browser
https://genome-cancer.soe.ucsc.edu The UCSC Cancer Genomics Browser is 
a suite of web-based tools to visualize, 
integrate, and analyse cancer genomics 
and its associated clinical data.
United States National Cancer Institute’s 
Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET)
http://target.nci.nih.gov/dataMatrix/
TARGET_DataMatrix.html
TARGET data sets include genomic 
characterization, full clinical information, 
and sequencing files for five common 
types of childhood malignancies: acute 
lymphoblastic leukaemia, acute myeloid 
leukaemia, neuroblastoma, osteosarcoma, 
and Wilms tumour.
Fig. 3.1.5. Figurative depiction of somatic mutations present in a single cancer genome, 
part of a catalogue of somatic mutations in the small cell lung cancer cell line NCI-H2171. 
Individual chromosomes are depicted on the outer circle, followed by concentric tracks 
for point mutation, copy number, and rearrangement data relative to mapping position 
in the genome. Arrows indicate examples of the various types of somatic mutation 
present in this cancer genome.
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raw data) also presents formidable 
challenges.
International issues
The most intense cancer genome re-
search was initially concentrated in 
developed nations with a track record 
in large-scale genome research. 
When the International Cancer 
Genome Consortium was launched, 
a remarkable effort was made by 
funding agencies in many countries 
to participate, not only as a way of 
ensuring that cancers common in 
their respective populations were in-
vestigated but also to build capacity 
in next-generation sequencing tech-
nologies and allow their communities 
of scientists to be actively involved 
in cutting-edge research. For exam-
ple, India established the National 
Institute of Biomedical Genomics in 
Kalyani, West Bengal, to conduct a 
Consortium project to study gingi-
vo-buccal cancer. This form of oral 
cancer, which accounts for 30% of 
all cancers in India [20], is due to 
the habit of chewing tobacco with 
betel quid.
At the halfway mark in the 
Consortium’s decade-long initiative, 
many types of cancer across the 
globe are being studied, but there 
are still obstacles (economic bar-
riers, limited infrastructures for 
biobanking, paucity of skills, etc.) 
in analysing some forms of cancer 
that are common in some low- and 
middle-income countries (notably 
in Africa). Several approaches that 
may be considered to resolve this 
include collaborations between 
cancer care workers in these 
countries and international lead-
ers in cancer research (including 
Consortium members), leveraging 
the expertise already established 
in these countries for conducting 
clinical trials for infectious diseas-
es, and establishing a distributed 
model for tumour banking driven by 
standard operating procedures.
Legal and regulatory frame-
works that differ among internation-
al jurisdictions have the potential to 
hinder the exchange of data among 
collaborating groups in different 
countries and also to limit the shar-
ing of data via the Internet. Some 
valid reasons for placing restrictions 
on data include protection of pri-
vacy and the potential that misuse 
could harm individuals. For these 
reasons, the International Cancer 
Genome Consortium implemented 
robust governance procedures for 
handling data from human subjects, 
including the adoption of common 
bioethical elements and harmonized 
consent procedures [8]. Moreover, 
the Consortium structured its 
databases to classify data that can-
not be used to identify individuals as 
“open”, or unrestricted and publicly 
accessible. In parallel to this, the 
Consortium created mechanisms 
to classify more sensitive genetic 
and clinical information that could 
be misused by third parties to re-
identify participants as “controlled”, 
and available only to scientists and 
research institutions agreeing to 
conditions stipulated in an access 
agreement. Oversight of this pro-
cess is conducted by an interna-
tional committee [8,21].
Conclusions and next steps
Cancer genomics is a research field 
that is growing rapidly as a result of 
new genomic technologies. Given 
the fundamental role that mutations 
play in the development of cancer, 
cancer genomes will continue to be 
analysed and mined for additional 
clues that will increase our under-
standing of cancer cells, for biomark-
ers that will be used as indicators of 
prognosis and treatment response, 
and for targets that will be evaluated 
as substrates for new cancer drugs. 
The impact of this progress is appar-
ent not only in the growing number of 
targeted agents being developed by 
biotechnology and pharmaceutical 
companies but also in the reduced 
time between identification of driver 
mutations and approval of a specific 
targeted therapy by regulatory agen-
cies [7].
The diversity of mutational pro-
cesses underlying development of 
cancer is evident from an analysis of 
4 938 362 mutations from 7042 can-
cers. The prevalence of mutations 
varied over more than 5 orders of 
magnitude; childhood cancers car-
ried the fewest, and cancers related to 
chronic mutagenic exposures, such 
as tobacco smoke or ultraviolet ra-
diation, exhibited the most (> 400 per 
megabase of DNA). Mutations were 
Fig. 3.1.6. Next-generation gene sequencing equipment in use at the Joint Genome 
Institute in Walnut Creek, California. Large-scale cancer genome studies are already 
applying next-generation sequencing technologies to tumours from 50 different cancer 
types to generate more than 25 000 cancer genomes.
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categorized on the basis of 96 pos-
sible scenarios, and 21 distinct mu-
tational signatures were defined in 
relation to 30 cancer classes [22].
It is expected that the growth 
in cancer genome information will 
continue exponentially, from thou-
sands to millions of tumours in the 
next decade. Most of this growth is 
happening as a consequence of new 
sequencing technologies that are be-
coming easier to adapt to clinical lab-
oratory environments. The feasibility 
of cancer clinical sequencing that 
is used in selecting therapies has 
been demonstrated in the clinical 
trials setting [23]. The challenges in 
converting cancer genome analyses 
into improved diagnosis, prognosis, 
and treatment are formidable, but 
the impact will be felt increasingly by 
health-care systems, clinicians, and 
patients [24].
Recently, the Cancer Genome 
Atlas Research Network docu-
mented point mutations and small 
insertions or deletions from 3281 
tumours across 12 tumour types, 
including a clinical association anal-
ysis. Overall, mutations in several 
genes, including BAP1, DNMT3A, 
KDM5C, FBXW7, and TP53, corre-
lated with poor prognosis, whereas 
mutations in two genes, BRCA2 and 
IDH1, often correlated with improved 
prognosis [25].
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• Cancer genome-wide associa-
tion studies have successfully 
identified many new susceptibil-
ity alleles in the human genome, 
most of which are unique to 
each type of cancer.
• Cancer genome-wide asso-
ciation studies will continue to 
discover an increasing fraction 
of the common susceptibility al-
leles, and have uncovered dis-
tinct genetic architectures for 
specific cancer susceptibilities.
• Findings from cancer genome-
wide association studies have 
provided new mechanistic in-
sights into cancer etiology, in-
cluding changes in the regula-
tion of key genes and pathways. 
Investigations of the relationship 
between germline susceptibility 
alleles and somatic alterations 
should uncover new pathways 
and targets for therapeutic and 
preventive measures.
• Clinical cancer genetics will 
profit from the determination of a 
more comprehensive catalogue 
of susceptibility alleles, across a 
spectrum of frequencies and ef-
fect sizes, which could be imple-
mented in precision medicine.
3.2
3 BIOLOGY
Genome-wide 
association studies
Stephen J. Chanock Dongxin Lin (reviewer)
Paul Pharoah (reviewer)
For nearly half a century, the herita-
ble contribution to cancer has been 
investigated, beginning with studies 
of families in which multiple mem-
bers developed the same type of 
cancer [1]. As the draft sequence of 
the human genome was completed 
[2,3], its annotation revealed a wide 
spectrum of genetic variation, from 
single base changes to large struc-
tural alterations and copy number 
variations [4]. Traditionally, investiga-
tors have focused on the single base 
substitution, known as the single- 
nucleotide polymorphism (SNP); 
the frequency of the alternative nu-
cleotide is captured by the minor al-
lele frequency (MAF). Differences 
in human populations are etched 
in the patterns of genetic variation; 
this includes both the correlation 
between nearby variants, known as 
linkage disequilibrium, and the ac-
tual frequencies of common variants, 
measured by the MAF. In turn, these 
differences have become attractive 
for investigating differences in inci-
dence for distinct cancers, by either 
population or exposure.
Cancer susceptibility alleles 
can be discovered by different 
approaches, such as linkage and 
association analyses; the tools 
have improved substantively, 
shifting from genotyping of sin-
gle tandem repeats and SNPs to 
whole-genome sequence analysis 
using next-generation sequencing 
technologies. Not all alleles have 
comparable estimated effects 
(Fig. 3.2.1) [5]. Linkage analyses in 
family studies are used to discover 
highly penetrant mutations, as in 
BRCA1 or TP53, which are rare but 
have a strong predictive value. Due 
to the limitations in available tools, 
only a small fraction of pedigrees 
have been explained by mutations 
in “cancer susceptibility genes”. 
These have provided a foundation 
for clinical cancer genetics.
Common susceptibility alleles 
are discovered by association stud-
ies, which compare allele frequen-
cies between affected and unaf-
fected individuals (Fig. 3.2.2). The 
estimated effect sizes are smaller 
for common variants and are neither 
necessary nor sufficient for cancer 
susceptibility (Fig. 3.2.1). Moreover, 
common variants contribute to a 
polygenic model for susceptibil-
ity, akin to complex diseases like 
diabetes and neurodegenerative 
disorders.
In 1996, Risch and Merikangas 
argued that linkage analysis for com-
plex diseases would be less efficient 
than association analyses in popula-
tions for mapping common variants 
with smaller effect sizes [6]. The field 
turned towards association studies, 
initially using the candidate gene 
approach, in which investigators 
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chose favourite genes or variants 
for testing, but with little success. 
Generally, reported findings failed 
to be replicated in subsequent stud-
ies, for a variety of reasons that 
included issues in study design, 
small sample sizes, and unrealistic 
expectations for effectively choos-
ing functional variants. The candi-
date gene approach yielded less 
than a dozen conclusive variants 
that confer susceptibility to different 
cancers. Notable examples include 
the association of bladder cancer 
with NAT2 variants or a common 
deletion of GSTM1 [7] as well as of 
aerodigestive cancers with coding 
variants in alcohol dehydrogenase 
genes (ADH1B and ADH7) [8]. Still, 
what emerged was an appreciation 
of the value of robust replication to-
gether with the scaling of studies to 
a size that would provide adequate 
power to conclusively detect variants 
on statistical grounds.
Principles of cancer GWAS
The advent of genome-wide asso-
ciation studies (GWAS) has substan-
tially accelerated discovery of com-
mon genetic susceptibility variants 
for a wide range of human diseases 
and traits. Advances in microar-
ray technologies have enabled re-
searchers to interrogate hundreds of 
thousands of SNPs in parallel using 
new analytical tools and standards. 
The underlying approach has been 
to conduct a statistical – or “ag-
nostic” – analysis of commercial 
SNP microarrays designed to tag 
common variants across the entire 
genome. Consequently, GWAS find 
markers, or surrogates of suscepti-
bility alleles, and rarely determine 
the “functional” variant, which can 
explain the association.
Many statistical tests are con-
ducted, because the primary ap-
proach has been to identify common 
SNPs with a main effect using the 
trend test, thus raising the spectre of 
false positives. The community has 
embraced a threshold of genome-
wide significance for reporting 
GWAS results, defined as a trend as-
sociation test with P ≤ 5 × 10–8 after 
adjustment as per the GWAS study 
design. Because of the small effect 
sizes of most common SNPs conclu-
sively associated with cancer risk, 
it is unlikely that the alleles incor-
porate a dominant effect. Follow-up 
studies or large meta-analyses are 
required to establish a conclusive 
finding [9]. Independent replication 
guards against the pursuit of false 
positives, which is important since 
the downstream cost of mapping 
and laboratory investigation is high 
with respect to time and resources 
[10]. The actual functional marker 
does not have to be tested; instead, 
a surrogate can be in linkage dis-
equilibrium and thus replicated in 
follow-up [11]. Occasionally, a com-
mon genetic marker may point to-
wards a less common variant with a 
Fig. 3.2.1. Mapping genetic susceptibility. Distribution of susceptibility alleles by frequency and strength of genetic effect, illustrat-
ing the distribution of susceptibility alleles as well as the feasibility of identifying variants through GWAS and sequence analysis.
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stronger effect, known as a synthetic 
association. However, most GWAS 
signals map to common variants with 
direct functional effects on cancer 
susceptibility.
GWAS are scalable for discov-
ery. For example, the Collabora-
tive Oncological Gene-environment 
Study has pooled existing scans 
and conducted large-scale replica-
tion to discover new loci in three 
hormone-related cancers: breast, 
ovarian, and prostate cancers [12–
14]. These studies have identified a 
larger fraction of the common vari-
ants that contribute to the compre-
hensive panel of independent loci. 
Since GWAS genotyping has been 
performed with different commercial 
and custom SNP microarrays, tech-
niques for imputation of data have 
been developed to combine data 
sets. Several imputation programmes 
successfully infer untested and highly 
correlated SNPs based on reference 
data sets, such as the International 
HapMap Project, the 1000 Genome 
Project, or the Division of Cancer 
Epidemiology and Genetics (United 
States National Cancer Institute) im-
putation set [4,15,16].
Cancer GWAS discoveries
In the past 6 years, the pace of 
GWAS findings has accelerated (Box 
3.2.1). Since the first cancer GWAS 
were published in 2007, nearly 400 
distinct genetic loci have been con-
clusively identified for more than two 
dozen different cancers – including 
common cancers, such as breast, 
colon, and prostate cancers, as 
well as rarer paediatric cancers, like 
Ewing sarcoma and neuroblastoma 
[17–20]. Moreover, GWAS have iden-
tified susceptibility loci for specific 
subtypes of cancers, such as estro-
gen-negative breast cancer [21].
Reported cancer GWAS find-
ings are associated with cancer 
susceptibility. With rare exceptions, 
the etiological markers are not asso-
ciated with clinical outcomes, includ-
ing metastatic disease or survival. 
Several neuroblastoma loci discrimi-
nate between aggressive and milder 
disease. Of the more than 75 inde-
pendent loci identified for prostate 
cancer, not one accurately discrimi-
nates between aggressive and non-
aggressive disease. Recently, vari-
ants in SLC39A6 were conclusively 
associated with survival in individu-
als with oesophageal squamous 
cell carcinoma [22]. Still, the lack 
of correlation between etiological 
loci and clinical outcomes suggests 
that distinct regions of the genome 
may contribute to the development 
of cancer but not necessarily the 
progression of cancer.
Fig. 3.2.2. Genetic analysis of GWAS. Multiple steps are conducted, including the choice 
of SNPs across the genome (usually included on a commercial SNP microarray) based 
on linkage disequilibrium in a region, enabling the selection of a surrogate to test for 
the region. Association analysis is conducted in a case–control setting, examining all 
SNPs in a Manhattan plot, followed by replication analyses that pinpoint markers on 
chromosomes, which are fine-mapped and investigated in the laboratory. MAF, minor 
allele frequency.
1. Discovery of new regions in 
the genome associated with 
diseases/traits
• New candidate genes and 
regions
2. Clues for mechanistic insights 
into the contribution of com-
mon genetic variation to can-
cer biology
• Etiology
• Gene–environment/lifestyle 
interactions
• Outcomes and 
pharmacogenomics
3. Challenge of genetic markers 
for risk prediction for individ-
ual or public health decisions
• Common variants represent a 
fraction of the genetic contri-
bution to risk
• Polygenic risk models
Box 3.2.1. Current status of genome-wide association studies.
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Gene–environment interactions and breast cancer
Federico Canzian
GWAS have recently identified sev-
eral genetic loci associated with risk 
of breast cancer. They are the latest 
addition to a list of established breast 
cancer risk factors, which are mainly 
environmental or lifestyle-related.
Exploring the possible interplay 
between genetic variants and estab-
lished breast cancer risk factors can 
(i) provide hints on the function of 
the novel genetic loci, and in gen-
eral on biological mechanisms of 
breast cancer etiology, and (ii) help 
in formulating better risk prediction 
models, with a potential impact on 
prevention.
Given the small risk modification 
conferred by each environmental 
and genetic risk factor, large-scale 
association studies, involving many 
thousands of cases and controls, 
are needed to explore gene–envi-
ronment interactions. Several such 
studies have recently been pub-
lished, on up to 26 000 breast can-
cer cases and 32 000 controls [e.g. 
1–3]. They involved between 7 and 
17 SNPs and established risk factors 
including age at menarche, parity, 
age at first live birth, breastfeeding, 
menopausal status, age at meno-
pause, use of hormone replacement 
therapy, body mass index, height, 
tobacco use, alcohol consumption, 
number of previous breast biopsies, 
and family history of breast cancer. 
Both prospective cohorts [1,2] and 
retrospective series of breast cancer 
cases and controls [3] were used. 
Most of the study subjects were 
Caucasians, with some studies done 
in Asian populations.
Results obtained so far [1–3] 
suggest that two-way interactions 
between known risk SNPs and es-
tablished breast cancer risk factors 
are unlikely to be strong. None of 
the large-scale studies reported sta-
tistically significant gene–environ-
ment interactions, after correcting 
for multiple testing. These studies 
were well powered, having greater 
than 90% power to detect interaction 
odds ratios as low as 1.06. Higher-
order interactions were not tested 
as they would require much larger 
sample sizes.
Previous reports suggested the 
existence of a few statistically sig-
nificant gene–environment interac-
tions, for example between SNPs 
in FGFR2 and use of hormone re-
placement therapy, family history 
of breast cancer, age at menarche, 
and parity. None of these associa-
tions were observed in the larger 
studies. Considering the relatively 
small sample size and the modest 
statistical significance of the interac-
tions reported in the original studies, 
the most likely explanation is that 
these could be chance findings.
New GWAS on breast cancer 
risk, and meta-analyses of exist-
ing ones, are still being performed; 
therefore, more breast cancer 
susceptibility loci will be known in 
the near future. Consequently, new 
gene–environment interaction stud-
ies will be needed. Furthermore, all 
studies published so far assumed a 
multiplicative model of interaction. It 
remains to be seen whether signifi-
cant gene–environment interactions 
can be detected by exploring differ-
ent models, such as supra-additive 
interactions.
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Nearly all cancer GWAS markers 
have a MAF greater than 10%, with 
a handful in the 5–10% range [23]. 
This is a consequence of the design 
of the first-generation SNP micro-
array chips and the smaller sample 
sizes used. With larger meta-analy-
ses and follow-up studies planned, 
further discovery in the MAF space 
between 2% and 10% will occur. An 
emerging concept is that there could 
be major differences in the underly-
ing genetic architecture of different 
types of cancer [24]. For example, 
the range of effect sizes and allele 
frequencies varies between prostate 
cancer and breast cancer, which in-
cludes BRCA1, BRCA2, TP53, and a 
set of moderately penetrant genetic 
mutations.
In the first wave of cancer GWAS, 
the per-allele estimated effect sizes 
were small, with odds ratios between 
1.1 and 1.4. In paediatric cancer 
GWAS, estimates of 1.6–1.8 are 
not unusual, perhaps suggesting 
stronger drivers of cancer devel-
opment. One notable exception for 
young adults is in testicular cancer 
GWAS, for which the per-allele ef-
fect estimate is greater than 2.5 
for KITLG on chromosome 12 [25]. 
This is not surprising since testicu-
lar cancer has a high heritability in 
family studies. It is notable that as 
sample sizes increase, it is possible 
to find smaller estimated effect sizes. 
The Collaborative Oncological Gene- 
environment Study consortium has 
discovered new breast and pros-
tate cancer signals but with effect 
sizes of 1.05–1.15 (see “Gene– 
environment interactions and breast 
cancer”).
Few of the cancer GWAS sig-
nals map to a coding change in a 
plausible candidate gene. Most 
signals map to non-coding regions. 
Approximately one quarter map to 
intergenic regions, in which there 
are no adjacent correlated markers 
that map to characterized genes. 
Together, these findings suggest that 
the majority of the common genetic 
variants contribute to cancer through 
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perturbations of the regulation of 
known or novel pathways.
Most cancer GWAS signals are 
unique to a cancer type, but there 
are a few highly informative regions 
that harbour susceptibility alleles for 
multiple cancers, thus linking distinct 
cancers and suggesting shared 
pathways. A region flanking the MYC 
oncogene on 8q24 harbours at least 
five independent loci associated with 
prostate cancer as well as loci as-
sociated with four other cancers 
(breast, colon, and bladder cancers 
and chronic lymphocytic leukaemia) 
[23]. GWAS have detected strong 
signals for the human leukocyte an-
tigen (HLA) regions for cancers of 
the immune system or those driven 
by viral infections (e.g. cervical, liver, 
and nasopharyngeal cancers) (see 
“DNA repair polymorphisms and hu-
man cancer”).
A region on 5p15.33 contain-
ing the telomerase gene, TERT, 
harbours multiple susceptibility al-
leles for many cancers, including 
rare and common SNP alleles [26]. 
Rare mutations in TERT track with 
dyskeratosis congenita (an inher-
ited bone-marrow failure syndrome) 
and idiopathic pulmonary fibrosis. 
Cancer GWAS have discovered 
susceptibility alleles for at least 10 
different types over at least five 
independent signals. Moreover, 
a protective allele for one cancer 
can confer susceptibility to another 
cancer; notably, the same allele has 
inverse effects for two skin cancers, 
basal cell carcinoma and melanoma. 
The pleiotropy in this region hints 
at complex gene–gene or gene– 
environment interactions.
Whereas most of the initial 
GWAS were conducted in subjects 
of European ancestry, recently more 
have been conducted in subjects of 
Asian and African ancestry. Prostate 
cancer GWAS in men of African an-
cestry identified new independent 
loci on 8q24 as well as a new re-
gion on 17q21 [27]. Studies in Asia 
have concentrated on cancers nota-
ble for high incidence, such as gas-
tric adenocarcinoma, oesophageal 
squamous cell carcinoma, and lung 
cancer in nonsmokers [28,29].
The underlying population genetic 
histories of distinct groups have im-
portant implications for the discovery 
of susceptibility alleles because the 
underlying linkage disequilibrium 
can vary greatly. In many regions 
of the genome, differences in MAFs 
between continental populations 
(e.g. European, Asian, and African 
descent) can account for variance in 
the detection of susceptibility alleles. 
For example, the MAF of a SNP is 
sufficiently high in men of African 
ancestry for the SNP to be detected 
in a GWAS of prostate cancer in 
African-American men, but because 
of its low MAF in Europeans, it is not 
easily detected in GWAS of European 
men [27].
Until recently, cancer GWAS 
lumped disparate study designs to-
gether and rarely addressed envi-
ronmental exposures. Still, a hand-
ful of alleles have been shown to 
interact with specific exposures. In 
a study of oesophageal squamous 
cell carcinoma in China, a gene–
environment interaction was ob-
served between the variants in the 
ADH/ALDH genes and alcohol con-
sumption [30]. In bladder cancer, 
a novel marker for NAT2 interacts 
with smoking, correlating with low 
or intermediate acetylation status. 
In fact, common genetic variants 
have been shown to modify the ef-
fect of smoking on bladder cancer 
[31]. A GWAS of lung cancer in non-
smoking Asian women discovered 
regions not observed in lung can-
cer GWAS dominated by smokers 
[29]. Also, there was no signal in 
nonsmoking women across 15q24, 
a region strongly correlated with 
smoking behaviour and lung cancer 
in smokers, suggesting that the re-
ported signals are primarily related 
to tobacco use.
Analysis of associated risk factors 
collected in cancer GWAS has been 
extremely informative for tobacco 
use, alcohol consumption, and an-
thropometric measures (e.g. height, 
weight, and waist size). Cross-
disease consortia (e.g. diabetes and 
cardiovascular disease) have com-
bined numbers to accelerate discov-
ery of common risk factors. Already, 
more than 200 independent loci have 
been identified for height [32].
Investigation of GWAS 
signals
Each region should be fine-mapped 
to determine optimal variants for 
functional analyses, mainly because 
of the large number of highly corre-
lated variants. The pattern of linkage 
disequilibrium, often with apparent 
differences between ancestral popu-
lations, is examined to winnow down 
possible variants. Choosing the opti-
mal ones also requires bioinformat-
ics assessment using new public da-
tabases, such as the Encyclopedia 
of DNA Elements (ENCODE) project 
[33]. ENCODE has begun to system-
atically shed light on the biology of 
the regulation of the genome, spe-
cifically cataloguing signposts and 
markers of biological activity. This 
resource can be used for individual 
variants but also to look at patterns 
or pathways, as recently suggested 
for breast cancer susceptibility loci 
identified by GWAS [34]. A greater-
than-expected fraction of cancer 
susceptibility alleles map to regula-
tory regions, suggesting that com-
mon variants confer susceptibility 
primarily through perturbations in 
regulatory events [23].
Laboratory investigation is re-
quired to explain the biological basis 
of the SNPs that directly associate 
with the cancer of interest. Each indi-
vidual variant has to be studied sepa-
rately, and a combination of different 
approaches and tools is required, 
which explains the markedly slower 
pace of characterization (Fig. 3.2.3). 
For example, investigation of a pros-
tate cancer GWAS marker, which 
maps to the β-microseminoprotein 
gene (MSMB) on 10q11, revealed 
that the risk allele in the promoter 
region decreases transcriptional ac-
tivity, lowering expression in pros-
tate cancer tissue [35]. Expression 
decreases as prostate cancer pro-
gresses from early to late stages; 
loss of MSMB expression can be 
associated with disease recurrence 
after radical prostatectomy. Still, the 
finding may not be fully explained by 
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DNA repair polymorphisms and human cancer
Paolo Vineis
A wide range of DNA damage can 
be inflicted, both from extracellular 
agents – including environmental 
exposures – and via endogenous 
mechanisms. Genotoxic chemicals 
bind to DNA, forming adducts that 
in turn can be repaired by the DNA 
repair machinery (Fig. B3.2.1) or 
lead to permanent DNA damage. 
DNA damage can lead to cancer 
and other diseases. Therefore, it is 
plausible that inherited sequence 
variants in DNA repair genes are 
involved in cancer development.
Five main mechanisms are in-
volved in DNA repair: base excision 
repair, which corrects non-bulky 
damage; nucleotide excision repair, 
which corrects lesions that disrupt 
the double helical structure of DNA; 
mismatch repair, which corrects 
replication errors; double-strand 
break repair, which corrects dou-
ble-strand breaks through two dif-
ferent pathways, homologous and 
non-homologous recombination; 
and direct repair, which corrects 
methylated or alkylated bases [1]. 
Rare, highly penetrant mutations 
of DNA repair genes (such as the 
XP family, involved in the heritable 
disease xeroderma pigmentosum) 
are associated with a high risk of 
cancer, whereas the evidence is 
weaker for common SNPs with low 
penetrance.
A systematic review and meta-
analysis, based on systematic cri-
teria, showed that out of 241 as-
sociations investigated, only three 
associations were graded as having 
strong epidemiological credibility 
of cumulative evidence [2]. These 
associations were between two 
SNPs – rs1799793 and rs13181 – 
in the ERCC2 gene and lung cancer 
(recessive model), and between 
rs1805794 in the NBN gene and 
bladder cancer (dominant model). 
An update of this meta-analysis 
has since been performed [3], and 
the authors found partially incon-
sistent results. In addition, none of 
the cancer GWAS published until 
2011 showed highly statistically 
significant associations for any of 
the common DNA repair gene vari-
ants that would place DNA repair 
genes among the top 10–20 hits 
identified in GWAS. This suggests 
that it is unlikely that DNA repair 
gene polymorphisms per se play 
a major role. This is not surprising 
since in a multistep, multigenic pro-
cess such as carcinogenesis, single 
polymorphisms in single genes are 
unlikely to alter the expression or 
function of specific proteins to the 
extent of producing a pathological 
phenotype. However, the combined 
effect of several SNPs in a gene or 
in multiple genes could have more 
impact.
Pathway approaches using novel 
genotyping technologies will en-
able more comprehensive studies 
of multiple SNPs in multiple genes, 
and it will be possible to investigate 
gene–environment interactions more 
rigorously than before, using novel 
statistical methodology. The com-
bined effect of multiple SNPs in sev-
eral genes in one or more relevant 
DNA repair pathways could have a 
greater impact on pathological phe-
notypes than SNPs in single genes, 
but this has been investigated only 
occasionally.
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Fig. B3.2.1. DNA damage, repair mechanisms, and consequences. (A) Common 
DNA damaging agents (top), examples of DNA lesions induced (middle), and the 
most relevant DNA repair mechanisms responsible for the removal of those lesions 
(bottom). (B) Acute effects of DNA damage on cell-cycle progression, leading to 
transient arrest in the G1, S, G2, and M phases (top), and on DNA metabolism 
(middle). Long-term consequences of DNA injury (bottom) include point mutations 
or chromosome aberrations and their biological effects. cis-Pt, cisplatin; CPD, 
cyclobutane pyrimidine dimer; EJ, end joining; HR, homologous recombination; 
MMC, mitomycin C; (6-4)PP, 6-4 photoproduct; UV, ultraviolet.
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MSMB alone. The gene on the other 
side of MSMB, NCOA4, is also up-
regulated by the GWAS promoter 
SNP, and NCOA4 forms chimeric 
transcripts with MSMB [36,37]. 
Also promising is the relationship 
between the MSMB allele and uri-
nary levels of β-microseminoprotein, 
which was validated as a serum bio-
marker of prostate cancer in previ-
ous investigations.
The value of fine-mapping is 
critical for exploring GWAS markers. 
Prokunina-Olsson et al. uncovered 
a novel gene, IFNL4, created by a 
complex dinucleotide variant (e.g. a 
single bp missense contiguous to a 
deletion) in strong linkage disequi-
librium with the published marker 
on chromosome 19 associated with 
clearance of hepatitis C virus infec-
tion, a major risk factor for liver can-
cer [38]. Earlier investigators focused 
on variants upstream of the nearest 
gene, IFNL3 (previously IL28B). The 
deletion allele generates a frameshift, 
which leads to a novel protein that 
induces an interferon-type response, 
apparent on close inspection of RNA 
sequencing data in primary human 
hepatocytes. The complex IFNL4 ge-
netic variant has a strong effect on 
hepatitis C virus clearance, especial-
ly in individuals of African ancestry. 
The strength of the estimated effect 
on both spontaneous and treatment-
induced clearance of hepatitis C virus 
is significantly larger than most can-
cer GWAS signals, prompting pursuit 
in clinical studies.
Understanding the biological 
basis of a GWAS signal can even-
tually lead to clinical translation. A 
bladder cancer GWAS locus maps 
to the prostate stem cell antigen 
gene (PSCA) [39]. Based on RNA 
sequencing followed by functional 
analysis, a promoter SNP, charac-
terized in fine-mapping, influences 
messenger RNA (mRNA) PSCA 
expression [40]. The creation of 
an alternative translation start site 
leads to increased expression of 
PSCA on the cell surface [41]. The 
actual genotype could predict PSCA 
protein expression and identify blad-
der cancer patients harbouring the 
PSCA variant, who may benefit from 
immunotherapy with anti-PSCA 
humanized antibody, an emerging 
therapy for different cancers.
SNP markers have yet to be 
incorporated into clinical practice, 
despite the opinions of some com-
mercial groups. Adequate testing 
and validation have not been con-
ducted in the clinical setting. Once 
a catalogue approaching a compre-
hensive set of common susceptibility 
alleles has been defined for a given 
cancer, it will be possible to explore 
applications in large validation stud-
ies. Already, it is possible to begin to 
develop the models to design and 
conduct the validation studies [42]. 
Fig. 3.2.3. Laboratory investigation of GWAS SNPs. Cartoon depiction of the steps after fine-mapping, beginning with the assess-
ment of whether a marker resides in a coding region and continuing through the bioinformatics analysis and assessment of functional 
elements before the experimental studies are conducted. mRNA, messenger RNA; miRNA, microRNA, RNASeq, RNA sequencing.
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In a recent analysis of ovarian can-
cer, it appears that women harbour-
ing germline mutations in BRCA1 or 
BRCA2 may actually have improved 
survival, partly due to increased sen-
sitivity to standard chemotherapeu-
tic agents [43]. So far, analyses of 
small numbers of cancer susceptibil-
ity SNPs have failed to confirm their 
utility using receiver operator curves 
[44]. Continued discovery is required 
to generate the comprehensive set 
of common and uncommon variants 
per disease, which could be used to 
reclassify risk status for either pre-
vention or early intervention.
Future directions
Cancer GWAS will continue to dis-
cover susceptibility alleles but are 
now poised to investigate pharma-
cogenomics and outcome analy-
ses, particularly with large studies 
on the horizon that are well phe-
notyped. The major discoveries of 
cancer GWAS represent an impor-
tant transition in the development of 
integrative scientific collaborations 
because they have relied on a net-
work of epidemiologists, geneticists, 
and analysts, who have uncovered 
genetic markers for risk. The next 
frontier lies in the investigation of 
the underlying biology that can ex-
plain the contribution of susceptibil-
ity alleles to disease pathogenesis 
or progression, which in turn could 
lead to more effective strategies for 
prevention or treatment.
The development of next-gen-
eration sequence analysis tools 
represents a major opportunity to 
map common and uncommon sus-
ceptibility alleles as well as highly 
penetrant mutations in families. 
There are daunting challenges in 
quality control of genome sequence 
data, including a substantively larg-
er number of variants for testing, 
which compounds the challenge 
of distinguishing true signal from 
background noise [45]. To define 
the comprehensive set of uncommon 
variants (with a MAF between 0.5% 
and 5%), hybrid approaches will be 
required. Recently, two groups con-
verged on susceptibility mutations 
in MITF for melanoma based on not 
only family- and population-based 
association studies but also labo-
ratory insights into the underlying 
biology of disruption of sumoylation 
of MITF protein [46,47].
The next generation of stud-
ies will focus on two major exten-
sions of the GWAS approach: (i) 
investigation of the interrelationship 
between germline susceptibility 
alleles and somatic alterations [43]; 
and (ii) testing the clinical and public 
health applicability of the full spec-
trum of cancer susceptibility alleles 
identified through GWAS, which in-
cludes rare, highly penetrant muta-
tions, less common alleles with mod-
erate penetrance, and the common 
alleles with small effect sizes. The 
susceptibility alleles discovered by 
cancer GWAS are not yet ready for 
clinical implementation. To develop 
accurate and useful recommenda-
tions for genetic counselling in the 
new age of complex disease, more 
discovery is needed that extends 
into the fraction of the uncommon 
variants and rare mutations. New 
paradigms for implementing suscep-
tibility alleles in precision medicine 
represent long-term goals and are 
expected to be applied to classifica-
tion of risk groups that could be of-
fered early detection or intervention.
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• Expression of coded genetic 
information contained in DNA 
determines an organism’s phe-
notype through synthesis of 
functional gene products; the 
synthesis of such proteins and 
RNA is regulated at the tran-
scriptional and translational 
levels.
• In cancer, malignant transforma-
tion of normal cells results from 
structural changes in DNA and 
is mediated by aberrant expres-
sion of multiple genes.
• By reference to gene expres-
sion profiles, tumours have 
been subclassified into catego-
ries with distinct biological and 
clinical properties; this process 
sometimes identifies genetic 
changes and gives rise to thera-
peutic targets.
• The human genome is esti-
mated to encode for more than 
1000 microRNAs that regulate 
the translation of more than 60% 
of genes and hence determine 
gene expression.
• Currently, large-scale inter-
national collaborative cancer 
studies, based on next-genera-
tion sequencing technology, are 
generating a comprehensive 
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catalogue of oncogenic alter-
ations evident in particular tu-
mour types.
Gene expression is the process of 
translating the information speci-
fied through the sequence of bases 
in DNA into functional products, 
including proteins and non-coding 
RNA, such as ribosomal RNA, trans-
fer RNA, microRNA (miRNA), and 
small nuclear RNA, among others 
(Fig. 3.3.1). In eukaryotes, transcrip-
tion is performed by three types of 
RNA polymerases, each of which 
requires a promoter DNA sequence 
and a set of DNA-binding transcrip-
tion factors to initiate the process. 
The promoter sequence is almost 
always located just upstream of the 
transcription start site, which cor-
responds to the 5′ end. Binding of 
regulatory proteins to an enhancer 
sequence results in a shift in chro-
matin structure, which either pro-
motes or inhibits RNA polymerase 
and transcription factor binding. 
Euchromatin, which has a more 
open structure, is associated with 
transcription, whereas heterochro-
matin is associated with transcrip-
tional inactivity (Fig. 3.3.2A).
Only a fraction of the genes in 
a particular cell are expressed at a 
given time. The variety of gene ex-
pression profiles is determined by 
distinct sets of transcription regula-
tors. Transcription creates precursor 
messenger RNA (pre-mRNA), which 
further undergoes a series of modi-
fications, leading to mature mRNA. 
These modifications include the en-
zymatic reactions of 5′ capping and 
3′ cleavage and polyadenylation. 
Protein-coding sequences in DNA 
account for only 1–2% of the human 
genome [1]. The increased diversity 
at the level of primary mRNA and 
proteins can be accounted for by 
alternative RNA splicing, which cre-
ates a series of different transcripts 
originating from a single gene by re-
moving or retaining some introns or 
exons in particular mature mRNAs. 
The resulting transcripts can po-
tentially be translated into different 
proteins. Each mRNA is composed 
of three parts: a 5′ untranslated re-
gion, an open reading frame, and a 
3′ untranslated region.
Regulation of gene 
expression
Regulation of gene expression can 
occur at any step of expression 
and includes various systems that 
control and determine which genes 
are switched on or off and to what 
extent the genes are expressed. 
Transcriptional regulation of gene 
expression levels occurs in three 
main ways: genetic (involving direct 
interaction with DNA), modulation 
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(involving interaction with transcrip-
tion machinery), and epigenetic 
(involving non-sequence changes 
in DNA). Genes contain in their se-
quence several protein-binding sites 
around the coding regions, such as 
enhancers, insulators, and silenc-
ers. These sites facilitate binding 
of transcription factors, resulting in 
blocking or activation of transcription. 
Furthermore, the activity of transcrip-
tion factors can also be modulated 
by post-translational protein modifica-
tions such as acetylation, phosphory-
lation, or glycosylation (Fig. 3.3.2B).
Epigenetic changes, and spe-
cifically DNA methylation, modulate 
transcription by altering the accessi-
bility of DNA to proteins. Particularly 
important for regulation of gene ex-
pression levels are post-transcrip-
tional modifications, including 5′ cap-
ping and 3′ polyadenylation, which 
protect mRNA from degradation 
during nuclear export. Once generat-
ed, mature RNA isoforms are subject 
to many levels of regulation, includ-
ing the regulation of translation by 
miRNAs and regulatory factors, the 
use of alternative translation start 
sites, RNA localization, and mRNA 
stability and turnover. Direct inhibi-
tion of protein translation by toxins 
and antibiotics is less frequent. In 
addition, a substantial number of 
isoforms can be an effect of single-
nucleotide polymorphisms (SNPs), 
small genetic differences between 
alleles of the same gene. Finally, pro-
tein expression can also be reduced 
by degradation, in which unneeded, 
damaged, and improperly folded pro-
teins are labelled for degradation by 
ubiquitination.
Dysregulation of gene 
expression in cancer
Malignant transformation is accom-
panied and characterized by disrup-
tion of genetic information and aber-
rant expression of multiple genes. 
These changes enhance the survival 
of tumour cells and alter their prolif-
erative capacity, leading to tumour 
formation. The fact that the majority 
of cells within a tumour mass share a 
common gene expression profile has 
encouraged systematic analyses of 
differential gene expression in hu-
man tumour samples to provide an 
estimate of the degree of genetic and 
epigenetic dysregulation.
Measurement of gene 
expression
To monitor gene expression, ideally 
the amount of each final gene prod-
uct, which is in most cases a protein, 
should be measured. However, due 
to the limitations of protein-based 
assays, pre-mRNA expression is 
frequently studied. Several methods 
have been developed for quantifica-
tion of mRNA levels. These include 
northern blotting, quantitative re-
verse transcription polymerase chain 
reaction (qRT-PCR), RNase pro-
tection assays, microarrays, serial 
analysis of gene expression (SAGE), 
and next-generation RNA sequenc-
ing (RNA-seq). While northern blot-
ting and qRT-PCR are often used to 
Fig. 3.3.1. Schematic overview of the protein-coding gene expression pathway in eukaryotic organisms. E, enhancer sequence; 
T, terminator (transcription termination site); m7G, 7-methylguanylate cap.
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Therapeutic implications of dysregulated DNA damage signalling
Peter Bouwman and Jos Jonkers
The intimate link between cancer 
and DNA damage signalling is clear 
from the fact that many tumour sup-
pressor genes are involved in DNA 
repair [1,2]. Well-known examples 
are BRCA1 and BRCA2, which are 
important for DNA repair by homol-
ogous recombination. In addition, 
many known carcinogens such as 
tobacco smoke, alcohol, ultraviolet 
radiation, and ionizing radiation are 
known to cause DNA damage.
Paradoxically, tumours can also 
be treated by DNA-damaging ir-
radiation or chemical compounds. 
Although DNA damage also affects 
normal cells, tumour cells are often 
more vulnerable because of defects 
in DNA repair pathways or critical 
cell-cycle checkpoints. Especially 
defects in homology-directed repair 
(HDR) of DNA double-strand breaks 
can be exploited therapeutically. It 
has recently become clear that this 
is possible not only by directly dam-
aging the DNA but also via inhibi-
tion of PARP enzymes. Inhibition of 
PARP1 and PARP2 can block alter-
native repair pathways and result 
in trapping of PARP to DNA, which 
is detrimental for HDR-deficient 
cells [3].
Fig. B3.3.1. DNA damage response (DDR)-related mechanisms of therapy resistance. Loss of function of DNA repair genes 
can cripple the affected pathway to the extent that tumour cells become highly sensitive to certain types of DNA damage. 
In addition, the remaining repair pathways may become essential for survival. Resistance to chemotherapy can be a result 
of partial activity of mutated alleles. Such hypomorphic mutations can be sufficiently affected to lead to tumour formation, 
yet too active to result in hypersensitivity to targeted therapy. In case mutations lead to a completely inactivated (null) allele, 
chemotherapy may select for mutations that revert the original defect or select for mutations in other DDR genes that result 
in pathway rewiring. Crosses symbolize inactivation. Tumour cells with wild-type levels of DDR activity are indicated in green, 
cells with a partially active DDR pathway are shown in beige, and cells with impaired DDR are shown in purple.
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Despite their exquisite sensitivity 
to DNA damage, tumours with HDR 
defects can eventually become re-
sistant to therapy. Apart from mech-
anisms that result in decreased 
intracellular drug concentrations, 
resistance may also be caused by 
altered DNA damage signalling [1,2]. 
Of note, tumours with mutations in 
a specific DNA repair gene do not 
always show the same response to 
therapy; missense mutations in a 
specialized region will have differ-
ent effects compared with mutations 
that completely abolish expression. 
Furthermore, tumours often con-
sist of heterogeneous populations 
of cells that may share a common 
ancestor but have acquired different 
additional mutations or epigenetic 
alterations. Data from preclinical 
models suggest that this may result 
in increased capacity to repair DNA 
damage, and hence resistance to 
therapy. It has also been shown 
that therapy-resistant BRCA1- and 
BRCA2-associated tumours may re-
store their HDR defect by genetic re-
version. Secondary mutations may 
overcome the original defect, result-
ing in the expression of (partially) 
functional BRCA1 or BRCA2 protein. 
Alternatively, DNA repair pathways 
may be perturbed to withstand DNA-
damaging therapy. Recent data sug-
gest that this is possible in respect 
of the two major pathways for repair 
of DNA double-strand breaks, error-
free homologous recombination and 
intrinsically error-prone non-homol-
ogous end joining (NHEJ). The HDR 
defect of BRCA1-deficient cells 
can, for instance, be suppressed 
by loss of the NHEJ protein 53BP1. 
Stratification of patients with specific 
DNA repair defects and combina-
tions of targeted therapeutics will be 
required to maximize the likelihood 
of successful treatment. To avoid 
resistance, the development of bio-
markers for the activity of factors 
involved in DNA damage response 
will be of critical importance.
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verify the results for particular genes 
or for some low-expression genes, 
microarrays, SAGE, and RNA-seq 
are used to obtain broad coverage 
of the genome. Now that identifica-
tion of genome-wide sets of protein-
coding genes is feasible, combined 
with the discovery of miRNAs, many 
researchers have taken advantage 
of array-based approaches to search 
for gene expression patterns within 
most cancer types.
In the context of cancer, gene 
expression profiling with DNA mi-
croarrays has been used to iden-
tify individual transcripts and regu-
latory gene networks mediating 
disease pathogenesis, to discover 
molecular targets for drug develop-
ment, to more accurately classify 
tumours, and to identify molecular 
markers useful for disease diagno-
sis and prognosis or as predictors 
of clinical outcomes. In addition 
to detecting changes in transcrip-
tional levels, the recently developed 
RNA-seq technique can detect 
other abnormalities in the cancer 
transcriptome, such as SNPs, al-
ternative splice variants, novel cod-
ing and non-coding transcripts, and 
gene fusions. Due to decreasing 
costs, RNA-seq is becoming more 
common as a method for cancer 
gene expression profiling. RNA-seq 
is also superior to microarray tech-
niques, given its unbiased approach 
in probe selection. However, the 
requirement for increased amounts 
of sample RNA and the challeng-
ing bioinformatics analyses of gen-
erated data remain limitations of 
this technique.
Fig. 3.3.2. (A) Representation of “closed” and “open” chromatin structures. 
(B) Overview of major post-translational modifications that may play essential roles in 
the regulation of gene expression and be altered in the course of disease processes. 
Modifications are specified in relation to part of the N-terminal tail of a histone 
protein; the single letters indicate specific amino acid residues that may be subject 
to particular modifications.
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Gene expression microarray 
studies in cancer
Microarray profiling technology, 
which has been most widely used 
to study gene expression in cancer, 
represents an important develop-
ment in genomic marker research 
and has been evaluated as a tool 
for decision-making in clinical 
practice. Microarray studies aim to 
identify genes that are differentially 
expressed between known groups 
of samples (class comparison), to 
discover unknown patterns of gene 
expression (class discovery), and 
to develop classifiers associated 
with disease or treatment outcome 
(class prediction). For that purpose, 
both supervised and unsupervised 
methods of analysis have been used 
to search for molecular signatures 
associated with known classes and 
to discover new classes of a dis-
ease. Even though diagnosis and 
tumour subclassification are still 
dominated by histological analysis 
for most cancers, these methods 
have proven to be insufficient to 
distinguish between subclasses in 
several types of cancer.
Specifically, consistent definition 
of diffuse large B-cell lymphoma has 
proven difficult due to discrepancies 
between inter- and intra-observer 
reproducibility [2]. Gene expres-
sion profiling has enabled the sub-
classification of diffuse large B-cell 
lymphoma tumours into categories 
with distinct biological properties 
and prognoses. This has led to the 
identification of two subtypes: ger-
minal centre B-like and activated 
B-like diffuse large B-cell lymphoma 
[3]. For patients with germinal centre 
B-like disease, the 10-year survival 
rate was about 80%, whereas for 
those with activated B-like disease, 
the 8-year survival rate was about 
40%.
In some tumour types, such as 
breast cancer [4] and leukaemia [5], 
molecular markers have been ad-
juncts to histological classification 
for decades. Perhaps the best 
known example is the contribution 
of expression profiling to the clas-
sification of breast tumours, which 
has resulted in the development of 
the PAM50 Breast Cancer Intrinsic 
Classifier, which sorts breast cancer 
into the major molecular subtypes 
of basal-like, human epidermal 
growth factor receptor 2 (HER2)-
positive, luminal A, and luminal B 
(Fig. 3.3.3A). Gene expression sig-
nature studies performed in melano-
ma have also led to the development 
of a protein-based test measuring 
expression of five genes that can 
distinguish malignant melanoma 
from benign tissue [6].
The use of gene expression sig-
natures has also enabled the iden-
tification of prognostic subclasses. 
The more successful examples of 
gene expression profiles as prog-
nostic indicators have been their 
use to define the risk of relapse 
in patients with early-stage breast 
cancer. Three profiles have proven 
prognostic ability: the MammaPrint 
70-gene profile, the Oncotype DX 
21-gene recurrence score, and 
the Rotterdam 76-gene prognos-
tic signature [7–9]. These profiles 
were obtained using tumour-derived 
mRNA either applied on DNA micro-
arrays or by RT-PCR assay. All three 
tests are used in clinical practice to 
predict prognosis and assist thera-
peutic intervention. Using a similar 
approach, a 12-gene expression sig-
nature has been developed for colon 
cancer as an independent predictor 
of recurrence in patients with stage 
II disease, which aids the more ac-
curate identification of patients who 
will not benefit from chemotherapy 
[10]. In addition, other studies have 
identified a 133-gene prognostic sig-
nature in adult acute myeloid leukae-
mia with normal karyotype as well as 
new prognostic subtypes in diffuse 
large B-cell lymphoma [11,12]. Gene 
expression signatures to assess the 
risk of recurrence in patients with 
non-small cell lung cancer [13] and 
in several other cancer types have 
also been proposed.
Involvement of non-coding 
RNAs in cancer
Recently, the functional relevance 
of the non-protein-coding portion of 
the genome became evident in the 
context of both normal development 
and disease pathogenesis. Currently, 
a total of 9173 small RNAs are anno-
tated by the GENCODE project (ver-
sion 16) [14], the majority of which 
correspond to four major classes: 
small nuclear RNAs, small nucleolar 
RNAs, miRNAs, and transfer RNAs. 
Other classes of short and midsize 
non-coding RNAs include PIWI-
interacting RNAs (piRNAs), transcrip-
tion initiation RNAs, promoter-associ-
ated small RNAs, transcription start 
site-associated RNAs, and promoter 
upstream transcripts. GENCODE 
also contains 13 220 long non-coding 
RNA genes, a heterogeneous group 
of non-coding transcripts longer than 
200 nucleotides encompassing main-
ly large intergenic non-coding RNAs 
and transcribed ultraconserved re-
gions (T-UCRs).
The most widely studied class 
of non-coding RNAs with functional 
importance are miRNAs. miRNAs 
are small RNA polymers, of approxi-
mately 21 nucleotides, that mediate 
post-transcriptional gene silencing 
through translational repression [15]. 
The human genome is estimated to 
encode for more than 1000 miRNAs 
that regulate the translation of more 
than 60% of protein-coding genes. 
The biogenesis of miRNAs involves 
a multistep process (Fig. 3.3.4). 
miRNAs are implicated in essentially 
all biological processes, given that a 
single miRNA can target hundreds 
of mRNAs. Aberrant miRNA expres-
sion has been observed in many 
diseases, including cancer, where 
miRNAs can operate as either onco-
genes or tumour suppressor genes. 
In addition to single miRNAs, such 
as miR-21 and miR-10b, clusters 
of miRNAs, such as the miR-17-92 
cluster, have been reported as on-
cogenes that are upregulated in 
cancers and that regulate tumour 
cell proliferation and metastasis. 
In contrast, members of the let-7 
and miR-34 families are tumour 
suppressors, which are downregu-
lated in many cancers. Under normal 
circumstances, these miRNAs inhibit 
cancer growth by targeting various 
oncogene-encoding mRNAs for deg-
radation. Notably, some miRNAs can 
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Fig. 3.3.3. Successful gene expression profiling applications in breast cancer. (A) Hierarchical clustering for the PAM50 classifier 
genes normalized to the 5 control genes using 171 formalin-fixed, paraffin-embedded procured breast samples. The cluster den-
drogram shows the five significant groups previously identified and designated as luminal A, luminal B, HER2-positive, basal-like, 
and normal. (B) Expression data matrix of 70 prognostic marker genes from sporadic breast tumours from 78 patients diagnosed at 
age less than 55 years with tumour size less than 5 cm and no lymph node involvement (I). Each row represents a tumour and each 
column a gene. Genes are ordered according to their correlation coefficient with the two prognostic groups. Tumours are ordered by 
the correlation to the average profile of the good prognosis group (II). Solid line, prognostic classifier with optimal accuracy; dashed 
line, with optimized sensitivity. Above the dashed line, patients have a good prognosis signature; below the dashed line, the prog-
nosis signature is poor. The metastasis status for each patient is also shown (III): white indicates patients who developed distant 
metastases within 5 years after the primary diagnosis; black indicates patients who continued to be disease-free for at least 5 years.
function as both an oncogene and a 
tumour suppressor, depending on the 
cell and cancer type; hence, miRNA 
expression profiles should be identi-
fied in each cancer type.
Genome-wide miRNA expres-
sion profiling microarray studies 
have shown that effectively all can-
cers present an altered miRNA pro-
file. In one of the first studies, two 
miRNAs were identified as tumour 
suppressors controlling the patho-
genesis of B-cell chronic lympho-
cytic leukaemia. Both miR-15a and 
miR-16-1 were found in a region 
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of chromosome 13 (13q14) that is 
frequently deleted in chronic lympho-
cytic leukaemia cells [16]. In solid 
tumours, specific miRNA expres-
sion profiles were also investigated, 
including colon adenocarcinoma, 
breast carcinoma, glioblastoma, 
hepatocellular carcinoma, thyroid 
carcinoma, and lung cancer. A large 
miRNA profiling analysis of 540 
samples covering 6 solid tumours 
(breast, lung, stomach, prostate, co-
lon, and pancreas) identified 43 dys-
regulated miRNAs compared with 
normal tissues [17]. Attempts have 
been made to assess the correlation 
of outcome and relapse with miRNA 
expression levels in lung [18], colon 
[19], and liver [20] cancers. These 
findings, together with the high sta-
bility of miRNAs in serum samples, 
make miRNAs attractive candidates 
as both diagnostic and prognostic 
indicators in the clinical setting.
Several studies have demon-
strated an association of circulat-
ing miRNAs with overall survival 
and early detection. A group of four 
miRNAs – miR-486, miR-30d, miR-1, 
and miR-499 – are related to de-
creased overall survival of patients 
with non-small cell lung cancer [21]. 
In a study of ovarian cancer, miR-21, 
Fig. 3.3.4. Model for the biogenesis and post-transcriptional suppression of microRNAs (miRNAs). The nascent primary miRNA 
(pri-miRNA) transcripts are first processed into precursor miRNAs (pre-miRNAs) of approximately 70 nucleotides by the RNase III 
enzyme Drosha inside the nucleus. Pre-miRNAs are transported to the cytoplasm by exportin 5 and are processed into miRNA:miRNA* 
duplexes by another RNase III enzyme, Dicer. Only one strand of the miRNA:miRNA* duplex is preferentially assembled into the 
RNA-induced silencing complex (RISC), which subsequently acts on its target by translational repression or messenger RNA (mRNA) 
cleavage, depending, at least in part, on the level of complementarity between the small RNA and its target. ORF, open reading 
frame; UTR, untranslated region.
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miR-92, miR-93, miR-126, and 
miR-29a were found to be overex-
pressed in cancer patients before 
therapy compared with healthy 
controls. The same study suggest-
ed miR-21, miR-92, and miR-93 as 
potential early-detection biomarkers 
for ovarian cancer [22]. Other class-
es of non-coding RNAs, such as 
small nucleolar RNAs, piRNAs, and 
piRNA-like transcripts, have been 
found to be implicated in malignant 
processes in a range of tumour 
types, although the mechanisms 
underlying the oncogenic effects of 
these non-coding RNAs are largely 
unknown. The differential expression 
of small nucleolar RNAs has recently 
been demonstrated in non-small cell 
lung cancer [23]. T-UCRs and large 
intergenic non-coding RNAs have 
also been shown to be relevant in 
tumorigenesis. Many large intergen-
ic non-coding RNAs are differentially 
expressed in cancers with different 
clinical outcomes. Aberrant expres-
sion signatures of T-UCRs have 
been described for chronic lympho-
cytic leukaemia, colorectal cancer, 
and hepatocellular carcinoma [24]. 
In addition, many T-UCRs show im-
portant complementarity to specific 
miRNAs, suggesting that T-UCRs 
could act as miRNA targets [25]. 
One of the best understood exam-
ples of the involvement of large in-
tergenic non-coding RNAs in cancer 
is the overexpression of homeobox 
transcript antisense RNA (HOTAIR) 
in human neoplasia. This large inter-
genic non-coding RNA may have an 
active role in modulating the cancer 
epigenome and in mediating cell 
transformation [25,26].
Gene fusions
Fusion genes are hybrid genes 
formed through translocations, in-
terstitial deletions, or chromosomal 
inversions of two previously sepa-
rate genes (Fig. 3.3.5). Gene fusions 
are a known mechanism for onco-
gene activation in several malignan-
cies, such as haematological can-
cers (e.g. leukaemia and lymphoma), 
sarcoma, and prostate cancer [27]. 
Oncogenic gene fusions may lead 
to a gene product with a different 
function from those of the two fu-
sion partners. Examples of note in-
clude the oncogenic gene fusions 
BCR-ABL in chronic myeloid leukae-
mia [28], TEL-AML1 in acute lympho-
blastic leukaemia [29], recurrent 
translocations involving ETS family 
members such as TMPRSS2-ERG 
in prostate cancer [30], EWS-FLI1 in 
Ewing sarcoma [31], and EML4-ALK 
in lung cancer [32]. Even though 
gene fusions have been widely de-
scribed in rare haematological ma-
lignancies and sarcomas [27], the 
discovery of recurrent gene fusions 
in prostate [30], lung [32], and breast 
cancer [33] suggests a putative role 
in other solid tumours.
Clinical relevance
Despite great advances in molecu-
lar profiling of cancers, only a few 
findings have been successfully 
translated into clinical applications. 
Many studies have shown the abil-
ity of gene expression profiling to 
identify diagnostic, prognostic, and 
predictive molecular markers or 
signatures. However, a substantial 
proportion of these biomarkers, 
identified in retrospective studies, 
have failed in subsequent validation 
studies. Also, many of the signatures 
were developed without a clear fo-
cus on the intended clinical use, and 
proper independent validation stud-
ies establishing their medical utility 
have rarely been performed. Indeed, 
the contribution that expression sig-
natures may make to clinical practice 
has been questioned [34].
Fig. 3.3.5. Schematic overview of the process of formation and structure of fusion genes. The two vertical red lines at the top of the 
panel indicate break points on each of two chromosomes, to generate, as one product, a fused chromosome giving rise to a mes-
senger RNA encoding the corresponding fusion protein.
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Of all the gene expression signa-
tures identified for cancer, only a few 
have become commercially avail-
able. These include the MammaPrint 
70-gene signature for breast cancer 
prognosis (Fig. 3.3.3B) [35], which 
is the only assay for breast cancer 
management that has been cleared 
by the United States Food and Drug 
Administration (FDA), in February 
2007, and the Oncotype DX 21-gene 
signature for breast cancer [36].
Since then, some academic in-
stitutions in the Netherlands and 
the USA have initiated translation 
of these gene expression profiles 
into clinical practice. There is still 
concern about incorporation of gene 
expression signatures into routine 
clinical practice before confirmation 
of their efficacy from suitably pow-
ered randomized controlled trials. 
This has resulted in the initiation 
of large prospective clinical trials 
called MINDACT and TAILORx, to 
test the efficacy of MammaPrint and 
Oncotype DX, respectively, in pre-
dicting the benefit of adjuvant che-
motherapy in breast cancer patients. 
Interestingly, a recent multicentre 
study showed that the medical on-
cologist’s treatment recommenda-
tion was changed for almost one 
third of patients on the basis of the 
Oncotype DX 21-gene assay [37].
Development of targeted 
therapy
Gene expression profiling can con-
tribute to more effective therapy 
through its diagnostic, prognos-
tic, and predictive value as well as 
through target discovery. Accurate 
diagnosis will minimize the side-ef-
fects from non-beneficial treatments. 
Perhaps most revealing is the fact 
that 70–80% of breast cancer pa-
tients who receive chemotherapy 
based on traditional predictors would 
have survived without it. Since the 
early 1990s, targeted therapies have 
been developed, such as inhibitors 
targeted to proteins encoded by 
mutated or overexpressed cancer 
genes. One of the most remark-
able examples is imatinib, a potent 
inhibitor of ABL kinase in chronic 
myeloid leukaemia, which was ap-
proved as the first-line treatment for 
this disease by the FDA in 2001 [38]. 
Imatinib was discovered in 1992 and 
is regarded as the first generation of 
targeted drugs. Furthermore, trastu-
zumab, a monoclonal antibody that 
targets HER2, was a groundbreak-
ing drug in the treatment of HER2-
positive breast cancer.
Recently, non-coding RNAs and 
the proteins involved in their biogen-
esis and activity have become tar-
gets of new therapeutic approaches. 
Therapies inhibiting miRNA function 
based on base-pair complementarity 
have been developed and include 
three main classes: locked nucleic 
acids, anti-miRNA oligonucleotides, 
and antagomirs. Several strategies, 
called miRNA replacement therapy, 
have also been proposed to restore 
the function of downregulated tumour 
suppressor miRNAs. However, these 
therapies are currently in the early 
stages of development and have 
been studied mostly in mouse mod-
els and non-human primates. Finally, 
an approach aimed at restoring the 
“global miRNAome” entails the use 
of histone deacetylase inhibitors and 
DNA demethylating agents. These 
agents, even without target specific-
ity, have been shown to release the 
epigenetic silencing of tumour sup-
pressor non-coding RNAs, such as 
miRNAs and T-UCRs [25,39].
Large-scale cancer genome 
studies, such as the International 
Cancer Genome Consortium and the 
Cancer Genome Atlas, are already 
applying next-generation sequenc-
ing technologies to tumours from 50 
different cancer types to generate 
more than 25 000 cancer genomes 
at the genomic, epigenomic, and 
transcriptomic levels and should 
generate a complete catalogue of 
oncogenic alterations. In addition, 
initiatives such as the Encyclopedia 
of DNA Elements integrate multiple 
technologies to encode all known 
functional elements of the genome, 
including the study of novel RNA 
transcripts, protein-coding regions, 
transcription factor binding sites, 
and chromatin structure such as 
DNA methylation patterns. These 
will provide a comprehensive cata-
logue of oncogenic alterations, some 
of which may prove to be new thera-
peutic targets.
Fig. 3.3.6. A GeneChip loaded with RNA from a single tumour, to identify mutations in 
expressed genes that may account for the tumour’s growth and response to therapy.
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Strengths and limitations
The advent of high-throughput gene 
expression technologies such as mi-
croarrays and RNA-seq has made it 
possible to assess the expression of 
tens of thousands of genes in a single 
experiment. Initial microarray studies 
raised concerns about reproducibil-
ity. To prevent common procedural 
failures and to establish high-quality 
tools for the microarray community, 
the FDA initiated the MicroArray 
Quality Control project in 2005 [40]. In 
addition, to standardize all microarray 
(and now RNA-seq) data, every new 
publication in the field is required to 
follow MIAME (Minimum Information 
About a Microarray Experiment) 
guidelines and to deposit expres-
sion profile data in an open data-
base. The largest publicly accessible 
repositories of microarray and other 
high-throughput functional geno-
mics data are the Gene Expression 
Omnibus at the United States 
National Center for Biotechnology 
Information [41] and ArrayExpress 
[42].
Microarray technology allows 
the identification of both single 
genes and multigene alterations 
at the level of molecular pathways 
and networks, providing a broader 
view of a disease. However, gene 
expression profiling studies, both 
microarray and RNA-seq, of-
ten generate immense amounts 
of data that are challenging to 
interpret and need to be subjected to 
more advanced bioinformatics data 
analysis. Furthermore, even though 
changes at the transcriptional level 
are important, it is essential to keep 
in mind that they are just a part of 
the bigger picture. The majority of 
cellular functions are carried out by 
proteins, and biological changes can 
be modulated not only through alter-
ations at the protein level but also by 
post-translational modifications such 
as glycosylation, methylation, acety-
lation, and phosphorylation. These 
modifications could change protein 
conformation and lead to changes 
in activity. Several consortia are 
systematically studying the genome, 
the transcriptome, the epigenome, 
and the proteome. The key to making 
the best use of this information lies in 
the integration of these data. These 
technological advances coupled with 
systems biology promise exciting 
prospects of understanding the basis 
of cancer and developing improved 
diagnostic tools and therapies.
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Summary
• Epigenetics refers to all heri-
table changes in gene expres-
sion and associated phenotypic 
traits that are not coded in the 
DNA sequence itself, and these 
changes are mediated by DNA 
methylation, histone modifica-
tions, and non-coding RNAs.
• Epidemiological and laboratory-
based studies either confirm or 
implicate that epigenetic chang-
es are induced by environmen-
tal and lifestyle factors and that 
they are involved in a variety of 
human cancers, and possibly in 
other chronic disorders.
• Epigenetic changes in cancer 
provide unique biomarkers, and 
those in non-cancer tissues can 
reflect past exposure to carcino-
genic factors.
• The suppression of epigenetic 
changes can, in principle, be 
used for cancer prevention, and 
reversibility of these changes 
is now exploited in cancer 
treatment.
Recent advances in the field of epi-
genetics have had a tremendous 
impact on our understanding of 
biological processes and complex 
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human diseases. As a result, aca-
demic, medical, and public attention 
has turned to the potential applica-
tion of these new advances in medi-
cine and various fields of biomedical 
research. In addition to conceptual 
advances, the emergence of pow-
erful technologies that enable the 
detection of epigenetic changes in 
high-throughput and genome-wide 
settings has dramatically acceler-
ated cancer research and opened 
up new perspectives, resulting in a 
broader appreciation of the impor-
tance of epigenetics in the etiology 
of human cancer.
In the past, the term “epigenet-
ics” was used to describe all biologi-
cal phenomena that do not follow 
normal genetic principles; nowa-
days, the term refers to the study 
of all changes in gene expression 
transmitted across cell generations 
that do not involve changes in DNA 
sequence, i.e. mutations. One of the 
most remarkable recent discoveries 
is that different epigenetic phenom-
ena share common underlying mo-
lecular mechanisms. There are three 
main epigenetic mechanisms: DNA 
methylation, histone modifications, 
and non-coding RNAs (Fig. 3.4.1), 
all of which are known to be critical 
for high-fidelity propagation of gene 
activity states in a cell type-specific 
manner.
Consistent with the importance 
of epigenetic mechanisms in criti-
cal cellular processes, dysregula-
tion of epigenetic mechanisms has 
been linked to disease, most nota-
bly cancer. Virtually all critical pro-
cesses found in cancer cells, such 
as silencing of tumour suppressor 
genes, activation of oncogenes, ab-
errant cell-cycle regulation, and de-
fects in DNA repair, can be caused 
not only by genetic changes, includ-
ing mutation, but also by epigenetic 
alterations. Accordingly, exploiting 
epigenetics may have potential in the 
prevention and treatment of cancer.
Epigenetic mechanisms
The three main epigenetic mecha-
nisms (DNA methylation, histone 
modifications, and RNA-mediated 
gene silencing) have been studied 
primarily in the context of gene ex-
pression. However, they are increas-
ingly recognized as important for 
other chromatin-based processes, 
such as DNA repair and replication, 
as well as in the integration of envi-
ronmental signals [1]. The patterns 
of DNA methylation and histone 
modifications are cell type-specific 
and are propagated autonomously 
and with high fidelity over many cell 
generations.
The best-studied epigenetic 
mechanism is DNA methylation. 
The methylation of DNA refers to the 
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covalent addition of a methyl group to 
the 5-carbon position of cytosine in a 
CpG dinucleotide. DNA methylation 
has long been considered a highly 
stable epigenetic modification; how-
ever, it is now accepted that DNA 
methylation marks may be more 
dynamic than previously thought. 
Indeed, recent studies showed that 
the Tet family of proteins may be in-
volved in active DNA demethylation. 
The capacity of Tet proteins to hy-
drolyse methyl cytosines (producing 
5-hydroxymethylcytosine) and to act 
on fully methylated or hemi-methyl-
ated DNA has been reported [2].
The second epigenetic mecha-
nism encompasses various histone 
modifications. These are post-
translational alterations of histone 
proteins that interact with DNA to 
Fig. 3.4.1. Different types of epigenetic information. DNA methylation, histone modifications, and RNA-mediated gene silencing 
constitute three distinct mechanisms of epigenetic regulation. DNA methylation (Me) is a covalent modification of the cytosine (C) 
that is located 5′ to a guanosine (G) in a CpG dinucleotide. Histone (chromatin) modifications refer to covalent post-translational 
modifications of N-terminal tails of four core histones (H3, H4, H2A, and H2B). The most recently discovered mechanism of epigenetic 
inheritance involves RNAs, which in the form of microRNA (miRNA) acting with messenger RNA (mRNA) can alter gene expression 
states in a heritable manner.
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form a complex known as chroma-
tin. Histone modifications include 
acetylation, methylation, phos-
phorylation, and ubiquitination of 
specific residues in the N-terminal 
tails of histones. Histone modifica-
tions regulate several cellular pro-
cesses, including gene transcription, 
DNA repair, and DNA replication [3]. 
There is growing evidence that aber-
rant histone modifications and the 
dysregulation of gene products in-
volved in these modifications are 
implicated in human neoplasms, 
and thus the importance of histone 
modifications in cancer and other 
diseases is becoming increasingly 
recognized [4].
The third class of epigenetic 
mechanisms is mediated by non-
coding RNAs, in the form of either 
long non-coding RNAs or small 
RNAs (microRNAs), which also par-
ticipate in the stable maintenance 
of gene activity states over cell divi-
sions [5] (see “The non-coding RNA 
revolution in medical research”). 
Experimental evidence suggests 
that there is intimate and mutually 
reinforcing cross-talk between the 
three epigenetic mechanisms in set-
ting up and maintaining the genome-
wide expression programme in a 
tissue-specific and lineage-specific 
manner.
Epigenome changes 
in cancer
Consistent with the critical role of 
epigenetic mechanisms in the con-
trol of cellular processes, a plethora 
of studies have revealed that the epi-
genome is markedly dysregulated 
in virtually all malignancies [6]. Two 
forms of aberrant DNA methylation 
are found in human cancer: the over-
all loss of 5-methylcytosine (global 
hypomethylation) and gene promot-
er-associated (CpG island-specific) 
hypermethylation [7]. While the pre-
cise consequences of genome-wide 
hypomethylation, including activa-
tion of cellular proto-oncogenes and 
induction of chromosome instability, 
are still debated, hypermethylation 
of gene promoters is associated 
with gene inactivation. When hyper-
methylated, gene promoters become 
unable to bind the factors that are 
responsible for gene expression [8], 
and therefore the gene is not tran-
scribed. A large number of studies 
have indicated that the silencing of 
tumour suppressor genes and other 
cancer-related genes may occur 
through hypermethylation of their 
promoters.
Histone modifications are also 
dysregulated in cancers. The iden-
tification and functional charac-
terization of chromatin modifying 
and remodelling complexes have 
revealed an important role for his-
tone modifications in normal cellular 
processes and cancer development. 
Histone modification patterns have 
been found to modulate accessibility 
The non-coding RNA revolution in medical research
Pier Paolo Pandolfi
The existence of a previously unrec-
ognized RNA language by which all 
RNA transcripts communicate in 
extensive interconnected networks 
has been proposed. The lone code 
currently available to decipher gene 
function, the triplet amino acid code 
described almost 50 years ago, can 
be applied to only 2% of the human 
genome. Recent work by several 
groups of investigators has chal-
lenged the traditional view of RNAs 
as solely templates for protein 
synthesis, and suggested instead 
a model in which these complex 
molecules have important protein-
independent functions, including a 
crucial role in post-transcriptional 
gene regulation. It may now be pos-
sible to systematically functionalize 
the entire transcriptome, which en-
compasses both protein-coding and 
non-coding transcripts. Notably, the 
transcriptome represents the ma-
jority of the human genome and is 
heavily dysregulated in cancer.
A proposed RNA language is 
based on the hypothesis that tran-
scripts regulate and communicate 
with each other by competing for 
common microRNAs. Transcripts 
acting in this fashion are termed com-
peting endogenous RNAs (ceRNAs). 
CeRNA-mediated regulation may 
involve cross-talk between multi-
ple unrelated RNA molecules in 
complex networks. This ceRNA 
language imparts a novel trans-
regulatory function to transcripts 
independent of their protein-coding 
function, and may shed light on 
regulatory networks that have been 
overlooked by conventional protein-
coding studies.
This hypothesis was ultimately 
confirmed by studying the interac-
tion between the messenger RNA 
(mRNA) encoding for the PTEN tu-
mour suppressor gene and its close-
ly related pseudogene, PTENP1, 
which acts as a tumour suppres-
sor through this new mechanism. 
Extending the analysis to mRNAs 
has identified several new regula-
tors of PTEN, such ZEB2 and VAPA, 
which are novel tumour suppressor 
molecules whose function was not 
previously associated with the proto-
oncogenic PI3K/AKT pathway. More 
recently, work has focused on the 
BRAF pseudogene BRAFps and its 
role in promoting MAPK activation 
through regulation of its parental 
gene, BRAF. BRAFps is overex-
pressed in human cancers and is 
oncogenic in mice engineered to 
express high levels of it. This trans-
formative new dimension of gene 
regulation has significant implica-
tions for the systematic functionali-
zation of the entire transcriptome, 
and represents a paradigm shift for 
biomedical research at large.
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to DNA during gene transcription 
and DNA repair. Dysregulation of 
histone modifications may promote 
induction of mutations and genomic 
instability in cancer. Interestingly, 
a recent study revealed that chro-
matin organization has a major im-
pact on regional mutation rates in 
human cancer. Furthermore, recent 
sequencing efforts have revealed 
that many genes involved in his-
tone modifications and chromatin 
remodelling are recurrently mutated 
in a wide range of human cancers. 
Many recent studies have also pro-
vided evidence that the dysregula-
tion of non-coding RNAs is involved 
in the development of human neo-
plasia [6].
Although epigenetic changes 
have been implicated in differ-
ent stages of tumour development 
and progression, the challenge is 
to identify functionally important 
epigenetic changes, which may be 
referred to as “drivers” in the same 
way this term is used for mutations, 
and hence differentiated from “pas-
senger” events, which are evident 
but not functionally important. 
Current epigenetic studies, includ-
ing major international sequencing 
projects, are expected to generate 
information establishing the com-
prehensive epigenomic profiles of 
human cancers. These findings 
seem likely to facilitate mechanistic 
studies, leading to the development 
of epigenetic therapies and new 
biomarkers.
Environmental factors
Unlike the genome, which is replicat-
ed identically in every single cell of 
an organism, the epigenome shows 
wide-ranging variability across dif-
ferent cell types, and may also vary 
within populations of the same cell 
type under the influence of environ-
mental stressors. Epigenetic mecha-
nisms have been suggested to play 
critical roles in physiological re-
sponses to environmental exposures 
(Fig. 3.4.2). Different changes in the 
epigenome are involved in mediat-
ing gene expression programmes re-
quired for an organism’s adaptation 
to environmental exposures. Studies 
in different model systems have pro-
vided important information on the 
role of epigenetic mechanisms in 
response to environmental stresses 
[1,9–12].
Many physical and chemical 
carcinogens and relevant infectious 
agents, to which individuals are en-
vironmentally exposed, are consid-
ered to promote cancer development 
through disruption of epigenetically 
maintained gene expression pro-
grammes. In addition, studies on 
monozygotic twins have highlighted 
epigenomic changes in response to 
environmental factors and associ-
ated disease susceptibility. While the 
importance of environment in the de-
velopment of a wide variety of can-
cers is well supported by both epi-
demiological and laboratory-based 
studies, the mechanisms by which en-
vironmental exposures dysregulate 
Fig. 3.4.2. Epigenetics as an interface between the genetic code and the environment. 
Epigenetic mechanisms regulate many cellular processes directly or indirectly and play 
critical roles in cellular responses to environmental and endogenous stimuli. There is 
intimate and self-reinforcing cross-talk between different types of epigenetic information. 
This is proposed to constitute the “epigenetic code” that modulates the genetic code 
in response to endogenous and environmental cues. The epigenetic code is important 
to maintain gene expression profiles and chromatin structure in a heritable manner 
over many cell generations and may dictate cellular outcomes by regulating cellular 
processes such as gene transcription, proliferation, and DNA repair. Dysregulation of 
epigenetic mechanisms may promote the development of abnormal phenotypes and 
diseases, including cancer.
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the epigenome remain poorly char-
acterized [1,9–13].
An interesting connection be-
tween the epigenome and metabo-
lism in cancer has recently emerged. 
For example, cells with mutations in 
the isocitrate dehydrogenase genes 
IDH1 and IDH2 (events that frequent-
ly occur in human gliomas) exhibit 
accumulation of the oncometabo-
lite d-2-hydroxyglutarate, resulting 
in inhibition of α-ketoglutarate de-
pendent dioxygenases involved in 
DNA and histone demethylation [14]. 
Therefore, dysregulation of IDH1/
IDH2 represents a novel oncogenet-
ic mechanism linking cellular metab-
olism and epigenome dysregulation 
in cancer.
The development of powerful 
epigenomic technologies and the 
availability of large population-based 
cohorts offer excellent opportuni-
ties to test the role of repeated and 
chronic exposure to environmental 
epimutagens and aberrant changes 
in the epigenome in the etiology 
of specific cancers. Prospects for 
epigenetic testing in the context of 
carcinogen identification and evalu-
ation may be discerned [15].
Epigenetic changes as novel 
biomarkers
Epigenetic changes, especially DNA 
methylation, are expected to be use-
ful as novel biomarkers. Before a 
tumour develops, DNA methylation 
changes can accumulate at high lev-
els in normal-appearing tissues, un-
like mutations [16], and methylation 
patterns often reflect past exposure 
to carcinogenic stimuli [17]. Also, 
the accumulation level of aberrant 
DNA methylation can be correlated 
with risk of cancer development [18]. 
Such a correlation has been well 
documented for gastric cancers, and 
has been implicated for many other 
cancers, including liver, colorectal, 
oesophageal, breast, and renal can-
cers. Therefore, DNA methylation 
profiles and patterns of methylation 
in non-cancer tissues can be used 
as a unique biomarker for past ex-
posure to carcinogens and the risk 
of future cancers (Fig. 3.4.3).
Sites of DNA methylation in par-
ticular cancers can be used as a 
biomarker to detect cancer cells or 
cancer cell-derived DNA and also 
to elucidate the pathophysiology of 
tumours. DNA methylation can be 
sensitively detected by technolo-
gies based on polymerase chain 
reaction; DNA itself is more stable 
than RNA or proteins. In addition, 
most cancer cells have an ample 
number of aberrantly methylated 
genes [16]. Therefore, DNA meth-
ylation has multiple advantages as 
a biomarker to detect cancer cells 
or cancer cell-derived DNA. Once 
specificity of DNA methylation of a 
given gene in a population of can-
cer cells is established, such aber-
rant DNA methylation can be de-
tected sensitively and stably. Such 
cancer detection systems are already 
commercially available, and multi-
ple targets are under development 
[19,20].
The pathophysiology of tumours, 
as determining or relevant to patient 
prognosis, responsiveness to thera-
py, and the presence of lymph node 
Fig. 3.4.3. DNA methylation as a biomarker for past exposure and future risk of cancers. 
Exposure to specific carcinogens, such as Helicobacter pylori infection and tobacco 
smoke, is known to induce aberrant DNA methylation of specific genes in normal-
appearing tissue, which can be used as biomarkers for past exposure. The degree of 
epigenome damage, measured as the level of aberrant DNA methylation (the fraction 
of cells with methylation), correlates with risk of cancer development for some types of 
cancers, and can be used as a cancer risk marker.
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metastasis, can also be characterized 
using DNA methylation. In sharp 
distinction from patterns of gene ex-
pression, DNA methylation may indi-
cate that a particular gene cannot be 
expressed even if its expression is 
induced in the future (Fig. 3.4.4). For 
example, if the promoter region of 
O6-methylguanine methyltransferase 
is determined to be methylated at 
biopsy of a brain tumour, this gene 
will never be expressed even after 
future chemotherapy involving an 
alkylating agent, and in the absence 
of such repair, such chemotherapy 
will be effective. In contrast, if the 
same gene is not expressed simply 
because of the lack of its induction 
at biopsy, its expression can be in-
duced upon chemotherapy, and the 
chemotherapy may be ineffective 
[21].
DNA methylation of multiple 
genes (the CpG island methylator 
phenotype) is associated with 
patient prognosis in several types 
of cancers, including colorectal and 
gastric malignancies, as well as 
neuroblastomas. Specifically, the 
CpG island methylator phenotype in 
neuroblastoma provides prognostic 
information that is more precise than 
amplification of the MYCN onco-
gene, one of the clearest prognostic 
indicators in clinical oncology [22].
Epigenetic therapy and 
prevention
One of the most important as-
pects of epigenetic change, which 
distinguishes such change from 
mutation, is reversibility induced 
by drugs [23,24]. DNA methyla-
tion can be reversed by the action 
of DNA demethylating agents, 
and two such drugs have been 
approved by the United States 
Food and Drug Administration and 
are used for treatment of haemato-
logical disorders [25]. Notably, using 
these two drugs, clinical responses 
were achieved in patients with my-
elodysplastic syndrome, for whom 
blood transfusions used to be the 
sole effective treatment. Histone 
deacetylation can be reversed by 
histone deacetylase inhibitors, and 
in this context two drugs have been 
approved for treatment of cutaneous 
lymphoma [26]. The mode of action 
of epigenetic drugs is different from 
that of cytotoxic drugs, and low-
dose and long-term administration 
is seen to be important, especially 
for DNA demethylating agents [23]. 
Recent cancer genome studies have 
revealed previously unknown muta-
tions of epigenetic regulators, and 
these mutated regulators are ex-
pected to provide novel therapeu-
tic targets in the future [24]. Other 
potential targets for therapy may be 
microRNAs (see “Causes and con-
sequences of microRNA dysregula-
tion in cancer”).
The reversibility of epigenetic 
changes is also useful for cancer 
prevention. As a proof of concept, 
in experimental animals tumours 
such as those of the colon and 
prostate have been suppressed by 
DNA demethylating agents [27,28]. 
However, it must be recognized that 
DNA methylation is physiologically 
essential to repress some genes, 
and nonspecific demethylation is ex-
pected to lead to long-term adverse 
effects [29]. Therefore, to render 
epigenetic cancer prevention prac-
ticable for the human population, the 
specificity of preventive agents for 
genes with aberrant epigenetic mod-
ifications must be improved. Also, it 
is now possible to identify individuals 
at extremely high risk of some can-
cers by assessing accumulation 
levels of aberrant DNA methylation. 
These individuals represent a popu-
lation likely to benefit from effective 
chemoprevention. Since epigenetic 
cancer prevention has great poten-
tial, multiple relevant studies are re-
quired in a timely manner.
Fig. 3.4.4. Detection of inability to be expressed. The statuses of being unable to be 
expressed and of not being expressed are different. For example, expression of the 
DNA repair protein O6-methylguanine methyltransferase can be repressed by DNA 
methylation or by the lack of its transcriptional activation. If O6-methylguanine meth-
yltransferase expression was repressed by DNA methylation at the time of biopsy, it 
cannot be induced even by implementation of chemotherapy with an alkylating agent. 
In contrast, if expression of the gene was repressed by lack of transcriptional activa-
tion, it can be induced by chemotherapy. Since O6-methylguanine methyltransferase 
repairs DNA damage introduced by the alkylating agent, the effect of chemotherapy 
is diminished by its induction. DNA methylation can predict whether such induction of 
gene expression will happen. Pol II, RNA polymerase II.
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Causes and consequences of microRNA dysregulation in cancer
Carlo M. Croce
Since the discovery of miR-15a and 
miR-16-1 deletions in chronic lym-
phocytic leukaemia, many labora-
tories around the world have shown 
microRNA (miRNA) dysregulation 
in all tumours studied, including the 
most common, such as lung, breast, 
prostate, and gastrointestinal can-
cers. Such dysregulation, like the 
dysregulation of oncogenes and 
tumour suppressor genes, can be 
caused by multiple mechanisms, 
such as deletion, amplification, mu-
tation, transcriptional dysregulation, 
and epigenetic changes.
Since miRNAs have multiple tar-
gets, their function in tumorigenesis 
could be due to their regulation of 
a few specific targets – possibly 
of even one – or of many. A future 
challenge will be identifying all of the 
targets of the miRNAs involved in 
cancer and establishing their con-
tributions to malignant transforma-
tion. An additional challenge will be 
identifying all of the miRNAs that are 
dysregulated by pathways that are 
consistently dysregulated in vari-
ous types of human cancers. This 
point is of particular importance be-
cause instead of focusing on specific 
alterations in protein-coding onco-
genes or tumour suppressor genes – 
which may be difficult to treat – the 
focus may be on their downstream 
miRNA targets. If these miRNA tar-
gets are crucial for the expression 
of the malignant phenotype and the 
cancer cells depend on their dysreg-
ulation for proliferation and survival, 
the use of miRNAs or anti-miRNAs 
may be expected to result in tumour 
regression.
Genomic analyses for alterations 
in miRNA genes or for copy num-
ber alterations in various human 
tumours by deep sequencing are 
in progress but have not been com-
pleted. These studies could provide 
additional information about the 
involvement of miRNAs in cancer 
and in many other diseases. Over 
the past few years, a shift from con-
ventional chemotherapy to targeted 
therapies has occurred, and miRNAs 
and anti-miRNAs will contribute 
extensively to targeted therapies.
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Summary
• Cancers are increasingly seen 
as metabolic diseases, as ex-
emplified by several oncogenes 
coding for metabolic enzymes 
and the impact of metabolic im-
balance associated with obesity 
and other lifestyle factors known 
to increase cancer risk.
• The metabolome is the sum of 
low-molecular-weight metabo-
lites in a particular sample and 
at a given time. Metabolomics 
is the systematic study of varia-
tions in the metabolome in par-
ticular situations, consequent 
upon various environmental or 
health conditions.
• Metabolomics provides a glob-
al view of metabolism and fa-
cilitates discovery of the role of 
metabolic pathways essential for 
cancer cell proliferation and the 
identification of new biomarkers 
for cancer diagnosis, prognosis, 
and recurrence.
• Metabolomics applied to cohorts 
in the context of metabolome-
wide association studies should 
contribute to the identification of 
novel risk factors for cancer.
3.5
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Metabolic change 
and metabolomics
Augustin Scalbert
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Genetic alterations have been con-
sidered as critical to the develop-
ment of cancers. However, close 
connections also exist between 
metabolic change and cancer devel-
opment. From one perspective, the 
metabolism of tumour cells differs 
from that of normal cells, and sev-
eral oncogenes code for metabolic 
enzymes or alter the expression of 
these enzymes. From another per-
spective, associations between life-
style, metabolism, and cancer risk 
are increasingly being reported. 
Obesity, which results in major met-
abolic imbalance, increases the risk 
of several malignancies, including 
colon, postmenopausal breast, en-
dometrial, kidney, liver, pancreatic, 
thyroid, and oesophageal cancers. 
Cancers are thus increasingly seen 
as metabolic diseases. However, the 
contribution of metabolic dysfunc-
tion to the onset or development of 
cancer remains poorly understood.
The development of metabo-
lomics and major progress in related 
analytical techniques have contrib-
uted to an improved understanding 
of the links between metabolism and 
cancer. Hundreds or thousands of 
metabolites can now be measured 
simultaneously in biospecimens 
to give a highly detailed picture of 
metabolic profiles in tumour tissues 
or biofluids. Metabolomics combines 
these highly sensitive analytical 
techniques with powerful methods 
for data analysis to characterize 
subtle metabolic changes associ-
ated with cancer. This approach has 
already led to the discovery of new 
biomarkers for cancer and to a better 
understanding of the mechanisms 
underlying the etiology of cancers.
Metabolism and cancer
Salient features of cancer cells com-
pared with normal cells are their high 
rates of glycolysis and glutamine 
metabolism, which allow malignant 
cells to meet their high energy and 
anabolic requirements. Production 
of lactic acid from glucose, even 
under non-hypoxic conditions, as 
commonly exhibited by tumour tis-
sue is a feature that has been recog-
nized for more than 70 years and is 
known as the Warburg effect. Such 
metabolism offers several advan-
tages to cancer cells, including a 
high rate of adenosine triphosphate 
(ATP) production and the production 
of intermediate metabolites like cit-
rate in a truncated tricarboxylic acid 
cycle to feed biosynthetic pathways 
and support the production of mac-
romolecules for cell proliferation, of-
ten resulting in a fine-tuning of these 
metabolic pathways. Otto Warburg 
sought to explain this effect as the 
result of damage to respiratory pro-
cesses. However, it is now known 
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that dysregulation of glycolysis is a 
better explanation [1].
Connections between some ma-
jor oncogenes or tumour suppressor 
genes and metabolism have been 
identified, and this finding has fo-
cused attention on metabolic dys-
regulation as a possible key mecha-
nism leading to cancer. Mutations in 
the tumour suppressor gene TP53 
enhance glucose transport and me-
tabolism, whereas mutations in the 
oncogenic transcription factor MYC 
enhance the expression of most gly-
colytic enzymes, lactase dehydroge-
nase A, and enzymes required for 
nucleotide biosynthesis and one-
carbon metabolism [2].
Oncogenes also play a key role 
in enabling cancer cells to adapt to 
environmental changes and adjust 
their metabolism accordingly. At an 
early stage of tumorigenesis, the on-
cogene ERBB2 was demonstrated 
to commit the metabolism of cancer 
cells detached from their normal ma-
trix towards proliferation rather than 
apoptosis [3]. Detached cells usually 
undergo apoptosis and autophagy, 
but overexpression of this oncogene 
rescues the cancer cells, restores 
glucose transport and the pentose 
phosphate pathway, and improves 
the redox status of the cells.
Metabolic genes associated 
with aggressive cancer and stem 
cell character were systematically 
investigated within a list of about 
2700 genes encoding all known hu-
man metabolic enzymes and trans-
porters [4]. Some of these genes 
had previously been shown to be 
highly expressed in tumours com-
pared with normal tissues and also 
highly expressed in stem cells as 
assessed in a human breast cancer 
xenograft model. Sixteen of these 
genes were demonstrated to be 
required for tumorigenesis, includ-
ing genes encoding transporters for 
mitochondrial ATP and for lactate as 
well as enzymes contributing to the 
glycolysis, pentose phosphate, and 
nucleotide biosynthesis pathways. 
This study also established the key 
role played by phosphoglycerate de-
hydrogenase, the first enzyme in the 
serine biosynthetic pathway, which 
drives the conversion of glutamine 
to tricarboxylic acid cycle intermedi-
ates for anabolic processes.
The role of metabolic alterations 
and adaptations in tumorigenicity is 
thus increasingly recognized. These 
metabolic alterations are now con-
sidered a new hallmark of cancer 
[5]. This has led to the development 
of new therapeutic approaches tar-
geted at the modulation of corre-
sponding signalling pathways or at 
the direct inhibition of some of the 
enzymes in the metabolic pathways 
involved in tumorigenicity. These 
approaches include inhibition of 
glycolysis, amino acid biosynthe-
sis, and the mTOR and phosphati-
dylinositol 3-kinase (PI3K) signalling 
pathways [6].
Understanding the interactions 
between altered metabolism and 
cancer biology is important not 
only for therapeutic intervention 
for cancer but also for prevention 
of malignant development. Obesity 
and certain metabolic characteristics 
(the metabolic syndrome) are well-
established risk factors for several 
cancers, and various mechanisms 
have been proposed to explain such 
interactions [7]. These include the di-
rect effects of adiposity on the secre-
tion of pro-inflammatory cytokines 
and adipokines, and indirect effects 
such as insulin resistance and high 
insulinaemia commonly associated 
with obesity or an increase in the lev-
els of steroid hormones. Alterations 
of metabolic profiles associated with 
obesity (e.g. excess circulating free 
fatty acids), other lifestyle factors, 
or some genetic factors may also 
increase cancer risk.
Metabolomics, through an in-
depth characterization of metabolic 
profiles in cells, tissues, and human 
biofluids, may help elucidate both 
mechanisms of carcinogenesis 
and those underlying associations 
between lifestyle and cancer risk. 
Metabolomics can also be used to 
identify novel early biomarkers for 
cancer and to characterize new risk 
factors for cancer.
Metabolomics to better 
understand mechanisms 
of carcinogenesis
The metabolome – the sum of 
low-molecular-weight metabolites 
at a given time – is the most fun-
damental biochemical indicator of 
biological systems and is an in-
dicator of both genetic and envi-
ronmental conditions (Fig. 3.5.2). 
Metabolomics has been defined as 
the systematic study of variations 
of the metabolome under particular 
conditions [7] and involves assess-
ing the metabolome in blood, urine, 
or tissues using modern and pow-
erful analytical techniques based 
on mass spectrometry or nuclear 
magnetic resonance (NMR) spec-
troscopy. The sensitivity of these 
analytical techniques and the large 
number of metabolites detected al-
low the characterization of biologi-
cal phenotypes with unprecedented 
precision, the identification of novel 
biomarkers for diseases and expo-
sure to disease risk factors, and a 
better understanding of the etiology 
of diseases (Fig. 3.5.3).
Fig. 3.5.1. Campaign poster from the 
Collectif National des Associations 
d’Obèses (France): “Obesity kills. Do you 
still think it’s funny? Obesity is a serious 
condition that kills 55 000 people per year 
in France. It is neither a fault nor an inevi-
tability, still less a joke.” Obesity has been 
shown to increase susceptibility to diabe-
tes and cancer.
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Two different metabolomic ap-
proaches can be distinguished. In 
the targeted approach, sets of tens 
or hundreds of metabolites identified 
a priori are quantified simultaneously 
in a single analytical operation, most 
often by mass spectrometry. In the 
untargeted approach, hundreds (with 
NMR spectroscopy) or thousands 
(with mass spectrometry) of me-
tabolites are detected in individual 
profiles from large sets of samples 
(Fig. 3.5.4). Metabolites overex-
pressed or underexpressed in differ-
ent groups of samples (e.g. plasma 
samples from case and control sub-
jects) are identified using multivari-
ate statistics and their structures es-
tablished a posteriori by comparing 
their spectra to those stored in large 
metabolite databases.
When applied to tumour cells or 
animal models of cancers, metabo-
lomics, through the wealth of data 
generated in a typical experiment, 
allows the formulation of novel hy-
potheses, which can then be tested 
in hypothesis-driven targeted ex-
periments. Two recent publications 
show how metabolomics contributed 
to establishing the oncogenicity of 
glycine and glycine decarboxylase. 
In a metabolic survey of 60 primary 
human cancer cell lines from 9 com-
mon tumour types, 111 metabolites 
were measured in the cell culture me-
dium [8]. About two thirds of the me-
tabolites were found to be secreted 
and one third consumed during cell 
growth. Hierarchical clustering analy-
sis of the metabolites permitted the 
recognition of several clusters related 
to different metabolic pathways (gly-
colysis, tricarboxylic acid cycle, nu-
cleotide and polyamine metabolism) 
with no major distinction according 
to tissue of origin. Glycine consump-
tion was found to be highly correlated 
to proliferation of transformed cells. 
This unique observation led to the 
recognition of the key role played by 
the mitochondrial glycine synthesis 
pathway in cancer cell proliferation.
Further confirmation of the role 
of glycine in cell proliferation was 
derived from another study, on stem 
cells from human lung tumours [9]. 
In this investigation, metabolomics 
was applied to characterize the 
role of a specific enzyme, glycine 
decarboxylase, in overall metabo-
lism. Glycine decarboxylase was 
demonstrated to be one of the most 
upregulated genes in stem cells 
compared with other lung tumour 
cells. This enzyme catalyses the 
breakdown of glycine to the methyl 
donor 5,10-methylenetetrahydro-
folate, which is required for the syn-
thesis of nucleotides. Comparison 
of metabolic profiles of several cell 
lines overexpressing glycine de-
carboxylase or with this enzyme 
knocked down revealed alterations 
in the glycine pathway, glycolysis, 
and pyrimidine synthesis. The on-
cogenic character of glycine decar-
boxylase was further confirmed by 
higher mortality among non-small 
cell lung cancer patients exhibiting 
high expression of this enzyme in 
their tumours.
Metabolomics to identify 
novel biomarkers for cancer
Metabolomics has been used in 
various case–control studies to 
identify novel biomarkers for cancer 
Fig. 3.5.2. The metabolome is the most downstream biochemical expression of the 
phenotype and is influenced by both genetic and environmental factors.
Fig. 3.5.3. The human metabolomes and the applications of metabolomics to cancer 
research.
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diagnosis, prognosis, or recurrence. 
New biomarkers were discovered by 
comparing metabolic profiles in tu-
mours and benign adjacent tissues or 
blood or urine samples from patients 
and matched controls. Good exam-
ples of these novel biomarkers include 
hydroxylated ultra long-chain fatty 
acids for colorectal cancer [10] and 
27-nor-5β-cholestane-3,7,12,24,25 
pentol glucuronide for ovarian cancer 
[11]. In these two particular studies, 
serum samples were analysed by 
high-resolution mass spectrometry to 
detect features in metabolic profiles 
that provided for clearest discrimi-
nation between cases and controls. 
Relevant chemical structures were 
established by mass spectrometry 
and NMR spectroscopy.
The potential presented by me-
tabolomics may be evident with 
reference to particular tumours. 
Because of its asymptomatic nature, 
hepatocellular carcinoma is usually 
diagnosed at late and advanced 
stages. For this tumour type, emerg-
ing high-throughput metabolomics 
technologies have been applied to 
the discovery of candidate biomark-
ers for cancer staging, prediction of 
recurrence and prognosis, and treat-
ment selection [12].
Certain novel biomarkers are rel-
atively rare metabolites. More com-
mon metabolites, when assembled 
in marking sets (metabolic signa-
tures), may also constitute powerful 
biomarkers for cancer. Such marking 
sets characteristic of particular can-
cers have also been identified using 
metabolomics. Amino acid profiles 
in plasma were shown to permit the 
discrimination of patients with five 
different cancers from matched con-
trols regardless of disease stage 
[13]. These characteristic profiles 
were also evident at an early stage, 
showing the value of these amino 
acids as biomarkers for detection of 
disease. Some of these amino acids 
were systematically increased or de-
creased independent of the cancer 
site, suggesting the existence of 
a generic metabolic signature for 
cancer. Other metabolomic studies 
also showed consistent alteration 
in the level of other metabolites. 
A systematic analysis of metabolic 
signatures from 117 preclinical 
and clinical metabolomic studies 
revealed that, besides alterations 
in amino acids, metabolism of glu-
tathione, bile acids, galactose, 
triglycerides, phospholipids, and 
nucleotides as well as ammonia re-
cycling and the glycolytic and glu-
coneogenic pathways were consis-
tently affected in cancers [14].
In all such metabolomic studies, 
a key step is biomarker validation. 
The large number of metabolic vari-
ables and the low number of sub-
jects (commonly 50–200, depend-
ing on the study) increase the risk 
of false discovery. It is therefore es-
sential to validate the new biomark-
ers in an independent population. 
Unfortunately, validation has been 
largely overlooked in most metabo-
lomic studies published thus far. 
The identification of sarcosine as a 
biomarker for prostate cancer [15] 
raised expectations of a possible 
way to improve diagnosis, but this 
result could not be validated in a 
later study [16]. Examples of good 
study design for biomarker valida-
tion can be recognized in a few me-
tabolomic studies [10,11]. To limit the 
risk of false discovery and better ap-
praise the value of biomarkers, it will 
be important to gain further insight 
into the potential confounding effects 
of factors such as body mass, age, 
gender, postmenopausal status, mi-
crobiome, drug treatment, or smok-
ing – all known to affect the meta-
bolome – and then conduct studies 
taking into account the influence of 
these factors.
Metabolomics to identify risk 
factors for cancer in cohort 
studies
Metabolomics is a powerful means 
to compare individual phenotypes in 
populations. A good illustration of the 
power of the approach is given by its 
application to the identification of the 
invariant part of the metabolome in 
a given individual. The analyses of 
the metabolome by NMR spectros-
copy in a small set of urine samples 
from 22 subjects allowed the rec-
ognition, with 100% confidence, of 
Fig. 3.5.4. Metabolomic workflow. MS, mass spectrometry; NMR, nuclear magnetic 
resonance spectroscopy.
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the donor of the samples [17]. The 
rapid development of more sensitive 
mass spectrometry techniques now 
permits the generation of metabolite 
profiles with much greater detail and 
the comparison of individual pheno-
types in large groups of subjects, 
as is done in most epidemiological 
studies.
Several thousands of different 
metabolites constituting the human 
metabolome have been described 
in diverse biospecimens. So far, this 
considerable amount of metabolic 
information has been exploited to a 
very limited extent. The human me-
tabolome includes both a stable and 
an unstable fraction. These were 
characterized by NMR spectros-
copy in repeated plasma and urine 
samples collected 4 months apart, 
and the stable fraction was found 
to account for 60% and 47% of the 
plasma and urine metabolomes, re-
spectively [18]. The unstable fraction 
reflects exposures to environmental 
and lifestyle factors, which occur 
only episodically. This fraction is not 
easily exploited in epidemiological 
studies unless repeated samples are 
available.
In contrast, the stable fraction 
captures both genetic and envi-
ronmental variations of individual 
phenotypes, and its evolution over 
a lifetime can be described. Its mea-
surement opens up wide perspec-
tives to study the prevalence and risk 
of diseases in cohort studies. The 
first metabolome-wide association 
studies (MWAS) (to be compared to 
the well-established genome-wide 
association studies) have recently 
been published. These studies are 
aimed at identifying the metabo-
lites and metabolic pathways most 
strongly associated with a disease 
or with intermediate end-points. In 
a case–control study nested in the 
Framingham Offspring cohort, 61 
metabolites were measured in plas-
ma samples collected at baseline 
(average follow-up, 12 years; 189 
cases and 189 controls), and 5 ami-
no acids were identified that were 
strongly associated with the risk of 
type 2 diabetes [19]. These amino 
acids include three branched-chain 
amino acids previously known for 
their ability to promote insulin resis-
tance. No such MWAS studies have 
yet been published on cancer.
The fraction of the human meta-
bolome that varies with environmen-
tal exposure rather than genetic fac-
tors has been called the exposome 
[20]. The exposome notably reflects 
dietary exposure. Characteristic 
metabolic features could be identi-
fied in vegetarians and in low and 
high meat consumers, or in sub-
jects consuming specific foods [21]. 
Variations in the urinary metabolome 
across countries as measured in 
the International Population Study 
on Macro/Micronutrients and Blood 
Pressure (INTERMAP) cohort 
were found to be partly explained 
by metabolites directly derived 
from foods consumed in various 
amounts in these countries [22,23]. 
Measurement of the exposome in 
exposome-wide association stud-
ies (EWAS) should enable the iden-
tification of the environmental fac-
tors most strongly associated with 
cancer risk [21].
The few examples given here 
show the great potential of me-
tabolomics for cancer research. 
Such studies have already con-
tributed to elucidating the role of 
unexpected metabolic pathways of 
major importance in carcinogenesis. 
Investigation of metabolic processes 
has enabled the identification of nov-
el biomarkers for cancer diagnosis. 
The application of metabolomics to 
molecular epidemiology also shows 
great potential to identify novel risk 
factors for cancer.
Metabolomics, among all “omics” 
technologies, is the one most recently 
introduced into biological and medi-
cal research. Techniques for metabo-
lomics, although not yet fully mature, 
have considerably improved over the 
past few years, and there is now little 
doubt that metabolomics will emerge 
as an essential tool, complementary 
to the well-established genomics, 
transcriptomics, and proteomics ap-
proaches, to identify novel biomark-
ers for cancer and to better under-
stand the etiology of the disease.
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Summary
• Stem cells are defined by their 
capacity to self-renew, which is 
essential for the maintenance of 
a stem cell pool, and to differen-
tiate according to different line-
ages, as required for the integ-
rity and functioning of particular 
tissues.
• Because of their long half-life, 
stem or progenitor cells may be 
particularly affected by genetic 
and epigenetic changes, and 
may thereby contribute to cancer 
development.
• “Cancer stem cell” is an op-
erational term used to define a 
distinct subpopulation of tumour 
cells functionally, with reference 
to aberrant renewal potential and 
the capacity to confer tumour 
heterogeneity.
• Although the origin of cancer 
stem cells has not been estab-
lished, cancer stem cells as cur-
rently identified share many key 
properties with embryonic stem 
cells, including unlimited prolif-
erative potential and the capacity 
to migrate.
• Research on stem cells and can-
cer stem cells may indicate novel 
approaches to cancer therapy.
3.6
3 BIOLOGY
Stem cells and 
cancer stem cells
Zdenko Herceg
Hector Hernandez Vargas
Gianpaolo Papaccio (reviewer)
The pace of discovery in the field 
of stem cells has drawn academic, 
political, and public attention to stem 
cells as tools for innovation in medi-
cine and biomedical research. Stem 
cells are found in all multicellular or-
ganisms and are likely to be present 
as a discrete population in most tis-
sues. Stem cells can be grown in 
culture and differentiated into spe-
cialized cells that exhibit properties 
specific to various tissues. The land-
mark discovery by Takahashi and 
Yamanaka that induced pluripotent 
stem cells, which have properties in 
common with embryonic stem cells, 
could be derived from differentiated 
cells – notably, skin fibroblasts [1] – 
led to the award of the Nobel Prize 
in Physiology or Medicine 2012 and 
has been reproduced using a variety 
of human cell types [2]. Furthermore, 
several studies have described the 
generation of induced pluripotent 
stem cell lines from individuals har-
bouring both simple and complex ge-
netic diseases [3]. Therefore, stem 
cells have been seen as an essential 
resource in cloning and regenerative 
medicine.
Stem cells share important char-
acteristics with malignant cells. A bet-
ter understanding of the behaviour 
and properties of stem cells could 
be exploited to devise a range of 
novel agents for and/or approaches 
to cancer therapy. Although technical 
advances that enable the isolation 
and manipulation of embryonic stem 
cells, and hence the possibility of 
human cloning, have provoked in-
tense ethical debate, these concerns 
should not detract from a recognition 
of the tremendous potential of stem 
cells for the treatment of various hu-
man diseases, such as neurodegen-
erative disorders and cancer [4,5].
Embryonic and tissue-
specific stem cells
All cells in the body are descended 
from a single cell: the fertilized egg 
or zygote. From the moment of fer-
tilization of an egg until death, an 
organism passes through several 
developmental stages (Fig. 3.6.1). 
Multiplication of cells from the fer-
tilized egg gives rise to different 
cell types, as evident in complex 
organisms. This process involves 
populations of stem cells that can 
be propagated indefinitely in culture 
under adequate conditions. These 
cells are designated embryonic 
stem cells and can give rise to any 
cell type and reconstitute the entire 
embryo. In addition, many adult tis-
sues contain a discrete population 
of undifferentiated cells with prop-
erties of stem cells. These cells are 
described as tissue-specific stem 
cells, also called somatic stem cells 
or adult stem cells. Haematopoietic 
stem cells are the best-characterized 
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tissue-specific stem cells and can 
generate all blood lineages and ma-
ture blood elements. Adult stem cells 
have been identified in many other 
tissues, such as the brain, skin, and 
liver. Although only a few types of 
tissue-specific stem cells have un-
dergone rigorous identification and 
characterization, stem cells are likely 
present in any tissue that is able to 
undergo renewal.
Tissue-specific stem cells also 
have the capacity to perpetuate 
themselves through self-renewal 
and to produce the various mature 
cells of a particular tissue through 
differentiation [6]. Tissue-specific 
stem cells constitute a very minor 
cell population in adult tissues, but 
this population is essential for the 
maintenance of tissue homeostasis. 
Dysregulation of tissue-specific stem 
cells may initiate diseases, most 
notably cancer.
The two characteristics of stem 
cells that distinguish them from all 
other cells are self-renewal and multi-
potency. Self-renewal is the capacity 
of a cell to divide and produce identi-
cal daughter cells over a long time 
period. This crucial property allows 
stem cells to persist for the lifetime 
of an organism. Multipotency is the 
capacity of stem cells to differentiate 
into many highly specialized cells, 
such as neurons, muscle fibres, 
and blood elements. Multipotency 
is necessary for the maintenance 
of integrity and functionality of many 
Fig. 3.6.1. Embryonic stem cells, derived from the inner cell mass of the blastocyst, are pluripotent and can give rise to all cell types 
of the body. Somatic stem cells, sometimes termed adult stem cells, are also capable of self-renewal and, with appropriate signals, 
differentiate into various cell types of the organ from which they are derived. The extent to which somatic stem cells are capable of 
differentiating into cell types from alternative lineages is controversial.
Fig. 3.6.2. Embryonic skin-derived progenitor cells. Cancer stem cells share many 
properties with embryonic stem cells.
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tissues. Stem cells are essential for 
the development of each organism 
and thus can be considered to be a 
critical resource from the beginning 
of embryonic life until death. Given 
the potential of stem cells, their 
function and proliferation are sub-
ject to a range of control processes. 
Dysregulation of the surveillance 
mechanisms for proliferation and dif-
ferentiation of stem cells may initiate 
a shift in the balance between self-
renewal and differentiation, leading to 
either stem cell loss, which is associ-
ated with degenerative disorders, or 
abnormal proliferation of stem cells, 
which may be a source of malignant 
cells.
Cancer stem cells
Stem cells were discovered more 
than 30 years ago and have been ex-
ploited extensively for the generation 
of genetically modified animal mod-
els, such as knockout mice, which 
are essential in cancer research. 
However, the first identification of 
human stem cells and, in particular, 
so-called cancer stem cells resulted 
in the cancer research community 
giving almost unprecedented atten-
tion to these entities. Tumours have 
long been considered to be derived 
Stem cells in cancer: determinants of clinical outcome?
John E. Dick
The cellular and molecular basis for 
intratumour heterogeneity is poorly 
understood. Tumour cells can be 
genetically diverse due to mutations 
and clonal evolution, resulting in in-
tratumour functional heterogeneity. 
Cancer stem cell models postulate 
that tumours are cellular hierarchies 
sustained by cancer stem cell het-
erogeneity due to epigenetic differ-
ences; that is, all cells present after 
long-term tumour growth are derived 
from cancer stem cells. There is 
strong evidence for the cancer stem 
cell model in acute myeloid leukae-
mia (AML). Examination of the gene 
signatures specific to either AML 
stem cells or normal haematopoietic 
stem cells indicates that they share 
a set of genes that define a common 
stemness programme. Only these 
stem cell-related gene signatures 
were significant independent predic-
tors of patient survival in large clini-
cal databases. Thus, determinants of 
stemness influence clinical outcome 
of AML, establishing that leukaemia 
stem cells are clinically relevant and 
not artefacts of xenotransplantation. 
In an effort to determine whether the 
clonal evolution and stem cell mod-
els of cancer can be unified, two 
different studies were performed 
examining cancer stem cells at both 
the functional and the genetic level.
In Philadelphia chromosome-
positive B-cell acute lymphoblastic 
leukaemia (B-ALL), diagnostic pa-
tient samples had extensive sub-
clonal genetic diversity, and through 
the use of xenotransplant assays, 
this diversity was established to have 
originated from within the leukaemia-
initiating cells. Reconstruction of 
their genetic ancestry showed that 
multiple leukaemia-initiating cell sub-
clones were related through a com-
plex branching evolutionary process, 
indicating that genetic and functional 
heterogeneity are closely connected. 
This research highlights the need to 
develop effective therapies to eradi-
cate all genetic subclones to prevent 
further evolution and recurrence.
In a related functional and genet-
ic study, a highly reliable xenograft 
assay was used for primary colo-
rectal cancer. With a combination of 
DNA copy number alteration profil-
ing, targeted and exome sequenc-
ing, and lentiviral lineage tracing, the 
repopulation dynamics of many sin-
gle lentivirus-marked lineages from 
colorectal cancers were followed 
through serial xenograft passages. 
The xenografts were genetically sta-
ble on serial transplantation. Despite 
this genetic stability, the prolifera-
tion, persistence, and chemother-
apy tolerance of lentivirus-marked 
lineages were variable within each 
clone. Thus, apart from genetic di-
versity, tumour cells display inher-
ent functional variability in tumour 
propagation potential, a mechanism 
that maximizes tumour fitness, con-
tributing to both tumour survival and 
therapy tolerance.
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Fig. 3.6.3. Genetic and epigenetic changes in susceptible cells may be an early event in 
the development of cancer and give rise to cancer stem cells and contribute to tumour 
heterogeneity. The origin of cancer stem cells may be early stem or progenitor cells, or 
differentiated cells distinguished by abnormal expression and function of a set of genes 
that may contribute to reprogramming into a pluripotent state.
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from a single cell that has been sub-
ject to transformation into a cancer-
initiating cell through a series of ge-
netic and epigenetic lesions. These 
initial events allow for the expansion 
of transformed cells and the forma-
tion of a population of altered cells, 
or a clone, with the capacity to grow 
and divide in defiance of normal cel-
lular control. Continuing selection of 
“fitter” and more aggressive cells re-
sults in a generation of cancer clones 
capable of invading and destroying 
neighbouring tissues and migrating 
to distant organs to form metastatic 
tumours. The identity of that original 
“target cell” is not known (Fig. 3.6.3). 
However, recent studies indicate that 
many genetic and epigenetic chang-
es underlying the aggressive and 
destructive behaviour of cancer are 
orchestrated by a discrete population 
of cancer cells with stem cell proper-
ties. These cells are known as cancer 
stem cells.
The cancer stem cell hypothesis 
states that cancer clones are main-
tained exclusively by a fraction of 
rare cells with stem cell properties 
[7]. A hierarchical organization has 
been established for several human 
cancers. In those cases, tumours are 
organized into undifferentiated cells 
that can drive disease progression 
and differentiated cells with less ca-
pacity to drive disease progression, 
consistent with the cancer stem cell 
model [8]. Many cancers have been 
found to contain cells with proper-
ties of stem cells. However, in most 
cases the existence of cancer stem 
cells has been documented function-
ally: the presence of cancer stem 
cells in the bulk of cancer cells is 
discerned by their capacity to form 
tumours after transplantation into an 
immunocompromised animal host, 
most commonly a mouse. These 
assays reveal that only a small frac-
tion of cancer cells are capable of 
forming new tumours in the host. 
Importantly, these cells not only can 
form tumours upon transplantation 
but also can recapitulate tumour het-
erogeneity [9]. However, until very 
recently, the isolation of a cancer 
stem cell population using molecular 
signatures, cell surface markers, or 
mutation profiles has proven to be 
extremely difficult [7,10,11].
Recently, numerous studies 
have shown that cancer stem cells 
can be enriched via different cell 
surface markers, such as CD133, 
CD44, CD90, and EpCAM (CD326) 
(Table 3.6.1) [12–30]. However, al-
though some markers are common to 
different types of cancer stem cells, 
so far no single marker (or combi-
nation of markers) has been shown 
to be able to distinguish these cells 
across all cancer types. This lack 
of universal expression of surface 
markers limits their use. In addition, 
surface markers should be interpret-
ed carefully, considering the tissue 
context and functional assessments 
(e.g. tumorigenic, clonogenic, and 
sphere formation assays) and co-
expression with stemness markers 
[11]. In spite of these weaknesses, 
many studies have taken advantage 
of surface markers to shed light on 
the biology of putative cancer stem 
cells. Some markers are common 
to several malignancies (e.g. CD44, 
CD133) and, interestingly, some 
markers are common to normal 
stem or progenitor cells (e.g. CD133, 
EpCAM). Indeed, the cell surface ex-
pression of the human prominin-1 
(CD133) antigen is common to hae-
matopoietic progenitors, and it is 
among the most frequently studied 
markers of cancer stem cells [31].
In addition to surface markers, 
cancer stem cells may share many 
key properties with embryonic stem 
cells. These properties include in-
finite proliferation potential and the 
capacity to invade tissues and or-
gans and to promote formation of 
blood vessels for their own oxygen-
ation. Therefore, cancer stem cells 
may contribute to the heterogeneity 
of most human cancers [8]. Although 
important progress has been made 
in the identification of cancer stem 
cells, their origin remains obscure. 
Cancer stem cells are believed to 
arise in different ways. First, cancer 
stem cells can be derived from nor-
mal tissue-specific stem cells as a 
result of specific genetic and epige-
netic changes that abrogate prolif-
eration control in the normal cells. 
Second, differentiated cells that 
normally have a limited lifespan can 
regain stem cell properties, that is 
de-differentiate and become can-
cer stem cells. Third, normal stem 
cells may fuse with various differ-
entiated cells and the resulting hy-
brid cells may be cancer-initiating 
cells with stem cell properties [32]. 
These hypotheses are not mutually 
Table 3.6.1. Surface marker phenotypes commonly used to identify cancer stem cells
Tumour type [source of data] Cancer stem cell marker
Acute myeloid leukaemia [12] CD34+/CD38–
Breast cancer [13,14] CD44+/CD24lo, CD133+
Gall bladder cancer [15] CD44+/CD133+
Gastric cancer [16] CD44+
Glioblastoma [17,18] CD133+
Head and neck cancer [19] CD44+
Hepatocellular carcinoma [20–23] CD133+, CD13+, CD90+, EpCAM+
Lung cancer [24] CD133+
Melanoma [25] CD20+
Oesophageal cancer [26,27] CD90+, CD44+
Ovarian cancer [28] CD133+
Pancreatic cancer [29] CD133+
Prostate cancer [30] CD133+/CD44+/α2β1hi
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exclusive, and the genesis of cancer 
stem cells may involve more than 
one mechanism.
Genomic determination of 
stem cell identity
Although the features that distin-
guish stem cells from differentiated 
cells have been known for many 
decades, the genetic basis of stem 
cell identity only began to be under-
stood recently. The development of 
powerful methodologies in genomics 
for genome-wide screening enabled 
the identification of genes and gene 
networks that maintain stem cells in 
a special state. With these methods, 
a limited number of genes have been 
discovered that are necessary and 
sufficient to maintain self-renewal 
and pluripotency – the two distin-
guishing features of stem cells. 
These genes have been referred to 
as “masters of stemness”. The genes 
Oct4, Sox2, and Nanog belong to 
this exclusive category [33]. These 
genes encode transcription factors 
that control the transcription of other 
genes (Fig. 3.6.4). Such signal trans-
duction pathways maintain stem cell 
behaviour and identity. When the rel-
evant genes are inactivated or mu-
tated, stem cells may differentiate 
into specialized cells and the stem 
cell pool may be rapidly depleted. 
Depletion of the stem cell pool can 
impede regeneration and compro-
mise the integrity of normal tissue, 
leading to degenerative disease [34].
The discovery of stem cell mas-
ter genes has enabled another, even 
more insightful branch of research: 
the transition of differentiated cells 
into immature pluripotent (stem) 
cells. This phenotypic reversal or de-
differentiation essentially involves 
enabling specialized cells such as 
neurons or muscle fibres to regain 
stem cell properties, which would 
allow the generation of practically 
any type of cell. Such a scenario 
may solve important ethical issues 
associated with the use of embryos 
as a source of stem cells, as demon-
strated by recent studies [3]. Several 
laboratories have demonstrated that 
the introduction of as few as four 
master genes into either human or 
murine differentiated cells mediates 
the emergence of stem cells. This 
remarkable phenomenon provides 
support for the argument that differ-
entiated cells can be reprogrammed 
and that the course of events that 
normally characterizes differentia-
tion can be reversed. An important 
implication of these findings is that 
Fig. 3.6.4. Cell reprogramming factors can induce pluripotent stem cells, with potential 
applications in therapy. iPSCs, induced pluripotent stem cells.
Fig. 3.6.5. Reprogramming can alter any cell of the body so that it may function as 
a pluripotent stem cell. Shown are human induced pluripotent stem cells derived 
from dermal fibroblasts. Immunofluorescence analysis with an antibody against 
Nanog protein (red) is used to indicate that Nanog (a master transcription factor 
critically involved in stem cells and a widely used marker of the pluripotent state) is 
expressed and that cells have been successfully reprogrammed.
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cancer stem cells may also arise by 
non-genetic changes that confer 
certain features on differentiated 
cells. This hypothesis is supported 
by the knowledge that all cells, in-
cluding stem cells, in any given or-
ganism share an identical genome.
Experimental evidence from vari-
ous recent studies suggests a simi-
lar conclusion to that just described: 
cell differentiation is not unidirec-
tional, and different factors may lead 
to reversal of cell differentiation un-
der either physiological or pathologi-
cal conditions. In the same way that 
tumorigenesis may be identified 
with the acquisition of self-renewal 
and pluripotency in vivo, manipula-
tion of differentiated cells in vitro 
may lead to a controlled version 
of the same process. Conversely, 
cells with established stemness 
features may acquire characteris-
tics of partial differentiation. The 
balance between stemness and a 
differentiated character appears to 
be different during critical periods 
of life, such as embryonic develop-
ment. An extrapolation of the same 
idea is evidenced by the increasing 
interest being accorded to the ef-
fects of early-life exposures on the 
development of later disease. In this 
sense, early in utero life represents 
a critical period where pluripotency 
and differentiation networks interact 
dynamically and where environmen-
tal exposures may have an impact 
beyond that initially perceived.
Stem cells and cancer therapy
Much current interest in stem cells 
and cancer stem cells is predicated 
on the realization that this tiny, yet 
critical, population of cancer cells 
represents an opportunity to devise 
novel strategies for cancer therapy 
[35]. Many currently used protocols 
for cancer therapy are now under-
stood to fail – marked by the reap-
pearance of disease – due to an 
inability to eradicate cancer stem 
cells. Classic chemotherapy regimes 
have been developed to rapidly shrink 
tumours. However, these changes 
are often transient and are followed 
by recurrence (Fig. 3.6.6). Such a 
clinical course suggests that the ther-
apy used specifically targets rapidly 
growing tumour cells, whereas more 
slowly growing cancer stem cells may 
be spared. Thus, major challenges 
will be (i) to discover efficient ways 
to identify and isolate tissue-specific 
stem cells and cancer stem cells, (ii) 
to gain insights into the mechanisms 
of self-renewal and pluripotency of 
normal stem cells and cancer stem 
cells, and (iii) to identify genetic and 
epigenetic events that are critical to 
cancer-initiating reprogramming and 
cancer stem cell development (see 
“Stem cells in cancer: determinants 
of clinical outcome?”).
The ever-increasing research ef-
forts in the field of stem cells have 
the potential to identify processes 
that are currently unknown and yet 
key in cancer development, which will 
ultimately have a major impact on the 
development of novel strategies to 
control and perhaps eliminate cancer.
Fig. 3.6.6. Conventional therapies may reduce tumour size by killing mainly differenti-
ated tumour cells. If the putative cancer stem cells are less sensitive to these therapies, 
then cancer stem cells will remain viable after therapy and re-establish the tumour. By 
contrast, if therapies can be targeted against cancer stem cells, then they might more 
effectively kill the cancer stem cells, rendering the tumours unable to maintain them-
selves or grow. Thus, even if cancer stem cell-directed therapies do not shrink tumours 
initially, they may eventually lead to cures. CSC, cancer stem cell.
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Summary
• The tumour microenvironment 
refers to the biochemical and 
cellular composition of the tis-
sue encompassing a tumour 
and comprises a heterogeneous 
population of cancer cells, a va-
riety of non-cancer cells, soluble 
proteins, blood vessels, peritu-
moural lymphatic vessels, and 
a supporting structural matrix.
• Bidirectional signalling between 
cancer cells and stromal cells 
leads to enhanced cancer cell 
division, suppressed immune 
cell function, and resistance 
to therapeutic intervention, all 
of which result in poor clinical 
outcome.
• Cancer-associated inflammation 
parallels disease progression, 
and tumours have been charac-
terized as “wounds that do not 
heal”.
• Accumulating evidence sug-
gests that combined therapeutic 
regimens that both target cancer 
cells (e.g. chemotherapy) and 
modify the tumour microenvi-
ronment (i.e. anti-angiogenic 
therapy) are superior to treat-
ments directed against only 
cancer cells.
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Over the past several years, it has 
become increasingly apparent that 
the reciprocal signalling that takes 
place between cancer cells and the 
cellular and molecular components 
of the surrounding tissue plays a 
decisive role in determining tumour 
growth, metastasis, and responsive-
ness to therapy. Tumour growth is 
accompanied by an ever-increasing 
recruitment and activation of previ-
ously quiescent cells, whose cumu-
lative response is one that perpetu-
ates disease progression (Fig. 3.7.1). 
Treatment efforts are hindered by a 
unique set of physiological param-
eters present in the tumour micro-
environment. Consequently, much 
effort is currently directed towards 
the development of therapeutic 
strategies that both target cancer 
cells and modify the tumour micro-
environment. Several key aspects 
of the tumour microenvironment are 
described in this chapter.
Tumour vasculature
The proximity of a cancer cell to a 
blood vessel determines its fate; 
cancer cells located within 75 μm 
of a blood vessel enter the cell di-
vision cycle, whereas cancer cells 
located farther than 150 μm from 
a vessel undergo programmed cell 
death [1]. Tumour growth to a size 
beyond a few millimetres in diam-
eter leads to hypoxia and nutrient 
deprivation, which activate the “an-
giogenic switch” and allow tumours 
to progress [2]. Cancer cells pro-
duce cytokines and growth factors 
that act in an autocrine manner to 
promote their own expansion, and in 
a paracrine fashion to convey infor-
mation to quiescent adjacent cells. 
The initial target cells for signal-re-
leasing cancer cells are resident mi-
crovascular endothelial cells, which 
respond by activating programmes 
that culminate in the formation of 
new vascular networks (i.e. angio-
genesis) (Fig. 3.7.2). Angiogenesis 
diminishes the metabolic pressures 
associated with unrestricted cancer 
cell division and increases the likeli-
hood of cancer cell dissemination. 
The tumour microenvironment be-
comes enriched in vascular en-
dothelial growth factor (VEGF), a 
primary mediator of pathological 
angiogenesis.
Angiogenesis is most pronounced 
at the interface between tumour and 
normal tissue, although the intensity 
of the neovascularization response 
varies between different types of tu-
mours (Fig. 3.7.3). Angiogenesis is 
greatest in glioblastoma and renal cell 
carcinoma and least in tumours of the 
prostate and lung [3]. Some cancer 
cells (e.g. melanoma cells) may forgo 
angiogenesis altogether and satisfy 
their metabolic demands by prolifer-
ating along the length of pre-existing 
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blood vessels in a process referred 
to as vessel co-option. Cancer cells 
may co-opt blood vessels when chal-
lenged with anti-angiogenic agents.
Pharmacological suppression of 
angiogenesis as a means to control 
tumour growth is an area of intense 
investigation. Several inhibitors of 
the VEGF signalling pathway are 
currently in clinical use; these in-
clude bevacizumab, a monoclonal 
antibody that neutralizes VEGF, and 
small-molecule inhibitors of the ty-
rosine kinase receptor VEGFR2 
(e.g. sorafenib, sunitinib). The ad-
dition of bevacizumab to standard 
therapy was found to increase 
overall survival in patients with 
advanced malignancies, including 
non-small cell lung cancer and met-
astatic colorectal cancer. However, 
many tumours are inherently resis-
tant to anti-angiogenic agents, and 
those tumours that initially respond 
to treatment eventually become re-
fractory to therapy and recur.
Independent investigations con-
cluded that cancer cells circumvent 
anti-VEGF therapies by upregulat-
ing alternative angiogenic proteins, 
such as basic fibroblast growth fac-
tor and interleukin-8. Recent data 
suggest that stromal cells also 
contribute to resistance to anti-
VEGF agents. Indeed, preclinical 
studies using cross-species hybrid-
ization of microarrays concluded 
that most of the gene expression 
changes associated with acquired 
resistance of non-small cell lung 
cancers to bevacizumab occur in 
stromal cells [4]. The epidermal 
growth factor receptor (EGFR) 
gene was identified as a network 
hub activated on stromal cells of 
bevacizumab-resistant non-small 
cell lung tumours. Co-localization 
studies revealed a 10-fold increase 
in the number of pericytes express-
ing the activated form of EGFR 
in experimental bevacizumab- 
Fig. 3.7.1. Illustration depicting the complexity of the interplay between cancer cells and stromal cells. (A) Transforming growth 
factor β (TGF-β) produced from initiated epithelial cells activates tissue fibroblasts. Activated fibroblasts (myofibroblasts) generate 
hepatocyte growth factor (HGF), which binds to the MET receptor on epithelial cells. Activation of MET signalling has been shown to 
stimulate pathways that promote cell division, motility, and anti-apoptotic activity. (B) Cancer cells produce the pro-angiogenic protein 
vascular endothelial growth factor (VEGF), in response to declining oxygen tension. (C) VEGF is chemotactic for macrophages, which 
contribute to the pool of pro-angiogenic proteins. (D) Myofibroblast-derived HGF activates invasive and migratory programmes in 
cancer cells, allowing them to penetrate structurally deficient angiogenic vessels and spread to distal tissues. (E) Interleukin-1 (IL-1) 
produced by myofibroblasts leads to the recruitment of inflammatory cells. (F) Tumour-associated macrophages generate VEGF-C, 
which signals for lymphangiogenesis, increasing the likelihood of lymph node metastasis. (G) Macrophages and myofibroblasts 
secrete matrix metalloproteinases (MMPs), which remodel the extracellular matrix. (H) Cancer cell chemokines including chemokine 
ligand 2 (CCL2) and CCL5 direct circulating monocytes to the tumour. Macrophage colony-stimulating factor (MCSF) promotes the 
differentiation of monocytes to macrophages. (I) Cancer cell-derived IL-6 and IL-10 polarize macrophages to an M2 phenotype with 
pro-angiogenic and immunosuppressive properties.
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resistant tumours compared with 
control tumours. Dual inhibition of 
VEGFR and EGFR pathways re-
duced pericyte coverage of tumour 
blood vessels and, moreover, de-
layed emergence of the resistant 
phenotype [4].
In other animal models of can-
cer, tumour refractoriness to anti-
VEGF therapy was dependent on 
the tumour’s ability to prime and re-
cruit CD11b+Gr1+ granulocyte-mac-
rophage cells [5]. Cancer cells and 
tumour-associated fibroblasts syn-
thesize and secrete granulocyte- 
macrophage colony-stimulating 
factor and stromal cell-derived 
factor 1, which stimulate myeloid 
recruitment into the tumour micro-
environment. In addition to provid-
ing a rich reserve of angiogenic 
proteins, CD11b+Gr1+ cells also 
suppress the immune response 
of CD4+ and CD8+ T cells through 
several different mechanisms, in-
cluding upregulation of reactive 
oxygen species, nitric oxide, and 
immunosuppressive cytokines.
Physiological parameters of 
the tumour microenvironment
Tumour blood vessels are distinct 
from normal vessels in that they 
are dilated, tortuous, and heteroge-
neously distributed, and comprise 
constitutively activated endothe-
lial cells. VEGF renders the tumour 
vascular bed hyperpermeable to 
macromolecules, and extravasated 
proteinaceous fluid accumulates 
in the tumour matrix due to a lack 
of functional intratumour lymphatic 
vessels. Consequently, tumour in-
terstitial colloid osmotic pressures 
are significantly greater than those 
of normal tissues and most tumours 
have grossly elevated interstitial fluid 
pressures. The elevated interstitial 
fluid pressure creates a barrier to 
transcapillary transport, which lim-
its the uptake of therapeutic agents 
in tumours. Interventions that lower 
interstitial fluid pressure, such as 
anti-VEGF therapies, are reported 
to normalize the tumour vasculature 
and improve drug uptake.
Chemotherapy and radiotherapy 
require optimal tumour blood flow to 
achieve maximal benefit, whereas 
anti-angiogenic therapies and vas-
cular disrupting agents seek to 
completely abolish neoplastic blood 
flow. Blood flow to tumours is het-
erogeneous, and marked variability 
exists even in tumours with a simi-
lar histological classification growing 
in the same anatomical region [6]. 
Elevated interstitial fluid pressure 
may compress tumour blood ves-
sels and diminish tumour blood flow. 
Blood flow fluctuations (and vascular 
stasis) occur frequently in the tumour 
circulation and are associated with 
periods of hypoxia. Fluctuations in 
erythrocyte flux in tumour blood 
vessels predispose tumour cells 
to periods of transient hypoxia and 
reoxygenation.
Estimates indicate that 50–60% 
of advanced tumours contain het-
erogeneously distributed hypoxic 
regions. There are two forms of hyp-
oxia in human tumours. Diffusion-
limited hypoxia refers to limitations in 
the diffusion distance of oxygen from 
a blood vessel. The diffusion dis-
tance of oxygen from tumour blood 
Fig. 3.7.2. Morphological classification of tumour vasculature in hepatocellular carcinoma. Three human hepatocellular carcinomas 
were stained with anti-CD34 antibody to show their vasculature. The vasculature can be (A) capillary-like microvessels, (B) a mixture 
of capillary-like and sinusoid-like vasculature, or (C) sinusoid-like vasculature. The prognosis of patients harbouring these three 
vasculature types differs; capillary-like microvessels correspond to the best prognosis and sinusoid-like tumour vasculature the worst.
A B C
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vessels has been measured and is 
approximately 120 μm. Perfusion-
limited hypoxia results from non-uni-
form blood flow patterns caused by 
structural and functional alterations 
in tumour vessels. For example, a 
rapidly expanding tumour may im-
pinge on its vasculature and tem-
porarily or permanently block blood 
flow, thereby creating areas deficient 
in oxygen. Arteriovenous shunting 
is also a common feature in tumour 
circulation; approximately one third 
of arterial blood can pass through 
tumours without taking part in the 
microcirculatory exchange process.
The oxygenation status of tu-
mours has important clinical im-
plications. Radiotherapy and che-
motherapy are significantly more 
effective in an aerobic environment. 
Aerobic cells are 3 times as sensi-
tive as hypoxic cells to the effects 
of radiation. Hypoxia acts as a 
physiological selective pressure for 
variants with diminished apoptotic 
potential, enhanced genetic instabil-
ity, and increased invasive capacity. 
Oxygen deprivation is associated 
with increased metastasis and poor 
outcomes in patients with head 
and neck carcinomas and cervical 
cancer.
Studies evaluating the genetic 
stability of the stromal compart-
ment have yielded conflicting results. 
Examinations of formalin-fixed, par-
affin-embedded archival tumours 
reported loss of heterozygosity 
(LOH) and changes in copy number 
of certain loci in cancer-associated 
fibroblasts, whereas studies per-
formed on fresh-frozen tissues failed 
to detect chromosomal changes in 
cancer-associated fibroblasts. A re-
cent genome-wide copy number and 
LOH analysis of fresh-frozen breast 
and ovarian cancers using array 
analysis for hundreds of thousands 
of single-nucleotide polymorphisms 
reported that LOH and copy num-
ber alterations are extremely rare 
in cancer-associated fibroblasts [7].
There is no debate about the im-
portance of inflammation to carcino-
genesis and neoplastic progression 
(see “Inflammation and cancer” in 
Chapter 2.4). Epidemiological re-
ports indicate that chronic inflamma-
tion in select organs increases the 
risk for development of cancer and 
that non-steroidal anti-inflammatory 
drugs reduce the incidence of, and 
mortality from, several tumour types 
[8]. An inflammatory component is 
also present in the microenvironment 
of tumours that are not epidemio-
logically related to inflammation. In 
general, cancer-associated inflam-
mation parallels disease progres-
sion and contributes to cancer cell 
division and survival, angiogenesis, 
metastasis, subversion of adaptive 
immunity, and reduced response to 
therapy [8].
Tumour-associated 
macrophages
Macrophages are among the most 
represented innate immune cells 
in the tumour microenvironment. A 
correlation exists between high mac-
rophage content and poor prognosis 
in many human tumours. Circulating 
monocytes traffic to tumours in re-
sponse to chemokines including 
chemokine ligand 2 (CCL2) and 
CCL5, growth factors such as VEGF, 
and vasoactive peptides including 
endothelins. Cancer cell-derived fac-
tors mediate the differentiation and 
orientation of incoming monocytes. 
Macrophage colony-stimulating fac-
tor promotes the differentiation of 
monocytes to resident macrophag-
es, whereas interleukin-6 (IL-6) and 
IL-10 polarize macrophages towards 
an M2 phenotype [9]. Results from 
clinical and experimental studies 
suggest that the functional proper-
ties of M2 macrophages favour tu-
mour progression. M2 macrophages 
possess limited antigen-presenting 
capacity and suppress Th1 adaptive 
immunity while actively promoting 
angiogenesis and tissue remodel-
ling processes.
Tumour-associated macrophag-
es are also a major source of matrix 
metalloproteinases (MMPs), a family 
of zinc-containing endopeptidases, 
which play a critical role in tissue 
remodelling processes. MMPs are 
Fig. 3.7.3. Novel assays for measuring surrogate markers of tumour angiogenesis 
activity. The complex biology of angiogenesis inhibitors has accentuated the need to 
develop technologies that can be used to assess the effects of biological markers. A 
compilation of data from multiple assays, including measuring angiogenic factors in 
serum, plasma, and urine; tumour biopsy analysis; radiological imaging; and, recently, 
ex vivo analyses of isolated peripheral blood cells (labelled circulating endothelial cells) 
may facilitate defining the optimal biological dose for subsequent clinical studies of 
angiogenesis inhibitors.
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initially expressed as inactive zymo-
gens, and activation requires cleav-
age of an autoinhibitory pro-domain. 
MMP-mediated proteolytic destruc-
tion of the extracellular matrix results 
in the release of matrix-embedded 
bioactive fragments and growth fac-
tors that encourage cancer cell divi-
sion, angiogenesis, and neutrophil 
recruitment processes. Expression 
and activity levels of MMPs are up-
regulated in most human cancers 
and correlate with advanced tumour 
stage, increased invasion and me-
tastasis, and shortened survival [10].
Macrophages express an exten-
sive array of pro-angiogenic proteins 
sufficient to trigger the angiogenic 
switch or amplify an ongoing neovas-
cularization response. Conditions 
that enhance angiogenic activity in 
macrophages include hypoxia and 
elevated levels of pyruvate, lactate, 
and hydrogen ions, all of which are 
characteristic of the tumour micro-
environment. Macrophage-produced 
VEGF and prostaglandins diminish 
endothelial cell barrier function by in-
creasing the permeability of tumour 
vasculature. Macrophage-derived 
VEGF-C and VEGF-D ligands signal 
for peritumoural lymphangiogenesis, 
which may increase the spread of 
cancer cells to regional lymph nodes.
Microenvironment in 
metastasis
Most deaths due to cancer result 
from the progressive growth of me-
tastases that are resistant to con-
ventional therapies. The process 
of metastasis involves a complex 
series of interrelated steps that 
begins when cancer cells detach 
from the primary mass and invade 
the surrounding stroma (Fig. 3.7.4). 
Carcinoma cells at the invasive front 
adopt morphological features and 
patterns of gene expression that 
are characteristic of mesenchymal 
cells during a process referred to 
as epithelial–mesenchymal tran-
sition (EMT). EMT plays a critical 
role during embryonic development 
and contributes to tissue repair pro-
cesses in the adult. Disseminating 
carcinoma cells reactivate this de-
velopmental programme and re-
press epithelial proteins E-cadherin, 
β-catenin, and cytokeratin and up-
regulate mesenchymal-associated 
proteins N-cadherin, vimentin, and 
fibronectin. Recent studies suggest 
that cancer cells undergoing EMT 
may also acquire stem cell-like 
properties and become resistant to 
Fig. 3.7.4. The process of metastasis consists of sequential, interlinked, and selective steps. Each step of the metastatic process 
is considered rate-limiting in that failure of a tumour cell to complete any step effectively terminates the process. The formation of 
clinically relevant metastases represents the survival and growth of a unique subpopulation of cells that pre-exist in primary tumours. 
See the text for a detailed description of the individual steps of the metastatic process.
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anticancer therapies [11]. Reciprocal 
signalling between cancer cells and 
cancer-associated fibroblasts is re-
ported to stimulate EMT in some ex-
perimental models. Invading cancer 
cells gain access to the systemic cir-
culation by penetrating thin-walled 
blood vessels and lymphatic chan-
nels. Circulating cancer cells are re-
tained in target organs by adhering 
to microvascular endothelial cells 
or the sub-endothelial basement 
membrane. Extravasated cancer 
cells are thought to undergo mes-
enchymal–epithelial transition in the 
secondary tissue, by a yet-unknown 
mechanism. Cancer cells that leave 
the cell cycle or are unable to trig-
ger the angiogenic switch may en-
ter a period of dormancy or undergo 
apoptosis.
The process of metastasis is ex-
tremely inefficient in that less than 
0.1% of circulating tumour cells 
eventually form metastases. That 
certain tumours have a tendency to 
form metastases in specific organs 
provided the foundation for the “seed 
and soil” hypothesis, which was pro-
posed well over a century ago. In 
essence, Paget’s hypothesis states 
that tumour cells (“seed”) grow pref-
erentially in the microenvironment 
of select organs (“soil”). In the con-
cluding sections of this chapter, the 
discussion focuses on the microen-
vironment of the brain and bone, two 
frequent target organs of metastasis.
Brain microenvironment
Estimates indicate that approximate-
ly 200 000 cases of brain metasta-
ses occur each year in the USA, and 
that 20–40% of patients with sys-
temic cancers develop brain metas-
tases during the course of their dis-
ease. Brain metastasis has several 
unmet clinical needs; there are few 
clinically relevant tumour models, 
no targeted therapies exist that are 
specific for brain metastases, and 
the median survival for untreated pa-
tients is 5 weeks [12]. Most brain me-
tastases arise from primary tumours 
that originate in the lung (40–50%), 
breast (15–20%), or skin (5–10%). 
Patients tend to present with multiple 
brain metastases, 80% of which are 
located in the cerebral hemispheres.
Comparative genome expres-
sion analysis was used to study the 
molecular mechanisms that medi-
ate breast cancer cell arrest and 
extravasation in the brain. Cyclo-
oxygenase 2 (COX-2), heparin-
binding EGF-like growth factor (HB-
EGF), and α-2,6-sialyltransferase 5 
(ST6GALNAC5) were identified as 
key regulatory molecules that control 
the passage of breast cancer cells 
through the blood–brain barrier [13]. 
ST6GALNAC5 enhances the affin-
ity of breast cancer cells for brain 
endothelial cells, whereas COX-2 
increases the permeability of brain 
vasculature. Autocrine activation 
of breast cancer cell EGFR by HB-
EGF signals for invasion of the brain 
parenchyma.
Results from real-time imag-
ing studies suggest that survival of 
cancer cells in the central nervous 
system is dependent on their abil-
ity to communicate with vascular 
endothelial cells. Failure to stimu-
late angiogenesis leads to regres-
sion of lung adenocarcinoma cell 
brain metastases, whereas the in-
ability to locate cerebral vessels for 
co-option leads to activation of cell 
death programmes in melanoma 
brain metastases [14]. Brain en-
dothelial cells also protect brain me-
tastases from the cytotoxic effects 
of chemotherapy. Unlike endothelial 
cells from other regional circulations, 
brain endothelial cells constitutively 
express the P-glycoprotein trans-
porter on their apical membrane, 
which mediates the efflux of several 
chemotherapeutic agents, including 
vinblastine, methotrexate, vincris-
tine, doxorubicin, and etoposide. 
P-glycoprotein also limits the cen-
tral nervous system uptake of sev-
eral small-molecule targeted thera-
pies, such as erlotinib, gefitinib, and 
imatinib.
One hallmark of human brain 
metastases is reactive astroglio-
sis, the process in which astro-
cytes alter their patterns of gene 
expression and undergo changes 
in cell morphology. Astrogliosis is 
characterized by upregulation of 
the intermediate filament protein 
called glial fibrillary acidic protein, 
and hypertrophy of astrocyte cellular 
processes. Astrocytes encircle and 
infiltrate brain metastases, and the 
magnitude of astrogliosis parallels 
tumour growth. The precise mecha-
nism responsible for astrogliosis 
remains unclear. Results obtained 
from co-culture systems using as-
trocytes and human cancer cells 
demonstrated that astrocytes protect 
cancer cells from chemotherapeutic 
agents through gap junction-medi-
ated communication that results in 
upregulation of GSTA5, BCL2L1, and 
TWIST1 survival genes in cancer 
cells [15].
Bone microenvironment
Bone metastasis is also a signifi-
cant public health concern; it oc-
curs in up to 70% of individuals with 
advanced cancer of the breast or 
prostate and in approximately 40% 
of patients with carcinomas of the 
lung or kidney. The pathophysiology 
of bone metastasis involves several 
different cell populations and a va-
riety of regulatory proteins. Bone 
metastases are classified as either 
osteoblastic or osteolytic, depending 
on whether the pathology involves 
bone formation or bone destruc-
tion. Pathological bone remodelling 
results in significant skeletal compli-
cations, including pain, hypercalcae-
mia, fractures, spinal cord compres-
sion, and immobility.
The highly vascularized me-
taphyseal bone found at the ends 
of long bones, ribs, and vertebrae 
is a target site for bone-homing tu-
mour cells. The bone is enriched in 
several cytokines and growth fac-
tors that act as homing signals for 
cancer cells. Studies suggest that 
stromal cell-derived factor 1 and its 
receptor, CXCR4, may direct the traf-
ficking of a variety of cancer cells to 
bone. Stromal cell-derived factor 1 is 
constitutively expressed in the bone 
microenvironment by fibroblasts, 
endothelial cells, and osteoblasts. 
Neutralizing antibodies and synthetic 
peptide antagonists directed against 
CXCR4 expressed on prostate and 
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breast cancer cells were found to re-
duce the number of bone metasta-
ses in experimental models. CXCR4 
was identified as one of a small set 
of genes that mediate breast cancer 
metastasis to bone. Activation of 
CXCR4 on cancer cells transduces 
Src-dependent survival signals and 
increases their affinity for microvas-
cular endothelial cells.
Several factors have been im-
plicated in the skeletal remodelling 
that accompanies metastatic bone 
cancer. One of the most studied 
mediators of bone metastasis is 
parathyroid hormone-related peptide 
(PTHrP). More than 90% of breast 
cancer bone metastases are PTHrP-
positive, whereas only 20% of breast 
cancers in non-bone metastatic sites 
express PTHrP. PTHrP produced by 
breast cancer cells binds to parathy-
roid hormone receptor 1 on osteo-
blasts and stimulates upregulation 
of receptor activator of nuclear fac-
tor κB ligand (RANKL). RANKL then 
binds to its receptor on osteoclasts 
and promotes cell differentiation and 
activation. Bone resorption liberates 
from the bone matrix transforming 
growth factor β, which then binds to 
its receptor on cancer cells and ac-
tivates a positive feedback loop by 
signalling for increased production 
of PTHrP from cancer cells. Agents 
that target RANKL and interfere 
with osteoclastogenesis decrease 
the incidence of skeletal complica-
tions and are the current standard 
of care for patients with bone me-
tastasis [16].
Fig. 3.7.5. The role of platelet-derived growth factor receptor β (PDGFR-β) in the pathogenesis of hormone-refractory prostate 
cancer bone metastasis. (A) Circulating prostate cancer cells ensure their retention in the bone by exploiting their sialyl LewisX 
antigen to adhere to E-selectin expressed on bone endothelial cells. (B) Extravasating tumour cells express interleukin-6 (IL-6), which 
is chemotactic for monocytes and imparts M2 functional properties to macrophages. Tumour necrosis factor α (TNFα) produced 
by macrophages stimulates prostate cancer cells to increase their production of IL-6. (C) TNFα activates osteoclasts and signals 
for activation of the bone remodelling process. (D) Transforming growth factor β (TGF-β) released from the bone matrix binds to 
its receptor on prostate cancer cells, where it stimulates production of platelet-derived growth factor (PDGF). (E) PDGF acts in an 
autocrine manner by binding to PDGFR-β expressed on cancer cells and stimulating cell division. (F) Phosphorylation of PDGFR-β 
on tumour-associated endothelial cells promotes activation of angiogenic programmes in resident endothelial cells.
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Mortality from prostate cancer 
usually results from metastasis 
of hormone-refractory prostate 
cancer cells. The spread of pros-
tate cancer to the bone is thought 
to involve both anatomical com-
ponents (i.e. the Batson venous 
plexus) and site-specific molecular 
adhesive interactions between the 
tetrasaccharide sialyl LewisX anti-
gen on prostate cancer cells and 
its receptor E-selectin, which is 
constitutively expressed on bone 
endothelial cells. Preclinical studies 
of androgen-independent prostate 
cancer cells implanted into the bone 
of mice implicated platelet-derived 
growth factor receptor β (PDGFR-β) 
in metastatic progression in that in-
hibition of PDGFR-β activation with 
imatinib therapy produced apoptosis 
of both cancer cells and the tumour-
associated blood vessels. PDGFR-β 
signalling promotes survival of bone 
endothelial cells, and the receptor 
is expressed in its phosphorylated 
form on tumour-associated endothe-
lial cells and cancer cells in clinical 
bone marrow samples from prostate 
cancer patients. PDGFR-β was also 
identified as one of the five genes 
that predicted recurrence after pros-
tatectomy. The role of PDGFR-β in 
hormone-refractory prostate cancer 
bone metastasis is illustrated in 
Fig. 3.7.5.
Conclusion
Over the past 5 years, the number of 
investigations into the cellular inter-
actions that take place in the tumour 
microenvironment has increased 
dramatically. During this same pe-
riod, both the United States National 
Cancer Institute and the European 
Commission have established major 
research initiatives focused exclu-
sively on an improved understand-
ing of the cellular communication 
that takes place between cancer 
cells and the stromal compartment. 
One consequence of these efforts 
has been the realization that thera-
peutic targeting of both cancer cells 
and components of the microenvi-
ronment leads to improved clinical 
outcomes. Continued study of the 
complex cross-talk between cancer 
cells and the microenvironment of 
target organs of metastasis is likely 
to yield new opportunities for thera-
peutic intervention.
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Summary
• Signalling pathways regulate a 
plethora of biological processes 
in all cells of complex organisms.
• Consistent with mediating cell 
survival, proliferation, response 
of growth factors, and related bi-
ological processes, components 
of such signalling pathways are 
often variously modified by mu-
tation or epigenetic effects in 
different types of cancer.
• A range of small-molecule inhib-
itors and monoclonal antibod-
ies are categorized as targeted 
therapies because the benefits 
these agents provide depend 
upon perturbation of particular 
signalling pathways in malignant 
cells.
• One particularly well-studied 
signalling network is the epi-
dermal growth factor receptor 
(EGFR) pathway. Due to the role 
of this pathway in maintaining 
the transformed phenotype in 
tumours such as non-small cell 
lung cancer and squamous cell 
carcinoma of the head and neck, 
the EGFR pathway is a promi-
nent target for pharmacological 
inhibition.
• A major problem with therapies 
aimed at inhibiting signalling 
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pathways is that tumour cells 
manifest a wide array of strate-
gies, which render them refrac-
tory to drug treatment.
• Modern whole-genome se-
quencing techniques offer great 
potential for the provision of op-
timal targeted therapy on an in-
dividual basis, as demonstrated 
by their initial successful appli-
cation in the clinic.
Responsiveness to extracellular 
signals is a fundamental attribute of 
all living organisms. For instance, 
bacteria sense nutrition gradients 
through signalling cascades medi-
ated by transmembrane receptors, 
which result in bacterial motion to-
wards nutrients [1]. This paradigm 
of receptor-mediated signal trans-
duction reaches its highest level of 
complexity in mammals, where hun-
dreds of different cell types commu-
nicate with each other – both locally, 
as involving the paracrine system, 
and over relatively vast distances, as 
identified by the endocrine system. 
Virtually every biological process is 
at least co-regulated by the integra-
tion of extracellular signals from cells 
and organs. This chapter focuses on 
the molecular events that mediate 
signal transduction, how these sig-
nalling cascades are dysregulated 
in cancer, and how targeting these 
signalling networks may increase the 
efficiency of anticancer therapy.
Receptor tyrosine kinases – 
molecular biology and 
functions
In humans, various signalling cas-
cades with distinct molecular proper-
ties play key roles in health and dis-
ease. The major signalling pathways 
perturbed in various tumour types 
(Table 3.8.1) mediate organ devel-
opment and homeostasis in normal 
tissue. The receptor tyrosine kinases 
identify a specific group of receptor 
molecules [2]. In humans, 58 differ-
ent receptor tyrosine kinases have 
been identified, grouped into 20 
subfamilies. Members of the ERBB 
receptor subfamily, namely ERBB1 
(also named epidermal growth factor 
receptor [EGFR]), ERBB2, ERBB3, 
and ERBB4, all play important roles 
in development and homeostasis but 
are dysregulated in various human 
tumours and therefore constitute 
therapeutic targets in the treatment 
of cancer [3].
Generally, receptor tyrosine kinas-
es function as homodimers and het-
erodimers, including the ERBB family 
members. Each monomer consists of 
an extracellular N-terminal domain, 
which primarily serves as a binding 
site for various ligands; a hydropho-
bic transmembrane domain; and an 
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Table 3.8.1. Features of the major signalling pathways and representative cancers in which these pathways play a role
Pathway Molecular features of signal transduction
Examples 
of associated 
cancers
RTKs Receptor tyrosine kinases (RTKs) initiate phosphorylation cascades that involve adaptor 
proteins and various mitogen-activated protein kinases (MAPKs), ultimately modulating 
transcription of genes involved in proliferation and differentiation.
Most cancers
PI3K Activation by RTKs leads to the chemical modification of components of the cell membrane, 
which through a multistep process leads to increased cell growth and survival.
Ovarian cancer
JAK-STAT Activation by receptors, like cytokine receptors or the RTK family. Directly activates proteins 
called signal transducer and activator of transcription (STATs).
Lymphoma
NF-κB Cytokine receptors activate a complex protein network, which through proteolysis of inhibitory 
factors ultimately leads to the nuclear translocation and activation of transcription factors 
belonging to the NF-κB family.
Lymphoma, breast 
cancer
Notch Activation of the transmembrane receptor Notch leads to the proteolysis of its intracellular 
domain, which shuttles to the nucleus and ultimately serves as a transcription factor.
Pancreatic cancer
Hedgehog Ligand binding to the receptor Patched leads to its inactivation and inhibits the repressive role of 
Patched on another receptor, Smoothened. Activated Smoothened initiates a signalling cascade 
that results in changes in gene expression.
Basal cell 
carcinoma, 
medulloblastoma
WNT In a very complex signalling cascade, activation of various receptors by WNT ligands inhibits the 
activity of an important cytoplasmic kinase, GSK3B, which in turn stabilizes β-catenin protein, 
which subsequently shuttles to the nucleus and serves as a transcription factor.
Colon cancer
TGF-β Activation of the TGF-β receptors phosphorylates proteins called SMADs, which subsequently 
enter the nucleus and regulate expression of genes required for processes such as proliferation 
or cell motility.
Breast cancer, 
colon cancer
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K, phosphatidylinositol 3-kinase; TGF-β, transforming growth factor β.
intracellular C-terminal region con-
taining the catalytic kinase domains 
(Fig. 3.8.1). Signal transduction is 
initiated by binding of a ligand to the 
extracellular domain of a receptor 
molecule, inducing homodimeriza-
tion when a second identical receptor 
molecule is involved, or heterodimer-
ization, which involves a different re-
ceptor molecule, usually of the same 
family, with subsequent conforma-
tional changes. Dimerization causes 
activation of the intracellular kinase 
domain within the receptor. This leads 
to phosphorylation (usually in trans) of 
various tyrosine residues, which are 
located in the C-terminal part of these 
proteins (Fig. 3.8.1). In biochemical 
terms, the phosphate group (PO4) of 
ATP, the phosphate donor in most 
biochemical reactions, is covalently 
linked to a tyrosine residue of the re-
ceptor by the catalytic activity of its 
kinase domain. As is discussed later, 
these two steps, namely receptor di-
merization and ATP catalysis, under-
pin therapeutic strategies targeting 
signalling pathways [4].
Once receptor phosphorylation 
has occurred, multiple proteins en-
sure that the original signal is ampli-
fied and transduced within the cell 
to different compartments. Adaptor 
proteins bind to the phosphorylated 
residues of the receptor tyrosine ki-
nases and propagate the stimulus by 
protein–protein interactions, many of 
which result in further phosphoryla-
tion events. Particular propagators 
of the signalling cascade initiated by 
ERBB receptors are the protein SOS 
and the small GTPase RAS, which 
are frequently mutated in various 
cancers. Cellular processes affected 
by ERBB signalling include (i) the reg-
ulation of gene expression, mediated 
mainly by mitogen-activated protein 
kinase (MAPK)-regulated activity of 
the activator protein 1 (AP1) tran-
scription factors; (ii) AKT-mediated 
cell survival; and (iii) changes in cell 
motility, controlled by RHO and RAC 
proteins. This signalling cascade is 
kept in a dynamic state as multiple 
molecular mechanisms mediate the 
turnover of activated receptor ty-
rosine kinases. These mechanisms 
range from the dephosphorylation of 
the cytoplasmic domains by phos-
phatases to the internalization and 
ubiquitin-mediated degradation of 
receptor complexes, all intended 
to terminate the activating signal. 
Mutations in genes that are required 
for turning off activated receptor 
tyrosine kinases may contribute to 
cancer development.
Functions of ErbB signalling 
in health and disease
Analyses of mice carrying mutated 
alleles of the genes encoding the 
various ErbB receptors have great-
ly contributed to understanding the 
role of these proteins in various tis-
sues and organs. In general, the ge-
netic inactivation of ErbB2, ErbB3, 
or ErbB4 leads to early embryonic 
lethality in mice [5]. Likewise, mice 
lacking Egfr show embryonic lethal-
ity or die during the first weeks af-
ter birth, depending on the genetic 
background, with defects in sev-
eral epithelia and in the brain [6]. 
Conditional inactivation of the Egfr 
allele has contributed to overcoming 
this early lethality and therefore to 
an improved understanding of the 
function of Egfr signalling in adult tis-
sues [7]. The analysis of animals in 
which Egfr was specifically mutated 
in distinct cell types has revealed 
roles in epithelial development and 
differentiation as well as in liver 
regeneration and proper brain pat-
terning and function. Egfr signal-
ling in these tissues induces (i) the 
246
suppression of differentiation at the 
expense of proliferation and (ii) pro-
survival signalling. Increased pro-
liferation and aberrant cell survival 
contribute to cancer development, 
and indeed various studies in mice 
have revealed the role of aberrant 
Egfr signalling in different models of 
murine tumorigenesis.
Multiple components of the 
ERBB signalling network may be 
mutated in cancer. EGFR stimulates 
basic cellular functions such as pro-
liferation and cell survival, and muta-
tions that lead to enhanced EGFR 
signalling are frequently found in tu-
mour cells [8]. Several different mu-
tations may result in pro-tumorigenic 
signalling through EGFR; the most 
notable involve (i) overexpression, 
(ii) activating mutations, (iii) hetero-
dimerization with other ERBB family 
members, (iv) autocrine ligand pro-
duction, and (v) reduced downregu-
lation of ERBB signalling (Fig. 3.8.2). 
Interestingly, different types of muta-
tions are found in different tumours. 
For example, EGFR overexpression 
is frequently found in brain, liver, and 
colon cancers, whereas activating 
mutations are found in non-small cell 
lung cancer (e.g. EGFRL858R) and 
glioblastomas (e.g. EGFRvIII: dele-
tion of exons 2–7). Mechanistically, 
overexpression may be caused by 
higher transcriptional activity of the 
corresponding genes or by gene 
amplification. Often, in individual 
tumours of patients with a particular 
type of cancer, increased transcrip-
tional activity as well as gene dupli-
cation can be observed, alone or 
together with activating mutations, 
such as in colorectal cancer or non-
small cell lung cancer.
Role of EGFR in distinct types 
of cancer
EGFR and glioblastoma
Both gene amplification and activat-
ing mutations of EGFR can be found 
in patients with glioblastoma multi-
forme. Two subtypes of glioblastoma 
can be distinguished, based on their 
ontogeny: primary glioblastomas 
arise de novo, whereas secondary 
glioblastomas develop from low-
grade astrocytoma. Interestingly, 
97% of primary glioblastomas are 
known to contain additional cop-
ies of the EGFR gene but show no 
mutations in the tumour suppres-
sor p53 protein encoded by TP53. 
In addition to EGFR amplification, 
the EGFRvIII mutation is frequently 
encountered in glioblastoma, and 
overall more than 60% of all types 
of glioblastoma show dysregulated 
EGFR expression or function. In 
contrast, secondary glioblastomas 
are associated with frequent mu-
tations in TP53, while EGFR am-
plifications or mutations are rare. 
Unfortunately, targeted anti-EGFR 
therapies have been shown to have 
very limited success in the treatment 
of glioblastomas [9].
EGFR, skin cancers, and 
tumours of the head and neck
Skin cancer is one of the most fre-
quent diseases in humans worldwide. 
One of its most common forms is 
squamous cell carcinoma, and EGFR 
is frequently amplified and EGFR 
overexpressed in squamous cell car-
cinoma. In melanoma, a frequently 
metastatic skin cancer, EGFR is often 
amplified in late-stage tumours.
In addition to squamous cells 
in skin tumours, EGFR is also fre-
quently overexpressed in head and 
neck squamous cell carcinomas 
(HNSCCs), which arise from mu-
cosal epithelia of the head and neck 
(lips, oral and nasal cavities, larynx, 
or pharynx). High EGFR levels are 
found in 90% of all HNSCCs and in-
dicate a poor prognosis. More than 
80% of HNSCC patients with nor-
mal EGFR expression survive longer 
than 5 years, compared with 25% of 
patients in whom EGFR overexpres-
sion has been detected. Currently, 
the most frequently used therapeu-
tic approach in HNSCC patients is 
a combination of radiotherapy and 
targeted anti-EGFR therapies [10].
EGFR and non-small cell lung 
carcinoma
Non-small cell lung carcinoma refers 
to any type of epithelial lung cancer 
other than small cell lung carcinoma. 
Lung cancers account for about one 
third of all cancer deaths worldwide, 
and more than 80% of all lung tu-
mours can be classified as non-small 
Fig. 3.8.1. (A,B) Structural change in the transmembrane protein epidermal growth factor 
receptor (EGFR) caused by binding of its ligand. (A) EGFR (blue) is a transmembrane 
receptor with an extracellular ligand-binding domain (the ligand EGF is shown in red), a 
transmembrane domain (the membrane is drawn in grey), and an intracellular domain. 
(B) Binding of EGF leads to receptor dimerization and activation of the intracellular kinase 
domains. (C) Principles of signal transduction via ERBB receptors: (1) ligand binding 
leads to receptor dimerization and the activation of the intracellular kinase domain; 
(2) various adaptor proteins and kinases lead to the transduction of the signal into the 
nucleus; (3) activation of transcription factors results in induction of gene expression.
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cell lung carcinomas, which are main-
ly adenocarcinoma and squamous 
cell carcinoma. The most common 
genetic mutations found in non-small 
cell lung carcinoma affect the genes 
that express EGFR and K-RAS, a 
signalling protein downstream of re-
ceptor tyrosine kinases, demonstrat-
ing the role of dysregulated ERBB 
signalling in this disease. EGFR and 
K-RAS mutations are mutually exclu-
sive, indicating that a constitutively 
active downstream mediator (RAS) of 
the ERBB cascade does not require 
increased receptor levels for onco-
genicity. Non-small cell lung carcino-
mas frequently display specific EGFR 
mutations, which are very rarely ob-
served in other cancers, and which 
result in expression of mutated EGFR 
protein with constitutively active ki-
nase domains. Anti-EGFR targeted 
therapies are singularly effective in 
patients harbouring these mutations, 
although ultimately hampered by the 
development of resistance [11].
Therapeutic approaches that 
target signal transduction
Various molecular strategies aimed 
at the functional inactivation of onco-
genes are currently being developed 
and tested in numerous clinical trials 
[3]. At present, however, all types of 
anticancer drugs that inhibit recep-
tor tyrosine kinases either belong to 
the class of small-molecule inhibi-
tors or are recombinant antibodies 
that bind and inhibit the specific 
receptors (Table 3.8.2). Advances 
in resolving protein structures have 
facilitated the design of small mole-
cules targeting oncoproteins specifi-
cally. For a protein to be “druggable” 
by this approach, the protein must 
have an active domain shaped like 
a cleft or a pocket that is accessible 
to water. Small-molecule inhibitors of 
protein kinases, exemplified by the 
intracellular domains of the ERBB 
receptors, primarily affect enzymatic 
activity by inhibiting ATP catalysis 
occurring within the kinase domain 
(Fig. 3.8.3).
Several parameters influence the 
efficacy of small-molecule inhibitors. 
Drugs binding irreversibly to their 
target permanently inhibit kinase 
function, as opposed to the activity 
of reversible inhibitors. Irreversible 
inhibition is more effective but 
much more toxic. Another param-
eter is the specificity of the drug – 
either targeting the ATP-binding 
domain of a kinase, which usually 
leads to a highly specific drug, or 
targeting ATP itself. Recent studies 
demonstrate frequent interactions 
of protein kinase inhibitors, previ-
ously believed to be specific, with 
multiple other protein kinases. These 
off-target effects present a major 
challenge since they might be the 
cause of potentially detrimental side-
effects. However, in some cases this 
non-selectiveness can prove benefi-
cial, as in the case of sorafenib [12]. 
Sorafenib was originally identified as 
a RAF inhibitor, but the clinical suc-
cess of this agent is attributable to 
an inhibitory effect on the kinases 
of the vascular endothelial growth 
factor receptor 2 (VEGFR2), plate-
let-derived growth factor receptor 
(PDGFR), and fibroblast growth fac-
tor receptor (FGFR) types. Similarly, 
oral multikinase inhibitors such as 
sunitinib target PDFGRs, VEGFRs, 
KIT, RET, CSF1R, and FLT3 and 
have been successfully used for 
the cure of renal cell carcinoma and 
imatinib-resistant gastrointestinal 
stromal tumours.
As well as small-molecule inhibi-
tors, monoclonal antibodies to the 
extracellular domain of transmem-
brane receptors have been success-
fully established for the treatment 
of certain types of cancer [13]. An 
example is the chimeric antibody 
cetuximab, which inhibits hetero-
dimerization and consequently the 
activation of the signalling cascade 
downstream of EGFR (Fig. 3.8.3). In 
addition, antibodies may act via the 
induction of an anti-tumour immune 
response by a process designated 
antibody-dependent cytotoxicity. 
The difference in size between the 
small-molecule inhibitor erlotinib and 
the antibody cetuximab is illustrated 
in Fig. 3.8.3.
Clinical application of 
targeted therapies
In most cases, tumours from patients 
with non-small cell lung carcinoma 
exhibit hyperactive EGFR signalling. 
Hence, when drugs that selectively 
Fig. 3.8.2. Various types of structural change that may result in alterations of ERBB 
expression and that have been described in cancer cells.
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Table 3.8.2. Monoclonal antibodies and small-molecule inhibitors currently in clinical use that target diverse signal transduction 
pathways
Generic name Target EMA-approved indications FDA-approved indications
Monoclonal antibodies
Bevacizumab VEGF Metastatic colorectal cancer, breast 
cancer, non-small cell lung cancer, 
renal cell carcinoma, grade IV glioma; 
epithelial ovarian, fallopian tube, or 
primary peritoneal cancer
Metastatic colorectal cancer, non-small 
cell lung cancer, glioblastoma, metastatic 
renal cell carcinoma
Cetuximab EGFR Head and neck squamous cell 
carcinoma, EGFR-positive K-RAS wild-
type colorectal cancer
Head and neck squamous cell carcinoma, 
EGFR-positive colorectal cancer
Ipilimumab CTLA-4 Unresectable or metastatic melanoma Unresectable or metastatic melanoma
Panitumumab EGFR K-RAS wild-type metastatic colorectal 
cancer (conditional)
K-RAS-negative metastatic colorectal 
cancer
Pertuzumab HER2 HER2-positive unresectable or 
metastatic breast cancer
HER2-positive metastatic breast cancer
Trastuzumab HER2 HER2-positive breast cancer; HER2-
positive gastric or gastro-oesophageal 
junction adenocarcinoma
HER2-positive breast cancer, HER2-
positive gastric or gastro-oesophageal 
junction cancer
Small-molecule inhibitors
Afatinib EGFR, HER2, HER4 Treatment of EGFR tyrosine kinase 
inhibitor-naive adult patients with locally 
advanced or metastatic non-small 
cell lung cancer with activating EGFR 
mutation(s)
First-line treatment of patients with 
metastatic non-small cell lung cancer 
whose tumours have EGFR exon 19 
deletions or exon 21 (L858R) substitution 
mutations as detected by an FDA-
approved test
Axitinib VEGFR, PDGFR Advanced renal cell carcinoma Advanced renal cell carcinoma
Cabozantinib VEGFR, MET, RET None Metastatic medullary thyroid cancer
Crizotinib ALK, MET ALK-positive non-small cell lung cancer 
(conditional)
ALK-positive non-small cell lung cancer
Dabrafenib V600E BRAF None BRAF V600E-positive unresectable or 
metastatic melanoma
Erlotinib EGFR EGFR mutation-positive non-small cell 
lung cancer, pancreatic cancer
Non-small cell lung cancer, pancreatic 
cancer
Gefitinib EGFR Locally advanced or metastatic EGFR 
mutation-positive non-small cell lung 
cancer
Non-small cell lung cancer
inhibit EGFR, namely the small-
molecule inhibitors gefitinib and 
erlotinib, first became available, 
efficient treatment of this disease 
was anticipated. However, from the 
outset, clinical trials indicated that 
only a small percentage of patients 
responded well to treatment [14]. It 
became apparent that the therapy 
was beneficial for patients carrying 
mutations in the kinase domain of 
EGFR but not for individuals with 
tumours that overexpress wild-type 
EGFR. However, secondary EGFR 
mutations arose, specifically in pa-
tients initially responsive to gefitinib 
and erlotinib, and these mutations 
rendered the protein resistant to 
inhibition by these compounds. In 
preclinical trials, treatment of such 
gefitinib/erlotinib-resistant tumour 
cells with other classes of drugs, 
such as the EGFR/ErbB2 inhibitor 
lapatinib or the irreversible kinase 
inhibitor afatinib, overcame resis-
tance towards anti-EGFR therapy. 
However, due to toxicity, a com-
binatorial treatment has yet to be 
adopted clinically.
In HNSCC patients in whom ab-
normally activated EGFR signalling 
has been detected, a combination of 
radiotherapy and the EGFR-targeting 
antibody cetuximab is widely used at 
present. Cetuximab is a humanized 
mouse antibody, and binding of this 
antibody to the extracellular part of 
EGFR not only inhibits the activation 
of the downstream signalling cas-
cade but also inhibits receptor turn-
over and renders tumour cells more 
immunogenic, leading to increased 
levels of antibody-dependent cellular 
toxicity. However, similarly to non-
small cell lung carcinoma patients 
treated with gefitinib and erlotinib, 
HNSCC patients quickly develop 
resistance to cetuximab [15]. In gen-
eral, the use of EGFR-targeted drugs 
currently leads to prolonged survival 
of patients diagnosed with cancer, 
but not to reduced mortality.
In summary, the use of drugs 
inhibiting the function of EGFR and 
ALK, anaplastic lymphoma kinase; CSF1R, colony-stimulating factor 1 receptor; EGFR, epidermal growth factor receptor; EMA, European Medicines 
Agency; FDA, United States Food and Drug Administration; GnRH, gonadotropin-releasing hormone; mTOR, mammalian target of rapamycin; PDGFR, 
platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Generic name Target EMA-approved indications FDA-approved indications
Imatinib PDGFR, KIT KIT-positive gastrointestinal stromal 
tumours, adjuvant or unresectable
KIT-positive gastrointestinal stromal 
tumours, adjuvant or unresectable
Lapatinib EGFR, HER2 HER2-positive breast cancer 
(conditional)
HER2-positive breast cancer
Pazopanib VEGFR, KIT, PDGFR Advanced renal cell carcinoma, 
advanced soft tissue sarcoma 
(conditional)
Advanced renal cell carcinoma, advanced 
soft tissue sarcoma
Regorafenib PDGFR, KIT, RET, 
VEGFR
None Metastatic colorectal cancer
Sorafenib VEGR, PDGFR, 
CRAF, FLT3
Hepatocellular carcinoma, advanced 
renal cell carcinoma
Unresectable hepatocellular carcinoma, 
advanced renal cell carcinoma
Sunitinib VEGFR, PDGFR, KIT, 
FLT3, RET, CSF1R
Advanced renal cell carcinoma, 
unresectable or metastatic malignant 
gastrointestinal stromal tumours, 
pancreatic neuroendocrine tumours
Advanced renal cell carcinoma, 
progressive gastrointestinal stromal 
tumours, pancreatic neuroendocrine 
tumours
Trametinib V600 BRAF None BRAF V600-positive unresectable or 
metastatic melanoma
Vandetanib VEGFR, EGFR, RET Medullary thyroid cancer (conditional) Medullary thyroid cancer
Vemurafenib V600 BRAF BRAF V600-positive unresectable or 
metastatic melanoma
BRAF V600E-positive unresectable or 
metastatic melanoma
Small-molecule allosteric inhibitors
Everolimus mTOR Advanced renal cell carcinoma; 
unresectable pancreatic neuroendocrine 
tumours; hormone-receptor-positive, 
HER2-negative postmenopausal 
breast cancer; subependymal giant cell 
astrocytoma (conditional)
Advanced renal cell carcinoma; 
unresectable pancreatic neuroendocrine 
tumours; subependymal giant cell 
astrocytoma; hormone-receptor-positive, 
HER2-negative postmenopausal breast 
cancer
Temsirolimus mTOR Advanced renal cell carcinoma Advanced renal cell carcinoma
Small-molecule Smoothened antagonist
Vismodegib Smoothened receptor None Metastatic or recurrent basal cell 
carcinoma
Recombinant decoy receptor
Ziv-aflibercept VEGFR Metastatic colorectal cancer Metastatic colorectal cancer
Antibody–drug conjugate
Ado-trastuzumab 
emtansine
HER2 None HER2-positive metastatic breast cancer
Hormonal agents
Abiraterone Androgen synthesis–
CYP17A1 inhibition
Metastatic castration-resistant prostate 
cancer
Metastatic castration-resistant prostate 
cancer
Anastrazole Aromatase None Hormone-receptor-positive postmeno-
pausal breast cancer, or hormone-recep-
tor-negative disease after tamoxifen
Bicalutamide Androgen receptor None Metastatic prostate cancer
Degarelix GnRH receptor Advanced prostate cancer Advanced prostate cancer
Enzalutamide Androgen receptor None Metastatic castration-resistant prostate 
cancer
Exemestane Aromatase None Estrogen-receptor-positive postmeno-
pausal breast cancer, or estrogen-recep-
tor-negative disease after tamoxifen
Flutamide Androgen receptor None Prostate cancer
Goserelin GnRH receptor None Prostate cancer, palliative treatment of 
premenopausal breast cancer
Letrozole Aromatase None Postmenopausal breast cancer
Leuprorelin acetate GnRH receptor None Palliative treatment of prostate cancer
Tamoxifen Estrogen receptor None Metastatic breast cancer
ALK, anaplastic lymphoma kinase; CSF1R, colony-stimulating factor 1 receptor; EGFR, epidermal growth factor receptor; EMA, European Medicines 
Agency; FDA, United States Food and Drug Administration; GnRH, gonadotropin-releasing hormone; mTOR, mammalian target of rapamycin; PDGFR, 
platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Table 3.8.2. Monoclonal antibodies and small-molecule inhibitors currently in clinical use that target diverse signal transduction 
pathways (continued)
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other receptor tyrosine kinases 
achieves an initial response, but 
the regrowth of tumours resistant 
to these drugs is commonly ob-
served; such a scenario is attribut-
able to inherent genetic instability, 
as evidenced by rapid mutation. 
Emergence of new mutations under 
the selective pressure of treatment 
with receptor tyrosine kinase inhibi-
tors allows tumour cells to contin-
ue growth despite drug treatment. 
Ideally, this scenario is resolved by 
the identification of secondary mu-
tations and the development of new 
treatment strategies. Although great 
progress has been made in develop-
ing targeted anticancer drugs to be 
applied specifically in preselected 
cancer patients, mechanisms of 
resistance have yet to be fully 
elucidated.
A better understanding of resis-
tance mechanisms would lead to the 
identification of new targets against 
which new drugs could be designed 
and developed. Importantly, mecha-
nisms mediating resistance to broad 
classes of drugs have to be identi-
fied and to be distinguished from 
processes specific to particular 
agents. The search for biomarkers, 
which predict the response of certain 
tumours or patients to therapeutic 
treatment, has thus become a focus 
of many pharmaceutical companies 
and research laboratories [16].
The catch of anticancer 
therapy: acquired drug 
resistance
Research addressing mechanisms 
of resistance to therapy targeted 
against signalling pathways, includ-
ing anti-EGFR drugs, has markedly 
increased in recent years. Currently, 
recognized resistance mechanisms 
to anti-EGFR drugs include (i) addi-
tional mutations of EGFR; (ii) com-
pensatory signalling via other recep-
tors, such as VEGFR, insulin-like 
growth factor receptor (IGFR), 
and AXL; (iii) increased expres-
sion of VEGF, which modulates 
angiogenesis and may reduce lo-
calized drug concentration; and 
(iv) mutations in molecules down-
stream of EGFR, such as RAS or 
RAF (Fig. 3.8.4). Such downstream 
activating mutations render the tu-
mour cells independent of EGFR 
function and therefore refractory 
to treatment with drugs against 
EGFR [17].
Mutations in downstream media-
tors of EGFR signalling commonly 
occur in tumours exhibiting neither 
EGFR mutation nor overexpression. 
An example involves metastatic 
melanoma, in which an activating 
mutation in BRAF, V600E, is fre-
quently found. Recently, treatment 
of metastatic melanoma with the 
BRAF inhibitor vemurafenib yield-
ed promising initial results [18]. In 
one clinical study, more than 50% 
of patients receiving vemurafenib 
experienced prolonged survival 
compared with untreated pa-
tients, and in an independent study 
more than 80% of treated patients 
showed partial to complete regres-
sion of tumours compared with 
non-treated individuals. However, 
tumour regression lasted only 
2–18 months, and subsequently 
vemurafenib-resistant tumours ap-
peared. Furthermore, vemurafenib 
had severe side-effects, giving rise 
in some cases to cutaneous squa-
mous cell carcinoma or keratoacan-
thoma [19].
New insights gained from the 
genomic revolution
The new millennium has seen the 
complete sequencing of the human 
genome and genomes of other im-
portant organisms and pathogens. 
In particular, recent advances in 
whole-genome sequencing are 
revolutionizing modern medicine 
[20]. A pioneering study compar-
ing the whole genomes of tumour 
and normal cells in a patient with 
acute myeloid leukaemia led to the 
discovery of various somatic mu-
tations in malignant cells, one of 
them affecting the gene encoding 
the receptor tyrosine kinase FLT3 
[21], demonstrating the power of 
modern genomic techniques. With 
such powerful tools available, a ma-
jor goal for cancer therapy comes 
within reach: the identification of ge-
netic mutations responsible for can-
cer development as well as those 
occurring during cancer progres-
sion. This would enable treatment 
strategies to be adapted based 
on the genetic changes during the 
course of the disease. In particu-
lar, mutations in cellular processes 
that “drive” tumorigenesis present 
attractive targets for therapeutic in-
tervention. Notably, more than half 
of the “tumour driver” gene classes 
Fig. 3.8.3. (A) The action of tyrosine kinase inhibitors (TKIs) and inhibitory antibodies 
(cetuximab). TKIs inhibit signal transduction by blocking the activation of the receptor 
through inhibition of the kinase domain. In contrast, cetuximab impairs the dimerization 
of epidermal growth factor receptor (EGFR). (B) Size comparison between ATP and 
erlotinib, and between EGFR and cetuximab. Erlotinib is a small-molecule inhibitor and 
is approximately the same size as ATP, the molecule essential for the phosphorylation 
of the receptor after dimerization. Cetuximab and EGFR are approximately 400 times 
bigger, as indicated by the magnifying glass.
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are constituted by components of 
signalling pathways [22]. Whole-
genome sequencing of cancer pa-
tients leads to the discovery of se-
quence variations that can be used 
to predict whether a patient or an 
individual tumour can respond to a 
certain drug, which is referred to as 
pharmacogenomics [23].
Prospects
Ever-expanding knowledge about 
signal transduction networks un-
derpins the design of novel agents 
and improved anticancer strategies. 
However, greater knowledge also re-
veals another degree of complexity in 
relation to contemporary understand-
ing of tumour biology. Consequently, 
for every drug that successfully tar-
gets a specific pathway, multiple re-
sistance mechanisms following from 
the initial treatment may be antici-
pated. Such an outlook, if applicable 
universally, is daunting but may be 
offset by the following considerations.
First, the expanding repertoire of 
drugs targeting proteins mediating 
every step of a signalling cascade 
will also increase our repertoire for 
ameliorating secondary and subse-
quent mutations. Perhaps even more 
importantly, modern screening tech-
niques of gene expression patterns, 
or the identification of novel biomark-
ers of individual tumours, will allow 
more informed development of com-
binations of therapeutics that have 
the highest chance of success in an 
individual patient. The introduction of 
massively parallel DNA sequencing 
technologies will soon provide com-
prehensive data at low cost. The 
term “personalized medicine” will no 
longer connote response to a single 
agent but will indicate therapy based 
on the biological characteristics of 
individual tumours, specified with 
reference to tumour progression in 
real time [24].
We thank Thomas Bauer for the artwork and 
design of the figures. 
Fig. 3.8.4. Resistance mechanisms against drugs targeting the ERBB signalling network: 
(1) activating mutations in downstream effector molecules make the pathway completely 
independent of receptor function; (2) activating mutations in the kinase domain lead to 
constitutively active receptors; (3) mutations in the extracellular domain interfere with 
binding of cetuximab; (4) overproduction of vascular endothelial growth factor (VEGF) 
leads to altered angiogenesis and reduced exposure to drugs; (5) compensatory signal-
ling via other receptors.
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• Inflammation and immunity affect 
cancer initiation, progression, 
dissemination, co-morbidities, 
and response to therapy. Cancer 
often originates in chronically 
inflamed tissue, due to infections 
or other causes. Tumour-elicited 
inflammation contributes to pro-
gression and dissemination. 
Cancer incidence is reduced by 
eliminating the causes of inflam-
mation or by prolonged use of 
non-steroidal anti-inflammatory 
drugs.
• Anti-tumour immunity is evident 
in established tumours and may 
affect progression negatively or 
positively. Histological evidence 
of a brisk immune response is 
correlated with more favourable 
prognosis. Tumours, however, 
use various mechanisms to 
escape the immune response.
• Tumour immunotherapy proto-
cols have used pro-inflammatory 
therapies, cytokines, antibodies, 
adoptive T-cell transfer, and a 
variety of therapeutic vaccines, 
with mixed success. Antibodies 
that block immune checkpoints 
may prevent tumour immune 
evasion. When successful, im-
munotherapy provides more du-
rable remissions than cytotoxic 
3.9
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or targeted therapies, suggest-
ing that combined treatment 
protocols may prove efficacious.
Cancer cells initially maintain altered 
morphological and functional char-
acteristics of their tissue of origin, 
representing almost a caricature of 
it. The organism does not ignore 
the growing tumour but reacts to it 
similarly to the response evoked by 
tissue damage and, as in wound re-
pair, by establishing a symbiotic rela-
tionship that favours tumour growth 
and dissemination. An adaptive im-
mune response reminiscent of that 
against foreign pathogens is also 
often present, with variable effects 
on tumour growth. Inflammation and 
immunity likely have an instrumental 
role in cancer initiation, progression, 
and dissemination and are also re-
sponsible for co-morbidities such as 
anorexia/cachexia [1] (Fig. 3.9.1).
The study of cancer etiopatho-
genesis and the identification of ther-
apeutic targets were initially focused 
on intrinsic cancer cell traits that af-
fect the ability of malignant cells to 
proliferate and invade local or dis-
tant tissues [2]. For a tumour to thus 
establish itself or form metastases, 
not only are the transformed cells 
(the “seed”) important, but equally 
so is the tissue that receives them 
(the “soil”) [3]. Hence, the tumour 
microenvironment is key, not only as 
a participant in the neoplastic pro-
cess but also as a possible thera-
peutic target [2]. The tumour is a 
complex organized tissue formed 
by both the transformed clonal cells 
and stromal cells. The genetic and 
epigenetic evolution of successful 
malignant cells is dependent on their 
fitness to the microenvironment, re-
sulting in optimal access to nutri-
ents and tissue remodelling. The 
microenvironment of most tumours 
is infiltrated by innate and adaptive 
immune inflammatory cells that influ-
ence the survival and adaptation of 
the transformed cells.
Inflammation and cancer
Chronic inflammation related to 
bacterial, viral, or parasitic infec-
tions has been associated with the 
etiopathogenesis of about one fifth 
of cancer cases worldwide, particu-
larly in developing or less-developed 
countries [4]. Particular pathogens 
such as Helicobacter pylori, human 
papillomaviruses (HPV), Epstein–
Barr virus, and hepatitis B and C 
viruses account for the majority of 
those cases. Some of these patho-
gens, for example HPV or Epstein–
Barr virus, directly transform the in-
fected cells, whereas others, such 
as H. pylori, induce tissue inflamma-
tion that favours cancer initiation and 
progression (Fig. 3.9.2). However, 
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the inflammatory response to onco-
genic pathogens may also act as a 
tumour promoter. Cancer resulting 
from infection can be prevented by 
prophylactic vaccination, as is the 
case for HPV and hepatitis B virus, 
or by antibiotic treatment in the case 
of H. pylori. Early data indicate that 
HPV vaccines are efficient not only 
in preventing infections but also in 
preventing development of precan-
cerous lesions in the cervix and at 
other anatomical locations [5]. A re-
duction in the prevalence of H. pylori 
in Caucasian individuals in the USA 
and other areas of the world has 
been paralleled by a dramatic de-
cline in stomach cancer incidence, 
although accompanied by increased 
incidence of oesophageal adenocar-
cinoma, which may be associated 
with concurrent increases in obesity 
and gastro-oesophageal reflux or 
with bacterial dysbiosis in the upper 
digestive tract in the absence of H. 
pylori [6]. The chronic nature of the 
cancer-inducing infections and the 
persistence of pathogenic genes 
in malignant cells suggest the pos-
sibility of targeting infection-driven 
cancer with post-exposure vaccines 
to prevent cancer development 
or with therapeutic vaccine to treat 
established cancers.
Other cancers, not associated 
with infection, originate in chroni-
cally inflamed tissues injured by 
chemical or physical agents, such 
as irradiation or lung-irritating 
particles, or are dependent on condi-
tions resulting from mutation of di-
gestive enzymes or of inflammatory 
genes. In the absence of pathogens, 
altered composition or interaction 
with the commensal microbiota at 
the body interfaces may result both 
locally and systemically in a distort-
ed inflamed state that favours cancer 
initiation; an example is increased 
risk of colon cancer in patients with 
inflammatory bowel diseases char-
acterized by intestinal dysbiosis and 
chronic inflammation. Intestinal dys-
biosis may also mediate increased 
cancer incidence in obese popula-
tions, the pathogenesis of cancer 
co-morbidities, and chemotherapy 
side-effects [1].
Infiltrating inflammatory and im-
mune haematopoietic cells charac-
terize inflamed tissue, but epithelial, 
stromal, and endothelial cells also 
produce and respond to inflammatory 
mediators, affecting their proliferation 
and functions and attracting haema-
topoietic cells. Activation of onco-
genes such as Ras, Myc, Ret, and 
Src is associated with intrinsic inflam-
mation through production of growth 
factors, cytokines, chemokines, and 
tissue remodelling enzymes acting 
on the transformed cells with an au-
tocrine feedback loop, while simulta-
neously reprogramming the tumour 
microenvironment and attracting hae-
matopoietic cells and affecting their 
functional differentiation [7].
Chronic inflammation favours 
cancer initiation by multiple mech-
anisms, including genetic and 
epigenetic instability mediated in 
part by reactive oxygen species 
that induce or amplify DNA dam-
age after toxic insults. Inflammation 
also acts as a tumour promoter by 
providing growth factors and tissue 
remodelling factors and by support-
ing angiogenesis. Once the tumour 
is established, cancer-induced 
inflammation, revealed by tumour- 
Fig. 3.9.1. The multiple links between inflammation and cancer. With time (left to right), a tumour progresses in size and metastasizes 
(right). Inflammation (intrinsic in the tissue of tumour origin or induced by the growing tumour, purple) contributes to the mechanisms 
of tumour induction/progression, co-morbidities, or response to therapy (red). Tumour-specific immune response (blue) generally 
has an anti-tumour effect, which should be evaded or redirected for the tumour to progress.
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associated haematopoietic cells, is a 
constant in most tumours, including 
those not known to originate from 
an inflamed tissue. Tumour-elicited 
inflammation mediates promotion, 
facilitates tumour dissemination, 
and creates an immunosuppressive 
environment responsible for im-
mune escape [8]. Thus, for exam-
ple, the oncogene-driven secretion 
of granulocyte-macrophage colony-
stimulating factor (GM-CSF) endows 
tumour-infiltrating myeloid cells with 
immunosuppressive activity.
Anti-inflammatory therapies 
and cancer prevention
Regular use of aspirin or other non-
steroidal anti-inflammatory drugs 
over extended periods decreases 
cancer incidence and specifically re-
duces the risk of colorectal cancer or 
polyp recurrence [9]. Meta-analysis 
of randomized trials of cardiovas-
cular disease prevention in which 
patients took aspirin daily for more 
than 7.5 years indicated that the 
20-year risk of cancer death was 
reduced by 40% for gastrointesti-
nal cancers and by approximately 
20% for all solid cancers, including 
lung, brain, and prostate cancers 
and melanoma [10]. Non-steroidal 
anti-inflammatory drugs inhibit the 
cyclooxygenases COX-1 and COX-2 
that catalyse the production of pros-
taglandins from fatty acids. Drugs like 
aspirin inhibit both COX-1 and COX-2 
and thus are toxic to the stomach and 
intestinal lining, whereas COX-2 in-
hibitors do not alter the gastrointesti-
nal homeostasis, although their cardi-
ovascular toxicity has severely limited 
their use, especially for prophylactic 
therapies. While cyclooxygenase in-
hibitors are anti-inflammatory, their 
preventive effect on cancer may also 
be due to non-inflammation-related 
effects of prostaglandins on vaso-
dilation, angiogenesis, DNA muta-
tion rate, epithelial cell adhesion, or 
apoptosis. At the concentrations used 
in cardiovascular studies, aspirin in-
hibits cyclooxygenases but has no 
effect on major pathways of cancer-
related inflammation, such as those 
downstream of activation of nuclear 
factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), which are 
inhibited only at much higher dos-
ages. The inflammatory pathways 
hijacked by tumours to promote their 
own progression are also required for 
physiological tissue homeostasis, re-
sistance to infections, and response 
to tissue damage. Targeting these 
molecular pathways without affect-
ing their physiological roles may be 
difficult.
Anti-tumour immunity and 
immunosurveillance
Tumour cell immunogenicity refers to 
the ability of tumour cells to express 
antigens recognized by the immune 
system. These tumour antigens can 
be: molecules encoded by cancer-
germline genes that tend not to be 
efficiently presented by central tol-
erance-inducing medullary thymic 
epithelial cells; tumour-specific an-
tigenic polypeptides resulting from 
mutation of key regulatory genes, 
for example the products of acti-
vated oncogenes; oncogenic viral 
proteins; and molecules selectively 
overexpressed by tumours, including 
wild-type p53 [11]. For recognition by 
T cells, antigenic peptides are pre-
sented by major histocompatibility 
complex (MHC) molecules: class I 
for CD8 cytotoxic T cells and class II 
for CD4 helper T cells. Loss of MHC 
expression prevents tumour immu-
nogenicity, although tumour antigens 
can be cross-presented by antigen-
presenting cells, such as dendritic 
cells, in the tumour microenviron-
ment. Tumour antigens exposed 
on the cell surface are recognized 
by antibodies that may have both 
anti-tumour and pro-tumour effects 
(see “Role of the innate and ac-
quired immune systems in mam-
mary development and breast 
cancer”). Similarly, anti-tumour 
T-cell-mediated immunity may have 
variable effects on tumour growth. 
Certain types of immune response, 
in particular T helper type 1 (Th1) 
responses, are generally considered 
to be anti-tumour, whereas Th2 re-
sponses are pro-tumour growth or 
favourable to metastasis formation 
[12]. The more recently described 
Th17 response in different situations 
may be either pro- or anti-tumour.
Anticancer immunity is evi-
denced by patients with paraneo-
plastic neurological degeneration 
and smouldering tumours in whom 
neurological disorders are triggered 
by an antibody response to neuronal 
antigens expressed on tumour cells 
[13]. Historically, the presence of 
lymphocyte infiltrates in tumours has 
been considered a positive prognos-
tic factor for several tumour types. 
Fig. 3.9.2. Gastric corpus with chronic (lymphoplasmacellular) and active (neutrophilic) 
inflammation, due to Helicobacter pylori infection.
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Role of the innate and acquired immune systems in mammary development 
and breast cancer
Zena Werb
The tumour-promoting role of the 
immune system has long been rec-
ognized. Postnatal development of 
the mammary gland occurs in an 
immunocompetent environment. In 
breast cancer, the immune environ-
ment is compromised, allowing neo-
plastic progression and metastasis 
to proceed. Activation of CD4+ T 
cells by antigen-presenting cells 
is evident within the developing 
mammary gland, and production of 
interferon-gamma by T helper type 
1 (Th1) effector T cells negatively 
regulates postnatal mammary gland 
development.
First, the importance of tissue 
antigen-presenting cells was dem-
onstrated, by depletion of CD11chigh/
MHCIIhigh mammary antigen-pre-
senting cells in vivo in mice and ex 
vivo in three-dimensional primary or-
ganotypic cultures, which increased 
ductal invasion and epithelial 
branching. Second, depletion of α/β 
T cells, blocking antibodies to MHCII 
and CD4, and T-cell proliferation as-
says all suggested that regulation 
of mammary postnatal organogen-
esis by antigen-presenting cells and 
CD4+ T cells is antigen-mediated. 
The production of interferon-gamma 
by Th1 effector cells inhibited mam-
mary postnatal organogenesis by 
acting directly on the mammary lu-
minal epithelial cells. These results 
suggest a novel regulatory role for 
the adaptive immune system in nor-
mal tissue remodelling, even in the 
absence of injury or inflammation.
As tumours develop, the inflam-
matory compartment changes dra-
matically. Tumour-associated mac-
rophages and antigen-presenting 
cells and CD11b+Gr1+ cells increase 
markedly, starting very early before 
malignant conversion. While the tu-
mour antigen-presenting cells still 
interact with T cells, the T cells no 
longer are activated for anti-tumour 
functions. These myeloid cells also 
increase in tissues distant from the 
primary tumour, establishing sites 
for metastasis. The expansion of in-
flammatory cells contributes to the 
events stimulating tumour growth 
and metastasis. Characterization 
of the molecular pathways that 
regulate these populations will lead 
to identification of pathways and 
molecules that could be targeted 
to prevent tumour progression and 
metastasis.
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In human colon cancer, a particular 
immune contexture, characterized 
by a high density of Th1/cytotoxic 
memory T lymphocytes located both 
in the centre and at the invasive 
margin of the primary tumour, is 
positively correlated with disease-
free and overall survival and lower 
incidence of relapse and metastasis 
[14], a finding that is being extended 
to other tumour types. This immu-
noscore classification distinguishes 
high- and low-risk patients in both 
initial and advanced stages of the 
disease, and it is independent and 
more informative than conventional 
staging methods.
The historical concept of immuno-
surveillance has been more recently 
defined by studies in experimental 
animals that have identified major 
phases of tumour growth regulated 
by the anti-tumour immune response: 
elimination of nascent tumours, equi-
librium with dormant tumours, edit-
ing of progressing tumours, and fi-
nally escape and uncontrolled growth 
[15]. A role for immunosurveillance in 
humans is indicated by increased 
cancer incidence in immunosup-
pressed patients. Such kidney trans-
plant recipients or HIV-infected pa-
tients appear to have a strikingly 
increased risk of tumour types of 
possible viral etiology. However, 
epidemiological evidence of an in-
creased risk of other tumour types – 
such as colon and breast tumours, 
which have an increased incidence 
in immunodeficient mice – is less 
compelling. Immunodeficient mice 
have increased infections and mi-
crobial dysbiosis, and this may com-
pound the effect of lack of immunity 
on tumour susceptibility. Long-term 
clinical cancer dormancy is often ob-
served – for example, in survivors of 
breast cancer and melanoma – and 
transplantation of organs from these 
patients into immunosuppressed re-
cipients results in break of dorman-
cy and donor tumour progression. 
However, the relative contribution 
of an immune equilibrium compared 
with the contribution of other ho-
meostatic mechanisms in clinical 
cancer dormancy remains to be fully 
defined [16].
Tumour immune escape
Even in the presence of immuni-
ty, clinical tumours progress and 
disseminate; spontaneous regres-
sions are rare. Tumour growth can 
be attributed in part to the induc-
tion of inefficient types of immune 
response, such as Th2 rather than 
Th1, and by an immunosuppres-
sive tumour microenvironment. 
The activity of both effector T and 
B cells, as well as that of antigen-
presenting cells, is depressed in the 
tumour microenvironment. Tumour 
immunosuppression is maintained 
by immunoregulatory cell types, 
such as regulatory T and B cells, as 
well as myeloid-derived suppressor 
cells. Immunosuppressive or anti-
inflammatory molecules, such as 
interleukin-10 (IL-10), vascular en-
dothelial growth factor, transform-
ing growth factor β, IL-4, IL-13, nitric 
oxide, arginase, and indoleamine 
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2,3-dioxygenase, are produced in 
the tumour microenvironment [12].
One of the major mechanisms 
of tumour escape is the loss or mu-
tation of tumour antigens, as dem-
onstrated experimentally by the 
immmunoediting of tumour cells in 
immunocompetent animals, as well 
as by decreased or lost expression 
of MHC molecules on the cell sur-
face [15].
Immunity is modulated by a 
series of co-stimulatory recep-
tor–ligand pairs expressed on an-
tigen-presenting cells and T cells 
that amplify the T-cell response 
to antigen–MHC complexes [17]. 
The CD28/B7 family represents 
the best example of co-stimulatory 
molecules. Other members of this 
family are co-inhibitor molecules – 
such as, for example, CTLA-4 – 
that downregulate immune re-
sponses when no longer needed. 
Tumours may escape the immune 
response by using these recep-
tors and mechanisms involved in 
the physiological downregulation 
of the immune response. The pro-
grammed cell death 1 (PD1) recep-
tor and its ligand PD-L1 (also called 
B7-H1) are particularly relevant 
because PD-L1, unlike B7-1/B7-2, 
is selectively upregulated on many 
human tumour cells (Fig. 3.9.3).
Tumour immunotherapy
Since the early attempts of Coley 
to cure solid tumours with bacterial 
preparations (“Coley toxin”), investi-
gators have attempted to harness the 
immune system to reject cancer by 
stimulating innate resistance or using 
adaptive immunity for cancer therapy. 
Various bacterial preparations have 
been used to induce inflammation 
and innate resistance, with some 
positive results, specifically including 
the use of bacillus Calmette–Guérin 
(BCG) for the topical treatment of 
bladder cancer [18]. Granted the role 
of innate receptors in the inflamma-
tory response to bacterial products, 
use of Toll-like receptor (TLR) ligands 
in cancer therapy has been investi-
gated; the TLR7 ligand imiquimod 
is approved for skin cancer, and the 
TLR4 ligand monophosphoryl lipid A 
as an adjuvant in a HPV vaccine.
Many pro-inflammatory cytokines 
have shown promise in experimental 
animals but have proven ineffective 
or highly toxic in clinical trials. Type I 
interferon and IL-2 are approved as 
single agents for cancer therapy. 
Interferon is approved for adjuvant 
therapy of melanoma and for the 
treatment of certain haematopoietic 
malignancies, of Kaposi sarcoma, 
and, in combination with anti-angi-
ogenic compounds, of renal cancer. 
With the development of targeted 
therapies, the use of interferon for 
melanoma has been declining. IL-2 
is approved for advanced melanoma 
and renal cell carcinoma. Other im-
munoregulatory cytokines that af-
fect T-cell expansion and activation, 
such as IL-7, IL-12, and IL-15, are 
being clinically tested, alone or as 
part of immune-enhancing therapy. 
Granulocyte colony-stimulating factor 
and GM-CSF are approved to short-
en the time to neutrophil recovery and 
reduce the incidence of infections af-
ter cancer chemotherapy.
Immunotherapy based on the 
adoptive transfer of either naturally 
occurring tumour-infiltrating T cells 
or T cells engineered to express 
genes encoding well-defined anti-
tumour T-cell receptors or designed 
chimeric receptors mediate tumour 
regression in a large proportion of 
patients with metastatic cancer, 
particularly when infused after lym-
phodepletion [19]. Current efforts are 
focused on increasing the accuracy 
of targeting tumour antigens and the 
associated vasculature, as well as 
Fig. 3.9.3. Timeline and milestones of the development of therapies involving anti-CTLA-4 and anti-PD-1, from gene discovery to 
clinical development.
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on identification and purification of 
T-cell subsets that are more efficient 
in expanding and mediating tumour 
eradication.
Since the development of mono-
clonal antibody technology, great 
effort has been devoted to using 
antibodies in cancer therapy [20]. 
Therapeutic antibodies can be di-
rected against surface antigens se-
lectively expressed on tumour cells. 
These antibodies induce tumour cell 
death by antibody-dependent cell-
mediated cytotoxicity, recruiting 
effector cells such as natural killer 
cells and macrophages via binding 
of the Fc portion of the immuno-
globulin G antibodies to Fc receptors 
expressed on effector cells. The 
cytotoxic effect can be amplified by 
conjugating radioisotopes, cytotox-
ic drugs, or toxins to the antibody. 
Alternatively, cell-mediated cytotox-
icity can be facilitated by chimeric 
antibodies combining specificity 
for tumour antigens with specificity 
for activating receptors on immune 
cells, thus cross-linking tumour and 
effector cells while activating cyto-
toxic mechanisms. Unconjugated 
anti-CD20 and anti-CD5 antibodies 
and radioisotope- or ozogamicin- 
conjugated anti-CD20 and anti- 
CD33 antibodies are approved for 
haematopoietic malignancies, and 
unconjugated anti-HER2 antibodies 
for breast cancer. Another mecha-
nism of action of antibodies in cancer 
is the functional inhibition of growth 
factor receptors or pro-tumour fac-
tors. Anti-epithelial growth factor re-
ceptor and anti-vascular endothelial 
growth factor unconjugated antibod-
ies are approved for colorectal can-
cer and other solid tumours.
Unlike the success of prophylac-
tic vaccines against oncogenic vi-
ruses, efficient therapeutic vaccines 
able to induce an immune response 
against established tumours have 
been difficult to develop. Although 
knowledge of the mechanisms of 
tumour immunity has been exten-
sively applied in both experimental 
and clinical trials, clinical responses 
to tested cancer vaccines have been 
modest, and T-cell-mediated anti-
tumour immunity elicited by vaccines 
was followed by clinical response 
in only a minority of patients [19]. 
Different formulations of antigens 
and adjuvants, including gene-based 
vaccination, have been used to har-
ness the immunostimulatory ability 
of dendritic cells, either by adop-
tively transferring them after in vitro 
activation and exposure to tumour 
antigens or by targeting them in vivo 
with tumour antigen-conjugated an-
tibodies directed against their sur-
face receptors [21]. Sipuleucel-T, 
the only approved vaccine for 
metastatic hormone-independent 
prostate cancer, has in clinical trials 
significantly but modestly increased 
survival by approximately 4 months 
[19]. Sipuleucel-T is prepared by ex-
posing the patient’s dendritic cells 
to a fusion protein containing GM-
CSF and the antigen prostatic acid 
phosphatase.
The poor efficacy of cancer vac-
cines is probably due to persistence 
of an immunosuppressive tumour 
microenvironment, which prevents 
the development of the anti-tumour 
response [18]. Immunosuppression 
might be reversed by developing 
better adjuvants or by blocking im-
munosuppressive factors, such as 
transforming growth factor β, in-
doleamine 2,3-dioxygenase, or 
IL-10. Use of antibodies that 
block co-inhibitory molecules has 
Fig. 3.9.4. Generation and regulation of anti-tumour immunity. Active cancer immuno-
therapy may target antigen presentation at the level of dendritic cells, promote generation 
of anticancer T cells, and reverse the immunosuppressive mechanisms of the tumour 
microenvironment. The dendritic cells that have captured tumour antigens from dead 
or dying tumour cells (A) migrate to the draining lymph nodes, where they present 
captured antigenic peptides on major histocompatibility complex (MHC) class II and class 
I molecules to T cells (B), inducing an anticancer effector T-cell response if immunogenic 
maturation stimuli are present (C) or alternatively, in their absence, inducing tolerance 
and immunosuppression (D). Depending on the maturation stimulus, dendritic cells will 
differentially express co-stimulatory molecules and produce immunoregulatory cytokines, 
affecting the quality and the class of the T-cell response. Interaction of CD28 or OX40 
with B7-1/B7-2 or OX40L favours protective T-cell responses, whereas interaction of 
CTLA-4 with B7-1/B7-2 or of PD-1 with PD-L1/PD-L2 will suppress T-cell responses. 
Effector T cells will re-enter the tumour microenvironment (E), where their anticancer 
ability will be limited by immunosuppressive mechanisms that include upregulation of 
PD-L1/PD-L2 on the cancer cell surface and release of IL-10, vascular endothelial growth 
factor, transforming growth factor β, IL-4, IL-13, nitric oxide, arginase, and indoleamine 
2,3-dioxygenase. NK, natural killer cell; Treg, regulatory T cell.
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promise. The monoclonal antibody 
to CTLA-4 (ipilimumab) is approved 
for use in patients with metastatic 
melanoma; increased survival is 
reasonably attributable to amplifica-
tion of the endogenous anti-tumour 
T-cell response (Fig. 3.9.4). In sev-
eral clinical trials, antibodies against 
PD1 receptor or its ligand PD-L1 
are showing significant responses 
in patients with melanoma or other 
solid tumours, such as lung cancer 
[17]. These new drugs may amplify 
the anti-tumour immune response 
elicited by cancer vaccines or the 
endogenous immune response in-
duced after tumour destruction by 
certain therapies, resulting in clinical 
benefit. A downside of any therapy 
that increases anti-tumour immu-
nity by reversing physiological im-
mune checkpoints is that regulation 
of self-tolerance and antimicrobial 
resistance are also affected, with 
possible autoimmune and inflam-
matory side-effects.
Combination of chemo- 
therapy, targeted therapy, 
and immunotherapy
Cytotoxic agents have underpinned 
cancer therapy. Increasingly, agents 
that specifically target molecular 
pathways underlying malignant 
transformation have been developed 
(see Chapter 3.8). Both cytotoxic and 
targeted drugs may adversely affect 
the anticancer immune response. 
However, in experimental animals, 
certain drugs, including some widely 
used chemotherapy compounds, in-
duce immunogenic cell death, which 
favours generation of a tumour-spe-
cific immune response able to eradi-
cate or delay tumour progression. 
Immunogenic cell death is charac-
terized by expression of endogenous 
activators of inflammation – surface 
exposure of the endoplasmic reticu-
lum protein calreticulin, and release 
of ATP and high-mobility group 
box 1 protein – resulting in effec-
tive cross-presentation of tumour 
antigens and protective anticancer 
immunity [22] (see “Premortem 
autophagy and endoplasmic reticu-
lum stress as immunogenic signals 
in cancer therapy”). In addition, 
certain chemotherapeutic agents 
induce the intratumour expression 
of T-cell-attracting chemokines [23].
Combination of non-specific 
or targeted tumour therapies with 
immunotherapy approaches may 
provide successful cancer therapy. 
Although cytotoxic and targeted 
therapies are effective, clinical 
responses are often temporary. 
Experimental and clinical evidence 
suggests that immunotherapy, 
when successful, provides durable 
responses or even tumour eradica-
tion [18]. Immunity may be able to 
destroy cancer stem cells that are 
unresponsive to standard or tar-
geted therapies. While cytotoxic or 
targeted therapy may select tumour 
cells that became insensitive or had 
mutations in the targeted genes, 
strong anticancer immunity may de-
stroy a small proportion of mutated 
Premortem autophagy and endoplasmic reticulum stress as immunogenic 
signals in cancer therapy
Guido Kroemer
The ultimate goal of anticancer 
therapy is the induction of tumour 
cell death. Physiological cell death, 
which occurs as a continuous by-
product of cellular turnover, is non-
immunogenic or even tolerogenic, 
thereby avoiding autoimmunity. 
However, cancer cell death elicited 
by radiotherapy and some chemo-
therapeutic agents, such as an-
thracyclines and oxaliplatin, can be 
immunogenic. Immunogenic death 
involves changes in the composition 
of the cell surface, as well as the 
release of soluble immunogenic sig-
nals that occur in a defined temporal 
sequence. This “key” then operates 
on a series of receptors expressed 
by dendritic cells (the “lock”) to allow 
for the presentation of tumour anti-
gens to T cells and for the initiation 
of a productive immune response. 
Immunogenic cell death is char-
acterized by the early cell-surface 
exposure of calreticulin, which deter-
mines the uptake of tumour antigens 
by dendritic cells. The late release of 
the high-mobility group box 1 pro-
tein, which acts on Toll-like recep-
tor 4, is required for the presenta-
tion of antigens from dying tumour 
cells. In addition, the release of ATP 
from dying cells causes the P2RX7 
purinergic receptor-dependent acti-
vation of the NLRP3 inflammasome 
in dendritic cells, thereby allowing 
them to release interleukin-1β and 
to polarize tumour antigen-specific 
CD8 T cells towards a Tc1 cytokine 
pattern.
It may be hypothesized that the 
immune system determines the 
long-term success of anticancer 
therapies and that this immune re-
sponse is dictated by immunogenic 
tumour cell death. Thus, therapeu-
tic failure can result from failure to 
undergo immunogenic cell death 
(rather than cell death as such). 
Agents that fail to induce immu-
nogenic cell death cannot yield 
a long-term success in cancer 
therapy. Moreover, tumours that 
are intrinsically unable to undergo 
immunogenic cell death are incur-
able. Importantly, it appears that 
mitochondrial events determine 
whether cancer cells die in response 
to chemotherapy, while an endoplas-
mic reticulum stress response com-
bined with autophagy determines 
whether this cell death is perceived 
as immunogenic. Strategies may be 
developed to restore the immuno-
genicity of cell death in the context of 
deficient autophagy or endoplasmic 
reticulum stress.
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cells present within the antigenic 
tumours. Anti-tumour immunity not 
only mediates direct cytotoxicity of 
antigenic tumour cells but also ac-
tivates humoral and cellular inflam-
matory mechanisms that damage 
tumour cells as well as their microen-
vironment, stroma, and vasculature 
by cross-presentation of tumour an-
tigen on stromal antigen-presenting 
cells. Progress in understanding 
these mechanisms will define opti-
mal clinical protocols that combine 
different therapeutic approaches 
with immunotherapy.
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Summary
This Perspective summarizes sets 
of epidemiological data on early 
childhood tumours favouring their 
etiology as a result of interactions 
between specific host-cell chromo-
somal modifications and infectious 
events. This is discussed mainly for 
acute lymphoblastic leukaemia but 
also for neuroblastomas and brain 
tumours. In contrast to the major-
ity of previous publications, this re-
port underlines evidence in support 
of a prenatal infection, resulting in 
immune tolerance for the infecting 
agent. Episomally persisting single-
stranded DNA viruses with a circular 
genome are discussed as potential 
candidates. Prenatal infections have 
been documented for torque teno 
(TT) viruses. They are widespread 
in all human populations, replicate in 
cells of bone marrow and the periph-
eral blood, and respond to interferon 
treatment. Thus far, in part due to 
the type heterogeneity of this virus 
family, no follow-up studies are avail-
able demonstrating induction of im-
mune tolerance in cases of prenatal 
infections.
If we include the approximately 
10% of gastric cancers linked to 
Epstein–Barr virus infections and 
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the increasing percentage of head 
and neck cancers linked to high-
risk human papillomavirus (HPV) 
infections, then slightly more than 
20% of the global cancer incidence 
can be linked to infectious events 
[1]. Many of the existing links were 
originally identified based on epide-
miological observations. This poses 
an interesting question: can we 
identify malignant disorders where 
epidemiological data may point to 
an infectious origin, although no 
convincing supportive evidence has 
thus far been obtained by different 
approaches? Cancers that could be 
considered from this perspective 
have been discussed before [2].
Particular childhood 
malignancies
This Perspective will concentrate on 
a specific set of childhood malignan-
cies: acute lymphoblastic leukaemia 
(ALL), neuroblastomas, and central 
nervous system (CNS) cancers, 
with some sidestepping to acute my-
eloid leukaemia (AML) and Hodgkin 
disease. None of the malignancies 
discussed here has been consistently 
connected to infectious disorders, ex-
cept for Hodgkin disease, where 25–
35% of cases in developed countries 
have been linked to Epstein–Barr 
virus infections. Since the major-
ity of epidemiological studies have 
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tolerance could explain 
the epidemiology of 
common childhood 
cancers
Harald zur Hausen
in collaboration with Ethel-Michele de Villiers
analysed ALL data, this cancer will 
be specifically emphasized.
At least two events contribute to 
ALL development, according to pre-
vailing views: chromosomal modifica-
tions acquired during the fetal period 
and an additional postnatal event, 
commonly discussed as an unspeci-
fied infection [3–6]. Specific chromo-
somal translocations, for example 
TEL-AML and t(11;19)(q23;p13), have 
been documented for the prenatal pe-
riod [7] (reviewed in [8]). They occur, 
however, “at a substantially higher 
frequency (~100×) before birth than 
the cumulative incidence or risk of 
disease, reflecting the requirement 
for complementary and secondary 
genetic events that occur postnatally” 
[8], and they are thus not sufficient to 
cause leukaemia [9].
This Perspective summarizes 
sets of epidemiological data favour-
ing the interaction of specific molecu-
lar modifications with an infectious 
event. In contrast to the majority of 
previous publications, it underlines 
evidence in support of a prenatal in-
fection, resulting in immune tolerance 
for the infecting agent.
Infections that mediate 
protection
During the past decades, several re-
ports have described a protective ef-
fect of multiple infections during early 
childhood for ALL (reviewed in [10], 
[11]), neuroblastomas [12–14], CNS 
cancers [15], and Hodgkin disease 
[16,17]. Only a few studies have failed 
to confirm these observations for leu-
kaemias (reviewed in [10], [11]). Some 
publications referred to a higher risk 
of ALL development after maternal in-
fections during pregnancy (reviewed 
in [10]). Early immunization against 
Haemophilus influenzae type b seems 
to reduce the risk of ALL [18,19]. Even 
human leukocyte antigen (HLA) hap-
lotype may influence ALL susceptibil-
ity [20,21]. Interestingly, about 2% of 
childhood cancers are present at the 
time of delivery. Neuroblastomas are 
the most frequent connatal malig-
nancy among the tumours discussed 
here, followed by CNS tumours and 
leukaemias (reviewed in [22]).
Attendance at day-care centres, 
number of siblings, and less breast-
feeding during the first year of life 
have been implicated as surrogate 
markers for multiple infections and for 
the likelihood of childhood infection. 
Breastfeeding for more than 6 months 
has been repeatedly reported as a 
protective factor for ALL development 
(see reviews in [10], [11]). The protec-
tive role of communicative contacts 
is well documented by the lower risk 
for subsequent siblings compared with 
the first-born child in a pooled analy-
sis from five states in the USA [13]. In 
addition, allergies acquired during the 
first year of life have been identified as 
protective factors. Most studies to date 
have reported an inverse association 
between allergies and childhood leu-
kaemia (reviewed in [23]).
Thus far, protective factors for 
ALL, and to a more limited degree for 
neuroblastomas and CNS tumours, 
have been discussed. Several risk 
factors can also be clearly identified; 
they concern, in particular, a high so-
cioeconomic status and a protected 
environment. The rate of ALL is clear-
ly higher in countries with high stan-
dards of living than in poorer socie-
ties [24]. As an overriding risk factor, 
however, were considered molecular 
changes, specifically chromosomal 
translocations, occurring during the 
intrauterine phase of life [4–8,25]. 
These observations soon led to the 
conclusion that ALL arises in utero 
already, although it has quickly been 
recognized that genetic modifications 
are not sufficient for leukaemia de-
velopment [8,9]. It became a com-
mon postulate that, as the regular 
course, first a genetic event occurs 
during the fetal period, followed by 
a second one, possibly an infection, 
during the postnatal phase.
Specific predictions
If infections are involved in the eti-
ology of those childhood cancers 
discussed here, the occurrence 
of connatal neuroblastomas, CNS 
tumours, and ALL would be an in-
dication for prenatal (fetal) infec-
tions with a high likelihood of inter-
action with specific chromosomal 
modifications. Prenatal infections 
with subsequent postnatal persis-
tence will result in acceptance of 
the respective antigens by the im-
mune system of the carrier, and 
thus in immune tolerance [26–28]. 
Anticipating prenatal infections and 
a resulting immune tolerance of the 
persisting agent, several predic-
tions can be made:
• The respective tumours should not 
increase under conditions of immu-
nosuppression (in organ allograft 
recipients and persons with HIV 
infection);
• The agent should retain its suscep-
tibility to antiviral cytokines (e.g. 
interferons);
• Interferon-inducing nonspecific in-
fections should negatively interfere 
with the suspected infection;
• Interferon-inducing allergic condi-
tions should also negatively inter-
fere with the suspected infection;
• Interferon that is present in breast 
milk should also have protective 
properties;
• Conditions that avoid multiple in-
fections in early childhood should 
increase the risk for these tumours;
• The cancer risk for the first-born 
child (with a reduced risk for early 
childhood infections) should be 
higher than that for subsequent 
siblings (with a higher risk for com-
municative infections);
• Prenatal chromosomal modifica-
tions have been identified as risk 
factors but not as sufficient for can-
cer induction; thus, there should be 
a syncarcinogenic interaction be-
tween these modifications and the 
respective infection.
Immune tolerance has not yet 
been proven for antigens in the tu-
mours discussed here. In case it 
exists for antigens of potentially on-
cogenic agents, it is anticipated that 
immunosuppression should not fa-
vour an enhanced outgrowth of the 
respective tumour type. However, 
antiviral cytokines (e.g. interferon-
gamma), whose synthesis is not 
exclusively controlled by the lym-
phatic system, should retain a 
broad function in antiviral defence 
[29]. Similarly, nonspecific infec-
tions leading to interferon synthesis 
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should interact protectively. In this 
respect it seems to be interesting 
that enhanced interferon-gamma 
synthesis has been described for 
allergic conditions [30–33] and was 
also demonstrated in human breast 
milk for extended breastfeeding pe-
riods [34–37].
The major risk factors are obvi-
ously specific chromosomal trans-
locations and gene modifications, 
which, as discussed before, clearly 
emerge as risk factors but are not 
sufficient to trigger malignant growth. 
The other major predisposing factor 
for the tumour types analysed here 
appears to be the absence of mul-
tiple infections during the first year 
of life, lack of many communicative 
contacts, and an environment not 
exposing the infant to conditions of 
poor hygiene.
If we take prenatal infection 
and resulting immune tolerance for 
granted, all these data are readily 
compatible with a model we pro-
posed in 2005 [38]. It is shown, with 
some minor modifications, in Fig. 
P3.1. If “Peri- and postnatal res-
piratory infections” is replaced by 
“Interferon-gamma production due 
to allergic conditions or prolonged 
breastfeeding”, the basic features of 
the scheme remain unaltered.
Prenatal infections implicated
Do prenatal infections exist that would 
fit into this picture? Obviously sev-
eral infections have been identified 
as occurring during fetal life, among 
them cytomegalovirus and rubella 
infections, in part with grave conse-
quences for the developing fetus. If 
we analyse, however, those infections 
that would fit into the criteria outlined 
here, very few of the identified agents 
would remain. Besides vertical 
transmission, additional properties 
should be subsequent development 
of immune tolerance, replication or 
effective persistence within the pre-
cursor cells of ALL and possibly the 
other cancers discussed here, and 
finally responsiveness to interferon. 
Polyomaviruses and anelloviruses 
(torque teno [TT] viruses) emerge as 
potential candidates [11,38].
Particularly anelloviruses seem 
to represent promising candidates. 
Vertical transmission of TT virus 
DNA has been demonstrated by 
detection in umbilical cord blood 
[39–41]. These viruses replicate in 
mononuclear cells of bone marrow 
and the peripheral blood [42–44] 
and, as shown by interferon treat-
ment of hepatitis C virus carriers, 
they respond well to interferon 
treatment [45–47]. The question 
of whether these viruses induce 
immune tolerance after prena-
tal infections remains open and is 
currently difficult to study in view 
of their remarkable heterogeneity. 
Their analysis is being complicated 
by observations of frequent intrage-
nomic rearrangements, resulting in 
novel open reading frames [48,49]. 
A synergistic function with specific 
cellular genetic modifications still 
requires further investigation.
It would be difficult, if not impos-
sible, to reconcile a chain of mu-
tational events with the published 
epidemiological data available con-
cerning the etiology of the tumours 
discussed here. A prenatal infection 
with resulting immune tolerance, 
however, acting syncarcinogenical-
ly with cellular gene modifications, 
seems to be in line with all epide-
miological observations thus far re-
ported. Virological studies, however, 
have not yet led to the identification 
of responsible infectious factors.
Fig. P3.1. The target cell conditioning model based on prenatal or perinatal torque 
teno (TT) virus-like infections. Transplacental as well as perinatal infections should 
lead to virus persistence and an increasing viral load. Multiple intermittent infections 
with interferon-inducing agents should reduce the viral load substantially and thus 
decrease the risk for virus-induced chromosomal modifications.
Prenatal 
infection 
Peri- and 
postnatal 
respiratory 
infections 
A protected environment should result in 
a high load and high multiplicities of 
infection, increasing the risk for infection 
of cells with specific chromosomal 
modifications 
Intermittent infections cause 
interferon induction 
Thus, frequent infections should lower 
the load of a persisting agent and reduce 
the risk for infection of cells with specific 
chromosomal translocations 
Viral load 
Time of delivery 
Prenatal 
period 
Clonal 
expansion 
Time 
Perinatal 
infection 
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Preventing cancer by avoiding exposure to particular 
carcinogens follows from knowledge of causation. 
Priorities for cancer prevention differ on national, 
and sometimes local, scales. Certain individual life-
style choices are also identified as key to reducing 
cancer incidence. Tobacco-related mortality has 
prompted measures from supporting smoking cessa-
tion to adopting an international treaty. In communi-
ties where cancers are clearly attributable to alcohol 
drinking and/or avoidable sunlight exposure, corre-
sponding behaviour change is warranted. Beyond 
exposure to specific carcinogens, various cancer 
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prevention of diabetes, heart disease, and cancer, 
particularly in high-income countries. Primary pre-
vention of some infection-caused cancers is achiev-
able by vaccination, and regulatory measures have 
been proven to reduce or eliminate cancer caused by 
workplace or environmental pollutants. Secondary 
prevention by detecting premalignant or early stages 
of disease can reduce morbidity and mortality from 
particular tumours.
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Summary
• Tobacco use, particularly ciga-
rette smoking, remains a major 
cancer control priority as well 
as being a priority for other ar-
eas of disease prevention.
• The WHO Framework Conven-
tion on Tobacco Control is at 
the centre of international ef-
forts to reduce tobacco-related 
harms.
• Uptake and continuation of to-
bacco use by individuals is in-
fluenced by personal and soci-
etal/environmental factors. The 
practice of tobacco companies 
to actively market their prod-
ucts is a major influence.
• Government-supported tobac-
co control policies are neces-
sary to constrain the activities 
of the tobacco industry, to deter 
tobacco use, and to encourage 
existing users to quit.
• A comprehensive tobacco con-
trol programme requires poli-
cies that adequately regulate 
the practices of tobacco com-
panies, by eliminating their ca-
pacity to promote their products; 
do all that is possible to reduce 
the harmfulness and allure of 
tobacco products; create a dis-
incentive to use these products 
through high taxes; protect peo-
ple from involuntary smoking; 
ensure that the public is ad-
equately informed; and support 
services to help those unable to 
quit unassisted.
Cigarette smoking is the most fre-
quent form of tobacco use and a 
major cause of cancer as well as 
many other diseases, but stopping 
use can reverse some of the dam-
age and prevent other risks from 
continuing to rise [1]. Other forms 
of tobacco are also harmful. Most of 
the harms to health are caused by 
the delivery of carcinogens and ad-
ditional toxic substances, not by the 
nicotine, which is the main psycho-
active substance in tobacco and the 
core reason people use and contin-
ue to use tobacco. Tobacco use is 
also partly sustained by beliefs that 
users hold and by the roles that to-
bacco use plays in society, both of 
which are influenced by tobacco in-
dustry marketing. Quitting smoking 
can be facilitated by an environment 
where non-smoking has become 
the norm, but this is not sufficient 
for many smokers. Non-smokers 
need to be protected from involun-
tary smoking. The importance of 
tobacco control to health and the 
need for coordinated international 
action has been recognized by the 
international community through 
the WHO Framework Convention 
on Tobacco Control (FCTC) [2].
Prevention of initiation and pro-
motion of cessation are the two 
main objectives guiding efforts to-
wards reducing smoking. Along 
with protecting others from invol-
untary smoking and reducing the 
4.1
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Fig. 4.1.1. Campaign poster from the 
French association Droits des Non-
Fumeurs (Non-Smokers’ Rights): “The 
tobacco industry also has a social com-
mitment. Every year, we solve the prob-
lems of thousands of French pensioners. 
The tobacco industry kills 73 000 people 
every year. Keep trusting them.”
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harmfulness of tobacco products, 
these form the four pillars of a com-
prehensive approach to tobacco 
control. The ideal is to prevent up-
take, but this is never likely to be 
universal, so other strategies are 
needed as well. This chapter focus-
es on reducing cigarette smoking, 
although much of the discussion 
can be generalized to the control of 
other forms of tobacco use.
Tobacco use: the scope of the 
challenge
The prevalence of cigarette smok-
ing varies greatly across the world 
and also varies greatly by sex [3] but 
remains unacceptably high every-
where. In several countries, more 
than 50% of men smoke cigarettes; 
these include China, Indonesia, and 
the Russian Federation, three of the 
largest countries. In some African 
countries, less than 10% of men 
smoke. Overall, far fewer women 
than men smoke. In some small 
countries, more than 40% of wom-
en smoke, but the prevalence is 
less than 5% in many countries, in-
cluding China. Use of other smoked 
products, notably bidis, is very high 
in India and other parts of South 
Asia. Use of a variety of smokeless 
tobacco products is most prevalent 
in South Asia and parts of Africa, 
where smokeless tobacco products 
are often the main form of tobacco 
use among women, and in parts of 
Scandinavia among men.
Tobacco use is addictive, due 
to the psychoactive effects of the 
nicotine. However, the addiction is 
more to the way in which the nico-
tine is delivered than to the drug 
itself. Cigarettes are the most ad-
dictive form of nicotine delivery, 
whereas nicotine provided in trans-
dermal patches to facilitate cessa-
tion appears to have no addiction 
potential. There is evidence that 
it is easier to quit smokeless to-
bacco use than cigarette smoking 
[4]. Hence, the development and 
maintenance of addiction or depen- 
dence is a biopsychosocial phe-
nomenon [5,6]. Rituals associated 
with tobacco use, sustained in part 
by social conventions, become part 
of what is hard to give up. Tobacco 
dependence develops as the cumu-
lative effect of tobacco use, usu-
ally in adolescence, and becomes 
a barrier – physiological or/and psy-
chological – to stopping use [7].
The majority of smokers start 
using tobacco as teenagers, with a 
younger age of initiation in high-in-
come countries compared with mid-
dle- and low-income countries [8]. 
The stages in the development of 
the habit in a tobacco user include 
never-use, trial, experimentation, 
and established use (with varying 
degrees of dependence), followed 
by an often-repeated cycle of quit 
attempts and relapse, leading to 
either permanent cessation or con-
tinued use [9]. Preventing initial trial 
or progression of use after initial 
trial are the most important goals 
of tobacco control policies, as their 
achievement effectively eliminates 
the health risk, but while a popula-
tion of smokers persists, additional 
efforts are required.
Tobacco control is grounded 
in the harms of the behaviour. 
Smoking behaviour is maintained 
by two sets of factors: the experi-
enced effects of tobacco use, and 
the ways in which smoking has 
become socially useful. As smok-
ing became more prevalent, ritu-
als associated with it became part 
of the prevailing culture of coun-
tries, as illustrated by the offering 
of cigarettes to others to facilitate 
socialization and the giving of cig-
arettes as gifts. These factors not 
only help sustain use but also pro-
vide reasons for use and reasons 
to oppose efforts to control use. 
The denormalization of smoking 
involves eliminating as far as possi-
ble these social benefits of tobacco 
use, leaving only the experienced 
effects to be overcome for those 
motivated to quit. Denormalization 
takes time, and much of it occurs 
as a side-effect of strong public 
education campaigns and the in-
troduction of smoke-free places. 
As smoking becomes less valued 
socially, policy-makers may more 
easily enact stronger laws to further 
constrain use, thus creating a vir-
tuous cycle of activity. Changing 
the social conditions or normative 
context to discourage tobacco use 
reduces the incentives to take up or 
continue smoking and should make 
quitting easier. However, part of 
the addiction is caused by factors 
within the individual; thus, norma-
tive change, while helping to drive 
down the prevalence of smoking, is 
not enough to assist many smokers 
who remain unable to quit [10].
Measurement and evaluation
Central to any systematic, scientifi-
cally grounded approach to reduc-
ing the tobacco epidemic is regular 
monitoring of smoking prevalence 
and high-quality evaluation of the 
impacts of control efforts. There 
are now coordinated international 
efforts to monitor use [11]. The key 
instruments are the Global Adult 
Tobacco Survey [12] and the Global 
Youth Tobacco Survey [13]. The 
Global Adult Tobacco Survey is a 
more recent innovation and has not 
extended to many countries yet. The 
use of the Global Youth Tobacco 
Survey is more widespread (Figure 
4.1.2). There are similar pre-exist-
ing surveys of both adults and chil-
dren in most developed countries.
Trends indicated by survey data 
provide key indicators of progress. 
Surveys should be sufficiently large 
as to provide data about important 
subgroups, for example to indicate 
whether progress is equivalent 
across levels of socioeconomic sta-
tus or by sex. Youth surveys are de-
terminative in monitoring efforts to 
prevent uptake.
Volume 12 of the IARC Hand-
books of Cancer Prevention, on 
methods for evaluating tobacco 
control policies, presents an exten-
sive set of measures or variables, 
collected from multiple surveys, 
to monitor the natural history of 
tobacco use [14]. However, cross-
sectional repeat surveys, while an 
excellent method for assessing 
prevalence and changes in preva-
lence, lack specificity to reveal the 
mechanisms by which any observed 
changes have taken place. Cohort 
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higher rates than boys in 
3% of the countries.
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Fig. 4.1.2. Global Youth Tobacco Survey (GYTS): monitoring of cigarette smoking in (A) boys and (B) girls. Regions: AFR, Africa; 
AMR, the Americas; EMR, Eastern Mediterranean; EUR, Europe; SEAR, South-East Asia; WPR, Western Pacific.
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or panel studies are much more 
powerful in this regard. A good ex-
ample of high-quality evaluation is 
the International Tobacco Control 
Policy Evaluation project, which 
not only uses cohorts of smokers 
within countries but also attempts 
to measure all of the main theorized 
mediators of policy effects as well 
as indicators of policy reach and 
proximal impact. These data are 
generated using parallel surveys 
in different countries, which permit 
results in a country that implements 
a policy to be compared with those 
in control countries that do not, and 
also allow for exploration of pos-
sible differences in policy impact 
because of cultural traditions or the 
presence of complementary poli-
cies and the history of past efforts. 
These methods can also help to 
tease out interactions between mul-
tiple policies. This kind of approach 
is realizing the intention of the WHO 
FCTC to be an evidence-grounded 
treaty, by generating valid scientific 
data that are used to inform policy.
Tobacco control interventions
The two main domains and the key 
elements of tobacco control that 
are considered in this section are 
outlined in Fig. 4.1.3 [14]. The first 
is tobacco industry control, which 
is directed at regulating the mar-
keting resources of the industry 
and targets the product, its price, 
its availability, and its packaging. 
The second is tobacco use control, 
which focuses more directly on us-
ers or on individuals vulnerable to 
become users, and includes restric-
tions on where people can smoke, 
educational interventions, and pro-
vision of support for cessation. Both 
types of controls are shown in Table 
4.1.1.
Price and taxation
Price is a factor that theoretically 
acts to reduce consumption inde-
pendently of whether people be-
lieve that use is harmful. Imposition 
of taxes to increase the retail price 
of tobacco reduces the prevalence 
and frequency of tobacco use in 
the population. Similarly, decreas-
ing prices are associated with in-
creased use. Taxation is considered 
the single most effective interven-
tion to change tobacco behaviours 
[15,16], but this may be because 
its impact is easy to quantify as it 
typically occurs immediately after 
the price changes, whereas other 
strategies, for example educational 
interventions, have rather more dif-
fuse and longer-term effects.
Because price increases re-
duce consumption and smoking 
prevalence, ensuring that the price 
is as high as possible is a key to-
bacco control strategy. A significant 
proportion of the retail price of a to-
bacco product involves taxes, and 
a change in the tax rate is the main 
way that governments can influence 
the retail price. Although WHO rec-
ommends that excise taxes should 
account for a minimum of 70% of 
the retail price of tobacco prod-
ucts, this level has been achieved 
by only a few countries in the world 
[17,18] and sometimes only for 
some tobacco products. Apart from 
taxes, other ways that governments 
can influence retail prices include 
banning gifts with cigarette pur-
chases, price controls exemplified 
by minimum price laws, and strong 
enforcement of penalties for evad-
ing tobacco taxes. These options 
necessitate registration of manu-
facturers and monitoring of national 
production as well as efforts to min-
imize smuggling [16]. There is now 
a Protocol to the WHO FCTC – the 
Protocol to Eliminate Illicit Trade in 
Tobacco Products – that, when im-
plemented, should help internation-
al coordination to reduce the illegal 
trade in tobacco products, which is 
currently a major problem in some 
countries [2].
The impact of tobacco taxes on 
prices can also be lessened by le-
gal responses to the tax increase 
[16]. For instance, in anticipation 
of or in response to a tax increase, 
tobacco companies can limit price 
increases by reducing profit mar-
gins, sometimes targeted at those 
Fig. 4.1.3. Schematic overview of tobacco control interventions and how they relate to 
tobacco products, users, and potential users.
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products most used by young peo-
ple and/or lower-income smokers. 
Companies can also turn a sud-
den tax increase into a series of 
gradual increases in the hope that 
consumers will not notice and thus 
the impact on consumption will be 
less. Where products are differen-
tially taxed, consumers can shift to 
products that are taxed less and are 
thus cheaper.
The demand for tobacco prod-
ucts is inversely related to price. 
The magnitude of this response is 
measured by the price elasticity of 
the demand for tobacco products, 
usually expressed in terms of the 
percentage change in use that 
results from a 10% increase in 
price. The more price-elastic the 
demand, the more effective is a 
tobacco price increase in lowering 
use. The price elasticity of demand 
can be estimated by using aggre-
gate data or with household-level 
or individual-level data, based on 
surveys. Individual-level data allow 
the effect of price on consumption 
to be assessed by sex, age group, 
socioeconomic status, and other 
attributes of the population, poten-
tially revealing differences between 
subgroups in sensitivity to price 
changes. Aggregate data do not 
allow the effects on prevalence to 
be separated, independent of con-
sumption per user.
There is an inverse relation-
ship between cigarette prices and 
cigarette consumption across all 
countries. Data from the USA and 
the United Kingdom, where most 
studies have been conducted, in-
dicate that the magnitude of the 
price elasticity of cigarette demand 
is about –0.4 (range, –0.2 to –0.6); 
that is, for a 10% increase in price 
a 4% decrease in consumption is 
Table 4.1.1. Tobacco control interventions
Intervention Aims Examples
Tobacco industry controls – targeted at producers
Product controls To reduce use, and to reduce harmfulness of products Rules preventing the establishment of new products 
(prohibition of marketing and sales of snus in the 
European Union, with the exception of Sweden); rules 
limiting the appeal of products (bans on the use of 
flavourings or imposing limits on constituents); rules 
restricting the levels of constituents and emissions 
(upper limits on tar, nicotine, and carbon monoxide)
Price controls To reduce use in current users, and to deter use in 
never-users and former users
Increase in excise taxes passed onto the retail price of 
tobacco products; price policies that include a minimum 
price floor to counteract industry’s marketing discounts
Promotion 
controls
To reduce use and appeal of products Bans on paid advertisement, sponsorship, and place-
ment of products, including restrictions on packaging 
(generic packaging); bans on product price-reducing 
promotions
Availability 
controls
To reduce availability of products and discourage use in 
certain venues
Restrictions on the number and types of outlets; 
restrictions about to whom products can be sold (age 
limits and vending machines); ban on sales in bars
Packaging 
controls
To reduce cues to use, and to make the product less 
attractive
Rules on descriptors of package content; ban on sales 
of single cigarettes; establishment of a minimum pack 
size
Form and content 
of warnings
To discourage use and inform the public of adverse 
health effects
Inclusion of facts about the harms of tobacco use or the 
health benefits of quitting use; information about toxin 
levels
Provisions to 
detect compliance 
with tax directives
To limit tobacco tax avoidance and evasion Use of tax stamps and of systems for tracking and 
tracing tobacco products
Tobacco use controls – targeted at users or potential users
Rules about use To reduce use, and to protect non-users Smoke-free policies that protect non-smokers and also 
have effects on users (reduction in consumption)
Public 
communication 
campaigns
To disseminate to as many people as possible the 
messages of anti-tobacco campaigns
Mass media campaigns to promote programmes 
designed to inform people while minimizing the risk of 
awakening the desires of experimenting with tobacco
Programmes to 
disseminate the 
availability of 
tobacco cessation 
services
To increase the level of information about cessation 
resources in place to increase their use
Rules regulating cessation medications, availability of 
services, and existence of subsidies on medications 
and services (among these: quitlines, “quit to win” 
campaigns, brief advice from physicians, nurses, and/or 
other health-care providers)
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observed [8]. Elasticity estimates 
from other high-income countries 
are more varied. Greater elastic-
ity is often observed in low- and 
middle-income countries, with esti-
mates between –0.2 and –0.8 [16]. 
In those environments with elas-
ticity estimates that are very low, 
cigarettes are very cheap or their 
affordability has risen significantly 
over time (due to increased earn-
ings), rendering tax increases less 
effective.
A smaller number of studies 
have assessed the effect of increas-
es in cigarette prices on smoking 
cessation in adults. Higher taxes 
and prices reduce the duration of 
smoking, increase quit attempts, 
and increase the number of smok-
ers who successfully quit [16,19]. 
About half of the impact of the price 
increase is on adult prevalence and 
about half is on the number of ciga-
rettes consumed by adult smokers 
[16]. Limited evidence indicates 
that all other tobacco products are 
similarly price-elastic. Some stud-
ies have documented substitution 
among these products in response 
to increases in their relative prices, 
specifically between cigarettes and 
smokeless tobacco after increases 
in taxes on cigarettes, and between 
cigarettes and cigars after increas-
es in the price of cigarettes [20].
Price elasticity for tobacco prod-
ucts within countries also depends 
on income levels of potential con-
sumers. Indeed, after considering 
potential confounders, as aggre-
gate income increases the aggre-
gate demand for tobacco typically 
increases. The policy implication is 
that the price of tobacco products 
must increase at least as fast as in-
come growth to avoid tobacco prod-
ucts becoming more affordable. 
Younger tobacco users are expect-
ed to be more sensitive to increases 
in prices or taxes than adults be-
cause they have less disposable 
income and a lower level of tobacco 
dependence [16]. Younger users 
are also more influenced by peer 
use and are more concerned with 
immediate costs than with health 
outcomes in the long term. These 
expectations have been confirmed. 
Both smoking prevalence and inten-
sity among young people diminish in 
response to cigarette price increas-
es. The magnitude of the overall 
elasticity in high-income coun-
tries, where most studies has been 
conducted, ranges between –0.50 
and –1.2 [16].
Restrictions on tobacco 
promotion
Many of the techniques now ubiq-
uitous in mass marketing were first 
used, or first perfected, for selling 
manufactured cigarettes [21,22]. 
Advertising and other forms of pro-
motion can be a powerful force for 
increasing product use. Legislative 
bans or other agreements to elimi-
nate tobacco advertising are thus 
a critical aspect of tobacco con-
trol efforts (Article 13 of the WHO 
FCTC) (Table 4.1.2). Advertising in-
volves far more than advertisements 
on television, on billboards, or in 
In  1 week
your sense of taste 
and smell improves
In  5 years
your risk of a stroke has 
dramatically decreased
In  12 months
your risk of heart 
disease has halved
In  12 weeks
your lungs regain 
the ability to 
clean themselves
In  5 days
most nicotine 
is out of 
your body
In  8 hours
excess carbon 
monoxide is out 
of your blood
In  1 year
a pack-a-day
smoker will 
save over 
$4,000
In  3 months
your lung function 
begins to improve
STOP SMOKING
START REPAIRING
Advertisement
australia.gov.au/quitnow
Authorised by the Australian Government, Capital Hill, Canberra
GO TO THE APP STORE OR ANDROID MARKET NOW TO 
DOWNLOAD My QuitBuddy FOR FREE
Fig. 4.1.4. Campaign poster from the Australian Department of Health and Ageing 
describing the gradual positive effects that quitting tobacco has on the human body.
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newspapers; it also includes posters 
and the display of the products at 
point of sale as well as the branding 
and associated designs on the pack-
aging. Internet advertising should 
also be recognized, but its control 
may require international coopera-
tion. A comprehensive policy also 
requires cigarettes to be kept from 
view – to eliminate the promotional 
aspect of large, prominent cigarette 
displays – and removing as much 
branding as possible from packag-
ing, ultimately by plain packaging 
(see “Australia’s plain packaging of 
tobacco products”). Restrictions on 
advertising need to be reasonably 
extensive before effects on use can 
be detected, at least in part due to 
the capacity of the industry to shift 
promotion to channels that are still 
permitted [8].
Availability of products
Tobacco remains one of the most 
readily available consumer prod-
ucts on the market. Many countries 
have prohibited sales to minors. A 
few countries, like France, limit to-
bacco sales to specialist retailers. 
In most countries, however, to-
bacco is still available in places like 
convenience stores, which, in turn, 
are often frequented by children. 
The density of tobacco outlets is 
related to the prevalence of smok-
ing in the area [23]. An increased 
focus on restricting where tobacco 
products can be sold is anticipated 
in future policy initiatives.
Product regulation
Use of filters is the only viable way 
of cleaning up tobacco smoke. 
However, use of filters is severely 
limited in its efficacy because filters 
either remove nicotine or create 
conditions where nicotine cannot be 
carried as effectively into the lungs, 
thereby diminishing consumer ap-
peal. While cigarettes and other 
forms of smoked tobacco continue 
to be used, it is important to pro-
gressively reduce the toxicity of 
these products as far as possible. 
It is possible to remove the bulk of 
toxins from smokeless forms of to-
bacco, so this is a viable strategy for 
reducing the harm that smokeless 
tobacco causes. Low-toxin smoke-
less tobacco causes far less harm 
than other forms of tobacco [24], 
but it does contain carcinogens [25]. 
These products also contain nico-
tine, which reinforces future use, 
thus prolonging the duration of the 
habit and increasing the cumulative 
use, thereby increasing the likeli-
hood of damage to health.
The main forms of product regu-
lation have been to set limits on 
the amount of tar, nicotine, and, 
often, carbon monoxide produced 
by cigarettes as determined using 
a standard machine. This prompted 
companies to market certain ciga-
rettes as “light” and “mild”, imply-
ing that these products were less 
harmful, sometimes by suggesting 
that they were an alternative to quit-
ting. However, cigarettes that actu-
ally delivered low levels of nicotine 
were not used in the long term by 
individual consumers. The industry 
addressed this problem by using 
filter ventilation: small holes in the 
paper surrounding the filter, thereby 
permitting air to mix with the smoke. 
This allowed cigarettes that, al-
though they were determined by a 
testing machine to be low in tar and 
nicotine yield, actually delivered 
similar amounts of nicotine and the 
accompanying tar to smokers as 
did regular cigarettes [26]. Smokers 
compensated for the dilution effect; 
they blocked some of the holes and 
took larger and deeper puffs [27]. 
The WHO FCTC mandates pro-
hibiting the misleading use of the 
terms “mild” and “light”, and recom-
mends removing misleading yield 
measures from packaging where 
Table 4.1.2. Key Articles of the WHO Framework Convention on Tobacco Control
Article Description
Article 5.3 Designed to restrict the influence of the tobacco industry in 
decision-making related to implementation of the treaty.
Article 6 Price and tax measures to reduce the demand for tobacco. 
Guidelines recommend trying to raise taxes so that they account for 
at least 70% of the retail price.
Article 8 Protection from exposure to tobacco smoke.
Article 9 Regulation of the contents of tobacco products.
Article 10 Regulation of tobacco product disclosures.
Article 11 Packaging and labelling of tobacco products. Mandates health 
warnings covering at least 30% of both main surfaces of packages. 
Guidelines suggest graphic warnings covering at least 50% of the 
package and consideration of plain packaging.
Article 12 Education, communication, training, and public awareness. 
Requires public education and training of health professionals, and 
participation of civil society in such activities.
Article 13 Tobacco advertising, promotion, and sponsorship. Requires 
prohibiting this as far as possible within constitutional limits.
Article 14 Demand reduction measures concerning tobacco dependence and 
cessation. Mandates developing guidelines and programmes for 
delivery of effective aids and services to help smokers quit.
Article 15 Illicit trade in tobacco products. Expanded with first Protocol to the 
treaty, requiring a range of actions to control international trade so 
as to eliminate illicit trade.
Article 16 Sales to and by minors. Designed to stop sales to minors, and 
includes suggestions for bans on vending machines and other 
channels where restrictions on sales may be problematic.
Articles 20–22 Research, which includes surveillance, intervention development, 
and evaluation to ensure that the WHO Framework Convention on 
Tobacco Control is evidence-based and progress can be monitored.
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Australia’s plain packaging of tobacco products
Simon Chapman
On 1 December 2012, Australia 
became the first country to require 
that all tobacco products be sold 
in standardized “plain” packaging. 
The Tobacco Plain Packaging Act 
2011 mandates an identical stan-
dard for all brands for all aspects 
of packaging [1]. Parallel legislation 
mandated graphic health warnings, 
now the world’s largest at 75% of 
the pack’s front surface and 90% 
of the back surface [2]. All brands 
are now sold in the same dull brown 
colour; the only differentiation is 
the brand name and variant, print-
ed in a standard font. All aspects 
of the new design reflect detailed 
research with smokers about the 
options that are the least attrac-
tive and cause the most concerns 
about health [3].
The Australian government in-
troduced the bill following advice 
from its Preventative Health Task 
Force, which argued that Australia’s 
tobacco advertising ban failed to 
address what had long been a ma-
jor loophole: the role of the pack 
as advertising. As with all other in-
dustries, internal tobacco industry 
documents and the tobacco trade 
press discuss candidly the central 
role of packs in promoting the at-
tractions of brands and smoking.
Plain packaging is anticipated 
to have less effect on older, heavily 
dependent smokers, who tend to 
be brand-loyal and less image-con-
scious. However, without branding, 
future generations will grow up nev-
er having seen category A carcino-
gens packaged in attractive packs. 
Today’s 20-year-olds in Australia 
have never seen local tobacco ad-
vertising, and youth smoking rates 
are at an all-time low. Plain packs 
are expected to turbocharge this 
trend.
A large-scale evaluation of 
the impact of the packaging com-
menced well before it was im-
plemented. Early feedback sug-
gests that many smokers believe 
their cigarettes now taste worse 
than before, an effect predictable 
from market research into how 
packaging powerfully conditions 
expectations and consumers’ ex-
perience of products. Reports 
are also common that smokers 
feel that the large health graphic 
health warnings are disturbing and 
embarrassing.
The new law has already sur-
vived a tobacco industry challenge 
in the Australian High Court, with 
only one judge of seven not sup-
porting the government. The in-
dustry campaigned vigorously 
against the policy and is expected 
to engage in heavy price discount-
ing to try and show the world that 
the policy failed and should not be 
adopted elsewhere. The govern-
ment can counteract this by raising 
the tobacco tax.
Australia’s historic plain ciga-
rette packaging legislation is a 
weapons-grade public health pol-
icy now causing major concern in 
the international industry because 
of its potential to have a domino 
effect on other countries’ tobacco 
control policies. No other product 
is subject to such complete con-
trol, sending a powerful message 
to the population that tobacco is an 
exceptionally unhealthy product, 
deserving exceptional controls.
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significantly in Australia, from text-only health warnings (left) until the introduction 
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packaging (right) on 1 December 2012.
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they had been mandated. These 
bans have had a limited impact [28]. 
Consumers experience these ciga-
rettes as slightly less harsh and in-
terpret this reduced averseness as 
reduced harmfulness [29]. The core 
problem of filter ventilation has not 
been addressed, and remains [27].
Reducing product toxicity is one 
aim of Articles 9 and 10 of the WHO 
FCTC (Table 4.1.2). Product regu-
lation also needs to consider both 
the addictiveness and the related 
attractiveness of tobacco products 
that continue to be harmful. Several 
countries, including Canada and 
Brazil, now ban all or nearly all addi-
tives to cigarettes that are designed 
to affect flavour. Products contain-
ing high levels of toxins still domi-
nate the market in many countries.
One recent product develop-
ment that has evoked interest as a 
harm reduction option is electronic 
cigarettes (e-cigarettes), also re-
ferred to as electronic nicotine de-
livery systems (ENDS). This prod-
uct is designed to deliver nicotine 
to the lungs without combustion. 
Several groups of ex-smokers use 
and promote e-cigarettes as low-
harm alternatives to smoking. The 
safety and efficacy of this product 
as a cessation aid is under study. 
Like smokeless tobacco, the po-
tential role of e-cigarettes in reduc-
ing smoking is unclear [30], but 
evidence is emerging that e-ciga-
rettes will be a much easier product 
to switch to and that they may be 
effective cessation aids [31].
Smoke-free laws
Smoke-free legislation is primarily 
designed to protect non-smokers. 
Comprehensive laws that are well 
complied with greatly reduce invol-
untary smoking. Smoke-free poli-
cies also contribute to a reduction in 
the level of daily cigarette consump-
tion by smokers, to a drop in the 
prevalence of smoking, and to de-
ter smoking initiation among young 
people [32,33]. Bans on workplace 
smoking reduce daily cigarette con-
sumption by an average of 2–4 ciga-
rettes. One large United States study 
found that after controlling for poten-
tial confounders, the percentage of a 
state’s population that was covered 
by smoke-free air laws was correlat-
ed with a decreased odds of suscep-
tibility to smoking, current smoking, 
and established smoking in young 
people [33]. Comprehensive smoke-
free policies create strong anti-
smoking norms that lead to volun-
tary interventions such as smoking 
bans in private homes, which reduce 
exposure of children to second-
hand smoke, with resulting effects 
in reducing adult smoking. Regular 
efforts are needed to remind the 
population of the health benefits of 
smoke-free environments, including 
mass anti-tobacco campaigns and 
dissemination of information about 
the availability of cessation services 
or medications.
Globally, exposure to second-
hand smoke varies significantly 
across countries, and a large part 
of the world’s population continues 
to be exposed to the health hazards 
of involuntary smoking both at work 
and at home. For example, 63% of 
Chinese workers report being ex-
posed to smoke in their workplace 
(see “Tobacco and China”). The 
proportion of adolescents living in 
homes where others smoke in their 
presence can be high even in high-
income countries.
Educational efforts
The knowledge that tobacco use is 
harmful is central to any efforts to 
control its use, although sometimes 
the pervasiveness of this knowl-
edge makes demonstrating effects 
from specific interventions difficult. 
The two main ways of informing 
the public are through mass media, 
increasingly via the Internet, and 
by provision of warning material 
on tobacco packaging. For young 
people, school-based education is 
another source of information, al-
though it has only modest effects 
on preventing uptake unless com-
plemented with other strategies 
[34]. Warning labels on packaging 
can improve knowledge and gener-
ate concerns about smoking, and 
thereby stimulate increased quitting 
[35], although their net effect on 
cessation is probably small. Large 
graphic warnings are the most ef-
fective. The mass media are the 
main source of health information 
for most people and, even taking 
the Internet into account, remain 
the main source of unsolicited in-
formation. The mass media convey 
new information and remind people 
about knowledge they already pos-
sess but have forgotten or are ig-
noring (see also Chapter 4.3). The 
more attention is paid to tobacco in 
the mass media, the more quitting-
related activity occurs [36].
Fig. 4.1.5. Campaign material from the Vietnamese Ministry of Health: “Tobacco has 
ravaging effects on your body and your baby’s. Quit today. From 01/01/2010, make 
sure to strictly implement the provisions of the government smoking ban in public 
places and workplaces.”
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Well-constructed advertisements 
about the harms of smoking raise 
the profile of the issue and make 
the harms more personally relevant, 
thus encouraging smokers to quit 
and others not to start or resume 
smoking [37,38]. Part of the preven-
tive effect seems to stem from dis-
gust associated with the unattractive 
and disfiguring aspects of disease 
linked to smoking, rather than from 
anxiety about future harms. Anti-
smoking advertisements appear to 
have their effects by essentially the 
same mechanisms as health warn-
ings on packs. Television advertise-
ments can convey a much more 
engaging message than compa-
rable pack warnings, but smokers 
are exposed to them far less often. 
Although advertising is expensive, it 
can reach large numbers of people 
quite cheaply per person influenced, 
so it is very cost-effective.
The mass media are effective 
in reaching smokers in lower socio-
economic groups, especially when 
the advertising is both designed to 
be seen as relevant and shown in 
programmes that these groups tend 
to view, and is at least as effective 
in influencing these groups as in 
influencing smokers in more socio-
economically advantaged groups. 
Smokers in less-advantaged socio-
economic groups may also require 
more intensive assistance if they 
are to quit successfully. Having 
the issue of smoking prominent in 
the mass media can also motivate 
health professionals by making 
them more aware and also more 
Tobacco and China
Judith Mackay
The epidemic
The Chinese government owns the 
world’s largest tobacco company. 
China is the largest producer and 
consumer of tobacco, with about 
350 million smokers, mostly male. 
One third of all cigarettes smoked 
in the world are smoked in China. 
In 2010 it was estimated that 53% 
of the male population and 2.4% 
of the female population in China 
were smokers [1]. Tobacco current-
ly causes 1.2 million deaths annu-
ally in China (equal to 3000 deaths 
every day), the highest number for 
any one country – and this figure 
is predicted to rise to more than 
3 million by 2030 [2]. More than 
70% of the population are regularly 
exposed to second-hand smoke. 
Only recently have small numbers 
of smokers attempted to quit.
Economic costs
Smoking puts great pressures on 
economic development. Between 
2000 and 2008, the attributable 
costs of tobacco use in China 
quadrupled, from US$ 7.2 billion 
to US$ 28.9 billion, or 0.7% of the 
gross domestic product [3].
Tobacco control action
In 1979, the Ministries of Health, 
Finance, and Agriculture jointly is-
sued the Circular of Publicity on the 
Harm of Smoking and Control on 
Smoking. Since the 1980s, central 
and local governments have passed 
and expanded laws for the control 
of smoking in public places, pro-
tection of minors, and bans on to-
bacco promotion, and have issued 
many circulars. In 1997, Beijing 
hosted the 10th World Conference 
on Tobacco or Health, opened 
by President Jiang Zemin, which 
brought considerable attention to 
the issue of smoking. China ratified 
the WHO Framework Convention 
on Tobacco Control (FCTC) in 2005 
and was the second country to sign 
the Protocol to Eliminate Illicit Trade 
in Tobacco Products in 2013. China 
is one of only four countries where 
tobacco control is included in both 
the National Development Plan and 
the United Nations Development 
Assistance Frameworks.
Obstacles and challenges
The obstacles and challenges are 
common to most countries, and in-
clude a focus on curative, not pre-
ventive, medicine. The state tobac-
co monopoly has jurisdiction over 
most tobacco control in China – a 
clear conflict of interest. The pub-
lic still lacks accurate awareness of 
the harms of smoking and second-
hand smoke. There is no national 
ban on smoking in public places 
and the workplace, where smok-
ing is still very common. City-level 
smoke-free initiatives are neither 
comprehensive nor well-enforced. 
China has weak text-only package 
warnings and no graphic warnings. 
Very cheap brands discourage 
smokers from attempting to quit. 
Despite some bans on direct tobac-
co advertising, there is heavy expo-
sure to tobacco promotion through 
event sponsorships, outdoor dis-
plays, and entertainment media [2].
The future
As part of comprehensive tobacco 
control action, the responsibility for 
tobacco control legislation and the 
WHO FCTC should be removed 
from the dominion of the state to-
bacco monopoly, coupled with an 
effective taxation policy.
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likely to raise the issue with their 
clients. The new social media, 
which includes the Internet and mo-
bile telephony, provides both huge 
challenges and opportunities for 
tobacco control. The challenges 
come from the difficulty of regulat-
ing any pro-smoking activity. The 
opportunities arise from the poten-
tial of social media to provide more 
genuine personal engagement and 
the opportunity for well-informed 
members of the community to be-
come active in communicating the 
messages.
Cessation aids
There is now a range of effec-
tive medications for smoking ces-
sation when used for periods of 
about 6–12 weeks [39–41]. These 
medications, which include nico-
tine itself (as nicotine replacement 
therapy) plus three other drugs (bu-
propion, varenicline, and cytisine, 
which impinge on different aspects 
of the brain’s reward system), are all 
demonstrably effective. There is ev-
idence that using medication for an 
extended period can at least delay 
relapse, but only for the period dur-
ing which the drug is being used.
A wide range of behavioural 
interventions, including structured 
self-help manuals, tailored self-
help resources, quitlines, and face-
to-face individual or group pro-
grammes, all help smokers to quit, 
and the success rates increase with 
increased involvement, up to sev-
eral sessions [40,42]. The effective-
ness of such interventions is direct-
ly related to their intensity, typically 
measured by the amount of sup-
port, at least up to about four sub-
stantial sessions, but beyond that, 
there is little evidence that even 
more intensive interventions are ef-
fective. Intensive advice-based pro-
grammes are increasingly delivered 
via the telephone rather than face-
to-face. Use of automated advice 
programmes, consisting of tailored 
personalized advice on the Internet 
and/or short, frequent advice mes-
sages to mobile phones, is mark-
edly increasing. Both forms of au-
tomated intelligent programmes are 
effective. Combining advice-based 
programmes with medication gives 
the best results as the two seem to 
have largely independent effects 
[40]. There is no evidence of re-
duced relapse associated with any 
intervention after it ceases [43].
Factors that influence smokers 
to try to quit are somewhat different 
to those that influence success in 
quitting [44]. Evidence is also begin-
ning to emerge that determinants of 
short-term success may differ from 
those for long-term maintenance 
[10]. If so, different strategies are 
needed to help those who survive 
the difficult early weeks to maintain 
cessation in the long term, which 
is the ultimate challenge. Although 
this aspect is rarely subject to 
specific investigation, population-
based studies indicate that a small 
percentage of ex-smokers continue 
to use nicotine replacement therapy 
in the long term. E-cigarettes cur-
rently hold the most promise of be-
ing viable substitutes for the largest 
number of smokers, but research 
is needed to document or confirm 
both safety and effectiveness as a 
cessation aid.
The outcome of interventions is 
not only a matter of how effective 
those interventions are when used 
but also a function of what propor-
tion of smokers are prepared to 
use them in their quit attempts. As 
noted above, reference to smoking 
behaviour in the media drives peo-
ple to seek help, as does product-
specific advertising. To achieve the 
highest cessation rates requires 
a population of smokers who are 
motivated to quit, who are prepared 
to use the best possible help, and 
who are able to access aids that will 
maximize success. Uptake of help, 
particularly advice-based help, re-
mains low, even when services are 
subsidized or free. This is probably 
due to a combination of beliefs that 
“I should be able to do this by my-
self” and deep ambivalence about 
change in relation to tobacco use 
and other dependencies. Use of 
services is also influenced by the 
way the services are provided. For 
example, in the United Kingdom, 
there is much greater use of face-
to-face services than there is of a 
well-organized and readily avail-
able network of other services. 
However, in most other countries 
that have systems to provide help, 
telephone-based quitlines are gen-
erally preferred to face-to-face 
services, at least in part due to the 
convenience.
Comprehensive efforts
As recognized by the WHO FCTC, 
efforts on multiple fronts are re-
quired if significant progress is to be 
made in tobacco control [2]. There 
are huge challenges. In low- and 
middle-income countries, govern-
ments may have other priorities and 
sometimes lack the infrastructure 
to support policy. In high-income 
countries, smoking is increasingly 
concentrated among less-advan-
taged socioeconomic groups, fur-
ther exacerbating inequalities. Much 
remains to be done, but progress is 
being made.
Fig. 4.1.6. A WHO poster for World No 
Tobacco Day 2013 calls for legislative 
bans on tobacco advertising, promotion, 
and sponsorship.
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Summary
• In trials, weight loss and in-
creased physical activity have re-
duced the risk of diabetes among 
participants.
• Behavioural weight manage-
ment programmes typically 
produce weight losses of about 
7–10% of initial body weight after 
6–12 months of treatment, and 
increasingly include extended-
care sessions.
• Typical goals in behavioural 
weight loss programmes in-
clude reducing caloric intake by 
approximately 500–1000 kcal 
(2000–4000 kJ) per day and in-
creasing participation in moder-
ate-intensity physical activity to 
250 minutes or more per week.
• Behavioural weight management 
programmes focus on using self-
monitoring, problem-solving, and 
goal setting to enact changes 
to the antecedents and conse-
quences of behaviour.
• Benefits of adhering to weight 
loss, physical activity, and relat-
ed guidelines are being evaluat-
ed in relation to reduced cancer 
incidence in relevant trials.
4.2
4 PREVENTION
Changing behaviours – 
physical activity and 
weight control
Rena R. Wing
Kathryn R. Middleton
Christine M. Friedenreich (reviewer)
Isabelle Romieu (reviewer)
Earlier chapters in this Report (see 
Chapter 2.6 and Chapter 3.5) present 
strong observational evidence that 
obesity and physical inactivity may 
be related to the development of 
some forms of cancer (see “Energy 
restriction, age, and cancer risk”) and 
suggest plausible biological path-
ways for this association. Indeed, 
epidemiological studies suggest that 
physical activity and weight loss can 
lower breast cancer risk and improve 
survival, evidence that researchers 
have suggested warrants further clini-
cal trials investigating the impact of 
behavioural weight management on 
preventing cancer and improving sur-
vival [1]. To develop such studies, it 
is important to understand the basic 
strategies that might be used to help 
individuals change their weight and/
or their physical activity, and the type 
of results that can be achieved.
Outcomes of behavioural 
weight loss programmes
Behavioural programmes typically 
produce weight losses of about 
7–10% of initial body weight after 
6–12 months of treatment. These 
weight losses have been shown 
to have clinically significant health 
benefits. The strongest evidence 
comes from the Diabetes Prevention 
Program, a multicentre randomized 
controlled trial, which demonstrated 
that behavioural weight loss led to 
significantly larger reductions in dia-
betes incidence than did treatment 
with metformin [2]. In that study, more 
than 3000 overweight or obese in-
dividuals with impaired glucose tol-
erance were randomly assigned to 
receive lifestyle intervention, met-
formin (a drug usually used to treat 
diabetes), or placebo. The goals of 
the lifestyle intervention included 
weight loss of at least 7% of initial 
body weight (by decreasing dietary 
fat intake, reducing total caloric in-
take, and increasing physical activ-
ity) and increasing participation in 
moderate-intensity physical activity 
to 150 minutes per week. To reach 
these goals, a 16-session core cur-
riculum was delivered to participants 
individually over the first 6 months of 
the study, with continuing contact (at 
least once every 2 months) during the 
remainder of the trial. The Diabetes 
Prevention Program trial was stopped 
early (after an average of 3.2 years 
of follow-up) because of the positive 
effects of lifestyle intervention on dia-
betes incidence.
The lifestyle intervention resulted 
in an average weight loss of 6.5 kg at 
the end of the core curriculum and 
a weight loss of 4.5 kg at 3 years. 
Of participants in this arm, 49% 
achieved the 7% weight loss goal 
at 6 months and 37% at the final 
visit. On average, physical activity 
increased to 224 minutes per week 
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at the end of the core curriculum and 
227 minutes at the end of the trial. 
The exercise goal was achieved by 
74% of participants at week 24 and 
67% at the final visit.
Although they are relatively mod-
est, these weight losses and increas-
es in physical activity produced dra-
matic effects on diabetes incidence. 
The lifestyle intervention reduced the 
risk of developing diabetes by 58% 
relative to placebo. Weight loss was 
the dominant predictor of the reduced 
incidence of diabetes. Moreover, 
when participants were followed up 
for 10 years, the benefits of lifestyle 
intervention for preventing diabetes 
were still apparent, although there 
were no longer any differences in 
weight loss between the three arms. 
As diabetes has been demonstrated 
to be an independent predictor of 
cancer mortality (beyond body mass 
index) [3], the impact of intervention 
on diabetes incidence suggests that 
these trials may be beneficial for low-
ering cancer mortality.
The findings from the Diabetes 
Prevention Program, indicating that 
modest weight losses and increases 
in physical activity can be achieved 
and can have important health ben-
efits, have been confirmed recently 
in another clinical trial, called Look 
AHEAD. The Look AHEAD study 
involved more than 5000 overweight 
or obese individuals with type 2 
diabetes, who were assigned to an 
intensive lifestyle intervention or the 
control group [4]. The lifestyle inter-
vention was similar to that used in 
the Diabetes Prevention Program, 
but participants were given a higher 
physical activity goal of 175 minutes 
per week and encouraged to lose 
10% of their initial body weight, and 
meal replacement products were pro-
vided to increase adherence to the 
dietary prescription. The intervention 
was delivered in group format with 
periodic individual sessions; partici-
pants were seen weekly for the first 
6 months, seen 3 times per month 
for months 7–12, and then seen or 
contacted by phone or e-mail at least 
twice a month. Participants in the life-
style intervention arm had lost an av-
erage of 8.6% of their body weight at 
1 year (vs 0.7% in the control group). 
At 4 years, participants in the inten-
sive lifestyle intervention group had 
maintained on average a loss of 4.7% 
of their initial body weight, whereas 
the control group had maintained 
a loss of 1.1%. Fitness levels also 
improved markedly in the lifestyle 
intervention group relative to the 
control group at both 1 year and 
4 years. Improvements in glycae-
mic control and in several important 
cardiovascular risk factors were 
greater in the intensive lifestyle in-
tervention group than in the control 
group throughout the 4 years [5]. The 
long-term results of the Look AHEAD 
trial, which indicate many health ben-
efits of intensive lifestyle intervention 
but a lack of benefit for cardiovascular 
morbidity and mortality, will be de-
scribed in future publications.
Indications of possible cancer-
related benefits of behavioural weight 
loss programmes have been evi-
dent for more than a decade. Thus, 
a randomized trial of a physical- 
activity-based weight management 
programme in breast cancer survi-
vors (n = 68) demonstrated larger 
weight losses in the treatment group 
compared with the control group 
(5.7 kg vs 0.2 kg) and favourable 
changes in levels of inflammatory 
cytokines for intervention partici-
pants but not for control participants 
[6]. Furthermore, within participants 
assigned to the treatment group, par-
ticipation in physical activity was sig-
nificantly associated with favourable 
changes in interleukin-6 levels.
Theoretical premise of 
behavioural weight loss 
programmes
Behaviour-based weight loss pro-
grammes, such as those used in 
the Diabetes Prevention Program 
and Look AHEAD trials, are based 
primarily on social learning theory 
[7]. These programmes focus on 
helping individuals make long-term 
changes in both their eating and 
exercise behaviours to produce 
weight loss and maintenance. This 
approach assumes that providing in-
formation about diet and activity may 
be important and helpful to individu-
als but is not sufficient. Rather, it is 
important to help people understand 
their current eating and exercise 
behaviours and the variables that 
are influencing these behaviours 
(e.g. to appreciate the learned con-
nection between going to the mov-
ies and eating popcorn). Behavioural 
treatment programmes then focus 
on teaching participants strategies 
for changing the variables that are 
Fig. 4.2.1. An 8-year-old girl from the Rayerbazar area of Dhaka, Bangladesh, breaks 
through the ribbon during a race. Positive experiences and attitudes to physical activity 
may lead to long-term benefits in relation to diabetes and cancer.
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leading to inappropriate eating and 
sedentary behaviour as well as ways 
to evaluate the effect of the changes 
on their eating and exercise habits 
and ultimately their body weight.
Format of behavioural weight 
loss programmes
Typically, behavioural weight loss 
programmes are offered in group set-
tings, with about 10–20 participants 
treated together. Groups are often 
closed-format; participants all start 
at the same time and remain in the 
same group. Meetings (typically 
60 minutes long) are held weekly for 
6 months, every 2 weeks for the next 
6 months, and then monthly for the 
following 6 months. This extended 
schedule of treatment contact has 
been shown to improve long-term 
outcomes [8]. Groups are typically 
led by a multidisciplinary team of 
nutritionists, exercise physiologists, 
and behavioural therapists. The pro-
tocols for the lifestyle intervention 
used in the Diabetes Prevention 
Program and Look AHEAD trials are 
available online.
Energy balance
Change in body weight is influ-
enced by the balance of caloric 
intake relative to caloric expendi-
ture. Thus, behavioural interven-
tions typically focus on lower-
ing caloric intake – typically by 
approximately 500–1000 kcal 
(2000–4000 kJ) per day – while 
increasing physical activity. The 
dietary and physical activity com-
ponents of the energy balance are 
reviewed below, and recommenda-
tions are offered.
Energy restriction, age, and cancer risk
Piet van den Brandt
Caloric restriction (CR) – reduced 
energy intake without malnutrition – 
is the most robust nutritional inter-
vention known to date that increases 
lifespan in many species, such as 
yeast, nematodes, fruit flies, and 
mammals [1]. In rodents exposed to 
young-onset CR (age, 1–3 months), 
CR inhibits spontaneous and in-
duced tumours in various organs. 
Effects of middle-age-onset CR on 
cancer risk are less clear, although 
beneficial effects are seen on age-
related processes. In mice, a CR 
of 15–53% below usual ad libitum 
intake resulted in a proportionate 
linear reduction of 20–62% in tu-
mour incidence. Effects of CR seem 
larger on spontaneous tumours: a 
meta-analysis showed 55% fewer 
spontaneous mammary tumours, 
with no heterogeneity according to 
study characteristics such as age, 
duration and degree of CR, and nu-
trient type.
Two 20-year-long randomized 
trials in nonhuman primates have 
evaluated the effects of long-term 
CR on mortality and cancer risk in 
rhesus monkeys. In the Wisconsin 
National Primate Research Center 
(WNPRC) trial, an adult-onset CR 
of 30% non-significantly reduced 
overall mortality; incidence of cancer 
(gastrointestinal adenocarcinoma) 
was reduced by 50% compared with 
apes fed ad libitum. The National 
Institute on Aging (NIA) trial investi-
gated moderate CR in young and old 
monkeys and found no differences 
in survival. Nevertheless, cancer 
incidence was significantly reduced 
in monkeys with young-onset CR 
compared with controls [2]. Several 
differences between these two trials 
limit the ability to draw conclusions, 
including less CR, a healthier control 
diet, and no ad libitum controls in 
the NIA trial.
Indications that energy restric-
tion may be important for cancer in 
humans stem from observational 
research. Overweight, as an indica-
tor of a positive energy balance, is 
positively related to risk of various 
cancers. With respect to CR, Dutch 
and Norwegian cohort studies of in-
dividuals who experienced 50–70% 
reduced food rationing (for < 1 year) 
in early life during the Second 
World War showed subsequently 
decreased risk of colorectal cancer 
[3] and (less consistently) of breast 
cancer, which may be due partly to 
confounding and malnutrition.
Ecological evidence on CR 
without malnutrition comes from 
Okinawans, who consume 15% few-
er calories than mainland Japanese 
and have markedly lower cancer 
mortality rates. One randomized 
controlled trial is currently under 
way on effects of short-term CR 
(20–25% reduction for 6–12 months) 
in overweight subjects. Risk factors 
for coronary heart disease and 
cancer improved, but CR adherence 
was low in the longer-term group. 
However, applying CR to subjects of 
normal weight to achieve a low-nor-
mal body mass index of < 21 kg/m2 
(as in nonhuman studies) differs 
from applying CR to overweight or 
obese individuals when studying 
health effects [1].
Possible mechanisms underly-
ing beneficial effects of CR involve 
metabolic adaptations to CR, effects 
of CR on tumorigenic processes, for 
example upregulated DNA repair 
and downregulated insulin/IGF-1/
mTOR pathways [1], and epigenetic 
influences [3]. In summary, CR 
has beneficial effects on longevity 
and cancer incidence in different 
species; effects seem clearer with 
young-onset CR. Effects in humans 
remain promising but uncertain due 
to the relatively few randomized con-
trolled trials that have concluded.
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Diet
Calorie goals given to participants 
typically vary by baseline body 
weight [9]. Individuals who weigh 
200 pounds (90 kg) or less at base-
line are given calorie goals of approx-
imately 1200 kcal (5000 kJ) per day, 
whereas those who weigh more than 
200 pounds (90 kg) are given goals of 
1500–1800 kcal (6250–7500 kJ) per 
day. These goals should lead to ca-
loric intake deficits of approximately 
500–1000 kcal (2000–4000 kJ) per 
day, which are associated with a 
weight loss of 1–2 pounds (0.5–1 kg) 
per week. In addition, participants are 
recommended to decrease their fat 
intake, typically by consuming less 
than 25% of caloric intake from fat. 
Furthermore, participants are encour-
aged to increase intake of fruits and 
vegetables while decreasing intake of 
foods that observational studies sug-
gest may be associated with obesity, 
such as sugar-sweetened beverages 
and high-fat snack foods [10].
Physical activity
Participants in behavioural weight 
loss programmes are encouraged 
not only to decrease their caloric in-
take but also to increase their level 
of participation in physical activity. 
This is often approached in two ways: 
(i) by increasing participation in 
moderate-intensity physical activ-
ity and (ii) by increasing overall life-
style physical activity. The American 
College of Sports Medicine [11] 
recommends 150–200 minutes per 
week of moderate-intensity activity 
(such as brisk walking) for individuals 
trying to maintain weight, and more 
than 250 minutes per week for those 
trying to lose weight. Participants 
are encouraged to work up to these 
goals by gradually adding 10 minutes 
per week above baseline. In addition, 
participants typically track unstruc-
tured, lifestyle physical activity using 
pedometers or accelerometers and 
aim to gradually increase their activ-
ity to reach a goal of 10 000 steps 
per day.
Key components of weight 
management programmes
In addition to providing information 
about diet and physical activity, other 
key components of weight manage-
ment programmes focus on improv-
ing self-regulatory skills and changing 
the antecedents and consequences 
of dietary and physical activity behav-
iours. These key components are dis-
cussed below.
Goal setting
Self-regulation is generally viewed as 
an internal process that involves goal 
setting, self-monitoring, and evalu-
ation of success or failure of goal 
achievement. Setting clear goals 
for caloric intake and physical activ-
ity provides structure and direction. 
Individuals are encouraged to set 
goals that are short-term (typically a 
weekly weight loss goal vs a “goal 
weight”), measurable (e.g. eating an 
apple as a snack on three days dur-
ing the week vs “eating more fruit”), 
and attainable (e.g. setting a starting 
activity goal to walk for 15 minutes 
three days per week vs running for 
an hour every day).
Self-monitoring
Self-monitoring, a key step in evaluat-
ing progress towards goal achieve-
ment, may involve keeping records 
of body weight, caloric intake (as indi-
cated by food consumed), and physi-
cal activity (by using a pedometer or 
accelerometer). Self-monitoring al-
lows individuals to assess their prog-
ress towards goals and to receive 
feedback on the adequacy of their 
goal-directed behaviours. Adherence 
to self-monitoring has been demon-
strated to be significantly associated 
with success in both weight loss and 
long-term maintenance of weight loss 
[12].
Problem-solving skills
Problem-solving is a process by 
which individuals can address bar-
riers to behaviour change [13]. 
Typically, problem-solving includes 
five distinct steps (Box 4.2.1). An ex-
ample of a problem-solving partici-
pant worksheet is shown in Fig. 4.2.2. 
The five-step problem-solving model 
is generally viewed as an iterative 
process, and if the chosen solution 
does not adequately address the 
barrier, individuals are encouraged 
to cycle back to steps 3 and 4 to try 
alternative solutions.
Changing behavioural 
antecedents
Behaviour is affected both by ante-
cedents – events that happen before 
the given behaviour – and by conse-
quences, which are both positive or 
negative events that occur after the 
behaviour (Fig. 4.2.3). For example, 
an individual’s choice of lunch can 
Step 1.
Positive problem orientation.
The view that problems are a nor-
mal part of behaviour change ver-
sus evidence of overall failure.
Step 2.
Problem definition.
Individuals clearly describe the bar-
rier to change in objective, concrete 
terms.
Step 3.
Generation of alternatives.
Individuals brainstorm potential so-
lutions, seeking quantity of ideas 
over quality.
Step 4.
Decision-making.
Participants evaluate decisions to 
decide which would be the best so-
lution to the given problem.
Step 5.
Solution implementation 
and verification.
Participants implement the chosen 
solution and evaluate (through self-
monitoring) whether this solution 
works.
Box 4.2.1. Problem-solving skills training: the five-step problem-solving model.
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be affected by their environment, and 
specifically the availability of nearby 
restaurants, and by thoughts and 
feelings (such as cravings, or feeling 
stressed or upset). These anteced-
ents can often be manipulated by 
participants to assist with health be-
haviour change, as discussed below.
Stimulus control
Environmental factors have been 
demonstrated to affect both eating 
behaviours and physical activity. 
For example, the easy availability of 
high-calorie, highly palatable “junk 
food” can increase caloric intake, 
and lack of recreation facilities, safe 
walking areas, or sidewalks can de-
crease participation in physical ac-
tivity. Individuals have some control 
over their environments and can 
often enact positive environmental 
change at home and work.
Changing cognitions
Thoughts and feelings can also rep-
resent the antecedents in Fig. 4.2.3. 
According to the cognitive behav-
ioural model of behaviour, an individ-
ual’s thoughts affect their feelings, 
which can then affect behaviour. 
Thus, a person having the thought 
“I’ll never be able to lose weight” is 
likely to feel upset, frustrated, or an-
gry, which may lead to the behaviour 
of overeating or avoiding planned 
exercise. The process of cogni-
tive restructuring involves identify-
ing maladaptive thoughts, labelling 
these thoughts, and replacing them 
with more rational thoughts. For ex-
ample, the thought “I’ll never be able 
to lose weight” can be replaced with 
the thought “I may have had a chal-
lenging week, but I’ve lost 15 pounds 
so far and can recover from this slip.”
Changing behavioural 
consequences
In addition to changing behavioural 
antecedents, the consequences of 
behaviour can be modified to affect 
future behaviour. Individuals will be 
more likely to engage in a behaviour 
if it is tied in with a reward versus 
a punishment. Thus, manipulating 
the consequences of behaviour can 
lead to positive behaviour change. In 
general, individuals are encouraged 
to use non-food rewards, such as 
stickers, positive notes, buying new 
clothing, and so on. Increasing social 
support for behaviour change and 
use of programmatic incentives have 
also been demonstrated to lead to 
positive behaviour change.
Social support
A group format for lifestyle weight 
management interventions has been 
used to invoke social support for in-
dividual behaviour change. Group 
cohesion has been shown to en-
hance the effectiveness of weight 
management treatment, even for 
people who indicate before interven-
tion that they would prefer individual 
treatment. Sharing success at be-
haviour change with the group can 
elicit positive support, acting as a 
social reward for the individual.
Incentives
The use of incentives in weight 
management stems from literature 
in behavioural economics, which has 
demonstrated that people tend to 
discount long-term rewards in favour 
of short-term gains. This applies to 
weight management in that long-
term benefits of improved dietary and 
activity behaviours, including weight 
loss and improvements in metabolic 
risk factors, can be less motivat-
ing than short-term benefits such 
as the pleasure of eating or being 
Fig. 4.2.2. An example of a problem-solving worksheet for programme participants.
Fig. 4.2.3. The A-B-C model of behaviour.
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sedentary. Incentives for behaviour 
change and weight loss can provide 
additional reinforcement to the con-
sequence end of the model shown 
in Fig. 4.2.3. Monetary incentives 
or deposit contracts, where partici-
pants deposit money that is returned 
only if they meet programme goals, 
have been shown to improve initial 
treatment results, but their long-term 
effects are still unclear [14].
Maintenance of weight loss
Long-term maintenance of weight 
loss has remained a substantial 
challenge [15,16]. After an interven-
tion ends, individuals tend to regain 
lost weight, typically regaining one 
third to one half within 1 year of the 
end of treatment and returning to 
baseline weight within 3–5 years 
after treatment [17]. Research has 
focused on identifying factors that 
improve the long-term maintenance 
of weight loss; to date, one of the 
most successful factors has been 
the provision of extended care. A 
recent review of the literature on 
maintenance of weight loss sug-
gested that the provision of extended 
care leads to the maintenance of an 
additional 3.2 kg of weight loss over 
17.6 months after the intervention 
compared with the control group [8]. 
Researchers are currently working 
to develop additional approaches to 
improving long-term maintenance of 
weight loss.
In addition, individual factors 
that promote long-term mainte-
nance have been investigated. 
Using a national registry of people 
who have been successful in losing 
at least 13.6 kg and maintaining this 
loss for at least 1 year, research-
ers have found that people who are 
successful at maintaining weight 
loss tend to continue to consume 
a low-calorie, low-fat diet, eat 
breakfast, regularly self-monitor 
body weight and food intake, and 
engage in high levels of physical 
activity [18].
Dissemination and novel 
interventions
While behavioural weight manage-
ment programmes have demonstrat-
ed efficacy and effectiveness, dis-
semination remains a barrier to wide 
access to treatment. Cost and avail-
ability of trained staff often limit the 
reach of these programmes, espe-
cially the high-intensity programmes 
most often delivered in research 
settings: typically 3–6 months of 
weekly groups, followed by several 
months of extended-care groups, 
meeting every 2 weeks and then 
monthly. Thus, increasing research 
has focused on lower-cost deliv-
ery of these programmes, includ-
ing stepped-care, phone-based, 
and Internet-based programmes. 
Interventions using newer self-
monitoring technologies, including 
activity monitors and smartphone 
applications that allow individuals to 
track their weight, food intake, and 
activity, hold promise as access to 
computers and smartphones across 
the population has been increasing 
substantially.
Fig. 4.2.4. A display of fresh produce on a market stall in the Netherlands. Increasing 
intake of fresh fruits and vegetables and avoiding bringing high-fat snack foods into the 
home can lead to health benefits.
Fig. 4.2.5. The National Health Service in the United Kingdom has a website on healthy 
living, called Change4Life. The “Eat well” section of the website enables people to plan 
healthy meals.
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EPIC as a model study vehicle
Elio Riboli
The European Prospective Inves- 
tigation into Cancer and Nutrition 
(EPIC) was developed at IARC, in 
close collaboration with several 
major national research institu-
tions, as a long-term multicentre 
prospective cohort study in west-
ern Europe designed specifically 
to investigate the relationship be-
tween lifestyle, diet, and cancer. 
Enrolment of EPIC participants 
began in 1992, with the invitation 
of mainly healthy subjects aged 
35–70 years from the general pop-
ulation in certain geographical ar-
eas. By the end of the recruitment 
phase, in 2000, EPIC was the larg-
est prospective cohort study with 
a baseline biorepository aimed at 
investigating cancer etiology, with 
521 330 participants from 23 study 
centres in 10 European countries.
Participants completed ques-
tionnaires on diet and lifestyle 
factors, including physical activ-
ity, and underwent measurements 
of anthropometric characteristics 
(e.g. weight, height, waist and hip 
circumferences), blood pressure, 
and pulse rate. Anonymized data 
are stored in a central secured da-
tabase at IARC. EPIC was the first 
prospective study to collect and 
store blood from such a large num-
ber of participants: 388 467 blood 
samples of 30 ml each were col-
lected and aliquoted into 28 plastic 
straws stored in liquid nitrogen, with 
aliquots divided between the central 
biorepository at IARC and each na-
tional centre. Since initial baseline 
collection, EPIC participants have 
been followed up to monitor changes 
in major dietary and lifestyle fac-
tors. Follow-up aimed at identifying 
cancer cases and dates and causes 
of death occurring among the EPIC 
cohort is principally based on record 
linkage with data from population 
cancer registries and regional or 
national death registries [1].
The design of the EPIC co-
hort is key to facilitating stud-
ies of cancer etiology. It was the 
first prospective study with a be-
spoke biorepository of its size 
in the world. Wide geographical 
coverage also means that EPIC 
includes populations with varying 
dietary and lifestyle habits and dif-
ferent underlying cancer incidence 
rates; this strategy was conceived 
to increase the overall statistical 
power to identify diet–disease re-
lationships. The range of data as 
well as biological samples that 
were collected before diagnosis 
from the same population enables 
integrated analyses of cancer risk 
factors. Finally, through long-term 
follow-up spanning almost two 
decades, more than 60 000 newly 
incident cancer cases have been 
reported, giving scope for well-
powered studies.
EPIC has proven to be a power-
ful resource to investigate the asso-
ciation between complex nutritional, 
metabolic, and genetic characteris-
tics and cancer risk. An example 
is the identification using EPIC 
of links between metabolic syn-
drome and cancer risk. Metabolic 
syndrome is a cluster of metabolic 
abnormalities, including abdominal 
obesity, elevated blood pressure, 
abnormal glucose metabolism, and 
dyslipidaemia. It was shown that 
individual components of meta-
bolic syndrome, such as insulin 
resistance (as measured by serum 
C-peptide levels) and central obe-
sity, are associated with increased 
risk of several types of cancer [2]. 
While metabolic syndrome was 
associated with colorectal cancer 
risk, this could be accounted for by 
individual components of the syn-
drome, namely abnormal glucose 
Fig. B4.2.1. Relative risk of premature death in men and women in EPIC in relation to waist circumference, adjusted for body 
mass index, age, smoking status, education level, alcohol consumption, physical activity, and height.
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metabolism and central obesity, in-
dicating that complex definitions of 
metabolic syndrome may not be of 
additional clinical utility in identify-
ing individuals at increased risk of 
colorectal cancer.
Concerning central obesity, 
EPIC data allowed clarification of 
the apparent paradox by which 
being very slim (body mass index 
[BMI], 20–23 kg/m2) and being 
overweight (BMI, 26–30 kg/m2) 
appeared to be associated with 
similarly higher risk of all-cause 
mortality in adult life, compared 
with having a medium BMI (about 
24–25 kg/m2). This paradox was 
often described as a J-shaped 
risk function of BMI versus mortal-
ity rates. EPIC showed that waist 
circumference adjusted for BMI is 
linearly related to the risk of pre-
mature death, that having a slim 
waist is associated with the lowest 
mortality, and that the apparent ex-
cess is due to individuals with low 
BMI but with low muscular mass 
and excess abdominal adiposity 
(Fig. B4.2.1) [3].
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Given the evidence that ex-
cess body weight and low levels 
of physical activity are associated 
with cancer risk and poorer survival 
outcomes (see “EPIC as a model 
study vehicle”), there is a need to 
conduct clinical trials to determine 
whether behavioural weight loss 
interventions can improve surviv-
al and/or help to prevent cancer 
[1]. Behavioural weight loss pro-
grammes are effective in helping 
participants lose 7–10% of their ini-
tial body weight; these weight losses 
produce numerous health benefits 
and should be evaluated further for 
cancer prevention and survival. A 
current randomized controlled trial, 
including 962 patients in 40 centres, 
is investigating the impact of physi-
cal activity on disease outcome in 
colon cancer survivors [19].
Data relating to cancer out-
comes affected by adherence to 
weight control and/or physical 
activity guidelines are becoming 
available. Consequences of adher-
ence to World Cancer Research 
Fund recommendations were moni-
tored among approximately 30 000 
postmenopausal women aged 50–
76 years at baseline in 2000–2002 
Fig. 4.2.6. Paradoxically, sport shown on television may play a role in determining 
sedentary behaviour.
with no history of breast cancer. 
Meeting these cancer prevention 
recommendations, specifically those 
related to alcohol, body fatness, 
and intake of plant foods, was as-
sociated with reduced breast cancer 
incidence [20]. Benefits to cancer 
survivors have also been observed 
[21]. Cancer prevention through 
promotion of physical activity and 
dietary change in cancer screen-
ing settings is also being explored 
[22]. Future trials will investigate 
the role of weight loss and/or in-
creased physical activity in primary 
prevention of various tumour types. 
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Summary
• Population-wide campaigns can 
be an effective and efficient way 
to modify cancer risk in popu-
lations where more immediate 
channels of personal commu-
nication and influence are not 
feasible.
• In the design and evaluation of 
campaigns, a balance should 
be struck between influencing 
the environment and context in 
which individual cancer-related 
behaviours take place, and the 
intrapersonal determinants of 
those behaviours.
• Hypothesized causal pathways 
for change in individuals should 
be specified in advance, as this 
will help focus the interventions 
that make up the campaign as 
well as defining measures of 
outcome that will demonstrate 
and explain effects.
• Campaign messages need to 
take into account psychological 
factors that oppose, and facili-
tate, change in cancer-related 
behaviour.
• All campaigns should be subject 
to evaluation using specified cri-
teria, particularly with reference 
to novel elements.
4.3
4 PREVENTION
Designing and evaluating 
population-wide campaigns
David Hill
Melanie Wakefield
Joakim Dillner (reviewer)
Surendra S. Shastri (reviewer)
• While campaigns should be 
sensitive to local cultural fac-
tors, there is evidence that many 
campaigns can be successfully 
re-used or adapted for use in dif-
ferent countries.
When is a campaign the right 
approach?
Population-wide campaigns for pri-
mary or secondary prevention of 
cancer should be considered when 
the risk or risk factors for a prevalent 
cancer are spread widely through a 
population. Such campaigns invari-
ably make use of mass media, of-
ten through carefully planned paid 
advertising, as well as other simul-
taneous communication and policy 
interventions. Campaigns would 
not normally be considered for rare 
tumours or those concentrated in 
subpopulations, such as in certain 
occupations or locations, or for in-
fluencing risk behaviours in small 
demographic subgroups. There are 
almost certainly other more effec-
tive and efficient alternative ways to 
directly communicate and influence 
risk in such cases, for instance by 
communicating at antenatal clinics 
where pregnant smokers are con-
centrated, or by using broadcast or 
print media in the preferred language 
of a targeted population subgroup.
Campaigns in cancer preven-
tion are often conceived and fund-
ed by public health authorities as 
time-limited operations, whereas 
in reality their objectives can rarely 
be achieved or maintained without 
long-term investment of time, effort, 
and money. A cancer prevention 
campaign is better thought of as a 
health service for which the need is 
continuous (such as palliative care 
or ambulances) than as a “project” 
that has a defined end.
This chapter considers cam-
paigns where the objective is to 
change a defined cancer-related 
behaviour in members of a defined 
population. It is not concerned with 
cancer “awareness-raising” cam-
paigns. Indeed, such campaigns are 
of questionable public health value. 
Sometimes awareness-raising cam-
paigns can do harm, as when pros-
tate cancer awareness leads to inap-
propriate screening for the disease 
and to harms that at least arguably 
outweigh any benefits [1,2]. Neither 
should campaigns be undertaken as 
a substitute for potentially effective 
public health policy and regulation. 
Rather, they should build on good 
policy and generate public accept-
ance of the need for regulations 
that facilitate change in behaviours 
known to increase cancer risk.
Campaigns can be implemented 
for primary or secondary prevention, 
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but their use in secondary preven-
tion is more limited. Since second-
ary prevention depends principally 
on there being a means of detecting 
cancer early enough for treatment to 
be more effective than otherwise, 
health services (for screening, diag-
nosis, and treatment) need to be in 
place before the appropriate target 
group is invited or persuaded to at-
tend. Contacting individuals directly 
with invitation letters is far more ef-
fective than public advertising of a 
service alone [3], so a campaign is 
not likely to be a major element in 
secondary prevention. In addition, 
unless the relevant health services 
are equally available to all members 
of a target population, population-
wide campaigns would generate de-
mand that could not be met. Thus, 
when screening services are intro-
duced into a population in stages, it 
makes little sense to use mass me-
dia to communicate. However, as-
suming that all required services are 
ready, there may be a limited role 
in the early stages for mass com-
munication to engender a level of 
awareness and public understand-
ing to prime acceptance of personal 
invitations when they arrive. Later in 
the programme’s life, there may also 
be a role for mass media in refresh-
ing public interest should participa-
tion rates start to fall [4]. Overall, 
mass media campaigns alone are 
unlikely to achieve desired participa-
tion rates for secondary prevention 
programmes.
Habitual and non-habitual 
behaviours
There is a fundamental distinction 
to be made between strategies de-
signed to change risky habitual be-
haviours such as tobacco use, over- 
nutrition, under-exercising, and al-
cohol consumption, and strategies 
aimed to prompt an individual to act 
only once or twice – such as human 
papillomavirus (HPV) or hepatitis B 
virus (HBV) vaccination – or inter-
mittently, as is required for effective 
screening. Campaigns to change 
habitual behaviours are far more 
difficult to implement successfully. 
The norm is for incremental change, 
at best, in population rates of a ha-
bitual target behaviour, whereas 
participation rates approaching 
50% may rapidly follow the introduc-
tion of a screening or vaccination 
service that was supported by direct 
invitations and media publicity [5,6].
Habits are the result of a per-
son’s lifelong operant learning 
history, and are likely to be highly 
resistant to change. In the case of 
tobacco at least, the difficulties of 
reversing a habit are further com-
plicated by the addictive qualities of 
nicotine. Nevertheless, campaigns 
have been shown to be effective 
in changing population risk behav-
iours, including tobacco use, albeit 
at incremental levels. It is notewor-
thy that small percentage changes 
in risk factor behaviours equate to 
large numbers of people when a risk 
factor is common, and that where 
relative risks are large, the potential 
for reducing early death is substan-
tial. Furthermore, small percentage 
changes that are sustained over 
several years add up to big effects. 
As well as initiating trends, cam-
paigns play a vital role in sustaining 
them [7,8].
Types of campaign message
Formulating the campaign message – 
what the communication actually 
says to the target individual and how 
it is said – is at the core of campaign 
planning. Judicious application of 
psychological knowledge is helpful, 
if not essential. It is important that 
campaign planners are explicit about 
the way in which their message is 
expected to influence the receiver, 
because this sharpens the focus of 
the intervention and assists in formu-
lating measures to evaluate whether 
the campaign is “working”. Many lab-
oratory studies have investigated the 
underlying nature of effective health 
messages – for instance, the rela-
tive merits of gain- or loss-framed 
wording [9] – but the applicability 
of results obtained to population-
wide communications is uncertain. 
A smaller number of studies have 
explored message characteristics 
as they apply to broadcast cancer 
prevention campaigns [10].
A common issue is when, and 
when not, to use confronting, shock-
ing, or “scary” message content [11]. 
One would hesitate to use such mes-
sages to promote participation in 
cancer screening. This is because 
people contemplating a screening 
offer are likely in a psychologically 
conflicted “approach–avoidance” 
state of mind, in which they are at-
tracted by the possibility that they will 
get a reassuring all-clear report but 
at the same time are fearful of (and 
wishing to avoid) the possibility of a 
cancer diagnosis. Hence, a message 
Fig. 4.3.1. Series of images from a video used by Australia’s National Tobacco Campaign 
in 1997–2001. This particular advertisement highlighted how smoking causes arteries to 
become blocked, graphically emphasizing that “every cigarette is doing you damage”.
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emphasizing how bad cancer can 
be might simply amplify avoidance 
without influencing approach ten-
dencies. Positive portrayals of the 
reassurance offered by a favourable 
test result might be more effective. 
In contrast, scary messages are ap-
propriate for a person contemplating 
quitting smoking, who has an “avoid-
ance–avoidance” conflict between 
wanting to avoid lung cancer and 
wanting to avoid withdrawal symp-
toms. Messages that increase the 
desire to avoid lung cancer – by us-
ing vivid imagery, or eliciting pow-
erful negative emotions through the 
use of personal testimonials or by 
dramatizing someone confronting 
a situation in which members of 
the target audience could envision 
themselves – might well tip the bal-
ance in favour of behaviour change 
in the smoker, who may then be 
more willing to tolerate withdrawal 
symptoms to avoid the feared health 
consequences.
In recent years, there has been a 
body of work on the efficacy of spe-
cific cancer prevention messages 
in different populations around the 
world, and certain principles stand 
out. At least in tobacco control, mes-
sages that communicate the serious 
health harms of smoking by elicit-
ing emotional discomfort in viewers 
elicit similar responses in smokers 
in many countries of the world, sug-
gesting great potential for sharing 
and recycling of advertisements 
across jurisdictions. These kinds of 
messages have high memorability, 
elicit early responses predictive of 
smoking behaviour change across 
many population subgroups within 
and between countries, and are more 
likely to generate cessation attempts 
in response to campaign exposure. 
This suggests that they are likely to 
be effective messages for wide dis-
semination [12–16]. Overall, this re-
search supports the assumption on 
which many campaigns have been 
based: that an underlying dynamic 
of health behaviour change arises 
from a desire to reduce psychologi-
cal discomfort felt when continuing 
to engage in the risk behaviour.
Campaign formulation
Prevention campaigns are usually 
created and implemented by teams 
of professionals from varying back-
grounds, who all contribute according 
to their skills. The teams may include 
behavioural scientists, medical ex-
perts, health promotion specialists, 
copywriters, graphic designers, film-
makers, media specialists, journal-
ists, and so on. Consistent messag-
ing therefore needs to be built on a 
shared understanding of the way in 
which the communications are ex-
pected to influence the behaviour 
of people who are the targets of the 
campaign. Ideally, a small group, 
which includes a behavioural scien-
tist experienced in such campaigns, 
would develop a behavioural model 
tailored to this campaign. Useful 
models can be found in the literature 
(Box 4.3.1) [17,18].
Models are based on principles 
derived from basic research in the 
behavioural sciences, for instance, 
in the fields of cognition, social 
learning, operant conditioning (pos-
itive and negative reinforcement), 
memory, modelling, motivation, and 
self-efficacy. By their nature, mod-
els in the theoretical literature are 
comprehensive and it is not always 
useful to try to apply them entirely 
in formulating a campaign. Rather, 
the planning group should take in-
spiration from them and then cre-
ate and articulate a model suited to 
the intended campaign. The model 
becomes the reference point for 
all those who apply their creative 
talents to developing the campaign 
[19].
Fig. 4.3.2. Poster from the Spanish 
Association against Cancer (AECC) cam-
paign for skin cancer prevention: “Stand 
up to the sun. Protect yourself against the 
sun. Whenever outside, put sunscreen 
on. At the beach or swimming pool, wear 
a shirt, a hat, and sunglasses. Don’t let 
them go into the sun between 12 and 
4 pm. Even in the shade, you have to pro-
tect yourself.”
Hill and Dixon [18] proposed a set 
of principles they call the “Big Five”, 
which encapsulate a large body of 
psychological and behavioural re-
search on determinants of human 
behaviour.
Few, if any, cancer-related be-
haviours are the result of a 
single influence, so it follows 
that the more determinants a 
campaign can activate simulta-
neously, the more likely it is that 
change will occur.
Change in behaviour is likely to 
occur to the extent that a person:
1. Wants to do it (motivation)
2. Sees others doing it (modelling)
3. Has the capacity to do it (re-
sources and self-efficacy beliefs)
4. Remembers to do it (memory)
5. Is reinforced for doing it, or suf-
fers for not doing it (positive and 
negative reinforcement).
The “Big Five” principles can be 
used in campaign planning as a 
checklist to maximize forces for 
population behaviour change.
Box 4.3.1. “Big Five” principles of behaviour change
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As well as making explicit the in-
tended pathways of influence of cam-
paign communications, the elements 
of a behavioural model enrich the 
campaign by providing a checklist of 
opportunities to intervene. Most be-
haviours, and certainly those behav-
iours involved in cancer prevention, 
have multiple “causes”. It therefore 
follows that the more of these causes 
can be influenced by the campaign, 
the more likely it is that behaviour 
change will occur. For instance, a 
campaign that not only modelled the 
desired behaviour in a respected per-
son but also strengthened motivation 
by communicating a fresh reason to 
change and promised positive rein-
forcement would more likely be ef-
fective than one that relied solely on 
modelling.
Market segmentation
Commercial marketing assumes a 
product or products that can be ren-
dered relatively more attractive to a 
consumer. Different products can be 
created, varied, and packaged for 
population segments in ways that 
recommended health behaviours 
cannot. But even assuming that a 
behaviour can be equated to a prod-
uct, one cannot create variants of the 
behaviour simply to suit the tastes of 
population segments.
Experience with primary preven-
tion campaigns generally suggests 
that at any given time only a certain 
proportion of those at risk are ready 
to consider behaviour change. This 
is the segment that mass communi-
cations are most likely to activate. 
This is also a reason why campaigns 
need to extend over long periods: 
so that they will influence new seg-
ments or “waves” of people as they 
become ready to change.
That good health and avoiding 
disease is a universal (i.e. “unseg-
mented”) human aspiration probably 
explains the fortunate finding that 
anti-smoking television advertise-
ments made in high-income coun-
tries can readily be adapted for ef-
fective use in campaigns in low- and 
middle-income countries [12,16,20].
Channels of communication
The choice of channels to reach a 
target audience should be based on 
analysis of that population group’s 
exposure to various communication 
channels. Such data are usually 
available commercially in low- and 
middle-income countries as well as 
high-income countries. This analysis 
will underpin media planning deci-
sions about relative balance of effort 
and expenditure between television, 
radio, print, outdoor, transit, direct 
mail, and so on.
Although social media such as 
Facebook and Twitter are likely to be 
a means to achieve advocacy goals 
and strengthen the impact of broad-
cast campaigns to change cancer-
related behaviour, the evidence base 
remains small [21]. However, prom-
ising results have been reported for 
pioneering work in low- and middle-
income countries, including Viet 
Nam and Egypt [22,23].
Evaluation
It is helpful to think of a campaign as 
a hypothesis (or set of hypotheses) 
to be tested. Whether the campaign 
will “work” can never be known in 
advance, no matter how well ground-
ed it is in prior research. Every new 
campaign will have novel elements, 
if only because it should be formu-
lated to resonate with the specific 
culture in which it is implemented. 
Those implementing campaigns 
should pay as much attention to 
evaluation as to implementation, 
since that is the path to continuous 
improvement.
Careful pre-testing of campaign 
elements can lead to final improve-
ments in communications before the 
campaign is launched. It may give 
useful insights into how the campaign 
will be received and how to manage 
misunderstandings or other difficul-
ties that may arise [23]. Most cam-
paigns rely heavily on self-reports 
from individuals, so it is important 
to use forms of questioning that 
minimize response bias [24] and 
that preferably have been validated 
objectively (e.g. biochemical valida-
tion of smoking status, or unobtru-
sive observation).
Fig. 4.3.3. The “Move against Cancer” 
campaign of the Lalla Salma Association 
Against Cancer (Morocco): “30 minutes 
of daily exercise is enough to reduce the 
risks of cancer. Do not wait to be in danger. 
Move against cancer.”
Fig. 4.3.4. Front page of a leaflet produced 
by the Hong Kong Cancer Fund as part of 
a campaign for cervical cancer preven-
tion: “Dual protection: regular Pap test and 
vaccination. The best protection against 
cervical cancer.”
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It is when measures of campaign 
effectiveness are being considered 
that the investment in clear articu-
lation of hypothesized pathways 
of influence, as mentioned above, 
becomes apparent. The campaign 
evaluation should aim to quantify 
change at as many points as pos-
sible in the pathway, not merely 
the targeted risk behaviour itself. 
For instance, a campaign aiming to 
get smokers to make a cessation 
attempt by broadcasting new mes-
sages about macular degeneration 
should use representative sam-
ple surveys to assess population 
changes in knowledge about macu-
lar degeneration and to test whether 
such knowledge was associated with 
intentions to quit, as well as to as-
sess changes over time in quitting 
behaviour itself.
As well as being effective, cam-
paigns should be cost-effective – 
meaning they should achieve pre-
vention outcomes at a lower per 
capita cost than alternative ap-
proaches. For example, there is 
good evidence that anti-tobacco 
campaigns and skin cancer preven-
tion campaigns are cost-effective 
[25,26]. Unsurprisingly, tobacco 
control campaigns (together with 
rigorous evaluations) have been the 
most common, leading to a substan-
tial knowledge base, some of which 
has relevance for campaigns on 
other cancer risk behaviours.
Examples of successful 
campaigns
Anti-tobacco
An early, landmark campaign was 
the New South Wales “Quit. For Life” 
campaign (starting in 1983), which 
used a powerful image of tar being 
squeezed from a sponge to convey 
the build-up of carcinogenic partic-
ulate matter in lungs from tobacco 
smoke. The campaign resulted in 
an estimated short-term reduction 
in smoking prevalence of 2.8% [27]. 
This effect was replicated with the 
onset of the campaign in the adjoin-
ing state of Victoria the following 
year [28].
California conducted a well-
funded and long-term campaign 
and showed reductions in smoking 
prevalence, resulting in a 4% differ-
ence between California and the 
rest of the USA in 1995, although 
momentum later waned, probably as 
a result of decreased government 
funding and increased pro-tobacco 
advertising [29].
New York State used strong 
graphic and emotional content in 
a televised mass media campaign 
supplemented by advertisements 
to build confidence in the ability to 
quit smoking, and between 2003 and 
2009 reported a fall in prevalence of 
18%, compared with a fall of only 5% 
nationally [30].
In Massachusetts, after the in-
troduction of a comprehensive cam-
paign that included significant price 
(tax) increases in 1993, the preva-
lence of smoking fell at an average 
annual rate of 4% until 1999, in con-
trast to little or no change in the rest 
of the USA, excluding California [31].
A national television and radio 
campaign to warn of the hazards 
of smokeless tobacco use in India 
was shown to produce effects on 
precursors of behaviour change, in-
cluding intentions to modify smoke-
less tobacco use, in the target pop-
ulation [32].
Sun protection
The commencement of the SunSmart 
campaign in Victoria, Australia, in 
1989 was followed by a significant 
improvement in sun-related beliefs 
and behaviours and a reduction in 
prevalence of sunburn (assumed to 
be an intermediate marker of car-
cinogenic risk), after adjusting for 
ambient levels of ultraviolet radia-
tion at the time observations were 
made [33], and long-term follow-up 
showed a continuing effect [34].
Diet/nutrition
The “1% or Less” campaign was an 
intensive 6-week mass media cam-
paign to promote the use of low-fat 
milk in Wheeling, West Virginia, in 
the USA. After the campaign, 34% of 
milk drinkers indicated that they had 
changed to low-fat milk, compared 
with 3.6% in the control community 
[35]. Also, sales of low-fat milk in-
creased from 29% to 46% in the in-
tervention community.
Physical activity
The VERB campaign (Fig. 4.3.6), 
which was implemented nationally 
in the USA from 2002 to 2006, used 
commercial advertising and market-
ing techniques to increase physical 
activity levels in children. Changes 
that suggested an effect of the cam-
paign were reported in attitudes and 
behaviour [36].
Campaign principles applied 
to subpopulations
Using Vietnamese-language media, 
a campaign to promote colorectal 
cancer screening among Vietnamese 
Americans in Alameda and Santa 
Clara counties in California in 2004–
2006 resulted in greater screening 
participation than in comparison 
communities that did not receive the 
campaign [37].
Also using Vietnamese-language 
media, a campaign in Houston, 
Fig. 4.3.5. A campaign for breast cancer 
prevention in Singapore: “Are you ob-
sessed with the right things? The differ-
ence between a pimple and breast cancer 
is that of life and death. Regular breast 
checks are the best way to fight cancer. 
Show support for the women in your life 
by purchasing a Pink Ribbon.”
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Texas, to promote the receipt of 
three hepatitis B virus vaccinations 
for Vietnamese American children 
aged 3–18 years resulted in in-
creased knowledge among parents 
about such vaccinations and a sig-
nificantly higher increase in the rate 
of vaccinations compared with a 
control community [38].
The cancer prevention 
environment
All behaviour is a product both of 
intra-individual factors and of the en-
vironments in which behaviours take 
place. Campaigns take place in, and 
can be affected both positively and 
negatively by, the prevailing social, 
policy, and regulatory environments. 
So the best campaigns not only rely 
on a conducive environment; suc-
cessful prevention campaigns help 
to create such environments.
Ideally, to make a public health 
impact, the social and regulatory en-
vironments will need to move in con-
cert with successive phases of public 
communication campaigns.
Fig. 4.3.6. One of many posters used for the VERB campaign in the USA. The 2002–
2006 campaign was aimed at increasing and maintaining physical activity among tweens 
(ages 9–13).
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Summary
• Extensive research during the 
past few decades has provided 
strong evidence for preven-
tion of cancer and other major 
noncommunicable diseases. 
Although preventive actions 
among people at high risk are 
important and there are multiple 
tumour-specific measures, the 
greatest potential for cancer pre-
vention in the general population 
is through integrated health pro-
motion and policies that target 
certain lifestyle-related risk fac-
tors to prevent noncommunica-
ble diseases.
• The WHO Global Strategy for 
the Prevention and Control of 
Noncommunicable Diseases 
targets four behavioural risk 
factors – tobacco, unhealthy 
diet, physical inactivity, and 
harmful use of alcohol – 
with specific strategies.
• The WHO Framework Convention 
on Tobacco Control describes the 
most effective measures, espe-
cially for demand reduction, and 
is binding for the countries that 
have ratified it.
• The WHO Global Strategy on 
Diet, Physical Activity, and 
Health includes a range of 
4.4
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evidence-based interventions 
to influence diet and physical 
activity in the general popula-
tion. Emphasis is placed on 
measures to promote produc-
tion, availability, and marketing 
of healthier food stuffs.
• The WHO Global Strategy to 
Reduce the Harmful Use of 
Alcohol describes initiatives to 
reduce the harmful use of alco-
hol, with emphasis on alcohol 
policy.
• The major challenge to fram-
ing preventive measures for 
noncommunicable diseases is 
the gap between the scientific 
knowledge of risk and its ex-
trapolation to achieve reduced 
incidence.
During the past two decades, the 
globalization of public health priori-
ties has proceeded rapidly. Studies 
of the burden of disease worldwide 
have established that noncommu-
nicable diseases (NCDs) are now 
the main causes of death, not only 
in developed countries but also in 
developing countries [1]. A landmark 
publication was The World Health 
Report 2002, which documented 
both the change in the burden of 
disease and the impact of the main 
risk factors [2].
As a consequence of the 
emerging NCD epidemic, the WHO 
Global Strategy for the Prevention 
and Control of Noncommunicable 
Diseases was approved by the 
World Health Assembly in 2000 [3]. 
It was based on the global increase 
of NCDs, the causal role of certain 
behaviour-linked risk factors, the ac-
cumulated scientific evidence indi-
cating possibilities for NCD preven-
tion, and the experience in several 
countries.
The potential of NCD 
prevention
The WHO Global Strategy for 
the Prevention and Control of 
Noncommunicable Diseases [3] 
acknowledged for the first time that 
NCDs are a priority area for WHO. 
The strategy focused on the four 
main groups of NCDs: cardiovascu-
lar disease, cancer, diabetes, and 
chronic pulmonary disease. It in-
cluded comprehensive NCD control 
activities but emphasized prevention 
as the key public health approach.
Although the causal role of the 
main risk factors for NCDs was es-
tablished beyond any reasonable 
doubt before 2000, the understand-
ing of the great potential of NCD pre-
vention has grown most rapidly since 
then. In Finland, large reductions 
in the age-specific rates of cardio-
vascular disease and cancer have 
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occurred as a result of the preventive 
work begun in the 1970s [4].
In the early years of NCD preven-
tion, emphasis was placed on early 
detection, individual treatment, and 
education about causative agents. 
This is commonly known as the 
“high-risk” approach. However, both 
epidemiological and behavioural/
social considerations emphasize 
“population-based” prevention as 
the most effective public health ap-
proach [5,6].
The WHO Global Strategy 
for the Prevention and Control of 
Noncommunicable Diseases in-
troduced the concept of integrated 
prevention. It was recognized that 
although specific activities related 
to different diseases are needed, 
the most effective public health ap-
proach requires intervention to re-
duce the impact on the entire popu-
lation of risk factors that are common 
to several major NCDs. The WHO 
strategy specifically addresses to-
bacco use, unhealthy diet, physical 
inactivity, and harmful use of alcohol.
This chapter discusses cancer 
prevention in the general popula-
tion through this integrated NCD 
prevention perspective. This is the 
most cost-effective and sustainable 
public health approach to achiev-
ing a major reduction of the cancer 
burden in general populations. 
However, it should be recognized 
that several other measures, dis-
cussed elsewhere in this Report, can 
substantially contribute to cancer 
prevention. These include various 
screening programmes, measures to 
control certain infectious diseases, 
and action to prevent skin cancers 
by restricting exposure to ultraviolet 
radiation and to prevent lung cancer 
by addressing outdoor and indoor 
air pollution, specifically including 
clean stove programmes in relevant 
countries.
Population-based integrated NCD 
prevention targets risk-related behav-
iours or lifestyles in the community 
as a whole and requires emphasis 
on the built and social environments 
as determining lifestyle, and on 
broad health promotion and policy 
interventions. This has also led to 
consideration of the social determi-
nants of particular lifestyles, and pos-
sibilities to influence them [7]. The 
early approaches to health educa-
tion have, more recently, been sup-
plemented by attempts to influence 
environments – physical and social. 
Such an “ecological” approach calls 
for comprehensive activities by differ-
ent authorities, which may be equat-
ed to multisectoral actions, among 
which are policy measures by differ-
ent sectors of the government, such 
as the Finnish initiative Health in All 
Policies [8].
Since the 2000 WHO strategy on 
NCDs, WHO has developed several 
major methodologies and tools for 
national interventions directed to-
wards four behavioural risk factors: 
tobacco use, unhealthy diet, physical 
inactivity, and harmful use of alcohol.
WHO Framework Convention 
on Tobacco Control
The WHO Framework Convention on 
Tobacco Control (FCTC) was adopt-
ed in 2003 [9]. As of September 
2013, 177 countries have ratified it. 
This is first time that international law 
has been used in the field of public 
health. The WHO FCTC specifies ev-
idence-based elements of success-
ful tobacco control; most initiatives 
are directed towards reducing de-
mand for tobacco products. Demand 
may be reduced through education 
and communication (Fig. 4.4.1). 
Comprehensive educational, pub-
lic awareness, and training pro-
grammes on tobacco control are di-
rected towards health workers, other 
professionals, community groups, 
and decision-makers. Reducing 
tobacco use is difficult because of 
the strong addictive effects of nico-
tine and also because of the social 
dependence. Both pharmacological 
and non-pharmacological methods, 
the latter involving psychological and 
educational approaches, have been 
developed to effectively help tobac-
co users to quit. Tobacco control 
policies should include measures to 
provide cessation services [10].
The global tobacco epidemic 
is an immediate outcome of the 
powerful leverage of the multina-
tional tobacco industry, exercised 
through advertising, promotion, 
sponsorship, and lobbying. Thus, 
an important component of tobacco 
control is a comprehensive ban on 
advertising, promotion, and sponsor-
ship. In relation to this challenge, an 
international agreement is especially 
important because of the cross-bor-
der spread of advertising material.
Price and tax measures are ef-
fective and important means of re-
ducing tobacco consumption, par-
ticularly among young people (see 
Chapter 4.1). Although there are no 
safe tobacco products, national or 
other relevant authorities can in-
troduce regulations on testing and 
measuring tobacco products, and on 
levels of particular components in, 
and emissions from, these products.
Exposure to second-hand to-
bacco smoke, especially indoors, 
is recognized as causing multiple 
NCDs [11] and adversely affects vul-
nerable groups within the population, 
such as children. Smoke-free envi-
ronments discourage people from 
initiating smoking and continuing to 
smoke. Thus, any tobacco control 
policy should include prohibition of 
smoking in indoor workplaces, on 
public transportation, in other indoor 
settings, and in public places such 
as stadiums.
Packaging for tobacco products 
should not promote the product by 
presenting misleading messages. 
Such misleading messages may in-
clude terms like “low tar”, “light”, “ul-
tralight”, or “mild”. Tobacco packages 
Fig. 4.4.1. An anti-smoking message 
painted on a pedestrian crossing in the 
Orchard Road area of Singapore.
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should carry large and clear health 
warnings in text or in the form of pic-
tures, and/or be generic (Fig. 4.4.2). 
Australia was the first country to 
adopt the plain packaging of ciga-
rettes [12].
The WHO FCTC specifies a 
range of measures to reduce sup-
ply. The sale of tobacco to minors 
should be prohibited, and this leg-
islation should be comprehensively 
enforced. Vending machines should 
be placed so that children cannot 
obtain access. Surprisingly, a non-
trivial percentage of the tobacco 
used worldwide is smuggled, man-
ufactured illicitly, or counterfeited. 
Therefore, elimination of illicit trade 
in tobacco products is an issue 
requiring international collaboration 
by relevant authorities.
Although the scientific basis for 
tobacco control is very strong, fur-
ther research is needed in several 
areas, including, for example, the 
vulnerability of particular popula-
tions. It is important for every coun-
try to identify its own research needs 
in the light of local circumstances. 
Monitoring trends in tobacco use in 
the general population and in sub-
groups is crucial. It is also important 
to monitor determinants and patterns 
of tobacco use, as well as the im-
pact of activities related to tobacco 
control.
In 2009, the WHO FCTC 
Secretariat published a report on the 
global implementation of the con-
vention [13]. The report concluded 
that the implementation varies sub-
stantially. Overall, most countries 
report high implementation rates for 
measures on packaging and label-
ling, sales to minors, and education 
and training. In general, implemen-
tation rates for programmes direct-
ed towards cessation remain low.
Promoting healthy diet and 
physical activity
Diet and physical activity are differ-
ent from tobacco smoking in many 
fundamental respects [14]. Tobacco 
smoking is a very harmful practice 
and, in principle, not needed at 
all. Diet and physical activity are 
part of everyday life. Physical ac-
tivity and eating a healthy diet are 
positive behaviours to be promoted 
[15]. Also, the health implications of 
diet are multiple and complicated. 
Furthermore, although there are 
general recommendations, the re-
lationships of different nutrients and 
foods to different NCDs vary.
In 2004, WHO adopted a Global 
Strategy on Diet, Physical Activity, 
and Health [16]. This strategy pro-
vides countries with a comprehensive 
range of options to influence dietary 
practices and physical activity in their 
populations (Fig. 4.4.3). As back-
ground for this strategy, WHO, in col-
laboration with FAO, published the 
report Diet, Nutrition and Prevention 
of Chronic Diseases [17]. Based on 
expert advice, the report reviewed 
the evidence relating to nutrition as a 
means of preventing cardiovascular 
disease, cancer, diabetes, obesity, 
osteoporosis, and dental caries.
The WHO strategy’s recommen-
dations concerning diet for popu-
lations and individuals were the 
following:
• Achieve energy balance and a 
healthy weight.
• Limit energy intake from total fats, 
and shift fat consumption away 
from saturated fats to unsaturated 
fats; eliminate the intake of trans-
fatty acids (also called trans fats).
Fig. 4.4.2. New graphics and warnings on cigarette packaging are being implemented 
in several countries. This example from Brazil includes “Horror, Danger, Gangrene, 
Impotence, Pain, Death”. Although community awareness of smoking as a cause of lung 
cancer predominates, morbidity and mortality due to smoking include the consequences 
of respiratory, cardiovascular, and other diseases.
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• Increase consumption of fruits 
and vegetables, legumes, whole 
grains, and nuts.
• Limit the intake of free sugars.
• Limit salt (sodium) consumption.
Individuals were encouraged to 
engage in optimal levels of physi-
cal activity throughout their lives. 
Different types and amounts of 
physical activity are required to 
achieve different health outcomes; 
at least 30 minutes of regular, 
moderate-intensity physical activ-
ity on most days reduces the risk 
of cardiovascular disease, diabetes 
(Fig. 4.4.4), colon cancer, and prob-
ably breast cancer.
The strategies – both policies 
and necessary actions to achieve 
them – must be adopted compre-
hensively, taking a long-term per-
spective and engaging all sectors 
of society. The complex interactions 
between personal choices, social 
norms, and economic and envi-
ronmental factors must be recog-
nized. A life-course perspective is 
essential, and the strategies should 
be part of broad public health 
programmes. Priority should be 
accorded to activities targeting the 
lowest-income population groups 
and communities.
Governments
Governments have a primary steer-
ing role and are encouraged to act 
within the context of comprehensive 
NCD prevention and health promo-
tion. National strategies should 
identify the required measures and 
should include specific goals, ob-
jectives, and actions. Governments 
should take action in the following 
areas:
• Education, communication, and 
public awareness.
• Marketing, advertising, sponsor-
ship, and promotion.
• Labelling of food products.
• Health claims.
School policies and programmes 
should support the adoption of 
healthy diets and physical activity of 
children, and health services should 
target the habits of patients and the 
general population. Governments 
should also invest in research and 
evaluation of nutrition and physical 
activity in the general population. 
National institutions for public health, 
nutrition, and physical activity have 
an important role to play in the im-
plementation of programmes and in 
monitoring and evaluation.
Private sector and civil society
The private sector can also influ-
ence dietary practices and physi-
cal activity [18]. The food industry, 
retailers, catering organizations 
(including those responsible for 
meals at schools or workplaces), 
sporting-goods manufacturers, ad-
vertising and recreation businesses, 
and the media may all contribute to 
the adoption of good health prac-
tices. Moreover, commentaries note 
that food systems are rarely driven to 
deliver optimal human diets but pre-
dominantly to maximize profits, with 
increased obesity as the immediate 
outcome [19].
Recommendations to the food 
processing industry may include the 
following:
• Limit the levels of saturated fats, 
trans fats, sugars, and salt in 
products.
• Continue to develop and provide 
affordable, healthy, and nutritious 
choices to consumers.
• Introduce new products with better 
nutritional value than was previ-
ously available.
• Provide consumers with adequate 
and understandable product and 
nutritional information.
• Practise responsible marketing.
• Provide simple, clear, and con-
sistent food labels and evidence-
based health claims.
• Assist in the development and im-
plementation of physical activity 
programmes.
Workplaces provide settings for 
health promotion and disease pre-
vention, and should make provision 
for healthy food choices and encour-
agement of physical activity.
Civil society and nongovernmen-
tal organizations can advocate for 
healthy lifestyles and influence the 
food industry to provide healthy prod-
ucts. Such organizations can mobilize 
community sentiment and influence 
the public agenda. Nongovernmental 
and civic groups can support the dis-
semination of information on healthy 
diets and physical activity.
Alcohol control
Alcohol consumption is among the 
top 10 causes of mortality worldwide, 
Fig. 4.4.3. Poster from the Strong4Life 
campaign to prevent childhood obesity, in 
Atlanta, USA. Obesity increases the risk 
of diabetes, cardiovascular disease, and 
certain cancers – the major noncommuni-
cable diseases – worldwide.
Fig. 4.4.4. Testing of blood glucose with a 
blood glucose meter, used to help manage 
diabetes. Reduced incidence of diabetes, 
cardiovascular disease, and certain tu-
mour types may be identified as benefits 
from reduced obesity, an outcome sought 
through adoption of better dietary practices 
and increased physical activity.
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The global economics of chronic and noncommunicable diseases
Felicia Marie Knaul and Andrew Marx
Chronic and noncommunicable dis-
eases (CNCDs) have massive rami-
fications for global poverty, financial 
security, and equity [1,2]. The World 
Economic Forum’s Global Risks 
2010 report ranked chronic disease 
among the three most likely and 
severe risks facing the planet, with 
potential economic losses of more 
than US$ 1 trillion [1].
Between 2005 and 2015, income 
losses of US$ 558 billion in China 
and US$ 237 billion in India are pre-
dicted due to stroke, heart disease, 
and diabetes alone [3]. And the eco-
nomic impact of CNCDs on low- and 
middle-income countries (LMICs) 
will become more severe over time, 
particularly affecting working-age 
populations. Although the predict-
ed proportion of deaths from NCDs 
among those aged 15–59 years will 
fall globally by 2030, it will increase 
in LMICs [2].
Tobacco is a huge economic 
risk for LMICs. Tobacco’s estimat-
ed annual burden of US$ 500 bil-
lion exceeds the total yearly health 
expenditure of all LMICs combined. 
Tobacco consumption is estimated 
to reduce global economic gross do-
mestic product by 3.6% per year. If 
consumption continues to rise, the 
global annual economic cost of to-
bacco may reach US$ 1 trillion be-
tween 2020 and 2030 [4].
The estimated annual cost of 
scaling up interventions to reduce 
risk factors such as tobacco use 
and harmful alcohol consumption is 
only US$ 2 billion for all LMICs – 
less than US$ 0.40 per person. After 
including additional interventions 
such as vaccinations against hepa-
titis B virus to prevent liver cancer 
and against human papillomavirus 
to prevent cervical cancer, the an-
nual cost increases to US$ 9.4 bil-
lion: an annual per capita investment 
of less than US$ 1 for low-income 
countries, US$ 1.50 for lower-mid-
dle-income countries, and US$ 3 for 
upper-middle-income countries [3].
A 50% rise in chronic disease 
incidence and mortality, such as 
that projected for Latin America 
from 2002 to 2030, could slow an-
nual economic growth by more than 
2%, widening disparities between 
high-income countries and LMICs 
[5]. This projected economic burden 
exceeds any to date, including those 
from malaria and HIV/AIDS [3].
CNCDs also have a tremendous 
negative impact on the economic 
well-being of families. CNCDs, es-
pecially cancer, increase the risk 
of catastrophic health expenditure, 
impairing the ability of families to 
invest in education and nutrition. In 
South Asia, for example, the chanc-
es of catastrophic expenditures from 
hospitalizations are 160% higher for 
cancer than for infectious disease 
[6]. As typified by data from Egypt, 
people with NCDs have a 25% lower 
probability of being employed [7]. 
Furthermore, the burden of caregiv-
ing generally falls heavily on women 
and girls, exacerbating gender ineq-
uities by reducing their labour force 
participation and access to educa-
tional opportunities [2].
Inadequately investing in pre-
vention and treatment of CNCDs 
is recognized as short-sighted 
and misguided [1]. In the face of 
resource constraints, a short-term 
view would encourage LMICs to 
focus only on achieving the United 
Nations Millennium Development 
Goals. Yet, ignoring CNCDs plac-
es many countries at risk of not 
meeting many of the Millennium 
Development Goals because of es-
calating health costs and the health 
risks to mothers, infants, and young 
children [3]. Failure to protect pop-
ulations from preventable health 
risks will inevitably and severely 
detract from both economic devel-
opment and social well-being [3].
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responsible for 2–3 million deaths 
per year [20]. NCDs are among the 
adverse health outcomes of alcohol 
consumption, which extend from 
the acute effects of intoxication, 
which contributes to accidents and 
anti-social behaviour, to chronic in-
jury, including liver disease, certain 
cancers (Fig. 4.4.5), and cardiovas-
cular disease.
A special aspect of alcohol con-
sumption is its addictive nature. Thus, 
alcohol is “no ordinary commodity” 
[21]. While certain adverse health 
consequences of drinking, including 
road accidents and criminal assault, 
are usually a result of “harmful use”, 
the prevalence of harmful use is close-
ly related to the level of alcohol con-
sumption in the general population. 
Accordingly, interventions should not 
be confined to “high-risk interventions” 
among problem users, but should 
address general alcohol policy and 
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be population-based interventions. 
There is consensus about effective 
interventions to reduce alcohol con-
sumption [21]. Price and availability 
are the most effective matters for 
interventions. Among other interven-
tions are measures to limit drinking 
and driving, and mini-interventions 
in health services. Information cam-
paigns alone seem to have no direct 
impact.
In 2010, WHO adopted the 
Global Strategy to Reduce the 
Harmful Use of Alcohol [22]. This 
strategy includes evidence-based 
policies and measures concerning 
pricing, availability, and market-
ing. Pricing policies are important 
because consumers are sensitive 
to changes in the price of alcohol. 
Policy options include: taxation, es-
pecially taking account of the alcohol 
content of particular beverages; re-
stricting the use of price reductions 
for promoting sales; establishing 
minimum prices; and price conces-
sions for non-alcoholic beverages. 
Pricing policies should take account 
of inflation and variation in incomes 
over time. Strategies that regulate 
the availability of alcohol through 
regulation, policies and programmes 
include: appropriate systems to reg-
ulate production, wholesaling, and 
serving (regulations may include 
government monopolies, regulating 
hours or days of sale, or sales in cer-
tain places or during certain events); 
minimum age for youth being permit-
ted to purchase these products; and 
policies to reduce illicit production 
or smuggling. Marketing policies 
should be aimed at reducing the im-
pact of advertising and other mar-
keting, particularly as these matters 
affect young people. Frameworks 
should be established to regulate the 
nature of, and amount of expenditure 
on, marketing and sponsorship.
Health services are central to 
mitigating harm at the individual 
level among those with conditions 
caused by alcohol. Health services 
should address prevention through 
initiatives to reduce consumption 
and through treatment interven-
tions for individuals and their fami-
lies. Mini-interventions, in the form of 
identification of persons at risk and 
brief interventions, have proven to 
be cost-effective.
Conclusion
A range of evidence-based inter-
ventions have been identified to 
reduce the deleterious effects of 
major lifestyle-related risk fac-
tors common to cancer and other 
NCDs. This approach was recog-
nized in recent global political de-
velopments that culminated in the 
United Nations High-Level Meeting 
on the Prevention and Control of 
Noncommunicable Diseases that 
took place in 2011 in New York [23]. 
Influencing the behavioural risk fac-
tors common to several major NCDs 
in the general population is a cost-ef-
fective and sustainable public health 
approach immediately relevant to 
cancer prevention. Although effec-
tive treatment of cancer patients is a 
necessity, it is generally recognized 
that more should be done to prevent 
the otherwise increasing burden of 
malignant disease.
Fig. 4.4.5. Poster from the 2012 Government of Western Australia campaign on alcohol 
and cancer risks. Intoxication and addiction are widely recognized hazards of drinking; 
chronic disease, including cancer, may be less well known.
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Summary
• A range of legislative measures, 
and corresponding regulations, 
affect exposure to carcinogens, 
although very few are specifi-
cally framed in that context.
• Certain behaviours determine 
personal exposure to carcino-
gens, primarily involving tobac-
co smoking, alcohol consump-
tion, or deliberate sun exposure. 
Such exposures may be af-
fected by legislative measures, 
which reflect societal attitudes 
and concerns and are thus not 
necessarily framed with specific 
reference to a carcinogenic risk.
• Beyond national or subnation-
al initiatives, the international 
WHO Framework Convention 
on Tobacco Control establish-
es treaty obligations on Parties 
to adopt relevant legislation, 
among other measures.
• Prevention of occupational can-
cer underpins the banning of a 
limited number of agents, includ-
ing asbestos, and the specifica-
tion of workplace exposure lim-
its for many other carcinogenic 
substances. However, work-
related carcinogenic risks that 
are not identified with specific  
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agents are not amenable to such 
action.
• The incidence of cancer attribut-
able to atmospheric, waterborne, 
or foodborne contaminants may 
be reduced by regulatory inter-
vention that results in decreased 
exposure to pollutants. In cer-
tain instances, health benefits 
have been established.
• Community awareness of regu-
lations to prevent or limit carcin-
ogen exposure is often focused 
on particular circumstances of 
involuntary exposure, rather 
than on measures that reduce 
such exposure by affecting 
behaviour.
Scope
A range of legal processes, includ-
ing international treaties, national 
and subnational legislation, and as-
sociated regulatory measures, are 
directed at, or relevant to, cancer 
control. Such measures rely on the 
outcomes of medical and scientific 
research, including behavioural re-
search, and are discussed in that 
context in this chapter. This approach 
represents a very limited perspective. 
A comprehensive consideration of le-
gal processes relevant to cancer con-
trol would involve describing not only 
relevant measures but also their 
implementation as reflected in moni-
toring and inspection, their interpre-
tation as indicated by litigation and 
consequential judicial determinations 
(see Chapter 6.6), and their impact as 
indicated, for example, by research to 
establish the efficacy of a particular 
measure in reducing exposure, and 
ultimately in reducing any related bur-
den of disease.
Regulatory measures adopted 
under legislation to address the risk 
presented by exposure to carcino-
gens are almost invariably specific 
to particular classes of agents or cir-
cumstances of exposure. There are 
controls on occupational, environ-
mental, pesticide, pharmaceutical, 
and foodborne exposures. One of the 
most developed regulatory frame-
works can be seen in the USA. In that 
country, relevant legislation includes 
the Clean Air Act, the Clean Water 
Act, the Toxic Substances Control 
Act, the Food Quality Protection Act, 
the Comprehensive Environmental 
Response, Compensation, and Lia-
bility Act (commonly known as the 
Superfund law), the Occupational 
Safety and Health Act, and the Food, 
Drug and Cosmetic Act. In common 
with similar legislation in other coun-
tries, regulations adopted under such 
measures serve to limit exposure to 
carcinogens. Rarely, if ever, is legis-
lation oriented towards cancer pre-
vention; the Delaney Clause (1958), 
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an amendment (now repealed) to 
the United States Food, Drug and 
Cosmetic Act, is an exception [1]. 
However, as a means of limiting 
or preventing exposure to carcino-
gens, regulatory processes and the 
corresponding enabling legislation 
play a crucial role. The range of mat-
ters relevant to cancer control and 
appropriately subject to legislation 
and/or regulation expands in parallel 
with the understanding of the term 
“environment” (see “Environmental 
pollution: old and new”).
Apart from limiting exposure to 
carcinogens, cancer control may 
be furthered by legislation cover-
ing a broad scope. The health-care 
budget is a major aspect of many 
national economies and is likely to 
specify expenditure for cancer con-
trol, particularly involving diagno-
sis of, treatment of, recovery from, 
and palliation of malignant disease. 
Lesser funding, but possibly with 
wider ramifications, may involve ser-
vices relating to population-based 
cancer screening or the instiga-
tion of vaccination programmes. 
Statutory action underpins the op-
eration of population-based cancer 
registries. The entire health-care 
workforce is dependent on educa-
tion and training, which is supported 
by legislation. Against such a broad 
background, this chapter is limited to 
measures to prevent or reduce the 
likelihood of exposure to carcino-
gens in various contexts.
In discussions of conditions un-
der which exposure to carcinogens 
may occur, a distinction is often 
made between behaviours and un-
avoidable situations or involuntary 
circumstances [2]. Rarely are rec-
ognized or suspected carcinogens 
summarily subjected to regulatory 
control by the imposition of a ban. 
To address behavioural exposures 
to carcinogens, banning particu-
lar products or agents is often not 
practicable, even if that option is 
mentioned to emphasize a particu-
lar cause-and-effect relationship. In 
relation to behavioural exposures, 
legislative measures short of bans 
may have a marked and demonstra-
ble effect on the likelihood of expo-
sure to carcinogens.
Minimizing behaviour-related 
exposures
The circumstances of behaviour-
related carcinogenic risk were first 
identified largely in high-income 
countries but are now recognized 
in many instances as occurring 
worldwide. Such behaviour-related 
exposures include tobacco smoking, 
alcohol consumption, and excessive 
food intake, as well as unnecessary 
sun exposure, which is particular to 
fair-skinned populations. For these 
factors, although cancer is just one 
of the adverse health outcomes, 
it is often the focus of community 
awareness because it is generally 
acknowledged as the most feared 
disease. Accordingly, advocacy di-
rected towards the adoption of rel-
evant measures may be framed pri-
marily with reference to cancer. The 
benefits of adopting measures to re-
duce exposure to behaviour-related 
carcinogens may extend beyond re-
ducing the incidence of cancer.
Tobacco smoking
The WHO Framework Convention on 
Tobacco Control (FCTC), the first-
ever international treaty on health 
under the auspices of WHO, marks 
a peak in statutory measures calcu-
lated to reduce the burden of disease 
[3]. The WHO FCTC is one of the 
fruits of medical and biological evi-
dence that tobacco smoking causes 
a broad spectrum of diseases, spe-
cifically including cancer. Certain 
legislative measures that may be 
adopted to reduce tobacco consump-
tion have also been established by 
research and hence can be adopted 
Fig. 4.5.1. The Legislative Palace in Mon- 
tevideo, Uruguay, is the site where the 
Uruguayan parliament meets. Governments 
worldwide have adopted legislation estab-
lishing a range of statutory authorities to 
regulate, for example, exposure to carcino-
gens through the use of certain categories 
of consumer and other products.
Fig. 4.5.2. A poster illustrating the WHO Framework Convention on Tobacco Control as 
the theme of World No Tobacco Day 2011.
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Environmental pollution: old and new
Rodolfo Saracci
“Environmental pollution” is a term 
collectively denoting all agents nox-
ious to health that contaminate the 
human environment. In the broad 
sense, “the environment” includes 
everything outside the genetic en-
dowment of an individual. Hence, 
blood represents the body’s internal 
environment, and food, cosmetics, 
and tobacco smoke are elements of 
the personal environment, while air, 
soil, and water as they occur in the 
home, in buildings, at workplaces, 
and outdoors constitute the environ-
ment in the stricter and more usual 
sense of the word.
Noxious pollutants of the envi-
ronment (in the stricter sense) have 
been a scourge since time imme-
morial. For centuries, inadequate 
sanitation of water polluted with 
sewage caused a heavy burden of 
infectious disease and death. Early 
industrial development added ur-
ban overcrowding, facilitating the 
transmission of pathogenic micro-
organisms, and a massive increase 
in the volume of waste and in toxic 
chemicals from industrial sources. 
The same still occurs today, particu-
larly in low-income areas of contem-
porary megacities, exposing large 
populations to the combined risks 
of “old” infectious diseases, most 
often acute, and of “new”, pollutant-
induced ailments like chronic re-
spiratory diseases and a variety of 
cancers, which develop slowly over 
years or decades after the beginning 
of the exposures.
The occurrence of cancers in-
duced by environmental contami-
nants depends on several circum-
stances. Pollutants may be present 
at low concentrations, producing 
weak effects, in places where effec-
tive hygiene facilities and regulations 
are available, as in high-income 
countries. Instead, an increase in 
cancer risk may derive from the 
fact that several carcinogenic pol-
lutants are often jointly present and 
active within the same medium, 
for example polycyclic aromatic 
hydrocarbons, benzene, arsenic, 
and other inorganic chemicals in 
urban air or chlorination by-products 
in drinking-water. Time of exposure 
plays a role; for instance, exposure 
during the perinatal period or in early 
life might predispose to onset of can-
cers both in childhood and in adult 
life. Whereas pollutants are often 
present at relatively low concentra-
tions in the general environment, 
high concentrations can occur lo-
cally around point sources, typically 
industrial discharges of fumes in air 
or disposal of waste in waters and 
soils. Given the variety of exposure 
circumstances, the proportion of 
all cancers attributable to carcino-
genic pollutants varies from place 
to place and with time. However, 
“overall” estimates applicable to 
whole countries or regions have 
been attempted, with attributable 
fractions ranging from 1% (or even 
less) to 5–10%.
as specific measures recognized in 
the WHO FCTC. Parties to the WHO 
FCTC undertake to increase tobacco 
taxes; protect citizens from exposure 
to tobacco smoke at work and in oth-
er places; ban tobacco advertising, 
promotion, and sponsorship, and ap-
ply restrictions to advertising where 
constitutional constraints preclude 
a complete ban; prohibit the use of 
deceptive terms such as “light” and 
“mild”; regulate the packaging and 
labelling of tobacco products, in-
cluding adoption of health warnings; 
regulate the testing of emissions 
from tobacco products; promote 
public awareness of tobacco con-
trol issues; implement programmes 
to provide for cessation of tobacco 
use; adopt measures to combat il-
licit trade in tobacco; prohibit the 
sale of tobacco products to minors; 
and implement policies to support 
alternative sources of income for 
tobacco workers, growers, and in-
dividual sellers.
Some of these provisions, such 
as those related to cessation pro-
grammes, are not immediately ad-
dressed by and through legislation. 
Otherwise, many of the policies may 
be wholly or largely achieved through 
legislation to reduce the use of tobac-
co products. Banning the production 
and sale of tobacco products is not 
envisaged under the WHO FCTC and 
is not considered to be an option in 
most countries. However, legislative 
measures to control or discourage 
practices that contribute to ill health 
have the potential to contribute mark-
edly to cancer control as well.
The measures adopted by par-
ticular countries, or by countries in 
partnership, to implement tobacco 
control legislation vary both in the 
terms of their design and in the time 
frame for their implementation. In 
some instances, the prerogative may 
lie with state or provincial govern-
ments to adopt particular legislation. 
Both the attributable risk of smoking 
Fig. 4.5.3. The Tobacco Legislation Amend- 
ment Bill 2012, passed by the Legislative 
Assembly of New South Wales, Australia, 
provides a basis for regulations to limit 
smoking in public places.
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for lung cancer and the relative risk 
are so large that the effect of particu-
lar measures to discourage smoking 
may be readily evident in terms of 
case numbers – a scenario that does 
not apply to many cancer prevention 
initiatives. Thus, lung cancer rates in 
California during 1988–1997 could be 
distinguished from those in the rest of 
the USA, an outcome correlated with 
legislative measures against tobacco 
use adopted in California [4].
Legislation to control tobacco use 
is particularly relevant to developing 
countries, in many of which tobacco 
consumption has risen dramatically. 
This challenge is being addressed. In 
India, for example, beginning with the 
Cigarettes Act of 1975, several leg-
islative strategies and programmes 
to curb tobacco use have been im-
plemented, with limited success; 
currently, the Cigarettes and Other 
Tobacco Products Act of 2003 is de-
signed to curb the use of tobacco, to 
protect and promote public health [5]. 
Tobacco control initiatives are also 
being undertaken in China [6].
Alcohol consumption
In countries where consumption of 
alcoholic beverages is legal, the harm 
attributable to alcohol consump-
tion may be limited by encouraging 
personal responsibility for drinking 
behaviour and by adopting a range 
Fig. 4.5.4. Young men buy alcohol from a vendor at a local market in India. In countries 
where the sale of alcoholic beverages is permitted, consumption is primarily a matter of 
personal choice. However, the community may regulate availability by specifying that, for 
example, people must be of a certain minimum age to legally purchase alcohol.
Table 4.5.1. Text of alcohol warning labels from eight countries
Country Text of label
Brazil “Avoid the risks of excessive alcohol consumption”
Ecuador “Warning. The excessive consumption of alcohol restricts your capacity 
to drive and operate machinery, may cause damage to your health, and 
adversely affects your family”
Mexico “Excessive consumption of this product is hazardous to health”
Portugal “Drink alcohol in moderation”
Republic 
of Korea
One of three messages, including:
“Warning: Excessive consumption of alcohol may cause liver cirrhosis or liver 
cancer and, especially, women who drink while they are pregnant increase the 
risk of congenital anomalies”
Thailand “Warning: Drinking liquor reduces driving ability” and “Forbidden to be sold to 
children under 18 years old”
USA “GOVERNMENT WARNING:”
“According to the Surgeon General, women should not drink alcoholic 
beverages during pregnancy because of the risk of birth defects” or 
“Consumption of alcohol impairs your ability to drive a car or operate 
machinery, and may cause health problems”
Zimbabwe “Alcohol may be hazardous to health if consumed to excess” or “Operation of 
machinery or driving after the consumption of alcohol is not advisable”
of regulatory options. In contrast to 
tobacco use, the immediate focus 
on harm induced by irresponsible al-
cohol consumption involves, for ex-
ample, traffic accidents and violent 
assaults. A longer-term view is that 
alcohol consumption contributes to 
chronic disease, including cancer. 
WHO has adopted a Global Strategy 
to Reduce the Harmful Use of Alcohol, 
which addresses the affordability, 
availability, and promotion of alcohol – 
all matters that are subject to statu-
tory regulation. Commentary on this 
WHO initiative refers specifically to 
the prospect of expansion of the alco-
hol market in low- and middle-income 
countries. For example, in Thailand, 
alcohol consumption was once low, 
but the adult per capita consumption 
rose from 0.26 l in 1961 to 8.47 l in 
2001 [7].
During the past decade, leg-
islative progress in the European 
Commission and in Australia and 
New Zealand to reduce alcohol-relat-
ed cancers, among other harms, has 
been modest at best, and there are 
differences between countries in the 
involvement of the alcohol industry 
in developing relevant measures [8]. 
In Canada, as in many similar coun-
tries, the minimum legal drinking age, 
service to minors, and drinking and 
driving are subject to regulation, and 
there are measures addressing the 
price of alcohol, density of outlets, 
server intervention, control systems, 
and community interventions [9]. 
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At least 15 countries have adopted 
warning labels for alcoholic beverag-
es, and the health effects mentioned 
include effects on the unborn in some 
countries; some of these warnings 
are shown in Table 4.5.1. Cancer 
is rarely addressed in this context, 
although reduced consumption of 
alcohol will contribute to lower inci-
dences of cancers of the oral cavity, 
oesophagus, liver, female breast, and 
some other sites.
Exposure to ultraviolet 
radiation
Unlike virtually all other carcinogens, 
ultraviolet radiation, primarily from 
the sun, presents a risk to a particu-
lar racial group, namely fair-skinned 
people. Among such people, the 
extent of avoidable sun exposure 
is determined by behaviour and by 
circumstances. For children, there 
is a recognized need to address 
sun protection policies under broad 
strictures concerning safety [10]. 
Regulatory measures that specify 
requirements for childcare centres 
have been adopted in particular 
jurisdictions, as exemplified by re-
quirements in Germany [11].
The initial focus of calls to limit 
provision of commercial indoor tan-
ning operations was the protection 
of adolescents and young adults. 
Unequivocal evidence of increased 
melanoma risk caused by use of 
ultraviolet-emitting tanning devices, 
as specified in IARC Monographs 
Volume 100D, has resulted in access 
to indoor tanning becoming increas-
ingly restricted around the world [12]. 
Commercial tanning services are 
set to be banned in most Australian 
states in the next few years, and 
other countries may follow.
For people who work outdoors, 
appropriate sun protection may 
involve adoption of particular be-
haviours, complemented by provi-
sion of protective clothing, which 
may be subject to regulation. It is 
arguably the task of health educa-
tion to improve the recognition by 
adults of the hazard presented by 
recreational sun exposure. However, 
the limited progress that has been 
made in encouraging young people 
to be “sunsmart” – a term used in 
Australian campaigns – is prompting 
consideration of other options, pos-
sibly including regulation [13].
Diet
Regulatory measures to reduce obe-
sity are relevant to cancer control but 
are adopted in the broad context of 
controlling diabetes and cardiovas-
cular disease. Measures to encour-
age good nutrition are available and 
are being further developed (See 
“Taxing sugar-sweetened beverag-
es: the Brazilian case”), but these 
are not aimed at reducing exposure 
to agents generally recognized as 
carcinogens. In terms of involuntary 
exposure to carcinogens via food, 
most attention has been focused on 
aflatoxin contamination [14]. A sin-
gular focus on cancer resulting from 
food contamination underpinned 
historic United States legislation – 
the Delaney Clause mentioned 
Fig. 4.5.5. A polyvinyl chloride production plant in Turkey. Occupational exposure to 
specific carcinogens such as vinyl chloride can be readily controlled through regulation of 
relevant concentrations in the workplace; control of occupational exposure to non-specific 
waste products, or their impact on the wider community, is more difficult to address.
Table 4.5.2. International limit values (2007) for ortho-toluidine
Country Limit value (8 hours) Limit value (short-term)
ppm mg/m3 ppm mg/m3
Belgium 2 8.9
Canada, Québec 2 8.8
Denmark 2 9 4 18
France 2 9
Hungary 0.5
Poland 3 9
Spain 0.2 (skin) 0.89 (skin)
Switzerland 0.1 0.5
USA, OSHA 5 22
United Kingdom 0.2 0.89
OSHA, United States Occupational Safety and Health Administration.
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above – but any such risk is now 
considered to be best addressed in 
the context of general food safety 
legislation [15].
Preventing involuntary 
exposures
Protecting people from injury caused 
by exposures over which individu-
als have little or no control is a par-
ticular responsibility of government. 
Within that broad scope, the pros-
pect or proof of cancer causation 
has prompted a range of legislative 
measures, depending on the con-
text in which relevant exposures may 
occur.
Occupational exposures
Prevention of occupational cancer 
can be seen in the broader context 
of avoiding adverse workplace-re-
lated health effects due to a broad 
spectrum of agents. Occupational 
cancer is wholly preventable by 
regulatory controls when causation 
is attributable to a specific chemical 
or chemicals, as distinct from when 
increased risk is identified among 
people engaged in a particular type 
of work. The adoption of occupation-
al exposure limits for carcinogens is 
a fundamental regulatory approach 
and generally involves national stan-
dards [16]. In Europe, Registration, 
Evaluation, Authorisation and Re- 
striction of Chemicals (REACH) reg-
ulations are being implemented [17].
Compared with high-income 
countries, higher levels of exposure 
to many occupational carcinogens 
may occur in low- and middle-
income countries. The statutory 
determination of limits for occupa-
tional exposure to toxic compounds 
is being adopted worldwide, as ex-
emplified by initiatives in China [18]. 
Specific information may be gained 
from the respective regulatory stan-
dards themselves. For carcinogens, 
international standards for indus-
trial chemicals are systematically 
summarized in the relevant IARC 
Monographs. As an example, for the 
industrial chemical ortho-toluidine, 
which is categorized by IARC as 
Group 1 (carcinogenic to humans) on 
the basis of sufficient evidence for 
causation of bladder cancer in cer-
tain workers, exposure limits have 
been adopted by various countries 
(Table 4.5.2).
From carcinogenicity data to 
regulatory control
Measures to prevent occupational 
cancer or other cancers have of-
ten been implemented years, if 
not decades, after unequivocal 
evidence of carcinogenic risk was 
available. Many statutory authorities 
evaluate evidence of carcinogenic-
ity, and international collaboration 
in this field is epitomized by the 
IARC Monographs. Initially, from 
the early 1970s, IARC Monographs 
Programme evaluations were based 
on epidemiological evidence, when 
available, together with animal bio-
assay data. The evaluation process 
was expanded to include mechanis-
tic data, allowing due recognition of 
the likely human hazard from, for 
example, agents that are carcino-
genic in experimental animals but 
for which epidemiological evidence 
may be scant. Conversely, bioassay 
findings may be qualified by biologi-
cal data that suggest differences 
between mechanisms of tumour in-
duction in certain rodents and those 
in humans.
This consideration of the over-
all weight of evidence – including 
that from mechanistic studies – has 
resulted in IARC evaluations in 
Group 1 (carcinogenic to humans) 
or Group 2A (probably carcinogenic 
to humans) that would previously not 
have occurred in view of insufficient 
epidemiological information. As a re-
sult, an imperative may be evident 
to regulatory authorities without the 
need to await more definitive epide-
miology data. Analysing progress 
and limitations with respect to the 
next step – from the categorization 
Table 4.5.3. Evidence, IARC evaluations, and United States regulations concerning 
beryllium
Year Event
1930s First industrial uses of beryllium and first reported cases of beryllium-related 
pneumonitis
1946 Chronic beryllium disease reported for the first time
1949 AEC adopts a 2.0 μg/m3 exposure limit for weapons workers
1970 High lung cancer rates reported among beryllium workers with prior 
respiratory illness
1971 OSHA adopts a 2.0 μg/m3 exposure limit
1972 IARC Monographs Volume 1: inadequate evidence in humans; sufficient 
evidence in animals
1979 IARC Monographs Supplement 1: Group 2B (possibly carcinogenic to 
humans)
1980 Increased lung cancer incidence reported in three studies of beryllium 
workers
1980 IARC Monographs Volume 23: limited evidence in humans; Group 2A 
(probably carcinogenic to humans)
1987 IARC Monographs Supplement 7: limited evidence in humans confirmed
1989 DOE proposes a 0.5 μg/m3 exposure limit for DOE weapons and clean-up 
workers
1993 IARC Monographs Volume 58: sufficient evidence in humans; Group 1 
(carcinogenic to humans)
1999 DOE issues a 0.2 μg/m3 exposure limit for DOE weapons and clean-up 
workers
2006 California OSHSB adopts a 0.2 μg/m3 exposure limit (8-hour TWA)
2009 ACGIH recommends a 0.05 μg/m3 exposure limit (8-hour TWA)
2012 OSHA exposure limit, 2.0 μg/m3; NIOSH recommended exposure limit, 
0.5 μg/m3; EPA ambient air limit, 0.01 μg/m3 (30-day TWA)
ACGIH, American Conference of Governmental Industrial Hygienists; AEC, United States Atomic 
Energy Commission; DOE, United States Department of Energy; EPA, United States Environmental 
Protection Agency; NIOSH, United States National Institute for Occupational Safety and Health; OSHA, 
United States Occupational Safety and Health Administration; OSHSB, Occupational Safety and Health 
Standards Board; TWA, time-weighted average.
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Taxing sugar-sweetened beverages: the Brazilian case
Rafael Moreira Claro
Progressively more governments 
around the world are focusing on 
ways to use fiscal policies to rectify 
decades of subsidies for a variety of 
foods and other goods linked with 
poor health [1]. WHO has recom-
mended such policies for more than 
a decade as a way to influence food 
prices and encourage healthy eat-
ing. Evidence based on the Brazilian 
market indicates that taxing sugar-
sweetened beverages would be an 
effective way to control and reduce 
the consumption of these products 
[2].
Trends of prices and consump-
tion of sugar-sweetened beverages, 
between 1986 and 2003, obtained 
in three household budget surveys 
representative of the 11 major met-
ropolitan areas of Brazil, clearly 
demonstrate how changes in price 
can affect the consumption of these 
products (Fig. B4.5.1). As the price 
of sugar-sweetened beverages de-
creased from R$ 5.7 per 1000 kcal to 
R$ 3.6 per 1000 kcal, their consump-
tion increased significantly from 
0.8% to 2.2% of the total calories ac-
quired for household consumption. 
Since the prices of all other foods 
and beverages remained stable dur-
ing this period, the reduction in the 
price of sugar-sweetened beverages 
was likely to be even more evident 
to the population.
The likely impact of taxing sugar-
sweetened beverages in Brazil was 
assessed using national representa-
tive data from the early 2000s [2]. A 
statistically significant reduction in 
the consumption of these products 
is expected as a result of increases 
in price: every 1% increase in price 
would lead to a 0.84% reduction 
in consumption in the Brazilian 
population.
Given that sugar-sweetened 
beverages are a health hazard re-
gardless of their type, initially no 
caloric sweetened beverage should 
be exempted from taxation, to avoid 
substitution between types of sugar-
sweetened beverages [1]. In addi-
tion, effective taxation would have 
to affect the price of these bever-
ages on all occasions where they 
are consumed, in the household or 
away from it.
Even though taxing of sugar-
sweetened beverages has the 
potential to improve health regard-
less of how the revenue is used, 
the popularity of such an initiative 
is likely to increase if the revenues 
are used to support programmes or 
policies that promote a healthy life-
style (such as healthy eating initia-
tives in schools) [3]. Data from the 
most recent national food intake sur-
vey, conducted in 2008–2009, show 
that approximately 6.8 billion litres of 
sugar-sweetened beverages were 
consumed by the Brazilian popula-
tion during the study period of 1 year 
(about 750 ml/person/week); thus, 
an excise tax of 30% per litre (an 
average increase of R$ 0.3 in the 
price per litre) would be high enough 
to reduce consumption significantly 
and also generate a revenue of 
R$ 2.2 billion, or almost US$ 1 bil-
lion, an amount sufficient to fund 
investments in promoting a healthy 
lifestyle or subsidizing healthy foods.
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Fig. B4.5.1. Trends in food prices and consumption of sugar-sweetened beverages 
in major metropolitan areas of Brazil in 1986–1987, 1995–1996, and 2002–
2003. Food prices were adjusted for inflation to represent January 2009 values. 
Consumption of sugar-sweetened beverages is shown as a percentage of the total 
calories acquired for household consumption.
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of carcinogenicity to the implementa-
tion of regulatory controls – is inher-
ently complicated because it largely 
identifies national or multinational 
prerogatives. Progress, or lack of 
it, is readily evident by considering 
specific agents.
An international ban on asbestos 
is in prospect [19], but progress to 
this point has taken decades. The 
categorization of asbestos as carci-
nogenic to humans readily followed 
unequivocal epidemiological find-
ings. The first IARC Monograph on 
asbestos, in 1973, referred to associ-
ations between asbestosis and lung 
cancer that had been reported in 
1935, and specified “epidemiological 
proof” of the link between exposure 
to asbestos and increased risks of 
bronchial carcinoma and mesothe-
lioma. Yet, despite more documenta-
tion of attributable injury over half a 
century, regulatory action was pre-
cipitated not by specific research 
findings, nor by authoritative evalua-
tion of the available data overall, but 
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by the prospect of litigation involv-
ing causation being recognized and 
compensation being required [20].
Soon after the introduction of 
beryllium in industrial processes 
in the 1930s, the first reports of 
related pneumonitis and chronic 
beryllium disease were published. 
Some decades later, the carcino-
genicity of beryllium became evi-
dent: high lung cancer rates were 
recorded, in particular among beryl-
lium workers with prior respiratory ill-
ness. IARC Monograph evaluations 
of beryllium over four decades have 
shown a progression, with unequivo-
cal animal data being complemented 
by successively more definitive epi-
demiological findings, culminating 
in a Group 1 evaluation by 1993 
(Table 4.5.3). This path has been 
paralleled by increasingly stringent 
restrictions – years, and occasion-
ally decades, after the relevant sci-
entific findings. In some instances, 
beryllium-induced toxic injury apart 
from cancer, namely multiple types 
of respiratory disease, has motivated 
regulatory action.
Pollution
As discussed in Chapter 2.9, air pol-
lution causes a minor fraction of lung 
cancer in high-income countries. 
Typically, such pollution, which may 
include carcinogens such as ben-
zene, formaldehyde, and 1,3-buta-
diene, is subject to statutory control, 
as exemplified by the United States 
Clean Air Act legislation [21]. In 
many jurisdictions, there are regu-
latory controls on vehicle emissions 
[22,23]. The efficacy of regulatory 
measures to reduce adverse health 
effects of atmospheric pollution is 
being progressively established [24].
While such progress in the USA 
and similar high-income countries is 
encouraging, this outcome must be 
set against the knowledge that two 
thirds of the global burden of disease 
attributable to air pollution occurs in 
the low- and middle-income coun-
tries of South-East Asia [25]. The 
relative lack of regulatory control 
of atmospheric pollution for much 
of the world’s population is indicat-
ed by the general lack of relevant 
measurement data outside North 
America and the European Union. 
Between 1990 and 2005, a 6% in-
crease in global population-weight-
ed average ambient concentration 
of fine particles in the atmosphere 
occurred, highlighted by increased 
concentrations in East, South, and 
South-East Asia and decreases in 
North America and Europe.
The maximum permissible lev-
els of particular water contaminants 
are specified by regulation in many 
countries. In relation to cancer 
control, the immediate and over-
whelming concern is arsenic. Other 
carcinogens recognized as water 
contaminants include benzene, tri-
chloroethylene, and chromium VI. In 
1942, a United States standard of 
50 μg/l for arsenic was set; in 2001, 
it was reduced to 10 μg/l, the level 
that had been adopted by WHO as a 
guideline for drinking-water in 1992. 
However, introducing the appropriate 
regulatory response in developing 
countries where large populations 
have much higher concentrations 
of arsenic in drinking-water, often 
exceeding 100 μg/l, is complex [26].
Statutory authorities and 
consumer protection
Adverse effects caused by the 
availability or use of particular com-
mercial products are often the re-
sponsibility of statutory authorities 
that have power in relation to, for 
example, pesticide licensing or con-
sumer products, including cosmet-
ics. Provisions to protect consumers 
were invoked in several countries to 
ban the use of the flame retardant 
tris(2,3-dibromopropyl) phosphate in 
children’s sleepwear [27]. In some 
countries, provisions against mis-
leading advertising have served to 
prevent the marketing of cigarettes 
using terms such as “light” or “mild”, 
because of the perception, albeit 
invalid, that such products present a 
reduced health risk compared with 
others on the market [28]. Brazil and 
the European Union were among the 
first jurisdictions to act [29].
Typically, the responsibility of 
statutory authorities, or the outcome 
of consumer protection legislation, 
does not involve specification of can-
cer control. However, public outrage 
at perceived inadequate protection 
against exposures to carcinogens 
means that the media often tends to 
focus on involuntary exposures and 
regulatory inactivity. Accordingly, 
the community readily recognizes 
a need for regulatory intervention 
to prevent or reduce exposure to 
carcinogens when such measures 
address involuntary exposures, ex-
emplified by those occurring in the 
workplace or as a result of pollution. 
However, regulatory measures to in-
fluence behaviour may well have the 
greatest impact on cancer incidence 
and mortality.
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Summary
• Hepatitis B virus (HBV), which 
causes chronic hepatitis, cirrho-
sis, and a large fraction of liver 
cancer cases, is a very common 
infection in some areas of the 
world.
• Highly effective vaccines against 
HBV and liver cancer have been 
available since 1982, and most 
countries include HBV vaccina-
tion in their childhood immuniza-
tion programmes.
• A group of about 12 human 
papillomaviruses (HPVs), par-
ticularly HPV types 16 and 18, 
cause most cervical and anal 
cancers and an important frac-
tion of vulvar, vaginal, penile, and 
oropharyngeal cancers.
• Two prophylactic vaccines con-
sisting of empty viral capsids 
of HPV types 16 and 18 were 
recently developed. The vac-
cines are safe and prevent al-
most 100% of anogenital infec-
tions and precancerous lesions 
among previously unexposed in-
dividuals, with enormous poten-
tial for cancer control worldwide.
• HPV vaccination of adolescent 
girls is now recommended and is 
slowly being implemented in low- 
and middle-income countries, 
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where more than 80% of cervical 
cancer cases worldwide occur.
A notable fraction of human cancers 
(16%) are caused by infections and 
are largely amenable to effective pre-
ventive interventions [1]. Among the 
most important infections associated 
with cancers are hepatitis B virus 
(HBV), hepatitis C virus, human pap-
illomavirus (HPV), and Helicobacter 
pylori (see Chapter 2.4).
Chronic infection with HBV is one 
of the most important causes of liver 
cancer (hepatocellular carcinoma) 
worldwide, particularly in highly 
endemic areas like sub-Saharan 
Africa, the Amazon basin, China, 
the Republic of Korea, and countries 
in South-East Asia [2]. Vaccines 
against HBV have been available 
for several decades and are part of 
childhood vaccination programmes 
around the world. The efficacy of the 
vaccine in preventing chronic HBV 
infection and liver cancer has now 
been clearly demonstrated among 
children and adolescents, and it is 
expected to reduce incidence of 
adult hepatocellular carcinoma in 
many areas when vaccinated popu-
lations reach adulthood.
HPV is a very common sexu-
ally transmitted virus that causes 
Fig. 4.6.1. View from the Chiang Kai-shek Memorial Hall, in Taipei. Taiwan, China, 
launched a nationwide hepatitis B virus vaccination programme for newborn 
infants in July 1984.
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cancers of the cervix, anus, vulva, 
vagina, penis, and oropharynx 
among individuals in whom HPV 
infection is not cleared. Recently, 
highly effective vaccines have be-
come available to prevent infection 
by HPV16 and 18, the types respon-
sible for most HPV-related cancers. 
Vaccine efficacy and cost-effective-
ness are maximal among previously 
unexposed women, and HPV vac-
cination is being implemented pro-
gressively among adolescent girls in 
developed and developing countries. 
The vaccines are efficacious to pre-
vent infections and lesions at all the 
anatomical sites where they have 
been investigated, and mass vac-
cination programmes are expected 
to reduce incidence and mortality 
from cancers associated with these 
viruses in the next few decades [3]. 
This chapter summarizes some of 
the epidemiological features of 
HBV and HPV infections and their 
associated cancers and discusses 
the characteristics and performance 
of vaccines against them.
Hepatitis B virus
Hepatitis B virus and liver 
cancer
HBV is a highly contagious DNA 
virus transmitted by exposure to in-
fected blood and other body fluids, 
including semen and vaginal fluids. 
The virus is transmitted from mother 
to infant and from child to child, as 
well as by unsafe injections, sexual 
contact, and blood transfusions. 
Perinatal transmission from infect-
ed mothers to their newborn infants 
or from one child to another is very 
common in highly endemic areas, 
and the virus can also be transmitted 
by fomites [4].
HBV infection is a major global 
health problem. Worldwide, an es-
timated 2 billion people have been 
infected with HBV, and more than 
360 million have chronic liver infec-
tions. HBV causes a life-threatening 
liver infection, namely hepatitis B, 
which often leads to chronic liver 
disease. The occurrence of chronic 
infection is inversely related to the 
age of acquisition, from 90% among 
people infected perinatally to less 
than 5% among otherwise healthy 
adults [5]. HBV-driven persistent 
inflammation, liver necrosis, and re-
generative proliferation lead to cir-
rhosis and hepatocellular carcinoma. 
Among people chronically infected, 
it is estimated that 25% will die from 
liver disease, including cancer. HBV 
is responsible for 50–90% of liver 
cancer cases in high-risk areas [6]. 
These cancers can also develop 
without fibrosis because HBV may 
have a direct carcinogenic effect [4].
Hepatitis B virus vaccine
A vaccine against HBV has been avail-
able since 1982. The current vaccine 
is a recombinant HBV surface antigen 
produced in yeast or mammalian cells 
into which the HBV surface antigen 
gene has been inserted using plas-
mids. The expressed HBV surface 
antigen self-assembles into spherical 
particles that expose the highly im-
munogenic “a” determinant. Alum 
(aluminium phosphate) is generally 
used as an adjuvant. HBV vaccine, 
of which the initial dose (of a total of 
three recommended doses) is given 
within the first 24 hours after birth, is 
95% effective in preventing HBV in-
fection and its chronic consequences, 
even when antibody levels become 
undetectable, and was the first vac-
cine against a major human cancer 
[7]. The vaccine has an outstanding 
record of safety and effectiveness. 
Since 1982, more than 1 billion dos-
es of HBV vaccine have been used 
worldwide. In many countries where 
8–15% of children previously became 
chronically infected with HBV, vacci-
nation has reduced the rate of chronic 
infection to less than 1% among im-
munized children.
Prevention of liver cancer has 
been demonstrated in children 
and adolescents in the early vac-
cinated cohorts in Taiwan, China, 
where a nationwide HBV immu-
nization programme for newborn 
infants was initiated in July 1984 
[8,9]. Immunization has lowered 
the prevalence of chronic HBV 
carriers, incidence of hepatocellu-
lar carcinoma, and mortality from 
fulminant hepatitis [10]; these ef-
fects are evident in the birth cohort 
born in 1981–1984, which received 
HBV vaccines at preschool ages 
instead of in infancy. The Republic 
of Korea also initiated mass HBV 
vaccination in the early 1980s [11].
A high incidence of liver cancer 
in Qidong City, China, was attrib-
utable to endemic HBV infection 
and dietary exposure to aflatoxin, 
Fig. 4.6.2. A child getting vaccinated in The Gambia. Hepatitis B virus vaccination trials 
in progress in the country are expected to yield results in the next few years.
316
prompting dietary interventions and 
the initiation of neonatal HBV vac-
cination. As recently reported, liver 
cancer incidence has fallen dramati-
cally: compared with 1980–1983, 
age-specific liver cancer incidence 
rates in 2005–2008 had significantly 
decreased by 14-fold at ages 20–
24 years, and consistent data were 
reported for other cohorts [12].
In 2010, 179 countries reported 
inclusion of the HBV vaccine in their 
national infant immunization pro-
grammes. This is a major increase 
compared with 31 countries in 
1992, the year that the World Health 
Assembly passed a resolution to rec-
ommend global vaccination against 
HBV. Nearly 70% of children born 
worldwide received three doses of 
the HBV vaccine (Fig. 4.6.3).
Human papillomaviruses
Human papillomaviruses and 
cancer
HPV is considered a necessary 
cause of cervical cancer, with an 
attributable fraction of nearly 100%. 
Multiple epidemiological studies over 
the past three decades have con-
firmed the etiological role of about 13 
HPV types in cervical cancer; HPV16 
and 18 are detectable in about 70% 
of tumours. The natural history and 
molecular mechanisms involved in 
cervical carcinogenesis are well un-
derstood [13].
In the cervix, HPV is a sexually 
transmitted infection acquired by 
most women shortly after initiation 
of sexual activity. The most com-
mon morphological manifestation 
of HPV infection consists of minor 
epithelial abnormalities (equivocal 
and low-grade cellular changes). 
The initial infection regresses spon-
taneously in the majority of women, 
but among those women where the 
infection becomes persistent, pre-
cancerous lesions (advanced intra-
epithelial neoplasia) can develop. If 
not treated, these lesions can lead to 
cervical cancer after several years. 
HPVs have well-identified oncogenes 
whose products interact with tumour 
suppressor gene proteins of the host 
to induce malignant transformation 
[14]. Prevention of a necessary cause 
of disease, by definition, should pre-
vent the disease.
An important fraction of other 
anogenital cancers, including can-
cers of the anus, vulva, vagina, and 
penis, are also HPV-related, and in 
these tumours HPV16 is the strongly 
predominant type. Although mo-
lecular mechanisms similar to those 
observed in the cervix are probably 
involved, there is limited knowledge 
of the natural history of these tumours 
[13]. Importantly, and similarly to the 
cervix, most of these tumours show 
an important increase among immu-
nodeficient individuals. Apart from 
the lesions in the anogenital tract of 
both men and women, HPV is impli-
cated in a geographically variable 
and pathologically distinct fraction of 
cancers of the oropharynx [15], and 
the incidence of this cancer has re-
cently tended to increase in several 
developed countries. In fact, in the 
USA, where the increase in incidence 
Fig. 4.6.3. Immunization coverage with three doses of hepatitis B virus vaccine in the national infant immunization schedule, 2010.
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Early implementation and monitoring of HPV vaccination in Bhutan
Tandin Dorji and Ugyen Tshomo
Bhutan was the first low-income 
country to introduce vaccination 
against human papillomavirus 
(HPV), the necessary cause of 
cervical cancer. Cervical cancer 
is the most common cancer in 
Bhutanese women. To help prevent 
the disease, the Ministry of Health 
developed a national vaccination 
programme. The Ministry’s con-
siderations included disease inci-
dence, the limited reach of screen-
ing, the poor outcomes associated 
with late diagnosis of disease, and 
the feasibility of a HPV vaccina-
tion programme. For national in-
troduction of HPV vaccination, the 
Ministry recommended immuniza-
tion with quadrivalent (HPV6, 11, 
16, and 18) vaccine for 12-year-old 
girls and a “catch-up” campaign for 
girls aged 13–18 years in the first 
year of the programme. In 2010, a 
pharmaceutical company provided 
free quadrivalent HPV vaccine for 
all girls aged 12–18 years, and for 
the next 5 years the Australian 
Cervical Cancer Foundation fund-
ed the vaccine for 12-year-old girls. 
Health workers administered the 
vaccine in schools; girls not at 
school received the vaccine at 
health facilities. In 2010, more than 
130 000 doses of quadrivalent HPV 
vaccine were administered, with a 
three-dose vaccination coverage 
rate of 92%. There were no seri-
ous adverse events, and the vac-
cine was well tolerated. The rapid 
implementation, acceptability, and 
success of this national HPV vac-
cination catch-up programme are 
attributed to strong political com-
mitment and a well-functioning pri-
mary health-care system. Bhutan’s 
experience provides an example 
for other low-income countries 
considering the introduction of 
HPV vaccination.
Monitoring of HPV vaccination is 
challenging: it will take two or three 
decades before its impact on the on-
set of cervical cancer will become 
manifest in cancer registry data. In 
the near term, the most feasible and 
informative outcome of vaccination 
is the decrease in the prevalence of 
HPV infection and, most notably, the 
variation in the ratio between HPV 
types prevented by the current vac-
cines and other HPV types in sen-
tinel populations of sexually active 
adolescents and young women. A 
timely demonstration of the effec-
tiveness in Bhutan will sustain the 
willingness of other low-income 
countries to continue their efforts. 
Therefore, in 2012 the Ministry 
of Health of Bhutan, in collabora-
tion with Jigme Dorji Wangchuck 
National Referral Hospital and 
IARC, started a study that will regu-
larly evaluate HPV prevalence in 
cervical cells and urine samples of 
women aged 18 years or older. By 
2016, the early impact of vaccination 
will start to be detectable in women 
aged 25 years or younger. An expan-
sion of cervical screening and a shift 
from the current cytology-based 
screening to HPV-based screening 
in the country is also being consid-
ered in the framework of the same 
project. This investment will improve 
cervical cancer prevention in older 
women and could ultimately serve 
as the basis for long-term vaccina-
tion monitoring.
Reference
Ladner J et al. (2012). BMC Public Health, 
12:370. http://dx.doi.org/10.1186/1471-2458-
12-370 PMID:22621342
Fig. B4.6.1. Staff of the Jigme Dorji Wangchuck National Referral Hospital in 
Thimphu, Bhutan.
of oropharyngeal cancer is observed 
mainly among men, the number of 
HPV-related cancers is expected to 
be higher in men than in women in 
the next few decades, attributable 
in part to the consideration that 
screening has greatly lowered rates 
of cervical cancer in that country 
[16]. HPV16 is responsible for about 
60% of cervical cancer tumours, but 
in HPV-associated tumours of other 
anogenital sites and the oropharynx 
this viral type is more predominant, 
responsible for about 90% of the 
HPV-positive cases.
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Introduction and monitoring of a national HPV vaccination programme in 
Rwanda
Agnès Binagwaho, Maurice Gatera, and Fidele Ngabo 
Cervical cancer is the most com-
mon cancer among women in 
Rwanda, where, before 2011, nei-
ther cervical cancer screening nor 
human papillomavirus (HPV) vac-
cination were available in public 
health facilities. In 2010, however, 
the Rwandan Ministry of Health de-
veloped a National Strategic Plan 
for the Prevention, Control, and 
Management of Cervical Lesions 
and Cancer. A multidisciplinary 
committee devised a strategic plan 
for the preparation, implementa-
tion, and evaluation of a national 
HPV vaccination programme, of 
which the key aspects included: 
(i) a public–private partnership 
with a pharmaceutical company to 
provide free vaccine for 3 years of 
HPV vaccinations and offer reduced 
prices for future doses; (ii) a delivery 
approach based on school grade; 
(iii) a strong community involve-
ment in identifying and vaccinating 
girls absent from, or not enrolled in, 
school; and (iv) a nationwide sen-
sitization campaign preceding the 
delivery of the first dose.
Since 2011, girls enrolled in pri-
mary grade six have been receiving 
the full three-dose course of HPV 
vaccine, with additional outreach 
to the small number of 12-year-old 
girls not at school. During the pro-
gramme’s second and third years 
(2012 and 2013), a “catch-up” phase 
targeting girls in the third year of 
secondary school has ensured com-
plete coverage of all pre-adolescent 
and adolescent girls. In 2014 and be-
yond, only girls in primary grade six 
will be vaccinated.
In its first year, Rwanda’s HPV 
vaccination programme achieved a 
three-dose vaccination coverage of 
93.2% among an estimated 98 762 
eligible girls in grade six. Rwanda 
is the first example of a successful 
nationwide delivery of HPV vac-
cine in a country eligible for support 
from the GAVI Alliance, and should 
motivate other countries to expand 
their vaccination programmes to 
include the HPV vaccine, with due 
customization according to their 
epidemiological, economic, political, 
and health system contexts. This is 
especially timely now that the GAVI 
Alliance has included the vaccine in 
its immunization package and the 
price has been lowered to US$ 5 
per vaccine dose for GAVI Alliance-
eligible countries.
Rwanda’s HPV vaccination 
programme is expected to have an 
important impact on the future bur-
den of cervical cancer in Rwanda. 
In the short term, however, reliable 
evidence of the effectiveness of the 
vaccination programme is crucial to 
help national planners sustain in-
vestment in the programme. Thus, 
a collaboration with IARC is under 
way to provide timely high-quality 
data on the impact of the vaccina-
tion programme on the prevalence 
of HPV infection. Such evidence of 
vaccine effectiveness should also 
facilitate the introduction of success-
ful programmes into other low- and 
middle-income countries.
Reference
Binagwaho A et al. (2012). Bull World Health 
Organ, 90:623–628. http://dx.doi.org/10.2471/
BLT.11.097253 PMID:22893746
Fig. B4.6.2. A young Rwandan mother 
and her child.
Human papillomavirus 
vaccines
Two non-infectious subunit vaccines 
against HPV have been developed, 
both composed primarily of virus-like 
particles and produced by expres-
sion of the HPV L1 gene in insect 
cells (bivalent vaccine) or yeast 
(quadrivalent vaccine). The L1 gene 
codes for most of the viral capsid, 
and after producing the L1 protein, 
it self-assembles as virus-like par-
ticles, which are highly antigenic. 
They produce a strong antibody 
response that prevents infection by 
neutralizing infectious virus in the 
mucosa at the time of contagion. A 
comprehensive review has recently 
been published [3].
The bivalent vaccine includes 
HPV16 and HPV18 virus-like parti-
cles and is produced with a complex 
adjuvant system (ASO4) consisting 
of monophosphoryl lipid A and alum. 
The quadrivalent vaccine, produced 
with alum adjuvant, includes HPV16 
and HPV18 virus-like particles and, 
in addition, HPV6 and HPV11 virus- 
like particles, the viral types respon-
sible for most benign genital warts.
Both vaccines are almost 100% 
effective in preventing cervical HPV 
infections and precancerous lesions 
associated with the oncogenic vi-
ruses included in the vaccine for-
mulations (HPV16 and 18) among 
women not previously infected, and 
the vaccines are therefore mainly 
recommended for adolescent girls 
before initiation of sexual activity. 
A summary of demonstrated ef-
ficacy of the two cervical cancer 
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Table 4.6.1. Key findings from clinical trials of HPV VLP vaccines
Study group Outcome Quadrivalent vaccine Bivalent vaccine
Young women Infection efficacy Proven Proven
 CIN2+ efficacy Proven Proven
 CIN3 efficacy Proven Proven
 VIN/VaIN 2/3 efficacy Proven Provena
 Genital warts efficacy Proven Not a target
 Anal infection efficacy Not provenb Proven
 Partial cross-protection infection Proven Proven
 Partial cross-protection CIN2+ Proven Proven
 Therapeutic efficacy None None
 Safety No concerns No concerns
Mid-adult womenc Infection efficacy Proven Provena
 CIN2+ efficacy Proven Not proven
 Immunogenicity Proven Proven
 Safety No concerns No concerns
Young men Infection efficacy Proven Not proven
 Genital warts efficacy Proven Not a target
 Anal infection efficacy Proven Not proven
 AIN2+ efficacy Proven Not proven
 Safety No concerns No concerns
Children Infection efficacy Not proven Not proven
 Disease efficacy Not proven Not proven
 Immunogenicity Proven Proven
 Safety No concerns No concerns
AIN2+, anal intraepithelial neoplasia, grade 2 or worse; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; VaIN, vaginal intraepithelial 
neoplasia; VIN, vulvar intraepithelial neoplasia; VLP, virus-like particle.
a Meeting abstract, not yet published.
b “Not proven” indicates that no data have been reported.
c See comments in the text on cost-effectiveness for this group.
vaccines is presented in Table 4.6.1 
[3]. Although there is evidence of 
protection by both vaccines against 
HPV infection and disease among 
women older than 25 years, the 
benefit–cost ratio is reduced, in part 
because of the lower incidence of 
lesions among women infected by 
HPV later in life [17].
The vaccines also afford limited 
protection against HPV types phylo-
genetically related to HPV16 and 18. 
Cross-protection against persistent 
infection of 6 months or more has 
been reported against HPV31 for 
the quadrivalent vaccine and against 
HPV31, 33, 52, 45, and 51 for the 
bivalent vaccine. However, the sig-
nificance of early protection against 
these additional types is not clear 
and needs to be monitored over 
the long term and against cervical 
disease. Neither of the vaccines is 
effective against established infec-
tions [18].
The quadrivalent vaccine has 
been shown to also prevent the 
majority of vulvar and vaginal HPV 
infections and lesions associated 
with HPV16 and 18, as well as genital 
warts (caused by HPV6 and 11). The 
bivalent vaccine has been shown to 
prevent anal HPV16 and 18 infections 
in young women (Table 4.6.1). Based 
on cross-sectional studies of women 
aged 18–24 years who received Pap 
screening in family planning clinics 
throughout Australia, there was a de-
crease of 77% in prevalence of HPV 
types targeted by the quadrivalent 
vaccine from the period before 
(2005–2007) to the period after 
(2009–2010) the vaccine was widely 
implemented (Fig. 4.6.4) [19]. Among 
men, the quadrivalent vaccine has 
been shown to effectively prevent 
external genital lesions, including 
genital warts and penile, perianal, or 
perineal intraepithelial lesions, and 
among men who have sex with men 
it has been demonstrated to prevent 
anal intraepithelial neoplasia.
Trials of the bivalent and quad-
rivalent vaccines in terms of infection 
and lesional end-points have been 
reviewed [20]. Among HPV-negative 
women, both vaccines have demon-
strated high efficacies against per-
sistent HPV infections and cervical 
cancer precursors. The quadrivalent 
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vaccine is efficacious (> 75% vaccine 
efficacy) against any of the more se-
vere precursors of vulvar, vaginal, 
and anal cancers.
Both vaccines have demonstrat-
ed an excellent safety record in the 
several years since they were li-
censed and have now been incorpo-
rated into vaccination programmes 
in most developed countries. They 
are recommended for girls before 
initiation of sexual activity, with ad-
ditional “catch-up” programmes for 
young women in some countries. 
Although the efficacy has not been 
shown for younger children, immu-
nogenicity bridging studies have 
shown that the level of the antibody 
response to the vaccine is stronger 
in adolescent boys and girls than 
in young adult women [21]. In gen-
eral, among women and men of all 
ages, the vaccines induce a strong 
immune response to both antigens 
that persists for at least 8 years, 
without evidence of declining effi-
cacy so far.
More than 40 countries have 
already introduced HPV vaccina-
tion, mainly among women [22], 
with a high uptake in some regions 
but not in others. It will probably 
only be possible to determine the 
extent of attributable reduction in 
cervical cancer incidence after 
several decades, particularly be-
cause vaccination programmes 
have only recently been initiated 
in developing countries (see “Early 
implementation and monitoring of 
HPV vaccination in Bhutan” and 
“Introduction and monitoring of 
a national HPV vaccination pro-
gramme in Rwanda”). Vaccination 
of boys to prevent certain cancers 
in men and to prevent transmission 
of infection to women is under way 
in some developed countries. Some 
areas have implemented vaccina-
tion programmes with alternative 
schedules, including the application 
of only two doses, based on immu-
nogenicity data showing very simi-
lar antibody responses, particularly 
among young girls. In addition, data 
from a clinical trial in Costa Rica 
indicated evidence of protection 
from fewer than three doses of the 
bivalent vaccine against persistent 
infections with relevant viral types 
[23]. In the same trial, reduced prev-
alence of oral HPV infection was 
evident 4 years after vaccination – 
a result that has implications for 
the prevention of HPV-associated 
oropharyngeal cancer, which is in-
creasingly common [24].
New vaccines are being devel-
oped that could overcome some 
of the limitations of current HPV 
vaccines. In particular, additional 
protection against other HPV types 
could eventually eliminate the need 
for screening. In the meantime, 
modified screening alternatives will 
have to be implemented in vaccinat-
ed populations, and screening ac-
tivities will need to continue for the 
majority of adult women currently 
alive, who will not benefit from this 
extraordinary preventive tool.
Fig. 4.6.4. Differences in human papillomavirus (HPV) genoprevalence between pre-
vaccine and post-vaccine populations. * P < 0.05 for difference in percentages between 
groups. CI, confidence interval; excl, excluding; HR-HPV, high-risk HPV.
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Summary
• Early detection and treatment 
of cancer requires accessible, 
high-quality health services with 
adequate human, financial, and 
technical resources.
• Population-based screening pro-
grammes of appropriate quality 
can reduce morbidity and mor-
tality from breast, cervical, and 
colorectal cancers. Provided ev-
idence-based methods are used 
that have been tested under local 
conditions, these programmes 
can offer a more effective alter-
native to early symptomatic de-
tection of disease.
• Cervical cancer screening may 
involve visual inspection of the 
cervix, cervical sampling for 
cytology, or testing for human 
papillomavirus infection.
• Screening tests for colorectal 
cancer include faecal occult 
blood testing and faecal im-
munochemical testing. Flexible 
sigmoidoscopy and colonosco-
py are also used.
• Screening with mammography 
permits detection of early-stage 
breast cancers.
• To maximize the benefit and min-
imize harm, screening should be 
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implemented only in organized, 
population-based programmes 
with adequate resources for 
planning and training, identifica-
tion and invitation of the target 
population, and quality assur-
ance, including monitoring and 
evaluation.
• Lack of governmental commit-
ment to provide the requisite 
sustainable resources can be a 
serious barrier to successful im-
plementation of cancer screen-
ing programmes.
Detection of cancer in its early 
stages and the provision of prompt 
appropriate treatment are impor-
tant elements in cancer control. The 
aim of early detection is to reduce 
mortality and other serious conse-
quences of advanced disease. This 
goal may be accomplished if earlier 
treatment improves life expectancy, 
locoregional control of disease, and 
quality of life, and/or permits equally 
effective therapy with fewer side-
effects (Fig. 4.7.1). Key to achieving 
the potential impact of early detec-
tion of cancer is universal access to 
prompt and effective diagnostic and 
treatment services. Comprehensive, 
multidisciplinary quality assurance is 
essential to maintain an appropriate 
balance between overall benefit and 
inherent risk. The concept of early 
detection of cancer has evolved 
since the landmark publication by 
Wilson and Jungner in 1968 [1]. In 
recent decades the principles es-
tablished in that publication have 
been extended through experience 
gained from implementation of pop-
ulation-based cancer screening pro-
grammes [2]. Due to the complexity 
of the issues that have impacts on 
the effectiveness and appropriate-
ness of early detection of cancer, 
this chapter provides an overview 
of key concepts and sources of in-
formation and calls attention to not 
only the opportunities but also the 
limitations of cancer screening.
Early detection 
Early detection of 
symptomatic cases
Early diagnosis is particularly rel-
evant for cancers of the breast, cer-
vix, mouth, larynx, colon, rectum, 
and skin. Before evidence-based 
screening methods became avail-
able, early detection was achieved 
by improving diagnostic and thera-
peutic methods and by the educa-
tion of health-care professionals and 
the general public to promote early 
recognition of symptomatic disease. 
Some early signs of cancer include 
lumps, sores that fail to heal, abnor-
mal bleeding, persistent indigestion, 
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and chronic hoarseness. Increased 
awareness of cancer warning signs 
can have a significant impact on 
the burden of disease, particularly 
in those health-care systems in 
low- and middle-income countries 
in which most patients are currently 
diagnosed with very-late-stage ma-
lignancy [3]. Universal access to 
adequate diagnosis and treatment 
is still lacking in many countries and 
is a serious barrier to the control of 
symptomatic disease.
Early detection of 
asymptomatic cancer
In high-income countries, popu-
lation-based screening has been 
shown to be effective in reducing 
cancer-specific mortality, comple-
menting early symptomatic detection 
of breast, cervical, and colorectal 
cancers [4–6]. The main objective 
of screening is to discover latent 
disease among those who are pre-
dominantly asymptomatic and to 
enable adequate treatment before 
the cancer poses a more serious 
threat to the individual and places 
an additional burden on the com-
munity [1]. Early treatment of in-
vasive lesions, including surgical 
removal of early invasive breast 
cancer or endoscopic resection 
of early colorectal cancer, can 
be less detrimental than treat-
ment of symptomatic disease [7,8]. 
Moreover, detection of premalignant 
lesions followed by treatment with 
cryotherapy or the loop electrosur-
gical excision procedure for intra-
epithelial cervical neoplasia, or by 
endoscopic excision of colorectal 
adenomas, prevents progression to 
cervical and colorectal cancer, re-
spectively [5,8,9]. Randomized trials 
among people at average risk invited 
to participate in population-based 
screening have shown a reduction 
in cervical and colorectal cancer in-
cidence and mortality [6,9].
For cervical cancer, the impact 
of screening is evident when trends 
in incidence over decades are com-
pared across 38 countries [10]. 
Strong downward trends occurred 
in the highest-income countries, 
whereas no clear changes, includ-
ing some increases, were recorded 
in lower-income settings (Fig. 4.7.2). 
Due to improvements in survival, the 
full benefit of mammography screen-
ing in terms of the number of breast 
cancer deaths prevented becomes 
evident only after a follow-up period 
of more than two decades. In a large 
randomized trial, follow-up of 133 065 
participants over 29 years showed a 
31% reduction in breast cancer mor-
tality in the group assigned to screen-
ing compared with the control group; 
furthermore, most of the deaths 
prevented by screening would have 
occurred after a follow-up period of 
more than 10 years [11]. Two recent 
studies have also provided insight 
into long-term effects of colorectal 
cancer screening [12]. One report es-
timated that screening colonoscopy 
 
Screening
Earlier treatment
Appearance of symptoms
Diagnosis
Start of treatment
Serious consequences
Serious consequences
A
B 
Serious consequences
Detectable by screening
Diagnosis
Start of 
treatment
C
“Usual care”
Earlier diagnosis by 
better awareness
Diagnosis
Life expectancy
Improved life expectancy
Significantly improved life expectancy
Start of
treatment
Time 
Early detection of selected cancers through symptoms or by screening
Fig. 4.7.1. (A) There is usually a delay between the appearance of symptoms and the 
start of treatment of a cancer. Treatment delays or the unavailability of treatment are 
serious problems worldwide. (B) Earlier diagnosis and treatment of some cancers due 
to better awareness of symptoms may increase life expectancy and reduce serious 
consequences of the disease. (C) Still earlier detection and treatment of some asymp-
tomatic cancers through screening can significantly increase life expectancy and further 
reduce serious consequences of the disease (for methods, see Table 4.7.1). Ideally, 
the delays between the appearance of symptoms, diagnosis, and start of treatment of 
cancer should be as short as possible. Organized screening programmes also tend to 
decrease the interval between diagnosis and start of treatment.
Fig. 4.7.2. Comparison of age-standardized incidence trends of cervical cancer, for 
ages 30–74 years, between countries of northern Europe and countries of Asia/Africa.
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would have prevented 40% of colo-
rectal cancers over a 22-year pe-
riod in 88 902 individuals, while the 
other found that annual faecal occult 
blood testing reduced mortality by 
32% in a 30-year follow-up of 46 551 
participants.
A considerably shorter time pe-
riod was sufficient to demonstrate 
the efficacy of colorectal cancer 
screening using once-only flexible 
sigmoidoscopy between the ages of 
55 and 64 years. After 11.2 years of 
follow-up of 170 038 participants in 
a randomized controlled study, colo-
rectal cancer incidence and mortal-
ity were reduced by 23% and 31%, 
respectively, in the screening group 
compared with the control group [13].
A population-based screening 
programme for detection of asymp-
tomatic disease will also detect cases 
that are symptomatic, but the detec-
tion, on average, will result in earlier 
treatment for the asymptomatic cases 
than for the cases of symptomatic dis-
ease. It is therefore anticipated that 
the numbers of detected cancers with 
a favourable prognosis will be higher 
in a population-based screening pro-
gramme of appropriate quality, and 
over time the effective diagnosis and 
treatment of these cases will result in 
a greater decrease in disease-spe-
cific mortality than can be achieved 
by early detection of symptomatic 
cancer alone. However, early detec-
tion may also lead to diagnosis or pro-
longation of illness without improving 
a patient’s prognosis. Randomized 
controlled trials are therefore used to 
eliminate lead-time, length, and se-
lection bias in the evaluation of the 
effect of cancer screening [4].
The evidence-based screening 
methods currently used in population-
based cancer screening programmes 
are shown in Table 4.7.1. Suitable 
screening tests for cervical cancer 
include cervical sampling for conven-
tional cytology (Pap smear; Fig. 4.7.3) 
or liquid-based cytology; testing for 
human papillomavirus (HPV) infec-
tion; and visual inspection of the 
cervix with acetic acid (Fig. 4.7.4). 
Screening for breast cancer by mam-
mography (Fig. 4.7.5) permits early 
detection of small breast cancers, 
most of which have not yet metas-
tasized and can be successfully 
treated, although some of these might 
never have presented clinically in 
the subject’s lifetime (overdiagnosis). 
Bowel cancer screening using faecal 
occult blood testing, flexible sigmoid-
oscopy, or colonoscopy may lead to 
the diagnosis of colorectal polyps 
(Fig. 4.7.6), removal of which during 
colonoscopy may prevent their pro-
gression to colorectal cancer. Early 
colorectal cancer that can be effec-
tively treated by endoscopic removal 
or surgical excision may also be de-
tected. Evidence-based programmes 
for population-based screening of 
other major cancers, such as can-
cers of the ovary, liver, oesophagus, 
lung, and prostate, have not yet been 
established.
For high-risk groups, visual 
screening (Fig. 4.7.7) has been shown 
to be efficacious in early detection and 
prevention of deaths from oral cancer 
[14]. Results of a large randomized 
controlled trial in the USA showed 
that screening people at high risk of 
lung cancer based on age and smok-
ing history with low-dose computed 
tomography can reduce the number 
of deaths due to lung cancer [15]. The 
United States Preventive Services 
Task Force recently announced a draft 
Table 4.7.1. Evidence-based screening methods currently used in national or regional 
cancer screening programmes
Target cancer Screening method
Breast Mammography
Cervical Cytology (conventional and liquid-based)
Human papillomavirus testing
Visual inspection of the cervix with acetic acid
Colorectal Faecal occult blood testing or faecal immunochemical testing
Flexible sigmoidoscopy
Colonoscopy
Fig. 4.7.3. Pap smear suggestive of high-grade precancerous lesion: cervical intraepi-
thelial neoplasia grade 3 (CIN3). Inflammatory smear contains many parabasal cells with 
enlarged nuclei with irregular chromatin (black arrow) and some cells with eosinophilic 
cytoplasm (purple arrow).
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recommendation for annual screening 
for lung cancer using this procedure 
in people at high risk [16].
Determinants of harm and 
benefit
Screening should be conducted only 
after careful consideration of both 
harms and benefits. Knowledge has 
developed about health economic 
and cost–benefit analysis predicated 
on the potential health benefits and 
risks in addition to the financial costs 
of cancer screening for the people 
affected [17–19]. Before screen-
ing programmes are launched, an 
analysis of the expected costs and 
the benefit should be performed us-
ing data collected in feasibility and 
pilot studies in the relevant health-
care environment. These analyses 
should be repeated at intervals in 
established programmes, typically 
every 10 years, and before adopt-
ing major modifications of existing 
protocols. The methods applied in 
cost–benefit analysis are complex, 
and in interpreting the results, the 
underlying assumptions as well as 
the balance between the main ben-
efits and harms of screening should 
be kept in mind.
Despite the considerable poten-
tial of cervical and colorectal cancer 
screening to prevent invasive cancer 
through detection and treatment 
of precancerous lesions, the key 
measure of benefit for any such 
screening programme is mortal-
ity reduction, rather than increased 
detection of early-stage disease. A 
secondary benefit of earlier diagnosis 
arises because smaller cancers can 
often be treated with less debilitating 
procedures and medications.
The primary harm from screening 
is morbidity and mortality from the 
procedures for detection and diagno-
sis, and the side-effects of treatment 
prompted by screening. Exposure to 
these risks in the absence of any direct 
health benefit is of particular concern. 
Such a situation may arise due to 
false-positive tests or procedures, 
or from overdiagnosis, i.e. diagnosis 
through screening of cancers that 
would not have been detected symp-
tomatically during the lifetime of an 
individual. Unfortunately, overdiag-
nosed cancers cannot be individually 
identified; the likely number of such 
cases may be estimated after many 
years of follow-up in a randomized 
screening trial where screening was 
never offered to the relevant controls. 
A related potential harm of screening 
is overtreatment, which is not limited 
to those cases that are overdiag-
nosed. Overtreatment may occur if 
less-intensive treatment protocols 
appropriate to early-stage lesions 
are not available or are not followed.
Quality assurance plays an im-
portant role in keeping overdiagnosis 
and overtreatment in an appropriate 
range. Studies in Europe address-
ing overtreatment in breast cancer 
screening have demonstrated that 
mastectomy rates decreased mark-
edly after the introduction of popula-
tion-based mammography screening 
Fig. 4.7.4. Outcomes of visual inspection of the cervix with acetic acid: (A) negative, 
(B) positive. The circumorificial acetowhite lesion on the right (B) is suggestive of 
cervical intraepithelial neoplasia.
Fig. 4.7.5. (A) A normal oblique view mammogram of the left breast of an asymptomatic 
57-year-old woman. (B) A small invasive cancer detected at screening 2 years later. 
This cancer could not be detected with palpation even after it had been detected with 
mammography.
A B
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[20,21]. Two recent reviews estimated 
that for every one or two overdiag-
nosed cases, at least one death 
due to breast cancer was avoided, 
a balance between benefit and harm 
considered to be appropriate [22,23].
The potential for overdiagnosis 
is substantial when screening for 
prostate cancer by determining se-
rum prostate-specific antigen levels 
[24]. Whereas data from the Prostate, 
Lung, Colorectal, and Ovarian 
Cancer Screening Trial in the USA 
[25], unlike results from the European 
Randomized Study of Screening for 
Prostate Cancer [26], have not indi-
cated a disease-specific mortality 
reduction, both trials suggest that 
systematic screening would result 
in significant levels of overdiagno-
sis. Due to uncertainties about the 
benefits and the risks, population-
based prostate cancer screening is 
not supported by currently available 
evidence.
Since estimation of overdiagnosis 
requires the application of complex 
statistical methods,all such estimates 
are subject to uncertainty. Whereas 
cancer-registry-based studies tend to 
be imprecise and underestimate the 
benefits of screening, calculations of 
the mortality benefit based on precise 
individual data tend to be highly ac-
curate. Although many people con-
sider the benefit of an averted cancer 
death to greatly outweigh the risks 
of overdiagnosis and overtreatment, 
strict quality assurance practices 
must be maintained to minimize all 
risks associated with screening.
Organization of screening
People eligible for population-based 
screening are defined by age and/or 
gender, as well as the cancer bur-
den for the relevant tumour type. 
In most countries breast cancer 
screening is offered to normal-risk 
women from the age of 40–50 years 
and extending to the age of 70–
75 years, typically at 2-year inter-
vals. Cervical cancer screening is 
generally offered to women from the 
age of 25–30 years and extending to 
the age of 60–65 years. The recom-
mended interval commonly varies 
between 3 and 5 years. In low- and 
middle- income countries, cervical 
screening may be provided in a nar-
rower age range or only once or a 
few times in a lifetime. Colorectal 
cancer screening is generally of-
fered to women and men from the 
age of 50 years and extending to 
the age of 74 years. Depending on 
the screening protocol, which may 
use faecal occult blood testing, fae-
cal immunochemical testing, flexible 
sigmoidoscopy, or colonoscopy, the 
recommended interval commonly 
varies between 2 and 10 years, 
and endoscopic screening may be 
performed only once in a lifetime 
[27,28].
Screening of high-risk groups 
is generally not considered a pop-
ulation-based strategy since only a 
small portion of the total population 
is affected [3]. For evidence-based 
screening of high-risk groups, a pro-
grammatic approach can be recom-
mended, provided the quality and 
the cost-effectiveness of the screen-
ing process are assured.
Organized programmes
For a programme to be considered 
an organized screening programme, 
a public cancer screening policy 
documented in a law, or an official 
regulation, decision, directive, or 
recommendation is required. The 
policy should define, as a minimum, 
the screening protocol and repeat 
interval, and determinants of eligi-
bility for screening. The screening 
examinations should be financed by 
public sources (apart from a pos-
sible co-payment in high-income 
countries). Provision of screening 
in organized programmes is recom-
mended because these include an 
administrative structure responsible 
for service delivery, quality assur-
ance, and evaluation [29].
The rules and regulations appli-
cable to an organized programme 
generally provide for a team at 
the national or regional level that 
is responsible for implementa-
tion, i.e. for coordinating the de-
livery of the screening services, 
maintaining the requisite quality, 
and reporting on performance and 
results. Such organizational and 
managerial elements generally 
Fig. 4.7.6. A colonoscopy performed as part of the Lampang Province colorectal cancer 
screening programme in Thailand. Inset at lower right shows a large bowel polyp being 
removed during the colonoscopy.
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provide for supervision and monitor-
ing of most steps in the screening 
process, as well as comprehensive 
guidelines and rules defining stan-
dard operating procedures. In addi-
tion, a quality assurance structure 
is required, and a means of ascer-
taining the population burden of the 
disease must be available so that the 
programme can be evaluated [4].
Population-based 
programmes
Population-based screening pro-
grammes identify and individually 
invite each person in the eligible 
population to attend each round 
of screening. Individual invitations 
aim to give each person in the eli-
gible population an equal chance 
of benefiting from screening and 
to thereby reduce health-care 
inequalities [29]. The invitations 
should be supported by effective 
communication for groups with lim-
ited access to screening, such as 
less-advantaged socioeconomic 
groups. This communication, in turn, 
should support an informed deci-
sion about participation, based on 
information about the risks and ben-
efits of screening [30,31]. Invitations 
indicating a date, time, and place 
for the screening examination have 
been most effective in high-resource 
settings. These invitations have usu-
ally been sent by letter, often followed 
up with reminders to non-respond-
ers. Recent experience with call 
centres and electronic messaging 
via mobile phones suggests that 
such methods of communication 
warrant further investigation [30].
Opportunistic programmes
“Opportunistic” screening is a less 
cost-effective form of screening 
and is less amenable to quality as-
surance than is population-based 
screening. Such screening relies 
on a health-care provider taking the 
initiative to offer screening or to en-
courage individuals to participate in 
a screening programme, or to under-
take screening outside the context 
of any programme (so-called wild 
screening). In high-resource set-
tings, opportunistic screening has 
been associated with lower overall 
impact of screening and lower par-
ticipation rates [32]. In addition, the 
total volume of resources consumed 
tends to be significantly higher with 
opportunistic screening. This leads 
to overuse of screening resources 
by part of the target population and 
underuse by, or lack of coverage of, 
the rest of the population [33,34].
Importance of quality 
assurance
The importance of quality assur-
ance in cancer screening goes 
beyond the need to ensure that 
any medical intervention is per-
formed adequately, efficiently, and 
with minimum risk and maximum 
benefit. At any given time, only a 
small number of people invited to 
attend population-based screening 
(usually < 1%) will have undetected 
cancer or precancerous lesions that 
can be treated effectively. Therefore, 
only a small number of people can 
derive a direct health benefit from 
attending screening. However, all 
participants are exposed to the risks 
of screening, and although these are 
slight, the risks add up. To achieve 
the benefit of cancer screening, 
quality must be optimal at every 
step in the screening process, in-
cluding identification and personal 
invitation of each eligible individual; 
performance of the screening test, 
examination, or procedure; diagnos-
tic work-up of people with detected 
abnormalities; and, when neces-
sary, treatment, surveillance, and 
aftercare (Fig. 4.7.8) [6]. In practice, 
the process of screening is much 
more complex than the schematic 
diagram in Fig. 4.7.8 suggests. For 
example, in a quality-assured colo-
rectal cancer screening programme 
using a faecal occult blood testing 
kit, receipt of the test result indicat-
ing whether diagnostic work-up is 
warranted involves at least five dif-
ferent activities. Diagnostic work-up 
and clinical management of the le-
sions detected in screening require 
multidisciplinary teamwork and can 
be complicated. That is why orga-
nized, quality-assured screening 
programmes follow comprehen-
sive quality assurance guidelines 
with evidence-based standards, 
procedures, and protocols of best 
practice that are continuously being 
improved [6,7,35].
Evaluation of the impact of a 
screening programme on cancer 
mortality is a long-term objective of 
quality assurance. The actual effect 
cannot be exactly quantified because 
mortality in the screened population 
would have to be compared with mor-
tality in the same population in the 
absence of screening. To estimate 
the effect, various study designs 
have been used, such as comparing 
screened and matched unscreened 
populations, time trends in mortality, 
case–control studies, and modelling 
studies. However, changes attribut-
able to improved awareness and 
treatments cannot be completely 
Fig. 4.7.7. Early-stage oral cancer detected by visual screening.
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disentangled from the outcomes of 
screening programmes. Evidence on 
the effectiveness of population-based 
cancer screening is predominantly 
available from programmes in high-
income countries.
To fully evaluate the impact of a 
screening programme, the potential 
harms mentioned above must also 
be determined, such as those due 
to false-positive tests and overdi-
agnosis. Since the full impact of a 
screening programme will not be 
known for many years after its ini-
tiation, it is also necessary to pro-
actively monitor and continuously 
improve performance of all activi-
ties in the screening process from 
the outset, i.e. long before the im-
pact is actually discernible. That will 
permit the timely recognition of steps 
that must be taken to continuously 
improve communication, organiza-
tion, professional performance, and 
equipment.
Low coverage of the target popu-
lation substantially limits the effec-
tiveness and the cost-effectiveness 
of any programme. Health-care pro-
fessionals, responsible authorities, 
and governments should also be 
aware of this and other constraints 
that may limit the achievable impact 
of cancer screening programmes. 
A common pitfall is the adoption of 
non-validated working models and 
methods. Of prime importance is 
the availability and sustainability of 
adequate human, financial, and tech-
nical resources to ensure that the 
programme achieves an appropriate 
balance between benefit and harm.
Outlook
It may take several years to imple-
ment a population-based cancer 
screening programme, from the 
beginning of planning to completion 
of roll-out across an entire country or 
region. Determinants of successful 
implementation of population-based 
cancer screening programmes have 
been developed for application to 
screening for any target cancer. 
Insights into the implementation of 
such programmes are provided in 
Chapter 4.8, which illustrates the 
need for comprehensive quality as-
surance in the establishment and de-
livery of multidisciplinary screening 
services at all resource levels. It also 
shows the importance of universal 
access to prompt and effective diag-
nostic and treatment services, which 
is a common goal in all attempts to 
improve cancer control through early 
detection.
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Summary
• Global implementation of popu-
lation-based cancer screening 
reveals heterogeneity, and broad 
knowledge is restricted to three 
cancer types: breast, cervical, 
and colorectal cancer.
• In many high-income countries 
and some middle-income coun-
tries, population-based screen-
ing programmes for breast and 
cervical cancer have been estab-
lished for decades, or shorter pe-
riods, and some have achieved 
significant reductions in cancer-
specific mortality. Colorectal 
cancer screening programmes 
have been introduced more 
recently.
• There are few population-based 
screening programmes in low- 
and middle-income countries.
• Screening programmes require 
political commitment, engage-
ment of civil society, competent 
oversight, and adequate, sus-
tainable resources.
• Programme management should 
have the authority to coordinate 
all activities essential for provi-
sion of screening services, in-
cluding training, documentation, 
monitoring, and other aspects of 
quality assurance.
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• Programmes should be imple-
mented gradually, tailoring ex-
pansion of the screening service 
to the capacity of the health-care 
system and with optimal accessi-
bility for less-advantaged groups 
in the target population.
Implementation of quality-assured 
population-based cancer screen-
ing programmes affects very large 
numbers of people in the eligible age 
range (see Chapter 4.7). The pro-
cess requires many years, beginning 
with the development and testing of 
a comprehensive quality assurance 
system to ensure the provision of 
cost-effective, affordable, and ac-
ceptable services for the entire target 
population. Carefully planned, long-
term investment of time and financial 
resources is justified because the 
impact of a population-based pro-
gramme goes far beyond the ser-
vices provided. Screening can stim-
ulate health systems development 
and raises the level of awareness 
of cancer symptoms among health-
care professionals and the general 
public. A quality-assured population-
based screening programme raises 
the standards of cancer diagnosis 
and treatment throughout the medi-
cal community. Professionals trained 
to meet the standards of the screen-
ing programme may also care for 
patients outside the programme. 
These factors, in combination, lead 
to an overall improvement in the level 
of cancer care [1].
Criteria for successful 
implementation of screening
Successful implementation of pop-
ulation-based cancer screening 
programmes requires expertise in 
areas relevant to other prevention 
activities, such as motivation, com-
munication, and reinforcement of 
efforts designed to prevent cancer 
[2]. The ability to mobilize large num-
bers of health-care professionals, 
other stakeholders, and the target 
population itself in collective actions 
focused on a common goal is cru-
cial to the success of any screening 
programme [3].
Programme implementation be-
gins with a planning and feasibility 
phase, which includes large-scale 
pilot studies to evaluate whether 
screening conducted as planned 
fulfils the key performance targets 
and is likely to be cost-effective. It 
may take several years to collect suf-
ficient data for valid conclusions to 
be drawn about routine implementa-
tion and to make any necessary ad-
justments to the screening protocol 
warranted by the pilot results. Pilot 
studies are also needed to provide 
information on the cost-effective-
ness of screening in the context of 
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an individual country. After success-
ful pilot studies, gradual, quality-
controlled roll-out of the programme 
across the country begins, with the 
health-care system controlling the 
pace of programme expansion, with 
particular reference to specialized 
training of staff and investment in in-
frastructure. The entire process of 
programme implementation rarely 
takes less than 10 years [1].
Certain conditions are essen-
tial to assure quality in population-
based screening programmes. 
These include long-term political 
commitment and competent over-
sight, adequate and sustainable 
resources, engagement of the com-
munity, international collaboration, 
and autonomous programme man-
agement with effective coordination 
of all activities, particularly commu-
nication and training, organizational 
development, and control of pro-
gramme resources [4]. Programme 
resources include a dedicated 
budget and staff, computerized in-
formation systems, and registries 
for cancer, population, and screen-
ing, all based on individual data 
[5]. Successful implementation of 
effective screening programmes 
requires national investment [6]. 
In a fully established programme, 
the proportion of the expenditure 
devoted to quality assurance in a 
high-resource setting should be no 
less than 10–20% [7]. A substantial 
proportion of these resources are 
required for well-organized informa-
tion systems, such as those used 
by cancer and screening registries, 
to provide reports on test results 
for participants and health profes-
sionals, to confirm that appropriate 
action follows a positive screening 
test, and to monitor performance 
and evaluate the impact of any 
screening programme [4].
Setting priorities in 
implementing screening 
programmes
Given the substantial resources 
required for successful implemen-
tation of population-based cancer 
screening programmes, efforts to 
improve early detection of cancer 
should be integrated into national 
comprehensive cancer control plans 
that establish overall priorities in the 
health-care agenda and take into ac-
count all relevant activities, such as 
national or regional programmes for 
reproductive health [8,9].
In most high-income countries, 
the burden of cancer has resulted 
in coordinated efforts to implement 
population-based screening for all 
of the tumour types for which evi-
dence-based methods are currently 
established (breast, cervical, and 
colorectal cancer). In other coun-
tries, due to the comparatively long 
period required to successfully es-
tablish population-based screening 
programmes, time trends in cancer 
incidence and mortality should be 
taken into account when prioritizing 
potential target cancers for screen-
ing [1]. On this basis, cancers cur-
rently suitable for screening in 
low- and middle-income countries 
include, for example, cervical can-
cer in sub-Saharan Africa, India, 
and Latin America; breast cancer in 
Latin America, the Middle East, and 
some countries in Asia; and colorec-
tal cancer in countries in transition, 
such as Brazil and China. Before 
a commitment is made to the roll-
out of a screening programme, the 
potential cost-effectiveness of the 
programme in the country should be 
taken into account. If pilot studies 
indicate that the cost per year of life 
saved by a given intervention is less 
than the per capita gross national 
product, a screening programme can 
be considered to be highly cost-ef-
fective in that setting [10].
The same principles of qual-
ity assurance for population-based 
screening apply to screening of 
high-risk groups or to early detection 
and treatment of symptomatic dis-
ease where significant proportions 
and numbers of patients are diag-
nosed with very-late-stage disease. 
Priority should be given to providing 
adequate resources for diagnosis 
and treatment of currently increas-
ing levels of symptomatic disease, 
for example through training of com-
petent staff. When access to prompt 
diagnosis and treatment is available, 
alternative strategies of early detec-
tion can be considered in countries 
where low incidence rates do not 
yet justify population-based screen-
ing programmes for asymptomatic 
Fig. 4.8.1. Immunochemical faecal occult blood testing kit used in the Lampang Province 
colorectal cancer screening programme in Thailand.
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people. In Iraq, for example, recent 
surveys show significant knowledge 
gaps in the educated population 
about the relative importance of 
breast cancer in the Iraqi population 
and the performance of breast self-
examination, suggesting a potential 
to increase early detection of breast 
cancer through better awareness 
[11]. Morocco is currently establish-
ing universal access to comprehen-
sive cancer diagnosis, treatment, 
and palliative care according to the 
2010–2019 national cancer control 
plan. This includes a nationwide 
early detection programme for clini-
cally detectable breast cancer [12].
Screening programmes in 
high-income countries
The first population-based can-
cer screening programmes were 
launched in middle- and high-income 
countries in the 1960s to 1980s, for 
cervical cancer screening. These 
programmes were based on con-
ventional cytology, and many led to 
reductions of 50–80% in cervical 
cancer mortality within two to three 
decades of implementation [13]. In 
recent years, primary cervical cancer 
screening by human papillomavirus 
(HPV) testing has been established 
as more accurate and effective. HPV 
testing is therefore expected to be-
come the preferred screening test for 
cervical cancer in the medium and 
long term [14,15].
The first population-based breast 
screening programmes based on 
mammography were initiated in 
Europe, Canada, and Australia in 
the late 1980s after randomized 
controlled trials showed the effi-
cacy of screening [16,17]. By 2012, 
population-based breast screening 
programmes were running or be-
ing established in 24 countries in 
the European Union and in several 
countries in Asia and the Americas. 
Screen-film mammography is be-
ing increasingly replaced by digi-
tal mammography [18]. Now that 
screening has been performed for 
more than two decades in several 
population-based programmes in 
Europe, methodologies used to 
estimate the impact of screening 
and the level of overdiagnosis have 
been evaluated using data from ser-
vice screening programmes [19]. 
Registry studies analysing popula-
tion breast cancer mortality rates 
over time underestimate the impact 
of screening on breast cancer mor-
tality because of their inability to ex-
clude deaths in women with breast 
cancer diagnosed before invitation 
to screening, and due to the inabil-
ity to discriminate between data of 
screened and unscreened women 
during the gradual implementation of 
a screening programme in a country 
or region [20].
Estimates of the impact of ser-
vice screening in Europe have re-
cently been obtained from a review 
of all available observational studies 
from which sufficient longitudinal in-
dividual data were available, directly 
linking a woman’s screening history 
to her cause of death. The authors 
considered that the most reliable es-
timates of reduction in breast cancer 
mortality were 25–31% for women 
invited for screening and 38–48% 
for women actually screened [21].
Reviews of all randomized clinical 
trials that evaluated annual or bien-
nial guaiac-based faecal occult blood 
testing indicate that trial participants 
allocated to screening had a 16% 
lower relative risk of colorectal cancer 
mortality [22]. Population-based colo-
rectal cancer screening programmes 
in developed countries are recent, 
and are still evolving in most coun-
tries. Acceptable and desirable levels 
of performance have recently been 
developed for the population-based 
programmes in Europe based on re-
sults achieved in randomized trials 
Fig. 4.8.2. Women lining up at Kanungu Health Centre IV in Uganda to receive HIV 
counselling and cervical cancer screening, and to learn more about available family 
planning services.
Fig. 4.8.3. Augusta Victoria Hospital in 
Jerusalem operates this mobile mammog-
raphy unit, which strives to identify women 
with breast cancer at an early stage so that 
they may be referred to the hospital for 
treatment, with better outcomes.
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and routine programmes [23]. Efforts 
are under way to improve programme 
performance in many countries [24].
Screening programmes 
in upper-middle-income 
countries
Opportunistic, large-scale cervical 
cancer screening has been conduct-
ed in some upper-middle-income 
countries for several years. The 
resulting impact on cervical cancer 
incidence and mortality has been 
limited, due to poor coverage and 
lack of quality assurance in cytol-
ogy screening, suboptimal adher-
ence by screen-positive women to 
further diagnosis and treatment, and 
lack of information systems to moni-
tor progress and assess impact. In 
Latin America, this has led to initia-
tives to reassess the approaches to 
cervical cancer control, taking into 
account opportunities to improve 
organization and quality assurance, 
as well as the introduction of HPV 
testing for cervical cancer screen-
ing, and HPV vaccination [25]. Self-
sampling has also been investigat-
ed and shows potential to increase 
cervical screening effectiveness by 
increasing participation, especially 
in women who are difficult to reach 
or who do not regularly attend cervi-
cal cancer screening [26]. In recent 
years, many of these programmes 
have been reorganized, and HPV 
testing is being integrated into rou-
tine screening in a phased manner 
in countries such as Argentina and 
Mexico. Sporadic and opportunistic 
mammography screening is wide-
spread, but population-based breast 
cancer screening programmes have 
yet to evolve in many upper-middle-
income countries. Colorectal cancer 
screening is less widespread; a na-
tional programme exists in Uruguay.
Screening programmes in 
lower-middle-income and 
low-income countries
Cancer screening programmes are 
operational in very few lower-middle-
income and low-income countries in 
Africa, Asia, Central America, and 
the Caribbean, despite the high risk 
of cervical cancer and the increasing 
incidence of breast cancer in these 
regions. Limited resources and inad-
equate development of health ser-
vices currently preclude introducing 
screening programmes in most of 
these countries. The challenges to 
introducing cytology screening and 
to improving treatment of screen-
positive women, as well as the lim-
ited impact of Pap smear screening 
in upper-middle-income countries, 
have prompted the search for alter-
native screening methods and algo-
rithms for cervical cancer control in 
low-resource settings. HPV testing 
and visual inspection of the cervix 
with acetic acid have been evalu-
ated as alternative methods, and 
single-visit approaches, involving 
diagnosis and treatment of screen-
positive women in the same sitting 
as screening, have been explored to 
improve compliance with treatment. 
Recent results from such studies 
have prompted the introduction of 
visual inspection of the cervix with 
acetic acid screening programmes 
in Bangladesh [27], Tamil Nadu state 
in India, Thailand [28], and Zambia 
[29], as well as demonstration 
programmes in 43 counties of 31 
provincial administrative areas in 
China and in several countries in 
sub-Saharan Africa (Fig. 4.8.4) and 
Central America. Implementation of 
acetic acid-based screening may 
improve development of screening 
infrastructure, which may, in turn, 
facilitate the introduction of HPV 
screening when simple and af-
fordable viral tests become widely 
available.
Limited resources and inad-
equate development of health ser-
vices preclude introducing mam-
mography screening programmes in 
most lower-middle-income and low-
income countries. Improving breast 
awareness may facilitate earlier clin-
ical diagnosis among symptomatic 
women in such settings, but these 
efforts may be counterproductive if 
the women cannot obtain timely di-
agnostic and therapeutic services. 
For the same reason, systematic ap-
proaches to early detection based 
on breast examination and imaging 
methods are required in countries 
that have an increasing burden of 
breast cancer but that currently lack 
adequate diagnostic and therapeu-
tic services [30,31]. Population-
based colorectal cancer screening 
Fig. 4.8.4. Women waiting to be screened during a cervical cancer prevention campaign 
organized by IARC and Conakry University Hospital, in the Republic of Guinea.
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does not exist in any low-income or 
lower-middle-income country, with 
the exception of Thailand, where 
a pilot colorectal cancer screening 
programme has been introduced as 
a forerunner to the phased national 
expansion.
Outlook
Breast, cervical, and colorectal 
cancer screening programmes have 
been improved globally through re-
search in terms of quality inputs, 
efficiency, and effectiveness. New 
research findings have catalysed 
the planning and organization of 
new screening programmes in some 
countries [32]. In the foreseeable fu-
ture, HPV vaccination programmes 
seem likely to reduce the prevalence 
of this viral infection and related pre-
cancerous lesions, necessitating 
more sensitive and objective screen-
ing tests [33]. Research has indicat-
ed the efficacy of mammography and 
faecal occult blood screening and 
paved the way for population-based 
screening programmes. Screening 
approaches for other tumour types, 
such as lung, ovarian, oesophageal, 
stomach, and prostate cancer, are 
currently being investigated in re-
search settings (Fig. 4.8.5), and in 
the case of gastric cancer also in 
the context of a population-based 
cancer screening programme in 
the Republic of Korea [34]. Unless 
these initiatives prove their efficacy, 
feasibility, and cost-effectiveness 
in those settings, population-based 
programmes are unlikely to be es-
tablished and widely implemented.
Population-based screening 
programmes for breast, cervical, 
and colorectal cancer have been 
introduced as part of cancer con-
trol in many high-income countries. 
Population-based cancer screening 
programmes do not exist in most 
low- and middle-income countries, 
where cancers are mainly detected 
through very-late-stage symptoms 
and many are not reported. Recent 
research may lead to new approach-
es to early detection and treatment 
using improved awareness of symp-
tomatic disease and population-
based screening of asymptomatic 
people.
Success in decreasing the bur-
den of cancer will depend on the 
acceptance by the population of a 
screening programme that is an-
chored in a comprehensive and 
well-structured cancer control pro-
gramme, and on the capacity of the 
health-care system to make efficient 
and appropriate diagnostic and ther-
apeutic services universally avail-
able for the cases detected early. 
Provision of adequate resources will 
be decisive.
International cooperation can 
enable countries to avoid common 
pitfalls in the implementation of 
screening programmes and other 
early detection programmes, and to 
share knowledge about successful 
methods and approaches. Sharing 
of expertise may enable a country 
to implement programmes more suc-
cessfully and to avoid unnecessary 
expenditure and delay.
Fig. 4.8.5. A woman being screened for stomach cancer at the Osaka Cancer Prevention 
and Detection Center, in Japan, in research directed towards the development of a 
population-based protocol for this tumour type.
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“Nothing in biology makes sense
except in the light of evolution”  
— T. Dobzhansky (1973)
Summary
Epidemiologists, cell and molecular 
biologists, geneticists and geno-
mics experts, and oncologists can 
all lay claim to significant contri-
butions towards the advancement 
of our understanding of cancer 
and its causation and treatment. 
But the stark fact remains that the 
worldwide burden of cancer re-
mains huge and is escalating, and 
advanced or metastatic disease is 
mostly intransigent to treatment. 
Billions of dollars are riding on the 
premise that personalized medicine 
and targeted therapy will come to 
the rescue. But do we really have 
an adequate grasp of the underly-
ing biology? Do we have a coherent 
framework for accommodating and 
rationalizing all the multilayered 
complexity that exists? Here, I ad-
vance the argument that cancer is 
a complex adaptive system and that 
its causation, stepwise emergence, 
and therapeutic resistance all fol-
low an evolutionary biology logic. 
The implications of this perspective 
for cancer control are considerable.
Darwinian evolution by natural se-
lection is the fundamental law of 
biology and provides the frame-
work for an understanding of the 
totality of the living world, from 
extremophilic species to human di-
versity. Modern genomics provides 
a striking validation of evolutionary 
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Fig. P4.1. Speciation of living organisms: 
the ancestral tree. Charles Darwin’s spe-
ciation “tree” from his notebook B, 1837. 
Founder 1 gives rise, via a branching ar-
chitecture, to variants A, B, C, and D.
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principles, by revealing phylogenet-
ic relationships of species and sig-
natures of prior, positive selection. 
How odd, then, that medical prac-
tice, which deals with dysfunctional 
biology, should have, until very re-
cently, remained impervious to this 
principle [1]. How can we under-
stand emergent infectious diseas-
es, antibiotic resistance, modern 
chronic diseases, drug resistance 
in cancer, and our vulnerability to 
cancer without reference to how 
our biology has been sculpted by 
evolutionary processes? In this 
Perspective, I summarize the ar-
gument that evolutionary biology 
provides a coherent framework that 
recognizes and rationalizes the in-
herent, multilayered complexity of 
cancer. Proximate causes and a 
gene-centric view of cancer can 
be placed in context. Our apparent 
vulnerability to cancer and our lim-
ited success in treating advanced 
disease can be seen in a different 
light. And, critically, an evolutionary 
biology paradigm can contribute 
novel ideas to the challenge of how 
we might best control cancer.
For the historical context of these 
ideas and more detailed data and 
argument, see [2–8].
Evolutionary determinants of 
vulnerability to cancer
Evolution operates by stochastic, 
or random, genetic variation that 
provides the substrate for selec-
tion in the context of environmental 
selective pressures. Winners who 
survive and reproduce have the 
best adaptive phenotypes or fitness 
in relation to the prevailing selective 
forces. This is very different from 
intelligent design in that evolution 
can only select from random varia-
tion in prior forms, or from the best 
of what’s available. This is a short-
term fix strategy with “no eyes to the 
future” [9]. What is much less ap-
preciated is the baggage, liabilities, 
and limitations that this inevitably 
entails (Table P4.1). These consid-
erations can help rationalize the 
counterintuitive or paradoxical role 
of endogenous processes in can-
cer, the ubiquity of mutant clones 
and premalignant lesions, and the 
Table P4.1. Evolutionary determinants of vulnerability to cancer
Principle Liability Impact in cancer
Principle 1. 
Evolution just selects from the best 
available variants.
Limitations or imperfections of 
design, function, and specificity.
Error-prone replication.
Error-prone DNA repair.
Stem cells have inherent malignant potential: extensive, 
replicative, potential migratory phenotype, and quiescence 
option.
Beneficial adaptive responses: inflammation, wound healing, 
and angiogenesis facilitate cancer promotion.
Intrinsically mutagenic enzymes with off-target substrates: 
RAGs (lymphoid cancers), APOBECs/AID (multiple cancers/
lymphoid cancer).
Principle 2. 
Evolution has “no eyes to the 
future”; it just selects what fits 
best, now.
When environmental circumstances 
change, previously beneficial phe-
notypes become mismatched with 
our genetic heritage.
Contemporary lifestyles, especially in affluent or “developed” 
societies, are mismatched with human adaptation to more 
ancient environments:
High UVB exposure versus under-melanized skin: skin 
cancers.
Delayed first pregnancy, minimal breast feeding, 
estrogen-fuelling diets versus non-seasonal estrus: 
breast cancer, ovarian cancer.
Diminished infection in infancy versus programmed 
anticipation of infection in the immune system: childhood 
acute lymphoblastic leukaemia.
Principle 3. 
Natural selection can only operate 
on phenotypes that have impacts 
on survival and reproduction.
There is little or no evolutionary 
resilience for deleterious 
phenotypes in the post-
reproductive period.
Adaptive features that are 
beneficial for reproductive life can 
later impose a trade-off or penalty 
(= antagonistic pleiotropy).
Our adaptive phenotypes are optimized for reproductive life 
versus extensive (decades) post-reproductive longevity: 
time for accidents to happen (via liabilities 1 and 2 above) 
(= age-associated cancer incidence).
Principle 4. 
Natural selection will always 
happen when replicating units 
have diversity and there is 
competition for resources and 
selective pressures that influence 
fitness for reproduction and that 
vary in space and time.
Clonal escape. Progressive selection of more robust or resilient clonal 
variants, metastasis, and drug resistance.
AID, activation-induced deaminase; APOBEC, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like; RAGs, recombination activating genes; 
UVB, ultraviolet B.
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high frequency of cancer in ageing 
humans in modern societies.
Evolutionary considerations may 
also help us to understand why inher-
ent susceptibility to particular can-
cers, for example breast or prostate 
cancer, is highly variable within hu-
man populations. Recent genome-
wide association studies have pro-
vided an audit of inherited gene 
variants that increase risk [10]. Highly 
penetrant mutant alleles, such as 
BRCA1 and BRCA2, exist at relative-
ly high frequencies in certain popula-
tions. This is best rationalized not by 
any historical, adaptive benefit they 
endowed but from founder effects, 
i.e. an origin in an individual (2000–
3000 years ago for BRCA1) who 
survived a population bottleneck [11]. 
More common allelic variants are as-
sociated with much lower risk levels 
(odds ratios, 1.01–1.3) [10]. But why 
should such deleterious variants be 
common? A significant fraction of the 
variants that affect breast and pros-
tate cancer are in genes that encode 
proteins in estrogen or androgen 
metabolism and signalling and re-
sponse pathways [12–14]. One possi-
bility is that the relatively high frequen-
cy of these alleles reflects prior positive 
selection because of a beneficial effect 
on enhancing fertility [15]. Genomic 
signatures can reveal whether genes 
have been subject to positive, adap-
tive selection during human evolution 
and the approximate time frames in-
volved [16].
Clonal evolution and cellular 
adaptability
Cancer is a complex adaptive sys-
tem with emergent properties, 
some of which are both consistent 
with and deleterious to the host – 
metastasis and drug resistance in 
particular. Cellular adaptability de-
rives from two principal sources: 
genetic or mutational diversity, and 
epigenetic or phenotypic plasticity. 
Both are critical in cancer.
For the past 3 billion years, when-
ever replicating entities – molecules, 
cells, or individuals – have diversi-
fied and were confronted with a chal-
lenging or competitive environment, 
evolution by natural selection has 
occurred (principle 4 in Table P4.1) 
[17]. This is a, or even the, hallmark 
feature of cancer, at the somatic cell 
level – although curiously not listed 
as such [18]. Those 10 cellular fea-
tures that are considered cancer 
hallmarks, including angiogenesis, 
evading cell death, and immune 
evasion [18], all enhance fitness for 
survival and/or reproduction – the 
ultimate register of evolutionary suc-
cess. The idea that cancer involves 
sequential genetic changes in cells 
was evident from chromosome stud-
ies for many years [19,20] but was 
first clearly posited as the clonal 
evolution paradigm by Peter Nowell 
in 1976 [2]. Since then, technical ad-
vances in genetics, genomics, cell 
sorting, microscopy, and polymer-
ase chain reaction (PCR)-based as-
says, culminating in single-cell ge-
nomics [21–23], have validated this 
concept and revealed the extensive 
and dynamic intraclonal genetic di-
versity that exists in cancer [7]. The 
parallels with Darwinian evolution-
ary speciation in ecosystems, miss-
ing from the original vision [2], are 
now explicitly recognized [7].
Every patient’s cancer has a 
unique evolutionary trajectory or 
phylogenetic tree, with a branching 
Fig. P4.2. Speciation of a cancer clone. Diagram showing the phylogenetic tree or 
evolutionary relationships of seven genetically diverse subclones of acute lymphoblastic 
leukaemia (ALL), all derived from a single common ancestral cell. All cells have been 
interrogated for the eight mutations listed on the left. Those mutations were determined 
by exome sequencing and single-nucleotide polymorphism arrays on whole leukaemic 
sample B1 (7.1%) normal cells. (Data from [23] using microfluidic-based multiplex 
quantitative polymerase chain reaction for single-cell genetic analysis.) 0C, loss of 
both copies; 1C, loss of one copy; het, heterozygous; homo, homozygous.
Table P4.2. Cancer cells’ evolutionary resilience and routes to therapeutic escape
Component Basis of resistance/adaptability [source]
Genetic diversity Drug (or immunological) targets or components of cellular response 
mutate [61].
Drug target (e.g. mutant protein) is segregated in subclone.a
Epigenetic 
plasticity
Cells bypass redundant signalling pathways blocked by drugs [45].
Stem cells adopt quiescent “resistant” state [62,63].
a Suggested by clonal variegation of mutations [24,25].
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clonal architecture, as long recog-
nized in ecological speciation (Figs 
P4.1, P4.2). Some mutations are 
consistently present in all cells at 
the base or trunk of the phyloge-
netic tree, suggesting that they may 
be founder or initiating lesions, for 
example ETV6-RUNX1 mutations 
in acute lymphoblastic leukaemia 
(ALL) [23,24] and von Hippel–Lindau 
(VHL) gene mutations in renal carci-
nomas [25]. Genetically distinct sub-
clones of cancer frequently exist in 
distinctive, topographically different 
regions of tissues [25,26]. This is 
anticipated from evolutionary prin-
ciples (consider Galapagos Islands 
finches) and poses considerable 
problems for traditional approaches 
to biopsy-based sampling and prog-
nostics, as well as for biopsy-based 
genomics [27]. Although only a few 
studies have integrated serial sam-
ples from primary tumours, metasta-
ses, and post-therapeutic relapses 
or recurrences [8,24,28], the pat-
terns that emerge are of dynamic 
shifts in clonal architecture, with 
minor subclones emerging after se-
lective sweeps (Fig. P4.2). Dominant 
clones in relapse [29], drug-resistant 
recurrence [30,31], or metastasis 
[28] emerge from previously minor 
subclones whose existence can be 
traced back to primary samples.
The evolutionary dynamics of 
cancer are extremely variable, with 
intervals between initiation and di-
agnosis of 1–50 years. The pace 
of evolution is often characterized 
by long periods of stasis or slow 
change, with occasional abrupt or 
catastrophic changes [8,32], par-
alleling punctuated equilibrium in 
ecological evolution [33]. Oncogenic 
mutations are extremely common in 
all of us; premalignant lesions are 
probably ubiquitous, but only a frac-
tion of them evolve to fully fledged 
malignancy [34]. The implication of 
this modest evolutionary penetration 
is that restraints are largely effective 
and promotional factors are likely 
critical. The challenge for epidemi-
ologists is taking this protracted and 
“sluggish” natural history into ac-
count, especially with respect to the 
timing of causative exposures. For 
those interested in causation, cancer 
genomics may provide some vital 
clues. Although mutations are sto-
chastic in origin, sequencing reveals 
mutational signatures that are indic-
ative of underlying mechanisms of 
mutation and, in some cases, reflect 
the nature of genotoxic exposures 
[35–37].
Clonal evolution, as with specia-
tion in ecology, is contingent upon 
ecosystem (tissue-derived or fil-
tered) selective pressures, modu-
lated by inherited susceptibility 
and chance (Fig. P4.3). Chance is 
all-pervasive in evolutionary biolo-
gy and cancer because mutations 
are stochastic with respect to the 
functions encoded by genes [3]. 
The emergence of subclones with 
particular putative “driver” muta-
tions can be viewed as an adaptive 
response to selective pressures, of 
which environmental and therapeu-
tic exposures are clear examples. 
Intense therapeutic selective pres-
sure often has the exact opposite 
effect to that desired: the positive 
selection of previously silent and 
innocuous subclones. Metastases 
are likely to require adaptation to ec-
topic tissue, fermenting further evo-
lution. Adaptation of cancer cells via 
beneficial mutations involves both 
gain-of-function mutants (activat-
ing oncogenes) and loss-of-function 
mutants (deleted tumour suppressor 
genes), similar to bacteria adapting 
to adverse conditions [38]. The com-
plex mutation profiles of individual 
Fig. P4.3. Components of cancer clone evolution. The different colours represent 
genetically distinct subclones. The roulette wheel symbolizes the role of chance in 
all components. Endogenous selective pressures include inflammation, anoxia, and 
metabolic stress [57].
Table P4.3. Evolutionary parameters are predictive of cancer progression and 
clinical outcome
Evolutionary parameter Clinical outcome [source]
Measures of intraclonal 
genetic diversity (substrate for 
selection)
Progression of Barrett oesophagus [64] and chronic 
lymphocytic leukaemia [65].
Survival in head and neck cancer [66].
Burden of stem cells (units of 
selection)
Progression and outcome in multiple cancers ([67] and 
references therein; [68]).
Ecosystem diversity (selective 
pressures)
Survival in breast cancer [69].
Mathematical modelling [70].
An evolutionary foundation for cancer control 341
cancer cells reflect combinatorial 
impacts on cellular fitness and, in 
some cases, epistatic interactions 
of mutations, which occur in evolu-
tion in general [39]. Genetic insta-
bility and chromosomal aneuploidy, 
common features in cancer, are 
other adaptive tactics that acceler-
ate the pace of diversification and 
increase the probability of beneficial 
mutations arising. Bacteria use the 
same evolutionary trick under chal-
lenging conditions: blind, but more 
frequent, spinning of the roulette 
wheel (Fig. P4.3).
Epigenetic plasticity
The adaptive resilience of cancer 
cells is not solely dependent on 
mutation. Cells within individual 
genetically homogeneous clones 
have epigenetic plasticity and di-
verse alternative phenotypes that 
are spatiotemporally expressed 
(Fig. P4.4A) [40–42]. This facili-
tates evasion of a therapeutic chal-
lenge (Table P4.2). The adaptability 
of cells is further evidenced at the 
single-cell level. Each cell has an 
extensive, complex signalling net-
work that is highly dynamic, robust, 
and adaptable (Fig. P4.4B) [43]. In 
cancer, all functionally relevant mu-
tations [44] effectively corrupt these 
networks, resulting in dysregulation 
or resetting to a new steady state 
(e.g. “on” for proliferation). The 
critical nodes in the signalling net-
works of normal cells, as well as 
cancer cells, have built-in redun-
dancy, which provides yet another 
adaptive route to clonal escape in 
cancer, for example from targeted 
therapy (Table P4.2) [45]. The in-
trinsic adaptability or epigenetic 
plasticity of cells is itself an ancient 
evolutionary legacy reflecting built-
in safeguards to combat adverse 
circumstances, particularly for stem 
cells in more complex long-lived or-
ganisms. Cancer stem cells “hunker 
down” or adopt a dormancy (or qui-
escent) status under chemothera-
peutic challenge [46], an adaptive 
tactic of considerable evolutionary 
antiquity [47]. Those cells within 
subclones that have self-renewal 
or stem cell competence [48] are 
crucial to both clonal progression 
and adaptability as they are, in evo-
lutionary terms, the “units of selec-
tion” [49] by virtue of their capacity 
for extensive or unlimited self-re-
newal and proliferation [50]. In ac-
cordance with a status of “units of 
selection”, cancer stem cells within 
individual patients are genetically 
diverse [24] as well as phenotypi-
cally plastic [41].
Can we predict and thwart 
the evolutionary resilience of 
cancer?
Despite the enthusiasm and some 
successes for genome-guided per-
sonalized medicine and targeted 
therapeutics in cancer, it is evident 
Fig. P4.4. Epigenetic plasticity of cancer cells. (A) Illustration of the variation of 
phenotype within a single subclone. C, cell; D+, differentiating cells; Q, quiescent (out-
of-cycle) cells. (B) Depiction of the complex and dynamic signalling networks of an 
individual cell [43]. Dense coloured regions indicate critical signalling routes. Pathways 
involved are indicated around the outside of the cell. These data derive from genetic 
(mutational) analysis of gene interactions in yeast cells. We currently have no such 
wiring diagram for human cells. The figure underestimates complexity by showing 
interaction networks under single, steady-state conditions. The reality is considerably 
more dynamic and complex.
B
A
Q D+ D+
C
C
C
Self-renewing 
stem cells
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that the adaptive resilience of cancer 
cells usually wins out, a pyrrhic vic-
tory for the genetic and epigenetic 
adaptability of cells (Table P4.2). 
Evolutionary principles of natural 
selection suggest that the likeli-
hood of therapeutic failure should 
be predictable by quantitative mea-
sures of the major drivers of clonal 
diversity and selection. In strains of 
microbial species, mutation rates 
are predictive of the probability of 
drug-resistant mutants [51]. The 
same has long been anticipated for 
cancer, but here mutation rates are 
difficult to measure because of dy-
namic changes and topography of 
subclones. However, other evolu-
tionary parameters that should be 
predictive of the likelihood of mu-
tation-based drug resistance can 
be assayed and quantified: genetic 
diversity within the clone, the size 
of the selectable stem cell compart-
ment, and the diversity of the eco-
system. Recent data confirm these 
expectations (Table P4.3), with con-
siderable implications for instiga-
tion of tests that can predict cancer 
progression of early lesions or ther-
apeutic resistance. The implica-
tions for treatment itself are major. 
We are pollarding (or pruning) the 
major branches of the cancer clone 
phylogenetic tree, largely in igno-
rance of its architecture and intrin-
sic resilience. The common conse-
quence, post-therapeutically, is the 
illusory success of transient tumour 
shrinkage, followed by florid regen-
eration as residual minor clones 
adapt to the new circumstances.
Given the extraordinary adapt-
ability of cells, the sheer number of 
proliferative cycles (1011 per day in 
the small intestine and bone mar-
row), and the inherent risk of mu-
tation and the ubiquity of covert 
tumours [49], it is perhaps surpris-
ing that we don’t all have malignant 
cancer at an early age [52]. The rea-
son is that the success of multicel-
lularity as an evolutionary innovation 
some 600 million years ago required 
securing the maintenance of tissue 
integrity with multiple restraints on 
clonal expansion. This included the 
innovation of gene functions that can 
also operate as tumour suppressors 
[52–54]. And, despite the indulgenc-
es of human behaviour, these re-
straints remain largely successful up 
to and during our evolutionarily “use-
ful” reproductive lifetime. But the 
challenging reality is that approxi-
mately one in three individuals will 
receive a diagnosis of life-threat-
ening cancer. From an evolutionary 
perspective, the question that needs 
to be posed is: “How can we best 
thwart the evolutionary resilience 
of cancer?” The same issue is cen-
tral to the control of drug-resistant 
tuberculosis, malaria, and HIV [55]. 
Generally, we already know what to 
do for cancer (Fig. P4.5). The prob-
lem is where to put our efforts and 
resources, and what particular tac-
tics to adopt. The best way to stop 
evolution is clearly to prevent it start-
ing in the first place. But once it’s up 
and running, there are strategies 
available that are distinct from cur-
rent or conventional practice, some 
of which exploit cancer’s evolution-
ary features and ecological depend-
encies (Fig. P4.5) [56–60]. To do 
this effectively would require consid-
erable refocusing of current cancer 
research and therapeutic priorities. 
And a recognition of cancer’s indel-
ible, evolutionary character.
This Perspective is dedicated to the memory 
of Professor Pat Buffler.
Fig. P4.5. How can we thwart cancer’s evolutionary resilience? Numbers on the 
left indicate the percentage of cancers that might be prevented or controlled by 
implementing these three approaches. The proportion of 75% for prevention is based 
on original estimates by Doll and Peto [71]. (1) Vaccines for infection-associated 
cancers: human papillomavirus, Epstein–Barr virus, hepatitis B virus, hepatitis C virus, 
Helicobacter pylori, etc. (2) Smoking, chronic or intermittent, and exposure to intensive 
ultraviolet B radiation. (3) Diet and exercise. (4) Surgery for some premalignant 
lesions (skin, colon, cervix); non-steroidal anti-inflammatory drugs (e.g. aspirin) for 
premalignant lesions of the gastrointestinal tract and others [72]. (5) As for HIV [52], 
but applied to cancer [73,74]. (6) See [75]. (7) Molecules that cancer cells invariably 
depend upon or are addicted to, for example activated MYC, heat shock proteins, self-
renewal signalling. (8) Founder lesion in base or trunk of phylogenetic tree [24,25,76]. 
Target in every cancer cell, for example ABL kinase targeting with imatinib in chronic 
myeloid leukaemia [77]. (9) Targeting features of self-renewal signatures of cancer 
stem cells that are different from those of normal stem cells [63,78,79]. (10) Anti-
angiogenesis, anti-inflammatories, modest-dose cytostatic versus intensive cytotoxic 
therapy; see [58–60].
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Different tumour types may be characterized with ref-
erence to epidemiology, etiology, pathology, genetics, 
and prevention. Current knowledge in these fields is 
the culmination of decades, if not centuries, of re-
search, but progress has not been uniform. Notably, 
remarkable advances have accrued through a par-
ticular approach during a relatively short period. This 
edition of World Cancer Report corresponds to a new 
dimension in characterization of cancer as a genetic 
disease. Investigation of single genes – epitomized 
by oncogenes and tumour suppressor genes – has 
been eclipsed by sequencing of the whole genome, 
transcriptome, epigenome, or comparable entity for 
each of the major tumour types, typically involving 
multi-institutional collaborations based on hundreds of 
specimens. The benefits – definition of susceptibility, 
improved means of diagnosis, and development of 
targeted therapies – vary markedly between tumour 
types. It is clear that cancer is not a single disease 
but a multiplicity of different diseases. Identification 
of exogenous causes, screening methods, high-risk 
groups, means of diagnosis, and effective therapy 
vary across tumour types; in most cases the spectrum 
extends from comprehensive understanding to, as 
yet, no meaningful impact. Accordingly, knowledge 
about cancer must be specified with respect to each 
tumour type.
Cancer by 
organ site
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Incidence
Incidence is defined as the number 
of new cases of a disease arising in 
a given period in a specified popu-
lation. It can be expressed as an 
absolute number of cases per year 
or as a rate per 100 000 persons (or 
some other denominator) per year. 
The rate provides an approximation 
of the average risk of developing a 
cancer.
Mortality
Mortality is defined as the number 
of deaths due to a specific under-
lying cause occurring in a given 
period in a specified population. It 
can be expressed as an absolute 
number of deaths per year or as a 
rate per 100 000 persons (or some 
other denominator) per year.
Age standardization
In this Report, all incidence and 
mortality rates are age-standard-
ized. An age-standardized rate 
(ASR) is a summary measure of the 
rate that a population would have 
if it had a standard age structure. 
Standardization is necessary when 
comparing several populations (or 
the same population at different 
time points); age has a powerful 
influence on the risk of cancer, 
and populations differ with respect 
to their age distribution. Here, the 
ASR uses the World Standard 
Population (of Segi [1], as modi-
fied by Doll et al. [2]). The calcu-
lated incidence or mortality rate is 
then called the age-standardized 
incidence or mortality rate (World) 
and is conventionally expressed per 
100 000 persons.
Graphics
Maps, bar charts, pie charts, and time 
trend figures are shown in the global 
cancer burden overview (in Section 
1) and in site-specific chapters (in 
Section 5). In the chapters in Section 
5, maps, pie charts, and time trend 
figures are provided for both inci-
dence and mortality where important 
differences are in evidence (e.g. for 
breast cancer and colorectal cancer). 
For cancer sites where survival is rel-
atively low and has changed relatively 
little, the figures focus on incidence 
(e.g. for lung cancer and pancreatic 
cancer). The figures are generally dis-
played for men and women separate-
ly, although for certain sites, a choice 
has been made to select patterns and 
trends in either men or women where 
they are reasonably comparable (e.g. 
for leukaemia) or where certain sex-
specific features can be highlighted 
(e.g. for thyroid cancer).
Data sources
The graphics are built on three data 
sources. First, the maps and the pie 
charts are based on national inci-
dence and mortality estimates from 
GLOBOCAN 2012 [3]. This provides 
incidence, mortality, and prevalence 
estimates for 27 site-specific can-
cers and for all sites combined in 
184 countries worldwide. The un-
derlying principle in the estimation 
process is a reliance on the best 
available data on cancer incidence 
and/or mortality within a country 
to build up the global picture. The 
results are more accurate or less 
accurate for different countries, de-
pending on the extent and accuracy 
of locally available data. Second, 
the incidence time trends and bar 
charts are based on observed data 
series from regional or national 
population-based cancer registries, 
extracted from Cancer Incidence in 
Five Continents (CI5) Volumes I to 
X [4,5] and completed with more 
recent data available from corre-
sponding cancer registry websites. 
Third, the mortality data for the time 
trends and bar charts originate from 
the WHO Mortality Database [6] (or 
the Centers for Disease Control and 
Prevention [7] for the USA) and, ex-
cept for China, are available only at 
the national level.
Maps
The maps provide a global picture 
of the burden of a cancer site, by 
sex.
Pie charts
When both incidence and mortality 
pie charts are presented, the area 
of the mortality pie is proportional 
to the number of deaths relative to 
the number of new cases.
Bar charts
Bar charts of incidence and mor-
tality by cancer, and of incidence 
and mortality by registry/country 
for all sites combined, are shown 
in Chapter 1.1.
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Time trends of 0.5 was used for seven specific 
cancer sites (oesophagus, liver, 
pancreas, kidney, testis, thyroid, 
and nervous system) due to the 
small number of cases. As annual 
data for Uganda were not available, 
natural cubic spline interpolation 
was used to predict the values for 
the missing years. Care should be 
taken when comparing incidence 
graphs (time trends or bar charts) 
as the scales used on the vertical 
axes may differ.
Notes for bar charts
Average annual mortality rates for 
China are for 1996–2000. Average 
annual mortality rates for Australia 
are for 2000–2004.
Notes for time trends and bar 
charts
Countries represented by regional 
registries are marked with *; other-
wise, registries are national.
Countries represented by one 
or more than one regional regis-
try: China (Hong Kong Special Ad- 
ministrative Region and Shanghai), 
Colombia (Cali), India (Chennai and 
Mumbai), Japan (Miyagi, Nagasaki, 
and Osaka Prefectures), Spain 
(Granada, Murcia, Navarra, and 
Tarragona), Uganda (Kampala), and 
USA (the Surveillance, Epidemiology 
and End Results [SEER] 9 registries: 
states of Connecticut, Hawaii, Iowa, 
New Mexico, and Utah and metro-
politan areas of San Francisco–
Oakland, California; Detroit, Michi- 
gan; Seattle–Puget Sound, Wash- 
ington; and Atlanta, Georgia).
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To highlight recent temporal devel-
opments, time trends are described 
from about 1975 onwards. For all 
cancer sites, data were selected 
that cover the same set of 11 coun-
tries for incidence and 9 countries 
for mortality (no mortality data were 
available for Uganda or India, and 
mortality data for China were avail-
able only for specific cancer sites). 
For the USA, incidence and mortality 
data are shown separately for Black 
and White populations. A logarithmic 
scale is used for the age-standard-
ized rates to show the variety of pat-
terns between populations. 
Locally weighted regression 
curves were fitted to provide 
smoothed lines through the scat-
ter plot of ASR by calendar year. 
A bandwidth of 0.3 was used, 
i.e. 30% of the data were used in 
smoothing each point. A bandwidth 
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Summary
• Lung cancer is the most com-
mon cancer in men and the third 
most common in women.
• Tobacco smoking, including 
second-hand smoke, is the pre-
dominant cause of lung cancer 
worldwide. Other causes of lung 
cancer include radon, occupa-
tional exposure to polycyclic 
aromatic hydrocarbons, certain 
metals, asbestos, and crystalline 
silica, as well as exposure cir-
cumstances relevant to certain 
categories of work, and expo-
sure to outdoor air pollution, and 
specifically to particulate matter 
and diesel engine exhaust, and 
to indoor air pollution, including 
second-hand tobacco smoke 
and emissions from household 
combustion of coal.
• Historically, small cell lung car-
cinoma has been distinguished 
from non-small cell lung carcino-
ma, which includes the histologi-
cal types of adenocarcinoma, 
squamous cell carcinoma, and 
large cell carcinoma. Further 
subtyping is increasingly done 
on a molecular basis.
• Adenocarcinomas have driver 
mutations, most commonly involv-
ing EGFR and KRAS mutations  
5.1
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as well as ALK fusions; squa-
mous cell carcinomas have 
molecular alterations involv-
ing SOX2, TP63, FGFR1, and 
DDR2, and most small cell carci-
nomas express neuroendocrine 
markers and have TP53 and RB1 
mutations. Lung cancers from 
smokers exhibit up to 10 times 
as many mutations as tumours 
from never-smokers.
• Screening for lung cancer is un-
der development.
• Lung cancer is one of the most 
aggressive human cancers, 
with a 5-year overall survival of 
10–15%.
There are four major histological 
types of lung cancer: adenocarci-
noma, squamous cell carcinoma, 
small cell carcinoma, and large 
cell carcinoma. These tumours are 
defined primarily by morphology; 
however, in the past 10 years these 
tumours have started to be classified 
according to immunohistochemical 
and genetic characteristics as well.
Etiology
The most common cause of lung 
cancer is cigarette smoking; tobacco 
smoke is the most intensively inves-
tigated of all known carcinogens [1]. 
Local forms of tobacco smoking, 
such as bidis in India (Fig. 5.1.1), are 
also important. Risk is often related 
to the product of smoking rate and 
duration of smoking (“pack-years”), 
but more precise specification is 
possible. The lung cancer incidence 
rate is proportional to the fourth pow-
er of age in never-smokers, and the 
excess in smokers is proportional to 
the fourth power of smoking dura-
tion multiplied by the number of ciga-
rettes smoked per day [2]. Recent 
analysis based on European and 
Canadian cases indicated that ad-
enocarcinoma was the most preva-
lent lung cancer subtype in never-
smokers and in women; squamous 
cell carcinoma predominated in male 
smokers. Smoking exerted a steeper 
risk gradient on squamous cell car-
cinoma and small cell lung cancer 
than on adenocarcinoma [3]. Diverse 
indicators of injury to respiratory tis-
sue likely related to tumorigenesis 
are evident before the onset of clini-
cal disease (see “Earliest molecular 
evidence of tobacco-induced injury 
in the airway”). Smoking cessation 
efforts have resulted in a growing 
percentage of lung cancers among 
nonsmokers, particularly those with 
adenocarcinoma histology.
Although smoking is estimated 
to account for about 90% of lung 
cancer cases in high-income coun-
tries, a wide range of agents are 
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Epidemiology
Lung cancer
• Lung cancer remains the most 
frequent cancer worldwide. 
There were more than 1.8 million 
new cases (13% of total cancer 
incidence) and almost 1.6 mil-
lion deaths (20% of total cancer 
mortality), as estimated in 2012. 
More than one third of all newly 
diagnosed cases occurred in 
China.
• Lung cancer is the leading 
cause of cancer death in men 
in 87 countries and in women in 
26 countries. Age-standardized 
rates vary 80-fold internationally, 
are highest in North America, 
Europe, and East Asia, and tend 
to still be relatively low in many 
African countries and some 
Asian countries.
• Due to a high and rather stable 
case fatality rate, patterns and 
trends for mortality rates are sim-
ilar to those for incidence rates, 
irrespective of level of resource 
within a given country.
• Recent trends in lung cancer re-
flect the evolution of the smok-
ing epidemic. In men, incidence 
rates have peaked in a number 
of highly developed countries at 
a late stage of the tobacco epi-
demic, while rates continue to 
rise among women.
• Only in a few countries (Australia 
and the USA), where the tobacco 
epidemic is most advanced and 
smoking prevalence has been 
declining for several decades, 
are there recent downward in-
cidence trends among women.
Map 5.1.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for lung cancer in men, 2012.
Map 5.1.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for lung cancer in women, 2012.
recognized to cause lung cancer, and 
for others the evidence is less than 
definitive. A review of IARC Group 1 
carcinogens encountered at highest 
concentrations in an occupational 
context predominantly involved cau-
sation of lung cancer as covered in, 
although not restricted to, two vol-
umes of the IARC Monographs. One 
volume considered arsenic, met-
als, fibres, and dusts [4]. The other 
considered mainly organic com-
pounds [5], not only specific chemi-
cals but also certain categories of 
employment, including work as a 
painter and work in the rubber in-
dustry. In an analysis of the burden 
of occupational lung cancer in the 
United Kingdom, asbestos exposure 
contributed by far the largest number 
of cases [6]. Radon is also identified 
as a risk factor for lung cancer [7].
An editorial, prompted by publi-
cation of a meta-analysis based on 
17 cohorts in nine European studies, 
specified that air pollution may be 
recognized as a cause of lung cancer. 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.1.1. Estimated global number of new cases and deaths with proportions by major world regions, for lung cancer in 
both sexes combined, 2012
Chart 5.1.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for lung cancer in 
men, circa 1975–2012.
Chart 5.1.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for lung cancer in 
women, circa 1975–2012.
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Fig. 5.1.1. Older men smoking tobacco in India. Bidis, made of coarse and uncured 
tobacco, account for about 60% of smoked tobacco products in India, whereas ciga-
rettes account for 20%.
The data included a statistically sig-
nificant association between risk of 
lung cancer and particulate matter 
with a diameter less than 10 µm 
(PM10) (hazard ratio, 1.22; confi-
dence interval, 1.03–1.45) [8]. IARC 
recently concluded that long-term 
exposure to outdoor air pollution, 
and specifically particulate matter 
in outdoor air, causes lung cancer 
[9]. Such findings involve outdoor 
air pollution (see “Biomarkers of air 
pollution”). Categories of air pollu-
tion recognized to cause lung cancer 
also include exposure to second-
hand tobacco smoke and to emis-
sions from household combustion of 
coal [10,11].
Using defined terminology, the 
World Cancer Research Fund re-
ported convincing evidence for 
causation of lung cancer by arsenic 
in drinking-water and by β-carotene 
supplements, as well as probable ev-
idence of decreased risk consequent 
upon consumption of fruits and of 
foods containing carotenoids [12]. 
Rare familial cases occur, and com-
pared with nonfamilial cases these 
patients present with earlier patho-
logical stage and more cancers with 
adenocarcinoma subtype [13].
Pathology and genetics
Historically, small cell lung carcino-
ma has been distinguished from non-
small cell lung carcinoma (NSCLC), 
which includes the histological types 
of adenocarcinoma, squamous cell 
carcinoma, and large cell carcino-
ma. However, in the past decade, 
the distinction between adenocarci-
noma and squamous cell carcinoma 
has been increasingly recognized 
because of major differences in ge-
netics and also in responses to spe-
cific therapies [14]. Therefore, lung 
cancers are increasingly classified 
according to molecular subtypes, 
predicated on particular genetic 
alterations that drive and maintain 
lung tumorigenesis. Such driver 
mutations, and the associated con-
stitutively active mutant signalling 
proteins, are critical to tumour cell 
survival, leading to the development 
of novel targeted therapies. These 
driver mutations are best established 
for adenocarcinoma, and more re-
cently a list of oncogenic drivers for 
squamous cell carcinoma has been 
discerned, allowing the identifica-
tion of potential targeted therapies. 
Nevertheless, for the majority of lung 
cancers, there is as yet no clear first-
line chemotherapy targeting a driver 
signature.
A genetic basis of susceptibility 
to lung cancer generally, as distinct 
from susceptibility to particular tu-
mour types, has been extensively 
investigated. Large, collaborative 
genome-wide association studies 
have identified three separate loci 
that are associated with lung cancer 
(5p15, 6p21, and 15q25) and that 
include genes regulating nicotinic 
acetylcholine receptors and telo-
merase production. However, much 
about genetic risk remains to be 
discovered, and rarer gene vari-
ants, such as those of the CHEK2 
gene, likely account for most of the 
remaining genetic susceptibility [15]. 
Studies of single-nucleotide poly-
morphisms, based on carcinogen 
metabolism and DNA repair mediat-
ing susceptibility to tobacco smoke-
induced carcinogenesis, have pro-
vided limited insight.
Lung adenocarcinoma
Adenocarcinomas represent 40% 
of all lung cancers in the USA [16]. 
Most lung adenocarcinomas are 
diagnosed in the periphery of the 
lung (Fig. 5.1.2). Major changes to 
the 2004 WHO classification are 
recommended in light of the 2011 
International Association for the 
Study of Lung Cancer, American 
Thoracic Society, and European 
Respiratory Society classification of 
lung adenocarcinoma [17]. The term 
“bronchioloalveolar carcinoma” is no 
longer used.
In small biopsies or cytology 
specimens, a tumour is classified 
as adenocarcinoma if it shows 
clear glandular morphology such as 
acinar, papillary, lepidic, or solid with 
mucin patterns. In tumours that lack 
any clear adenocarcinoma or squa-
mous cell carcinoma morphology, 
the tumour requires further evalu-
ation with immunohistochemistry 
through a limited work-up using a 
single adenocarcinoma marker (i.e. 
TTF-1) and squamous marker (i.e. 
p63 or p40). If a tumour is positive 
for TTF-1 but negative for a squa-
mous marker, it is classified as 
“NSCLC, favour adenocarcinoma” 
[17]. However, if no adenocarcino-
ma or squamous differentiation is 
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Earliest molecular evidence of tobacco-induced injury in the airway
Avrum Spira
Cigarette smoke creates a molecular 
“field of injury” in all airway epithelial 
cells exposed to the toxins associ-
ated with that exposure (Fig. B5.1.1). 
It has been known from early au-
topsy observations of cellular atypia 
throughout the airways of smokers 
that the cellular injury produced by 
smoking involves the whole respi-
ratory tract. Several studies have 
shown that bronchial airway epithe-
lial cells of current and former smok-
ers with and without lung cancer dis-
play allelic loss, TP53 mutations, and 
changes in promoter methylation 
and in telomerase activity of non-
cancerous bronchial epithelial cells 
[1]. More recently, multiple groups 
have demonstrated that genome-
wide gene expression profiling of 
bronchial airway epithelial cells 
collected by brushing at the time 
of bronchoscopy reflects the physi-
ological response to and damage 
from exposure to cigarette smoke. 
The smoking-related changes in the 
airway transcriptome may be regu-
lated, in part, by changes in DNA 
methylation and microRNA expres-
sion in response to the toxic expo-
sure. While most of these genomic 
alterations (including those involved 
in xenobiotic metabolism and oxida-
tive stress) reverse within months 
of smoking cessation, a subset of 
these transcriptomic changes are 
irreversible among former smokers 
(including those who have stopped 
smoking for > 10 years) and may be 
associated with the increased risk 
of smoking-related lung disease in 
former smokers.
Based on the heterogeneity in 
the bronchial airway genomic re-
sponse to smoking, gene expres-
sion biomarkers in the cytologically 
normal bronchial airway epithelium 
have been developed for the early 
detection of lung cancer in current 
or former smokers being evaluated 
for clinical suspicion of disease [2]. 
These gene expression alterations 
in the airway have also been shown 
to reflect activation of oncogenic 
signalling pathways among high-
risk smokers that can be reversed 
with chemopreventive agents that 
target these pathways. Furthermore, 
methylation changes in the promoter 
region of cancer-related genes mea-
sured in sputum have been shown to 
be associated with lung cancer risk 
among smokers. This molecular field 
of injury has recently been extended 
to chronic obstructive pulmonary 
disease, where gene expression 
alterations in the bronchial airway 
have been found among smokers 
with obstructive airway disease.
These observations suggest 
that the entire respiratory tree is af-
fected by cigarette smoke, and that 
easily obtainable upper airway cells 
might provide insight into the types 
and degree of epithelial cell injury 
that have occurred in an individual 
smoker. Recent studies have indi-
cated that the gene expression re-
sponses to smoking in the bronchial 
airway also occur in the extratho-
racic airway epithelium that lines the 
mouth and nose [3]. This has led to 
the promise of genomic biomarkers 
of tobacco exposure and disease 
risk that can be developed in these 
non-invasive biosamples and can be 
applied to large-scale population-
based studies.
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Fig. B5.1.1. The molecular field of injury that is induced among airway epithelial 
cells throughout the respiratory tract. miRNA, microRNA; mRNA, messenger 
RNA; SNPs, single-nucleotide polymorphisms.
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identified by morphology or immuno-
histochemical staining, the tumour 
is classified as “NSCLC - not other-
wise specified”. This is necessary to 
preserve as much tissue as possible 
for molecular testing.
Adenocarcinoma in situ is an ad-
enocarcinoma of pure lepidic growth 
without invasion that measures 3 cm 
or less. Minimally invasive adeno-
carcinoma is a lepidic-predominant 
adenocarcinoma measuring 3 cm or 
less that has 5 mm or less of an in-
vasive component [17]. Invasive ad-
enocarcinomas are now classified 
according to the predominant sub-
type. This classification is based on 
comprehensive histological sub-
typing by estimating different his-
tological patterns in a semi-quanti-
tative manner in 5–10% increments 
(Fig. 5.1.3).
Multiple studies have demon-
strated consistent correlations of 
survival with the predominant sub-
types, with very favourable (adeno-
carcinoma in situ, minimally invasive 
adenocarcinoma, lepidic), interme-
diate (acinar, papillary), and poor 
(solid, micropapillary) prognostic 
categories. As expected, so far all 
cases reported as adenocarcinoma 
in situ and minimally invasive ad-
enocarcinoma have demonstrated 
5-year disease-free survival of 100% 
[14].
The majority of lung adenocar-
cinomas from never-smokers har-
bour a mutation in either EGFR or 
HER2 (ERBB2) or a fusion involv-
ing ALK or ROS1 [18]. Driver muta-
tions in adenocarcinoma occur in 
the EGFR, HER2 (ERBB2), KRAS, 
ALK, BRAF, PIK3CA, and ROS1 
genes (Fig. 5.1.4A). Mutations in 
KRAS and EGFR are mutually ex-
clusive, as are most of the kinase 
domain mutations listed above, ex-
cept for PIK3CA [19,20]. Several of 
these genes may have increased 
gene copy number or amplification, 
mostly of the mutant allele. EGFR 
(20%), HER2 (2%), and MET (1%) 
may be amplified preferentially 
on the mutant allele. MET ampli-
fication occurs more frequently in 
resistant disease and is associated 
with EGFR tyrosine kinase inhibi-
tion. All of these mutations offer 
the possibility of targeted therapy, 
although only three (EGFR muta-
tion, ALK and ROS1 fusion) are 
subject to targeted treatment with 
currently approved drugs: gefitinib 
or erlotinib for EGFR mutation and 
crizotinib for ALK and ROS1 fusion. 
Agents targeting the others are in 
development in phase 2 or phase 3 
(Table 5.1.1).
Whole-exome and whole-ge-
nome sequencing of DNA from 183 
pairs of lung adenocarcinoma tu-
mours and matched normal tissues 
Fig. 5.1.2. Gross appearance of lung ad-
enocarcinoma. The tumour is situated in 
the periphery of the lung, involving the sub-
pleural tissue with a tan grey cut surface.
Fig. 5.1.3. Adenocarcinoma histology. (A) Lepidic pattern: atypical pneumocytes line 
the alveolar walls with no invasive component. (B) Acinar pattern: cytologically malig-
nant tumour cells form round to oval-shaped glands. (C) Papillary pattern: malignant 
glandular cells grow along the surface of fibrovascular cores. (D) Micropapillary pattern: 
these tumour cells form papillae lacking fibrovascular cores. (E) Solid pattern: these 
malignant cells are growing in sheets with hyperchromatic nuclei. (F) Invasive mucinous 
adenocarcinoma: malignant cells grow in acinar and lepidic patterns. The tumour cells 
have abundant apical mucin and small, basally oriented nuclei.
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identified, among many other find-
ings, statistically recurrent somatic 
mutations in the splicing factor gene 
U2AF1 and truncating mutations af-
fecting RBM10 and ARID1A [21].
Adenocarcinomas from never-
smokers have a higher frequency of 
EGFR mutations (38% vs 14%) and 
ALK rearrangements (12% vs 2%) 
compared with tumours from former 
or current smokers [22]. Such a com-
parison in respect of NSCLC and ad-
jacent normal tissue from 17 patients 
identified 3726 point mutations and 
more than 90 insertions or deletions 
in the coding sequence, with an av-
erage mutation frequency more than 
10 times higher in smokers than in 
never-smokers (Fig. 5.1.5). Novel 
alterations were identified in genes 
involved in chromatin modification 
and DNA repair pathways, along with 
DACH1, CFTR, RELN, ABCB5, and 
HGF [23].
Squamous cell lung 
carcinoma
Squamous cell carcinoma accounts 
for approximately 20% of all lung 
cancers in the USA [16]. At diagno-
sis, most squamous cell carcinomas 
are located in the central portion of 
the lung, but in recent years, the fre-
quency of tumours located peripher-
ally appears to have been increasing.
In resection specimens, tu-
mours of this type are subclassi-
fied as squamous cell carcinoma, 
basaloid, clear cell, and small cell 
variants. Squamous differentiation 
is identified morphologically as 
intercellular bridging, squamous 
pearl formation, and individual cell 
keratinization (Fig. 5.1.6). In small 
biopsies or cytology specimens, in 
poorly differentiated tumours that 
lack clear squamous morphology, if 
the tumour is positive for p63 or p40 
but negative for TTF-1, the tumour is 
classified as “NSCLC, favour squa-
mous cell carcinoma”.
Genetic alterations in squamous 
cell carcinoma have been revealed 
as part of the Cancer Genome Atlas; 
the data involve genomic and epige-
nomic alterations in 178 squamous 
cell lung carcinomas. Most of the 
previously identified driver mutations 
were confirmed and several others 
discovered [24,25]. Although squa-
mous cell carcinomas have been 
regarded as tumours without spe-
cific molecular abnormalities, new 
discoveries allow most squamous 
cell lung cancers to be characterized 
with reference to available targeted 
therapies (Fig. 5.1.4B). If mutations 
in PIK3CA (20–30%), FGFR1 (20%), 
and DDR2 (4%) are considered, 
Fig. 5.1.4. (A) Mutation spectrum in adenocarcinoma. Mutations in TP53 and 
STK11/LKB1 are common occurrences, not included in the pie chart due to high overlap 
with other mutations. (B) Mutation spectrum in squamous cell carcinoma. Mutations 
in TP53 are a common occurrence, not included in the pie chart due to high overlap 
with other mutations.
Table 5.1.1. Molecular targeted therapies for lung cancer
Gene or genetic 
alteration Histological type Therapy
Targeted therapiesa
EGFR mutation Advanced adenocarcinoma EGFR tyrosine kinase inhibitor
Erlotinib, gefitinib
ALK fusion Adenocarcinoma Crizotinib
ROS1 fusion Advanced adenocarcinoma Crizotinib
Drugs in development
HER2 Adenocarcinoma Afatinib (BIBW 2992)
PI3KCA NSCLC Trastuzumab, PI3K inhibitor
BRAF NSCLC Sorafenib?
MET NSCLC Phase 2: rilotumumab  
(AMG 102), MetMAb
RAS Adenocarcinoma PI3K + MEK inhibitors
NSCLC, non-small cell lung carcinoma; PI3K, phosphatidylinositol 3-kinase.
a Approved by the United States Food and Drug Administration.
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about one half of squamous cell lung 
carcinomas have genetic alterations 
that are potential molecular targets. 
The most frequent mutations in 
tumours from patients were in 
TP53, CDKN2A (P16), PTEN, 
PIK3CA, KEAP1, and MLL2 [24,25]. 
Conspicuous regions of somatic 
copy number alteration, includ-
ing amplification, were evident, as 
had been previously detected for 
SOX2, PI3KCA, and FGFR1 [26], 
together with deletion at CDKN2A 
[24]. Other regions of marked gene 
copy alteration were discovered on 
chromosomal segments contain-
ing NFE2L2, MYC, CDK6, MDM2, 
FOXP1, PTEN, and NF1 [24].
Interestingly, many of the so-
matic alterations identified in squa-
mous cell carcinoma have been 
recognized as drivers of initiation 
and tumour progression. Two path-
ways affected by genetic alteration 
were the oxidative stress response 
pathway and the squamous differ-
entiation pathway. The oxidative 
stress response pathway, involving 
NFE2L2 and KEAP1 or CUL3, was 
evident in 30% of the cases, and the 
alterations described were mutually 
exclusive. The squamous differ-
entiation pathway was affected by 
gene alterations in 44% of cases; 
the affected genes included SOX2 
and TP63 (which were mutually 
exclusive in relation to Notch1 or 
Notch2 ALSCL4 loss-of-function 
mutations) and focal deletions of 
FOXP1. Messenger RNA (mRNA) 
expression profiling indicated altered 
expression, enhancing the recogni-
tion of these alterations as oncogen-
ic driver events. Therapeutic agents 
for DDR2 mutation (dasatinib) and 
FGFR1 amplification (FGFR1 ty-
rosine kinase inhibitor) are already 
available, and United States Food 
and Drug Administration (FDA) ap-
proval is currently anticipated for a 
target for PIK3CA.
Small cell lung carcinoma
Small cell lung cancer accounts for 
15% of all lung cancers in the USA 
Fig. 5.1.5. Graphical summary of the distinction, including extent of genomic mutation, 
evident when lung cancer and adjacent normal tissues from smokers and never-smokers 
are compared. (For details, see [23].)
Fig. 5.1.6. Squamous cell carcinoma. The tumour consists of nests of malignant cells 
with abundant eosinophilic cytoplasm. Abundant extracellular keratin is present.
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Biomarkers of air pollution
Paolo Vineis
Air pollution can induce cancer (par-
ticularly of the lung) through several 
mechanisms, including damage to 
DNA. Measurement of biomarkers 
related to air pollution can improve 
the investigation of the health ef-
fects, by facilitating improved expo-
sure assessment and increased un-
derstanding of mechanisms, thereby 
providing biological plausibility.
Demetriou et al. [1] have re-
viewed biomarkers for which there is 
consistent evidence in the literature 
to support the results of epidemio-
logical studies on the effects of am-
bient air pollution. Epidemiological 
evidence from the selected studies 
has been assessed using a set of 
criteria that evaluate their credibility. 
The criteria take into account the to-
tal number of subjects investigated, 
the degree of replication of findings 
across studies, and potential protec-
tion from bias and/or confounding. 
Overall, 524 papers were evaluated, 
which described the relationships 
between ambient air pollution and 
biomarkers of dose and early re-
sponse. Studies were ranked from A 
(strong) to C (weak). The biomarkers 
that fulfilled the criteria to achieve A 
or B scores were 1-hydroxypyrene, 
DNA adducts, chromosomal aberra-
tions, micronuclei, oxidative damage 
Fig. B5.1.2. Biological markers of exposure and effects of air pollution.
to nucleobases, and methylation 
changes. These biomarkers cover 
the whole spectrum of disease onset 
and progression, from external expo-
sure to tumour formation, and some 
have also been suggested as risk 
predictors of future cancer, reinforc-
ing causal reasoning (Fig. B5.1.2).
Overall, existing biomarkers of 
dose and effect appear to reinforce 
the causal nature of the associa-
tion between air pollution and lung 
cancer, although the markers in 
the review were not all specific to 
lung carcinogenesis. DNA adducts, 
chromosomal aberrations, micro-
nuclei, and oxidized nucleobase 
markers have been suggested to 
be predictive for the risk of cancer. 
1-Hydroxypyrene is a marker of in-
ternal dose, DNA adducts and oxi-
dized nucleobases are markers of 
the biologically effective dose, and 
micronuclei, chromosomal aberra-
tions, and DNA methylation are good 
markers of early biological effect. 
The available evidence is stronger 
for oxidized nucleobase markers, 
and the mechanisms supported by 
these biomarkers are likely to be 
central to the biological process of 
air pollution-induced lung cancer.
However, certain aspects of 
biomarkers used in epidemiological 
studies need to be clarified. These 
include their reliability, including 
inter-laboratory as well as inter-
technique variation.
Although chronic inflammation 
is probably relevant to particle-
induced lung carcinogenesis, the 
overall evidence is still relatively 
scant. Exposure to air pollutants 
has been associated with acute 
inflammation in the airways and to 
elevated levels of systemic markers 
of inflammation, such as C-reactive 
protein and fibrinogen. Recent stud-
ies found that medium-term expo-
sure to traffic-related air pollution 
may induce an increased inflamma-
tory/endothelial response, especial-
ly among people with diabetes [2]. 
So far the inflammatory response 
has mainly been associated with 
risk of cardiovascular diseases 
rather than of cancer [3].
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[16]. Most cases of this tumour type 
are diagnosed on the basis of a peri-
hilar mass. Tumour cells are small in 
size with a round to fusiform shape, 
scant cytoplasm, finely granular 
nuclear chromatin, and absent or 
inconspicuous nucleoli (Fig. 5.1.7) 
[27]. Necrosis is usually extensive 
and mitotic rates are high, averag-
ing 80 mitoses per 2 mm2 area [27]. 
Small cell lung cancer is reliably di-
agnosed in small biopsies and cytol-
ogy specimens.
Small cell lung cancer typically 
occurs in heavy smokers and is char-
acterized by the most aggressive 
growth among lung malignancies. 
No single molecularly targeted drug 
has yet shown any clinical activity in 
small cell lung cancer. Until recently, 
the relevant molecular genetics was 
poorly characterized except for the 
prevalence of inactivating muta-
tions in TP53 and RB1. However, 
the results of global lung cancer 
genome research have now been 
published, including the results of 
single-nucleotide polymorphism ar-
ray analysis, transcriptome sequenc-
ing, and full-genome sequencing of 
a total of 63 cases (Table 5.1.2) [28]. 
In addition to invariable p53/Rb in-
activation, mutations were found in 
CREBBP, EP300, and MLL, which 
all encode histone modifiers. Also 
detected were mutations in PTEN, 
SLIT2, and EPHA7, as well as focal 
amplification of the FGFR1 tyrosine 
kinase gene, thus identifying further 
oncogenic driver events nominally 
susceptible to targeted therapy that 
may be developed. This is an exam-
ple of how integrative computational 
genome analysis can provide func-
tionally tractable information in the 
context of a highly mutated cancer 
genome, due to the genotoxic effects 
of tobacco smoke.
Large cell lung carcinoma
Large cell carcinoma accounts for 
3% of all lung cancers in the USA 
[16]. Large cell carcinoma consists 
of sheets and nests of large polygo-
nal cells with vesicular nuclei and 
prominent nucleoli and is diagnosed 
on the basis of exclusion to the ex-
tent that the presence of squamous 
cell or glandular differentiation can 
be excluded by light microscopy 
[27]. The diagnosis of large cell car-
cinoma cannot be made on small bi-
opsies or cytology specimens and 
requires a resection specimen.
Prospects
Prevention
The primary approach to preven-
tion is smoking cessation, which 
has been proven effective in both 
men and women. This subject is 
not discussed here but is sepa-
rately addressed in this Report 
(see Chapter 4.1). Encouragement 
of smoking cessation by women 
has yet to make a major impact in 
Europe, where lung cancer mortality 
Fig. 5.1.7. Small cell carcinoma. The tumour consists of a cellular sheet of small tumour 
cells with scant cytoplasm, finely granular nuclear chromatin, and frequent mitoses, 
and nucleoli are absent.
Table 5.1.2. Genetic alterations in small cell lung carcinoma
Significantly altered (one or more alleles)
genes (drivers) Mode Percentage
TP53 Inactivation 100
RB1 Inactivation 100
CREBBP Mutation 18
EP300 Mutation 18
MLL Mutation 10
PTEN Mutation 10
SLIT2 Mutation 10
EPHA7 Mutation 5
FGFR1 Amplification 4
MYCL Amplification 16
E2F2 Amplification 5
CCN2 Amplification 5
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rates are still increasing in women. 
Prevention of occupational cancer 
and regulatory measures to ad-
dress air pollution are discussed in 
Chapter 4.5. In a region of China, 
decreased risk of lung cancer was 
associated with improvement of 
household stoves by adding a chim-
ney to reduce exposure to smoky 
coal emissions [29].
Screening
Among options to reduce mortality 
from lung cancer is the introduc-
tion of population-based screening. 
Several small randomized trials of 
low-dose computed tomography 
(CT) screening are under way in 
Europe. From the USA, a decisive 
outcome was reported for the 
National Lung Screening Trial 
[30] conducted from 2002 to 2004 
and involving 53 454 individuals 
screened either with low-dose CT 
or with chest radiography. The in-
cidence of lung cancer in the two 
groups was identical. The relative 
reduction in mortality from lung can-
cer through low-dose CT screening 
was 20% (P = 0.004). The rate of 
death from any cause was reduced 
in the low-dose CT group by 6.7% 
(P = 0.02) compared with the radi-
ography group, indicating that the 
screening was essentially reduc-
ing deaths from lung cancer. The 
United States Preventive Services 
Task Force has published a rec-
ommendation that CT screening 
be available to healthy individuals 
aged 55–79 years with at least a 
30 pack-year history of smoking 
and who have smoked within the 
past 15 years – estimated at about 
10 million people.
Limitations relevant to data 
from screening trials specifically in 
Europe are the healthy volunteer 
effect, which may bias results, the 
possibility that scanners currently 
used are technologically more ad-
vanced than those used during the 
trial, and the fact that the United 
States trial mentioned above was 
conducted in high-profile medical 
institutions, recognized for their 
expertise in radiology diagnosis 
and treatment of cancer. When the 
cause of death in the two arms of 
the trial was reduced to “no death by 
lung cancer”, the reduction in overall 
mortality was 3.2%, which was not 
statistically significant. Obviously, 
the cost-effectiveness of low-dose 
CT screening must also be consid-
ered in the context of competing 
interventions, particularly smoking 
cessation.
Other strategies for early detec-
tion of lung cancer, including par-
ticular molecular markers in blood, 
sputum, and urine, are being stud-
ied in specimens obtained as part of 
the American College of Radiology 
Imaging Network and related activ-
ity, but are not yet finalized. There is 
unfortunately no proven biomarker 
for lung cancer detection [31].
Prognosis
Lung cancer is one of the most 
aggressive human cancers, with 
a 5-year survival of 10–15% [16]. 
Patients with clinical stage IV lung 
cancer have a 5-year overall sur-
vival of 2%, and even for the lowest 
stage IA, 5-year overall survival is 
only 50% [32]. Lung cancer accounts 
for 13% of all cancers and 20% of 
all cancer deaths. In the USA, lung 
cancer is the second most common 
cancer in both men and women, ac-
counting for 14% of cancer cases in 
each sex, and is the most common 
cause of cancer mortality in both 
men and women, accounting for 
29% and 26% of cancer deaths, re-
spectively [33]. Poor survival of lung 
cancer patients is due, at least in 
part, to 80% of patients being diag-
nosed with metastatic disease and 
more than half of patients having dis-
tant metastases [16]. Advanced lung 
cancer has also been resistant to 
traditional chemotherapy. However, 
recent advances have led to exciting 
progress in therapies that are de-
pendent on histology and genetics. 
The level of scrutiny is exemplified 
by trials of adjuvant chemotherapy 
designed to differentiate not only 
between mutations in codons 12 
and 13 of KRAS, but also between 
different amino acid substitutions as 
determined by particular mutations 
at codon 12 [34].
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Summary
• Breast cancer is the most com-
mon cancer in women world-
wide. This chapter is concerned 
with female breast cancer.
• Well-characterized breast cancer 
risk factors include age, family his-
tory, reproductive factors, mam-
mographic density, and atyp- 
ia in a prior benign breast biopsy. 
Agents that cause breast cancer 
include alcohol consumption, 
use of combined estrogen–pro-
gestogen contraceptives and 
menopausal therapy, and expo-
sure to X- and γ-radiation.
• A small proportion of breast 
cancers are due to inherited 
mutations in high-penetrance 
breast cancer susceptibility 
genes (BRCA1 and BRCA2). 
Several lower-penetrance genes 
have also been associated with 
breast cancer, and there are 
many loci that are linked to an 
increased risk.
• Recent molecular and genetic 
studies have emphasized that 
breast cancer is a highly het-
erogeneous group of diseases 
that differ in their prognosis and 
response to treatment.
• Improved understanding of the 
molecular pathways and genetic 
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alterations that underlie the dif-
ferent breast cancer subtypes is 
leading to a more targeted and 
personalized approach to breast 
cancer treatment.
Etiology
The etiology of breast cancer is mul-
tifactorial, involving endocrine and 
reproductive factors including nul-
liparity, first birth after age 30, and 
hormonal history; environmental fac-
tors such as consumption of alcoholic 
beverages, use of certain contracep-
tives and menopausal (hormone re-
placement) therapy, and exposure to 
ionizing radiation; and lifestyle factors 
such as high-calorie diets and lack 
of exercise (see “Biological mecha-
nisms mediating reduced breast can-
cer risk through physical activity”). 
The annual incidence in industrial-
ized countries where such lifestyle 
factors have existed for some time is 
70–90 new cases per 100 000 wom-
en. Countries where industrialization 
is a more recent phenomenon have a 
rising incidence and higher mortality.
On the basis of a case–control 
study in Germany, population attrib-
utable risk (95% confidence inter-
val) for non-modifiable breast cancer 
risk factors (age at menarche, age 
at menopause, parity, benign breast 
disease, and family history of breast 
cancer) was 37.2% (27.1–47.2%) for 
all invasive tumours considered. Of 
the modifiable risk factors assessed, 
use of hormone therapy and physi-
cal inactivity had the highest impact, 
with population attributable risks of 
19.4% (15.9–23.2%) and 12.8% 
(5.5–20.8%), respectively, for in-
vasive tumours; all such findings 
varied depending on the estrogen 
and progesterone receptor status of 
tumours [1].
A small proportion of breast can-
cer is due to a familial predisposition, 
and two high-risk, high-penetrance 
genes have been identified: BRCA1 
and BRCA2. Mutations in these 
genes greatly increase the risk of 
developing breast cancer. Several 
lower-penetrance genes have also 
been identified, and there are many 
loci within the genome that are linked 
to an increased risk but for which the 
specific genes have yet to be iden-
tified (see Pathology and Genetics 
sections below).
Hence, for most patients with 
breast cancer, multiple factors – in-
cluding personal and family history 
as well as reproductive and lifestyle 
factors – are implicated in tumour 
development.
Pathology
Breast cancer is not a single disease 
and is heterogeneous both clinically 
and morphologically. The current 
WHO Classification of Tumours of 
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Epidemiology
Breast cancer
• Breast cancer is by far the most 
frequently diagnosed cancer and 
cause of cancer death among 
women. There were an estimated 
1.7 million new cases (25% of all 
cancers in women) and 0.5 mil-
lion cancer deaths (15% of all 
cancer deaths in women) in 2012.
• Breast cancer is the most com-
mon cancer diagnosis in women 
in 140 countries and the most fre-
quent cause of cancer mortality 
in 101 countries.
• Age-standardized incidence rates 
are highest in western Europe 
and lowest in East Asia. Incidence 
rates tend to be elevated in coun-
tries attaining the highest levels 
of human development. There is 
a greater than 2-fold difference 
between countries categorized 
as having low versus very high 
levels of development. 
• About 43% of the estimated new 
cases and 34% of the cancer 
deaths occurred in Europe and 
North America.
• Mortality rates vary approxi-
mately 2–5-fold worldwide; the 
case fatality rate is lower in coun-
tries with higher levels of human 
development.
• Whereas incidence has been 
generally increasing in most ar-
eas of the world, it has peaked 
and declined over the past dec-
ade in a number of highly devel-
oped countries.
• Mortality rates have been declin-
ing in a number of highly devel-
oped countries since the late 
1980s and early 1990s, a result 
of a combination of improved 
detection and earlier diagno-
sis (through population-based 
screening) and more effective 
treatment regimens.
Map 5.2.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for breast cancer in women, 2012.
Map 5.2.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for breast cancer in women, 2012.
the Breast (4th edition) [2] recogniz-
es more than 20 different subtypes.
Most breast cancers arise from 
epithelial cells (carcinomas); these 
tumours are subdivided into in situ 
and invasive lesions. In situ carcino-
mas are preinvasive lesions in which 
the malignant epithelial cells are still 
confined to the ductal/lobular tree of 
the breast and the basement mem-
brane surrounding the ducts and lob-
ules is intact to the extent that it has 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.2.1. Estimated global number of new cases and deaths with proportions by major world regions, for breast cancer 
in women, 2012.
Chart 5.2.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for breast cancer in 
women, circa 1975–2012.
Chart 5.2.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for breast cancer in 
women, circa 1975–2012.
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not been penetrated by cancer cells. 
Preinvasive lesions are further sub-
divided into ductal carcinoma in situ 
(DCIS) and lobular carcinoma in situ 
(LCIS). Despite the “ductal” versus 
“lobular” terminology, the fact that 
almost all carcinomas in the breast 
arise from the structural and func-
tional unit of the breast called the 
terminal duct lobular unit has been 
well established for some time [3]. 
The distinction between DCIS and 
LCIS is the result not of the micro-
anatomical site of origin (ducts vs 
lobules) but rather of a difference 
in the architectural and cytological 
features of the cells. DCIS and LCIS 
also differ in their distribution within 
the breast, in the associated respec-
tive risks of bilateral disease, and in 
their natural history.
Subsets of DCIS and LCIS have 
also been recognized. DCIS is sub-
classified according to nuclear grade 
and architectural features; high-grade 
DCIS has a greater risk of recurrence 
and progression to invasive cancer 
than do lower grades of DCIS [4]. 
LCIS is often a multifocal and multi-
centric disease and also carries a risk 
of bilateral involvement [5]. In its clas-
sic form, LCIS presents a small risk of 
progression to invasive cancer over 
a period of 20–25 years. Recently, 
a higher-grade variant, pleomorphic 
LCIS, has been recognized, but its 
natural history is unclear at present 
(Fig. 5.2.1) [6].
Invasive carcinoma character-
ized as “no special type”, also known 
as ductal carcinoma no special type 
or invasive ductal carcinoma, makes 
up the largest subset of invasive 
breast cancer. This designation 
identifies a heterogeneous group 
comprising tumours that are not 
easily categorized by specific mor-
phological features that characterize 
the “special subtypes”. Hence, it is 
a default diagnosis for all those tu-
mours (approximately 70%) that can-
not be assigned a “special subtype” 
designation. The most common of the 
special subtypes include lobular car-
cinoma, tubular carcinoma, mucinous 
carcinoma, carcinoma with medullary 
and apocrine features, micropapillary 
and papillary carcinomas, and meta-
plastic carcinomas (Fig. 5.2.2).
It is now well recognized that 
tumours of the breast exhibit both 
intratumour and intertumour het-
erogeneity. Histological grade is a 
measure of how closely a tumour 
resembles its tissue of origin and is 
an integral part of a pathology report. 
The current grading system assess-
es three parameters of the tumour: 
(i) the degree of architectural differ-
entiation (tubule formation), (ii) nu-
clear pleomorphism (nuclear grade), 
and (iii) proliferation (mitotic count/
index). Each parameter is given a 
score from 1 to 3, and the scores 
for the three parameters are added 
together. Tumours with a total score 
of 3–5 are grade 1 (low grade), those 
with scores of 6 and 7 are grade 2 
(intermediate grade), and those 
with scores of 8 and 9 are grade 3 
(high grade). Although this semi-
quantitative approach averages the 
intratumour heterogeneity that exists 
in many tumours, it remains a pow-
erful indicator of patient prognosis 
(Table 5.2.1).
Histological grade is also strongly 
associated with histological type and 
with patterns of molecular alterations, 
such as estrogen receptor (ER) and 
progesterone receptor (PR) expres-
sion and human epidermal growth 
factor receptor 2 (HER2) protein over-
expression and gene amplification.
The histopathological analysis 
of breast cancers also provides 
information on stage of disease – 
meaning the extent of disease 
involvement. This is determined in 
two ways: from the size of the can-
cer and from the assessment of 
regional lymph node involvement. 
Both these parameters provide 
powerful prognostic information for 
patient management. The overall 
staging for the patient is recorded 
with the American Joint Committee 
on Cancer staging system using the 
tumour–node–metastasis (TNM) 
classification. Additional prognostic 
data, such as lymphovascular per-
meation and degree of response to 
neoadjuvant therapy, can also be 
derived from the histopathological 
assessment.
The pathological assessment of 
tumours as described above is inex-
pensive and quick and can provide 
useful information on which to base 
Fig. 5.2.1. Ductal carcinoma in situ of low nuclear grade. (A) Classic lobular carci-
noma in situ is diagnosed because the characteristic cells distend and distort the acini. 
(B) Pleomorphic lobular carcinoma in situ. Nuclear enlargement, variability, and promi-
nent nucleoli are associated with abundant cytoplasm. (C) Cribriform pattern. Multiple 
adjacent ducts are distended by a sieve-like proliferation of monotonous uniform cells. 
The multiple spaces within the proliferation are rounded and distributed in an organized 
fashion. (D) This space shows a rim of viable cells with high-grade nuclei. There is 
comedo-type necrosis and calcification.
A
C
B
D
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plans for further management. 
Nonetheless, limitations are recog-
nized. Patients with a similar type 
or grade of breast cancer may have 
very different response to therapy 
or long-term outcome. There has 
been considerable progress over 
the past three decades in under-
standing the biology of breast can-
cer and in translating some of the 
molecular data into routine clinical 
practice.
Genetics
The assessment of ER and PR sta-
tus using immunohistochemistry, 
and of HER2 status using immuno-
histochemistry and in situ hybridiza-
tion, is now routine for all primary 
breast cancers, at least in the more 
developed countries. Such assess-
ment allows prognostication and also 
provides predictive data with regard 
to response to anti-estrogen therapy 
(e.g. tamoxifen) and anti-HER2 
therapy (e.g. trastuzumab) [7]. Such 
therapy is not appropriate for ap-
proximately 15% of tumours, which 
are designated “triple-negative” to 
indicate lack of expression of ER, 
PR, or HER2.
DNA microarray technology for 
gene expression profiling, which 
allows thousands of genes to be ex-
amined simultaneously, has been 
used to classify breast cancer, de-
velop signatures for “good” versus 
“poor” prognosis, and identify tu-
mours that may or may not respond 
to particular therapy [8]. This type of 
analysis has not only confirmed the 
two large subsets of breast cancer – 
ER-positive and ER-negative – but 
also brought to the fore differences 
within the ER categories. In ER-
positive tumours, the luminal B sub-
set has a worse prognosis than the 
luminal A subset, probably driven 
at least in part by higher prolifera-
tive activity. Within the ER-negative 
group, the triple-negative (ER-, PR-, 
and HER2-negative) and “basal-
like” groups are now recognized; 
these groups are not synonymous 
but show considerable overlap. The 
basal-like group comprises tumours 
that express proteins found in the 
contractile myoepithelial cell layer 
of normal breast (e.g. CK14, CK5/6), 
and a subset of these tumours have 
a propensity for early recurrence, 
especially involving metastasis in 
the brain and lungs [9]. This type of 
understanding is already determin-
ing management strategies and will 
lead, through clinical trials, to better 
targeted therapies.
For more than a decade, such 
gene expression profiling has been 
applied to define molecular pheno-
types of breast cancer. The luminal 
A and basal-like subtypes men-
tioned above are the two main sub-
types of five that have been identi-
fied (Fig. 5.2.4). In an evaluation 
of differences, signature genes of 
the luminal A subtype were genes 
Fig. 5.2.2. (A) Invasive carcinoma no special type, grade 2. (B) Classic invasive lobular 
carcinoma with uniform, single-file cells compared with (C). (C) Invasive pleomorphic 
lobular carcinoma with characteristic pleomorphic, atypical nuclei. (D) Tubular carcinoma. 
There is a haphazard distribution of rounded and angulated tubules with open lumina, 
lined by only a single layer of epithelial cells separated by abundant reactive, fibroblas-
tic stroma. (E) The neoplastic cells lining the teardrop-shaped tubules lack significant 
atypia. (F) Mixed metaplastic carcinoma with spindle, mesenchymal (chondroid), and 
squamous differentiation. (G) Neuroendocrine carcinoma of the breast. Alveolar pat-
tern with rounded solid nests of spindle cells invading a dense collagenous stroma. 
(H) Invasive micropapillary carcinoma. Tumour cell clusters with irregular central spaces 
proliferate within empty stromal spaces. Some clusters have reversed polarity with an 
“inside-out” morphology.
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Biological mechanisms mediating reduced breast cancer risk through 
physical activity
Christine M. Friedenreich
Physical activity has been associ-
ated with a 25–30% decrease in 
breast cancer risk, and research is 
now focused on understanding the 
biological mechanisms mediating 
this association, with the aim of de-
termining the optimal type, dose, and 
timing of activity needed for maxi-
mum risk reduction. Several mech-
anisms have been hypothesized 
(Fig. B5.2.1) [1], and intervention 
trials in postmenopausal, inactive, 
healthy women have investigated 
these pathways [2]. These studies 
have found that exercise decreases 
endogenous estrogens, adiposity, 
insulin resistance, leptin, and inflam-
mation, which are all associated in-
dependently with increased breast 
cancer risk. Other emerging hypoth-
esized mechanisms include oxida-
tive stress and genomic instability.
Exercise reduces the endog-
enous estrogen levels in pre-
menopausal women by induc-
ing anovulatory menstrual cycles 
or amenorrhea, or through other 
mechanisms. In postmenopausal 
women, exercise decreases circulat-
ing estrogens directly, and indirectly 
with exercise-induced weight loss. 
Obesity, an established risk factor 
for postmenopausal breast cancer, 
is decreased with physical activity. 
Obesity-related effects, notably in-
sulin resistance and altered levels 
of insulin-like growth factor 1 (IGF-1) 
and its binding protein IGFBP-3, 
in addition to altered production of 
adipokines, specifically leptin and 
adiponectin, may be important con-
tributors to increasing breast cancer 
risk. Mechanisms independent of 
changes in body fat are also rel-
evant. Exercise acutely enhances 
insulin sensitivity and glucose up-
take by skeletal muscle, which can 
be sustained through prolonged high-
intensity activity. With decreased cir-
culating insulin, free IGF-1 levels may 
also decrease because of lowered 
growth hormone-mediated hepatic 
synthesis of IGF-1 and/or increased 
synthesis of IGFBP-1.
Fig. B5.2.1. Biological mechanisms determining the optimal type, dose, and timing of physical activity needed for maximum 
reduction in breast cancer risk. IL-6, interleukin-6; SHBG, sex hormone-binding globulin; TNF-α, tumour necrosis factor α.
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involved in fatty acid metabolism and 
steroid hormone-mediated signalling 
pathways, in particular ER signalling, 
while the corresponding genes for the 
basal-like subtype were involved in 
cell proliferation and differentiation, 
the p21-mediated pathway, and the 
G1–S cell-cycle checkpoint. A mini-
mal set of 54 genes best discrimi-
nated between the two subtypes [10].
Such molecular analyses are 
also relevant to survival. One study 
used modelling of messenger RNA 
(mRNA), copy number alterations, 
microRNAs, and methylation [11]. 
For all breast cancers, the stron-
gest predictor of good outcome 
was acquisition of a gene signa-
ture that favoured a high T helper 
type 1 (Th1)/cytotoxic T lymphocyte 
response at the expense of Th2-
driven immunity.
Next-generation sequencing 
technology has also been applied 
to examine the genomes of 100 
breast cancers for somatic copy 
number changes and mutations in 
the coding exons of protein-coding 
genes [12]. The number of somatic 
mutations varied markedly between 
individual tumours. Strong correla-
tions were evident between number 
of mutations, age at which cancer 
was diagnosed, and cancer histolog-
ical grade, and multiple mutational 
signatures were observed, includ-
ing one, present in about 10% of tu-
mours, characterized by numerous 
mutations of cytosine at TpC dinucle-
otides. Driver mutations were identi-
fied in several new cancer genes, 
including AKT2, ARID1B, CASP8, 
CDKN1B, MAP3K1, MAP3K13, 
NCOR1, SMARCD1, and TBX3 
(Fig. 5.2.5). Among the 100 tu-
mours, there were driver mutations 
in at least 40 cancer genes and 73 
different combinations of mutated 
cancer genes. Overall, one of the 
most highly contributing genes to de-
velopment of breast cancer, TP53, is 
nonetheless probably only involved 
in 25% of cancers, although its role 
Table 5.2.1. Semi-quantitative method for assessing histological grade
Feature Score
Tubule and gland formation
Majority of tumour (> 75%) 1
Moderate degree (10–75%) 2
Little or none (< 10%) 3
Nuclear pleomorphism
Small, regular, uniform cells 1
Moderate increase in size and variability 2
Marked variation 3
Mitotic count
Dependent on microscope field area 1–3
Final grading
Add scores for tubule and gland formation, nuclear 
pleomorphism, and mitotic count:
Grade 1 Total score, 3–5
Grade 2 Total score, 6 or 7
Grade 3 Total score, 8 or 9
Chronic inflammation is asso-
ciated with sustained proliferation 
and oxidative stress, which togeth-
er promote malignancy. C-reactive 
protein, a marker of chronic low-
grade systemic inflammation, may 
have a predictive role for breast 
cancer risk. Exercise may protect 
against postmenopausal breast can-
cer by inducing an anti-inflammatory 
environment and subsequently pro-
tecting against chronic low-grade 
inflammation. Exercise may lower 
inflammation via reductions in adi-
posity and other pathways.
Oxidative stress plays an impor-
tant role in breast cancer carcino-
genesis – specifically, the oxida-
tion of DNA in carcinogenesis and 
tumour promotion. Epidemiological 
data also suggest associations be-
tween oxidative stress and breast 
cancer. As a part of a favourable 
biological adaptive response, ex-
ercise enhances the capacity of 
antioxidant and oxidative damage 
repair enzymes, and subsequently 
reduces oxidative damage.
Investigators have called for tri-
als of exercise and breast cancer 
incidence, to provide the ultimate 
level of evidence about the type, 
dose, and timing of activity needed 
for breast cancer prevention, but no 
studies are currently planned be-
cause of the considerable expense 
and time commitment required [3]. 
Thus, to date, the epidemiological 
research performed in healthy popu-
lations is restricted to evidence on 
intermediate end-points for breast 
cancer. Nonetheless, evidence ex-
ists that these pathways are amena-
ble to change by exercise.
References
1. Neilson HK et al. (2009). Cancer Epidemiol 
Biomarkers Prev, 18:11–27. http://dx.doi.
org/10.1158/1055-9965.EPI-08-0756 
PMID:19124476
2. Winzer BM et al. (2011). Cancer Causes 
Control, 22:811–826. http://dx.doi.org/10. 
1007/s10552-011-9761-4 PMID:21461921
3. Ballard-Barbash R et al. (2009). J Natl 
Cancer Inst, 101:630–643. http://dx.doi.
org/10.1093/jnci/djp068 PMID:19401543
Chapter 5.2 • Breast cancer 369
5 
O
R
G
A
N
 S
IT
E
C
H
A
P
TE
R
 5
.2
in subsets of breast cancers, such 
as triple-negative/basal-like, is much 
higher. A large number of genes 
appear to be implicated in a small 
percentage of tumours, and this 
will provide additional challenges 
to achieving the dream of a patient-
specific targeted and personalized 
medical intervention.
A better understanding of famil-
ial breast cancer due to germline 
mutations in BRCA1 and BRCA2 
is determining optimal patient man-
agement (see “Treatment deter-
mined by BRCA1/2 mutation”). The 
pathology of these tumours is well 
detailed now, and it is clear that most 
BRCA1-associated breast cancers 
are high-grade, medullary-like, and 
triple-negative, and have a basal-
like phenotype [13]. There are also 
data indicating that a proportion of 
ER-positive tumours in patients with 
BRCA1 mutations are also due to in-
activation of BRCA1 and may not be 
sporadic [14]. The morphological fea-
tures of BRCA2-associated tumours 
are more heterogeneous, although 
most are high-grade breast cancers. 
The pathology has been combined 
with various personal and family his-
tory factors to develop algorithms to 
predict the risk of carrying a BRCA1 
mutation, and these have been used 
in the clinic with varying degrees of 
success.
Prospects
Prevention
To date, most breast cancer pre-
vention strategies have focused on 
reducing the development of breast 
cancer in women considered to be at 
moderately or greatly increased risk 
of the disease based on calculated 
risks determined from prediction 
models, or in women with germline 
mutations in high-penetrance breast 
cancer susceptibility genes (BRCA1 
and BRCA2).
Several clinical trials have eval-
uated the effect on the develop-
ment of breast cancer of endocrine 
interventions using selective ER 
modulators (SERMs) and aromatase 
inhibitors. The results of the National 
Surgical Adjuvant Breast and Bowel 
Project’s Breast Cancer Prevention 
Trial [15] and Study of Tamoxifen and 
Raloxifene Trial [16] demonstrated 
that the SERMs tamoxifen and ralox-
ifene are each associated with about 
a 50% reduction in the development 
of breast cancer in women consid-
ered to be at moderately increased 
risk of breast cancer based on the 
Gail risk assessment model. In two 
other prevention trials, tamoxifen was 
associated with more modest reduc-
tions in the development of breast 
cancer. However, in both of these 
trials some of the women received 
Fig. 5.2.3. Adenocarcinoma of the breast 
below the nipple, in cross-section.
Fig. 5.2.4. Identification of breast cancer subtypes. (A) Correlation of breast tumour samples with five recognized subtypes of breast 
tumours. For this analysis, 526 out of 552 previously identified “intrinsic” genes were cross-mapped and subject to hierarchical clus-
tering. (B) Unsupervised hierarchical clustering of 20 breast tumour tissues analysed using the 526 mapped intrinsic genes (the two 
microarray replicates for each sample are shown). The level of expression of each gene in each sample, relative to the median level 
of expression of that gene across all the samples, is represented using a colour scale as shown in the key (green, below median; 
black, equal to median; red, above median). (Left panel) Scaled-down representation of the entire cluster of the 526 intrinsic genes 
and 20 tissue samples. (Right panel) Experimental dendrogram displaying the clustering of the tumours into three distinct subgroups.
370
hormone replacement therapy and 
this may have attenuated the che-
mopreventive benefit of tamoxifen 
[17,18]. Despite the demonstrated 
efficacy of tamoxifen and raloxifene 
in reducing the development of breast 
cancer, these SERMs have had lim-
ited patient acceptance in the chemo-
prevention setting.
The role of aromatase inhibitors 
in breast cancer prevention is also 
an area of active research. In one 
recent study, treatment with exemes-
tane was associated with a 65% 
relative reduction in the annual inci-
dence of invasive breast cancer in 
postmenopausal women at moder-
ately increased risk of breast cancer, 
with no serious toxicity and minimal 
effect on health-related quality of life 
[19]. The role of anastrozole in the 
chemoprevention setting is currently 
being evaluated. The reduction of 
breast cancer development associ-
ated with these endocrine interven-
tions has been notably limited to 
ER-positive tumours. These agents 
have not been effective in reducing 
the risk of ER-negative tumours, 
which account for about 20–30% of 
breast cancers and are associated 
with a poorer prognosis [20]. As a 
result, the potential role in breast 
cancer prevention of various drugs 
that target non-endocrine signal-
ling pathways is under active inves-
tigation. For example, recent data 
from the Women’s Health Initiative 
indicated that among postmeno-
pausal women with diabetes, treat-
ment with metformin was associated 
with a reduced incidence of breast 
cancer [21]. Other non-endocrine 
drugs being studied as possible 
breast cancer prevention agents in-
clude cyclooxygenase 2 inhibitors, 
retinoids, and receptor tyrosine 
kinase inhibitors, among others. 
However, clinical trials will be re-
quired to evaluate the role of these 
agents in breast cancer prevention.
Bilateral prophylactic mastec-
tomy is a highly effective strategy to 
prevent the development of breast 
cancer in women with BRCA muta-
tions. This procedure is associated 
with a 90% reduction in the devel-
opment of breast cancer in these 
Fig. 5.2.5. Recently identified breast cancer genes and involvement of the JUN kinase 
signalling pathway. (A) Representations of the protein-coding sequences and major 
domains in cancer genes relevant to breast cancer. Somatic mutations evident in tu-
mours are shown as circles: truncating (red), essential splice site (blue), missense 
(green), and in-frame insertion or deletion (yellow). Red lines indicate the positions of 
large homozygous deletions. aa, amino acids. (B) Pathways regulating the JUN kinases 
MAP2K7 and MAP2K8, indicating genes with mutations in this series. Genes in green 
are activated by mutations, whereas genes in purple are inactivated.
Fig. 5.2.6. Pregnancy before age 30 and 
breastfeeding reduce a woman’s total 
number of lifetime menstrual cycles, and 
both factors are associated with lower risk 
of breast cancer. (For more details, see 
Chapter 2.5.)
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women, and an even higher (95%) 
reduction in breast cancer among 
those who have also had their 
ovaries removed [22]. Bilateral 
prophylactic mastectomy is associ-
ated with an even greater (> 99%) 
reduction in breast cancer devel-
opment among women who were 
considered to be at high risk of the 
disease and who were cared for 
in community practices and were 
therefore not as highly selected 
as in referral centres [23]. Recent 
technical improvements in onco-
plastic surgery have resulted in 
better cosmetic outcomes in wom-
en who undergo post-mastectomy 
reconstruction and have, in turn, 
made the option of prophylactic 
mastectomy more appealing than in 
the past. The influence of modifying 
dietary and lifestyle factors on the 
prevention of breast cancer is also 
under active investigation [24].
Screening
Mammography remains the mainstay 
of population-based breast cancer 
screening although access to mam-
mographic screening varies widely 
around the world and the procedure is 
unavailable in most developing coun-
tries. Mammography results in the 
detection of more in situ lesions than 
would be identified otherwise and of 
invasive cancers that are smaller, 
of lower grade, more often node-
negative, and more often of special 
types (especially tubular carcinomas) 
than are evident in non-screened 
populations. Controversies remain 
about the magnitude of mortality 
reduction attributable to mammo-
graphic screening, the lower and 
upper age limits of the patients who 
should be screened, and the most 
cost-effective screening interval [25]. 
In addition, mammographic screen-
ing can result in overdiagnosis due 
to the detection of tumours that will 
never become a threat to life, as well 
as an excessive number of biopsies, 
and patient anxiety [25,26].
In recent years, technical ad-
vances have improved the sensitivity 
of mammography for at least a sub-
set of women [25]. In particular, in a 
Treatment determined by BRCA1/2 mutation
Susan M. Domchek
Germline mutations in BRCA1 and 
BRCA2 are associated with an in-
creased lifetime risk of breast and 
ovarian cancers, as well as other 
cancers such as male breast cancer, 
prostate cancer, and pancreatic can-
cer. The lifetime risk of breast cancer 
is 60–70% in women harbouring ei-
ther mutation. Interventions such 
as prophylactic mastectomy and 
prophylactic oophorectomy have 
been demonstrated to reduce the 
risk of breast and ovarian cancers 
in several observational cohort stud-
ies. Risk-reducing oophorectomy 
has also been associated with im-
proved overall survival [1]. In women 
diagnosed with breast cancer, the 
knowledge that there is an increased 
risk of developing a second primary 
breast cancer can factor into deci-
sion-making about local therapy with 
the option of bilateral mastectomy.
Due to the biological functions 
of BRCA1 and BRCA2 (particularly 
their roles in DNA damage repair of 
double-strand breaks), it has been 
postulated that there may be dif-
ferential responses of BRCA1/2-
associated tumours to different 
types of systemic therapy. In gen-
eral, BRCA-associated cancers 
(both breast and ovarian) appear 
to be more sensitive than sporadic 
cancers to chemotherapy. Emerging 
data suggest that specific chemo-
therapy type may matter clinically. 
Several small studies have reported 
high response rates in breast cancer 
to cisplatin-based chemotherapy 
given in both the pre-operative and 
metastatic setting [2]. For exam-
ple, in a study of 20 patients with 
BRCA1-positive metastatic breast 
cancer, the objective response 
rate to cisplatin chemotherapy was 
80%. There are no data available 
from randomized studies compar-
ing cisplatin with other agents, but 
the reported response rates and 
progression-free survival data are 
encouraging.
Novel agents called poly(ADP-
ribose) polymerase (PARP) inhibi-
tors are being studied in BRCA1 
and BRCA2 mutation carriers with 
both metastatic breast cancer and 
recurrent ovarian cancer. These 
drugs, which remain in clinical tri-
als, aim to exploit the fundamental 
defects in BRCA1/2-associated 
cancers via the concept of synthet-
ic lethality. Synthetic lethality refers 
to the idea that inhibition or muta-
tion of two pathways leads to cell 
death when inhibition or mutation of 
either alone does not. Initial reports 
have demonstrated high response 
rates in both BRCA1/2-associated 
metastatic breast cancer and recur-
rent ovarian cancer [3]. Interestingly, 
although PARP inhibitors do not ap-
pear to have activity in unselected 
sporadic triple-negative breast can-
cer, studies have been encouraging 
in sporadic high-grade serous ovar-
ian cancer.
Mechanisms of resistance to 
both cisplatin and PARP inhibitors 
are beginning to be elucidated. 
One very interesting mechanism 
is that of secondary or “reversion” 
mutations, which restore full-length 
protein. Studies are under way to 
determine the optimal use of both 
platinum agents and PARP inhibitors 
in BRCA1/2 mutation carriers.
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large clinical trial digital mammogra-
phy was shown to be more sensitive 
than traditional film mammography in 
younger women (aged < 50 years, or 
premenopausal) and in women with 
dense breasts. Breast tomosynthe-
sis, a variation of digital mammog-
raphy, produces three-dimensional 
digital images of the breast but has 
not been demonstrated to be more 
sensitive than standard digital mam-
mography. Both ultrasonography 
and magnetic resonance imaging 
may be of value as adjuncts to mam-
mography in selected cases. These 
techniques are associated with high 
false-positive rates and are not rec-
ommended for screening the general 
population [25]. Magnetic resonance 
imaging, however, may have a role in 
the screening of women with BRCA1 
germline mutations. Newer modali-
ties that may ultimately find a role 
in breast cancer screening include 
molecular imaging and functional im-
aging techniques [27]. Alternatives 
to mammography for breast cancer 
screening, particularly in developing 
countries, are being evaluated and 
include breast awareness and clinical 
breast examination (see Chapter 4.8).
Targeted agents
Selection of breast cancer treatment, 
particularly systemic therapy, is 
currently based primarily on clinical 
and pathological factors, supple-
mented by hormone receptor and 
HER2 status. The standard options 
for systemic therapy currently include 
hormone therapy, cytotoxic therapy, 
and HER2-targeted therapy, singly 
and in various combinations. Rapidly 
evolving knowledge of the molecu-
lar events and signalling pathways 
underlying the development and 
progression of breast cancer has 
led to the identification of a growing 
number of new therapeutic targets 
and to the development of drugs 
against these targets. Many clinical 
trials are currently under way world-
wide to evaluate the role of these 
new targeted therapies in the treat-
ment of patients with breast cancer. 
Newer targeted therapies that have 
been or are being evaluated, sin-
gly and in combination with each 
other and with traditional cytotoxic 
agents, include angiogenesis inhibi-
tors, tyrosine kinase inhibitors, in-
hibitors of mammalian target of rap-
amycin (mTOR), poly(ADP-ribose) 
polymerase 1 (PARP1) inhibitors, 
insulin-like growth factor 1 recep-
tor (IGF-1R) inhibitors, proteasome 
inhibitors, phosphatidylinositol 3-ki-
nase (PI3K) inhibitors, and others 
[28]. The ultimate goal of this re-
search is to be able to tailor breast 
cancer treatment for individual pa-
tients based on the particular mo-
lecular features of the tumour.
Fig. 5.2.7. A woman undergoing mammography screening. Her breast is being com-
pressed to obtain the optimal mammographic image.
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Summary
• Oesophageal carcinomas are 
less common than cancers of 
the colon and stomach but often 
prove lethal based on diagno-
sis of predominantly late-stage 
disease.
• The two main types of oesopha-
geal carcinoma are squamous cell 
carcinoma and adenocarcinoma.
• Both types are more common 
in men than women, but squa-
mous cell carcinomas are en-
countered in individuals from 
low-resource regions, whereas 
adenocarcinomas tend to arise 
in high-resource populations.
• Both types are successfully 
managed by mucosal ablation 
strategies if patients present 
with early-stage lesions, where-
as chemoradiation treatment of-
fers limited but slowly improving 
success in patients presenting 
with late-stage lesions.
• Screening protocols remain 
poorly developed for oesopha-
geal carcinomas.
Oesophageal cancer is a malig-
nant, usually epithelial neoplasm 
most commonly showing squamous, 
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glandular (adenocarcinoma), or neu-
roendocrine differentiation and aris-
ing in the oesophagus. Other, rarer 
types of malignant neoplasms can be 
encountered (adenoid cystic carci-
noma, adenosquamous carcinoma, 
muco-epidermoid carcinoma, mixed 
adenoneuroendocrine carcinoma, 
various sarcomas, and melanoma). 
Only squamous cell carcinoma and 
adenocarcinoma are addressed 
here as they account for most oe-
sophageal malignant neoplasms.
Oesophageal squamous cell 
carcinoma
Squamous cell carcinoma of the oe-
sophagus (Fig. 5.3.1) is a malignant 
epithelial neoplasm with squamous 
differentiation consisting of keratino-
cyte cells, often with intercellular 
bridges or production of keratin.
Etiology
Squamous cell carcinoma of the oe-
sophagus is characterized by great 
geographical variation. Pockets of 
high incidence (> 50 per 100 000 
people) occur in the Islamic Republic 
of Iran (e.g. Golestan Province; 
> 100 per 100 000), parts of China 
(e.g. Linxian, Henan Province; 
> 130 per 100 000), and Zimbabwe. 
Intermediate incidence is seen in 
East Africa, southern Brazil, the 
Caribbean, much of China, parts 
of Central Asia, northern India, and 
southern Europe; incidence is low 
in North America, northern Europe, 
and western Africa. There are some 
data correlating ethnicity with the 
risk of squamous cell carcinoma, 
indicating that Turkish or Mongolian 
people in Central Asia and African 
Americans in North America are 
more likely than other people in 
those regions to be diagnosed with 
squamous cell carcinoma.
Alcohol consumption and to-
bacco smoking and chewing are the 
strongest risk factors for the devel-
opment of oesophageal squamous 
cell carcinoma, although these 
associations display marked geo-
graphical variation. Cessation of 
smoking substantially reduces the 
smoking-associated risk. Intake of 
hot beverages (hot maté in parts of 
South America; hot tea, hot coffee, 
or hot soups elsewhere) is similarly 
Fig. 5.3.1. Ulcerated oesophageal squa-
mous cell carcinoma.
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Epidemiology
Oesophageal cancer
• Oesophageal cancer is the 
eighth most common cancer 
worldwide, with an estimated 
456 000 new cases (3% of all 
cancers) and 0.4 million can-
cer deaths (5% of all cancer 
deaths) in 2012. About 73% of 
all new cases occurred in coun-
tries at low or medium levels of 
human development, and 49% 
of all new cases occurred in 
China.
• Incidence and mortality rates 
are elevated in Central and 
East Asia as well as in eastern 
Africa. Incidence rates tend 
to be relatively low in west-
ern Africa and in some Latin 
American countries.
• Incidence varies 15-fold be-
tween countries worldwide 
in men and almost 20-fold in 
women. Incidence and mortal-
ity rates are 2–4 times as high 
in men as in women.
• Due to the high fatality rate, 
mortality rates are close to 
incidence rates, regardless of 
sex differences and human de-
velopment levels.
• Incidence and mortality trends 
are variable and reflect the 
changing prevalence and dis-
tribution of the underlying risk 
factors for oesophageal cancer 
and its main histological sub-
types (adenocarcinoma and 
squamous cell carcinoma). An 
increasing tendency to clas-
sify cancers located at the 
gastro-oesophageal junction 
as adenocarcinoma (rather 
than gastric cardia cancer) may 
also have had an impact on the 
overall trends.
Map 5.3.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for oesophageal cancer in men, 2012.
Map 5.3.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for oesophageal cancer in women, 2012.
associated with risk of oesophageal 
squamous cell carcinoma, as is in-
gestion of caustic substances (such 
as occurs in suicide attempts and in 
accidental swallowing of household 
toxins by children). Certain dietary 
habits (low intake of fresh fruits and 
vegetables, fresh meat or fish, and 
dairy products, and high intake of 
barbecued meats and pickled veg-
etables, which may result in expo-
sure to N-nitroso compounds) are 
associated with a high incidence 
of oesophageal squamous cell 
carcinoma. Use of opium, poor oral 
health, and poor nutrition all inter-
act to affect outcome in oesopha-
geal squamous cell carcinoma in 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.3.1. Estimated global number of new cases and deaths with proportions by major world regions, for oesophageal 
cancer in both sexes combined, 2012.
Chart 5.3.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for oesophageal 
cancer in men, circa 1975–2012.
Chart 5.3.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for oesophageal 
cancer in women, circa 1975–2012.
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high-risk areas. For example, in 
the Islamic Republic of Iran, opium 
intake is associated with poor out-
come in univariate analysis but not 
in adjusted models [1]. Other cir-
cumstances mediating increased 
risk include having Plummer–
Vinson syndrome (sideropenic dys-
phagia, including dysphagia due to 
oesophageal webs, glossitis, and 
iron-deficiency anaemia, usually in 
postmenopausal women), coeliac 
disease, and achalasia. Finally, ex-
posure to ionizing radiation, often 
from treatment for breast carcino-
ma, is a risk factor.
Given that alcohol consumption 
and tobacco use are the two major 
known causes of oesophageal squa-
mous cell carcinoma, an Australian 
study assessed respective popula-
tion attributable fractions based on 
305 cases and 1554 controls. The 
results were 49% (95% confidence 
interval [CI], 38–60%) and 32% 
(95% CI, 25–40%) of oesophageal 
squamous cell carcinoma cases 
attributable to smoking and heavy 
alcohol consumption, respectively. 
More than 75% of the oesophageal 
squamous cell carcinoma burden in 
men could be attributed to smokers 
with heavy alcohol consumption 
[2]. Polymorphisms in acetaldehyde 
dehydrogenase 2 (ALDH2) are key 
to individual susceptibility to upper 
aerodigestive tract cancer; patients 
with inactive ALDH2 are at high risk 
of oesophageal squamous cell carci-
noma [3]. In Asians, polymorphisms 
in the ALDH gene family are asso-
ciated with altered risk of oesopha-
geal squamous cell carcinoma. The 
effects of these polymorphisms are 
synergistic with alcohol consumption 
and smoking. In addition, the poly-
morphisms in ALDH associated with 
oesophageal carcinoma also result 
in accumulation of acetaldehyde, 
which causes flushing upon ingestion 
of alcohol (the “Asian flush”) in about 
one third of East Asians (Chinese, 
Japanese, and Koreans) [4]. 
Genome-wide association studies 
in Chinese individuals have identified 
several susceptibility loci, encom-
passing 5q11, 6p21, 10q23, 12q24, 
and 21q22 and including genes re-
lated to those encoding ALDH and 
thereby linked to the association 
between alcohol consumption and 
oesophageal squamous cell carci-
noma in both Chinese and Japanese 
people [5,6]. The prevalence of oe-
sophageal squamous dysplasia par-
allels rates of invasive oesophageal 
squamous cell carcinoma; it is typi-
cally found in 25% or more of adults 
older than 35 years in north central 
China, where the risk of this malig-
nancy is among the highest in the 
world [7].
Pathology and genetics
Oesophageal squamous cell car-
cinoma is defined as a squamous 
neoplasm that invades through the 
epithelial basement membrane into 
the lamina propria, submucosa, mus-
cularis propria, or deeper. Variable 
amounts of keratinization are 
seen, manifested by cells showing 
brightly eosinophilic opaque cyto-
plasm (Fig. 5.3.3A,B). Invasion into 
the lamina propria begins with the 
proliferation of rete-like projections 
of neoplastic squamous epithelium. 
Both horizontal and vertical spread 
are observed. Tumours can pene-
trate vertically through the oesopha-
geal wall and invade the intramural 
lymphatic channels and veins.
The development of oesophageal 
squamous cell carcinoma is under-
stood to be a multistep process that 
progresses from normal squamous 
epithelium to include intraepithelial 
neoplasia (dysplasia; Fig. 5.3.3C) 
and culminates in the growth of in-
vasive carcinoma. Mutation in the 
TP53 gene is an early event, some-
times detectable in intraepithelial 
neoplasia. Amplification of cyclin D1 
occurs in 20–30% of these tumours. 
Inactivation of CDKN2A, either by 
homozygous deletion or by de novo 
methylation, appears to be associ-
ated with advanced disease.
The scope of molecular analy-
ses applicable to all tumour types 
is indicated from studies identifying 
alterations in genes, proteins, and 
microRNAs in oesophageal squa-
mous cell carcinoma, of which 10 or 
more studies in each category are 
available. Epigenetic abnormalities 
are evident from DNA methylation, 
histone deacetylation, chromatin 
remodelling, gene imprinting, and 
non-coding RNA regulation studies 
[8]. High-throughput genotyping of 
metastatic tumours has identified 
phosphatidylinositol 3-kinase (PI3K) 
and BRAF mutations among the 
Fig. 5.3.2. A man makes tea in Rawalpindi, Pakistan. Intake of hot beverages like tea 
is associated with increased risk of oesophageal squamous cell carcinoma.
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somatic mutations evident [9]. In a 
separate study, inactivating NOTCH1 
mutations were identified in 21% of 
oesophageal squamous cell carcino-
mas from the USA but only rarely in 
such tumours from China [10].
Familial predisposition to oe-
sophageal cancer has been studied 
predominantly in association with 
focal non-epidermolytic palmoplan-
tar keratoderma (also known as ty-
losis), a rare condition in industrial-
ized countries (low-risk populations). 
This autosomal dominant inherited 
disorder of the palmar and plantar 
skin surfaces is associated with oe-
sophageal cancer. The causative lo-
cus, the tylosis oesophageal cancer 
(TOC) gene, maps to 17q25, with 
missense mutations (c.557T → C 
[p.Ile186Thr] and c.566C → T 
[p.Pro189Leu]) in RHBDF2, which 
encodes the inactive rhomboid 
protease RHBDF2 (also known as 
iRhom2) [11].
Prospects
The overall prognosis of oesophage-
al squamous cell carcinoma remains 
poor based on diagnosis of predomi-
nantly late-stage disease. Screening 
programmes to detect precursor and 
early-stage lesions have been im-
plemented in some high-risk popula-
tions. Radiofrequency ablation ther-
apy and other forms of endoscopic 
treatments appear promising for 
eradication of early lesions [12,13].
Oesophageal 
adenocarcinoma
Adenocarcinoma of the oesophagus 
is a malignant epithelial neoplasm 
with glandular differentiation arising 
predominantly from Barrett mucosa 
and typically encountered in the 
lower third of the oesophagus.
Etiology
Oesophageal adenocarcinoma is 
characterized by a high male-to-
female ratio (from 4 to 7), with a 
higher incidence among Caucasians 
and among subgroups with a high 
socioeconomic status [14,15]. The 
incidence and prevalence of oe-
sophageal adenocarcinoma was 
reported as rising during the last 
decades of the 20th century in a 
number of high-resource countries 
[14–16]. For example, in the USA, 
incidence rates for adenocarcinoma 
have been rising markedly, whereas 
rates for squamous cell carcinoma 
are declining steadily. From 1999 
to 2008, rates among White men 
increased substantially (1.8% per 
year), as among White women (2.1% 
per year) and Hispanic men (2.8% 
per year). No significant changes 
were observed for men or women 
of other racial/ethnic groups. While 
rates of oesophageal adenocarci-
noma have been increasing among 
Caucasians in some populations, 
it is extremely difficult to quantify 
the rate of increase from analysis 
of time trends in registry data, due 
partly to improvements in recording 
and capturing histology information 
(decreasing numbers of tumours 
without histological confirmation) 
but also because of changes in 
the assignment of cancers at the 
gastro-oesophageal junction, from 
the gastric cardia (or gastric, other/
non-specified) to the oesophagus.
Obesity is a strong risk factor for 
oesophageal adenocarcinoma, as is 
gastro-oesophageal reflux disease. 
The trend of increasing incidence 
rates of oesophageal adenocarci-
noma parallels the growing obesity 
epidemic and the prevalence of 
gastro-oesophageal reflux disease 
[15]. However, in a 2012 study in the 
USA, incidence rates of oesopha-
geal adenocarcinoma were 7-fold 
higher among White men than 
among Black men, despite data in-
dicating that the prevalence of obe-
sity is higher among Black men and 
women than among White men and 
women [15].
The countries with the high-
est incidence of this tumour type 
are the United Kingdom, Australia, 
the Netherlands, and the USA. 
Relatively lower incidence rates 
are reported from eastern Europe 
and Scandinavia. In Latin America, 
Asia, and Africa, oesophageal ad-
enocarcinoma remains uncommon, 
but it is possibly also underreported 
(particularly in Latin America).
Although familial association 
has been reported for patients with 
Fig. 5.3.3. Invasive squamous cell carcinoma and precursor lesions. (A) Nests of carcinoma cells with brightly eosinophilic cytoplasm 
in keeping with keratinization embedded in desmoplastic stroma from a mucosal biopsy. (B) This squamous cell carcinoma shows a 
basaloid pattern such that the cells are small and darkly stained owing to their high nuclear-to-cytoplasmic ratio. The clue that this is 
a squamous cell carcinoma is the overt keratinization at the right side of the field. (C) High-grade squamous dysplasia (intraepithelial 
neoplasia) of the oesophagus. This lesion has not invaded the basement membrane (Tis) but shows marked cytological alterations. 
In the oesophagus, such lesions are typically not associated with human papillomavirus.
A B C
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Risk of malignant progression in Barrett oesophagus patients
Liam J. Murray
Barrett oesophagus (BO) is a pre-
cursor of oesophageal adenocar-
cinoma. The magnitude of cancer 
risk in BO is crucial in determining 
whether the benefits of screening, 
surveillance, or treatment of BO out-
weigh any risks and whether such 
strategies are cost-effective. The 
published incidence of malignancy 
in BO varies widely, from 0 to 35.5 
cases per 1000 person-years of risk 
(pyr) [1]. To date, most studies have 
been small, and publication bias in 
favour of studies showing high risks 
has been demonstrated [2]. Other 
design issues, such as the inclusion 
of unrepresentative cohorts of BO 
patients (e.g. patients from tertiary 
referral centres), inclusion of those 
at high risk of progression (e.g. with 
high-grade dysplasia at baseline), 
incomplete follow-up of patients, 
or failure to exclude early incident 
(most likely prevalent) cancers, 
have resulted in overestimation of 
the risks of malignant progression 
in BO. Differing criteria for diagno-
sis of BO, for example inclusion of 
patients without specialized intes-
tinal metaplasia, and differing defi-
nitions of malignant progression, 
for example inclusion/exclusion of 
incident high-grade dysplasia, have 
also contributed to the variation in 
observed rates. The combined risk 
of oesophageal adenocarcinoma or 
high-grade dysplasia may provide 
a better estimate of malignant pro-
gression than risk of oesophageal 
adenocarcinoma alone, although 
it will overestimate risk as not all 
patients with high-grade dysplasia 
would progress to cancer in the ab-
sence of therapeutic intervention [3].
The best estimates of risk of ma-
lignant progression in BO are pro-
vided by population-based studies 
with long-term follow-up for a high 
proportion of patients (excluding 
those with high-grade dysplasia at 
baseline) and discounting events 
occurring soon after diagnosis. 
Several such studies have recently 
been published [4–8]. Even in these 
studies, differing BO definitions, dif-
ferent proportions of patients with 
low-grade dysplasia at baseline, and 
differing approaches to, and com-
pleteness of, follow-up have resulted 
in variable estimates of malignant 
progression. Among patients with-
out low-grade dysplasia at baseline, 
the incidence of oesophageal ade-
nocarcinoma/high-grade dysplasia 
ranged from 2.2 per 1000 pyr [4] to 
5.2 per 1000 pyr [6,8]; however, the 
higher estimates were not based on 
follow-up of all diagnosed cases and 
may have overestimated risk. Risk 
of oesophageal adenocarcinoma/
high-grade dysplasia was 2–6-fold 
higher in patients with low-grade 
dysplasia at baseline than in those 
without low-grade dysplasia.
Using currently available data, 
it is difficult to reach a definite con-
clusion about the risk of malignant 
progression in BO, but it is lower 
than previously thought and, in pa-
tients without low-grade dysplasia at 
baseline, appears to be lower than 
5 cases of oesophageal adenocar-
cinoma/high-grade dysplasia per 
1000 pyr.
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oesophageal adenocarcinoma, pop-
ulation-based studies show limited 
influence of familial risk, consistent 
with the rapid changes in incidence 
rates observed in many popula-
tions over a very short time period. 
The epidemiological features of ade-
nocarcinoma of the oesophagus and 
of the oesophago-gastric junction 
match those of patients with known 
intestinal metaplasia in the distal oe-
sophagus, i.e. Barrett oesophagus 
[15]. Barrett oesophagus has been 
identified as the single most impor-
tant precursor lesion and risk factor 
for oesophageal adenocarcinoma, 
irrespective of the length of the 
segment with intestinal metaplasia. 
Intestinal metaplasia of the oesopha-
gus develops when the squamous 
oesophageal epithelium is replaced 
by columnar epithelium during the 
process of healing after repetitive 
injury, typically associated with 
gastro-oesophageal reflux disease. 
Intestinal metaplasia can be detect-
ed in the majority of patients with 
oesophageal adenocarcinoma [17].
A meta-analysis of studies in pa-
tients with Barrett oesophagus dem-
onstrated an incidence of progres-
sion to adenocarcinoma of about 
6.1 per 1000 person-years, which 
reduced to 3.9 per 1000 person-
years when only high-quality studies 
were considered [18], correspond-
ing to a lifetime risk of about 10% 
in these patients. However, these 
results may be overestimations 
that reflect various types of bias in 
the studies. More recently, an Irish 
study reported a rate of 3.8 per 1000 
person-years [19], whereas a Danish 
study showed a considerably lower 
progression rate of only 0.12% per 
year [20], although obesity is far less 
prevalent in the Danish population 
than in the United States or Irish 
380
population (see “Risk of malignant 
progression in Barrett oesophagus 
patients”).
Chronic gastro-oesophageal re- 
flux disease is the usual source of 
mucosal injury and also provides 
an abnormal environment during 
the healing process that predis-
poses to intestinal metaplasia and 
adenocarcinoma. In a large Swedish 
study, individuals with long-stand-
ing and severe gastro-oesophage-
al reflux disease symptoms had a 
40-fold increased risk of oesopha-
geal adenocarcinoma [21]. Both 
experimental and clinical data in-
dicate that combined oesophageal 
exposure to both gastric acid and 
duodenal contents (bile acids and 
pancreatic enzymes) appears to be 
more carcinogenic than exposure 
to only gastric juice or duodenal 
contents. An association between 
alcohol consumption and oesopha-
geal adenocarcinoma has not been 
well established. A reduced risk of 
oesophageal adenocarcinoma is 
associated with Helicobacter pylori 
infection, and particularly H. pylori 
strains with the CagA protein. A 
protective effect has been suggested 
after the use of non-steroidal anti-
inflammatory drugs, but not all stud-
ies have supported such data.
Pathology and genetics
Adenocarcinoma in Barrett oesoph-
agus develops through a progres-
sive sequence of morphologically 
identifiable premalignant lesions 
termed “dysplasia”. Dysplasia is 
diagnosed by the presence and de-
gree of cytological and architectural 
atypia [22]. Low-grade dysplasia 
shows pits with relatively preserved 
architecture, or minimal distortion, 
containing cells with atypical nuclei 
limited to the basal portion of the 
cell cytoplasm. High-grade dyspla-
sia is diagnosed by the presence of 
marked cytological abnormalities 
and/or significant architectural com-
plexity of the glands (Fig. 5.3.4A). 
Cytological abnormalities include 
nuclear pleomorphism and loss 
of polarity, irregularity of nuclear 
contour, and increased nuclear-
to-cytoplasmic ratio. Architectural 
abnormalities of high-grade chang-
es include crypt budding, branch-
ing, marked crowding, and, rarely, 
a cribriform growth pattern.
Intramucosal adenocarcinoma 
(invasion into the lamina propria; 
T1a) show single cells or small clus-
ters of compact back-to-back glands 
within the lamina propria, a cribri-
form or solid pattern of growth with 
expansion and distortion of the ad-
jacent crypts, and a highly distorted/
irregular glandular proliferation not 
explained by the presence of pre-
existing glands. The presence of 
necrosis and/or desmoplasia is evi-
dence in favour of adenocarcinomas 
as well, although these features are 
rarely present in carcinomas limited 
to the mucosa.
Oesophageal adenocarcinomas 
are typically papillary and/or tubu-
lar. Most cases are of the intestinal 
type in the Laurén classification 
(Fig. 5.3.4B), whereas some are 
of the diffuse type. Multiple ge-
netic alterations are involved in the 
development and progression of 
Barrett oesophagus to oesophage-
al adenocarcinoma, encompassing 
tumour suppressor genes, onco-
genes, growth factor receptors, or 
enzymes that play important roles 
in diverse cellular functions such 
as cell-cycle control, apoptosis, cell 
signalling, cell adhesion and genetic 
stability, signal transduction, and 
DNA repair. Gains in the region of 
Fig. 5.3.4. Oesophageal adenocarcinoma and precursor lesions. (A) High-grade colum-
nar epithelial dysplasia in Barrett oesophagus. Note the markedly hyperchromatic nuclei 
at the surface of the sample (mucosal biopsy). This process in glandular mucosa is a 
precursor to adenocarcinoma. (B) Oesophageal adenocarcinoma. This gland-forming 
malignant neoplasm has the appearance of an intestinal-type adenocarcinoma, in the 
Laurén classification for gastric carcinomas.
A B
Fig. 5.3.5. Schematic of protein alterations in DOCK2 and ELMO1 detected by whole-
exome sequencing of oesophageal adenocarcinoma. Coding alterations in oesophageal 
adenocarcinoma are coloured either black (missense) or red (splice site or nonsense); 
silent mutations are depicted in grey. Conserved domain mapping is from UniProt. DHR, 
Dlg homologous region, ELMO, engulfment and cell motility; PH, Pleckstrin homology; 
SH3, SRC homology 3.
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8q (region of c-myc) and 20q, and 
losses at 3p (FHIT), 4q, 5q (APC) 
and 18q (SMAD4, DCC) have all 
been reported, with an increasing 
number of chromosomal alterations 
in the sequence from metaplasia to 
intraepithelial neoplasia to carci-
noma. Gene silencing by promoter 
hypermethylation has been demon-
strated frequently for the CDH1 gene 
(which encodes E-cadherin) and the 
APC, p16, MGMT, and HPP1 genes. 
Disorders of ARID are also noted.
Exome and whole-genome se-
quencing of 149 and 15 oesopha-
geal adenocarcinomas has been 
recently reported [23]. A mutational 
signature was defined by a high 
prevalence of A → C transversions 
at AA dinucleotides. Of 26 signifi-
cantly mutated genes, TP53, CDKN2, 
SMAD4, ARID4, and PIK3CA had 
been implicated previously. The new 
significantly mutated genes included 
chromatin modifying factors and 
candidate contributors SPG20, TLR4, 
ELMO1, and DOCK2 (Fig. 5.3.5). 
Functional analysis of the relevant 
mutations in ELMO1 identified in-
creased cellular invasion.
Prospects
Novel endoscopic techniques for ear-
ly detection and treatment of oesoph-
ageal adenocarcinoma offer prom-
ise. Ablation therapy for high-grade 
dysplasia (the strongest risk factor 
for adenocarcinoma) is probably 
cost-effective [24]. Ideal strategies 
for population-based screening in 
high-risk patients remain poorly es-
tablished and inconsistent.
A recent review [25] determined 
that endoscopic screening is inva-
sive, costly, and error-prone owing 
to sampling bias and the subjec-
tive diagnosis of dysplasia. Non-
endoscopic cell sampling methods 
(Fig. 5.3.6) are less invasive and 
more cost-effective than endoscopy, 
but the sensitivity and specificity of 
cytological assessment of atypia 
have been disappointing. The use 
of biomarkers to analyse samples 
collected using pan-oesophageal 
cell collection devices may improve 
diagnostic accuracy.
Fig. 5.3.6. Oesophageal cell collection using non-endoscopic devices. (A) The deflated balloon is inserted into the stomach. (B) Once 
deemed to be in the stomach, the balloon is inflated through the attached catheter and pulled up the oesophagus. Mucosal cells 
adhere to the balloon, which is then deflated and removed. A similar procedure based on the use of a cytosponge may also be used.
A B
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Summary
• Most stomach cancers (90%) 
are sporadic. In almost all coun-
tries, a steady decline in gastric 
cancer mortality rates has oc-
curred in the past few decades.
• Helicobacter pylori is the major 
environmental cause of gastric 
cancer development. Other fac-
tors contributing to risk include 
dietary composition – particu-
larly intake of pickled vegeta-
bles – and smoking.
• Molecular pathogenesis of gas-
tric cancer is complex. Genes 
related to receptor tyrosine ki-
nase (RTK)/RAS signalling are 
frequently amplified, in par-
ticular FGFR2, KRAS, ERBB2, 
EGFR, and MET. The product 
of the HER2 oncogene, when 
either overexpressed or ampli-
fied, is a prognostic factor.
• Hereditary gastric cancer con-
tributes to 1–3% of the bur-
den of stomach cancer. Two 
syndromes have been identi-
fied: hereditary diffuse gastric 
cancer and gastric adenocar-
cinoma and proximal polyposis 
of the stomach.
• Hereditary diffuse gastric can-
cer is caused by germline alter-
ations of the E-cadherin (CDH1) 
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gene; prophylactic gastrectomy 
is recommended for asymp-
tomatic carriers of pathogenic 
CDH1 mutations.
Most stomach cancers are gas-
tric carcinomas, which are malig-
nant epithelial neoplasms. Non-
epithelial tumours of the stomach 
predominantly include lymphomas 
and mesenchymal tumours. Gastric 
carcinomas represent a biological-
ly and genetically heterogeneous 
group of tumours with multifactorial 
etiologies, both environmental and 
genetic. They are characterized by 
broad morphological heterogene-
ity with respect to patterns of archi-
tecture and growth, cell differentia-
tion, histogenesis, and molecular 
pathogenesis.
Most cases of gastric cancer are 
sporadic, and familial clustering is 
observed in about 10% of cases. 
Hereditary gastric cancer accounts 
for a very low percentage of cases 
(1–3%), and two hereditary syn-
dromes have been characterized: 
hereditary diffuse gastric cancer 
and gastric adenocarcinoma and 
proximal polyposis of the stomach. 
Furthermore, gastric cancer can 
develop in the setting of other he-
reditary cancer syndromes.
Etiology
Gastric carcinogenesis is a multi-
step and multifactorial process that, 
in many cases, appears to involve 
a progression from normal mucosa 
through chronic gastritis (chronic in-
flammation of the gastric mucosa), 
atrophic gastritis (with loss of gastric 
glands), and intestinal metaplasia 
(substitution of gastric epithelium 
by intestinal epithelium) to dyspla-
sia (intraepithelial neoplasia) and 
carcinoma, a sequence of events 
that may last several years. This 
sequence has been designated as 
the Correa cascade of multistep 
gastric carcinogenesis [1]. However, 
the Correa model does not explain 
all carcinogenic steps of gastric can-
cer. Actually, a proportion of gastric 
adenocarcinomas arise in non-
intestinalized mucosa and retain a 
gastric phenotype (and gastric dif-
ferentiation is also observed in gas-
tric dysplasia, the ultimate precursor 
lesion of gastric adenocarcinoma). 
Also, in the recently identified syn-
drome gastric adenocarcinoma and 
proximal polyposis of the stomach 
(discussed below), gastric dyspla-
sia and gastric adenocarcinoma 
develop in fundic gland polyps of 
the proximal stomach and are re-
lated not to intestinal metaplasia 
but instead to foveolar hyperplasia. 
Together, this evidence shows that 
gastric adenocarcinoma can arise 
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Stomach cancer
• Stomach cancer is the fifth most 
common cancer worldwide, 
with an estimated 952 000 new 
cases (7% of total cancer in-
cidence) and 723 000 deaths 
(9% of total cancer mortality) 
in 2012. Almost three quarters 
of the new cases occurred in 
Asia, and more than two fifths 
occurred in China.
• There is a 10-fold international 
variation in stomach cancer inci-
dence; rates in men are approxi-
mately double those observed 
in women.
• The highest age-standardized 
incidence rates are in East Asia 
and central and eastern Europe. 
Incidence rates tend to be rela-
tively low in Africa and in North 
America.
• The case fatality rate is lower 
in countries with high levels of 
human development (overall 
mortality-to-incidence ratio, 
0.65) than in countries at low or 
medium levels of human devel-
opment (0.83).
• Over the past 50 years, inci-
dence and mortality rates of 
the non-cardia type of gastric 
cancer have been uniformly de-
creasing in almost all countries; 
rates of gastric cardia cancer 
have, however, been stable or 
increasing in the past two to 
three decades.
Map 5.4.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for stomach cancer in men, 2012.
Map 5.4.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for stomach cancer in women, 2012.
from the gastric epithelium. These 
findings challenge the classic pro-
posed histogenetic pathway from 
chronic atrophic gastritis through 
intestinal metaplasia to adenocar-
cinoma (with glandular structure), 
which is frequently designated as 
intestinal carcinoma (Laurén clas-
sification), a misnomer for these 
cases. Another type of gastric car-
cinoma, so-called diffuse carcinoma 
(Laurén classification), probably de-
velops de novo from gastric mucosa. 
Except for the diffuse carcinomas 
developing in a hereditary setting 
(discussed below), no precursor le-
sions have been well characterized 
for this type of gastric cancer.
Among environmental factors con-
tributing to increased risk of gastric 
cancer, Helicobacter pylori infection 
plays a major role. Almost all non-
cardia gastric cancers develop from 
a background of H. pylori-infected mu-
cosa [2]. H. pylori is a Gram-negative 
bacterium that colonizes the gastric 
mucosa. In 1994, IARC categorized 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.4.1. Estimated global number of new cases and deaths with proportions by major world regions, for stomach cancer 
in both sexes combined, 2012.
Chart 5.4.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for stomach cancer 
in men, circa 1975–2012.
Chart 5.4.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for stomach cancer 
in women, circa 1975–2012.
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H. pylori as a Group 1 carcinogen for 
gastric cancer [3] based on results 
of epidemiological studies that were 
available at that time; this conclu-
sion was later confirmed. H. pylori 
can be identified in gastric mucosa 
by routine stains, such as haema-
toxylin–eosin and modified Giemsa, 
and other ancillary methods such 
as Warthin–Starry staining and im-
munohistochemistry (Fig. 5.4.1). 
The infection is commonly acquired 
during early childhood and per-
sists throughout adult life unless 
eradicated.
Factors associated with coloni-
zation and pathogenicity of H. pylori 
include virulence factors – cagA in 
the cag pathogenicity island and the 
vacuolating cytotoxin vacA [4] – as 
well as outer membrane proteins of 
the bacterium. Strains producing the 
cagA protein that induce a greater de-
gree of inflammation are associated 
with gastric precancerous lesions and 
a greater risk of developing cancer of 
the distal stomach [4]. Although the 
risk of gastric cancer in some coun-
tries of Europe and North America has 
been related to vacA genotype, such 
relationships have not been observed 
in countries in East Asia, suggesting 
that consequences of variation in 
vacuolating activity are dependent on 
geographical region. Corpus-
predominant gastritis with multifocal 
gastric atrophy and hypochlorhydria or 
achlorhydria is seen in approximately 
1% of subjects infected with H. pylori. 
As a direct consequence of elevation 
in gastric pH, there is a change in gas-
tric flora, with colonization by anaero-
bic bacteria responsible for the forma-
tion of carcinogenic nitrosamines.
Certain dietary habits are as-
sociated with an increased risk of 
gastric cancer [5]. These include 
high intakes of salt-preserved and/
or smoked foods and low intakes of 
fresh fruit and vegetables. An analy-
sis of 60 relevant studies suggested 
a potential 50% higher risk of gas-
tric cancer associated with intake 
of pickled vegetables, and perhaps 
Fig. 5.4.1. Helicobacter pylori detected in the lumen of gastric glands and adherent to the apical pole of epithelial cells: 
(A) haematoxylin–eosin (inset: modified Giemsa); (B) Warthin–Starry; (C) immunohistochemistry.
Fig. 5.4.2. Food in Seoul, Republic of Korea, typically includes pickled vegetables, the 
consumption of which is associated with increased risk of gastric cancer.
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stronger associations in the Republic 
of Korea and China (Fig. 5.4.2) [6]. 
Intake of all meat, specifically in-
cluding red meat and processed 
meat, is also associated with an 
increased risk of gastric cancer in 
the distal stomach. The so-called 
“Mediterranean diet” was shown to 
be associated with a significant re-
duction in the risk of gastric cancer 
incidence; this diet is characterized 
as involving high consumption of 
fruit, vegetables, cereals, legumes, 
nuts and seeds, and seafood, with 
olive oil as the main fat source, mod-
erate alcohol consumption (particu-
larly red wine), a low to moderate 
consumption of dairy products, and 
a relatively low consumption of red 
and processed meat.
Tobacco smoking causes stom-
ach cancer; the epidemiological as-
sociation is not explicable by bias or 
confounding factors. Smoking also 
potentiates the carcinogenic ef-
fect of infection with cagA-positive 
H. pylori.
Polymorphisms of the interleukin-
1β (IL1B) gene, which contributes to 
initiation and amplification of inflam-
matory response, and of the inter-
leukin-1 receptor antagonist (IL1RN) 
gene, which modulates inflamma-
tion, are associated with individual 
or familial susceptibility to carcino-
genesis associated with H. pylori. 
Among individuals with alleles that 
predispose to inflammation, infection 
with H. pylori may cause increased 
production of gastric interleukin-1β, 
leading to severe and sustained in-
flammation that increases the risk of 
developing gastric cancer [7].
Pathology
Two major types of gastric carci-
noma were described by Laurén in 
1965 [8]: the intestinal and diffuse 
types, which display different clin-
icopathological profiles and molec-
ular pathogenesis, and often occur 
in distinct epidemiologic settings. 
Currently, five major types of gas-
tric cancer are recognized by WHO: 
tubular (Fig. 5.4.3A), papillary, mu-
cinous, poorly cohesive (with or with-
out signet ring cells) (Fig. 5.4.3B), 
and mixed [9]. Tubular and papillary 
carcinomas roughly correspond 
to the intestinal type in the Laurén 
classification, and poorly cohesive 
carcinomas (encompassing cases 
constituted, partially or totally, by 
signet ring cells) correspond to the 
diffuse type. Furthermore, rare vari-
ants account for about 10% of gastric 
carcinomas.
The gastric antrum (distal stom-
ach) is the most common site of gas-
tric carcinoma. Carcinomas of the 
oesophago-gastric junction have 
been most commonly reported in 
populations in North America and 
Europe, associated with gastro-
oesophageal reflux disease and 
other characteristics similar to ad-
enocarcinoma arising in Barrett 
oesophagus, and are unrelated to 
H. pylori infection. However, in parts 
of Asia, for example in China, but 
also for a subset of tumours diag-
nosed in North America and Europe, 
neoplasms of the proximal stomach 
arise in a setting of chronic atrophic 
gastritis with H. pylori infection and 
are similar to distal gastric cancer. 
Adenocarcinomas located entirely 
below the oesophago-gastric junc-
tion are considered gastric in origin, 
and for these tumours the use of the 
ambiguous and often misleading 
term “carcinoma of the gastric car-
dia” is discouraged in favour of “car-
cinoma of the proximal stomach”.
Early gastric carcinoma is an in-
vasive carcinoma limited to the mu-
cosa or submucosa, regardless of 
nodal status. The term “early” does 
not imply a stage in the genesis of 
the cancer but means that these are 
gastric cancers that can often be 
cured. However, if untreated, 63% of 
early gastric carcinomas progress 
to advanced tumours within 5 years. 
Countries with a high incidence of 
gastric cancer and in which asymp-
tomatic patients are screened have 
a high incidence of early gastric 
carcinomas, ranging from 30% to 
50% in Japan and the Republic of 
Korea, with lower figures for west-
ern Europe and North America 
(16–24%). Lymph-node metastasis 
occurs in 10–20% of all early gastric 
carcinomas and correlates with the 
depth of submucosal invasion and 
increasing tumour diameter.
Advanced gastric carcinoma 
invades the muscularis propria of 
the stomach and beyond. Most pa-
tients with advanced carcinoma have 
lymph-node metastatic disease for 
which only palliative surgery can be 
considered. Lymphatic and vascular 
invasion, often seen in advanced 
cases, indicate a poor prognosis. 
Gastric carcinomas can spread by 
direct extension to adjacent organs, 
metastasis, or peritoneal dissemina-
tion. Carcinomas of the intestinal type 
preferentially metastasize haema-
togenously to the liver, whereas 
Fig. 5.4.3. Main histological types of gastric carcinoma: (A) intestinal carcinoma 
(Laurén classification), tubular type (WHO classification); (B) diffuse carcinoma (Laurén 
classification), poorly cohesive type, with signet ring cells (WHO classification).
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Gastric cancer prevention
Il Ju Choi
Gastric cancer prevention consists 
of primary prevention (removing 
possible causes) and secondary 
prevention (early detection). Primary 
prevention is a feasible approach 
considering the marked decrease 
in gastric cancer incidence during 
the past century in industrialized 
countries. This decrease suggests 
the major effect of environmental 
factors on stomach cancer develop-
ment. Dietary intervention, includ-
ing increased intake of fresh fruit 
and vegetables and reduced intake 
of salt and processed or smoked 
meat, is a main primary prevention 
strategy.
Helicobacter pylori eradication is 
another promising strategy. Despite 
its importance, only two studies have 
evaluated gastric cancer develop-
ment as a primary outcome. The first 
study (of 1630 healthy individuals 
from a high-risk region of China, in 
2004) found that gastric cancer in-
cidence over 7.5 years was similar 
in H. pylori eradication and placebo 
groups. [1]. From these results, H. 
pylori eradication in the general 
population is currently not consid-
ered to have definite supporting 
data. Eradication of H. pylori, how-
ever, may decrease stomach cancer 
development in the subgroup with 
no precancerous changes such as 
atrophy or intestinal metaplasia. The 
second study (of 544 randomized 
patients who underwent endoscopic 
resection for early gastric cancer in 
Japan, in 2008) showed at a 3-year 
follow-up that risk of metachronous 
gastric carcinoma was reduced to 
one third in the eradication group 
[2]. This is the first randomized study 
showing that H. pylori eradication is 
effective for stomach cancer preven-
tion; however, it has the limitation of 
not being blinded and of having a 
short follow-up duration.
Currently, a study recruiting 
family members of gastric cancer 
patients, a high-risk population, is 
under way in the Republic of Korea 
(ClinicalTrials.gov: NCT01678027). 
Furthermore, a study with enough 
statistical power, with recruitment of 
a larger number of patients from the 
general population, is also needed 
before implementation of this strat-
egy in the general population from 
high-risk regions.
Secondary prevention is an-
other important aspect of gastric 
cancer prevention. In the Republic 
of Korea, where gastric cancer inci-
dence is the highest in the world, the 
National Cancer Screening Program 
has been providing biennial gastric 
cancer screening for people aged 
40 years or older since 1999. This 
is a unique screening programme, 
which uses endoscopy (which has a 
much higher sensitivity than radiol-
ogy with barium meal) as a primary 
screening tool. Probably owing to the 
screening effect, the 5-year survival 
rate of stomach cancer patients in 
the Republic of Korea has improved, 
from 46.6% in 1996–2000 to 67.0% 
in 2006–2010. Furthermore, endo-
scopic screening at 2-year intervals 
detects stomach cancer mostly as 
an early gastric cancer confined to 
the mucosal or submucosal layers 
(Fig. B5.4.1), and many such can-
cers can be cured by endoscopic 
resection rather than by surgical 
gastrectomy [3].
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Fig. B5.4.1. Early gastric cancer detect-
ed by screening endoscopy.
carcinomas composed of poorly co-
hesive cells (the diffuse type) pref-
erentially metastasize to peritoneal 
surfaces. Mixed carcinomas exhibit 
the metastatic patterns of both types. 
When the carcinoma penetrates the 
serosa, peritoneal implants generally 
flourish.
Genetic predisposition and 
hereditary syndromes
First-degree relatives of patients with 
gastric cancer are almost 3 times as 
likely as the general population to 
develop gastric cancer themselves. 
This may be partly attributable to 
H. pylori infection being common 
in families and to the potential 
role of IL-1 gene polymorphisms. 
Susceptibility to carcinogens may 
play a role as well. For example, 
polymorphisms of genes encod-
ing for glutathione S-transferase 
enzymes, known to metabolize 
tobacco-related carcinogens and 
N-acetyltransferase 1, increase the 
risk of gastric cancer development. 
There is evidence also of familial 
clustering: about 10% of stomach 
cancers show evidence of a famil-
ial component, and approximately 
1–3% of gastric cancers are a re-
sult of an inherited predisposition, 
of which the major type is hereditary 
diffuse gastric cancer [10]. Genome-
wide association studies have im-
plicated the prostate stem cell an-
tigen (PSCA) gene and the mucin 
1 (MUC1) gene as influencing sus-
ceptibility. Approximately 95% of the 
Japanese population have at least 
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one of the two risk genotypes, and 
approximately 56% of the population 
have both risk genotypes [11].
Hereditary diffuse gastric 
cancer
On the basis of clinical criteria, the 
International Gastric Cancer Linkage 
Consortium defined families with he-
reditary diffuse gastric cancer syn-
drome as meeting one of two criteria: 
(i) two or more documented cases 
of diffuse gastric cancer in first- or 
second-degree relatives, with at 
least one of them diagnosed before 
the age of 50 years, or (ii) three or 
more documented cases of diffuse 
gastric cancer in first- or second-
degree relatives, independent of age 
of diagnosis [12]. Women in these 
families have an elevated risk of 
lobular breast cancer. The criteria 
for genetic testing were updated in 
2010 [13].
Alterations of the CDH1 gene, 
which encodes E-cadherin, con-
stitute the genetic causal event of 
hereditary diffuse gastric cancer 
[14]. In clinically defined heredi-
tary diffuse gastric cancer, CDH1 
mutations are detected in 30–40% of 
cases. Most (75–80%) are truncat-
ing mutations, and the remainder are 
missense mutations. In addition to 
point mutations, large germline dele-
tions have been found in hereditary 
diffuse gastric cancer families that 
tested negative for point mutations.
A model of early development 
of diffuse gastric cancer in CDH1 
mutation carriers has been pro-
posed, encompassing precursor 
(intraepithelial) lesions (in situ carci-
noma and pagetoid spread of signet 
ring cells), early intramucosal car-
cinoma, and advanced cancer [15].
Gastric adenocarcinoma and 
proximal polyposis of the 
stomach
Recently, a new hereditary syndrome 
has been identified: gastric adeno-
carcinoma and proximal polyposis 
of the stomach, characterized by the 
autosomal dominant transmission 
of fundic gland polyposis, including 
areas of dysplasia or intestinal-type 
gastric adenocarcinoma, restricted 
to the proximal stomach, with no 
evidence of colorectal or duodenal 
polyposis or other heritable gastro-
intestinal cancer syndromes. The 
genetic defect behind this syndrome 
has not yet been elucidated [16].
Gastric cancer in other 
hereditary cancer syndromes
The risk of gastric cancer is also in-
creased in dominantly inherited can-
cer predisposition syndromes such 
as familial adenomatous polyposis 
and Lynch syndrome, and also in Li–
Fraumeni syndrome with germline 
mutation of TP53.
Molecular pathology
Gastric carcinoma is the result of 
accumulated genomic damage af-
fecting cellular functions essential 
for cancer development: self-suf-
ficiency in growth signals, escape 
from anti-growth signals, resistance 
to apoptosis, sustained replicative 
potential, angiogenesis induction, 
and invasive or metastatic poten-
tial. These genomic changes arise 
through three genomic instability 
pathways: microsatellite instabil-
ity, chromosomal instability, and a 
CpG island methylation phenotype. 
Furthermore, genetic and epigenetic 
changes affect oncogenes and tu-
mour suppressor genes [17].
Some oncogenes are preferen-
tially altered in a specific type of 
gastric cancer, such as HER2 and 
KRAS in the intestinal type. Human 
epidermal growth factor receptor 
2 (HER2) overexpression and/or 
amplification is present in 10–20% 
of gastric cancers, and it has been 
suggested that HER2 overexpres-
sion and/or amplification may be one 
of the molecular abnormalities linked 
to the development of gastric cancer, 
with a negative impact on progno-
sis [18]. Recently, a comprehensive 
survey of genomic alterations in 
gastric cancer revealed systematic 
patterns of molecular exclusivity and 
genes related to receptor tyrosine ki-
nase (RTK)/RAS signalling: FGFR2 
(in 9% of tumours), KRAS (9%), 
EGFR (8%), ERBB2 (7%), and 
MET (4%) [19]. These genes were 
frequently amplified in gastric can-
cer in a mutually exclusive manner 
Fig. 5.4.4. A woman gives her daughter a banana from an electrical refrigerator, in a 
photograph from 1946. Refrigerators have allowed better preservation of food, thus 
reducing the need for salt preservation.
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(Fig. 5.4.5), indicating five distinct 
gastric cancer patient subgroups. 
Collectively, these subgroups sug-
gest that at least 37% of gastric 
cancer patients may be potentially 
treatable by RTK/RAS-directed 
therapies. A separate study revealed 
KRAS mutations in 4.2% of gastric 
tumour samples from the United 
Kingdom, Japan, and Singapore, 
demonstrating that KRAS mutation 
and DNA mismatch repair deficiency 
have a role in a small subgroup of 
these tumours [20].
Some oncogenes are altered 
preferentially in diffuse carcinoma, 
such as BCL2 and FGFR2 (for-
merly K-sam). Other oncogenes 
are altered in both intestinal-type 
and diffuse carcinomas, including 
CTNNB1 (encoding β-catenin), MET, 
and MYC. Many tumour suppressor 
genes have been implicated in gas-
tric carcinoma development, includ-
ing APC and DCC in intestinal-type 
carcinomas and CDH1 and RB1 in 
diffuse carcinomas. Other tumour 
suppressor genes are altered in both 
types of gastric carcinoma, such as 
PTEN and TP53, although these 
are more common in intestinal-type 
carcinoma.
Prevention, screening, and 
targeted agents
The two major changes that could 
be made at a population level to 
reduce gastric cancer incidence are 
improvement in diet and reduction in 
the prevalence of H. pylori. These 
changes are already taking place 
in many populations, as a conse-
quence of economic development, 
and may explain the decline ob-
served in gastric cancer incidence. 
Active intervention in a population 
requires proof that the intervention 
is effective, and this can only come 
from randomized trials. Prevention 
of gastric cancer is a primary public 
health issue in Japan [21] and the 
Republic of Korea (see “Gastric 
cancer prevention”).
Radiology with barium meal is 
used in mass screening protocols 
in Japan, followed by endoscopy if 
an abnormality is detected. In the 
Republic of Korea, endoscopy is 
primarily used as a screening proce-
dure. Testing for serum pepsinogen 
is being evaluated for screening to 
identify high-risk patients and detect 
early cancers.
Endoscopy is a sensitive and 
specific diagnostic test for gastric 
cancer. Although detection of le-
sions associated with early gastric 
cancer can be improved using chro-
mo-endoscopy and narrow-band 
imaging, a substantial number of 
such lesions still escape detection. 
Tumour staging before deciding on a 
treatment plan involves endoscopic 
ultrasonography for characteriza-
tion of the primary tumour but is 
less useful for lymph-node staging, 
whereas computed tomography 
(CT) is used to detect lymph-node 
and liver metastases. Positron emis-
sion tomography in combination 
with CT imaging may be superior to 
either alone for preoperative stag-
ing. Laparoscopic staging may be 
the only way to exclude peritoneal 
seeding.
There is current interest in the 
immunohistochemical and in situ 
hybridization detection of HER2 ex-
pression in gastric cancer because 
there is evidence that these tumours 
may respond well to therapy with the 
humanized monoclonal antibody 
trastuzumab [22]. The European 
Medicines Agency and similar au-
thorities recommend HER2 testing 
by immunohistochemistry and fluo-
rescence in situ hybridization to iden-
tify patients who may benefit from 
targeted therapy with trastuzumab.
In families fulfilling the criteria 
for hereditary diffuse gastric cancer, 
screening for CDH1 germline alter-
ations is indicated. Asymptomatic 
carriers of pathogenic changes of 
the CDH1 gene are candidates for 
total prophylactic gastrectomy or 
annual endoscopic surveillance (in 
selected groups) as risk reduction 
strategies.
Fig. 5.4.5. Mutually exclusive and co-amplified genomic alterations in gastric cancer. 
(A) Focal regions exhibiting mutually exclusive patterns of genome amplification. 
Outermost circular track indicates genomic positions by chromosomes (black lines are 
cytobands, red lines are centromeres). Blue lines indicate pairs of focal regions (genes) 
exhibiting significant patterns of mutually exclusive genomic amplification. Genes in-
volved in receptor tyrosine kinase (RTK)/RAS signalling are highlighted in red. (B) Focal 
regions exhibiting patterns of genomic co-amplification. Orange lines indicate pairs of 
focal regions (genes) exhibiting significant patterns of genomic co-amplification. Genes 
involved in RTK/RAS signalling are highlighted in red.
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Summary
• Colorectal cancer is one of the 
most common cancers in men 
and women, representing al-
most 10% of the global cancer 
incidence. 
• Dietary composition, obesity, 
and lack of physical activity are 
established as contributing to 
risk of colorectal cancer, but the 
underlying causative biological 
processes are not defined.
• Most colorectal carcinomas de-
velop through an adenoma–car-
cinoma sequence, underpinning 
screening colonoscopy for ad-
enomatous polyp removal as a 
preventive option.
• Three molecular pathways op-
erate: (i) the chromosomal in-
stability pathway, characterized 
by inactivating mutations of the 
APC, TP53, and TGF-ß genes, 
mutations of KRAS, and activa-
tion of telomerase; (ii) the micro-
satellite instability pathway, char-
acterized by deficient mismatch 
repair, arising through mutation 
of mismatch repair genes or 
through promoter methylation of 
MLH1, resulting in a hypermu-
tated state; (iii) the CpG island 
methylation pathway, charac-
terized by a high level of gene 
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promoter methylation, along 
with typical morphology of the 
precursor lesions in the form of 
sessile serrated adenomas.
• Familial colorectal cancer com-
prises different syndromes, in-
cluding familial adenomatous 
polyposis, hereditary non-pol-
yposis colon cancer or Lynch 
syndrome, MUTYH-associated 
polyposis, and hamartomatous 
polyp syndromes.
• Inflammatory bowel disease, 
when long-standing, predispos-
es to colorectal cancer.
• KRAS mutation renders a tumour 
refractory to anti-EGFR agents, 
and is therefore predictive.
Colorectal cancer is defined as a 
carcinoma, usually an adenocar-
cinoma, in the colon or rectum [1]. 
The term “colorectal cancer” might 
suggest a homogeneous disease 
entity, but this is clearly not the 
case. The term “colorectal” is cus-
tomarily used as a topographical 
indication, but in reality the thera-
peutic approach for rectal cancer 
differs significantly from that for 
colon cancer, primarily due to the 
quite different anatomical setting 
of the rectum, which is embedded 
in a tight space with genitourinary 
organs nearby. Cancer in the right 
colon (caecum, ascending colon) is 
biologically different from that in the 
left colon (from the splenic flexure 
down), in terms of both molecular 
characteristics and response to tar-
geted treatment. Colorectal cancer 
can develop sporadically, in the 
context of a familial syndrome, or 
in the context of inflammatory bow-
el disease; each of these settings 
leads to a disease with distinct 
characteristics. Recent molecular 
profiling studies suggest that the 
heterogeneity of colorectal cancer 
extends beyond these more or less 
established categories [1–4].
Etiology
An evaluation by the World Cancer 
Research Fund [2] has determined 
that the evidence that physical activ-
ity protects against colon cancer is 
convincing; the evidence is convinc-
ing that consumption of red meat 
and processed meat, consumption 
of alcoholic beverages (for men, and 
probably for women), body fatness 
and abdominal fatness, and the 
factors that lead to greater adult at-
tained height, or its consequences, 
are causes of colorectal cancer. 
Consumption of garlic, milk, and 
calcium probably protects against 
colorectal cancer.
Therefore, with reference to 
specifying foods that increase risk 
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Epidemiology
Colorectal cancer
• Colorectal cancer represents al-
most 10% of the global cancer 
incidence burden in 2012, and is 
the third most common cancer in 
men (an estimated 746 000 cas-
es) and the second most com-
mon in women (614 000 cases). 
Colorectal cancer is the fourth 
most common cause of death 
from cancer worldwide, with an 
estimated 694 000 deaths.
• More than 65% of new cases 
occurred in countries with high 
or very high levels of human 
development; almost half of the 
estimated new cases occurred 
in Europe and the Americas. 
Colorectal cancer is now the 
third most common cancer in 
areas with high human devel-
opment, and the highest inci-
dence rates are in men in cen-
tral Europe (Slovakia, Hungary, 
the Czech Republic) and the 
Republic of Korea.
• Incidence varies 10-fold be-
tween countries worldwide, 
in both sexes, and rates tend 
to be relatively low in many 
African countries. As with inci-
dence, mortality rates are lower 
in women than in men, except in 
the Caribbean.
• The scale of the colorectal 
cancer incidence burden and 
its temporal development in a 
given country are key markers 
of human development transi-
tions, and incidence (and mor-
tality) is increasing in many 
countries transitioning towards 
higher levels of human develop-
ment. In contrast, trends appear 
to be stabilizing or declining in 
countries that have attained 
the highest levels of human 
development.
Map 5.5.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for colorectal cancer in men, 2012.
Map 5.5.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for colorectal cancer in men, 2012.
of colorectal cancer, the primary fo-
cus is on meat. Despite the strength 
of the epidemiological evidence, 
relevant biological processes are 
poorly defined. Cooked meat may 
contain two classes of carcinogens – 
heterocyclic amines and polycy-
clic aromatic hydrocarbons – but 
these are unlikely to account for 
the evident risk [3]. An indication 
of the recognized  complexity may 
be gained from the experimental 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.5.1. Estimated global number of new cases and deaths with proportions by major world regions, for colorectal 
cancer in both sexes combined, 2012.
Chart 5.5.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for colorectal cancer 
in men, circa 1975–2012.
Chart 5.5.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for colorectal cancer 
in men, circa 1975–2012.
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observation that dietary fat can 
alter the gut microbiota of mice 
indirectly by affecting bile acids 
and hence contributing to inflam-
matory bowel disease (see be-
low) [4]. Such a direct association 
between diet and carcinogenesis 
is complemented by current un-
derstanding that obesity may play 
a crucial role in mediating car-
cinogenesis via inflammation [5]. 
Obesity-enhanced inflammation is 
largely orchestrated by increases 
in adipose tissue macrophages, 
leading to the secretion of inflam-
matory cytokines, including tumour 
necrosis factor α (TNF-α), mono-
cyte chemoattractant protein 1, and 
interleukin-6 (IL-6), all of which are 
linked to colorectal cancer [6].
Colorectal cancer is considered 
primarily as a “lifestyle” disease; its 
incidence is high in countries with a 
diet high in calories and animal fat 
and with a largely sedentary pop-
ulation. One consequence of the 
lack of precise knowledge as to how 
multiple factors contribute to risk is 
that (chemo)preventive measures 
can only be, and are only, proposed 
in rather general terms. Solid evi-
dence exists for a role of non-ste-
roidal anti-inflammatory drugs in 
prevention of the progression from 
adenoma to carcinoma [7].
Pathogenesis
In the development of colorectal 
cancer, three distinct pathways 
operate: the chromosomal instabil-
ity pathway, the microsatellite insta-
bility pathway, and the CpG island 
methylator pathway [8–10].
Chromosomal instability 
pathway
The chromosomal instability path-
way is found in about 85% of spo-
radic colorectal cancers and is pro-
totypical for the molecular evolution 
of this malignancy. Chromosomal 
abnormalities (mostly a combination 
of allelic losses and gains) include 
newly discovered chromosomal 
translocations [11]. This category of 
colorectal cancers is characterized 
by mutations in the Wnt pathway 
genes APC (70%) or CTNNB (30%), 
a crucial element in their molecular 
carcinogenesis [12]. KRAS muta-
tions, usually in codons 12 and 13, 
occur in 45% of the cases and inter-
fere with anti-epidermal growth fac-
tor receptor (EGFR) therapy. TP53 
mutations are found in 70% of cas-
es. Loss of SMAD4 (which functions 
downstream of the TGF-β2 recep-
tor) occurs in later stages and con-
fers poor prognosis. In addition to 
these genes, recent evidence points 
towards more than 20 genes that 
are frequently mutated, including 
ARID1A, SOX9, and FAM123B/
WXT [11].
Morphologically, the sequence 
most likely starts as an aberrant 
crypt focus, a small focus of mu-
cosa in which the regular crypt ar-
chitecture is disturbed due to mu-
tations in KRAS or APC. Aberrant 
crypt foci with APC mutations show 
morphological signs of dysplasia, 
signifying a precancerous condi-
tion. Subsequent activation of telo-
merase confers unlimited lifespan to 
adenoma cells; TP53 mutations are 
involved in the progression from a 
low-grade adenoma to a high-grade 
adenoma, and other genes, includ-
ing SMAD, in the progression from a 
non-invasive adenoma to an invasive 
carcinoma (Fig. 5.5.1).
Microsatellite instability 
pathway
The microsatellite instability pathway 
is involved in about 15% of sporadic 
colorectal cancers. This genetic hall-
mark is due to an incompetent DNA 
mismatch repair system, as a result 
of promoter methylation of MLH1 (in 
sporadic microsatellite instability-
pathway colorectal cancer) or so-
matic mutations of the mismatch re-
pair genes (MLH1, MSH2, MSH6, or 
PMS2). Also, patients with a germ-
line mutation of one of the mismatch 
repair genes in Lynch syndrome fall 
into this category [10,13]. These 
Aberrant crypt focus Low-grade adenoma High-grade adenoma Carcinoma Metastases 
- P16 
- APC 
+ telomerase - TP53 - SMAD4 
Normal mucosa 
+KRAS 
Fig. 5.5.1. The chromosomal instability pathway in the development of colorectal cancer (after Vogelstein [8,9]). Morphologically, the 
adenoma–carcinoma sequence starts with a slight disturbance of crypt architecture and cytonuclear atypia, which is known as an 
aberrant crypt focus. Activating (+) KRAS mutations regularly occur in these lesions. Some of these may show features of epithelial 
dysplasia (as is shown in the second panel) and go on to develop into an adenoma. In this case, often inactivating (-) APC mutations 
are found. Low-grade adenomas are small and mostly tubular and have limited cytonuclear and architectural features of dysplasia. 
Once telomerase is activated (+), the lesions often show high-grade features: large, villous architecture and cytonuclear features 
(loss of polarity, nuclear pleomorphism, mitotic activity) of high-grade dysplasia. Progression towards invasive carcinoma is often 
accompanied by a TP53 mutation. Progression towards metastasis (haematogenous metastases most frequently in the liver, as 
shown in the right panel) is accompanied by further molecular events, such as inactivation (-) of SMAD4.
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cancers show a relatively high fre-
quency of BRAF (V600E) gene 
mutations. The early phases of 
development correspond to an 
adenoma–carcinoma sequence. 
Adenomas may be of the sessile 
serrated type with dysplasia, some 
of which progress to invasive carci-
noma. Carcinomas tend to be situ-
ated in the right colon, often with 
a mucinous or medullary histology 
with a host response characterized 
by a lymphocytic infiltrate. Cancers 
that arise through this pathway have 
a better prognosis but respond dif-
ferently to standard adjuvant chemo-
therapy by being less responsive to 
5-fluorouracil. When oxaliplatin is 
added, the survival benefit for can-
cers with microsatellite instability is 
maintained, whereas the addition of 
irinotecan does not seem to improve 
survival in such patients compared 
with those with microsatellite stable 
tumours, but this needs further con-
firmation [14].
CpG island methylator 
pathway
The CpG island methylator pathway 
[15,16] overlaps significantly with 
the microsatellite instability path-
way and is characterized by meth-
ylation of the promoter of a variety of 
genes (CpG island methylator phe-
notype), including MLH1, with resul-
tant microsatellite instability, which 
contributes to the accumulation of 
additional genetic abnormalities. 
Characteristically, an early muta-
tion of the BRAF gene (typically the 
V600E mutation) occurs. The CpG 
island methylator pathway is char-
acterized by morphologically rec-
ognizable precursor lesions. These 
resemble benign hyperplastic polyps 
but are large (> 1 cm) and flat, occur 
notably in the right colon, and show 
irregular crypt architecture but not 
necessarily features of dysplasia, as 
in the conventional adenoma–carci-
noma sequence (Fig. 5.5.2). These 
lesions are known as sessile serrat-
ed adenomas or polyps and have an 
increased risk for the development 
of colorectal cancer, the extent of 
which remains to be established.
Normal mucosa 
Hyperplastic polyp 
Sessile serrated 
adenoma/polyp 
SSA/P with  
low-grade dysplasia 
SSA/P with  
high-grade dysplasia Carcinoma 
BRAF mut 
CpG island 
hypermethylation 
MLH1 methylation 
microsatellite instability 
Accumulation of 
additional oncogene and 
tumour suppressor gene 
mutations 
Fig. 5.5.2. Schematic of the CpG island methylator pathway of colorectal carcinoma. 
An important difference from the chromosomal instability and microsatellite instability 
pathways is the early occurrence of CpG island methylation together with BRAF muta-
tions. Later in the pathway, gene aberrations that frequently occur in the other pathways 
are also found. SSA/P, sessile serrated adenoma/polyp.
Pathology and genetics
Colorectal cancer exemplifies 
stepwise progression [8,9] as it 
develops initially as a benign pre-
cursor lesion (adenoma), which 
can progress to an invasive le-
sion (adenocarcinoma) with the 
capacity to metastasize (meta-
static adenocarcinoma). The le-
sion arises from an intestinal 
clonogenic precursor cell (crypt 
base stem cell [17]) through the 
accumulation of multiple genetic 
abnormalities, most notably in the 
Wnt pathway in the form of inacti-
vating mutations of APC, activat-
ing mutations of KRAS, and sub-
sequent mutations of TP53 and of 
genes in the TGF-β pathway, which 
confer invasive and metastatic ca-
pacity (see “Lgr5 stem cells in self-
renewal and intestinal cancer”).
As outlined above, colorectal 
cancer comprises many different 
subtypes, which differ in morphol-
ogy, genetic background, associ-
ated conditions, molecular profile, 
clinical behaviour, and response to 
therapy. Categorization of colorec-
tal cancer as sporadic, associated 
with inflammatory bowel disease, 
or having familial tendency and 
associated with familial colorec-
tal cancer syndromes is clinically 
relevant.
Sporadic colorectal cancer
This is the prototypical cancer type in 
the colorectum. Histologically, these 
are adenocarcinomas that as a rule 
develop from a benign adenomatous 
polyp, which can be tubular, villous, 
or tubulovillous in architecture. Only a 
limited proportion (estimated at 10%) 
of benign adenomas progress to car-
cinoma; large adenomas with villous 
architecture have a high risk of pro-
gression [1]. Adenomas are treated 
by endoscopic polypectomy.
The primary modalities of spread 
of adenocarcinomas of the colo-
rectum are invasion into the bow-
el wall and metastasis into the re-
gional lymph nodes. In later stages, 
liver and lung metastases occur. 
Colorectal cancer is typically treated 
by surgery (hemicolectomy), with 
(adjuvant) chemotherapy depending 
on the disease stage; rectal cancer 
is often treated with a neoadjuvant 
chemo/radiotherapy protocol, fol-
lowed by surgery. Stage determines 
prognosis as well as the therapeutic 
approach (Table 5.5.1), notably as re-
gards the need for adjuvant therapy. 
For advanced stages, targeted 
therapy is available, targeting EGFR 
through monoclonal antibodies (ce-
tuximab, panitumumab), but only in 
KRAS wild-type tumours because 
KRAS mutation renders the tumour 
insensitive to anti-EGFR therapy [18].
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Lgr5 stem cells in self-renewal and intestinal cancer
Hans Clevers
The intestinal epithelium is the most 
rapidly self-renewing tissue in adult 
mammals. Lgr5 was originally iden-
tified as a Wnt target gene, tran-
scribed in colon cancer cells. Two 
knock-in alleles revealed exclusive 
expression of Lgr5 in cycling, co-
lumnar cells at the crypt base. Using 
an inducible Cre knock-in allele and 
the Rosa26-LacZ reporter strain, 
lineage tracing experiments were 
performed in adult mice. The Lgr5-
positive crypt base columnar cells 
generated all epithelial lineages 
throughout life, implying that these 
cells represent the stem cells of the 
small intestine and colon. Similar 
observations were made in hair fol-
licles and stomach epithelium.
Single-sorted Lgr5-positive stem 
cells can initiate ever-expanding 
crypt–villus organoids in three-di-
mensional culture. Tracing experi-
ments indicate that the Lgr5-positive 
stem cell hierarchy is maintained in 
these organoids. The data suggest 
that intestinal crypt–villus units are 
self-organizing structures, which 
can be built from a single stem cell 
in the absence of a non-epithelial 
cellular niche. The same technol-
ogy has now been developed for the 
Lgr5-positive stomach stem cells.
Intestinal cancer is initiated by 
Wnt pathway-activating mutations in 
genes such as APC. As in most can-
cers, the cell of origin has remained 
elusive. Deletion of APC in stem 
cells, but not in other crypt cells, 
results in progressively growing 
neoplasia, identifying the stem cell 
as the cell of origin of adenomas. 
Moreover, a stem cell/progenitor 
cell hierarchy is maintained in early 
stem cell-derived adenomas, lend-
ing support to the “cancer stem cell” 
concept. Fate mapping of individual 
crypt stem cells using a multicolour 
Cre reporter revealed that, as a 
population, Lgr5 stem cells have a 
lifelong persistence, yet crypts drift 
towards clonality within 1–6 months. 
Lgr5 cell divisions occur symmetri-
cally. The cellular dynamics are 
consistent with a model in which 
the resident stem cells double their 
numbers every day and stochasti-
cally adopt stem or telomerase ac-
tivator fates after cell division. Lgr5 
stem cells are interspersed between 
terminally differentiated Paneth cells 
that are known to produce bacteri-
cidal products. Paneth cells are 
CD24-positive and express EGF, 
TGF-α, Wnt3, and the Notch ligand 
Dll4, all essential signals for stem 
cell maintenance in culture. Co-
culturing of sorted stem cells with 
Paneth cells dramatically improves 
organoid formation. This Paneth cell 
requirement can be substituted by 
a pulse of exogenous Wnt. Genetic 
removal of Paneth cells in vivo re-
sults in the concomitant loss of Lgr5 
stem cells. In colon crypts, CD24-
positive cells residing between Lgr5 
stem cells may represent the Paneth 
cell equivalents. The data indicate 
that Lgr5 stem cells compete for 
essential niche signals provided 
by a specialized daughter cell, the 
Paneth cell.
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Inflammatory bowel disease
The generic term inflammatory bowel 
disease refers to two specific entities: 
Crohn disease and ulcerative colitis. 
Ulcerative colitis is restricted to the 
colon and/or rectum and is charac-
terized by a chronic inflammatory 
reaction restricted to the mucosa and 
submucosa. Crohn disease is char-
acterized by transmural inflammation 
and granulomas and can affect any 
part of the gastrointestinal tract but 
most commonly affects the terminal 
ileum. Chronic inflammatory dam-
age to the colon and rectum in both 
types of inflammatory disease con-
fers an increased risk of malignancy 
[19]. Some epidemiological evidence 
exists for an increased incidence of 
colorectal cancer in chronic colorectal 
schistosomiasis [20]. In the connec-
tion between inflammation and car-
cinogenesis, the transcription factor 
NF-κB is a key mediator, inducing 
expression of the pro-inflammatory 
mediators COX-2 and TNF-α, both 
of which play a role in colorectal car-
cinogenesis (see “Tumour-elicited 
inflammation and malignant progres-
sion in colorectal cancer”). Genome 
abnormalities in colorectal cancer in 
the context of inflammatory bowel 
disease are similar to those in spo-
radic colorectal cancer, but TP53 
mutations often occur early. APC 
mutations are less frequent.
Colorectal cancer associated 
with inflammatory bowel disease de-
velops through a dysplasia–carcino-
ma sequence (Fig. 5.5.3). Through 
endoscopic surveillance, dysplasia 
can be detected early on and colec-
tomy can then prevent the develop-
ment of an invasive carcinoma.
Familial colorectal cancer 
syndromes
Colorectal cancer clusters in fami-
lies in about 20% of cases, but a 
familial colorectal cancer syndrome 
can be pinpointed in less than half of 
these. When one or more relatives 
have been diagnosed with this ma-
lignancy, the risk of such cancer in-
creases 2–6-fold with an increased 
number of affected family members 
and the age at diagnosis of affected 
relatives. Although a variety of chro-
mosomal loci and, more recently, 
single-nucleotide polymorphisms 
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Table 5.5.1. Tumour–node–metastasis (TNM) classifications of carcinoma of the 
colon and rectum
T – Primary tumour
TX: Primary tumour cannot be assessed
T0: No evidence of primary tumour
Tis: Carcinoma in situ: intraepithelial or invasion of lamina propria
T1: Tumour invades submucosa
T2: Tumour invades muscularis propria
T3: Tumour invades subserosa or into non-peritonealized pericolic or perirectal tissues
T4: Tumour perforates visceral peritoneum and/or directly invades other organs or 
structures
T4a: Tumour perforates visceral peritoneum
T4b: Tumour directly invades other organs or structures
N – Regional lymph nodes
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph-node metastasis
N1: Metastasis in 1–3 regional lymph nodes
N1a: Metastasis in 1 regional lymph node
N1b: Metastasis in 2 or 3 regional lymph nodes
N1c: Tumour deposit(s), i.e. satellites, in the subserosa, or in non-peritonealized 
pericolic or perirectal soft tissue without regional lymph-node metastasis
N2: Metastasis in 4 or more regional lymph nodes
N2a: Metastasis in 4–6 regional lymph nodes
N2b: Metastasis in 7 or more regional lymph nodes
M – Distant metastasis
M0: No distant metastasis
M1: Distant metastasis
M1a: Metastasis confined to one organ
M1b: Metastases in more than one organ or the peritoneum
Stage grouping
Stage T N M
Stage 0 Tis N0 M0
Stage I T1, T2 N0 M0
Stage II T3, T4 N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage III Any T N1, N2 M0
Stage IIIA T1, T2
T1
N1
N2a
M0
M0
Stage IIIB T3, T4a
T2, T3
T1, T2
N1
N2a
N2b
M0
M0
M0
Stage IIIC T4a
T3, T4a
T4b
N2a
N2b
N1, N2
M0
M0
M0
Stage IVA Any T Any N M1a
Stage IVB Any T Any N M1b
have been identified (Table 5.5.2) 
that are associated with increased 
colorectal cancer risk, the less-pen-
etrant genes and/or gene–environ-
ment interactions responsible for 
such familial disease clusters have 
yet to be elucidated [12,13].
Familial adenomatous polyposis 
syndrome accounts for about 1% of 
all colorectal cancers and is char-
acterized by the development early 
in life of hundreds to thousands of 
adenomatous polyps in the colon 
(Fig. 5.5.4). Mucosal neoplasms 
higher up in the tubal gut, notably 
in the stomach, also occur. The 
syndrome is caused by mutations 
in the APC gene. The APC protein 
in the Wnt signalling pathway nor-
mally binds to β-catenin (in a nor-
mal epithelial cell, integrated in the 
E-cadherin–catenin cell adhesion 
complex), triggering its degradation 
in the proteasome [13]. APC loss 
results in accumulation of β-catenin 
in the nucleus, where it acts as a 
transcription factor, promoting tran-
scription of proliferation-stimulating 
genes, such as MYC and cyclin D1. 
Distinct genotype–phenotype corre-
lations exist [12,13]; some mutations 
(in codons 1250–1464) are associ-
ated with severe polyposis (> 1000 
adenomas), while others (before co-
don 157, after codon 1595, and in the 
alternatively spliced region of exon 
9) are associated with attenuated 
adenomatous polyposis coli (usu-
ally 10–100 adenomas and a 70% 
lifetime risk of colorectal cancer).
In Gardner syndrome, numerous 
gastrointestinal polyps occur in com-
bination with other neoplasms, in-
cluding osteomas, desmoid tumours, 
epidermoid cysts, and also dental 
anomalies. APC mutations respon-
sible for Gardner syndrome occur in 
a region encoding for the β-catenin 
binding site of the protein.
Mismatch repair deficiency 
syndrome, also known as heredi-
tary non-polyposis colon cancer or 
Lynch syndrome, is the most com-
mon hereditary colorectal cancer 
predisposition syndrome (about 3% 
of all such disease), with a lifetime 
risk of about 80% [13]. The syn-
drome is autosomal dominant and 
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is caused by mutations in one of the 
DNA mismatch repair genes (MLH1 
on chromosome 3p21, MSH2 on 
2p16, MSH6 on 2p16, and PMS2 on 
7p22). The mismatch repair protein 
complex corrects base mismatches 
or small insertions or deletions that 
occur during DNA replication. MLH1 
and MSH2 mutations are the most 
frequent (about 80%). MSH2 defi-
ciency can also occur through gene 
silencing by transcriptional read-
through of TACSTD1, a gene direct-
ly upstream of MSH2 that encodes 
the Ep-CAM protein. As a result of 
a germline deletion of the last exons 
of TACSTD1, its transcription is ex-
tended into MSH2, with functional 
loss of MSH2 activity.
These cancers exhibit micro-
satellite instability – increased vari-
ability in length of the dinucleotide 
repeats that occur throughout the 
genome. These are not necessarily 
pathogenic but are significant when 
they occur in key genes in processes 
such as cell proliferation, apoptosis, 
or DNA repair. Mismatch repair-de-
ficient cancers are characterized by 
point mutations (hypermutation) and, 
less often, by chromosomal rear-
rangements and allelic imbalances.
Mismatch repair-deficient can-
cers develop through an adenoma–
carcinoma sequence but not in as-
sociation with polyposis, typically 
occur in the right colon, and are 
often histologically of a mucinous 
or medullary type, with a strik-
ing lymphoid host reaction. The 
prognosis is better than that of 
mismatch repair-competent cancers, 
but mismatch repair-deficient can-
cers respond less well to adjuvant 
chemotherapy. These cancers also 
occur in other organs, including (in 
decreasing order of frequency) the 
endometrium, ovary, duodenum, 
urinary tract, stomach, pancreas, 
biliary tree, and brain.
The MUTYH-associated polypo-
sis (MAP) syndrome has been more 
recently identified and is estimated 
to account for about 2% of colorectal 
cancer. MAP syndrome resembles 
familial adenomatous polyposis in 
that multiple adenomatous polyps 
of the colorectum develop, with a 
very high lifetime risk of colorectal 
cancer. The number of adenomas 
ranges from very few to hundreds, 
and therefore MAP resembles at-
tenuated familial adenomatous 
polyposis. Extracolonic manifes-
tations occur, including duodenal 
adenomas or adenocarcinomas and 
various extra-intestinal neoplasms. 
MAP is an autosomal recessive 
disorder caused by biallelic muta-
tions in the MUTYH gene, located 
on chromosome 1p. The gene en-
codes a protein with an important 
function in the DNA base excision 
repair pathway.
Prognostic and predictive 
factors
Currently used criteria for stratifica-
tion of colorectal cancer patients in 
view of eventual adjuvant chemo-
therapy are primarily based on the 
classic tumour–node–metastasis 
(TNM) stage parameters tumour 
extension (T) and lymph-node me-
tastasis (N). However, these lack 
precision (Table 5.5.1), and better 
parameters are urgently needed.
Microsatellite instable carcino-
mas have a better prognosis than 
those that are microsatellite stable 
[10]. In addition, patients with micro-
satellite instable carcinomas might 
not benefit from 5-fluorouracil-based 
chemotherapy regimens, but this re-
mains controversial. For microsatel-
lite stable cancers, BRAF V600E 
mutations confer poor prognosis, 
notably in terms of survival after 
relapse. KRAS mutation status has 
no prognostic significance for over-
all survival of patients with stage II/
III disease [21]. Recently published 
tests such as Oncotype DX (based 
on multiplex reverse transcription 
polymerase chain reaction) and 
ColoPrint (microarray-based) might 
provide additional prognostic value 
but have not been independently 
validated [22]. New molecular 
approaches for prognostic classi-
fication are being developed [11, 
23–25] but need to be validated in 
a clinical setting.
KRAS mutation testing has be-
come the mainstay for advanced 
colorectal cancer because KRAS-
mutated carcinomas do not respond 
Chronic 
inflammation 
Low-grade dysplasia 
High-grade dysplasia 
Adenocarcinoma 
10 years? 
Promoter hypermethylation 
microsatellite instability 
-TP53 
-APC 
+KRAS 
-P27 
-P16 
+  gain of function mutation 
-   loss of function (through LOH, mutation, 
or promoter methylation) 
Fig. 5.5.3. The dysplasia–carcinoma sequence in colorectal carcinogenesis in inflam-
matory bowel disease. Chronic inflammation with the continuous liberation of oxygen 
radicals and inflammatory cytokines creates an environment that is both mutagenic 
and growth-stimulating. TP53 mutations occur early in this pathway, associated with 
the development of low-grade dysplasia. In addition, hypermethylation of CpG islands 
leads to promoter silencing of P16 and P27 among others. Accumulation of such events 
drives progression towards high-grade dysplasia. Additional events, such as KRAS 
mutations and activation of the Wnt pathway, for example through APC mutation, are 
involved in the progression towards invasive carcinoma. LOH, loss of heterozygosity.
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to anti-EGFR therapy (cetuximab, 
panitumumab). This is due to the 
fact that KRAS is downstream of 
EGFR in the MAPK pathway, which 
renders approaches targeting the 
upstream EGFR ineffective. Only 
about 40% of KRAS wild-type 
colorectal cancers respond to an-
ti-EGFR treatment, implying that 
other genes are involved, including 
PIK3CA, BRAF, NRAS, pTEN, and 
others unidentified as yet [21].
Prospects
Screening for colorectal cancer 
is done through the faecal occult 
blood test, which has a reason-
able sensitivity but low specific-
ity. There is now evidence that 
screening with flexible sigmoid-
oscopy can substantially reduce 
colorectal cancer incidence and 
mortality. Colonoscopy is increas-
ingly advocated, as colonoscopic 
polypectomy would, in principle, 
enable eradication of the disease. 
Molecular tests for disease-specific 
DNA abnormalities in faeces or in 
the blood are currently being de-
veloped [26].
The heterogeneity of colo-
rectal cancer continues to chal-
lenge clinicians and pathologists. 
Why cancers of a similar stage that 
are histologically indistinguishable 
behave differently in terms of recur-
rence and response to chemother-
apy has long been a mystery. The 
inclusion of molecular parameters 
in colorectal cancer classification 
improves on currently used classi-
fication systems [27]. Molecular an-
notation of large series of colorectal 
cancers with detailed follow-up data 
might now lead to new insights into 
molecular mechanisms that drive 
this heterogeneity. The Cancer 
Genome Atlas data [11], along with 
even more recent approaches to-
wards molecular classification of 
colorectal cancer [23,24], will in the 
near future allow the redefinition of 
colorectal cancer subtypes, with im-
pacts on clinical management. The 
most recent data point towards at 
least five molecularly defined sub-
types [24] – which partly overlap 
Table 5.5.2. Genetic syndromes associated with a possible risk of colorectal carcinoma
Syndrome Gene (chromosome) MIM number
Autosomal dominant inheritable colorectal carcinoma
No or few adenomatous polyps
Lynch syndromea,b MLH1 (3p21-p23)
MSH2 (2p21)
MSH6 (2p21)
PMS2 (7p22)
120435
Adenomatous polyps
Familial adenomatous polyposis (FAP)a and attenuated FAP APC (5q21-q22) 175100
Hamartomatous/mixed/hyperplastic polyps
Peutz–Jeghers syndrome LKB1/STK11 (19p13.3) 175200
Juvenile polyposis syndrome SMAD4 (18q21.1)
BMPR1A (10q22.3)
174900
Hereditary haemorrhagic telangiectasia syndromec ENG (9q33-q34.1)
ACVRL1 (12q11-q14)
187300
Hyperplastic polyposis syndromec MUTYH (1p34.1; 
autosomal recessive)
MBD4 (3q21.3)
Unassigned
Hereditary mixed polyposis syndromec CRAC1 (15q13-q21) 601228
PTEN hamartoma tumour syndrome (Cowden syndrome;
Bannayan–Ruvalcaba–Riley syndrome)c
PTEN (10q23) 158350/153480
Birt–Hogg–Dubé syndromec FLCN (17p11.2) 135150
Autosomal recessive inheritable colorectal carcinoma
Adenomatous, serrated adenomas and hyperplastic polyps
MUTYH-associated polyposisb MUTYH (1p34.1) 608456
MIM, Mendelian Inheritance in Man (www.omim.org).
a Turcot syndrome is a variant of Lynch syndrome, or familial adenomatous polyposis with brain tumours.
b Muir–Torre syndrome is a variant of Lynch syndrome, or MUTYH-associated polyposis with sebaceous gland tumours.
c Risk of colorectal carcinoma is not clear.
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Tumour-elicited inflammation and malignant progression in colorectal cancer
Michael Karin
with classifications based on well-
established classifiers (TNM, micro-
satellite instability) but do add an 
additional layer of complexity – that 
potentially will allow more refined 
subclassification. In addition, new 
therapeutic targets and prognos-
tic and predictive biomarkers will 
emerge.
Fig. 5.5.4. (A) Colon mucosa of a 24-year-old man with familial adenomatous polyp-
osis who underwent total colectomy. (B) Mucosa with multiple adenomatous polyps 
(haematoxylin–eosin stain).
A B
Whereas 2% of colorectal cancer 
arises in the context of pre-existing 
inflammatory bowel disease, espe-
cially ulcerative colitis, and is known 
as colitis-associated cancer, most 
colorectal cancer, including familial 
and sporadic cases, is found in indi-
viduals who do not show any signs 
of inflammatory bowel disease. Yet 
expression profiling has revealed the 
same inflammatory gene signature, 
which depends on activation of NF-
κB and STAT3, in both colitis-asso-
ciated cancer and colorectal cancer, 
findings that pose a question about 
the origin of the colorectal cancer-
elicited inflammatory response.
Early experiments established 
that activation of NF-κB, which leads 
to production of the pro-inflamma-
tory cytokine interleukin-6 (IL-6), 
a potent activator of STAT3, plays 
a critical role in the development 
of colitis-associated cancer. More 
recently, the origin and role of in-
flammation in the development and 
progression of sporadic malignancy, 
most of which is driven by loss of the 
tumour suppressor APC and activa-
tion of the β-catenin signalling path-
way, has been investigated. Studies 
focused on IL-23, a heterodimeric 
cytokine composed of a unique p19 
subunit and a p40 subunit, which it 
shares with IL-12. IL-23 expression is
strongly elevated in colorectal can-
cer relative to adjacent non-tumour 
tissue, and these findings have been 
extended to the CPC-Apc mouse 
model of colorectal tumorigenesis. 
In CPC-Apc mice, the major source 
of IL-23 expression in colorectal ad-
enomas is tumour-associated mac-
rophages. Importantly, ablation of 
IL-23 p19, either in all cells or only 
in bone marrow-derived cells, at-
tenuates the development and slows 
down the progression of colorectal 
cancer in CPC-Apc mice, and simi-
lar results were observed upon ab-
lation of IL-23 receptor (IL-23R). As 
IL-23R is not expressed on adenoma 
epithelial cells, IL-23 must exert its 
pro-tumorigenic effect via an indi-
rect mechanism. Indeed, IL-23 sig-
nalling promotes the polarization of 
IL-17-producing T cells (Th17) and 
the production of IL-6, both of which 
contribute to the development and 
progression of sporadic colorectal 
tumours in mice.
Importantly, molecular epidemio-
logical studies have revealed an IL-
23–Th17 signature that is upregulat-
ed in about 10% of human colorectal 
cancer patients, and have shown 
that the presence of this signature in 
stage I/II disease is associated with 
very poor prognosis and a marked 
decrease in disease-free survival.  
The mechanism responsible for the 
specific induction of IL-23 in tumour-
associated macrophages depends 
on Toll-like receptor/MyD88 signal-
ling, which appears to be activated 
in response to components of the 
colonic microflora that permeate the 
adenomas. Eubacterial 16S RNA 
has been detected in both murine 
and human colon adenomas, as well 
as increased penetrance of bacterial 
endotoxin into adenomas relative to 
surrounding non-cancerous tissue.
The development of colorectal 
adenomas in both mice and humans 
is associated with loss of protective 
mucins and junctional adhesion pro-
teins, and this is likely to be the pri-
mary mechanism that accounts for 
the selective entry of microbial prod-
ucts into the tumour and induction 
of the tumour-promoting IL-23–Th17 
signature. Future studies should fo-
cus on the therapeutic value of anti-
IL-23 or anti-IL-17 interventions and 
the genetic or environmental causes 
of the large variation in the magni-
tude of IL-17 production among hu-
man colorectal cancer patients.
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Summary
• The highest incidence rates of 
hepatocellular carcinoma are in 
regions with the highest preva-
lence of predisposing condi-
tions. In Asia and Africa, chronic 
hepatitis B virus and hepatitis C 
virus infections are the major 
causes, and in China and sub-
Saharan Africa, exposures to 
aflatoxins further increase risk.
• Incidence rates of hepatocellu-
lar carcinoma in men are more 
than twice those in women, re-
flecting greater rates of predis-
posing chronic liver disease and 
possibly hormonal influences. 
In North America and parts of 
Europe, rates are increasing 
due to chronic hepatitis C virus 
infection. Epidemic metabolic 
syndrome and non-alcoholic 
fatty liver disease are expected 
to lead to further increases.
• Universal infant vaccination 
against hepatitis B virus is rec-
ommended by WHO, while anti-
viral therapy for chronic hepatitis 
B and C virus infections will lead 
to reduced incidence of hepa-
tocellular carcinoma in relevant 
communities. Effective interven-
tions to reduce aflatoxin expo-
sure are also available.
5.6
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• For individuals with chronic liver 
disease, routine screening for 
hepatocellular carcinoma is rec-
ommended; individuals without 
chronic liver disease, or living 
in areas where such screening 
is not performed, are likely to 
present with symptoms of ad-
vanced disease.
• The Wnt/β-catenin pathway is 
commonly disrupted in hepato-
cellular carcinoma. Mutation of 
a particular codon in TP53 may 
be identified with environmental 
exposure to aflatoxin.
• Cholangiocarcinoma is un-
common except in South-East 
Asia where infections with liver 
flukes, such as Clonorchis and 
Opisthorchis species, are en-
demic. Cholangiocarcinoma re-
mains difficult to treat and is usu-
ally lethal.
The most common tumour type 
occurring in the liver is metastatic 
disease [1]. Of primary hepatic 
malignancies, hepatocellular car-
cinoma, composed of malignant 
hepatocytes, represents about 80% 
of tumours. Cholangiocarcinoma, a 
gland-forming adenocarcinoma de-
riving from the biliary tree, is the next 
most common [2]. Other, rare prima-
ry tumours include mucinous cystic 
neoplasm and intraductal papillary 
biliary neoplasm, the classifications 
of which have recently been aligned 
with pancreatic ductal malignancies, 
tumours of mixed hepatocellular and 
biliary phenotype, hepatoblastoma 
in children, and mesenchymal tu-
mours such as angiosarcoma [1].
Etiology
Hepatocellular carcinoma is gener-
ally more common in men than in 
women [1,3]. Men have higher rates 
of chronic hepatitis B virus (HBV) 
and hepatitis C virus (HCV) infection 
and chronic alcohol consumption. 
Sex hormones may also modulate 
hepatocarcinogenesis [4]. There 
are also differences in incidence ac-
cording to race and ethnic alignment 
[3]. For example, within the USA, 
Native Americans and Americans 
of Asian and Pacific Island descent 
have higher rates of hepatocellular 
carcinoma. Intermediate rates are 
seen in Hispanic/Latino individu-
als, African Americans, and Native 
Americans. Caucasians have the 
lowest rates. These variations are 
probably indicative of different 
rates of predisposing conditions 
and exposures; genetic and epige-
netic differences are also probably 
significant.
The global regions of greatest 
hepatocellular carcinoma preva-
lence correspond to those with 
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•  Liver cancer represents 6% 
and 9% of the global cancer in-
cidence and mortality burden, 
respectively. With an estimated 
746 000 deaths in 2012, liver 
cancer is the second most com-
mon cause of death from cancer 
worldwide.
• Liver cancer is the fifth most 
common cancer in men (554 000 
new cases, 8% of the total) and 
the ninth most common in wom-
en (228 000 cases, 3% of the to-
tal). Almost three quarters of the 
new cases occur in areas with 
low and medium human devel-
opment; more than half of the 
global incidence and mortality 
is in China.
• Given the high fatality of liver 
cancer (overall mortality-to-
incidence ratio, 0.95), the geo-
graphical patterns and trends 
for mortality are very similar to 
those observed for incidence. 
• By far the highest age-stan-
dardized incidence rate is seen 
in Mongolia. There are elevated 
incidence rates in East and 
South-East Asia, in Africa, and 
in Melanesia. Incidence rates 
tend to be lower in most highly 
developed regions.
Map 5.6.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for liver cancer in men, 2012.
Map 5.6.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for liver cancer in women, 2012.
high rates of predisposing condi-
tions (Maps 5.6.1, 5.6.2; Table 5.6.1)
[1,3]. Examples include South and 
East Asia, where HBV infection is 
endemic; Egypt, with its high rates 
of HCV infection from inadequate 
sterilization during mass vaccina-
tion campaigns; and sub-Saharan 
Africa, South-East Asia, and China, 
where marked exposure to aflatoxin 
occurs [3]. In China, the Republic 
of Korea, Japan, Zimbabwe, and 
Egypt, incidence rates are more 
than 20 per 100 000 people [3]. 
The lowest rates of hepatocellular 
carcinoma are those reported for 
North America, South America, and 
northern Europe, which typically 
have incidence rates of less than 
10 per 100 000 people [3].
Changing incidence rates of 
hepatocellular carcinoma reflect 
the changing distribution of predis-
posing conditions [1,3]. Thus, coun-
tries in Europe, North and South 
America, and Oceania, where HCV-
infected populations have expand-
ed, have experienced increasing 
hepatocellular carcinoma incidence 
[3]. Non-alcoholic fatty liver disease 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.6.1. Estimated global number of new cases and deaths with proportions by major world regions, for liver cancer in 
both sexes combined, 2012.
Chart 5.6.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for liver cancer in 
men, circa 1975–2012.
Chart 5.6.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for liver cancer in 
women, circa 1975–2012.
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is emerging as a relatively newly 
understood predisposing condition, 
and hepatocellular carcinoma inci-
dence rates are likely to increase 
in affected regions [5]. Increasing 
survival of individuals with chronic 
liver disease also may play a role in 
these upward trends [3].
In contrast, in East Asia incidence 
rates of hepatocellular carcinoma are 
declining [1,3]. In Japan, as the co-
hort of individuals infected by HCV 
in the first half of the 20th century 
shrinks, incidence of hepatocellu-
lar carcinoma is also declining. In 
China and Singapore, where HBV 
infection remains a major predispos-
ing condition, diminished aflatoxin 
exposure is leading to a decline in 
HBV-associated disease. Vaccination 
and treatment for HBV infection and 
new, more successful treatments for 
HCV infection will almost certainly 
lead to diminished rates of hepato-
cellular carcinoma in places where 
these are significant risk factors. 
Indeed, HBV vaccination has been 
well documented to prevent 70% of 
hepatocellular carcinoma incidence 
among vaccinated birth cohorts in a 
20-year follow-up study in Taiwan, 
China [6].
Sporadic cholangiocarcinomas 
and those associated with HCV, HBV, 
and primary sclerosing cholangitis 
are uncommon to rare [1]. However, 
in regions with endemic liver fluke 
infestations, such as north-eastern 
Thailand, incidence is as high as 88 
per 100 000 men and 35 per 100 000 
women [2].
Hepatocellular carcinoma is most 
commonly associated with chronic 
liver disease [1,3,5,7]. Although this 
malignancy usually occurs in the 
setting of cirrhosis, cirrhosis per 
se is not a premalignant lesion [8]. 
Rather, progression to cirrhosis and 
hepatocarcinogenesis take place in 
parallel over years to decades [1,9]. 
Cirrhosis is not, moreover, required 
for development of hepatocellular 
carcinoma [1,10]. The most impor-
tant etiological factors for hepatocar-
cinogenesis remain viral infections, 
usually involving HBV or HCV, and 
toxic injury, typically initiated by 
ingestion of aflatoxin or consump-
tion of alcohol [1,3]. Where HBV and 
HCV are endemic, there is a very 
high incidence of this malignancy. 
In such chronic infection, viral load 
is the major driver of the progres-
sion of viral hepatitis-related liver 
disease [10,11]. It should be noted 
that only about one quarter of pa-
tients with chronic HBV and HCV 
infection will develop hepatocellular 
carcinoma [2]. Risk calculators that 
incorporate age, sex, family history 
of hepatocellular carcinoma, alco-
hol consumption, serum alanine 
aminotransferase (ALT) level, and 
viral factors including HBV e anti-
gen (HBeAg) serostatus, viral load, 
and genotype have been developed 
to predict hepatocellular carcinoma 
caused by chronic HBV infection 
[12]. Co-infection with both hepatitis 
viruses further increases risk [13]. 
HIV infection also appears to be a 
risk factor for hepatocellular carci-
noma [14].
Aflatoxin (specifically, aflatoxin 
B1), a mycotoxin produced by moulds 
of the Aspergillus species, contami-
nates staple food crops in Africa 
and Asia [15]. Aflatoxin metabolites 
are present in the urine of affected 
individuals, as are aflatoxin–albu-
min adducts in serum [1,15]. These 
indicators may assist in identifying 
populations at risk and confirm the 
important influence of aflatoxin on 
the development of hepatocellular 
carcinoma. Risk attributable to afla-
toxin acts synergistically with HBV 
infection and possibly with HCV in-
fection [15]. Alcohol is another toxin 
that may also act synergistically with 
other causes, particularly HBV and 
HCV, and possibly cigarette smok-
ing [16].
Aflatoxin-specific mutations pro-
vide a singular relationship between 
the impact of a carcinogenic agent, 
the establishment of a biomarker, and 
inactivation of the relevant tumour 
suppressor gene [14]. Aflatoxin B1 is 
metabolized by members of the cy-
tochrome P450 CYP family, specifi-
cally including CYP3A4 and CYP3A5. 
These isoenzymes metabolize afla-
toxin B1 to its 8,9-exo-epoxide, which 
may react with DNA to form an afla-
toxin–N7-guanine adduct and with 
protein to generate aflatoxin–albumin 
adducts. Aflatoxin–albumin adducts 
may serve as biomarkers for aflatoxin 
exposure. In hepatocellular carcino-
mas from areas where exposure to 
aflatoxin is high, aflatoxin–DNA ad-
ducts result in a high prevalence of 
thymine substitutions at the third 
guanine in AGG sequences, thereby 
replacing serine for arginine in ex-
pressed proteins. This mutation is 
specifically recorded at codon 249 of 
p53 (TP53) and has been extensively 
monitored in hepatocellular carci-
noma patients and relevant controls 
Table 5.6.1. Risk factors for hepatocellular carcinoma and cholangiocarcinoma
Type of condition Hepatocellular carcinoma Cholangiocarcinoma
Epidemic Chronic HBV infection
Chronic HCV infection
Aflatoxin exposure
Liver flukes
Common Chronic alcohol consumption Primary sclerosing cholangitis
 Non-alcoholic fatty liver disease Recurrent pyogenic cholangitis
Rare Hereditary haemochromatosis
α-1-Antitrypsin deficiency
Chronic HCV infection
Chronic HBV infection
Non-alcoholic fatty liver disease
HBV, hepatitis B virus; HCV, hepatitis C virus.
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from many regions, and particularly 
in studies from China [17]. 
Metabolic diseases such as 
hereditary haemochromatosis and 
α-1-antitrypsin deficiency markedly 
increase the risk of hepatocellular 
carcinoma; Wilson disease probably 
does so with much less frequency 
[1]. Of probably greater importance 
is the metabolic syndrome, which is 
associated with obesity, diabetes, 
and non-alcoholic fatty liver dis-
ease and will become increasingly 
important as the global epidemics 
of obesity and diabetes continue to 
worsen [5]. Moreover, this syndrome 
is likely to act synergistically for car-
cinogenesis in people with chronic 
viral hepatitis [18].
Cholangiocarcinoma is usually 
sporadic beyond regions charac-
terized by endemic infections with 
foodborne liver flukes, such as those 
of the Clonorchis and Opisthorchis 
species [1,2]. The feeding, migrating 
flukes mechanically injure the biliary 
tree and incite abundant chronic in-
flammation that contributes to step-
wise progression, via increasingly 
atypical biliary intraepithelial neo-
plasia, to invasive cholangiocarci-
noma (Fig. 5.6.1) [1,2]. Inflammatory 
cholangiopathies, in particular pri-
mary sclerosing cholangitis, hepa-
tolithiasis, and recurrent pyogenic 
cholangitis, also can lead to biliary 
intraepithelial neoplasia and cholan-
giocarcinoma [1,19]. Increased rates 
of cholangiocarcinoma are also seen 
associated with non-alcoholic fatty 
liver disease, alcoholic liver disease, 
chronic HBV infection, and chron-
ic HCV infection, although these 
cholangiocarcinomas remain un-
common [19].
Pathology
Hepatocellular carcinoma may arise 
from malignant transformation of 
hepatocytes or of hepatobiliary stem/
progenitor cells [1]. In chronic liver 
disease, with or without cirrhosis, 
several precursor lesions have been 
described [20]. Most early lesions are 
recognized in established cirrhosis 
since mature hepatocellular carcino-
ma usually follows the development 
of such late-stage disease. However, 
all such lesions are recognized in 
pre-cirrhotic stages of scarring and 
regeneration as well [21]. The tumour–
node–metastasis (TNM) classifica-
tions of hepatocellular carcinoma are 
shown in Table 5.6.2.
Cellular atypias known as “large 
cell change” and “small cell change” 
are related to hepatocarcinogenesis, 
particularly in patients with chronic 
viral hepatitis [21]. Large cell change 
consists of atypical cells with pre-
served nuclear-to-cytoplasmic ratio. 
Small cell change consists of small, 
atypical hepatocytes with increased 
nuclear-to-cytoplasmic ratio. These 
cells appear in microscopic, expan-
sile clusters in the hepatic lobule.
Dysplastic nodules are usu-
ally seen in cirrhosis (Fig. 5.6.3) 
[1,9,20,21]. These are radiologi-
cally or grossly distinctive nodules 
and are further classified as low-
grade or high-grade based on the 
presence of cellular or architectural 
atypia [9,20,21]. Other high-grade 
changes include “nodule-in-nodule” 
lesions in which an expansile sub-
nodule shows cellular and architec-
tural features indicative of, but not 
yet prominent enough for diagnosis 
of, malignancy [1,9,20,21].
As premalignant lesions prog-
ress towards carcinoma, they initially 
spread around adjacent vascular 
and portal structures [9,20]. This 
can give rise to a radiologically sub-
tle “vaguely nodular” pattern of early 
hepatocellular carcinoma, some-
times lacking diagnostic features by 
computed tomography or magnetic 
resonance imaging (Fig. 5.6.4A) 
[9,20,21]. With stepwise progres-
sion to hepatocellular carcinoma, 
more highly proliferative and more 
poorly differentiated subnodules 
arise, which, with increasingly rapid 
growth, overtake the pre-existing 
Fig. 5.6.1. Biliary dysplasia related to liver 
fluke infestation. Low-grade biliary intraep-
ithelial neoplasia (BilIN-1) associated with 
an intraluminal liver fluke, Opisthorchis 
viverrini (haematoxylin–eosin; 10×).
Fig. 5.6.2. A young woman arranges maize in a seed house in Dumka, India. Crops 
stored in a hot and humid environment are particularly susceptible to contamination by 
strains of Aspergillus, resulting in dietary exposure to aflatoxins.
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Treating chronic hepatitis with antiviral drugs to prevent liver cancer
Mark R. Thursz
During the past decade there have 
been major advances in the treat-
ment of chronic viral hepatitis. 
Replication of hepatitis B virus (HBV) 
can be suppressed either by induc-
tion of immune responses with type 
1 interferon or with nucleos(t)ide 
analogue drugs. Interferon-based 
therapy succeeds in only about 30% 
of cases, so nucleos(t)ide analogues 
are the more popular treatment op-
tion. Nucleos(t)ide analogues need 
to be administered indefinitely to 
maintain viral suppression, to prevent 
progression to cirrhosis and from 
cirrhosis to decompensated cir-
rhosis. Furthermore, recent studies 
show resolution of cirrhosis with 
long-term treatment. However, the 
impact of viral suppression on the 
incidence of hepatocellular carci-
noma is more controversial. One 
randomized placebo-controlled trial 
demonstrated a reduced incidence 
of cancer in treated patients. Meta-
analysis of subsequent studies com-
paring successfully treated patients 
with historical controls or treatment 
failures now confirms that treatment 
reduces but does not eliminate the 
risk of hepatocellular carcinoma.
Chronic hepatitis C virus (HCV) 
infection can be cured using a com-
bination of pegylated interferon and 
the nucleoside analogue ribavirin in 
more than 50% of cases. Combining 
current treatment with novel pro-
tease inhibitors increases the cure 
rate to about 80%, and there are 
currently combinations of direct 
antivirals in trials that, used in the 
absence of interferon, can cure the 
infection in more than 95% of cases. 
As with HBV infection, elimination 
of HCV infection prevents progres-
sion of the disease to cirrhosis and 
cancer. However, as cirrhosis is an 
independent risk factor for hepato-
cellular carcinoma, elimination of 
the infection reduces but does not 
remove the risk of cancer.
Treatment of viral hepatitis, 
particularly if it is initiated before 
the onset of cirrhosis, is an effec-
tive method of reducing the bur-
den of hepatocellular carcinoma. 
However, several barriers prevent 
the widespread deployment of treat-
ment. First, chronic viral hepatitis is 
asymptomatic, and it is essential 
to screen at-risk populations to 
identify those who need treatment. 
Second, although some drugs avail-
able for treatment of HBV infection 
are also used to treat HIV infection, 
The Global Fund to Fight AIDS, 
Tuberculosis, and Malaria will not 
supply these drugs for patients with 
HBV infection. Third, treatment of 
HCV infection currently requires a 
high level of medical training, which 
is not universally available. Finally, 
in spite of a World Health Assembly 
resolution in 2010, treatment pro-
grammes for viral hepatitis have 
not been developed for low-resource 
settings.
Reference
Thursz M, Brown A (2011). Gut, 60:1025–1026. 
http://dx.doi.org/10.1136/gut.2010.236521 
PMID:21508419
Fig. B5.6.1. High-magnification micro-
graph of ground-glass hepatocytes, as 
seen in a chronic hepatitis B virus infec-
tion with a high viral load; liver biopsy, 
haematoxylin–eosin stain.
lesion and begin to push adjacent 
tissues aside to form a pseudocap-
sule [9,20]. These are features of 
“progressed” hepatocellular carci-
noma (Fig. 5.6.4B). Throughout these 
processes, there is increasing arteri-
alization, which slowly overtakes the 
contribution of portal venous blood 
until it is eventually eliminated in the 
progressed lesions, a process ex-
ploited for radiological assessment 
(Fig. 5.6.5A) [9,20]. In non-cirrhotic 
livers, hepatocellular adenomas are 
also potential precursors of hepato-
cellular carcinoma [14].
Cholangiocarcinoma is a gland-
forming adenocarcinoma usually 
identified in advanced stages when 
the initial, premalignant lesion has 
been overgrown (Fig. 5.6.1) [1,2]. 
Extrahepatic spread often occurs 
through lymphatic and perineural 
invasion [1]. Cholangiocarcinoma 
may be mass-forming, have multi-
focal nodules mimicking metastatic 
disease, or be a diffusely infiltrative 
process [1]. Since there is as yet no 
specific antigenic marker expression 
to immunohistochemically confirm 
biliary origin, confirmation of the 
diagnosis of cholangiocarcinoma 
requires clinical and radiological 
exclusion of metastasis from extra-
hepatic sites, particularly when there 
is no underlying hepatic disease that 
predisposes to biliary neoplasia [19].
Molecular and genetic 
alterations
No single sequence of molecular or 
genetic alterations contributes to the 
development of hepatocellular carci-
noma [1,22]. The two most common 
early mutational events lead to acti-
vation of β-catenin and inactivation 
of p53. The former are found in up to 
40% of these tumours and are more 
likely to be unrelated to HBV and to 
demonstrate genetic instability; the 
latter are found in up to 60% of hepa-
tocellular carcinoma and are strongly 
associated with aflatoxin B1 exposure. 
However, neither of these alterations 
is found in pre-malignant, low-grade 
or high-grade dysplastic nodules.
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The Wnt/β-catenin pathway is 
commonly disrupted in hepatocel-
lular carcinoma, mostly as a result 
of mutations in CTNNB1 or AXIN1, 
epigenetic silencing of CDH1, or 
changes in the expression of Frizzle 
receptors. Mutations have also been 
identified in genes in the interleu-
kin-6 (IL-6)/JAK/STAT pathways 
[1,22]. The Rb1 pathway may be 
disturbed by mutation, loss, or silenc-
ing of Rb1 or CDKN2A, or by reduced 
expression of other genes, such as 
CDKN1A.
Recently, a role has been dem-
onstrated for short interfering mi-
croRNAs as modulators of these 
pathways, suppressing HNF4α and 
resulting in malignant transformation 
of hepatocytes [23]. This finding links 
chronic inflammation and hepatic 
IL-6 directly to malignant transforma-
tion without initiating mutations. The 
elucidation of roles in hepatocarcino-
genesis of other microRNAs or oth-
er epigenetic mechanisms is likely 
to be fruitful in the coming years. 
Other pathways have shown less 
consistent changes in hepatocellular 
carcinoma progression, including 
the MAPK and PI3K/AKT/mTOR 
signalling pathways and those mod-
erated by growth factors [22].
Whole-genome sequencing of 88 
matched hepatocellular carcinomas 
and normal pairs, 81 of which were 
HBV-positive, indicated β-catenin to 
be the most frequently mutated on-
cogene (15.9%) and TP53 the most 
frequently mutated tumour suppres-
sor gene (35.2%) [24]. The Wnt/β-
catenin and JAK/STAT pathways 
were altered in 62.5% and 45.5% of 
cases, respectively, and prevalent 
pathways suggested a basis for cat-
egorization of tumours (Fig. 5.6.6).
IL-6 is implicated in the genesis 
of cholangiocarcinoma; its secretion 
by tumour cells enhances growth 
through autocrine mechanisms and 
may regulate activity of DNA trans-
methylases and hence alter expres-
sion of other genes, including EGFR. 
EGFR expression is a prognostic 
factor and a risk factor for tumour 
recurrence. Cholangiocarcinoma 
displays frequent mutations in cell-
cycle regulators (p53, p16) and in 
Table 5.6.2. Tumour–node–metastasis (TNM) classifications of hepatocellular 
carcinoma
T – Primary tumour
TX: Primary tumour cannot be assessed
T0: No evidence of primary tumour
T1: Solitary tumour without vascular invasion
T2: Solitary tumour with vascular invasion or multiple tumours, none > 5 cm in greatest 
dimension
T3: Multiple tumours, any > 5 cm, or tumour involving a major branch of the portal or 
hepatic vein(s)
T3a: Multiple tumours, any > 5 cm
T3b: Tumour involving a major branch of the portal or hepatic vein(s)
T4: Tumour(s) with direct invasion of adjacent organs other than the gall bladder or with 
perforation of visceral peritoneum
N – Regional lymph nodes
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph-node metastasis
N1: Regional lymph-node metastasis
M – Distant metastasis
M0: No distant metastasis
M1: Distant metastasis
Stage grouping
Stage T N M
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA T3a N0 M0
Stage IIIB T3b N0 M0
Stage IIIC T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T Any N M1
Fig. 5.6.3. Dysplastic nodule in cirrho-
sis. The distinctive nodule (arrow) in an 
explanted liver from a patient with end-
stage hepatitis B stands out from the sur-
rounding cirrhotic parenchyma in terms of 
colour and size. Dysplastic nodules, low-
grade and high-grade, can be discerned 
by computed tomography and magnetic 
resonance imaging based on size, arte-
rialization, and iron content. Histological 
examination of this lesion revealed a low-
grade dysplastic nodule, devoid of cellular 
or architectural atypia; nonetheless, even 
low-grade dysplastic nodules in chronic 
liver disease indicate an increased risk of 
hepatocellular carcinoma development in 
the liver as a whole.
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MAPK pathways, in particular KRAS 
mutations [1,22]. KRAS in the bile 
of patients with primary sclerosing 
cholangitis without cholangiocarci-
noma suggests that KRAS muta-
tions are probably an early event in 
cholangiocarcinogenesis. Altered 
expression of ERRB2/HER2 has 
been described. Also, SOCS3 inhibi-
tion by promoter methylation leads to 
the constitutive activation of the IL-6/
STAT3 pathway. Activation of that 
pathway, a potent mediator of local 
inflammatory reactions, provides an 
avenue for understanding the links 
between chronic biliary inflammation 
and carcinogenesis [22].
Detection
For individuals with chronic liver dis-
ease, routine screening for hepato-
cellular carcinoma is recommended; 
individuals without chronic liver dis-
ease, or living in areas where such 
screening is not performed, are likely 
to be diagnosed with symptoms of 
advanced disease [25]. Prospective 
screening, where possible, takes two 
forms: assessment of serum markers 
and repeated radiological examina-
tions. The most widely used serum 
marker is α-fetoprotein, although it 
is ineffective for early lesions [1,25]. 
Other markers have been assessed, 
such as serum PIVKA and des-gam-
ma-carboxy prothrombin, but none 
have reached the level of standard 
of practice [1].
Radiological examination in 
the course of late-stage (usu-
ally cirrhotic) liver disease, in con-
trast, is informative when possible 
[9,20,25]. Ultrasonography is gener-
ally insensitive for early lesions, but 
computed tomography and magnetic 
resonance imaging can often identify 
dysplastic nodules or early hepato-
cellular carcinoma [20]. If arterializa-
tion is complete, then there will be 
diagnostic features confirming this 
malignancy, including arterial en-
hancement, “washout” appearance, 
and pseudocapsule (Fig. 5.6.5B) 
[9,20]. Low-grade, high-grade, and 
vaguely nodular hepatocellular car-
cinoma, however, do not consis-
tently show all these features, and 
Fig. 5.6.4. Forms of early hepatocellular carcinoma (HCC). (A) The margins of a “vaguely 
nodular” HCC (arrows) are difficult to distinguish from the surrounding cirrhotic liver. 
Such lesions may or may not have completely characteristic imaging studies for defining 
them as HCC. Even biopsy diagnosis in such lesions may be difficult, relying on subtle 
changes indicative of microscopic stromal invasion. (B) A small but “progressed” HCC 
will have characteristic imaging features diagnostic of HCC. The pseudocapsule consists 
of atrophic hepatic tissue compressed by the rapidly expanding tumour.
Fig. 5.6.5. Pathological–radiological correlation of early stages of human hepatocar-
cinogenesis. (A) International consensus on the classification of small nodular lesions 
in cirrhotic liver. The diagnosis must consider the context of the lesion, especially the 
presence of cirrhosis, imaging findings, and growth rate. HCC, hepatocellular carci-
noma; H-DN, high-grade dysplastic nodule; hyper, hypervascular; hypo, hypovascular; 
iso, isovascular; IWP, International Working Party; L-DN, low-grade dysplastic nodule; 
MD, moderately differentiated; WD, well-differentiated. (B) Liver magnetic resonance 
image showing a 1.9 cm, well-circumscribed hepatocellular carcinoma in a hepatitis 
B virus-associated cirrhosis. The lesion is dark to background liver before contrast 
administration (PRE), avidly enhances immediately after contrast in the hepatic arterial 
phase (HAP), and displays central “washout” appearance with a peripherally enhancing 
pseudocapsule in the 3-minute delayed phase imaging (DEL).
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the current practice is to follow up 
such lesions with greater frequency, 
awaiting emergence of definitively 
diagnostic features or rapid increase 
in size [25]. Diagnosis of early le-
sions therefore does not depend on 
biopsy [20,25].
Cholangiocarcinoma has no 
specific serum markers that are di-
agnostic; however, in patients with 
conditions putting them at high risk, 
rising or high levels of serum mark-
ers such as CA19-9 and CEA may 
be helpful [26]. Repeat elevation 
of these markers after treatment 
can also be used to detect disease 
recurrence.
Prevention
Prevention of hepatic malignancies 
relies on removing the predisposing 
causes [26]. In coming decades, vac-
cination for HBV in endemic regions 
and screening of blood products for 
HCV should begin to diminish the in-
cidence of hepatocellular carcinoma 
[22,25]. Reducing aflatoxin-produc-
ing mould in stored food has already 
resulted in decreased hepatocellular 
carcinoma incidence, even in HBV-
infected populations [3,15]. Antiviral 
therapies, particularly when virus 
is eradicated, should also diminish 
incidence [25] (see “Treating chronic 
hepatitis with antiviral drugs to pre-
vent liver cancer”). Malignancies 
associated with non-alcoholic fatty 
liver disease may prove difficult to 
prevent [5].
For prevention of cholangiocar-
cinoma, cooking of infested fish ef-
fectively eliminates the possibility of 
human infection by tumour-causing 
flukes [2]. However, such a public 
health intervention may conflict with 
long-standing cultural practices that 
include eating raw fish dishes in 
areas like Thailand. Thus, although 
prevention is theoretically possible, 
this goal remains difficult and may 
be unlikely to be achieved in relevant 
populations.
S1 S2 
Cell proliferation 
S3 
Liver metabolism 
Immune   
response, 
angiogenesis 
AFP 
  Well/moderately 
differentiated 
CTNNB1, JAK1  (mut) 
TERT  (HBV) 
Poor survival Good survival 
MLL4 (HBV) 
TP53 (mut) 
Recurrence 
  Poorly/moderately 
differentiated 
20 40
P-value=0.013 
60 80 100 120 
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
Months
1
2
3
Month 
S3: n=32 
S1: n=20 
S2: n=18 Su
rv
iv
al
 p
ro
ba
bi
lit
y 
A 
B 
Fig. 5.6.6. Molecular subclassification of hepatocellular carcinoma (HCC). (A) Schematic 
summary of the gene expression, genetic, and clinical profiles of the three HCC sub-
classes. AFP, α-fetoprotein; HBV, hepatitis B virus integration; mut, mutation (somatic 
single-nucleotide variant). (B) Kaplan–Meier survival plot for the three HCC subclasses.
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Summary
• A majority of pancreatic can-
cers occur in countries with 
high or very high levels of hu-
man development. 
• Pancreatic cancer is the seventh 
most common cause of cancer 
death worldwide, with a 5-year 
survival rate of 5%. Infiltrating 
ductal adenocarcinoma is the 
most common tumour type 
(90%).
• The leading identified cause of 
pancreatic cancer is cigarette 
smoking. Body fatness is an es-
tablished risk factor. New-onset 
diabetes can be an early sign of 
the disease.
• Exome sequencing of ductal 
adenocarcinoma has demon-
strated 16 significantly mu-
tated genes – those previously  
recognized (KRAS, CDKN2A, 
TP53, SMAD4, MLL3, ATM, 
TGFBR2, ARID1A, and SF3B1) 
as well as novel genes, includ-
ing genes involved in chroma-
tin modification (EPC1 and 
ARID2), DNA damage repair, 
and other mechanisms (ZIM2, 
MAP2K4, NALCN, SLC16A4, 
and MAGEA6).
• Among other pancreatic neo-
plasms, serous cystadenomas 
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5 ORGAN SITE
Pancreatic cancer
Ralph H. Hruban Günter Klöppel (reviewer)
G. Johan Offerhaus (reviewer)
are characterized by VHL mu-
tations, solid-pseudopapillary 
neoplasms by β-catenin mu-
tations, intraductal papillary  
mucinous neoplasms by mu-
tations in GNAS, KRAS, and 
RNF43, and mucinous cystic 
neoplasms by mutations in 
RNF43, KRAS, and TP53.
• Inherited mutations in BRCA2, 
p16/CDKN2A, PRSS1, STK11, 
PALB2, and ATM and in DNA 
mismatch repair genes increase 
risk.
• Personalized therapy is slow-
ly becoming a reality with 
poly(ADP-ribose) polymerase 
(PARP) inhibitors or mitomycin 
C for cancers with BRCA2 or 
PALB2 mutations, and everoli-
mus for neuroendocrine tu-
mours with mTOR pathway 
abnormalities.
Pancreatic cancer is not one dis-
ease. Several distinct neoplasms 
with unique clinical and pathologi-
cal features may arise in the gland. 
About 95% of all pancreatic cancers 
develop in the exocrine pancreas, 
with about two thirds of these in the 
head of the pancreas. Infiltrating 
ductal adenocarcinoma is the most 
common of these neoplasms (ac-
counting for 90% of all pancreatic 
cancer), and to a large degree the 
epidemiology of pancreatic cancer 
reflects the impact of these tumours. 
Ductal adenocarcinoma is the most 
aggressive of pancreatic neoplasms 
[1]. Most patients are diagnosed with 
metastatic disease, and only 5% sur-
vive to 5 years.
Infiltrating ductal adenocarci-
noma is an infiltrating epithelial 
neoplasm with glandular (ductal) 
differentiation, usually demonstrat-
ing luminal and/or intracellular pro-
duction of mucin, and without a pre-
dominant component of any other 
histological type. An abundant des-
moplastic stromal response is a typi-
cal feature.
Pancreatic neuroendocrine tu-
mours are less common (1–2% of 
all pancreatic cancer) but have a sig-
nificantly better survival rate of 65% 
at 5 years [1]. In contrast, almost 
all patients with a serous cystad-
enoma are cured. Intraductal papil-
lary mucinous neoplasms (IPMNs) 
and mucinous cystic neoplasms are 
important because they are curable 
precursor lesions that, if left untreat-
ed, can progress to an incurable in-
vasive carcinoma.
All of the major tumour types of 
the pancreas have been sequenced. 
This revolution in our understand-
ing of these neoplasms has opened 
the door to an understanding of 
why pancreatic cancer aggregates 
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Epidemiology
Pancreatic cancer
• Pancreatic cancer is estimated 
to be the 12th most common 
cancer in men (178 000 cases) 
and the 11th most common in 
women (160 000 cases) world-
wide in 2012; 68% of the new 
cases occurred in countries at 
high or very high levels of human 
development.
• There were an estimated 330 000 
deaths from pancreatic cancer 
in 2012, and because of its very 
high fatality, pancreatic cancer is 
the seventh most common cause 
of death from cancer worldwide.
• In 2012, one third of the es-
timated new cases occurred 
in Europe. The highest age-
standardized incidence rates 
are found in central and east-
ern Europe, North America, 
Argentina, and Uruguay, and 
among women in Australia. 
Relatively low incidence rates 
are observed in most countries 
in Africa and East Asia.
• Given the overall mortality-to-
incidence ratio of 0.98, the geo-
graphical patterns and trends 
for mortality are very similar to 
those observed for incidence. 
• Trends in incidence and mortal-
ity rates in both sexes tend to be 
rather stable over time.
Map 5.7.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for pancreatic cancer in men, 2012.
Map 5.7.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for pancreatic cancer in women, 2012.
in some families, has helped in the 
identification of precursor lesions 
that are likely to progress to invasive 
cancer, and has created opportuni-
ties for personalized therapy.
Etiology
Non-modifiable risk factors for ductal 
adenocarcinoma of the pancreas in-
clude older age (most cases occur 
after the age of 65 years); race (in 
the USA, risk for Black populations 
is ≥ 1.5 that for White populations), 
and adult attained height. Cigarette 
smoking causes pancreatic cancer 
[2]. From meta-analysis, risk is sig-
nificantly increased, by 74% and 
20% for current and former smok-
ers, respectively; pooled analysis 
indicated a significant elevation of 
77% for current smokers and a non- 
significant increase of 9% for former 
smokers. Smoking is estimated to 
cause 20% of pancreatic cancer. 
Smoking cessation reduces risk, and 
by 20 years after cessation the risk 
for former smokers drops to that of 
never-smokers [3].
World Cancer Research Fund 
evaluations [4] specify convincing 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.7.1. Estimated global number of new cases and deaths with proportions by major world regions, for pancreatic 
cancer in both sexes combined, 2012.
Chart 5.7.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for pancreatic 
cancer in men, circa 1975–2012.
Chart 5.7.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for pancreatic 
cancer in women, circa 1975–2012.
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evidence that body fatness increases 
risk and probable evidence in rela-
tion to abdominal fatness, whereas 
evidence is limited for red meat con-
sumption; coffee drinking is unlikely 
to affect risk. Other risk factors for 
pancreatic cancer include diabetes 
and non-O ABO blood type [1,3]. 
Chronic pancreatitis is an established 
risk factor for pancreatic ductal ad-
enocarcinoma. However, most pa-
tients with this disease do not develop 
cancer, and most pancreatic cancer 
patients do not have a history of pan-
creatitis [5].
Pathology
Infiltrating ductal adenocarci-
noma of the pancreas elicits an 
intense desmoplastic stromal reac-
tion (Fig. 5.7.2) [1]. As a result, the 
bulk of the tumour is composed of 
collagen, stromal cells, inflamma-
tory cells, and blood vessels. This 
dense desmoplastic stroma has two 
important clinical implications. First, 
biopsies may miss the neoplastic 
cells. Second, the dense fibrosis 
may hinder the delivery of chemo-
therapeutic agents to the neoplastic 
cells [6]. Perineural invasion is also 
common, and many patients with 
pancreatic cancer experience pain.
Pancreatic intraepithelial neo-
plasia lesions are non-invasive mi-
croscopic epithelial proliferations 
in the smaller pancreatic ducts [7]. 
A growing body of evidence sug-
gests that pancreatic intraepithelial 
neoplasia can be a precursor to 
infiltrating ductal adenocarcinoma. 
These lesions harbour many of the 
same genetic mutations found in in-
filtrating ductal adenocarcinomas, 
and rare clinical cases have been 
reported of patients with pancreat-
ic intraepithelial neoplasia lesions 
who later developed an invasive 
pancreatic cancer. Although most 
of these precursor lesions are too 
small to be detected using currently 
available imaging techniques, they 
are a potential target for future early 
detection strategies.
Pancreatic ductal adenocarci-
nomas comprise a hierarchy of tu-
mour cells that have been hypoth-
esized by some to develop around 
a population of cancer initiating 
cells. Primary recognized markers 
of these cancer initiating cells are 
CD44, CD24, and ESA [8]. Immune 
cell infiltrates occur during tumour 
progression. Infiltration by immune 
cells with immunosuppressive ac-
tivities allows for an environment 
that fosters tumour growth and pro-
gression [5]. One contributing factor 
to the failure of systemic cytotoxic 
and targeted therapies may be the 
abundant tumour stromal content 
that is characteristic of pancreatic 
ductal adenocarcinoma. The stro-
ma, sometimes referred to as the 
tumour microenvironment, occupies 
the majority of the tumour mass and 
can be targeted in the development 
of novel therapy [9].
Genetics
The exomes of several ductal adeno-
carcinomas have been sequenced, 
and the most commonly mutated 
genes include an oncogene, KRAS, 
and three tumour suppressor genes, 
TP53, p16/CDKN2A, and SMAD4 
(Table 5.7.1) [10]. An understand-
ing of the genes targeted in ductal 
adenocarcinomas not only provides 
insight into the fundamental nature of 
these neoplasms but also has clini-
cal implications. For example, loss 
of Smad4 protein expression as as-
sessed by immunolabelling is a sur-
rogate marker for SMAD4 gene mu-
tations, and can be used to suggest 
origin in the pancreas for a tumour of 
unknown origin.
Exome sequencing and copy 
number analysis have more recently 
been reported for a prospectively ac-
crued clinical cohort (n = 142) of early 
(stage I and II) sporadic pancreatic 
ductal adenocarcinoma [11]. There 
were 16 significantly mutated genes, 
reaffirming known mutations (KRAS, 
TP53, CDKN2A, SMAD4, MLL3, 
ATM, TGFBR2, ARID1A, and SF3B1) 
and identifying novel mutated genes, 
including additional genes involved 
in chromatin modification (EPC1 and 
ARID2), DNA damage repair, and 
other mechanisms (ZIM2, MAP2K4, 
NALCN, SLC16A4, and MAGEA6). 
Also reported were somatic aberra-
tions in genes described as embry-
onic regulators of axon guidance, 
particularly SLIT/ROBO signalling. 
Loss of SLIT/ROBO signalling may 
be an alternative mechanism for dys-
regulating pathways downstream of 
their receptors, and in addition could 
influence the activity of inhibitors that 
target these upstream components, 
such as MET inhibitors (Fig. 5.7.3).
Approximately 10% of pancreatic 
cancer is believed to have a famil-
ial basis, and several genes have 
been identified that, when mutated 
in the germline, increase the risk of 
Fig. 5.7.1. A doctor examines a patient in 
relation to pancreatic disease. Worldwide 
pancreatic cancer rates are highest for 
African American men.
Fig. 5.7.2. Photomicrograph of infiltrating 
ductal adenocarcinoma of the pancreas. 
Note the haphazard arrangement of the 
glands and the intense stromal fibrosis.
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pancreatic cancer. These include p16/
CDKN2A, BRCA2, PALB2, PRSS1, 
STK11, and ATM, and DNA mismatch 
repair genes (Table 5.7.2) [12].
Prospects
Although ductal adenocarcinomas of 
the pancreas have seemed to present 
an impenetrable barrier to progress, 
several recent advances provide 
hope. First, although the desmoplas-
tic response may hinder the delivery 
of chemotherapeutic agents to the 
neoplastic cells, recent studies in 
animal models specifically targeting 
the stroma as a way to improve drug 
delivery have shown promise [6].
Second, recent studies of the 
genetic evolution of pancreatic 
neoplasia suggest that it takes many 
years for a genetically altered cell in 
the pancreas to invade and eventu-
ally metastasize. This suggests a 
large window of opportunity for the 
early detection of curable pancreatic 
neoplasia. If pancreatic intraepithe-
lial neoplasia and cystic precursor 
lesions with high-grade dysplasia 
(discussed below) can be identified 
early, they can be treated before an 
infiltrating ductal adenocarcinoma 
develops.
Third, the discovery of some of 
the genes responsible for the familial 
aggregation of pancreatic cancer 
means that it is now possible to identify 
a population at risk that would most 
benefit from early detection. With the 
exception of PRSS1, these germline 
alterations also increase the risk 
of extrapancreatic malignancies. 
Therefore, mortality can be reduced 
by screening for one of the extrapan-
creatic malignancies (Table 5.7.2). 
For example, germline p16/CDKN2A 
mutations increase the risk of both 
pancreatic cancer and melanoma, 
and careful skin examinations of car-
riers of p16/CDKN2A mutations can 
aid early detection [12].
Table 5.7.1. The most common genetic alterations in ductal adenocarcinoma
Gene Chromosome Mechanism of alteration Percentage of cancers
Oncogenes
KRAS2 12p Point mutation 95
BRAF 7q Point mutation 5 (especially those with MSI)
AIB1 20q Amplification Up to 60
AKT2 19q Amplification 10–20
MYB 6q Amplification 10
Tumour suppressor genes
p16/CDKN2A 9p Point mutation plus LOH, HD, promoter methylation 95
TP53 17p Point mutation plus LOH 75
SMAD4 18q Point mutation plus LOH, HD 55
USP9X X Unclear 50
FAM190A 4q Internal gene rearrangements Up to 40
EP300 22q Point mutation plus LOH 25
ARID1A 1p Point mutation plus LOH 8
MLL3 7q Point mutation 6
TGFbetaR2 3p HD, biallelic intragenic mutations 4–7 (especially those with MSI)
STK11/LKB1 19p Germline, point mutation plus LOH 4–6
FBXW7 4q Point mutation plus LOH < 5
MKK4 17p Point mutation plus LOH, HD 4
ATM 11q Point mutation plus LOH 3
TGFbetaR1 9q HD 2
ACVR1beta 12q Point mutation plus LOH, HD 2
ACVR2 2q Point mutation plus LOH, biallelic intragenic 
mutations
Tumours with MSI
HD, homozygous deletion; LOH, loss of heterozygosity; MSI, microsatellite instability.
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Finally, a small percentage of 
the genetic changes identified are 
targetable with existing therapeutic 
agents. For example, it has been sug-
gested that infiltrating ductal adeno-
carcinomas with biallelic inactivation 
of one of the Fanconi anaemia genes, 
including BRCA2 and PALB2, are 
more sensitive to poly(ADP-ribose) 
polymerase (PARP) inhibitors and 
to mitomycin C [6]. This suggests a 
paradigm for personalized therapy 
in which tumours can be biopsied 
or resected and the optimal therapy 
guided by genetic analyses of the 
neoplastic cells.
Other tumour types
Cystic neoplasms
Intraductal papillary mucinous 
neoplasms
IPMNs are non-invasive, usually pap-
illary, grossly visible mucin-producing 
epithelial neoplasms involving the 
larger pancreatic ducts (Fig. 5.7.4) [1].
Little is known about the epi-
demiology of these neoplasms, al-
though patients with an IPMN have 
an increased risk of developing co-
lon cancer. A review of computed 
tomography scans performed for in-
dications unrelated to the pancreas 
revealed pancreatic cysts in 2.6% 
of the patients scanned, and this in-
creased to a prevalence of 8.7% in 
individuals aged 80–89 years [13]. In 
individuals with a strong family history 
Table 5.7.2. Familial pancreatic cancer syndromes
Hereditary condition Gene (chromosome) Increase in lifetime risk 
of pancreatic cancer
Other cancers
Familial breast cancer, BRCA2 BRCA2 (13q) 3.5–10× Breast, ovarian, prostate
Hereditary pancreatitis PRSS1 (7q) 50–80× None
Familial atypical multiple mole melanoma p16/CDKN2A (9p) 20–34× Melanoma
Familial breast cancer, PALB2 PALB2 (16p) Unknown Breast
Peutz–Jeghers STK11 (19p) 100–132× Gastrointestinal tract, 
breast, and others
Hereditary non-polyposis colorectal 
cancer
MSH2 (2p)
MLH1 (3p)
PMS2 (7p)
MSH6 (2p)
8–9× Colorectal, endometrial, 
ureteral, and others
ATM ATM (11q) Unknown Breast?
Fig. 5.7.3. SLIT/ROBO signalling in pancreatic ductal adenocarcinoma. SLIT/ROBO 
signalling normally enhances β-catenin complex formation with E-cadherin and sup-
presses WNT signalling activity. Loss of ROBO1/2 signalling promotes stabilization of 
β-catenin, which decreases E-cadherin complex formation and cell adhesion and aug-
ments WNT signalling activity through increased nuclear translocation of β-catenin. In 
addition, SLIT/ROBO signalling can downregulate MET signalling activity; loss of ROBO 
signalling activity promotes MET signalling downstream and may have an impact on 
therapeutic strategies aimed at inhibiting MET activity at the receptor level. Aberrations 
in SLIT2 and/or ROBO1/2 affect 23% of patients.
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of pancreatic cancer, the prevalence 
of these cysts is as high as 40% [14]. 
IPMNs arise in the larger pan-
creatic ducts and, in contrast to 
pancreatic intraepithelial neoplasia, 
most are grossly visible [1]. IPMNs 
can have varying grades of dys-
plasia and can be classified by the 
predominant direction of differentia-
tion into intestinal, pancreatobiliary, 
oncocytic, and gastric subtypes. 
If untreated, as many as one third 
progress to infiltrating adenocarci-
noma. IPMNs that involve the main 
pancreatic duct are more likely to 
have an associated invasive car-
cinoma than are those that involve 
a smaller branch duct [15]. IPMNs 
are often multifocal, and multifocality 
has been established at the genetic 
level. The exomes of a series of well-
characterized IPMNs have recently 
been sequenced, and the three 
genes mutated most frequently in 
these neoplasms are KRAS, GNAS, 
and RNF43 (Table 5.7.3) [16,17]. The 
SMAD4 and TP53 tumour suppres-
sor genes are inactivated in some 
high-grade IPMNs.
IPMNs present a unique oppor-
tunity to cure pancreatic neoplasia 
before an invasive carcinoma devel-
ops. They are detectable using exist-
ing imaging technologies, and some 
will progress to invasive cancer if left 
untreated. However, the risk of over-
treating patients is significant. Not 
all cysts in the pancreas are IPMNs. 
Some are less aggressive serous 
cystadenomas. In addition, most 
IPMNs do not progress to infiltrat-
ing carcinoma. The Sendai criteria 
should be used as a guide for decid-
ing which IPMNs to resect and which 
to observe [15]. These criteria sug-
gest the resection of all main-duct 
IPMNs and the resection of branch-
duct IPMNs that cause symptoms, 
have an associated mural nodule, 
or are associated with dilatation of 
the main duct. Looking forward, it is 
easy to imagine that an evaluation 
of the genetic changes in cyst fluid 
samples will help guide the manage-
ment of pancreatic cysts.
Mucinous cystic neoplasms
Mucinous cystic neoplasms are non-
invasive mucin-producing epithelial 
neoplasms of the pancreas charac-
terized by a distinctive “ovarian-type” 
stroma. Most occur in adult women, 
with a female-to-male ratio of 20. The 
etiology is unknown.
In contrast to IPMNs, the cysts of 
mucinous cystic neoplasms usually 
do not communicate with the larger 
pancreatic ducts [1]. Most arise in 
the tail of the gland. Mucinous cystic 
neoplasms can show varying grades 
of dysplasia, and up to one third prog-
ress to infiltrating adenocarcinoma. 
The exomes of a series of mucinous 
cystic neoplasms have recently been 
sequenced, and the three genes mu-
tated most frequently in these neo-
plasms are KRAS, TP53, and RNF43 
(Table 5.7.3) [17].
As is true for IPMNs, mucinous 
cystic neoplasms offer an opportu-
nity to detect and treat early curable 
pancreatic neoplasia before an incur-
able invasive carcinoma develops. In 
contrast to IPMNs, mucinous cystic 
neoplasms do not have a significant 
risk of multifocal disease. Surgical re-
section of a non-invasive mucinous 
cystic neoplasm is therefore almost 
always curative.
Serous cystadenomas
A serous cystadenoma is a usually 
cystic neoplasm composed of uni-
form cuboidal glycogen-rich neoplas-
tic cells. There is a slight female pre-
dominance. Most cases are sporadic, 
but there is an association with von 
Hippel–Lindau syndrome.
The classic gross appearance of 
a serous cystadenoma is a neoplasm 
composed of innumerable small, thin-
walled cysts with a central star-shaped 
scar, often calcified [1]. The cysts are 
lined by cuboidal neoplastic cells with 
round, uniform nuclei. The VHL gene 
is inactivated in at least half of these 
tumours [17].
Since serous cystadenomas are 
almost always benign, the goal of 
treatment is not to resect these neo-
plasms unless they are very large or 
symptomatic. The challenge is that 
serous cystadenomas can mimic the 
more aggressive IPMNs on imaging. It 
is hoped that preoperative evaluation 
of cyst fluid for markers of VHL inacti-
vation will help guide the management 
of these lesions in the future.
Table 5.7.3. Genetic alterations in non-ductal neoplasms of the pancreas
Tumour type Gene (chromosome)
Intraductal papillary mucinous neoplasm GNAS (20q), RNF43 (17q), KRAS (12p), 
TP53 (17p), SMAD4 (18q)
Mucinous cystic neoplasm RNF43 (17q), KRAS (12p), TP53 (17p)
Solid-pseudopapillary neoplasm CTNNB1 (the β-catenin gene) (3p)
Serous cystic neoplasm VHL (3p)
Pancreatic neuroendocrine tumour MEN1 (11q), ATRX (X), DAXX (6p), 
TSC2 (16p), PTEN (10q), PIK3CA(3q)
Acinar carcinoma SMAD4 (18q), JAK1 (1p), BRAF (7q),  
RB1 (13q), TP53 (17p)
Fig. 5.7.4. Photomicrograph of an intra-
ductal papillary mucinous neoplasm with 
high-grade dysplasia. This neoplasm ex-
tensively involved the larger pancreatic 
ducts. Note the luminal mucin and the 
non-invasive nature of the lesion.
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Solid-pseudopapillary 
neoplasms
A solid-pseudopapillary neoplasm 
is a low-grade malignant epithelial 
neoplasm composed of poorly co-
hesive cells. Most occur in women 
(with a female-to-male ratio of 10), 
usually in their twenties. The etiology 
is unknown.
While solid-pseudopapillary neo-
plasms can be solid, most undergo 
cystic degeneration. When they de-
generate, the neoplasm has a dis-
tinct microscopic appearance with 
foam cells and the formation of 
pseudopapillae [1]. Genetically, solid-
pseudopapillary neoplasms are char-
acterized by mutations in CTNNB1, 
the β-catenin gene (Table 5.7.3) [17].
β-Catenin gene mutations result 
in an abnormal nuclear pattern of 
expression of the β-catenin protein. 
Immunolabelling for the β-catenin 
protein can therefore aid in diag-
nosis. Most solid-pseudopapillary 
neoplasms are cured by surgical 
resection.
Acinar carcinoma 
Interestingly, although the normal pan-
creas largely consists of acinar cells, 
cancers with acinar differentiation 
are rare (only 1–2% of the cancers) 
[1]. Some patients with an acinar cell 
carcinoma present with the devastat-
ing lipase hypersecretion syndrome, 
in which lipase is released by the 
neoplasm into the circulation, causing 
subcutaneous fat necrosis, polyarthral-
gias, and peripheral blood eosinophilia. 
Acinar cell carcinomas are fully malig-
nant neoplasms with a 5-year survival 
rate of only 25–50% [18].
Pancreatic neuroendocrine 
tumours
Pancreatic neuroendocrine tumours 
are epithelial neoplasms with signifi-
cant neuroendocrine differentiation, as 
can be demonstrated by the expres-
sion of synaptophysin or chromogra-
nin. Most occur in individuals aged 30–
60 years. Pancreatic neuroendocrine 
tumours may be sporadic or arise in 
patients with a genetic syndrome such 
as multiple endocrine neoplasia type 
1 (MEN1) or von Hippel–Lindau syn-
drome. The etiology is unknown.
Pancreatic neuroendocrine tu-
mours are richly vascular neoplasms 
usually composed of nests, trabecu-
lae, or sheets of relatively uniform 
cells with characteristic “salt and 
pepper” nuclei (Fig. 5.7.6) [1]. They 
are graded histologically based on 
the proliferation rate. Grade 1 pancre-
atic neuroendocrine tumours have a 
Ki-67 labelling index of 0–2%, grade 
2 an index of 3–20%, and grade 3 
(which are given the designation neu-
roendocrine carcinoma) an index of 
> 20%. Grade and stage are important 
prognosticators. The exomes of a 
series of these tumours have been 
sequenced, and three “mountains” 
were identified (Table 5.7.3). The 
MEN1 gene is inactivated in about 
45% of pancreatic neuroendocrine 
tumours, ATRX/DAXX in 43%, and 
one of the mammalian target of rapa-
mycin (mTOR) pathway genes (TSC2, 
PTEN, or PIK3CA) in 16% [19].
Surgery is the treatment of choice, 
but most patients have metastatic 
disease at diagnosis. Somatostatin 
analogues (including octreotide) have 
been shown to slow tumour growth, 
and several significant advances 
have recently been made in targeted 
therapy for these tumours. The multiple 
tyrosine kinase inhibitor sunitinib has 
shown promise in phase III clinical tri-
als, as has the mTOR pathway inhibitor 
everolimus. Although it has not been 
shown clinically, targeting the mTOR 
pathway may be most beneficial to pa-
tients with pancreatic neuroendocrine 
tumours that harbour mutations in an 
mTOR pathway gene [19,20].
Conclusions
A better understanding of the precur-
sors to invasive adenocarcinoma of 
the pancreas may form the basis for 
improved early detection. Genetic 
changes can be used to classify neo-
plasms and thereby guide therapy, 
and in a small but growing number of 
cases genetic mutations that produce 
a therapeutically targetable change 
offer a promise of advances towards 
a future of personalized medicine.
Fig. 5.7.5. Mucinous non-cystic adenocarcinoma of the pancreas. The Whipple resection 
specimen shows a well-demarcated tumour in the head of the pancreas with a nodular 
pattern and a gelatinous cut surface. The probe indicates the pancreatic duct, which 
runs into the minor papilla.
Fig. 5.7.6. Photomicrograph of a pan-
creatic neuroendocrine tumour. Note the 
nested growth pattern, the absence of a 
desmoplastic stroma, and the “salt and 
pepper” chromatin pattern.
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Summary
• Tobacco smoking, alone and in 
combination with alcohol, is the 
most important cause of head 
and neck cancer.
• Most head and neck cancers are 
squamous cell carcinoma.
• Infection by human papillomavi-
rus causes cancers of the oro-
pharynx and base of tongue.
• Nasopharyngeal carcinomas 
are common in parts of South-
East Asia and North Africa; their 
etiology involves Epstein–Barr 
virus, volatile nitrosamines, and 
genetic factors.
• Genetic alterations in oral and 
laryngeal cancer include acti-
vation of cyclin D1, MYC, RAS, 
PIK3CA, and EGFR and inac-
tivation of tumour suppressor 
genes such as p16 INK4A, TP53, 
and PTEN.
• Mutations in PI3K pathway 
genes are proposed as a pre-
dictive biomarker.
• Early-stage tumours of the up-
per aerodigestive tract can be 
cured; for late-stage disease, 
prognosis is poor.
5.8
5 ORGAN SITE
Head and neck cancers
Lester D.R. Thompson Paul Brennan (reviewer)
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Head and neck cancers are a related 
group of cancers that involve the oral 
cavity, pharynx (oropharynx, naso-
pharynx, hypopharynx), and larynx 
(Fig. 5.8.1). Most tumours of the 
oral cavity, larynx, and hypophar-
ynx are squamous cell carcinoma 
arising from the squamous cells that 
line these spaces. Other tumours 
that develop in this area (sinonasal 
tract, salivary glands) are relatively 
uncommon. Although related, there 
are four separate anatomical groups, 
with distinctly different etiologies but 
similar metastatic pathways.
Etiology
Cancers of the oral cavity 
and of the larynx and 
hypopharynx
The most significant causes of all 
head and neck cancers are tobac-
co use and alcohol consumption. 
These exposures account for the 
development of approximately 80% 
of such cancers globally, with some 
variation for different subsites (65% 
for oral cavity vs 86% for larynx) [1]. 
Smoking of cigarettes or bidis poses 
the most important risk for cancer 
development, related to the product 
of smoking rate in packs per day 
and duration of smoking in years 
(“pack-years”), and risk is higher for 
longer duration of smoking, smok-
ers of black tobacco or high-tar 
cigarettes versus blond tobacco, 
young age at start of smoking, and 
deep smoke inhalation. Cigar and 
pipe smoking also pose a risk, al-
though slightly less [1,2]. The rela-
tive risk is higher for glottic than 
for supraglottic carcinoma. Use of 
chewing tobacco or smokeless to-
bacco, and combinations with other 
substances such as paan or betel 
Fig. 5.8.1. The major anatomical sites 
within the head and neck include the na-
sal cavity, nasopharynx (A, purple), oral 
cavity, oropharynx (B, blue), larynx, and 
hypopharynx (C, green). The pharynx is 
divided using the junction between the 
hard and soft palate as the start of the 
nasopharynx; the inferior surface of the 
soft palate, uvula, base of tongue, tonsils, 
and tonsillar pillars within the oropharynx; 
and the hypopharynx extending from the 
superior border of the hyoid bone to the 
inferior border of the cricoid cartilage.
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Epidemiology
Laryngeal cancer
• Laryngeal cancer is the 14th 
most common cancer among 
men, but it is relatively rare in 
women: of the 157 000 esti-
mated new cases worldwide in 
2012, less than 19 000 occurred 
in women. The estimated total 
number of deaths from laryngeal 
cancer was about 83 000.
• About 53% of the cases occurred 
in countries at high or very high 
levels of human development; 
49% of the cases occurred in 
Asia.
• The highest incidence rates in 
men tend to be observed in east-
ern Europe and in certain coun-
tries in the Caribbean. 
Cancer of the lip, oral cavity, 
and pharynx
• For cancers of the oral cavity and 
pharynx, an estimated 529 000 
new cases occurred worldwide 
in 2012, with 292 000 deaths. 
When the main subsites (lip, 
oral cavity, nasopharynx, and 
pharynx) are examined sepa-
rately, they do not rank highly, 
but combined would rank above 
cervical cancer as the seventh 
most frequent type of cancer by 
incidence and the ninth most 
common cause of cancer death.
• The highest incidence rates 
are in Papua New Guinea, 
Bangladesh, Hungary, and Sri 
Lanka. The 120 000 new cases 
and 88 000 deaths occurring in 
India represent almost one quar-
ter and one third, respectively, 
of the total burden from these 
cancers.
• Incidence trends show a de-
cline since the 1990s in popu-
lations where the rates were 
high (India, China, Blacks in the 
USA, Australia), in both sexes. 
Conversely, some populations 
with historically rather low in-
cidence rates show increasing 
trends (e.g. Denmark, Japan).
Map 5.8.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for laryngeal cancer in men, 2012.
Map 5.8.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for pharyngeal cancer in men, 2012.
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.8.1. Estimated global number of new cases and deaths with proportions by major world regions, for laryngeal 
cancer in both sexes combined, 2012.
Chart 5.8.2. Estimated global number of new cases and deaths with proportions by major world regions, for oral and 
pharyngeal cancer in both sexes combined, 2012.
quid (betel leaf, areca nut, lime, 
and tobacco) poses an increased 
risk for oral cancer development, 
which is highest in India and in 
Taiwan, China, and especially 
affects the floor of the mouth [2]. 
The risk decreases within 10 years 
of smoking cessation and is the low-
est for groups of never-smokers, 
such as Seventh-day Adventists and 
Mormons. Compared with never- 
smokers/teetotallers, the relative 
risk of head and neck cancer is in-
creased between 10- and 100-fold 
in people who drink and smoke 
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Chart 5.8.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for laryngeal cancer 
in men, circa 1975–2012.
Chart 5.8.4. Age-standardized (World) incidence rates 
per 100 000 by year in selected populations, for oral and 
pharyngeal cancer in men, circa 1975–2012.
heavily. If there were total absti-
nence from drinking and smoking 
(or quid chewing) worldwide, the 
risk of oral, pharyngeal, and laryn-
geal cancers would be extremely 
low.
Alcohol consumption shows a 
strong multiplicative effect with to-
bacco, perhaps related to acetal-
dehyde, an intermediate metabolite 
of ethanol and a known carcinogen 
[3]. There are significant differences 
between countries in terms of per 
capita average alcohol consumption 
and the preferred type of beverage 
(beer, liquor, or wine). However, 
even with these differences, the 
most commonly consumed alco-
holic beverage appears to be the 
one most strongly associated with 
cancer risk. For increased alco-
hol consumption, the relative risk 
is higher for supraglottic and hy-
popharyngeal carcinoma than for 
glottic and subglottic carcinoma. 
There is a greater risk of pharyn-
geal and oral cancer related to the 
number of years of heavy drinking 
and not the number of drinks per 
day [1]. There is an increased rela-
tive risk of laryngeal carcinoma in 
patients who are heavy drinkers 
(> 8 drinks or > 207 ml/day) versus 
teetotallers or moderate drinkers, 
even without tobacco use. If indi-
viduals are classified as alcohol-
ics, there is an even stronger risk 
of cancer development. Tumours 
may develop within a background of 
field cancerization, with additional 
tumours arising from the same envi-
ronmental or epigenetic milieu that 
gave rise to the first tumour, often in 
adjacent head and neck sites.
Oral and oropharyngeal carcino-
mas are also associated with poor 
oral hygiene, habitual consumption 
of khat leaves, smoking marijuana, 
and drinking maté, but causality 
with mouthwash use or with coffee 
drinking is not established [4].
Industrial exposure by working 
in construction, metal, textile, or ce-
ramic jobs with exposure variously 
to isopropanol, polycyclic aromatic 
hydrocarbons, inorganic acid mists 
containing sulfuric acid and/or 
mustard gas, and diesel exhausts, 
and working in the food industry 
increase the risk of developing la-
ryngeal cancer, after controlling for 
alcohol consumption and tobacco 
use. Human papillomavirus (HPV) 
may play a minor causative role in 
laryngeal and oral carcinomas [5]. 
Gastro-oesophageal reflux disease 
is associated with an increased risk 
of laryngeal carcinoma, but may 
also act as a promoter when alcohol 
and tobacco are used.
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Cancers of the oropharynx 
and base of tongue
Infection with HPV is one of the 
major leading causes of cancers of 
the oropharynx, tonsil, and base of 
tongue. Due to the relatively high 
HPV infection rate in sexually ac-
tive people (> 50%), a significant in-
crease in the incidence of this type 
of cancer has occurred over the 
past several decades. This increase 
is correlated with changes in sexual 
habits, including the practice of oral 
sex, lifetime and recent number of 
sexual partners, the practice of pre-
marital sex, and earlier ages of initial 
sexual activity, all of which contrib-
ute to the likelihood of oral infection. 
Biologically active HPV prevalence 
in oropharyngeal cancers ranges 
from 28% in Europe to 46% in Asia 
and 47% in North America, although 
more recent studies show rates of 
65–70% [6]. HPV16 accounts for 
nearly all oropharyngeal cancers, 
while HPV18 is also a contributor to 
oral cavity cancers. The odds ratio 
for oropharyngeal oncogenic type-
specific HPV16 E6/E7 antibodies is 
72.8 (confidence interval, 16–330), 
which underscores the causal asso-
ciation of HPV with oropharyngeal 
carcinoma, along with integration of 
HPV DNA into the human genome 
[7], high HPV viral copy numbers 
[8], and high-level expression of 
HPV oncogenes (E6 and E7) in tu-
mours. HPV also plays a causative 
role in selected oral (20.2%, weight-
ed prevalence [WP]), sinonasal 
(29.6%, WP), laryngeal (23.6%, WP), 
and nasopharyngeal (31.1%, WP) 
tumours [5]. Marijuana use is also 
associated with HPV-positive oro-
pharyngeal cancer development [9].
Nasopharyngeal cancer
Nasopharyngeal carcinoma exhibits a 
strong association with Epstein–Barr 
virus (EBV) infection, occupational 
exposures to wood dusts and formal-
dehyde, cigarette smoking, radiation 
exposure, consumption of specific 
preserved or salted foods, malaria 
infection, and genetic predisposi-
tion, as determined by multivariate-
adjusted hazard ratios [10].
EBV is consistently implicated 
in nasopharyngeal carcinoma on-
cogenesis. EBV infection seems to 
be an early initiating event as EBV is 
found in precursor lesions and shows 
a clonal episomal form, indicating 
that the virus entered the tumour 
cell nucleus before clonal expansion 
started. This phenomenon results in 
nearly every tumour cell containing 
the full length of the EBV genome. 
Positive serology for the presence 
of immunoglobulin A antibodies to 
EBV capsid antigen is present in up 
to 93% of patients, with an increased 
titre correlated with high tumour bur-
den. This elevated titre may be used 
as a marker to screen populations 
in high-risk areas or to detect tu-
mour recurrence [11]. EBV-encoded 
early RNA is expressed in nearly all 
tumour cells. This type of infection 
shows a type II latency pattern, with 
expression of EBV nuclear antigen 1 
(EBNA1) and latent membrane pro-
tein 1 (LMP1). LMP1 can induce 
squamous hyperplasia, inhibit squa-
mous differentiation, activate NF-κB, 
and induce expression of epidermal 
growth factor receptor (EGFR).
Meta-analysis of 16 case–con-
trol studies showed that highest-
versus-lowest intake of preserved 
vegetables was associated with a 
2-fold increase in the risk of naso-
pharyngeal cancer, while high intake 
of non-preserved vegetables was 
associated with a 36% decrease in 
the risk of this cancer, irrespective of 
vegetable type or country of study. It 
is thought that high levels of volatile 
nitrosamines in preserved food may 
be a putative carcinogen. Based on 
case–control studies, consumption 
of salt-preserved food (specifically 
as Cantonese-style salted fish), fer-
mented foods, or foods with related 
preservation processes, including 
quaddid (dried mutton stored in oil), 
and consumption of rancid butter 
during weaning and early childhood 
have an adjusted relative risk of up 
to 7.5, increasing to 37.7 when con-
sumed at least once per week ver-
sus less than once per month at age 
10 years [12].
Fig. 5.8.3. Tobacco smoking and alco-
hol consumption are causes of head and 
neck cancers, specifically cancers of the 
oral cavity, pharynx, and larynx. People 
who both smoke and drink alcohol are at 
markedly greater risk of developing these 
cancers than those who either smoke or 
drink alcohol in the absence of the other 
habit, although both individually increase 
the likelihood of developing head and neck 
cancers.
Fig. 5.8.2. (A) Endoscopic view of a laryngeal cancer. (B) A laryngectomy specimen 
demonstrates an exophytic supraglottic squamous cell carcinoma.
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Pathology and genetics
Cancer of the oral cavity 
and of the larynx and 
hypopharynx
The squamous cell carcinomas of 
these two sites are similar one to 
another. There is in general a pro-
gression from epithelial hyperplasia 
through dysplasia to carcinoma in situ 
to invasive carcinoma (Fig. 5.8.4), 
but not all invasive tumours arise 
from an overlying dysplasia. There 
is a loss of maturation, architectur-
al disorganization, and increased 
pleomorphism and cell size with 
dyskeratosis and increased mitoses 
to a variable degree with each grade 
of dysplasia. Although the length of 
time from dysplasia to invasive car-
cinoma is quite variable, it is gener-
ally measured in years. It is during 
this interval that disease progression 
may be altered by changes in habits 
(smoking, alcohol consumption) or 
surgical intervention. Tumours are 
separated into keratinizing and non-
keratinizing, in situ versus invasive, 
and well, moderately, or poorly dif-
ferentiated (Fig. 5.8.5). Variants are 
uncommon.
The genetic alterations observed 
in oral and laryngeal cancer are 
complex and interrelated. These 
alterations include activation of 
proto-oncogenes such as cyclin D1 
(CDKN2A), MYC, RAS, PIK3CA, and 
EGFR and inactivation of tumour 
suppressor genes such as p16 INK4A, 
TP53, and PTEN. TP53 mutations 
and overexpression are seen in the 
progression of precursor lesions to 
invasive carcinomas, although this 
is reported with greater frequency in 
developed countries (40–50%) than 
in developing countries (5–25%). 
In contrast, tumours in patients 
from India and South-East Asia are 
characterized by the involvement of 
RAS oncogenes, including mutation, 
loss of heterozygosity (HRAS), and 
amplification (KRAS and NRAS). 
Mutations may also be seen in genes 
regulating squamous differentiation 
(such as NOTCH1, IRF6, and TP63) 
[13].
Cancers of the oropharynx 
and base of tongue
HPV-positive oropharyngeal car-
cinomas are distinct from HPV-
negative cancers. HPV-positive 
cancers tend to be smaller primary 
tumours but with increased nodal 
involvement (high N stage), show-
ing a poorly differentiated and non-
keratinizing or basaloid histology 
Fig. 5.8.4. The histological progression from normal to invasive squamous cell carcinoma is shown in parallel to genetic and epigenetic 
events. The accumulation of these genetic changes, and not the exact order, determines the progression to invasive carcinoma.
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compared with HPV-negative 
cancers [6]. The tumours can be 
separated histologically into non-
keratinizing, non-keratinizing with 
maturation, and keratinizing types; 
the first two types show the stron-
gest association with HPV [14]. 
The tumours form nests with broad 
pushing borders and limited stromal 
response, frequent mitoses, and 
comedonecrosis. The cells form a 
syncytium, with indistinct borders, 
with hyperchromatic nuclei lacking 
prominent nucleoli. These tumours 
lack any squamous maturation or 
keratin pearl formation. Keratinizing 
squamous cell carcinomas have sig-
nificant desmoplasia, with polygonal 
cells that show well-developed cell 
borders (intercellular bridges) and 
have abundant eosinophilic cyto-
plasm. Tumours that are intermedi-
ate (“with maturation”) are hybrid 
tumours but are much more closely 
associated with HPV than the kerati-
nizing type. Although not absolutely 
correlated, immunohistochemical 
expression of p16 (> 75% of cells 
with strong nuclear and cytoplas-
mic positive reaction) is considered 
an excellent surrogate marker for 
biologically active, integrated HPV 
infection. The interaction of HPV 
infection with TP53 mutations and 
EGFR expression requires further 
investigation as these markers typi-
cally show a negative correlation 
with tumour HPV status.
Nasopharyngeal cancer
WHO classifies nasopharyngeal can-
cer into three major subtypes: non-
keratinizing carcinoma, keratinizing 
carcinoma, and basaloid squamous 
cell carcinoma. Non-keratinizing 
carcinoma is the most common type 
and is most common in endemic 
populations, while the keratinizing 
and basaloid squamous cell carci-
noma types tend to be more com-
mon in non-endemic populations. 
Non-keratinizing carcinoma is further 
separated into two types: differenti-
ated (stratified cells with pleomorphic, 
hyperchromatic nuclei surrounded by 
well-defined cell borders, sharply de-
limited from the stroma but lacking a 
desmoplastic stromal response) and 
undifferentiated (a variable growth 
of cohesive cell nests to more indi-
vidual dyscohesive cells within a lym-
phoid stroma) (Fig. 5.8.6). The cells 
are large with indistinct cell borders, 
scant cytoplasm, and round nuclei 
with vesicular chromatin distribution, 
containing prominent nucleoli. An in 
situ or precursor lesion is rare. Viral 
infection works via many interrelat-
ed somatic genetic and epigenetic 
changes that synergistically contrib-
ute to the development of nasopha-
ryngeal carcinoma. This pathway is 
exceedingly complex, but the meth-
ylation of several tumour suppressor 
genes detected by nasopharyngeal 
brushings or in serum may aid in early 
detection and diagnosis.
Comprehensive genomic data 
are not available for nasopharyngeal 
cancer. One exome study based on 
biopsies indicated that the EBV-
encoded genome maintenance 
protein EBNA1 along with LMP1, 
LMP2, and BARF1 were expressed 
in the majority of specimens stud-
ied. Analyses also suggested that 
loss of the FHIT gene may be a 
driver of tumorigenesis [15]. In an-
other study based on paraffin-em-
bedded specimens, 41 microRNAs 
were differentially expressed be-
tween nasopharyngeal tumour and 
corresponding non-cancer tissue, 
and a signature set of five was iden-
tified [16].
Prospects
Biomarkers
For oral dysplasia, several biomark-
ers have been shown to increase 
the risk of progression to cancer, 
including loss of heterozygosity, par-
ticularly at the 3p ± 9p loci, survivin, 
matrix metalloproteinase 9 (MMP9), 
and DNA content. Other markers 
(p53, p73, MMP1, and MMP2), did 
not seem to predict progression [17]. 
HPV is a significant prognostic bio-
marker in oropharyngeal squamous 
cell carcinoma, with the widest risk 
stratification for survival of any head 
and neck biomarker yet described, 
and thus has potential for important 
therapeutic considerations [18]. 
Whole-exome sequencing of 151 
head and neck squamous cell car-
cinomas revealed the phosphati-
dylinositol 3-kinase (PI3K) pathway 
to be the most frequently mutated 
oncogenic pathway (30.5%) [19]. In 
a subset of HPV-positive tumours, 
PIK3CA or PIK3R1 was the only mu-
tated cancer gene. All tumours with 
concurrent mutation of multiple PI3K 
pathway genes were advanced, im-
plicating this pathway in tumour pro-
gression and suggesting its use as a 
predictive biomarker.
Screening
Screening programmes similar to cy-
tology for cervical cancer do not seem 
to be applicable for oropharyngeal or 
oral cancer. Cytological abnormalities 
Fig. 5.8.5. (A) A moderately differentiated, invasive, keratinizing squamous cell car-
cinoma of the oral cavity. (B) A poorly differentiated, non-keratinizing squamous cell 
carcinoma of the larynx.
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are rarely detected even when there 
is known invasive disease, perhaps 
due to the difficulty of sampling the 
deep tonsillar crypts and to the lack 
of an identifiable precursor lesion. 
Therefore, delayed diagnosis is com-
mon. Direct visual inspection of the 
oral cavity, oropharynx, nasophar-
ynx, and larynx (assisted by endos-
copy) or evaluation by imaging stud-
ies in high-risk individuals may lead to 
early diagnosis, although large-scale 
screening programmes remain to be 
established on a global or regional 
scale. Significantly reduced oral 
cancer mortality has been observed 
in high-risk individuals in India under-
going repeated rounds of screening 
by inspection of the oral cavity [20].
Screening for plasma EBV DNA 
levels might be helpful in detecting 
nasopharyngeal cancer, based on 
pooled meta-analysis data sensi-
tivity (91.4%; confidence interval, 
89.0–93.4%) and specificity (93.2%; 
91.2–95.0%) [11]. Screening of high-
risk families (family members of na-
sopharyngeal carcinoma patients) or 
patients in endemic areas by EBV se-
rology (for immunoglobulin A viral cap-
sid antigen), EBV DNA, or other tech-
niques (such as nasopharyngoscopy) 
has a potential benefit (sensitivity 
of 88.9% and specificity of 87.0%) 
as it detects cancers at a much ear-
lier stage than symptomatic cancers 
(by up to 10 years), which yields im-
proved disease-free survival.
Identification of high-risk 
groups
Patients with certain polymorphisms 
in enzymes involved in detoxifying 
alcohol (alcohol and aldehyde de-
hydrogenases [ADH]), show an in-
creased susceptibility to developing 
carcinoma [3]. There seems to be a 
protective effect for patients with the 
ADH1B R48H variant and the ADH7 
A92G variant, with a significant modi-
fication based on increasing alcohol 
consumption; each gene’s effect is 
independent of the other’s.
There is an increased risk of up-
per aerodigestive tract cancers in 
patients with the ADH1B Arg47Arg 
genotype, much greater than that for 
patients with a His47His genotype. 
Furthermore, there is a modulation 
of susceptibility when combined with 
alcohol consumption and interactions 
with the ALDH2 487Lys allele [21]. 
Additional genetic polymorphisms 
seen in association with head and 
neck cancer include those in the 
GSTM1, GSTT1, and EPHX1 genes, 
XPD Lys751Gln, and P53 codon 72 
Pro/Pro.
A family history of head and neck 
cancer in a first-degree relative in-
creased the risk (odds ratio, 1.7; 
confidence interval, 1.2–2.3), which 
was even higher when the relative 
was a sibling (2.2; 1.6–3.1). This risk 
was limited to subjects exposed to 
tobacco and alcohol (7.2; 5.5–9.5) 
[22]. Hence, if there is a family his-
tory of head and neck cancer, avoid-
ing exposure to tobacco and alcohol 
reduces risk.
There are certain inherited con-
ditions that are associated with an 
increased risk of developing head 
and neck cancer, including dys-
keratosis congenita and DNA repair 
pathway disorders, such as Bloom 
syndrome (helicase gene muta-
tions), Fanconi anaemia (germline 
mutations in FAA, FAD, and FCC 
caretaker genes), ataxia telangiec-
tasia (homozygotes), and xeroderma 
pigmentosum (XP genes). IARC has 
collected information from 15 centres 
to study alcohol-related cancer and 
genetic susceptibility in patients en-
rolled from these centres, with a clear 
preponderance of smokers and alco-
hol drinkers in head and neck cancer 
cases.
Prevention
Avoiding cigarettes and alcohol 
could prevent up to 80% of oral 
cancer and up to 90% of laryn-
geal and hypopharyngeal cancer. 
Interventions targeting smoking 
Fig. 5.8.6. (A) A non-keratinizing nasopharyngeal carcinoma showing prominent nucleoli 
and amyloid. (B) Most nasopharyngeal carcinomas have a very heavy inflammatory 
infiltrate, which can obscure the neoplastic cells. (C) Nearly every one of the neoplastic 
cells shows a strong nuclear reaction with Epstein–Barr virus-encoded small RNA.
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prevention or cessation are most 
effective when modelled by physi-
cians, individual counsellors, or 
workplace- and school-based pro-
grammes (see Chapter 4.1). Further, 
national smoke-free policies may 
have public health benefits for both 
alcohol- and tobacco-related health 
problems.
The prophylactic use of the bi-
valent (HPV16 and 18) or quad-
rivalent (HPV6, 11, 16, and 18) vac-
cines in males and females (aged 
9–26 years), if proven efficacious, 
holds great promise for primary 
prevention of HPV-associated oro-
pharyngeal cancers since such a 
high proportion of HPV-associated 
oropharyngeal carcinomas are 
HPV16-derived [23].
Chapter 5.8 • Head and neck cancers 431
5 
O
R
G
A
N
 S
IT
E
C
H
A
P
TE
R
 5
.8
References
1. Lubin JH, Purdue M, Kelsey K et al. (2009). 
Total exposure and exposure rate effects 
for alcohol and smoking and risk of head 
and neck cancer: a pooled analysis of 
case-control studies. Am J Epidemiol, 
170:937–947. http://dx.doi.org/10.1093/
aje/kwp222 PMID:19745021
2. Pednekar MS, Gupta PC, Yeole BB, Hébert 
JR (2011). Association of tobacco habits, 
including bidi smoking, with overall and 
site-specific cancer incidence: results 
from the Mumbai cohort study. Cancer 
Causes Control, 22:859–868. http://dx. 
doi.org/10.1007/s10552-011-9756-1 PMID: 
21431915
3. Xue Y, Wang M, Zhong D et al. (2012). 
ADH1C Ile350Val polymorphism and 
cancer risk: evidence from 35 case-con-
trol studies. PLoS One, 7:e37227. http://
dx.doi.org/10.1371/journal.pone.0037227 
PMID:22675424
4. Goldenberg D, Lee J, Koch WM et al. 
(2004). Habitual risk factors for head and 
neck cancer. Otolaryngol Head Neck Surg, 
131:986–993. http://dx.doi.org/10.1016/j.
otohns.2004.02.035 PMID:15577802
5. Isayeva T, Li Y, Maswahu D, Brandwein-
Gensler M (2012). Human papillomavirus in 
non-oropharyngeal head and neck cancers: 
a systematic literature review. Head Neck 
Pathol, 6 Suppl 1:S104–S120. http://dx. 
doi.org/10.1007/s12105-012-0368-1 PMID: 
22782230
6. Chaturvedi AK (2012). Epidemiology and 
clinical aspects of HPV in head and neck 
cancers. Head Neck Pathol, 6 Suppl 1:S16–
S24. http://dx.doi.org/10.1007/s12105-012-
0377-0 PMID:22782220
7. Gillison ML, Koch WM, Capone RB et al. 
(2000). Evidence for a causal associa-
tion between human papillomavirus and 
a subset of head and neck cancers. J Natl 
Cancer Inst, 92:709–720. http://dx.doi.
org/10.1093/jnci/92.9.709 PMID:10793107
8. Kreimer AR, Clifford GM, Snijders PJ et 
al.; International Agency for Research on 
Cancer (IARC) Multicenter Oral Cancer 
Study Group (2005). HPV16 semiquan-
titative viral load and serologic biomark-
ers in oral and oropharyngeal squamous 
cell carcinomas. Int J Cancer, 115:329–
332. http://dx.doi.org/10.1002/ijc.20872 
PMID:15688391
9. Gillison ML, D’Souza G, Westra W et al. 
(2008). Distinct risk factor profiles for hu-
man papillomavirus type 16-positive and 
human papillomavirus type 16-negative 
head and neck cancers. J Natl Cancer Inst, 
100:407–420. http://dx.doi.org/10.1093/
jnci/djn025 PMID:18334711
10. Hildesheim A, Wang CP (2012). Genetic 
predisposition factors and nasopharyngeal 
carcinoma risk: a review of epidemiological 
association studies, 2000–2011: Rosetta 
Stone for NPC: genetics, viral infection, and 
other environmental factors. Semin Cancer 
Biol, 22:107–116. http://dx.doi.org/10.1016/j.
semcancer.2012.01.007 PMID:22300735
11. Liu Y, Fang Z, Liu L et al. (2011). Detection of 
Epstein-Barr virus DNA in serum or plasma 
for nasopharyngeal cancer: a meta-analy-
sis. Genet Test Mol Biomarkers, 15:495– 
502. http://dx.doi.org/10.1089/gtmb.2011. 
0012 PMID:21410354
12. Jia WH, Qin HD (2012). Non-viral environ-
mental risk factors for nasopharyngeal car-
cinoma: a systematic review. Semin Cancer 
Biol, 22:117–126. http://dx.doi.org/10.1016/j.
semcancer.2012.01.009 PMID:22311401
13. Stransky N, Egloff AM, Tward AD et al. 
(2011). The mutational landscape of 
head and neck squamous cell carcino-
ma. Science, 333:1157–1160. http://dx. 
doi.org/10.1126/science.1208130 PMID: 
21798893
14. Chernock RD (2012). Morphologic features 
of conventional squamous cell carcinoma 
of the oropharynx: ‘keratinizing’ and ‘non-
keratinizing’ histologic types as the basis 
for a consistent classification system. Head 
Neck Pathol, 6 Suppl 1:S41–S47. http://dx. 
doi.org/10.1007/s12105-012-0373-4 PMID: 
22782222
15. Hu C, Wei W, Chen X et al. (2012). A 
global view of the oncogenic landscape 
in nasopharyngeal carcinoma: an inte-
grated analysis at the genetic and expres-
sion levels. PLoS One, 7:e41055. http://dx. 
doi.org/10.1371/journal.pone.0041055 
PMID:22815911
16. Liu N, Chen NY, Cui RX et al. (2012). 
Prognostic value of a microRNA signature 
in nasopharyngeal carcinoma: a microRNA 
expression analysis. Lancet Oncol, 13:633– 
641. http://dx.doi.org/10.1016/S1470-2045 
(12)70102-X PMID:22560814
17. Smith J, Rattay T, McConkey C et al. (2009). 
Biomarkers in dysplasia of the oral cavity: a 
systematic review. Oral Oncol, 45:647–653. 
http://dx.doi.org/10.1016/j.oraloncology. 
2009.02.006 PMID:19442563
18. Olthof NC, Straetmans JM, Snoeck R et al. 
(2012). Next-generation treatment strate-
gies for human papillomavirus-related head 
and neck squamous cell carcinoma: where 
do we go? Rev Med Virol, 22:88–105. 
http://dx.doi.org/10.1002/rmv.714 PMID: 
21984561
19. Lui VW, Hedberg ML, Li H et al. (2013). 
Frequent mutation of the PI3K pathway in 
head and neck cancer defines predictive 
biomarkers. Cancer Discov, 3:761–769. 
http://dx.doi.org/10.1158/2159-8290.CD-
13-0103 PMID:23619167
20. Sankaranarayanan R, Ramadas K, 
Somanathan T et al. (2013). Long term ef-
fect of visual screening on oral cancer in-
cidence and mortality in a randomized trial 
in Kerala, India. Oral Oncol, 49:314–321. 
http://dx.doi.org/10.1016/j.oraloncology. 
2012.11.004 PMID:23265945
21. Cadoni G, Boccia S, Petrelli L et al. (2012). 
A review of genetic epidemiology of head 
and neck cancer related to polymorphisms 
in metabolic genes, cell cycle control and 
alcohol metabolism. Acta Otorhinolaryngol 
Ital, 32:1–11. PMID:22500060
22. Negri E, Boffetta P, Berthiller J et al. 
(2009). Family history of cancer: pooled 
analysis in the International Head and 
Neck Cancer Epidemiology Consortium. 
Int J Cancer, 124:394–401. http://dx.doi.
org/10.1002/ijc.23848 PMID:18814262
23. D’Souza G, Dempsey A (2011). The 
role of HPV in head and neck can-
cer and review of the HPV vaccine. 
Prev Med, 53 Suppl 1:S5–S11. http://
dx.doi.org/10.1016/j.ypmed.2011.08. 
001 PMID:21962471
Websites
American Society of Clinical Oncology Head 
and Neck Cancer home page: 
http://www.cancer.net/cancer-types/head- 
and-neck-cancer
National Cancer Institute Head and Neck 
Cancer home page: 
http://cancer.gov/cancertopics/types/head- 
and-neck
National Cancer Institute Throat (Laryngeal 
and Pharyngeal) Cancer home page: 
http://cancer.gov/cancertopics/types/throat
The John Hopkins Medical Institution, Head 
and Neck Cancer home page: 
www.hopkinsmedicine.org/kimmel_cancer_ 
center/centers/head_neck/
Summary
Evidence that overweight, obesity, 
and physical inactivity are caus-
ally related to cancer is sufficiently 
strong to support strong actions to 
reduce these hazards. Multiple and 
increasingly intensive strategies will 
be needed to reverse the obesity 
epidemic, and actions are needed 
in many sectors and at all levels of 
society. Efforts to promote an overall 
healthy diet, including increases in 
fruits, vegetables, and whole grains 
and reductions in red meat, are well 
justified, but effects on risk of cancer 
specifically are likely to be modest. 
Continued research on diet, nutrition, 
and cancer is needed to expand the 
scientific basis for future progress to 
justify public health efforts.
A fundamental goal of research on 
diet and cancer is to identify con-
stituents of food – including both 
classic nutrients and other aspects 
of diet – that increase or decrease 
the risk of cancer. This quest in-
cludes epidemiological investiga-
tions, experiments in animals, and in 
vitro studies. When the weight of ev-
idence becomes sufficiently strong, 
this knowledge, which has usually 
been published piecemeal in scien-
tific journals, needs to be translated 
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into actions to prevent cancer. As 
discussed elsewhere in this Report, 
the process of research and transla-
tion leading to reductions in cancer 
rates has been highly successful for 
many types of exposures, including 
tobacco use, radiation, pharmaceu-
ticals, and occupational hazards. 
From these experiences, we have 
learned much about the process 
of cancer prevention that can be 
applied to dietary factors. Here, I 
briefly review our current state of 
knowledge on diet, nutrition, and 
cancer, public health approaches to 
translation of knowledge on diet and 
cancer, and suggestions for future 
public health directions.
Current state of knowledge
Research on diet, nutrition, and 
cancer was limited until the late 
1970s, when the large internation-
al differences in cancer rates and 
some animal studies suggested 
that some aspects of diet might 
play major roles in the cause and 
prevention of cancer. In response, 
many case–control studies were 
conducted, and large prospec-
tive studies were launched and 
are now producing abundant data. 
Progress has been more difficult 
than anticipated by many research-
ers, partly because of the complex-
ity of human diets but also due to 
the nature of cancer and its origins. 
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In particular, we have come to ap-
preciate that many cancers consist 
of distinct diseases with different 
causes, and also that the process-
es that lead to development of can-
cer can operate over a lifetime, thus 
making the study of diet and can-
cer exceedingly challenging. In our 
own research within several large 
prospective studies, we have also 
been investigating dietary factors 
in relation to risks of cardiovascular 
disease, diabetes, and many other 
outcomes, and clear associations 
between dietary factors and these 
diseases have emerged much more 
rapidly than for cancer, probably 
because the influences of dietary 
factors on the occurrence of these 
diseases are more immediate. This 
experience with other diseases has 
been important for research on 
cancer because it has documented 
that the methodologies to measure 
diet and to adjust for other factors 
do work well.
Despite the challenges of study-
ing diet and cancer, several impor-
tant conclusions have emerged. 
Most importantly, overweight and 
obesity have become established 
causes of many common cancers; 
this represents a major achieve-
ment in cancer research. Although 
the risks of cancer for an individual 
who is overweight or obese are not 
as great as they are for a tobacco 
smoker, in the USA and some 
other countries the much higher 
prevalence of overweight and obe-
sity than of smoking means that the 
numbers of cancer deaths caused 
by these two factors are now simi-
lar [1]. Because the health conse-
quences of obesity are not mani-
fested immediately, the impact of 
the recent, rapid increases in the 
prevalence of obesity on cancer 
rates will continue to grow even if 
there is no further increase in prev-
alence. Physical inactivity is also 
now well established as a risk factor 
for several cancers, in part through 
its contribution to overweight, but 
also directly. Consumption of red 
meat, particularly processed red 
meat, is related to modestly higher 
risks, and of fruits and vegetables 
to modestly lower risks of some 
forms of cancer.
Given currently available knowl-
edge, control of overweight and 
obesity must be a high priority for 
cancer prevention, and increas-
ing physical activity should be part 
of this effort. The dietary factors 
related to obesity are many and 
complex, but sugar-sweetened bev-
erages (e.g. soda) have emerged 
as a particularly important contrib-
uting factor in many places (see 
Chapter 2.6).
Importantly, overweight or obe-
sity, inadequate physical activity, 
and low intakes of fruits and vegeta-
bles, together with tobacco, are also 
major risk factors for cardiovascular 
disease and type 2 diabetes. Thus, 
programmes for the prevention of 
cancer should be closely integrated 
with activities for the prevention of 
these other diseases.
Public health approaches for 
cancer prevention through 
improved diets
To have a substantial impact on 
cancer rates, specific actions be-
yond the publication of papers in 
scattered scientific journals are 
needed. Knowledge is now often 
transmitted widely by the gener-
al media, such as television and 
newspapers, and some people will 
change their diets, become more 
active, or stop smoking based on 
this information alone. However, 
experience from tobacco control 
suggests that the impact of this will 
be limited. Also, with the Internet 
and other new channels of infor-
mation, the public is being deluged 
with information on diet and health 
that is often sensationalist and out 
of context with other data, leav-
ing many people more confused 
than they were with earlier, limited 
sources. Thus, a careful and coor-
dinated public health approach for 
translation of nutritional knowledge 
will be needed to have an optimal 
impact; six levels of action with in-
creasing intensity of intervention 
are described here [2]. Frieden 
has noted that, as compared with 
individual counselling and clini-
cal interventions, the greatest and 
most cost-effective public health 
impact will usually be achieved 
by changing the context so that 
the decisions of individuals are by 
default healthy ones, and by im-
proving underlying socioeconomic 
factors [3].
1. Education and awareness
This process often begins with sys-
tematic reviews and summaries of 
the scientific literature on a topic, 
such as those on diet, nutrition, 
and cancer conducted by the World 
Cancer Research Fund/American 
Institute for Cancer Research [4], 
WHO [5], or national governments 
[6]. These are often accompanied 
by dietary guidelines based on the 
available evidence, and should ap-
propriately consider all health out-
comes simultaneously. Although the 
guidelines are usually developed by 
committees and are presumably bet-
ter than judgements of individuals, 
collective biases and external influ-
ences can lead to recommendations 
that are not optimal. Thus, dietary 
guidelines are now being evaluated 
by determining whether adherence 
to them is actually associated with 
lower risk of cancer or other health 
outcomes [7]; this is a practice that 
should continue, to optimize our 
guidance. Although education alone 
often has modest impacts on behav-
iours, it is fundamentally important, 
in part because it can provide the 
foundation of support for more inten-
sive policies, such as taxation.
2. Food and menu labelling
Labelling is currently a topic of 
much debate and research that re-
quires integration of nutritional and 
behavioural sciences; the effects 
can be mediated by changes in con-
sumer choices and by motivating 
food suppliers to reformulate prod-
ucts or modify serving sizes. Given 
the importance of overweight and 
obesity, labelling of energy (caloric) 
content has been a major focus; the 
impacts of this are not yet clear, and 
continued research is needed.
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3. Economic strategies
These include taxation and subsi-
dies. Increasing the prices of soda 
has a clear effect on consumption 
[8] and for this reason has been 
fought by the powerful beverage in-
dustry. Taxes on soda can be read-
ily justified because the true costs 
of consumption to others, such as 
the health consequences, have not 
been internalized in the price. The 
scientific evidence base to support 
soda taxation has become much 
more solid in the past several years, 
and this should be pursued vigor-
ously as a public health strategy.
4. Promoting or limiting 
availability
Limiting sales of tobacco has been 
an effective strategy, and this inter-
vention is now becoming increas-
ingly used for food and soda. In 
many places, soda is now no longer 
available in schools, and the city of 
Boston, USA, does not allow the 
sale of soda on any city property. 
Like tobacco, sale of soda in hospi-
tals and other health-care facilities 
has become irrational, and is thus 
increasingly being eliminated in the 
USA. On the other hand, subsidies 
for whole grains, fruits, and vegeta-
bles can remove an important barri-
er to access for low-income popula-
tions and will promote consumption.
5. Fortification
Fortification has been an effective 
nutritional strategy to address many 
conditions, such as rickets, pellagra, 
goitre, and more recently congenital 
neural tube defects. Until now, this 
strategy has not been used specifi-
cally for cancer prevention, and con-
cerns have even been raised that 
folic acid fortification for prevention 
of neural tube defects may have in-
creased incidence of colorectal can-
cer. However, the concordance in 
time between increases in screening 
for colorectal cancer by colonosco-
py and folic acid fortification almost 
certainly accounts for an apparent 
increase in incidence [9]. Other evi-
dence suggests that additional folic 
acid may reduce incidence of colo-
rectal cancer with a latency of more 
than 10 years. At this time, there is 
not sufficient evidence to support 
fortification specifically for cancer 
prevention, but this might become 
an option if data suggesting a ben-
efit for vitamin D in reducing cancer 
risk become stronger.
6. Banning
We have a long regulatory history 
of banning specific food additives 
or colouring agents because of po-
tential human carcinogenicity, and 
more recently partially hydrogen-
ated oils have been banned in many 
countries, cities, and states because 
of their effects on cardiovascular 
disease. Banning whole foods or 
beverages is more difficult, and the 
experience of the USA with banning 
alcohol was notably unsuccessful. 
Short of absolute bans, a limit on the 
serving size of soda has been im-
plemented in New York City and is 
being considered elsewhere, and a 
proposal to limit the amount of sugar 
added to beverages has been sug-
gested. These strategies deserve 
consideration and evaluation.
Multisectoral approach for 
control of obesity
The rapid increases in obesity glob-
ally have led many organizations to 
develop strategies for controlling the 
epidemic. Because multiple factors 
contribute to unhealthy diets and 
inactivity, it is clear that interven-
tions to address single aspects of 
the problem will have modest im-
pacts, and multiple approaches will 
be needed. In most situations ac-
tions will be needed in the following 
sectors:
• schools and childcare settings;
• health-care facilities and systems;
• worksites;
• the food environment (to ensure 
availability and affordability of 
healthy food);
• the built environment (to promote 
physical activity);
• mass media (which is usually used 
to promote obesogenic foods);
• the economic sector (including 
taxes and subsidies, but also the 
analysis of cost and cost-effec-
tiveness of interventions).
Strategic plans encompassing 
the above-mentioned sectors can 
be developed at almost every level, 
from global to national to local com-
munities. The most effective level 
will vary depending on political re-
alities; many of these actions would 
be most effective on a national level, 
but in the USA, political gridlock and 
the powerful influences of the food 
and beverage industries often make 
national actions impossible. Thus, 
progress is frequently much easier 
at the city or state levels, where ex-
ternal influences may be less.
Indicators of effectiveness
Unlike smoking, for which some can-
cers are almost specific, nutritional 
factors are primarily associated with 
cancers that have many causes, so 
it will be difficult to evaluate effec-
tiveness of interventions by declines 
in cancer incidence. Instead, we will 
usually need to evaluate interven-
tions by changes in diet or activity or 
prevalence of overweight and obe-
sity. Some progress has been docu-
mented; in the USA, consumption 
of sugar-sweetened beverages has 
declined in recent years [8]. Also, 
in the past several years obesity 
rates among children have declined 
slightly in New York City and other 
cities where multilayered interven-
tions have been developed [10].
Conclusions
Continued research on diet, nutri-
tion, and cancer is needed to ex-
pand the scientific basis for future 
progress. However, evidence that 
overweight, obesity, and inactivity 
are causally related to cancer is suf-
ficient to justify strong public health 
actions to reduce these hazards. 
These actions are further justified 
by the many other adverse health 
effects of these risk factors. Multiple 
and increasingly intensive strategies 
will be needed to reverse the obesity 
epidemic, and actions are needed 
in many sectors and at all levels 
of society. We have now begun to 
see some evidence of success, but 
sustained efforts will be needed for 
many years.
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Summary
• Kidney cancer is most common 
in countries with higher levels of 
human development. 
• Most kidney cancers (70%) are 
clear cell renal carcinomas; 
related tumours are papillary 
(10–15%), chromophobe (about 
5%), and collecting duct (< 1%) 
renal cell carcinomas.
• Tobacco smoking is a cause of 
kidney cancer.
• Overweight and obesity are estab-
lished risk factors. Occupational 
exposure to trichloroethylene 
causes kidney cancer.
• Hypertension and acquired cys-
tic kidney disease with dialysis 
increase risk of renal cancer. 
Some renal cancer subtypes 
are associated with specific risk 
factors.
• Mutation or altered expression 
of the VHL gene has been ex-
tensively implicated in familial 
and spontaneous renal cell 
cancer.
• PBRM1 has been proposed as 
a second major clear cell renal 
carcinoma gene, with truncat-
ing mutations in about 40% of 
cases. Mutations in PBRM1 
and BAP1 anticorrelate, and 
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PBRM1 and BAP1 apparently 
regulate different gene expres-
sion programmes.
Most renal cancers are renal cell 
carcinomas, a heterogeneous class 
of tumours arising from different cell 
types within the renal parenchyma. 
Most are clear cell renal carcinomas 
(about 70% of renal cancer cases), 
followed by papillary (10–15%), chro-
mophobe (about 5%), and collecting 
duct (< 1%) renal cell carcinomas. 
Each of these renal cell tumour 
subtypes has distinct genetic char-
acteristics [1,2]. Other subtypes in 
the renal parenchyma include on-
cocytoma, which is a benign tu-
mour, and nephroblastoma (Wilms 
tumour), which occurs in children. 
Mesenchymal, mixed epithelial and 
mesenchymal, as well as other pri-
mary tumours or metastases are 
rare. The epidemiology of cancers 
of the renal pelvis differs from that 
of the renal parenchyma. Cancers 
of the renal pelvis are urothelial car-
cinomas and are similar to those of 
bladder urothelium.
Etiology
Lifestyle factors
Cigarette smoking causes renal 
cancer. Different meta-analyses con-
firmed that ever-smoking increases 
the risk of renal cancer compared 
with never-smoking [3,4]. There is 
also a dose-dependent increase in 
risk related to the number of ciga-
rettes smoked per day. Risk decreas-
es in the 5-year period after smoking 
cessation.
Using terminology adopted by 
the World Cancer Research Fund, 
there is convincing evidence that 
body fatness is a cause of kidney 
cancer. It is unlikely that coffee has 
a substantial effect, or that alcoholic 
drinks have an adverse effect, on the 
risk of this cancer [5]. Overweight, 
especially obesity, is a risk factor for 
renal cancer in both women and men 
[6]. The proportion of all cases of re-
nal cancer attributable to overweight 
and obesity has been estimated to 
be about 40% in the USA and up 
Fig. 5.9.1. The incidence of renal cell 
carcinoma increases significantly with in-
creasing body mass index, the most com-
mon measure of overweight and obesity.
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Epidemiology
Kidney cancer
• Kidney cancer is the ninth most 
common cancer in men (214 000 
cases) and the 14th most com-
mon in women (124 000 cases) 
worldwide in 2012; 70% of the 
new cases occurred in countries 
with high and very high levels of 
human development, with 34% 
of the estimated new cases 
in Europe and 19% in North 
America.
• There were an estimated 
143 000 deaths from kidney 
cancer in 2012 (91 000 in men, 
52 000 in women); kidney can-
cer is the 16th most common 
cause of death from cancer 
worldwide.
• The highest incidence rates are 
found in the Czech Republic. 
Elevated rates are also found in 
northern and eastern Europe, 
North America, and Australia. 
Low rates are estimated in much 
of Africa and East Asia.
• The case fatality rate is lower 
in highly developed countries 
(overall mortality-to-incidence 
ratio, 0.4) than in countries with 
low or medium levels of human 
development (0.5). Only 3.1% 
of the cases were diagnosed in 
Africa, but 5.7% of the deaths 
occurred in this region.
• Incidence and mortality rates 
have been increasing in many 
countries, across different lev-
els of human development.
Map 5.9.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for kidney cancer in men, 2012.
Map 5.9.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for kidney cancer in women, 2012.
to 40% in European countries [7,8]. 
The mechanisms by which obesity 
influences renal carcinogenesis 
are unclear. Sex steroid hormones 
may affect renal cell proliferation by 
direct endocrine receptor-mediated 
effects. Obesity with the combined 
endocrine disorders, such as de-
creased levels of sex hormone-
binding globulin and progesterone, 
insulin resistance, and increased 
levels of growth factors such as 
insulin-like growth factor 1 (IGF-1), 
may contribute to renal carcinogen-
esis. Recently, a case–control study 
has reported a stronger association 
of clear cell carcinoma with obesity.
Some case–control studies sup-
port a positive association between 
red meat intake and risk of renal 
cancer. The elevated risk of renal 
cancer is presumably due to the fat 
and protein content of meat. Several 
case–control studies found a protec-
tive effect of vegetables and fruits. 
However, the associations of meat 
and fruit with increased or reduced 
renal cancer risk are controversial [9]. 
There are studies showing an inverse 
association between alcohol intake 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.9.1. Estimated global number of new cases and deaths with proportions by major world regions, for kidney cancer 
in both sexes combined, 2012.
Chart 5.9.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for kidney cancer in 
men, circa 1975–2012.
Chart 5.9.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for kidney cancer in 
women, circa 1975–2012.
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and renal cancer risk [10]. Recent 
analyses of 13 prospective studies 
from North America and Europe 
found no association between intakes 
of red meat, processed meat, poultry, 
or seafood and renal cell carcinoma 
risk [9,11]. No histological subtype dif-
ferences were observed for associa-
tions with smoking, hypertension, or 
family history of kidney cancer [12].
Predisposing medical condi-
tions, use of pharmaceutical 
drugs, and hormonal and 
environmental factors 
Hypertension or its treatment has 
been associated with risk of renal 
cancer [13]. Use of hypertensive 
medication, including diuretics, has 
been associated with an elevated 
risk. The associations between risk 
of renal cancer and hypertension 
are independent of obesity. The 
biological mechanism for the asso-
ciation is not known. A few cohort 
studies have reported a significantly 
increased incidence of renal cancer 
among diabetic patients. However, 
diabetes may not be an independent 
risk factor because of its strong rela-
tion to obesity and hypertension [14]. 
Elevated levels of growth factors and 
growth factor receptors and insulin 
may mediate the possible relation-
ship between diabetes and renal 
cancer.
Acquired cystic kidney disease 
usually develops in patients on long-
term haemodialysis due to end-stage 
renal disease. The incidence of renal 
cancer is reported to be markedly 
increased in patients with end-stage 
disease (3–7%) [15]. Renal cancer 
occurring in end-stage renal disease 
has specific characteristics different 
from those of classic renal cancer. 
Papillary renal cell carcinoma was 
believed to be the most common 
subtype in end-stage renal disease. 
Currently, renal cancer associated 
with acquired cystic kidney disease 
is regarded as its own histological 
subtype, but all other subtypes (clear 
cell, papillary, and chromophobe re-
nal cell cancer) also occur in cystic 
and non-cystic end-stage kidneys. 
Potentially, renal hyperplastic cysts 
are the precursor lesions of some of 
these renal tumour types [16].
Phenacetin-containing analge-
sics are involved in the develop-
ment of urothelial cancer of the 
renal pelvis. Several studies have 
found also an elevated risk of re-
nal cancer with long-term use of 
phenacetin [17]. Among other an-
algesics, a few studies have found 
a positive association between 
acetaminophen – a metabolite 
of phenacetin – and renal cancer 
risk. There is also a potential risk of 
developing renal cancer for persons 
using non-aspirin, non-steroidal anti- 
inflammatory drugs (e.g. ibuprofen 
and naproxen). Aspirin and acet-
aminophen use were not associated 
with renal cell carcinoma risk [18].
Hormone-related factors have 
been suggested to play a role in 
renal cancer development, but 
several studies found no associa-
tions with use of oral contraceptives 
or hormone replacement therapy. 
Hysterectomy has been associ-
ated with increased risk of renal 
cancer in case–control studies 
[19]. The possible role of reproduc-
tive factors in renal cancer etiology 
remains poorly understood; cer-
tain hormone-related factors are 
associated with risk, but these as-
sociations cannot explain the lower 
incidence in women than in men.
Studies in Taiwan (China) and 
Chile have also linked arsenic in 
drinking-water with cancer of the 
kidney.
Occupation
Renal cell cancer is not considered 
an occupation-related cancer. There 
are associations with asbestos, gas-
oline and other petroleum products, 
lead, cadmium, and trichloroethy-
lene. Trichloroethylene is a solvent 
that has been widely used as a metal 
degreaser and chemical additive 
[20]. A meta-analysis of the associa-
tion between exposure to trichloro-
ethylene and clear cell renal cancer 
reported significant relative risks of 
kidney cancer: 1.3 overall and 1.6 
for high-exposure groups [21]. IARC 
has classified trichloroethylene as 
Group 1 (carcinogenic to humans) on 
the basis of causing kidney cancer; 
the determination involved relevant 
epidemiological data, together with 
carcinogenicity of the solvent in both 
rats and mice. Biotransformation of 
trichloroethylene, well character-
ized in humans and animals, occurs 
Fig. 5.9.2. A boy collects rainwater for drinking and cooking near an arsenic-contam-
inated tube well in a village in Rajbari District, Bangladesh. Arsenic in drinking-water 
causes cancers of the bladder, lung, and skin; a positive association has been observed 
between such exposure to arsenic and cancers of the kidney, liver, and prostate.
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primarily through oxidative metabo-
lism by cytochrome P450 enzymes, 
resulting in the generation of geno-
toxic metabolites [22].
Pathology
Clear cell renal cell carcinomas 
have a very vascular tumour stroma, 
frequently resulting in haemorrhagic 
areas [2]. The typical yellow tumour 
surface is due to the lipid content of 
the cells; cholesterol, neutral lipids, 
and phospholipids are also abundant 
(Figs 5.9.3, 5.9.4). Most renal cell 
carcinomas have little inflammatory 
response, but sometimes an intense 
lymphocytic or neutrophilic infiltrate 
with natural killer cells is present, 
and there is an association between 
a strong lymphocytic infiltration and 
worse outcome. Clear cell renal 
cell carcinomas most commonly 
metastasize haematogenously via 
the vena cava primarily to the lung.
Papillary renal cell carcinomas 
are characterized by epithelial 
cells forming papillae and tubules. 
Chromophobe renal cell carcinoma 
is distinguished by large polygonal 
cells with reticulated cytoplasm and 
prominent cell membranes. Some 
cells are irregular and multinucle-
ated. Perinuclear halos are com-
mon. Collecting duct renal cell car-
cinoma is extremely aggressive, 
with frequent metastasis already at 
diagnosis. These tumours are usu-
ally located in the central region of 
the kidney. Histologically, collecting 
duct cancer is characterized by a 
tubulopapillary architecture with a 
characteristic desmoplastic stroma 
reaction.
Genetics
Heritable tumours
Although most renal carcinomas 
are sporadic, 2–4% have a familial 
cause. Several genetic diseases 
are associated with renal cancer 
[1]. The risk of renal cancer for a 
first-degree relative of a patient with 
renal cancer is increased about 
2-fold. Each of the common his-
tological subtypes of renal cancer 
has a corresponding familial cancer 
syndrome. Table 5.9.1 provides a 
complete list of syndromes known 
to be associated with kidney can-
cer risk. The most common ones 
include von Hippel–Lindau (VHL) 
syndrome, hereditary papillary renal 
cell carcinoma syndrome, heredi-
tary leiomyomatosis and renal cell 
carcinoma syndrome, and Birt–
Hogg–Dubé syndrome.
In VHL syndrome, patients de-
velop haemangioblastoma of the 
central nervous system, retinal 
angiomas, and phaeochromocy-
tomas. Renal cancer is found in 
40–50% of VHL mutation carriers. 
The VHL gene produces a protein 
that targets hypoxia-inducible fac-
tor, a transcription factor. Loss of 
function leads to accumulation of 
hypoxia-inducible factor and sub-
sequent upregulation of vascular 
endothelial growth factor and other 
factors that promote angiogenesis 
and tumour growth. The risk of de-
veloping kidney cancer associated 
with different germline VHL alleles 
correlates with the degree to which 
their protein products are impaired 
in their ability to regulate hypoxia-
inducible factor.
Hereditary papillary renal cell 
carcinoma is caused by activa-
tion of the c-MET proto-oncogene. 
Mutations lead to constitutive activa-
tion of the receptor, which promotes 
tumour growth. This syndrome is 
characterized by multifocal papil-
lary renal cell carcinomas. Patients 
with hereditary leiomyomatosis and 
Fig. 5.9.3. Clear cell renal cell carcinoma. 
Typical cross-section of yellowish, spheri-
cal neoplasm in the upper pole of the kid-
ney. Note the tumour in the dilated throm-
bosed renal vein (arrow). In addition, there 
is a benign renal angiomyolipoma in the 
lower pole with a characteristic yellow cut 
surface due to fat cells (asterisk).
Fig. 5.9.4. Microscopic appearance of clear cell renal cell carcinoma.
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Table 5.9.1. Hereditary renal cell tumours
Syndrome Gene (chromosome) Protein Tumour type
Extrarenal manifestations
Dermis Other organs
von Hippel–Lindau 
syndrome
VHL (3p25) pVHL Multiple, bilateral clear 
cell RCC, renal cysts
– Haemangioblastoma 
of retina/central 
nervous system, 
phaeochromocytoma, 
pancreatic/renal 
cysts, neuroendocrine 
tumours, epididymal/
parametrial cysts, 
tumours of the inner 
ear
Hereditary papillary 
RCC syndrome
c-MET (7p31) HGFR Multiple, bilateral 
papillary RCC (type 1)
– –
Hereditary 
leiomyomatosis and 
RCC syndrome
FH (1q42) FH Papillary RCC (non-
type 1)
Leiomyoma Uterine leiomyoma/
leiomyosarcoma
Familial papillary 
thyroid carcinoma
? (1q21) ? Papillary RCC, 
oncocytomas
Papillary thyroid 
carcinoma
Hyperparathyroidism–
jaw tumour syndrome
HRPT2 (1q25) Epithelial–stromal 
mixed tumours, 
papillary RCC
– Tumours of the 
parathyroid glands, 
fibro-osseous jaw 
tumours
Birt–Hogg–Dubé 
syndrome
BHD (17p11) Folliculin Multiple chromophobe 
RCC, oncocytomas, 
papillary RCC
Facial 
fibrofolliculoma
Pulmonary cysts, 
spontaneous 
pneumothorax
Tuberous sclerosis TSC1 (9q34) Hamartin Multiple, bilateral 
angiomyolipomas, 
lymphangioleiomy-
omatosis
Angiofibroma, 
subungual fibroma
Cardiac rhabdomyo-
ma, adenomatous pol-
yps of the small intes-
tine, pulmonary/renal 
cysts, cortical tubers, 
subependymal giant 
cell astrocytomas
TSC2 (16p13) Tuberin Rare clear cell RCC
Constitutional 
chromosome 3 
translocations
? (3p13-14) ? Multiple, bilateral clear 
cell RCC
– –
RCC, renal cell carcinoma.
renal cell carcinoma syndrome fre-
quently have cutaneous leimyomas, 
and women often have a history of 
hysterectomy for uterine leimyomas 
at an early age. These patients show 
specific papillary renal cell carcino-
mas. In this syndrome, the FH gene 
shows loss-of-function mutations.
Birt–Hogg–Dubé syndrome is 
caused by germline loss-of-function 
mutations of the BHD gene and is 
characterized by fibrofolliculomas, 
lung cysts, and a spectrum of renal 
carcinomas including chromophobe 
renal cell carcinomas and oncocyto-
mas. This syndrome has been cor-
related also with mutations in the 
folliculin tumour suppressor gene.
Spontaneous tumours
In sporadic renal cell carcinoma, 
there is a genotype–phenotype 
correlation. Clear cell renal cell car-
cinoma is characterized by a loss of 
chromosome 3p and alterations of 
the VHL tumour suppressor gene 
by mutation or hypermethylation. 
pVHL is a multifunctional protein 
and a substrate recognition subunit 
of a ubiquitin ligase complex that 
binds directly to hypoxia-inducible 
factor. Papillary renal cell carcino-
mas demonstrate frequent trisomy 
or polysomy of chromosome 7 and 
17. Interestingly, activating mutations 
of the c-MET oncogene on chromo-
some 7 are rare in the sporadic 
forms of papillary renal cell cancer. 
Chromophobe renal cell cancer is 
characterized by multiple cytogenet-
ic changes, including monosomies 
of chromosomes 1, 2, 5, 10, 13, 17, 
and 21.
The role of a particular VHL mu-
tation in trichloroethylene-induced 
malignancy has been highlighted. 
Model studies suggest that the 
mutation, P81S, may result in cells 
less likely to initiate apoptosis in 
response to a range of stimuli, and 
hence provide a pro-tumour benefit 
[23].
Results of exome sequenc-
ing are becoming available. One 
study based on 101 cases identi-
fied inactivating mutations in two 
genes encoding enzymes involved 
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in histone modification – SETD2, a 
histone H3 lysine 36 methyltrans-
ferase, and JARID1C (also known 
as KDM5C), a histone H3 lysine 4 
demethylase – as well as mutations 
in UTX (KMD6A), a histone H3 ly-
sine 27 demethylase [24]. A separate 
investigation resulted in the identi-
fication of the SWI/SNF chromatin 
remodelling complex gene PBRM1 
as a second major clear cell renal 
carcinoma cancer gene, with trun-
cating mutations in 92 of 227 cases 
(41%) (Fig. 5.9.5) [25]. More recently, 
whole-genome and exome sequenc-
ing and other investigations have 
identified several putative two-hit 
tumour suppressor genes, includ-
ing BAP1 [26]. The BAP1 protein, 
a nuclear deubiquitinase, is inacti-
vated in 15% of clear cell renal cell 
carcinomas. Mutations in BAP1 and 
PBRM1 are inversely correlated in 
tumours; BAP1 and PBRM1 regulate 
seemingly different gene expression 
programmes.
Recently, a survey of more than 
400 clear cell renal cell carcinomas 
using different genomic platforms 
identified 19 significantly mutated 
genes, of which the eight most ex-
treme were VHL, PBRM1, SETD2, 
KDM5C, PTEN, BAP1, MTOR, and 
TP53. The PI3K/AKT pathway was 
recurrently mutated. Widespread 
DNA hypomethylation was associ-
ated with mutation of SETD2; muta-
tions involving the SWI/SNF chro-
matic remodelling complex were also 
implicated [27].
Kidney cancer has been charac-
terized as a metabolic disease be-
cause many of the known genes as-
sociated with kidney cancer – VHL, 
MET, FLCN, TSC1, TSC2, TFE3, 
TFEB, MITF, FH, SDHB, SDHD, and 
PTEN – are involved in the cell’s abil-
ity to sense oxygen, iron, nutrients, 
or energy. Understanding the meta-
bolic basis of kidney cancer may en-
able the development of novel forms 
of therapy for this disease [28].
Prospects
The main avoidable causes of kid-
ney cancer include cigarette smok-
ing, obesity, and hypertension, rep-
resenting opportunities for primary 
prevention [29]. Recent studies have 
shown associations between spe-
cific renal tumour subtypes and es-
tablished risk factors, for example 
end-stage kidney disease or specific 
genetic syndromes. Based on a spe-
cific molecular background, novel tu-
mour entities will be recognized as 
new distinct epithelial tumours within 
the future WHO classification system 
[2]. Further reports of these entities 
are required to better understand 
the nature and behaviour of rare and 
highly unusual tumours. The num-
ber of biomarkers in renal cell car-
cinoma is extensive and can range 
from diagnostic biomarkers, aiding in 
the classification of different tumour 
entities, to prognostic biomarkers 
for use as tools to stratify patient 
cohorts [30]. Systemic treatment of 
renal cell carcinoma has changed in 
the past years, with the development 
of new agents that target complex 
molecular pathways regulating tu-
mour angiogenesis, cell prolifera-
tion, and survival [31]. Predictive 
biomarkers allow the choice of the 
appropriate therapy in patients who 
present with advanced disease. 
They provide information on which 
patients will be responsive or resis-
tant to a targeted therapy. However, 
there are currently no available renal 
cancer biomarkers with enough reli-
ability for treatment prediction [32]. 
Potential candidates for novel prog-
nostic/predictive biomarkers may 
include microRNA profiles, different 
proteins, and/or multigene/protein 
assays. More novel molecular analy-
sis is being used to identify specific 
molecular pathways involved in vari-
ous tumour types and may identify 
potential new therapeutic targets.
Fig. 5.9.5. PBRM1 somatic mutations. Representation of PBRM1 transcript; boxes indicate the positions of the bromodomains 1–6 
(BD1–BD6), the bromo-adjacent homology domains (BAH1, BAH2), and the high-mobility group domain (HMG). Relative positions 
of mutations are indicated by symbols: nonsense mutations (stars), missense mutations (dots), frameshift deletions (red triangles), 
frameshift insertions (black triangles), and in-frame deletions (green triangles). Splice-site mutations are not depicted.
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Summary
• Bladder cancer is the ninth most 
common cancer worldwide, and 
urothelial carcinoma is the most 
frequent histological type (> 90%). 
About 70–80% of patients are 
diagnosed with non-invasive and 
low-grade tumours.
• Tobacco smoking remains the 
most important cause of blad-
der cancer. Arsenic and some 
occupational exposures also 
cause bladder cancer. Chronic 
infection and inflammation asso-
ciated with Schistosoma haema-
tobium is a cause of squamous 
cell carcinoma of the bladder.
• Non-invasive and invasive 
cancers show distinct genetic 
profiles, reflecting different mo-
lecular pathways of develop-
ment. Low-grade non-invasive 
tumours frequently show acti-
vating mutations of the FGFR3 
gene, which encodes fibroblast 
growth factor receptor 3, and 
inactivation of multiple tumour 
suppressors at chromosome 9. 
High-grade and invasive dis-
ease is accompanied by a high 
degree of genetic instability, 
aneuploidy, and alterations of a 
multitude of tumour suppressor  
genes and oncogenes, often in-
cluding TP53.
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• Despite improvement in diagno-
sis and therapy, the likelihood 
of recurrence and progression 
to invasively growing tumours 
must be recognized. As many as 
50–70% of these tumours recur, 
and about 10–20% progress to 
muscle-invasive disease. Only 
30–40% of patients with mus-
cle-invasive cancers survive 
5 years or longer.
There are five major histological 
types of bladder cancer, including 
non-invasive and invasive urothelial 
carcinoma, as well as squamous 
cell carcinoma, adenocarcinoma, 
and small cell carcinoma. All sub-
types develop from the urothelium 
and show characteristic morphologi-
cal features. Invasive cancers often 
show mixed features including more 
than one phenotype.
Etiology
The most important known cause 
of bladder cancer is tobacco smok-
ing [1]. The risk of developing blad-
der cancer is increased 2–6-fold 
in smokers compared with never-
smokers. Black tobacco smoke (com-
mon in southern Europe and Latin 
America) contains higher levels of 
N-nitrosamines and aromatic amines 
and poses a risk that is about twice 
that posed by the blond tobacco that 
is typically smoked in the USA and 
northern Europe. Tobacco smoke 
contains aromatic amines such as 
4-aminobiphenyl and 2-naphthyl-
amine, which are human bladder 
carcinogens in the context of occu-
pational exposure.
Arsenic contamination in drink-
ing-water is proven to cause bladder 
Fig. 5.10.1. Villagers surround a shallow 
tube well in a village in Comilla District, 
Bangladesh. The pump is marked with 
red paint to indicate arsenic-contaminated 
drinking-water.
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Epidemiology
Bladder cancer
• With an estimated 430 000 
new cases and 165 000 deaths 
in 2012, bladder cancer is the 
ninth most frequent cancer 
worldwide (in both sexes) and 
the 13th most common cause 
of cancer death.
• Incidence and mortality rates 
are elevated in North America, 
Europe, North Africa, the 
Middle East, and Australia and 
New Zealand. Rates tend to be 
rather low in many African and 
Asian countries and some Latin 
American countries.
• Incidence rates vary 10-fold 
between geographical regions, 
and 72% of the new cases oc-
curred in countries that have at-
tained high or very high levels of 
human development. Incidence 
and mortality rates in men are 
commonly 2–4 times those 
seen in women.
• Trends in bladder cancer inci-
dence are difficult to interpret 
without precise information on 
how cancer registries have dealt 
with papillomas over time. There 
have generally been declines in 
incidence and mortality in de-
veloped countries, but some ris-
ing trends have been observed 
in eastern Europe and in cer-
tain countries in developmental 
transition.
• While smoking- and occupation-
related urothelial bladder cancer 
tends to be the dominant form 
of bladder cancer in developed 
countries, squamous cell car-
cinomas are common in the 
Middle East and parts of Africa, 
as a result of chronic infection 
with Schistosoma haematobium.
Map 5.10.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for bladder cancer in men, 2012.
Map 5.10.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for bladder cancer in women, 2012.
cancer, particularly in parts of South-
East Asia. There is evidence that 
disinfection by-products – most typi-
cally, chemicals generated by water 
chlorination – could increase the risk 
of the disease [2]. Bladder cancer, 
along with cancers of the lung and 
skin, has been widely recognized 
as an occupational disease. Male 
precision metalworkers and met-
alworking machine operators, au-
tomobile mechanics, plumbers, 
workers in electronic components 
manufacturing, and landscape 
industry workers have signifi-
cantly elevated risks, increasing 
with the duration of employment. 
Historically, occupational exposure 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.10.1. Estimated global number of new cases and deaths with proportions by major world regions, for bladder 
cancer in both sexes combined, 2012.
Chart 5.10.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for bladder cancer 
in men, circa 1975–2012.
Chart 5.10.3. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for bladder cancer 
in women, circa 1975–2012.
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to aromatic amines was established 
as a causative agent for much oc-
cupational bladder cancer; more re-
cently, specific causative agents have 
been difficult to identify, but exposure 
to metalworking fluids is strongly im-
plicated [3].
Chronic inflammation of the 
bladder is a major risk factor, espe-
cially for squamous cell carcinomas. 
Chronic infection with the parasitic 
trematode Schistosoma haemato-
bium causing schistosomiasis has 
been associated with bladder cancer 
development in endemic countries, 
with a 2–15-fold increased risk of 
cancer in infected compared with 
non-infected subjects. Continuous 
mucosal irritation and chronic inflam-
mation from, for example, indwelling 
catheters or Schistosoma infection, 
can cause squamous metaplasia, 
dysplasia, and eventually squamous 
cell carcinomas of the bladder. 
Patients with long-term paraplegia 
are at markedly elevated risk for this 
tumour type due to chronic bladder 
infection.
Recent genome-wide association 
studies have identified multiple chro-
mosomal regions of which alterations 
are linked to the risk of developing 
bladder cancer [4]. Polymorphisms 
of the NAT2 and GSTM1 metabolic 
genes have emerged as the most 
consistent findings; the NAT2 slow 
acetylator phenotype is linked with 
a 2–3-fold increased risk of bladder 
cancer in former or current heavy 
smokers, and with a 1.3–1.5-fold in-
creased risk in patients with inacti-
vation of one of two GSTM1 alleles. 
Other recurrently identified candidate 
susceptibility loci include the urea 
transporter SLC14A1 and the pros-
tate stem cell antigen (PSCA) gene.
Pathology and genetics
The most important element in 
pathological evaluation of bladder 
cancer is recognition of the pres-
ence and extent of invasion. Non-
invasive tumours are restricted 
to the urothelial cell layers and 
do not penetrate the lamina pro-
pria. The current classification 
of non-invasive neoplasms of 
the bladder includes four groups: 
(i) papillary urothelial neoplasms of 
low malignant potential, which are 
characterized by an excellent prog-
nosis and often not identified as 
“cancer”, (ii) non-invasive papillary 
urothelial carcinomas (low-grade), 
(iii) non-invasive papillary urothelial 
carcinomas (high-grade), and (iv) 
flat carcinoma in situ. Invasive tu-
mours are subdivided according to 
the depth of invasion.
The nomenclature of bladder 
cancer was previously confusing 
because non-invasive and minimally 
invasive bladder tumours had been 
combined into the subgroup of “su-
perficial bladder cancers”, which was 
distinguished from the subgroup of 
“invasive bladder cancers”, a term 
Fig. 5.10.2. Urothelial carcinoma of the 
bladder. Transurethral biopsy.
Fig. 5.10.3. Putative model of bladder cancer development and progression, based on 
genetic findings. Thick arrows indicate the most frequent pathways, and dotted lines 
the rarest events. CIS, carcinoma in situ; NIHGC, non-invasive papillary urothelial 
carcinoma (high-grade); NILGC, non-invasive papillary urothelial carcinoma (low-grade); 
pT1, primary tumour, stage 1; pT2-4 primary tumour, stage 2–4; PUNLMP, papillary 
urothelial neoplasm of low malignant potential.
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restricted to muscle-invasive tu-
mours. Most non-high-grade non-
invasive papillary bladder carcinomas 
rarely progress to invasive cancer, 
and most invasive bladder cancers 
are not preceded by a non-invasive 
papillary carcinoma.
Bladder urothelial carcinoma
These tumours constitute more than 
90% of invasive bladder cancers 
and can exhibit either a papillary or 
a solid growth pattern. There is no 
single characteristic morphological 
or immunohistochemical feature that 
is specific for urothelial carcinoma. 
Therefore, unequivocal diagnosis of 
urothelial carcinoma relies on iden-
tification of precursor lesions such 
as carcinoma in situ. The histology 
of invasive urothelial carcinoma is 
highly variable. These carcinomas 
often contain areas of divergent 
differentiation.
Urothelial carcinoma consti-
tutes two genetically distinct sub-
groups with marked differences in 
their degree of genetic instability 
(Fig. 5.10.3). The first category in-
cludes the genetically stable tumours: 
papillary urothelial neoplasms of low 
malignant potential, non-invasive 
papillary urothelial carcinomas (low-
grade), and probably more than half 
of non-invasive papillary urothelial 
carcinomas (high-grade). The sec-
ond category (genetically unstable 
cancers) includes carcinoma in situ, 
about half of non-invasive papillary 
urothelial carcinomas (high-grade), 
and invasively growing cancers. Non-
invasive papillary urothelial carcino-
mas account for 70–80% of all blad-
der cancers and are characterized 
by a papillary tumour growth pattern 
and cells showing mild or moderate 
atypia.
Papillary urothelial neoplasms of 
low malignant potential and non-inva-
sive papillary urothelial carcinomas 
(low-grade) are characterized by few 
genomic alterations, typically includ-
ing partial or complete deletions of 
chromosome 9 as well as mutation 
of the FGFR3 growth factor receptor 
[5,6]. Chromosome 9 losses occur in 
about 50% of tumours, and at compa-
rable frequency also in tumours of all 
other grades and stages. Since chro-
mosome 9 deletions are also found 
in hyperplasia and normal-appearing 
urothelium, chromosome 9 aberra-
tions are seen as early key events 
in bladder cancer development. The 
frequent loss of the entire chromo-
some 9 suggests that multiple tumour 
suppressor genes on 9p and 9q might 
be jointly inactivated by one genetic 
event. Two tumour suppressor genes 
have been identified at chromosome 
9p21: the cell-cycle control genes 
CDKN2A (p16/p14ARF) and CDKN2B 
(also known as p15 INK4B or p15).
Additional tumour suppressor loci 
have been mapped to 9q, including 
the tuberous sclerosis 1 (TSC1) gene 
at 9q34 and the deleted in bladder 
cancer 1 (DBC1) gene at 9q32-q33. 
Deletion and mutation of TSC1 have 
been reported to occur in more than 
50% and in 15% of bladder cancers, 
and inactivation of this gene results 
in the loss of mTOR-mediated control 
of cell growth. The putative tumour 
suppressor DBC1 is often affected 
by homozygous deletions, although 
hypermethylation has been suggest-
ed as one of the earliest events in 
bladder cancer development. FGFR3 
mutations occur in 80–90% of papil-
lomas. In neoplastic lesions, the frac-
tion of FGFR3 mutations is inversely 
correlated with tumour stage and 
grade: FGFR3 mutations are pres-
ent in more than 60% of low-grade 
non-invasive tumours, 35% of high-
grade non-invasive tumours, 25% 
of minimally invasive (pT1) cancers, 
and 16% of muscle-invasive (pT2–4) 
cancers [7]. Gene amplifications 
and TP53 mutations are rare. DNA 
aneuploidy occurs in less than 50% 
of cases.
Invasive urothelial carcinomas 
differ markedly from non-invasive 
low-grade cancers. They are ge-
netically unstable, often exhibiting 
high-level amplifications and TP53 
mutations. Aneuploidy is strongly as-
sociated with tumour stage and grade 
and is found in more than 90% of cas-
es. Earlier studies reported frequent 
deletions involving chromosomes 2q, 
5q, 8p, 9p, 9q, 10q, 11p, and 18q and 
the Y chromosome, as well as gains 
of 1q, 5p, 8q, and 17q. In addition, 
high-level amplifications are frequent 
in these cancers. The most frequent 
amplification sites occurring in more 
than 10% of high-grade/invasive can-
cers include 11q13, the locus of the 
cyclin-dependent kinase 1 (CCND1) 
gene; 6p22, with the transcription 
factor gene E2F3; and 17q21, which 
harbours the human epidermal 
growth factor receptor 2 (HER2) gene 
(Table 5.10.1).
Methylation studies have re-
vealed – as for other cancers – that 
invasive bladder cancers exhibit a 
plethora of differentially methylated 
areas with hypermethylation in pro-
moter regions and hypomethylation 
in the gene body [8,9]. Genes sus-
pected to be dysregulated through 
methylation include 14-3-3 sigma, 
SYK, CAGE-1, PTEN, FOXO1, 
MAPK1, and PDK1, as well as vari-
ous HOX family transcription factors, 
inactivation of which has been linked 
to aggressive forms of the disease. 
Several microRNAs are differentially 
expressed in urothelial carcinomas, 
including miR-10a, miR-21, miR-30b, 
Fig. 5.10.4. An outdoor leather tannery in 
Fez, Morocco. Men work in the vats curing 
and dying leather from camels, cattle, and 
goats. Skins are first dipped in lye, then 
washed and placed in sulfuric acid. The 
solvents used in the tanning process have 
been associated with an increased risk of 
bladder cancer.
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Table 5.10.1. The most frequent chromosomal aberrations found in larger studies of bladder cancer (≥ 50 tumours analysed)
Aberration Chromosome arm
Non-invasive Invasive 
(pT1–4)
Peak of gain 
(amplification) or 
deletiona
Candidate 
gene(s)bLow-grade High-grade
Gains 1q 13% 17% 11% 1q21.2 (35%) SETDB1
2p 8–30% 10% 2p25 (10%)
3p 10% 3p25 (10–12%) RAF1
3q 1% 5% 10–25% 3q26 (10%) PIK3CA
4p 5% 4p16 (5%)
5p 2% 28% 25% 5p15 (1–25%) TRIO, SKP2
6p 1–5% 28% 16–24% 6p22 (3–25%) E2F3
7 5% 5% 10–20%
8p 8p11-p12 (2–4%) FGFR1
8q 5–10% 20% 20–50% 8q21 (4–7%)8q24 (1–33%)
TPD52
MYC
10p 3% 5% 10–20% 10p11-p14 (2–15%) MAP3K8
11q 5% 15% 20% 11q13 (10%) CCND1
12p 1% 5% 5%
12q 1–15% 5% 5–30% 12q13-q15 (3–5%) MDM2CDK4
16p 5% 16p13 (5%)
16q 5% 16q22 (5%)
17q 10–30% 33% 10–50% 17q12-q21 (10–20%) HER2, TOP2A
18p 10% 18p11 (1–10%) YES1
19q 10% 19q13 (2%) CCNE
20q 7–15% 33% 20–30% 20q11 (25%) BCL2L1
Deletions 2q 4–5% 39% 17–30% 2q36 (25%) CUL3
4p 2–5% 22% 10–30%
4q 1–10% 17% 10–30%
5q 4–20% 33% 16–30%
6q 1–10% 33% 19% 6q21-q24 (5%)
8p 5–15% 28% 30% 8p11-p12 (30%)
9p 36–45% 45% 31–47% 9p21 (30–50%) CDKN2A
9q 45% 38% 23–47% 9q34 (30–50%) DBC1
10q 5% 28% 18–28% 10q23 (20%)10q26 (30%)
PTEN
11p 10% 17% 24–43%
11q 6% 23% 22–34% 11q23 (10%)
13q 0–20% 17% 19–29% 13q14 (20%) RB1
14q 1% 10% 14q23-q24 (10%)
15q 8% 15q15 (8%)
16p 8%
16q 8% 16q13-q21 (8%)
17p 1–5% 11% 19–24% 17p13 (24%) TP53
18q 7–10% 39% 13–30% 18q21 (10%)
Y 10–20% 28% 15–37%
pT1–4, primary tumour, stage 1–4.
a In invasive cancers.
b Candidate oncogenes for gains, candidate tumour suppressor genes for deletions.
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miR-31, miR-100, miR-141, miR-143, 
mi-145, miR-192, miR-195, miR-
200a/b/c, miR-205, miR-452, and 
miR-708, and some of these have 
been linked to invasive growth or 
poor prognosis. Such findings em-
phasize the potential of microRNA 
measurements for diagnostic pur-
poses. Large-scale next-generation 
sequencing studies are lacking so far, 
but anecdotal reports on druggable 
FGFR fusions in bladder cancers 
have already suggested that these 
powerful new methods have the po-
tential to significantly advance our 
knowledge of bladder cancer.
Only few studies have analysed 
genetic changes in carcinoma in situ 
and in those high-grade non-inva-
sive papillary urothelial carcinomas 
with a particularly high degree of 
atypia (pTaG3). FGFR3 mutations, 
which are frequently found in papil-
lomas and papillary urothelial neo-
plasms of low malignant potential, 
are virtually absent in carcinoma 
in situ, whereas TP53 mutations, a 
hallmark of muscle-invasive bladder 
cancer, can frequently be found in 
carcinoma in situ already. The pat-
tern of deletions and amplifications 
found was similar to that of invasive 
cancers [10].
Bladder squamous cell 
carcinoma
These tumours account for about 
2–5% of all bladder cancers and 
represent a cancer with histologi-
cally pure squamous cell phenotype, 
sometimes accompanied by kerati-
nizing squamous metaplasia in the 
adjacent flat epithelium. There do 
not appear to be major differences 
between muscle-invasive urothelial 
carcinomas and schistosomiasis-as-
sociated squamous cell carcinomas. 
Frequent cytogenetic alterations in-
clude gains of 5p, 6p, 7p, 8q, 11q, 
17q, and 20q as well as deletions of 
4q, 5q, 8p, 13q, 17p, and 18q. Other 
key alterations of urothelial carci-
noma, such as mutation of TP53 
or overexpression of EGFR and 
HER2, are also found at compara-
ble frequencies in squamous cell 
carcinomas.
The genetics of non-schistoso-
miasis-associated squamous cell 
carcinomas indicate alterations not 
markedly different from those in 
muscle-invasive urothelial carcino-
mas. Differences may exist in ex-
pression levels. One study reported 
differential expression of keratin-10 
and caveolin-1 between the two 
subtypes [10], and a more recent 
validation of cytokeratin expression 
revealed a pattern of CK5/6 positiv-
ity and CK5/14 positivity plus CK20 
negativity and uroplakin negativity 
that identifies squamous cell differ-
entiation [11]. A particularly high in-
cidence of 14-3-3 gene methylation, 
but relatively infrequent methylation 
of the SKY gene, was reported for 
squamous cell carcinomas com-
pared with urothelial cancers, and 
loss of expression of both genes has 
been suggested to contribute to the 
aggressive clinical behaviour of non-
urothelial bladder tumours [12].
Bladder adenocarcinoma
Adenocarcinomas constitute less 
than 2% of all bladder cancers and 
are derived from the urothelium, 
showing a pure glandular pheno-
type. The growth pattern is variable, 
with enteric (colonic), signet ring cell, 
mucinous, clear cell, hepatoid, and 
mixed types.
Most adenocarcinomas found in 
bladder biopsies (90%) represent 
tumours of another origin infiltrating 
the bladder, such as adenocarcino-
mas of the prostate, colon, or ovary. 
Molecular data on pure primary ad-
enocarcinomas of the bladder are 
rare. Few cases of adenocarcinoma 
have been analysed cytogenetically, 
revealing a spectrum of chromosom-
al alterations that seemed similar to 
that found in urothelial carcinomas. 
An early study on 8 schistosomiasis-
associated adenocarcinomas report-
ed deletions of 3p, 4p, 4q, 9p, 9q, 
17p, 8p, 11p, and 18q [13]. In another 
series of 13 adenocarcinomas, 4 car-
ried mutations of the TP53 tumour 
suppressor [14], an alteration that is 
also frequently (30–50%) found in 
invasive urothelial carcinomas. More 
recently, epigenetic analysis identi-
fied frequent promoter methylation 
of the 14-3-3 and CAGE-1 genes in 
10 non-schistosomiasis-associated 
adenocarcinomas and 6 signet ring 
cell carcinomas [15].
Bladder small cell carcinoma
These tumours, accounting for about 
1% and 3% of all bladder cancers 
in men and women, respectively, 
are malignant neuroendocrine neo-
plasms that histologically mimic their 
pulmonary counterparts. All small 
cell cancers are invasive at diagno-
sis and typically appear as a large 
solid mass of small, uniform cells. 
About 50% of cancers have areas 
of urothelial carcinoma and, in rare 
cases, squamous cell carcinoma 
and/or adenocarcinoma.
Classic cytogenetic and mo-
lecular cytogenetic studies report 
frequent gains and losses at the 
same chromosomal loci often af-
fected in muscle-invasive urothelial 
carcinomas. The most frequent ab-
errations include deletions at chro-
mosomes 3p25-p26 (VHL), 4q, 5q, 
9p21 (p16), 9q32-q33 (DBC1), 10q, 
13q, and 17p13 (TP53) as well as 
gains at 5p, 6p, 8q, and 20q. High-
level amplifications affect 1p22-p32, 
3q26.3 (PIK3CA), 8q24 (MYC), and 
12q14-q21 (MDM2, CDK4). In ad-
dition, promoter methylation and 
expression studies suggested that 
silencing of the tumour suppres-
sors RASSF1, MLH1, DAPK1, and 
MGMT might contribute to the malig-
nant behaviour of small cell bladder 
cancers [16]. Recent genetic studies 
demonstrate transition from urothe-
lial carcinoma to small cell carci-
noma during the course of tumour 
progression. For example, identical 
patterns of loss of heterozygosity at 
five polymorphic loci and inactiva-
tion of the same copy of the X chro-
mosome were seen in the urothe-
lial and the small cell component, 
suggesting a common clonal origin 
[17]. In addition, identical point mu-
tations of TP53 were found in the 
invasive small cell component and 
in the urothelial in situ carcinoma, 
suggesting that small cell carcinoma 
might develop from in situ carcinoma 
of the bladder [18].
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Prospects
Prevention
Cessation of smoking is the most 
effective measure for prevention of 
bladder cancer. Intervention in re-
lation to proven or likely workplace 
exposures will prevent occupational 
bladder cancer, particularly in rela-
tion to work practices in low-income 
countries. Avoidance of arsenic-con-
taminated drinking-water should also 
be implemented. For squamous cell 
carcinoma, avoidance of infestation 
with Schistosoma haematobium is 
an effective intervention.
Screening
Attempts to perform population-
based screening have not been suc-
cessful due to the low incidence of 
bladder cancers and the low speci-
ficity (and sensitivity) of tests [19,20].
Targeted therapies
Urothelial carcinoma is one of the 
most heterogeneous cancer types. 
Molecular heterogeneity may com-
promise the efficiency of targeted 
drugs in this malignancy. Several 
drugs targeting genes frequently al-
tered in bladder cancer have exhib-
ited disappointing efficacy compared 
with other cancer types. Thus, in ad-
vanced bladder cancer, addition of 
gefitinib to cisplatin and gemcitabine 
did not improve response rates or 
survival [21]. In another phase II study 
(ClinicalTrials.gov: NCT00380029), 
neoadjuvant administration of anoth-
er EGFR inhibitor, erlotinib, showed 
some beneficial effects. Although 
mostly heterogeneous, HER2 over-
expression and amplification is found 
in about 10–30% of advanced blad-
der cancers. In a clinical trial investi-
gating the effects of combining che-
motherapy (paclitaxel, carboplatin, 
and gemcitabine) with trastuzumab, 
there was a 73% response rate and a 
median survival of 15.2 months [22]. 
Targeting FGFR3 – which is frequent-
ly mutated, particularly in low-grade 
non-invasive bladder cancers – has 
shown encouraging results in multi-
ple myeloma and bladder cancer cell 
lines [23]. At present, phase II clini-
cal trials are under way for several 
additional novel targeted agents, in-
cluding bevacizumab and aflibercept, 
which target VEGF, and the multiple 
tyrosine kinase inhibitors sunitinib, 
sorafenib, and lapatinib.
The prevalence and co-occur-
rence of actionable genomic alter-
ations in patients with high-grade 
bladder cancer have been assessed 
to underpin therapeutic drug discov-
ery [24]. Of the tumours examined, 
61% harboured potentially actionable 
genomic alterations. A core pathway 
analysis of the integrated data set 
revealed a non-overlapping pattern 
of mutations in the RTK/RAS/RAF 
(Fig. 5.10.5) and PI3K/AKT/mTOR 
signalling pathways and regulators 
of G1–S cell-cycle progression. The 
findings suggested that optimal de-
velopment of target-specific agents 
will require pre-treatment genomic 
characterization.
Fig. 5.10.5. Co-occurrence of alterations within the RTK/RAS/RAF signalling pathway 
in high-grade bladder cancer. Incidence (%) of amplifications, deletions, and mutations 
of selected receptor tyrosine kinases and downstream targets. The heat map (bottom) 
compares the distribution of each alteration across tumour samples.
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Summary
• Prostate cancer is the second 
most common cancer in men 
worldwide. Risk factors for pros-
tate cancer are age, family his-
tory, and race.
• Prostate cancers are mainly ad-
enocarcinomas and are indolent 
in many men, but there is also 
a lethal form. Gleason histo-
logical grade, serum prostate-
specific antigen (PSA) level, and 
stage are significant prognostic 
indicators.
• Recurrent protein-altering muta-
tions are rare in prostate can-
cer and are most often seen in 
the androgen receptor, PTEN, 
AKT1, and TP53 genes, usually 
in advanced-stage disease.
• Testicular cancer mostly affects 
young men. Risk factors include 
cryptorchidism, a prior testicu-
lar germ cell tumour, a family 
history of germ cell tumour, an-
drogen insensitivity syndrome, 
and gonadal dysgenesis with a 
Y chromosome.
• Testicular cancers are typically 
germ cell neoplasms, with his-
topathological classification into 
seminomatous and non-semino-
matous types, which has clinical 
significance. Testicular cancer is 
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a very curable malignancy, even 
after metastatic spread.
• Single gene mutations are un-
common in testicular germ cell 
tumours, but KIT, TP53, KRAS/
NRAS, and BRAF are the genes 
most commonly mutated and im-
plicated in pathogenesis.
Prostate cancer
Prostate cancer in most cases is 
acinar adenocarcinoma, a glandular 
malignancy. Primary sarcomas and 
other types of malignancy do arise 
in the prostate gland, but are rare.
Etiology
The major identified risk factors for 
development of prostate cancer are 
age, family history, and race. Age is 
strongly related to the detection of 
prostate cancer, either clinically or 
at autopsy. The incidence of pros-
tate cancer rises extremely steeply 
with age. Clinically, carcinoma of 
the prostate is most often detected 
in men older than 60 years. The 
likelihood of detection is nearly 40 
times greater for men older than 
65 than for men younger than 65. 
Only about 1% of prostate cancers 
are detected in men younger than 
50 years. Prostate cancer in chil-
dren is rare and is almost always 
rhabdomyosarcoma.
A man with a family history of 
prostate cancer has a significantly 
higher risk than one without such a 
history [1]. About 25% of men with 
prostatic carcinoma have a known 
family history [2]. The degree of 
risk is related to the age of the rela-
tives at diagnosis and the number of 
relatives affected. Men with either 
a father or a brother with a diagno-
sis of prostate cancer have an ap-
proximately 2–3 times greater risk 
of developing prostate cancer than 
men without a family history of the 
disease. The greatest risk, with an 
11-fold increase, is that for the father 
or the brother of a man diagnosed 
at about age 40 with prostate can-
cer, with an additional first-degree 
relative who has prostate cancer. 
Genetic factors clearly make a ma-
jor contribution to prostate cancer 
susceptibility, as highlighted by a 
twin cohort study indicating that 42% 
of prostate cancer cases exhibited 
heritable risk [3].
The role of race and ethnicity in 
prostate cancer etiology has been 
most intensively investigated in the 
USA, where the African American 
population is 1.6 times more likely 
to develop prostate cancer than the 
Caucasian population. Adjustment 
for recognized environmental, so-
cioeconomic, and health-care fac-
tors does not fully account for this 
difference. 
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Epidemiology
Prostate cancer
• Globally, prostate cancer is the 
second most frequently diag-
nosed cancer and the fifth most 
common cause of cancer death 
among men, with an estimated 
1.1 million new cases (15% of all 
cancers in men) and 0.3 million 
cancer deaths (7% of all cancer 
deaths in men) in 2012.
• In 2012, 60% of the estimated 
new cases and 41% of the 
deaths occurred in Europe and 
North America.
• Mortality rates are highest in 
countries and areas with pre-
dominantly Black populations – 
in the Caribbean and in parts 
of sub-Saharan Africa – but 
mortality rates are also high 
in certain northern European 
countries, such as the Nordic 
countries.
• Incidence rates of prostate 
cancer vary by more than 
25-fold in different parts of the 
world. The highest rates are 
in Australia and New Zealand 
(111.6 per 100 000), northern 
and western Europe, and North 
America.
• Prostate cancer was the most 
frequent type of cancer among 
men in 84 countries worldwide 
in 2012, largely in countries that 
have attained high or very high 
levels of human development, 
but also in several countries in 
Central and Southern Africa.
• Incidence rates increased dra-
matically in the late 1980s in 
North America as prostate-
specific antigen (PSA) testing 
became available; a similar pat-
tern developed in many of the 
highest-resource countries dur-
ing the 1990s. Incidence rates 
have levelled off in some of 
these countries but continue to 
uniformly increase in countries 
transitioning towards higher lev-
els of human development.
Map 5.11.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for prostate cancer, 2012.
Map 5.11.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for prostate cancer, 2012.
• Mortality rates, which histori-
cally increased with incidence, 
began to decrease in the 1990s 
in some of the highest-resource 
countries, likely as a result of a 
combination of curative treat-
ment and earlier detection of the 
disease.
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
Chapter 5.11 • Cancers of the male reproductive organs 455
5 
O
R
G
A
N
 S
IT
E
C
H
A
P
TE
R
 5
.1
1
Chart 5.11.1. Estimated global number of new cases and deaths with proportions by major world regions, for prostate 
cancer, 2012.
Chart 5.11.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for prostate cancer, 
circa 1975–2012.
Chart 5.11.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for prostate cancer, 
circa 1975–2012.
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Testicular cancer
• Testicular cancer is a relatively 
rare cancer overall but a com-
mon malignancy among young 
adult men (aged 15–39 years) 
in the most developed settings. 
Hence, while it is the 21th most 
frequently occurring cancer in 
men globally, with 55 000 new 
cases estimated in 2012 for all 
ages, it is by far the most com-
mon cancer in young men in 
countries that have attained 
high or very high levels of hu-
man development.
• Incidence rates of testicular 
cancer vary at least 25-fold 
in different parts of the world. 
The highest incidence rates are 
found in Caucasian populations 
in Europe (notably in Denmark, 
Norway, and Switzerland), Aus- 
tralia and New Zealand, and 
North America. Incidence rates 
are lowest in South-East Asia 
and throughout Africa.
• In 2012, 55.2% of all new cases 
of testicular cancer occurred in 
Europe and North America, but 
only 20.3% of the deaths. The 
fatality rate is one of the low-
est of all forms of cancer, al-
though it is considerably higher 
in countries classified as having 
low or medium levels of human 
development.
• Over the past 50 years, tes-
ticular cancer incidence rates 
have uniformly increased in 
many countries with predomi-
nantly Caucasian populations, 
and incidence appears to have 
peaked in several countries with 
the highest rates. In contrast, 
mortality rates have declined in 
line with improvements in treat-
ment, notably with the introduc-
tion of cisplatin therapy.
Map 5.11.3. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for testicular cancer, 2012.
Map 5.11.4. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for testicular cancer, 2012.
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Chart 5.11.4. Estimated global number of new cases and deaths with proportions by major world regions, for testicular 
cancer, 2012.
Chart 5.11.5. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for testicular cancer, 
circa 1975–2012.
Chart 5.11.6. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for testicular cancer, 
circa 1975–2012.
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Molecular factors that distinguish 
between races and are possibly 
causally related to the difference 
in incidence include the hormonal 
milieu of the tumour (with genetic 
mutations contributing to a higher 
dihydrotestosterone-to-testosterone 
ratio), decreased apoptosis due to 
lower BCL-2 levels, and overexpres-
sion of epidermal growth factor re-
ceptor [4]. Prostate cancer risk loci 
at 8q24 and 17q21 appear to be 
more frequent in men of African de-
scent; together, these two loci could 
explain up to 60% of the increased 
risk in men of African descent [4].
Probable risk factors for prostate 
cancer include diet and nutrition, and 
hormonal factors [5]. A diet typical 
of industrialized countries has been 
proposed to be an important risk 
factor for prostate cancer, given the 
large worldwide variation in the in-
cidence of prostate cancer and the 
increased risk in migrants and their 
offspring who move from low-risk 
to high-risk countries. Dietary and 
saturated fat, red/processed/grilled 
meat, and milk and dairy products 
may increase risk, whereas toma-
toes/lycopene, fish/marine omega-3 
fatty acids, soy, and cruciferous 
vegetables (such as broccoli, cau-
liflower, and Brussels sprouts) may 
decrease risk [5]. Studies on vitamin 
E are equivocal, and a large random-
ized intervention trial with vitamin E 
and selenium, the SELECT trial, did 
not demonstrate reduced prostate 
cancer incidence. Data on calcium 
and zinc are conflicting. Vitamin D 
intake does not seem to be related 
to prostate cancer risk. Vitamin A as 
β-carotene in vegetable sources is 
not consistently associated with risk.
Hormonal influences on pros-
tate cancer risk include androgens, 
the androgen receptor, and the 
insulin-like growth factor axis. The 
importance of androgens is sub-
stantiated by clinical trials on use 
of 5α-reductase inhibitors (e.g. fin-
asteride, dutasteride), which block 
the conversion of testosterone to the 
more active molecule in the prostate, 
dihydrotestosterone. These trials 
demonstrated a decrease in low-
grade prostate cancer incidence 
[6]. Circulating testosterone level is 
not, however, associated with pros-
tate cancer risk. Short CAG repeats 
in the androgen receptor gene – a 
structural variation that increases 
its activity – have been connected 
in some, but not all, studies with 
a higher risk of prostate cancer. 
Finally, circulating levels of insulin-
like growth factor, a polypeptide hor-
mone that increases cell proliferation 
and decreases apoptosis of prostate 
cells, are associated with increased 
prostate cancer risk.
Lifestyle factors including physi-
cal activity, cigarette smoking, and 
alcohol consumption have not been 
definitively linked to prostate cancer 
risk. Obesity does not appear to be 
linked to total prostate cancer inci-
dence, but it may be associated with 
the development of advanced-stage 
or fatal prostate cancer [5].
No infection has been defini-
tively linked to the development of 
prostate cancer, although there is 
a suggestion from two studies that 
Trichomonas vaginalis infection may 
be associated with an increased risk 
of prostate cancer, especially more 
aggressive disease [5]. Findings on 
the retrovirus XMRV, despite initial 
excitement, do not support a role for 
it in the etiology of prostate cancer 
[7]. Inflammation in the prostate is 
very common, and several separate 
lines of research, including epidemi-
ological, genetic, histopathological, 
molecular pathological, and animal 
studies, have pointed towards a po-
tential role for inflammation in pros-
tate carcinogenesis [8].
Cholesterol levels may have a 
role in prostate cancer risk. Lower 
total cholesterol is associated with 
a lower risk of high-grade prostate 
cancer, and use of statins, which 
lower serum cholesterol, may be 
Fig. 5.11.1. Few, if any, exogenous causes of prostate cancer have been clearly es-
tablished. Accordingly, old age is recognized as one of a very limited number of proven 
risk factors. Prostate cancer is most common in North America, northern and western 
Europe, and Australia and New Zealand.
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related to a lower risk of all prostate 
cancers and advanced or high-grade 
prostate cancer.
Pathology
Adenocarcinoma of the prostate 
is thought to arise most commonly 
from a precursor proliferation known 
as high-grade prostatic intraepithe-
lial neoplasia, which is an in situ 
proliferation of neoplastic prostatic 
epithelial cells (Fig. 5.11.2) [9]. The 
initial phase of the natural history of 
prostatic adenocarcinoma is growth 
into prostatic stroma. Of note, the 
prevalence of prostate cancer at au-
topsy, i.e. latent prostate cancer, is 
extremely high and increases with 
age. Rare latent cases are detected 
in the third decade, and it is of inter-
est that there is a frequency of about 
30% in the fourth and fifth decades 
in the USA. There is variation of the 
frequency of latent prostate cancer 
depending on the world region, with 
the highest frequency in industrial-
ized countries. Pathologically, most 
of these latent cancers are small and 
well differentiated, but a small minor-
ity of latent prostate cancers are of 
a similar grade, size, and stage to 
clinical prostate cancer.
For clinical prostate cancer, a 
pathological diagnosis of malig-
nancy is most often made based 
on light microscopic examination 
of fine-needle aspirates, sections 
of prostate needle biopsy tissue 
(Fig. 5.11.3), or sections of prostatic 
chips from transurethral resection 
of the prostate. Performance of 
an 18-gauge needle biopsy of the 
prostate is a common clinical ap-
proach when the patient has a pal-
pable prostatic nodule and/or an 
elevated serum prostate-specific 
antigen (PSA) level.
Key histological features of ma-
lignancy include an abnormal archi-
tectural growth pattern of the glands 
(Fig. 5.11.4), loss of basal cells, and 
nuclear atypia. The growth patterns 
depicted in Fig. 5.11.4 indicate the 
Gleason grade of the tumour, which 
is one of the most powerful prognos-
tic indicators for men with clinically 
localized prostate cancer. An ad-
ditional histopathological finding of 
clinical importance in needle biopsy 
tissue is the extent of the cancer. 
Gleason histological grade, serum 
PSA level, clinical stage, and extent 
of cancer in needle core tissue are 
often used to stratify patients with 
clinically localized cancer as to risk 
for aggressive disease and for man-
agement/treatment considerations.
The local spread of prostatic 
adenocarcinoma is into peripros-
tatic adipose tissue, the bladder 
neck, and the seminal vesicles. 
Such direct extension of the cancer 
is diagnosed in radical prostatec-
tomy specimens, and it is the light 
microscopic examination of these 
tissue sections that allows for as-
signment of pathological stage, 
Gleason grade in the whole gland, 
and surgical margin status, which 
are significant indicators of clinical 
outcome. Metastasis of prostatic ad-
enocarcinoma is mainly to the pelvic 
lymph nodes and to bone; for bone, 
the radiological and histological 
picture is typically of osteoblastic 
metastasis.
Genetics
The molecular genetics of prostate 
cancer may be separated into genet-
ic susceptibility in the germline and 
the genetics of established sporadic 
tumours. Susceptibility has been in-
vestigated in high-risk men identified 
with reference to African American 
heritage or familial disease. Genetic 
variants associated with prostate 
cancer susceptibility include more 
than 30 single-nucleotide polymor-
phisms identified by genome-wide 
association studies, with replicated 
single-nucleotide polymorphisms 
most often located in the 8q24 re-
gion [10]. However, these single-
nucleotide polymorphisms together 
account for only an estimated 25% 
Fig. 5.11.2. Prostatic intraepithelial neo-
plasia. There is a proliferation of neoplastic 
epithelial cells in pre-existing glands.
Fig. 5.11.4. Gleason grading diagram, 
modified version. This diagram displays 
the different growth patterns of adenocar-
cinoma of the prostate. Pattern 1 is the 
lowest grade and the least aggressive ad-
enocarcinoma, while pattern 5 is the high-
est grade and the most aggressive. The 
Gleason score is the sum of the grades for 
the two most common patterns.
Fig. 5.11.3. Adenocarcinoma of the pros-
tate in needle core tissue. This is an infil-
trative small gland malignancy.
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of familial risk. A susceptibility locus 
that appears to be specific to men 
of African descent has been identi-
fied at 17q21. Mutations in several 
specific susceptibility genes, includ-
ing RNASEL/HPC1, ELAC2/HPC2, 
MSR1, and HOXB13, have been 
identified. These highly penetrant 
genes from high-risk families likely 
account for only a small fraction of 
the genetic predisposition to pros-
tate cancer.
Another approach to suscepti-
bility has involved whole-genome 
sequencing of 1795 Icelanders. A 
new low-frequency variant at 8q24 
associated with prostate cancer in 
European populations was iden-
tified. This variant was only very 
weakly correlated with previously 
reported risk variants at 8q24, and 
its association remained significant 
after adjustment for all known risk-
associated variants [11].
The molecular genetic profile 
of established prostate cancer is 
characterized by structural genomic 
changes in oncogenes and tumour 
suppressor genes such as NKX3.1 
and PTEN, and amplification of the 
androgen receptor and MYC genes 
[12]. The prostate cancer genome 
undergoes frequent large-scale 
genomic rearrangements, including 
a common rearrangement produc-
ing ETS gene fusions. Although 
several ETS and non-ETS family 
members have been observed to 
be fused with TMPRSS2 or other 5′ 
fusion partners, most fusions involve 
TMPRSS2-ERG. In contrast, recur-
rent protein-altering mutations are 
rare in prostate cancer and are most 
often seen in the androgen recep-
tor, PTEN, AKT1, and TP53 genes, 
usually in advanced-stage disease. 
A molecular diversity model, where 
a wide range of possible pathways 
exist, has been proposed as a basis 
for pathological and genetic progres-
sion of prostate cancer (Fig. 5.11.5) 
[13].
Metastatic castration-resistant 
prostate cancer has been the subject 
of specific investigation. One study 
[14] reported low overall mutation 
rates even in such tumours subject 
to intensive therapy and confirmed 
the monoclonal origin of lethal dis-
ease. The analysis identified disrup-
tions of CHD1 that defined a subtype 
of ETS gene family fusion-negative 
prostate cancer. ETS2, which was 
deleted in approximately one third of 
metastatic castration-resistant pros-
tate cancers, was also dysregulated 
through mutation. Furthermore, re-
current mutations in multiple chro-
matin and histone modifying genes 
were evident, including MLL2 (mutat-
ed in 8.6% of prostate cancers), as 
was interaction of the MLL complex 
with the androgen receptor, which is 
required for androgen receptor-me-
diated signalling. There were novel 
recurrent mutations in the androgen 
receptor collaborating factor FOXA1.
Prospects
The most immediately applicable 
prevention strategies could include 
increased physical activity, intake of 
tomatoes and other foods contain-
ing lycopene, intake of foods con-
taining selenium, and avoidance 
of diets high in calcium. Hence, it 
would seem beneficial to empha-
size a diet consisting of a wide va-
riety of plant-based foods and fish. 
Chemoprevention with pharmaceu-
tical agents is not recommended at 
this time.
Screening for prostate cancer is 
controversial. Screening with serum 
PSA level has increased detection of 
all prostate cancers, including indo-
lent prostate cancers. PSA emerged 
as one of the most-used serum tests 
to screen for cancer, particularly in 
the USA but also in Europe. Recent 
Fig. 5.11.5. Two models of prostate cancer progression: a linear model compared with 
a molecular diversity model. In the molecular diversity model, not all pathways result in 
progression. Accumulation of molecular alterations associated with aggressive disease, 
such as the overexpression of EZH2 or PTEN mutations, may lead to invasive disease 
that progresses to metastatic disease, whereas other lesions, such as those with 5q or 
6q gain and overexpression of AZGP1, might be seen most often in indolent disease. 
Mutations and alterations associated with p53 and the androgen receptor (AR) are 
probably late events and may play a key role in the development of castration-resistant 
disease. SNP, single-nucleotide polymorphism.
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data from the Prostate, Lung, Colon, 
and Ovarian Cancer Screening Trial 
showed no benefit to screening, and 
the European Randomized Study 
of Screening for Prostate Cancer 
showed a 20% reduction in relative 
risk of cancer-specific mortality, 
which translated into an absolute 
reduction of prostate cancer-related 
deaths of 0.71 per 1000. Each trial 
has criticisms that may or may not 
have affected power and outcome, 
although the rate ratios comparing 
screening to not screening are simi-
lar. Definitive evidence for or against 
screening is still lacking [15].
The detection via screening of 
both clinically significant and poten-
tially clinically insignificant prostate 
cancer has created a dilemma as to 
which patients should receive aggres-
sive treatment [16]. Overtreatment of 
screen-detected tumours is a major 
concern. In the USA, most men with 
screen-detected cancers undergo 
aggressive treatment. Such treat-
ment is unlikely to yield a survival 
benefit in those with indolent disease 
or in men older than 65 years, but it 
can result in a considerable decrease 
in quality of life as a result of poten-
tially persistent urinary, sexual, and 
bowel dysfunction [16].
Active surveillance of such low-
risk disease is one strategy that 
could potentially counteract some of 
this overtreatment and has shown 
favourable outcomes in carefully se-
lected patients. However, the criteria 
for enrolment into an active surveil-
lance programme are not standard-
ized [17]. Inclusion criteria typically 
include low serum PSA level, low 
clinical stage, low Gleason grade 
(typically, Gleason score 6 or less), 
and a relatively small amount of 
cancer in needle core tissue [17]. 
Molecular markers in needle biopsy 
tissue hold promise for further re-
finement in identification of patients 
with potentially indolent versus ag-
gressive prostate cancer, and could 
help to stratify patients into active 
surveillance versus active treatment 
protocols.
Therapeutic targeting of prostate 
cancer based on genetic alterations 
is challenging since there are few 
recurrent genetic mutations. One 
promising target is the ETS gene 
fusions, seen in about one half of 
all prostate cancers [13].
Prostate cancer clinical biomark-
ers of benefit are under active inves-
tigation. Recent trials in patients with 
castration-resistant prostate cancer 
have incorporated the detection 
of circulating tumour cells, imag-
ing, and patient-reported outcome 
biomarkers including pain and 
elevated PSA level [18]. Application 
of any such putative biomarkers will 
require a series of prospectively de-
signed studies with adequate statisti-
cal support to demonstrate a clinical 
effect within a well-defined context.
Testicular cancer
Testicular cancer is in most cases a 
germ cell neoplasm. Sex cord stro-
mal tumours and lymphomas may 
also involve the testis but are dis-
tinctly uncommon.
Etiology
Established risk factors for tes-
ticular germ cell tumours include 
cryptorchidism, a prior testicular 
germ cell tumour, a family history of 
germ cell tumour, and various inter-
sex syndromes such as androgen 
insensitivity syndrome (testicular 
feminization) and gonadal dysgen-
esis with a Y chromosome [19,20]. 
Cryptorchidism carries about a 
4-fold increased risk of germ cell 
tumour development. Patients with 
a history of testicular germ cell tu-
mour have an increased incidence of 
contralateral testicular cancer, with 
an incidence of 2–5%, which trans-
lates into a 5–10-fold increased risk.
A small minority of testicular 
cancers appear to be familial, with 
approximately 2% of patients hav-
ing an affected family member. First-
degree male relatives of patients with 
testicular germ cell tumour have a 
3–10-fold increased risk of being di-
agnosed with testicular cancer. The 
mode of transmission is not known 
but may be autosomal recessive in 
nature [20]. Patients with androgen 
insensitivity syndrome have a 15-
fold increased risk of developing a 
testicular germ cell tumour, while the 
risk increase is 50-fold for patients 
with gonadal dysgenesis with a Y 
chromosome.
Several prenatal factors, includ-
ing maternal endogenous estrogen 
levels, and low birth weight have 
been suggested as risk factors, but 
the data are inconclusive [20]. One 
hypothesis is that in utero exposure 
to exogenous estrogens could result 
in increased risk of testicular cancer 
due to increased cryptorchidism and 
testicular dysgenesis. Several post-
natal factors, such as body size (es-
pecially height), nutrition, chemical 
exposure, occupation, infection, and 
physical activity, have been hypoth-
esized to be potentially associated 
with testicular cancer, but the data 
appear mixed [20]. The peak age at 
diagnosis (twenties and thirties) ap-
pears related to sex hormone activ-
ity and may reflect promotion of cells 
initiated during gestation. Finally, mi-
grant studies suggest the importance 
of as-yet-uncharacterized environ-
mental/dietary factors. For example, 
the incidence of testicular cancer in 
Finland is half that found in Sweden, 
and second-generation Finnish mi-
grants to Sweden have a testicular 
cancer incidence that approaches 
that of the Swedish population.
Pathology
The precursor for all types of germ 
cell tumours that originate in the 
post-pubertal testis is intratubular 
germ cell neoplasia. This lesion is 
seen in about 4% of cryptorchid tes-
tes, in approximately 5% of testes 
Fig. 5.11.6. Intratubular germ cell neo-
plasia in the testis. This is a precursor for 
most testicular cancers.
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contralateral to a testis with a germ 
cell tumour, and almost always adja-
cent to an invasive germ cell tumour. 
Histologically, intratubular germ cell 
neoplasia is characterized by the 
presence of large atypical germ 
cells inside seminiferous tubules 
(Fig. 5.11.6), which often have a 
thickened basement membrane. 
Cytologically, intratubular germ cell 
neoplasia cells often resemble 
seminoma cells. Most patients with 
isolated intratubular germ cell neo-
plasia develop an invasive germ cell 
tumour within 7 years. For patients 
with gonadal dysgenesis with a Y 
chromosome, gonadoblastoma acts 
as the in situ precursor proliferation.
Invasive germ cell tumours are 
broadly classified using histopatho-
logical criteria as seminomatous 
versus non-seminomatous [21]. 
Microscopically, classic seminoma 
comprises a solid growth of primi-
tive-appearing cells, separated by 
fibrous bands infiltrated by lym-
phocytes (Fig. 5.11.7). In infants 
and children, yolk sac tumour and 
teratoma are the most common 
histological types. Of note, pre-
pubertal teratomas are benign, 
whereas post-pubertal teratomas 
are malignant. In adults, pure semi-
nomas account for about 50% of all 
testicular germ cell tumours. Non-
seminomatous germ cell tumour 
types include embryonal carcino-
ma, yolk sac tumour, trophoblastic 
tumours (mainly choriocarcinoma), 
and teratoma. Mixed malignant 
germ cell tumours composed of dif-
ferent germ cell types are common, 
representing 30% of all testicular 
cancers. For these mixed tumours, 
the presence of embryonal carci-
noma and the percentage of the tu-
mour that is embryonal carcinoma 
are important prognostic indicators.
In addition to histological type, 
important histopathological attri-
butes of germ cell tumours in radi-
cal orchiectomy specimens include 
pathological stage and presence 
of lymphovascular invasion by the 
germ cell tumour. Serum tumour 
marker levels are important in stag-
ing and patient management and 
correlate with specific cell/tumour 
types. α-Fetoprotein is produced 
mainly by yolk sac tumours, whereas 
β-human chorionic gonadotropin is 
produced by syncytiotrophoblasts 
in choriocarcinoma and syncytio-
trophoblasts seen in seminoma with 
syncytiotrophoblasts or mixed malig-
nant germ cell tumours.
Testicular germ cell tumours 
spread by lymphatics, first to retro-
peritoneal para-aortic lymph nodes 
and then to mediastinal and supra-
clavicular lymph nodes. Haema- 
togenous dissemination is primar-
ily to the lungs, but the liver, brain, 
and bones may be involved. Clinical 
stage is critical in defining treatment 
and prognosis.
Genetics
Recently reported genome-wide 
association studies implicate six 
gene loci that predispose to testicu-
lar germ cell tumour development. 
These include KIT ligand (KITLG; 
also known as SCF), SPRY4, BAK1, 
TERT, ATF7IP, and DMRT1. KITLG, 
SPRY4, and BAK1 are involved in 
KIT signalling, TERT and ATF7IP 
maintain telomere length and are re-
activated in a range of tumour types, 
and DMRT1 is responsible for male 
sex determination [20,22]. Multiple 
new susceptibility loci for testicular 
germ cell tumours continue to be re-
ported [23,24].
The genetics of established pae-
diatric and adult germ cell tumours 
are distinct [19]. Paediatric tumours 
are mostly diploid, particularly tera-
tomas, and typically show deletion of 
1p, loss of 6q, and structural abnor-
malities of chromosome 2 and 3p. 
In contrast, invasive adult germ cell 
tumours are consistently aneuploid 
with gain of chromosomal material 
on 12p, usually in the form of iso-
chromosome 12p.
Parallels between the origin of 
testicular germ cell tumours and 
malignant ovarian germ cell tu-
mours have been considered with 
reference to germ cell develop-
ment, endocrinological influences, 
and pathogenesis [25]. The basis of 
analysis was genomic aberrations 
assessed by ploidy, cytogenetic 
banding, and comparative genomic 
hybridization.
The development of intratubu-
lar germ cell neoplasia may involve 
an aberrantly activated KITLG/KIT 
pathway and overexpression of em-
bryonic transcription factors such 
as NANOG and POU5F1, which 
leads to suppression of apoptosis, 
increased proliferation, and accu-
mulation of mutations in gonocytes. 
Single gene mutations are uncom-
mon in testicular germ cell tumours, 
but KIT, TP53, KRAS/NRAS, and 
BRAF are the genes most com-
monly mutated and implicated in 
pathogenesis. Different histologi-
cal subtypes of testicular germ cell 
tumours have different gene expres-
sion profiles, which reflect different 
directions of differentiation. Their 
distinct gene expression profiles are 
likely caused by epigenetic regula-
tion, in particular DNA methylation, 
but not by gene copy number alter-
ations [26].
Prospects
Prevention of testicular germ cell 
neoplasia is not currently feasible. 
There are no reliable screening tests 
for these cancers. Testicular self-
examination has not been shown to 
improve outcomes but is still advo-
cated by some medical professional 
organizations. Such examination 
may be more beneficial in men at 
increased risk of testicular cancer, 
including men with a history of crypt-
orchidism, testicular atrophy, or a 
family history of testicular cancer. 
Most patients present with a nodule 
or painless swelling of one gonad, 
or a painful testis, so these clinical 
Fig. 5.11.7. Seminoma of the testis, with 
large primitive neoplastic cells.
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findings should prompt evaluation. 
A systematic review of options for 
testicular cancer screening con-
cluded that no published random-
ized controlled trial of screening 
compared with no screening had 
established reduced testicular can-
cer-specific mortality [27].
There is a high cure rate for 
testicular germ cell neoplasia, us-
ing multidisciplinary management. 
The 5-year survival rates for men 
with localized disease, regional 
spread, and distant metastasis are 
99%, 96%, and 72%, respectively. 
For patients with intermediate- and 
poor-prognosis germ cell tumours, 
identification of molecular mecha-
nisms of therapy resistance and 
development of novel molecularly 
targeted therapeutic approaches 
are important goals.
464
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Summary
• Cancer of the vulva accounts 
for 3% of all female genital can-
cers and it mainly includes two 
different types of carcinomas. 
Keratinizing carcinomas pre-
dominate in older women and 
have little association with hu-
man papillomavirus (HPV) infec-
tion. Conversely, the majority of 
warty and basaloid carcinomas 
are caused by HPV.
• Cervical cancer, the fourth most 
common cancer among women 
worldwide, with about 70% of 
the cases occurring in develop-
ing countries, is caused by HPV. 
Precancerous lesions may be 
detected and treated; HPV vac-
cination offers the possibility of 
primary prevention. The most 
common somatic mutations 
were found for PIK3CA, and are 
associated with shorter survival.
• More than 80% of endometrial 
cancers occur as endometrioid 
carcinomas, a form that is as-
sociated with estrogen expo-
sure; obesity is estimated to 
account for up to 40% of cases 
worldwide. Principal genetic le- 
sions include microsatellite in-
stability and mutations of the 
PTEN, PIK3CA, ARID1A, KRAS, 
and CTNNB1 (β-catenin) genes, 
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whereas TP53 and PPP2R1A 
mutations, loss of E-cadherin, 
HER2/neu amplification, and 
loss of heterozygosity at multiple 
loci occur in non-endometrioid 
carcinomas.
• Ovarian cancer comprises sev-
eral tumour types, including the 
predominant (70%) high-grade 
serous carcinomas, which ex-
hibit TP53 mutations and BRCA 
abnormalities and are distin-
guished from low-grade serous 
carcinomas (< 5%), which usu-
ally exhibit KRAS and BRAF 
mutations. Endometrioid and 
clear cell carcinomas of the 
ovary have the same genetic 
abnormalities as their uterine 
counterparts. Most mucinous 
carcinomas involving the ovary 
are metastatic tumours from the 
gastrointestinal tract.
Vulvar cancer
Cancer of the vulva accounts for 3% 
of all female genital cancers and 
occurs mainly in women older than 
60 years. Squamous cell carcinoma 
is the most common type (86%). 
Fig. 5.12.1. A patient attends a counselling session with a service provider in the family 
planning unit at Orolodo primary health centre in Omuaran township in Kwara State, 
Nigeria.
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Epidemiology
Cervical cancer
• Cervical cancer is the fourth 
most common cancer (528 000 
new cases) and the fourth most 
common cause of cancer death 
(266 000 deaths) in women 
worldwide, as estimated in 
2012.
• The disease affects predomi-
nantly women in lower-resource 
countries; almost 70% of the 
global burden occurs in areas 
with low or medium levels of 
human development, and more 
than one fifth of all new cases of 
cervical cancer are diagnosed 
in India.
• Incidence rates of cervical can-
cer vary greatly from country to 
country. The disease is the most 
common cancer among women 
in 39 of the 184 countries world-
wide, and is the leading cause 
of cancer death in women in 
45 countries. These countries 
are mainly in sub-Saharan 
Africa, parts of Asia, and some 
countries in Central and South 
America.
• The lowest incidence rates 
tend to be in western Europe, 
North America, Australia and 
New Zealand, and the eastern 
Mediterranean.
• Over the past 30 years, cervi-
cal cancer rates have declined 
in many countries that are tran-
sitioning towards higher levels 
of human development. This 
trend reflects changing soci-
etal factors linked to economic 
Map 5.12.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for cervical cancer, 2012.
Map 5.12.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for cancer of the corpus uteri (endometrial cancer), 2012.
These tumours are divided into two 
groups: keratinizing squamous cell 
carcinomas, which have little asso-
ciation with human papillomavirus 
(HPV), and warty and basaloid carci-
nomas, which are strongly associated 
with high-risk HPV, mainly HPV16, 
and are increasingly often diagnosed 
in younger women in countries in 
which cervical screening is common.
Etiology
HPV infection causes a subset of 
squamous cell carcinomas of the 
vulva and vagina [1]. According to 
meta-analysis, HPV prevalence 
was 40.4% in vulvar carcinoma and 
69.9% in vaginal carcinoma [2]. Also 
strongly related to HPV are vulvar 
intraepithelial and vaginal intraepi-
thelial neoplasias. The meta-analysis 
supported the hypothesis that two 
distinct subsets of carcinomas of 
the vulva and vagina exist: one that 
is strongly associated with HPV and 
that may be preceded by high-grade 
lesions as cervical carcinoma, and 
another that arises independently of 
HPV infection [3].
HPV16 was found in more 
than three quarters of HPV-positive 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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progress but also points, in some 
countries, to the implementation 
of effective secondary prevention 
programmes.
• In contrast, rates are increasing 
in certain countries with high or 
very high levels of human devel-
opment, including several eastern 
European countries and former 
Soviet states. Recent changes in 
sexual behaviour have led to an 
increase in the risk of infection 
with high-risk human papilloma-
virus types in these populations, 
largely in the absence of effective 
screening programmes.
Cancer of the corpus uteri 
(endometrial cancer)
• Cancer of the corpus uteri (en-
dometrial cancer) is the sixth 
most common cancer in women 
(almost 5% of all cancers in wom-
en). There were an estimated 
320 000 new cases and 76 000 
deaths from the disease in 2012.
• Incidence rates vary 20–30-fold 
between countries; close to two 
thirds of the estimated new cas-
es occur in countries with very 
high or high levels of human 
development.
• Incidence rates are elevated in 
northern and eastern Europe 
and North America, and tend to 
be low in Africa and West Asia.
• About 48% of the new cases 
occurred in Europe and North 
America; 41% of the estimated 
new cases and 45% of the cancer 
deaths occurred in Asia.
Ovarian cancer
• With an estimated 239 000 new 
cases in 2012, ovarian cancer is 
the seventh most common cancer 
in women, representing 4% of all 
cancers in women.
• The fatality rate of ovarian cancer 
tends to be rather high relative to 
other cancers of the female repro-
ductive organs, and case fatality is 
higher in lower-resource settings. 
As a consequence, ovarian cancer 
is the eighth most frequent cause 
of cancer death among women, 
with 152 000 deaths.
• In 2012, almost 55% of all new 
cases occurred in countries with 
high or very high levels of human 
development; 37% of the new 
cases and 39% of the deaths 
occurred in Europe and North 
America.
• Incidence rates are highest in 
northern and eastern Europe, 
North America, and Oceania, and 
tend to be relatively low in Africa 
and much of Asia.
• Incidence rates have been de-
clining in certain countries with 
very high levels of human devel-
opment, notably in Europe and 
North America.
Map 5.12.3. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for ovarian cancer, 2012.
carcinomas of the vulva and vagina. 
Conversely, HPV18 was rarer in car-
cinomas of the vulva and vagina than 
in carcinoma of the cervix. HPV6 and 
11 were commonly detected in vulvar 
intraepithelial neoplasias but not in 
vaginal intraepithelial neoplasias [2].
There is substantial heteroge-
neity in HPV prevalence in vulvar 
squamous cell carcinomas. HPV 
prevalence was 69.4% in warty and 
basaloid carcinomas but only 13.2% 
in keratinizing carcinomas. HPV-
positive vulvar carcinomas occur in 
significantly younger women than do 
HPV-negative vulvar carcinomas [2], 
and HPV prevalence in vulvar carci-
nomas in North America was approxi-
mately twice that in other geographi-
cal regions [4], possibly attributable 
to enhanced surveillance of the vulva 
during cervical screening and some 
misclassification, together with higher 
HPV prevalence.
Risk factors for carcinomas of the 
vulva and vagina other than HPV in-
fection include sexual habits, smok-
ing, and immunosuppression [1]. 
Current HPV vaccines may prevent 
approximately 30% of vulvar carcino-
mas and 60% of vaginal carcinomas.
Precursor lesions
Two pathogenetic pathways, featur-
ing different precursor lesions, exist 
for vulvar squamous cell carcinomas, 
depending on HPV involvement.
Squamous intraepithelial lesions 
of the vulva are HPV-related in 90% 
of cases and range from low-grade 
vulvar intraepithelial neoplasia grade 
1 to the severe full-thickness dys-
plasia of high grade (grade 3) [5]. 
Patients are usually in their thirties 
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Chart 5.12.1. Estimated global number of new cases and deaths with proportions by major world regions, for cervical 
cancer, 2012.
Chart 5.12.2. Estimated global number of new cases and deaths with proportions by major world regions, for cancer of the 
corpus uteri (endometrial cancer), 2012.
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Chart 5.12.3. Estimated global number of new cases and deaths with proportions by major world regions, for ovarian cancer, 
2012.
Chart 5.12.4. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for cervical cancer, 
circa 1975–2012.
Chart 5.12.5. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for cancer of the 
corpus uteri (endometrial cancer), circa 1975–2012.
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or forties and often have multifocal 
or multicentric HPV-related disease 
[6,7]. Most low-grade lesions con-
tain low-risk HPV virus subtypes, 
whereas high-grade lesions contain 
high-risk subtypes, most commonly 
HPV16. The typical progression time 
from incident infection to clinical dis-
ease is 18.5 months [6]. Only about 
6% of high-grade lesions progress to 
invasive carcinomas, except in older 
or immunosuppressed women [7].
Patients with high-grade vulvar 
intraepithelial neoplasia of differen-
tiated or simplex type are usually 
postmenopausal and often have li-
chen sclerosus or lichen simplex 
chronicus [8]. Differentiated vulvar 
intraepithelial neoplasia is more likely 
(33%) to progress to invasive carcino-
ma than corresponding HPV-related 
disease [9]. In one study comparing 
the association of the two types of 
vulvar intraepithelial neoplasia with 
invasive carcinoma, the rates were 
24.2% for HPV-related grade 3 vulvar 
intraepithelial neoplasia and 83.3% 
for the corresponding differentiated 
lesions [6].
Pathology and genetics
Whereas low-grade squamous in-
traepithelial neoplasia is a rare di-
agnosis [6], high-grade disease is 
divided into warty and basaloid sub-
types. Warty lesions show a spiky or 
undulating surface. The thickened 
epithelium forms wide, deep rete 
pegs separated by thin dermal pa-
pillae. Hyperkeratosis is prominent. 
In contrast to warty lesions, basaloid 
lesions show a flat surface and a uni-
form population of immature cells. 
Keratinocytes undergo premature 
keratinization, and rete pegs often 
contain keratin pearls.
Superficially invasive squamous 
cell carcinoma is the earliest stage 
(stage IA) of invasive vulvar cancer 
and has an excellent prognosis [10]. 
Most invasive carcinomas of the vul-
va arise in a background of lichen 
sclerosus with or without differenti-
ated vulvar intraepithelial neoplasia. 
Tumours are frequently exophytic, 
but some may be ulcerative. Vulvar 
carcinomas are composed of inva-
sive nests of malignant squamous 
epithelium with central keratin pearls 
(Fig. 5.12.2). HPV-related tumours 
typically occur in younger patients 
and tend to have a similar morphol-
ogy [3,6]. Vulvar carcinomas grow 
slowly, extending to contiguous skin, 
vagina, and rectum. They metasta-
size initially to inguinal and femoral 
lymph nodes, and subsequently to 
pelvic lymph nodes [11].
Differentiated vulvar intraepithe-
lial neoplasia shows overexpression 
of p53 in the basal and suprabasal 
epithelial layers [7]. Cases of lichen 
sclerosus, differentiated vulval in-
traepithelial neoplasia, and invasive 
squamous cell carcinoma with iden-
tical TP53 mutations have been re-
ported [8]. TP53 mutation, however, 
is an uncommon and late event in 
vulvar carcinogenesis. Of greater 
utility in the diagnosis of high-grade 
squamous intraepithelial lesions is 
p16INK4A; as a reliable marker of high-
risk HPV [10], it is strongly positive 
throughout the epithelium [12].
Cervical cancer
Cervical cancer originates at the 
junction between the columnar epi-
thelium of the endocervix and the 
squamous epithelium of the ectocer-
vix, a site of continuous metaplastic 
change, especially at puberty and 
from after the first pregnancy until 
menopause. Persistent epithelial in-
fection with one or more oncogenic 
types of HPV may lead to the devel-
opment of precancerous lesions, a 
small proportion of which may prog-
ress to invasive cervical cancer over 
a period of 10–20 years [1].
Etiology
HPV infection is the most common 
sexually transmitted infection world-
wide, and the majority of sexually 
Chart 5.12.6. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for ovarian cancer, 
circa 1975–2012.
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active individuals of both sexes ac-
quire it at some time during their 
life. About 291 million women world-
wide have HPV infection of the cer-
vix at any time, corresponding to a 
prevalence of 10.4%, although the 
prevalence is higher among women 
younger than 25 years (16.9%) [13].
High HPV prevalence occurs in 
countries where the burden of cervi-
cal cancer is high (Fig. 5.12.3), i.e. in 
sub-Saharan Africa, Latin America, 
and India, but also in countries like 
Mongolia and China. Large differ-
ences in age-specific HPV preva-
lence are evident in several less-
developed countries (India, China, 
and African countries) [14]. More 
than 90% of new HPV infections at 
any age regress over 6–18 months 
[15]. Low-grade squamous intra-
epithelial lesions, also known as 
cervical intraepithelial neoplasia 
Fig. 5.12.3. Age-adjusted prevalence (percentage) of cervical human papillomavirus (HPV) DNA in sexually active women aged 
15–69 years in various countries.
Fig. 5.12.2. Keratinizing squamous cell carcinoma of the vulva. Anastomosing cords of 
neoplastic squamous cells, some with keratin pearls, are evident.
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grade 1 (CIN1), is an insensitive 
proxy of HPV infection and is not 
precancer. High-grade squamous 
intraepithelial lesions (CIN grade 2) 
include a heterogeneous group of 
lesions that are equivocal in cancer 
potential. In contrast, grade 3 dis-
ease represents the most clinically 
relevant lesion and is the best sur-
rogate end-point for cervical cancer 
in screening and vaccination trials. 
The probability of HPV clearance 
depends on the duration of the in-
fection [16].
The mean age at which women 
develop squamous intraepithelial le-
sions is 24–27 years for low-grade 
lesions (CIN1) and 35–42 years 
for high-grade lesions (CIN3). Half 
of low-grade lesions regress, 10% 
progress to high-grade lesions, and 
less than 2% become invasive can-
cer. The average time for low-grade 
squamous intraepithelial lesions 
to progress to high-grade lesions 
(CIN3) is about 10 years. At least 
20% of cases of CIN3 progress to 
invasive carcinoma in that time.
The strongest risk factors for 
persistence and progression are 
immunodeficiency and the type of 
HPV involved [1]. Of 13 HPV types, 
HPV16 is by far the likeliest to persist 
and cause CIN3 and cervical cancer. 
The proportion of HPV16 increases 
among HPV-positive women with 
the increase in lesion severity [17]. 
Conversely, the proportion of other 
high-risk HPV types is diminished in 
CIN3 and cervical cancer. Women 
who tested positive twice for HPV16 
after a 9–21-month interval had a 
3-year cumulative incidence of CIN2 
or worse of 40%. The corresponding 
cumulative incidence was 15% for 
HPV18 and 8.5% for other high-risk 
HPV types.
The most commonly detected 
HPV types in cervical cancer world-
wide are HPV16 (57%) and 18 (16%), 
followed by HPV58, 33, 45, 31, 52, 
Fig. 5.12.4. Interrelations of naming systems in precursor human papillomavirus (HPV)-related cervical lesions. This chart integrates 
multiple aspects of the disease. It illustrates the changes in progressively more abnormal disease states and provides terminology for 
the dysplasia/carcinoma in situ system, the cervical intraepithelial neoplasia (CIN) system, and the Bethesda system. The scheme 
also illustrates the corresponding cytological smear resulting from exfoliation of the most superficial cells as well as the equivalent 
histopathological lesions (top). SIL, squamous intraepithelial lesion.
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and 35 [17]. Therefore, current vac-
cines that prevent infection by HPV16 
and 18 should prevent about 75% of 
cervical cancers and 60% of high-
grade lesions (that need treatment 
when detected during screening), with 
small variations by region [17]. Future 
confirmation of cross-protection of 
HPV16 and 18 vaccines against other 
high-risk types [18] or the introduc-
tion of vaccines targeting additional 
high-risk HPV types would increase 
prevention (see Chapter 4.6).
Cervical cancer risk factors other 
than HPV infection are either weak in 
terms of the magnitude of association 
(smoking) or represent correlates of 
the probability of acquisition (number 
of sexual partners) or, possibly, the 
likelihood of progression of HPV in-
fection to cancer (age at first sexual 
intercourse and first birth, parity, and 
oral contraceptive use) [19].
CIN is a spectrum of epithelial 
changes that begins with minimal 
atypia and progresses through stag-
es of greater epithelial abnormali-
ties to invasive squamous cell car-
cinoma. The terms CIN, dysplasia, 
carcinoma in situ, and squamous 
intraepithelial lesion are commonly 
used interchangeably (Fig. 5.12.4). 
p16 immunohistochemistry is rec-
ommended when the differential di-
agnosis is between precancer (CIN2 
or CIN3) and a mimic of precancer, 
such as immature squamous meta-
plasia or reparative changes. Strong 
and diffuse block-positive p16 results 
support a diagnosis of precancerous 
disease [5].
Early phases of infection with all 
HPV types probably show episomal 
viral propagation throughout a poly-
clonal epithelial field, with low-grade 
squamous intraepithelial lesions 
(CIN1) cytology. These lesions mark 
a permissive infection, i.e. episomal 
HPV freely replicates and causes 
cell death. Huge numbers of virus 
must accumulate in the cytoplasm 
before being visible as a koilocyte 
(Fig. 5.12.4). In contrast, in most 
cases of CIN2/3, viral DNA integrates 
into the cell genome. Some 85% of 
CIN1 lesions, as well as many genital 
warts, contain low-risk HPV6 or 11. In 
contrast, cells in CIN2/3 usually have 
HPV types 16, 18, 58, 33, 45, 31, 52, 
and 35 [17].
Pathology and genetics
The association with HPV infection 
is equally strong for the two main 
histological types of cervical cancer: 
squamous cell carcinoma and adeno-
carcinoma. However, since most cer-
vical abnormalities caused by HPV 
infection are unlikely to progress to 
high-grade CIN or cervical cancer, 
other exogenous or endogenous fac-
tors acting in conjunction with HPV 
infection may be necessary for pro-
gression of the disease [1].
The normal process by which 
cervical squamous epithelium ma-
tures is disturbed in squamous 
intraepithelial lesions. In low-grade 
lesions (CIN1), the most pronounced 
changes are in the basal third of the 
epithelium. However, abnormal cells 
are present throughout the thickness 
of the epithelium, and nuclei in the 
upper levels are still abnormal [5]. 
Thus, the sloughed cells can be de-
tected as abnormal in Pap smears. 
In high-grade lesions (CIN2), most 
cellular abnormalities are in the 
lower and middle thirds of the epi-
thelium. High-grade squamous intra-
epithelial lesions are often detected 
on colposcopic examination. In the 
case of adenocarcinoma in situ, nor-
mal columnar epithelium is replaced 
by dysplastic glandular epithelium. 
However, morphological change 
comparable to CIN1 does not occur 
in the glandular epithelium.
Superficially invasive or microin-
vasive squamous cell carcinoma is 
the earliest stage of invasive cervical 
cancer. In this setting, stromal inva-
sion usually arises from an overly-
ing squamous intraepithelial lesion. 
Staging of microinvasive disease is 
based on width and depth of invasion 
[11]. The earliest invasive changes, 
sometimes termed early stromal 
invasion, appear as tiny irregular 
epithelial buds emanating from the 
base of CIN3 lesions. These small 
(< 1 mm) tongues of neoplastic epi-
thelial cells do not affect the progno-
sis of CIN3 lesions; hence, both can 
be treated similarly with conserva-
tive surgery.
Histologically, 85–90% of inva-
sive cervical cancers are squamous 
cell carcinoma, appearing as infiltrat-
ing networks of neoplastic cells in the 
stroma, with varying degrees of dif-
ferentiation, with or without keratini-
zation (Fig. 5.12.5). Adenocarcinoma 
and its variants constitute 10–15% 
Fig. 5.12.5. Squamous cell carcinoma, large cell, non-keratinizing type.
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of cervical cancers. The most com-
mon type of adenocarcinoma is the 
endocervical cell type, showing ab-
normal glands with varying size and 
shape with budding and branching, 
infiltrating the stroma (Fig. 5.12.6). 
Cervical cancer spreads by direct 
extension, through lymphatic ves-
sels and only rarely by the haema-
togenous route. Local extension into 
surrounding tissues (parametrium) 
results in ureteric compression [11].
Genome-wide association stud-
ies have identified loci associated 
with cervical cancer susceptibility, 
including those at 4q12 and 17q12 
in the Han Chinese population [20] 
and at 6p21.3 in a Swedish study [21]. 
A recent genetic analysis examined 
80 cervical tumours for 1250 known 
mutations in 139 cancer genes [22]. 
Validated mutations were detected 
in 48 of the 80 tumours (60%). The 
highest mutation rates were in the 
PIK3CA (31.3%), KRAS (8.8%), and 
EGFR (3.8%) genes. PIK3CA muta-
tion rates did not differ significantly 
between adenocarcinomas and 
squamous cell carcinomas. In con-
trast, KRAS mutations were identi-
fied only in adenocarcinomas (17.5% 
vs 0%), and a novel EGFR mutation 
was detected only in squamous cell 
carcinomas (0% vs 7.5%). There were 
no associations between HPV16 or 
HPV18 and somatic mutations or 
overall survival. In adjusted analyses, 
PIK3CA mutations were associated 
with shorter survival.
Prevention
Prophylactic vaccines against HPV 
currently available include monova-
lent (HPV16), bivalent (HPV16 and 
18), and quadrivalent (HPV6, 11, 16, 
and 18) virus-like particle vaccines. 
Furthermore, clinical trials examin-
ing the efficacy of a nonavalent vac-
cine are under way. In large clinical 
trials, vaccines have shown excel-
lent safety and nearly 100% efficacy 
in preventing persistent infections 
and the cervical precancers due 
to HPV16 and 18 [23,24]. Despite 
many barriers to implementation of 
the vaccine in resource-restricted 
environments, the vaccine has suc-
cessfully been introduced in sev-
eral developing countries [23] (see 
Chapter 4.6).
Early changes in the cervix, spe-
cifically squamous intraepithelial le-
sions, can be detected years before 
invasive cancer develops by screen-
ing tests such as conventional cy-
tology (Pap smear), liquid-based 
cytology, and HPV testing (Chapter 
4.7) [25]. Testing for HPV DNA of 
oncogenic types is gaining increas-
ing interest and application in cervi-
cal cancer screening. It has much 
greater sensitivity and only slightly 
lower specificity than Pap cytology. 
As a primary screening test followed 
by Pap triage of HPV-positive cases, 
HPV testing has the potential to im-
prove the overall quality of screening 
programmes [23]. Women with ab-
normal screening results are further 
investigated with colposcopy-direct-
ed biopsies.
Endometrial cancer
Endometrial carcinoma is a malig-
nant epithelial tumour, usually exhib-
iting glandular differentiation (adeno-
carcinoma), capable of invading the 
myometrium and spreading outside 
the uterus. More than 80% of cases 
are estrogen-related, well- to mod-
erately well-differentiated (endo-
metrioid) adenocarcinomas, which 
are usually confined to the corpus 
uteri at diagnosis and can be cured 
by hysterectomy. The remaining 
cases, however, are non-estrogen-
related high-grade carcinomas (non-
endometrioid serous and clear cell 
adenocarcinomas) associated with 
poor prognosis.
Etiology
Hormones play an important role 
in the etiology of endometrial carci-
noma. The “unopposed estrogens” 
hypothesis is widely accepted and 
explains most of the risk factors for 
endometrial cancer: early age at 
menarche, late age at menopause, 
nulliparity, hormone replacement 
therapy use, and obesity.
Obesity is the most important risk 
factor worldwide, estimated to ac-
count for 40% of endometrial cancer 
incidence. In premenopausal women, 
obesity is associated with anovula-
tory cycles during which the endome-
trial tissue receives continuous stim-
ulation. In postmenopausal women, 
obesity increases the concentration 
of endogenous estrogens, which are 
mainly produced by the aromatization 
of androgens in the adipose tissues. 
Fig. 5.12.6. Adenocarcinoma, endocervical or usual type.
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Excess weight is associated with 
insulin resistance and chronically 
elevated insulin concentrations in 
blood, and with increasing concen-
trations of sex steroids [26], factors 
that are associated with increased 
endometrial cancer risk. Type 2 and 
type 1 diabetes are strongly associ-
ated with an increase in endometrial 
cancer risk.
The use of oral contraceptives 
is associated with a long-lasting de-
crease in endometrial cancer risk, 
but only when they contain pro-
gestogen in addition to estrogens 
[27]. Use of hormone replacement 
therapy by postmenopausal women 
increases the risk of endometrial 
cancer about 2-fold [28]. Higher en-
dogenous estrogen concentrations 
in blood are associated with an in-
crease in endometrial cancer risk 
mainly in postmenopausal women, 
whereas higher endogenous an-
drogen concentrations are associ-
ated with an increase in endometrial 
cancer risk in both premenopausal 
and postmenopausal women [26]. 
Polycystic ovary syndrome – associ-
ated with increased blood androgen 
levels, and with infertility, amenor-
rhea, hirsutism and diabetes – has 
been consistently associated with an 
increase in endometrial cancer risk. 
Women who develop breast cancer 
are at increased risk, and are more 
likely to develop non-endometrioid 
rather than endometrioid endometri-
al carcinoma. Although this increase 
in risk could be explained partly by 
common risk factors between breast 
and endometrial malignancies, such 
as nulliparity or late age at meno-
pause, the use of tamoxifen for the 
treatment of breast cancer has also 
been questioned: women under ta-
moxifen therapy had a more than 
2-fold increase in endometrial can-
cer risk compared with non-users.
Pathology
Endometrial carcinomas are classi-
fied into two different clinicopatho-
logical types (Fig. 5.12.7) [29]. More 
than 80% are type I tumours, which 
are estrogen-related, low-grade en-
dometrioid carcinomas, often pre-
ceded by endometrial hyperplasia. 
They are usually confined to the uter-
us and have a favourable outcome. 
In contrast, approximately 10% of 
cases are type II tumours, which 
are non-endometrioid (mainly se-
rous and, less frequently, clear cell) 
carcinomas, arising occasionally 
in endometrial polyps or atrophic 
endometria. Type II tumours are not 
associated with estrogen stimulation 
or hyperplasia; they often, but not 
always, invade the myometrium and 
lymphovascular spaces, and they 
have a high mortality rate.
Fig. 5.12.7. Adenocarcinoma of the endometrium. (A) Endometrioid carcinoma (type I). 
Polypoid endometrial tumour with only superficial myometrial invasion. (B) Non-
endometrioid carcinoma (type II). Large haemorrhagic and necrotic tumour with deeper 
myometrial invasion. (C) Well-differentiated (grade 1) endometrioid adenocarcinoma. 
The neoplastic glands resemble normal endometrial glands. (D) Non-endometrioid (se-
rous) carcinoma exhibiting stratification of markedly atypical tumour cells with numerous 
mitoses. (E) Endometrioid carcinoma. MLH1 inactivation by promoter hypermethylation 
is the most common cause of the microsatellite instability phenotype in endometrioid 
endometrial carcinoma. Progressive accumulation of alterations secondary to micro-
satellite instability affects important regulatory genes and promotes carcinogenesis. 
(F) Non-endometrioid (serous) carcinoma usually shows a strong p53 immunoreaction 
as a result of (G) TP53 mutation.
A
C
E
B
D
F
G
476
Key surgical and pathological 
prognostic indicators include his-
tological type, histological grade, 
surgical/pathological stage, depth 
of myometrial invasion, lymphovas-
cular invasion, and cervical involve-
ment [30]. In 2009, a new staging 
classification of endometrial car-
cinoma was proposed [12]. Most 
endometrial cancers are sporadic, 
but 2–5% are familial (Table 5.12.1). 
Endometrial carcinoma is the most 
common extracolonic cancer in 
women with hereditary non-polypo-
sis colon cancer syndrome, a defect 
in DNA mismatch repair that is also 
associated with breast and ovarian 
cancers.
Genetics
A dualistic model of endometrial 
carcinogenesis has been proposed 
(Fig. 5.12.7) [31]. According to this 
model, normal endometrial cells 
would transform into endometrioid 
carcinoma through replication er-
rors, so-called “microsatellite insta-
bility”, and subsequent accumula-
tion of mutations in oncogenes and 
tumour suppressor genes. In con-
trast, alterations of TP53 and loss 
of heterozygosity on several chro-
mosomes would drive the process 
of neoplastic transformation into the 
acquisition of a non-endometrioid 
carcinoma phenotype.
Molecular genetic alterations in 
type I, i.e. endometrioid, carcino-
mas (Table 5.12.2) differ in some 
respects from those detected in 
type II (non-endometrioid) carci-
nomas (Table 5.12.3) [31]. Non-
endometrioid carcinomas may also 
derive from endometrioid carcinoma 
with microsatellite instability through 
tumour progression and subsequent 
TP53 mutations (Fig. 5.12.8) [31].
In sporadic endometrioid car-
cinomas, microsatellite instability 
results from promoter hypermeth-
ylation of hMLH1 and leads to 
mutations in several target genes 
(containing microsatellites) that are 
involved in apoptosis, cell prolifera-
tion, and cell differentiation. The 
wide range of mutations would be 
responsible for tumour heteroge-
neity. Inactivation of the tumour 
suppressor gene PTEN may result 
from microsatellite instability (45%), 
promoter hypermethylation (16%), or 
loss of heterozygosity (24%). PTEN 
inactivation releases the PI3K/AKT 
pathway, inhibiting apoptosis and 
resulting in tumour growth advan-
tage. Recent genomic and related 
analyses have indicated that most 
endometrioid tumours have few 
copy number alterations or TP53 
mutations but frequent mutations in 
PTEN, CTNNB1, PIK3CA, ARID1A, 
and KRAS, and novel mutations in 
the SWI/SNF chromatin remodelling 
complex gene ARID5B [32].
β-Catenin gene mutations occur 
in 20% of endometrioid carcinomas, 
correlate with MMP-7 and cyclin D1 
overexpression, and are associated 
with good prognosis. Mutation of the 
ARID1A gene and loss of the cor-
responding protein BAF250a have 
been found in 29–40% of endome-
trioid carcinomas, 18% of serous 
carcinomas, and 26% of clear cell 
carcinomas [33,34]. In contrast, non-
endometrioid carcinomas show TP53 
and PPP2R1A mutations, inactiva-
tion of p16 and E-cadherin, c-erbB2 
amplification, STK15 alterations, and 
Table 5.12.1. Hereditary syndromes with lifetime risk of endometrial cancer
Hereditary condition Gene (chromosome) Lifetime risk of endometrial cancer
Hereditary non-polyposis colorectal 
cancer
Lynch syndrome II
Muir–Torre syndrome
MSH2 (2p21)
MLH1 (3p21.3)
PMS2 (7p22.2)
MSH6 (2p16)
40–60%
Cowden syndrome PTEN (10q23.3) 5–10%
BRCA1 syndrome BRCA1 (17q) 2–3%
Table 5.12.2. Altered genes in endometrioid endometrial carcinoma
Gene Chromosome Mechanism of alteration
Percentage of 
cancers
Oncogenes
PIK3CA 3q26.3 Point mutation 24–39%
KRAS 12p12.1 Point mutation 10–30%
CTNNB1 (β-catenin) 3p21 Point mutation 14–44%
PIK3R1 5q13.1 Point mutation 43%
FGFR2 10q26 Point mutation 16%
Tumour suppressor genes
PTEN 10q23.3 Mutation, loss of 
heterozygosity
37–61%
ARID1A 1p35.3 Mutation 40%
MLH1 (MSI) 3p21.3 Promoter hypermeth-
ylation (epigenetic 
silencing)
30%
TP53 17p13.1 Mutation 10–20%
CDKN2A (p16) 9p21 Loss of heterozy-
gosity, epigenetic 
silencing
10%
SPRY2 13q31.1 Epigenetic silencing 20%
RASSF1A 3p21.3 Epigenetic silencing 48%
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loss of heterozygosity at multiple loci 
(Table 5.12.3) [29–31].
Targeted therapy
Endometrioid carcinomas with 
PTEN mutations have activation 
of the PI3K/AKT pathway and ge-
nomic instability. Accordingly, these 
patients are treated with poly (ADP-
ribose) polymerase (PARP) inhibitors 
[35]. Mammalian target of rapamycin 
(mTOR) is a kinase that regulates cell 
growth and apoptosis [36]. mTOR in-
hibitors have recently been developed 
as potential anticancer agents, and 
PTEN-mutated tumours are particu-
larly susceptible [37]. Angiogenesis 
is essential to the development and 
maintenance of any tissue. Increased 
production of vascular endothelial 
growth factor (VEGF), frequently ob-
served in hypoxia or inflammation, 
results in increased endothelial cell 
proliferation and decreased apopto-
sis [38]. VEGF overexpression is 
associated with a poor prognosis 
in endometrial cancer. The role of 
drugs inhibiting angiogenesis, such 
as bevacizumab and tyrosine kinase 
inhibitors, is being studied.
Ovarian cancer
The most common ovarian cancers 
are ovarian carcinomas, which are 
also the most lethal gynaecological 
malignancies. Based on histopathol-
ogy and molecular genetics, ovarian 
carcinomas are divided into five main 
types: high-grade serous (70%), en-
dometrioid (10%), clear cell (10%), 
mucinous (3%), and low-grade se-
rous carcinomas (< 5%), which to-
gether account for more than 95% 
of cases (Table 5.12.4; Fig. 5.12.9). 
These types are essentially distinct 
diseases, as indicated by differenc-
es in epidemiological and genetic 
risk factors, precursor lesions, pat-
terns of spread, molecular events 
during oncogenesis, response to 
chemotherapy, and prognosis [39]. 
Much less common are malignant 
germ cell tumours (dysgerminomas, 
yolk sac tumours, and immature 
Fig. 5.12.8. Pathogenesis of endometrial cancer: an alternative to the dualistic model. 
On the basis of molecular analysis, it has been suggested that non-endometrioid carci-
nomas may result from tumour progression from pre-existing endometrioid carcinomas. 
This would explain why these high-grade tumours often retain the molecular alterations 
of endometrioid carcinomas. Ca, carcinoma; MI, microsatellite instability; NE, normal 
endometrium.
Table 5.12.3. Altered genes in non-endometrioid endometrial carcinoma
Gene Chromosome Mechanism of alteration
Percentage of 
cancers
Oncogenes
PIK3CA 3q26.3 Point mutation and 
amplification
20–30%
PIK3R1 5q13.1 Point mutation 12%
ERBB2 (HER2/neu) 17q12 Amplification 30%
CCNE1 (cyclin E1) 19q12 Amplification 55%
STK15 (aurora 
kinase A)
20q13.2 Amplification 60%
CCND1 (cyclin D1) 11q13 Amplification 26%
Tumour suppressor genes
TP53 17p13.1 Mutation 90%
CDH1 (E-cadherin) 16q22.1 Loss of 
heterozygosity
80–90%
CDKN2A (p16) 9p21 Loss of heterozy-
gosity, epigenetic 
silencing
40%
PPP2R1A 19q13.41 Mutation 17–41%
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teratomas) (3% of ovarian cancers) 
and potentially malignant sex cord 
stromal tumours (1–2%), the most 
common of which are granulosa cell 
tumours.
Etiology
Ovarian carcinomas most commonly 
affect nulliparous women and oc-
cur least frequently in women with 
suppressed ovulation, typically by 
pregnancy or oral contraceptives. 
These tumours are generally con-
sidered to originate from the cells 
covering the ovarian surface or the 
pelvic peritoneum. Malignant trans-
formation of this mesothelium has 
been explained by the “incessant 
ovulation” theory [40]. Irritants, such 
as talc or asbestos, have also been 
implicated, as have hormonal fac-
tors. Elevated gonadotropin levels 
may contribute to malignant transfor-
mation. Pregnancy and oral contra-
ceptives are protective factors, and 
both cause a reduction in pituitary 
gonadotropins.
Family history of ovarian cancer 
accounts for 10% of cases; the risk 
is increased 3-fold when two or more 
first-degree relatives have been 
affected. Women with germline mu-
tations in BRCA1 or BRCA2 have a 
30–70% risk of developing ovarian 
cancer, mainly high-grade serous 
carcinomas, by age 70 [41]. BRCA1 
and BRCA2 are essential compo-
nents of the homologous recombi-
nation DNA repair system, required 
to repair DNA double-strand breaks 
[42]. Women with hereditary non-
polyposis colon cancer are also at 
greater risk for ovarian cancer, spe-
cifically endometrioid carcinoma.
The cell descriptors used to clas-
sify ovarian carcinomas – serous, 
mucinous, endometrioid, clear cell, 
transitional, and squamous – do not 
apply to cells in the normal ovary, 
and malignancy has long been at-
tributed to Müllerian “neometapla-
sia” of the ovarian surface epithelium 
(mesothelium). During embryonic 
life, the coelomic cavity is lined by 
mesothelium, which also covers 
the gonadal ridge and gives rise 
to Müllerian ducts, from which the 
fallopian tubes, uterus, and vagina 
develop. Thus, the tumour cells 
would resemble morphologically 
the epithelia of the fallopian tube, en-
dometrium, or endocervix. Although 
the mesothelial origin cannot be 
excluded, there is evidence that sev-
eral primary ovarian cancers have 
originated in other pelvic organs and 
involve the ovary secondarily. High-
grade serous carcinomas, especially 
in BRCA-positive patients, have 
been postulated to arise from pre-
cursor epithelial lesions in the distal 
fimbriated end of the fallopian tube, 
whereas endometrioid and clear cell 
carcinomas originate from ovarian 
endometriosis [43].
Pathology and genetics
Serous carcinoma
High-grade serous carcinoma and 
low-grade serous carcinoma (Fig. 
5.12.9, A and B) are fundamentally 
different tumour types. Low-grade 
serous carcinomas are usually as-
sociated with a non-invasive serous 
borderline component, carry KRAS 
and BRAF mutations, and are unre-
lated to TP53 mutations and BRCA 
abnormalities. In contrast, high-
grade serous carcinomas are not 
associated with serous borderline 
tumours and typically exhibit TP53 
mutations and BRCA abnormalities 
(Table 5.12.4) [44]. Most patients 
with high-grade serous carcinomas 
Table 5.12.4. Characteristics of the main types of ovarian carcinoma
Characteristic
Type
High-grade serous Low-grade serous Mucinous Endometrioid Clear cell
Usual stage at 
diagnosis
Advanced Early or advanced Early Early Early
Presumed tissue 
of origin/precursor 
lesion
Fallopian tube or 
tubal metaplasia 
in inclusions of 
ovarian surface 
epithelium
Serous borderline 
tumour
Adenoma–border-
line tumour–carci-
noma sequence; 
teratoma
Endometriosis, 
adenofibroma
Endometriosis, 
adenofibroma
Genetic risk BRCA1/2 ? ? Hereditary non-
polyposis colorectal 
cancer
?
Significant 
molecular 
abnormalities
p53 and pRb 
pathways
BRAF or KRAS KRAS PTEN, β-catenin,
ARID1A, PIK3CA
HNF-1β, ARID1A, 
PIK3CA
   KRAS  
   Microsatellite 
instability
 
Proliferation High Low Intermediate Low Low
Response 
to primary 
chemotherapy
80% 26–28% 15% ? 15%
Prognosis Poor Favourable Favourable Favourable Intermediate
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(> 80%) present with advanced dis-
ease (stage III).
The genomics of serous ovar-
ian adenocarcinomas has been as-
sessed using DNA sequences of 
exons from coding genes in 316 of 
these tumours and other data [45]. 
High-grade serous ovarian cancer is 
characterized by TP53 mutations in 
almost all tumours (96%); low-prev-
alence but statistically recurrent so-
matic mutations in nine further genes, 
including NF1, BRCA1, BRCA2, RB1, 
and CDK12; 113 significant focal DNA 
copy number aberrations; and pro-
moter methylation events involving 
168 genes. Analyses delineated four 
ovarian cancer transcriptional sub-
types, three microRNA subtypes, four 
promoter methylation subtypes, and 
a transcriptional signature associated 
with survival duration. Other data in-
volved the impact that tumours with 
BRCA1 or BRCA2 and CCNE1 ab-
errations have on survival. Pathway 
analyses suggested that homologous 
recombination is defective in about 
half of the tumours analysed, and 
that NOTCH and FOXM1 signalling 
are involved in serous ovarian cancer 
pathophysiology.
Consistent patterns of chromo-
somal change in patient cohorts 
suggest an underlying interdepen-
dency of gains and losses of par-
ticular genes in individual tumours 
[46], for example co-amplification of 
CCNE1 and the 20q11 locus involv-
ing the cell-cycle regulator TPX2, 
among other genes. Genome-wide 
association studies continue to 
identify susceptibility loci for ovar-
ian cancer, specifically including 
loci at 2q31 and 8q24 [47].
Endometrioid carcinoma
Endometrioid carcinoma, which re-
sembles its endometrial counterpart 
(Fig. 5.12.9C), is thought to arise by 
malignant transformation of endo-
metriosis and not from the ovarian 
surface epithelium. The most com-
mon genetic abnormalities in ovar-
ian endometrioid carcinoma are 
somatic mutations of the ARID1A, 
CTNNB1 (β-catenin), and PTEN 
genes, and microsatellite instabil-
ity (Table 5.12.4) [39,48]. Between 
15% and 20% of patients with en-
dometrioid carcinoma of the ovary 
also have endometrial cancer. If 
ovarian and endometrial cancers 
coexist, they generally arise inde-
pendently, although some may be 
metastases from one or the other, a 
distinction with important prognostic 
implications.
Mucinous carcinoma
Mucinous ovarian tumours are of-
ten heterogeneous. Benign, bor-
derline, non-invasive, and invasive 
carcinoma components may coex-
ist within the same tumour. Such a 
morphological continuum suggests 
that tumour progression occurs 
from cystadenoma and borderline 
tumour to invasive carcinomas. This 
hypothesis is supported by KRAS 
mutations in mucinous tumours: 56% 
of cystadenomas and 85% of carci-
nomas express mutated KRAS, and 
borderline tumours are intermediate 
(Table 5.12.4) [39]. Mucinous carci-
nomas are usually large, unilateral 
cystic masses (Fig. 5.12.9D). The 
finding of bilateral mucinous tumours 
should raise suspicion of metastases 
from a far more frequent mucinous 
carcinoma elsewhere (e.g. gastroin-
testinal tract).
Clear cell carcinoma
This enigmatic ovarian cancer is 
closely related to endometrioid 
adenocarcinoma, and often occurs 
in association with endometriosis. 
Fig. 5.12.9. Representative examples of the five main types of ovarian carcinoma, 
which together account for 98% of cases: (A) high-grade serous carcinoma, (B) low-
grade serous carcinoma, (C) endometrioid carcinoma, (D) mucinous carcinoma, and 
(E) clear cell carcinoma.
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It usually occurs after menopause. 
The most common genetic abnor-
malities are somatic mutations of 
the ARID1A, PTEN, and PIK3CA 
genes (Table 5.12.4) [39,48]. Clear 
cell carcinomas of the ovary resem-
ble their counterparts in the vagina, 
cervix, and corpus uteri; they show 
sheets or tubules of malignant cells 
with clear cytoplasm (Fig. 5.12.9E) 
or tubules lined by “hobnail” cells.
Prognosis
For patients with malignant ovarian 
tumours, survival is generally poor. 
The most important prognostic index 
is the surgical stage of the tumour at 
the time it is detected. A new staging 
classification of cancer of the ovary, 
fallopian tube, and peritoneum has 
been proposed by the International 
Federation of Gynecology and 
Obstetrics [49].
Targeted therapy
The most promising targets in clinical 
trials are angiogenesis and homolo-
gous recombination deficiency. To 
select patients for trials investigating 
these targets, predictive biomarkers 
are required. Other promising tar-
gets currently being studied based 
on ovarian cancer biology include 
folate receptor, PI3K/AKT, and Ras/
Raf/MEK pathways [50].
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Summary
• Most non-Hodgkin lymphomas 
are derived from either mature B 
or T lymphocytes, and they are 
morphologically, functionally, 
and genetically heterogeneous, 
with lymphoblastic malignancies 
being derived from precursor 
lymphoid cells.
• B-cell lymphomas are much 
more common than T-cell lym-
phomas, which account for only 
about 10% of cases.
• Many B-cell lymphomas are 
characterized by recurrent chro- 
mosomal translocations that tar-
get the immunoglobulin genes, 
whereas the molecular patho-
genesis of most T-cell lympho-
mas is as yet undiscovered.
• The classification of acute mye-
loid leukaemias is largely based 
on recurrent genetic abnormali-
ties, which have a major impact 
on prognosis and response to 
therapy.
• Chronic myeloid leukaemia is 
a myeloproliferative neoplasm 
that arises in a pluripotent stem 
cell and is invariably linked to 
the BCR-ABL1 fusion.
• The BCR-ABL1-negative my-
eloproliferative neoplasms are 
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heterogeneous in terms of the 
cellular targets – for example 
myeloid, erythroid, or megakar-
yocytic – and are commonly as-
sociated with mutations of JAK2.
Haematological malignancies in-
clude all cell types derived from a 
pluripotent bone marrow stem cell, 
and as such include neoplasms of 
the lymphoid, myeloid, mast cell, 
histiocytic, and dendritic cell line-
ages. The current approach to the 
classification of haematopoietic and 
lymphoid malignancies is based on 
the integration of morphological, 
phenotypic, genetic, and clinical 
features, which allows the identi-
fication of distinct disease entities 
[1]. Most lymphoid malignancies 
have been related to normal coun-
terparts in the B-cell (Fig. 5.13.1) 
and T-cell (Fig. 5.13.2) systems. For 
acute myeloid leukaemias, genet-
ics has taken priority over aspects 
of cellular differentiation. In recent 
years there has been great prog-
ress in the application of genomic 
methods, which has advanced our 
understanding of these neoplasms, 
led to the recognition of new entities, 
and pointed the way towards prom-
ising new therapies, exploiting the 
knowledge of molecular pathways 
of transformation.
Chronic lymphocytic 
leukaemia/small lymphocytic 
lymphoma
Chronic lymphocytic leukaemia (CLL), 
the most common adult leukaemia in 
industrialized countries, is a small 
B-cell lymphoid neoplasm composed 
of monoclonal memory B cells that 
most typically express CD23 and the 
T-cell-associated antigen CD5.
Etiology and pathology
CLL/small lymphocytic lymphoma 
includes a more aggressive sub-
set, with unmutated immunoglobu-
lin heavy-chain genes, and a less 
aggressive subset, with mutated 
genes. The diagnosis requires more 
than 5 × 109 peripheral blood CLL-
type cells/l, cytopenias or disease-
related symptoms, or extramedullary 
disease. Individuals who do not fulfil 
any of these criteria but who have 
monoclonal CLL-type B cells are 
now considered to have monoclo-
nal B-cell lymphocytosis (MBL) [2]. 
MBL can be divided into low-count 
and high-count MBL; cases of high-
count MBL progress to frank CLL 
at a rate of 1–2% per year [2]. Low-
count MBL (< 56 clonal B cells/μl) 
is found with sensitive techniques at 
a high frequency among older adults 
in the general population, and has 
a minimal propensity to progress. 
MBL is thought to be secondary to 
prolonged antigenic stimulation. 
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Epidemiology
Lymphomas
• There were almost 566 000 new 
cases of lymphoma worldwide 
in 2012, and about 305 000 
deaths.
• The ICD-10 codes used for lym-
phomas are:  Hodgkin lymphoma 
(C81); non-Hodgkin lymphoma 
(C82-85, C96); multiple myeloma 
and immunoproliferative diseas-
es (C88+C90).
• When the main entities (Hodgkin 
lymphoma, non-Hodgkin lym-
phoma, and multiple myeloma) 
are examined separately, the 
respective cancer types do not 
rank highly, yet in combination, 
lymphomas would rank as the 
seventh most common form 
of cancer in terms of cancer 
incidence.
• Incidence rates for lymphoma 
tend to be elevated in the most 
developed areas, including 
North America, Australia and 
New Zealand, and northern 
and western Europe. In global 
terms, the incidence is greatest 
in Israel, followed by Australia 
and the USA.
• Where such data series are 
available, both incidence and 
mortality rates of non-Hodgkin 
lymphoma have tended to in-
crease rather rapidly up until 
the mid-1990s in both sexes. 
Subsequently, incidence rates 
have stabilized, while mortal-
ity rates have declined in some 
settings. 
Map 5.13.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for lymphoma in men, 2012.
Map 5.13.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for lymphoma in men, 2012.
MBL with an atypical CLL-type phe-
notype and a non-CLL phenotype 
are also recognized. There are no 
known etiological factors for CLL; 
however, there is a familial predis-
position in 5–10% of cases.
Genetics
Genome-wide association studies 
have revealed multiple susceptibility 
loci for CLL, many with proximity 
to genes involved in apoptosis [3]. 
There is great interest in prognostica-
tion in CLL, which, in addition to mu-
tational status, is based on clinical, 
phenotypic (CD38, ZAP-70 expres-
sion), and molecular/cytogenetic fac-
tors, particularly TP53 deletions and 
mutations. Recently, next-generation 
sequencing studies have demonstrat-
ed numerous recurrent mutations in 
genes that are part of varied genetic 
pathways – each, however, present 
in only up to about 10–15% of cases. 
Among those receiving the most at-
tention are activating NOTCH1 mu-
tations and mutations in the splicing 
factor SF3B1, both adverse prognos-
tic indicators [4,5]. The hope is that 
this new knowledge may lead to more 
targeted and effective therapies.
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.13.1. Estimated global number of new cases and deaths with proportions by major world regions, for lymphoma in 
both sexes combined, 2012.
Chart 5.13.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for lymphoma in 
men, circa 1975–2012.
Chart 5.13.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for lymphoma in 
men, circa 1975–2012.
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Hairy cell leukaemia
Etiology and pathology
Hairy cell leukaemia is a rare neo-
plasm, typically of the post-germinal 
centre B-cell type, characterized by 
diffuse marrow and splenic red pulp 
involvement as well as often modest 
peripheral blood involvement by rela-
tively small B cells with oval to re-
niform nuclei and prominent “hairy” 
cytoplasmic projections. Hairy cell 
leukaemia is diagnosed based on 
its characteristic morphological ap-
pearance and its CD103+, CD25+, 
CD11c+, annexin A1+ phenotype. The 
etiology of hairy cell leukaemia is 
unknown.
Genetics
Virtually all cases have BRAF V600E 
mutations, an abnormality shared 
with other malignancies such as 
papillary thyroid carcinoma and mela-
noma but found in few other B-cell 
neoplasms (and not in the variant 
form of hairy cell leukaemia) [6]. 
This probable driver mutation leads 
to constitutive activation of the RAF/
MEK/ERK mitogen-activated protein 
kinase pathway. Although most pa-
tients with hairy cell leukaemia do 
well after treatment with purine ana-
logues, BRAF V600E mutations pro-
vide another therapeutic target with 
Map 5.13.3. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for leukaemia in men, 2012.
Map 5.13.4. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for leukaemia in men, 2012.
Leukaemias
• There were almost 352 000 
new cases of leukaemia glob-
ally in 2012, and about 265 000 
deaths. The disease ranks as 
the 11th most frequent in terms 
of cancer incidence and the 
10th most common cause of 
cancer death.
• The ICD-10 codes used for leu-
kaemias are C91-95.
• As with lymphomas, the inci-
dence rates of leukaemias tend 
to be highest in countries that 
have attained the highest levels 
of human development.
• Incidence rates are elevated 
in countries with high or very 
high levels of human develop-
ment, including Australia and 
New Zealand, North America, 
and much of Europe. There is 
less variation in mortality, al-
though rates are high in certain 
countries in North Africa and in 
Central and West Asia.
• Trends are somewhat difficult to 
decipher for leukaemia, but ob-
served incidence rates are gen-
erally stable with time, at least 
relative to trends in non-Hodg-
kin lymphoma. Mortality rates 
have fallen for certain subtypes 
in higher-income countries due 
to improving therapeutics. 
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Chart 5.13.4. Estimated global number of new cases and deaths with proportions by major world regions, for leukaemia in 
both sexes combined, 2012.
Chart 5.13.5. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for leukaemia in 
men, circa 1975–2012.
Chart 5.13.6. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for leukaemia in 
men, circa 1975–2012.
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BRAF inhibitors, already explored in 
other malignancies.
Plasma cell myeloma
Plasma cell myeloma, sometimes 
referred to as multiple myeloma, is 
a bone marrow-based, disseminated 
neoplasm composed of monoclonal 
post-germinal centre long-lived 
plasma cells, which must be distin-
guished from monoclonal gammop-
athy of undetermined significance 
and lymphomas with plasmacytic 
differentiation.
Etiology and pathology
Symptomatic plasma cell myelo-
ma requires a serum and/or urine 
monoclonal paraprotein, clonal 
plasma cells in the bone marrow, or 
a plasmacytoma and related end-
organ damage (hypercalcaemia, 
renal insufficiency, anaemia, bone 
lesions). Asymptomatic (smoulder-
ing) myeloma requires a serum 
paraprotein level of more than 30 g/l 
and/or at least 10% clonal bone mar-
row plasma cells and no myeloma-
associated end-organ damage or 
myeloma-associated symptoms. 
Other clinical variants include non-
secretory myelomas, most of which 
are still associated with serum-free 
light-chain abnormalities, and plas-
ma cell leukaemia, in which there 
are more than 2 × 109 circulating 
peripheral blood plasma cells/l or 
they make up more than 20% of all 
leukocytes. The etiology of plasma 
cell myeloma is totally unknown in 
most patients. The disease is more 
common in African Americans than 
in Caucasians.
Genetics
Upregulation of one of the cyclin 
D genes due to hyperdiploidy or 
translocations involving the immuno-
globulin heavy-chain gene and the 
CCND1, C-MAF, FGFR3/MMSET, 
CCND3, or MAFB genes is consid-
ered an important early event but is 
also found in monoclonal gammop-
athy of undetermined significance. 
Other important early events seen 
in a significant minority of patients 
include monosomy 13 or 13q14 
Fig. 5.13.1. Diagrammatic representation of B-cell differentiation. B-cell neoplasms correspond to stages of maturation. Most B cells 
are activated within the germinal centre, but T-cell independent activation can take place outside the germinal centre. This fact leads 
to cases of chronic lymphocytic leukaemia (CLL) that may or may not show evidence of somatic hypermutation. AG, antigen; DLBCL, 
diffuse large B-cell lymphoma; FDC, follicular dendritic cell; HCL, hairy cell leukaemia; GC, germinal centre; Ig, immunoglobulin; 
MALT, mucosa-associated lymphoid tissue; SLL, small lymphocytic lymphoma.
488
deletion and K-RAS or N-RAS acti-
vating mutations. A variety of other 
genetic and epigenetic events and 
pathways are implicated in disease 
progression, including the recent 
identification of therapeutically tar-
getable BRAF mutations in a small 
proportion of cases [7].
Follicular lymphoma
Follicular lymphoma, one of the most 
common adult lymphomas in indus-
trialized countries, is a neoplasm of 
germinal centre B cells with vary-
ing proportions of centrocytes and 
transformed centroblasts and almost 
always at least a partially follicular 
growth pattern.
Etiology, pathology, and 
genetics
Follicular lymphoma is diagnosed 
based on its morphological features, 
phenotype (CD20+, usually CD10+, 
BCL6+, and usually BCL2+), and fre-
quent IGH/BCL2 translocations or, 
much less commonly, BCL6 translo-
cations. This disease is graded based 
on the number of centroblasts pres-
ent. The more common grade 1–2 
follicular lymphoma is an indolent but 
generally widely disseminated and in-
curable neoplasm, and the grade 3 
cases (A and B, based on the pres-
ence or absence of centrocytes) are 
considered more aggressive. The eti-
ology is uncertain, but healthy individ-
uals with pesticide exposure have a 
greater prevalence of circulating cells 
with IGH/BCL2 translocations.
Typical cases need to be dis-
tinguished from paediatric follic-
ular lymphoma, a lymphoma that 
also occurs particularly in younger 
adults, based on morphological, im-
munophenotypic, and cytogenetic/
molecular differences [8], and from 
in situ follicular lymphoma/intrafol-
licular neoplasia/follicular lympho-
ma-like B cells of uncertain/unde-
termined significance, where there 
are scattered follicles with follicular 
lymphoma-like B cells but with an 
intact underlying lymphoid tissue 
architecture [9]. Primary duodenal 
follicular lymphoma is also distinc-
tive and often localized. Primary cu-
taneous follicular lymphoma belongs 
in the separate category of primary 
cutaneous follicle centre lymphoma. 
Most cases have well-recognized 
secondary cytogenetic/molecular 
abnormalities, but the critical trans-
formational events required in addi-
tion to BCL2 translocation remain to 
be established.
Mantle cell lymphoma
Mantle cell lymphoma is a mature 
B-cell lymphoma believed to be de-
rived from usually naive B cells of 
the inner mantle zone.
Etiology and pathology
The etiology of mantle cell lympho-
ma is unknown. In general it is a very 
aggressive and incurable lymphoma, 
but the clinical spectrum of mantle 
cell lymphoma is very broad. Both 
Fig. 5.13.2. Diagrammatic representation of T-cell differentiation. T-cell neoplasms correspond to different stages of maturation. 
Mature T cells include αβ and γδ T cells, both of which mature in the thymus gland. T-follicular helper (TFH) cells are a recently 
well-characterized subset of αβ T cells involved in many nodal peripheral T-cell lymphomas. AG, antigen; FDC, follicular dendritic 
cell; NK, natural killer.
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aggressive (blastoid and pleomor-
phic) and more indolent variants are 
recognized. One indolent and very 
distinctive variant is associated with 
blood, bone marrow, and sometimes 
splenic involvement without periph-
eral adenopathy and typically has 
mutated immunoglobulin heavy-
chain genes and few secondary cy-
togenetic/molecular abnormalities. 
The other variant that may not rep-
resent an overt malignancy is in situ 
mantle cell lymphoma/mantle cell 
lymphoma-like B cells of undeter-
mined/uncertain significance. These 
cases lack architectural destruction 
and show partially infiltrated follicu-
lar mantle zones, often at the mantle 
zone/germinal centre interface.
Genetics
Most cases have a CCND1 transloca-
tion and cyclin D1 expression, an ear-
ly but insufficient pathogenetic event 
and a useful diagnostic tool. Rare 
cases are cyclin D1-negative but, 
like most other MCLs, are SOX11+ 
and usually express cyclin D2 or D3. 
Otherwise, the diagnosis is made 
based on a characteristic morpholog-
ical appearance and a usual CD20+, 
CD5+, CD23– phenotype. In addition 
to CCND1 overexpression, mantle 
cell lymphoma is characterized by 
additional abnormalities leading to 
cell-cycle dysregulation, and assess-
ment of the proliferative fraction is an 
extremely important prognostic factor 
[10]. Disruption of the DNA damage 
response pathways and activation of 
cell survival mechanisms are also 
important in the pathogenesis of this 
disease, with many potentially target-
able abnormal signalling pathways. 
For example, NOTCH1 mutations 
similar to those seen in CLL/small 
lymphocytic lymphoma, and associ-
ated with more aggressive disease, 
were recently reported in 12% of 
mantle cell lymphomas.
Marginal zone lymphoma 
and lymphoplasmacytic 
lymphoma
These diseases are post-germinal 
centre B-cell neoplasms that show 
varying degrees of plasmacytoid 
differentiation.
Etiology, pathology, and 
genetics
Three distinct forms of marginal zone 
lymphomas are recognized: extra-
nodal, nodal, and splenic. Extranodal 
marginal zone lymphomas of mucosa- 
associated lymphoid tissue (MALT 
lymphomas) are relatively common; 
they have been reported in nearly 
every anatomical site but are most 
frequent in the stomach, lung, and 
salivary gland. Antigen drive has 
been implicated most clearly in gas-
tric MALT lymphoma, associated with 
Helicobacter pylori infection. The 
most common translocations iden-
tified in MALT lymphoma – t(11;18)
(q21;q21), t(1;14)(p22;q32), and 
t(14;18)(q32;q21) – share a common 
pathway, which leads to the activa-
tion of NF-κB and its downstream 
targets. Historically, it had been dif-
ficult to distinguish lymphoplasma-
cytic lymphoma from marginal zone 
lymphomas as both show evidence of 
plasmacytoid differentiation. Recent 
studies have identified mutations 
Fig. 5.13.3. The main activation cascades of JAK-STAT and NF-κB signalling are in-
volved in primary mediastinal B-cell lymphoma. Alternative pathway activation exists. 
Known gene alterations leading to constitutive pathway activity are shown in colour. The 
NF-κB signalling pathway is implicated in many forms of B-cell lymphoma.
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in MYD88 involving L265P in 91% 
of patients with lymphoplasmacytic 
lymphoma, nearly all of whom had 
clinical Waldenström macroglobulin-
aemia [11]. The mutation was shown 
to trigger IRAK-mediated NF-κB sig-
nalling. Mutations in MYD88 were 
rarely encountered in marginal zone 
lymphomas, facilitating distinction of 
these groups.
Diffuse large B-cell 
lymphoma
Diffuse large B-cell lymphomas 
(DLBCLs) are the most common 
histological group of lymphoma, 
representing up to 40% of cases 
worldwide.
Etiology, pathology, and 
genetics
DLBCLs are heterogeneous mor-
phologically, clinically, and at the 
genomic level. To address these is-
sues, DLBCLs were among the first 
cases to be analysed by comple-
mentary DNA array technology, and 
more recently also by genome-wide 
analysis [12]. A recent genome-wide 
association study identified 3q27 as 
a susceptibility locus for B-cell non-
Hodgkin lymphoma, and particularly 
for DLBCL, in the Chinese popula-
tion [13]. By gene expression pro-
filing, three groups were identified 
based on the differential expression 
of a large set of genes: the germi-
nal centre-like group, the activated 
B-cell-like group, and primary me-
diastinal (thymic) large B-cell lym-
phoma. The third group shares many 
features with classic Hodgkin lym-
phoma, showing activation of the 
NF-κB pathway (Fig. 5.13.3) [14]. 
More recently, frequent genetic 
defects have been identified in the 
B-cell antigen receptor (BCR) sig-
nalling and NF-κB pathways in the 
activated B-cell-like type, providing 
new insight into the pathogenesis of 
DLBCL and new potential therapeu-
tic targets [15,16]. In particular, in-
hibitors of BTK have shown promise 
in a variety of B-cell lymphomas [17]. 
Recurrent mutations in the germinal 
centre-like type of DLBCL appear 
to target histone-modifying genes 
[12,18]. Somatic mutations in EZH2 
also have been identified in follicular 
lymphoma, another tumour of germi-
nal centre derivation. 
Burkitt lymphoma
Etiology, pathology, and 
genetics
Burkitt lymphoma is the first subtype 
of lymphoma to be associated with 
a specific genetic aberration: trans-
locations involving MYC and one of 
the immunoglobulin genes, most 
commonly IGH. The translocation 
is common to all subtypes of Burkitt 
lymphoma, regardless of the pres-
ence of Epstein–Barr virus (EBV) 
or clinical features. Endemic Burkitt 
lymphoma is prevalent in equatorial 
Africa, corresponding in distribution 
to the malaria belt. It is universally 
positive for EBV, whereas sporadic 
and immunodeficiency-associated 
Burkitt lymphomas are EBV-positive 
in a smaller proportion of cases (15–
30%). Recent studies using genomic 
sequencing have identified recurrent 
somatic mutations that provide new 
insights into the pathogenesis of 
Burkitt lymphoma (reviewed in [19]). 
Three independent studies identified 
mutations in ID3 in a high proportion 
of cases, with mutations also seen 
in the transcription factor 3 (TCF3) 
gene. These studies link Burkitt lym-
phoma to the cells of the dark zone 
of the germinal centre. ID3 mutations 
were absent in DLBCL. Mutations in 
this pathway were seen in sporadic 
and immunodeficiency-associated 
Burkitt lymphoma, and in a some-
what lesser proportion of endemic 
cases of this disease.
Peripheral T-cell lymphoma
Peripheral T-cell lymphomas are mor-
phologically, immunophenotypically, 
and clinically heterogeneous and 
overall account for only about 10% 
of all non-Hodgkin lymphomas [20]. 
Classification schemes generally 
segregate nodal and extranodal 
lymphomas of this type; extranodal 
tumours are more often of cyto-
toxic origin [21]. Anaplastic large 
cell lymphoma was the first to be 
associated with a specific genetic 
alteration: translocations involving 
ALK and a variety of gene partners, 
leading to overexpression of ALK. 
Recently, mutations involving IDH2 
and TET2 have been identified in 
Fig. 5.13.4. A boy with Burkitt lymphoma receives treatment at Banso Baptist Hospital 
in Cameroon.
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angioimmunoblastic T-cell lympho-
mas and other peripheral T-cell 
lymphomas of T-follicular helper 
cell origin. However, as yet the mo-
lecular pathogenesis of most periph-
eral T-cell lymphomas remains to be 
discovered.
Hodgkin lymphoma
Hodgkin lymphomas are divided 
into classic Hodgkin lymphoma and 
nodular lymphocyte-predominant 
Hodgkin lymphoma. Both are de-
rived from B cells, but the B-cell 
programme is markedly disrupted 
in classic Hodgkin lymphoma, 
such that there is downregulation 
of most B-cell markers and func-
tions. Epigenetic alterations may be 
responsible in part for loss of the 
B-cell programme [22]. Studies of 
the tumour cells implicate the NF-κB 
Molecular detection of minimal residual disease in childhood leukaemia
Rosemary Sutton
Fig. B5.13.1. Minimal residual disease (MRD) levels in childhood leukaemia 
patients who relapse compared with patients who are cured by their treatment.
Minimal residual disease (MRD) 
is a highly clinically relevant prog-
nostic factor for patients with acute 
lymphoblastic leukaemia (ALL). 
Brüggemann et al. [1] cited 27 stud-
ies that provided evidence that MRD 
is important in determining patient 
outcome in clinical trials for chil-
dren or adults with newly diagnosed 
ALL, relapsed ALL, or bone mar-
row transplants for ALL treatment. 
Consequently, many current clini-
cal trials for childhood leukaemia 
patients include the stratification of 
patients into treatment risk groups 
based on initial MRD response to 
therapy measured in bone marrow 
aspirates using real-time quanti-
tative polymerase chain reaction 
(PCR) or quantitative flow cytometry 
methods [1].
In essence, leukaemia patients 
who relapse usually have a slower 
response to early therapy than pa-
tients who are cured by their treat-
ment (Fig. B5.13.1). PCR MRD 
techniques can detect residual dis-
ease at a sensitivity of about 1 in 
100 000 cells (10–5), with quantifi-
cation to 10–4 using definitions and 
standard procedures established by 
the EuroMRD group [2].
The molecular detection of sub-
microscopic residual cancer cells is 
clinically useful in many malignan-
cies and depends on having specific 
markers for the disease. The mark-
ers most commonly used in ALL are 
the unique gene rearrangements 
present in cells of T- and B-cell lin-
eage. The capacity of our immune 
systems to recognize millions of 
different antigens depends on the 
huge diversity of immunoglobulins 
and T-cell receptors, which results 
from the genetic rearrangement of 
numerous alternative gene seg-
ments present in the genes coding 
for these antigen receptor proteins. 
Each leukaemic clone therefore has 
one or more unique gene rearrange-
ments that can be used as molecular 
markers to distinguish the DNA of 
the leukaemic clone from the pa-
tient’s normal DNA.
In addition to markers based 
on antigen receptor genes, several 
recurrent translocations and micro-
deletions can be used as markers 
for smaller subsets of patients with 
childhood leukaemia to measure 
MRD in either genomic DNA or 
RNA samples from blood or mar-
row. In patients with Philadelphia 
chromosome-positive leukaemia, 
the BCR-ABL transcripts are mea-
sured by reverse-transcriptase PCR 
to detect disease recurrence at very 
low levels, allowing immediate inter-
vention to treat molecular disease. 
Leukaemia in infants often has 
translocations involving the mixed 
lineage leukaemia (MLL) gene with 
unique breakpoints, which provide 
useful MRD markers, particularly in 
this patient group. MRD markers for 
ALL based on recurrent deletions in 
genes implicated in normal lymphoid 
development, such as IKZF1 and 
CRLF2, are also likely to be used in 
the future, especially since they oc-
cur in higher-risk patients and their 
generic PCR MRD assays do not 
require DNA sequencing for each 
patient, making MRD diagnostics 
more accessible [3].
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and JAK/STAT signalling pathways. 
A subset of classic Hodgkin lympho-
ma, most often mixed cellularity sub-
type, is positive for EBV, but the viral 
programme does not appear to pri-
marily drive the neoplastic process.
Acute lymphoblastic 
leukaemia (ALL)/lympho- 
blastic lymphoma
Acute lymphoblastic leukaemia 
(ALL)/lymphoblastic lymphoma are 
neoplasms of precursor B cells or 
T cells (lymphoblasts) with features 
corresponding to stages of B-cell 
development in the marrow and 
T-cell development in the thymus 
(Figs 5.13.1, 5.13.2). They usually 
involve bone marrow and blood in 
the case of ALL but can present in 
extramedullary sites, typically in lym-
phoblastic lymphoma. Morphology 
and immunophenotyping suffice to 
establish the diagnosis, but recur-
ring cytogenetic abnormalities oc-
cur in 80% of ALL (Fig. 5.13.5), and 
many have proven important for risk 
stratification (see “Molecular detec-
tion of minimal residual disease in 
childhood leukaemia”). However, not 
all cytogenetic abnormalities are 
sufficient to establish a leukaemic 
clone, and cooperating molecular 
defects have long been suspected. 
Recently, whole-genome profiling 
in ALL has  identified several gene 
mutations and submicroscopic de-
letions that affect molecules crucial 
to B- and T-cell maturation, some of 
which correlate with clinical features. 
For example, 15% of paediatric B-cell 
ALL carries deletions or mutations 
of IKZF1 that affect transcriptional 
regulation of lymphoid maturation 
and confer a poor prognosis. Key 
genetic alterations in B-cell ALL, 
in addition to IKZF1, involve PAX5, 
JAK1, JAK2, CRLF2, and CREBBP. 
In T-cell ALL, activating mutations 
of NOTCH1 are found in about 
50% of cases and correlate with a 
favourable outcome. In the future, 
whole-genome analyses may allow 
for better characterization of ALL and 
identification of abnormalities for tar-
geted therapy [23–25].
Acute myeloid leukaemia
Acute myeloid leukaemia (AML) is 
a heterogeneous disease charac-
terized by increased blasts (usually 
≥ 20% myeloblasts, monoblasts plus 
promonocytes, and/or megakaryo-
blasts) in blood or bone marrow. In 
recent years, there has been im-
provement in survival, particularly in 
younger patients, but AML remains a 
fatal disease for most patients. The 
WHO classification of AML assigns 
patients to categories useful for pre-
dicting outcome. Some are classified 
according to genetic abnormalities 
that determine morphological and 
clinical features (AML with recurrent 
genetic abnormalities), others have 
morphology and/or genetics that 
relate them to myelodysplastic syn-
dromes (AML with myelodysplasia-
related changes), some are unique 
because they follow prior cytotoxic 
therapy (therapy-related myeloid 
neoplasms), and the remainder are 
classified by lineage involvement 
and degree of differentiation.
Currently, karyotype and age are 
the most powerful predictors of prog-
nosis [26,27]. Whole-genome and 
exome sequencing have revealed 
a plethora of gene mutations and 
submicroscopic genetic defects in 
this type of leukaemia. Although the 
prognostic significance of some al-
terations, particularly mutated FLT3, 
NPM1, and CEBPA, has been recog-
nized, the significance of many oth-
ers remains to be determined [28]. A 
separate study involving 200 cases 
reported that AML genomes have 
fewer mutations than those of most 
other adult cancers, with an aver-
age of only 13. A total of 23 genes 
were significantly mutated, and 
nearly all samples had at least one 
non-synonymous mutation in one of 
nine categories of genes relevant for 
pathogenesis, including transcrip-
tion factor fusions (18% of cases), 
the gene encoding nucleophosmin 
(NPM1) (27%), tumour suppressor 
genes (16%), DNA methylation-re-
lated genes (44%), signalling genes 
(59%), chromatin modifying genes 
(30%), myeloid transcription fac-
tor genes (22%), cohesin-complex 
genes (13%), and spliceosome-com-
plex genes (14%) (see “De novo DNA 
methyltransferases in normal and 
malignant haematopoiesis”) [29].
Fig. 5.13.5. Frequency of cytogenetic subtypes of paediatric acute lymphoblastic leu-
kaemia (ALL). Pie chart includes all major B-cell ALLs (shown in green) and T-lineage 
subtypes of ALL (shown in red), to illustrate the relative frequency of each. The recently 
described BCR-ABL1-like subtype and BCR-ABL1-positive ALL are shown in yellow 
to illustrate the high frequency of childhood B-cell ALL cases with genetic alterations 
activating tyrosine kinase and cytokine receptor signalling, which may be amenable to 
targeted therapy. Data are derived from front-line studies of childhood ALL.
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De novo DNA methyltransferases in normal and malignant haematopoiesis
Margaret A. Goodell
DNA methylation plays a central role 
in regulating gene expression during 
development and is known to be dis-
turbed in a variety of malignancies. 
The mechanisms through which 
aberrant DNA methylation contrib-
utes to malignancy development, 
and through which hypomethylating 
agents exert their effects, are poorly 
understood. De novo DNA methyla-
tion in murine haematopoietic stem 
cells has been studied as a model to 
address some of these fundamental 
questions.
Murine haematopoietic stem 
cells express high levels of both 
de novo DNA methyltransferases 
Dnmt3a and Dnmt3b. Using con-
ditional knockout mice, the role of 
Dnmt3a in murine haematopoiesis 
has been investigated. The data indi-
cate that in the absence of Dnmt3a, 
haematopoietic stem cell self-re-
newal is dramatically enhanced at 
the expense of differentiation. Serial 
stem cell transplantation augments 
this effect, such that phenotypically 
normal haematopoietic stem cells 
that fail to differentiate accumulate 
to high levels. Paradoxically, DNA 
methylation, examined genome-
wide, is both increased and de-
creased in Dnmt3a knockout hae-
matopoietic stem cells, with CpG 
islands preferentially hypermethyl-
ated, similar to the pattern of DNA 
methylation alterations in malignan-
cies. The differentiated progeny of 
Dnmt3a knockout haematopoietic 
stem cells exhibited aberrant contin-
ued expression of stem cell-specific 
genes that are normally repressed 
during differentiation. While muta-
tions in DNMT3A are prevalent in 
human acute myeloid leukaemia, no 
frank leukaemia development was 
observed in the mice within the time 
frame initially examined.
Haematopoietic stem cell-spe-
cific Dnmt3b knockout mice and 
Dnmt3a-Dnmt3b double-knockout 
haematopoietic stem cells have also 
been examined. In the absence of 
both de novo DNA methyltransfer-
ases, the haematopoietic stem cells 
accumulate even more dramatically 
than in the Dnmt3a knockout, even 
though loss of Dnmt3b alone has 
minimal impact. Introduction of on-
cogenes into the Dnmt3a knock-
out stem cells decreases the time 
to malignant transformation com-
pared with the oncogene or Dnmt3a 
knockout alone. These findings 
are pertinent to understanding the 
implications of mutations in DNA 
methyltransferases found in human 
haematological malignancies.
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Chronic myeloid leukaemia, 
BCR-ABL1-positive
Chronic myeloid leukaemia, BCR-
ABL1 is a myeloproliferative neo-
plasm arising in a pluripotent hae-
matopoietic stem cell and is always 
associated with the BCR-ABL1 
fusion gene resulting from the 
chromosomal translocation t(9;22)
(q34;q11.2). BCR-ABL1 encodes an 
oncoprotein with constitutively ac-
tivated tyrosine kinase activity that 
drives proliferation by interaction 
with the downstream pathways RAS, 
RAF, MYC, JUN kinase, and STAT. 
The natural history includes an ini-
tial chronic phase characterized by 
granulocytic proliferation and granu-
locytosis, followed by an accelerated 
phase and/or a myeloid or lymphoid 
blast phase. The development of 
tyrosine kinase inhibitors has dra-
matically improved overall survival, 
from a 10-year overall survival of 15–
20% before these drugs were avail-
able to 80–90% subsequent to their 
use. Point mutations in the tyrosine 
kinase domain of BCR-ABL result in 
resistance to many tyrosine kinase 
inhibitors, and disease progression. 
Most patients refractory to front-line 
therapy usually respond to newer-
generation tyrosine kinase inhibitors, 
but others may progress to the blast 
phase, which has a uniformly poor 
outcome [30].
BCR-ABL1-negative myelo- 
proliferative neoplasms
These diseases, which include poly-
cythaemia vera, essential thrombo-
cythaemia, and primary myelofibro-
sis, are clonal, stem-cell-derived 
neoplasms characterized by ex-
cessive production of differentiated 
myeloid cells, which are sometimes 
difficult to distinguish from reactive 
marrow proliferations. In 2005, it 
was found that almost all patients 
with polycythaemia vera and nearly 
50% with essential thrombocythae-
mia or primary myelofibrosis have an 
activating somatic mutation, JAK2 
V617F, encoding the cytoplasmic ty-
rosine kinase JAK2. This discovery 
proved that these myeloproliferative 
neoplasms have abnormal cell sig-
nalling pathways, providing an im-
portant diagnostic tool – the JAK2 
mutation – and raising expectations 
that tyrosine kinase inhibitors would 
emulate the successful therapy such 
agents mediated in chronic myeloid 
leukaemia. But additional data have 
shown that the JAK2 mutation is 
likely a secondary event and have 
also uncovered a complex layering 
of multiple genetic defects, particu-
larly affecting genes such as TET2, 
EZH2, and IDH1/IDH2 involved in 
epigenetic regulation [31]. These 
additional abnormalities may ac-
count for the only modest success 
to date using tyrosine kinase inhibi-
tors. Further improvements to under-
standing of the BCR-ABL1-negative 
myeloproliferative neoplasms will 
rely on their meticulous classifica-
tion to enable correlation with the 
underlying genetic milieu.
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Summary
• Malignant melanoma is an ag-
gressive human cancer; over the 
past few decades, its incidence 
has increased dramatically 
worldwide among Caucasian 
populations.
• The risk of developing malig-
nant melanoma varies mark-
edly according to racial back-
ground (skin pigmentation) and 
geographical location (sunlight-
derived ultraviolet radiation). 
Ultraviolet-emitting tanning de-
vices increase the risk of malig-
nant melanoma.
• For patients with localized mel-
anoma, prognosis is good with 
adequate surgical excision; 
metastatic melanoma is largely 
resistant to current therapies.
• Non-melanoma skin cancer 
includes squamous cell carci-
noma and basal cell carcinoma, 
which are malignant epithelial 
neoplasms that often arise on 
sun-exposed areas of the skin 
in fair-skinned populations. 
These cancers cause local tis-
sue destruction with functional 
and cosmetic deformity but are 
rarely a cause of death.
• Avoidance of excessive ultra-
violet radiation from sunlight or 
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tanning devices, particularly in 
young people, is the most effec-
tive way to prevent melanoma 
and non-melanoma skin cancer.
Cutaneous melanoma
Melanoma is the most aggressive 
form of skin cancer [1,2]. Cutaneous 
melanoma is a malignant prolifera-
tion of melanocytes, the pigment-
forming cells of skin.
Etiology
Environmental factors play impor-
tant roles in melanoma development 
and progression, including age, sex, 
degree of sun exposure, and ana-
tomical location, as well as individ-
ual susceptibility. Only 20–30% of 
melanomas arise in association with 
a melanocytic naevus, but the pres-
ence of dysplastic naevi has been 
shown to be an independent risk 
factor for the development of mul-
tiple primary melanomas [3]. Other 
risk factors include family history of 
melanoma and prior melanoma. In 
addition, rarely germline mutations 
have been found to confer risk; for 
example, mutations of the CDKN2A 
gene (on chromosome 9p21) have 
been found in 20–40% of families 
with dysplastic naevus syndromes in 
which at least three first-degree rela-
tives are affected by melanoma [4].
In addition to genetic factors, ul-
traviolet radiation from sun exposure 
also contributes to melanoma devel-
opment. Most melanomas (80%) are 
caused by ultraviolet damage to sen-
sitive skin, i.e. skin that burns easily, 
fair or reddish skin, skin with multiple 
freckles, or skin that does not tan and 
develops naevi in response to early 
sunlight exposure. Most damage 
caused by sunlight occurs in child-
hood and adolescence. Ultraviolet 
radiation is particularly hazardous 
when it involves sporadic intense ex-
posure, especially during childhood 
and early adolescence, for example 
through indoor tanning; children and 
adolescents are thus the most impor-
tant target group for prevention pro-
grammes [5].
Melanoma may occur anywhere 
on the skin, but in men most mela-
nomas occur on the back, whereas 
in women most occur on the legs. 
In addition, patterns of age-specific 
incidence of melanoma at different 
anatomical sites in fair-skinned pop-
ulations show that melanomas aris-
ing on intermittently exposed body 
sites are significantly more common 
among younger and middle-aged 
adults, whereas melanomas of the 
head and neck are most common 
among older people. The difference 
in incidence by anatomical site is not 
completely explained by differential 
exposure to ultraviolet radiation. 
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Epidemiology
Melanoma
• There were more than 232 000 
new cases of melanoma and 
about 55 000 deaths estimated 
in 2012; the relatively low mor-
tality rates are indicative of the 
reasonable prognosis.
• Incidence varies 100-fold be-
tween countries worldwide. 
Rates are highest in countries 
with predominantly Caucasian 
populations, and more than 
80% of the estimated new cases 
and close to 65% of the cancer 
deaths occurred in Oceania, 
Europe, and North America.
• Incidence rates in Australia and 
New Zealand are 2 times those 
observed in any other country. 
Incidence rates tend to be rather 
low in most African, Asian, and 
Latin American countries.
• Mortality tends to be higher in 
men than in women, related to 
sex differences in detection, 
body location of tumours, and 
subsequent prognosis.
• Incidence and mortality have 
been increasing over the past de-
cades in many populations that 
are predominantly Caucasian. Of 
note is the (cohort-specific) sta-
bilization and/or recent decline 
in incidence in certain high-risk 
populations (e.g. in Australia 
and among Whites in the USA). 
In low-risk populations (Asia, 
Africa, and to some extent Latin 
America), incidence rates have 
remained low and stable over 
time.
Map 5.14.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for melanoma in women, 2012.
Map 5.14.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for melanoma in women, 2012.
Moreover, melanoma can occur in 
areas of the body without sun expo-
sure as well as in any ethnic group.
Pathology
Melanomas occur primarily in the skin – 
more than 95% of cases – but are 
also found in the mucous membranes 
of the mouth, nose, anus, and vagina 
and, to a lesser extent, the intestine; 
melanocytes are also present in the 
conjunctiva, the retina, and the menin-
ges. Melanoma can be subtyped his-
tologically into superficial spreading 
melanoma, nodular melanoma, acral 
lentiginous melanoma, and lentigo 
maligna melanoma. A staging sys-
tem based on the histopathological 
parameters of the excised le-
sion, including multiple prognostic 
factors, is recommended [6]. The 
most robust independent prognos-
tic factor in melanoma is tumour 
thickness (Breslow depth), found by 
measuring the vertical depth from the 
granular cell layer of the epidermis 
to the deepest detectable melanoma 
cell. In recent years, two additional 
criteria, ulceration and mitosis, 
have been shown to be important in 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.14.1. Estimated global number of new cases and deaths with proportions by major world regions, for melanoma in 
both sexes combined, 2012.
Chart 5.14.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for melanoma in 
women, circa 1975–2012.
Chart 5.14.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for melanoma in 
women, circa 1975–2012.
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prognosis and have been includ-
ed in the classification system 
(Table 5.14.1).
Most acquired naevi feature 
small round, oval, or spindled me-
lanocytes. Small melanocytes with 
scant cytoplasm are evident in mel-
anomas in severely sun-damaged 
skin. Large round or oval epithelioid 
melanocytes occur both in benign 
proliferations and in melanoma.
The outcome of melanoma initial-
ly depends on the stage at presenta-
tion. Excellent prognosis with 5-year 
survival rates of more than 90% can 
be achieved for patients who present 
Table 5.14.1. Classification of melanoma and recommended surgical margins for 
primary melanoma
Classification Melanoma thickness Surgical excision margins
Tis In situ melanoma/no invasion of the dermis 5 mm
T1 ≤ 1 mm 10 mm
T1a Without ulceration and/or mitosis < 1/mm2  
T1b With ulceration and/or mitosis > 1/mm2  
T2a 1.01–2.0 mm 10 mm
T3 2.01–4.0 mm 20 mm
T4 > 4.01 mm 20 mm
a Levels T2–4 are classified a if ulceration is present, b if no ulceration is present.
Evaluating sunscreen as a measure to reduce the risk of melanoma
Adèle C. Green
For several decades it was debated 
whether sunscreen use could pre-
vent melanoma, even though it was 
biologically plausible that shielding 
the skin from excessive exposure to 
solar ultraviolet radiation in the long 
term would reduce the incidence of 
melanomas of the skin. Although 
many studies had examined this is-
sue, human evidence was inconclu-
sive because the studies were not 
randomized but observational. This 
means they were unable to distin-
guish the main drivers of sunscreen 
use from those of melanoma cau-
sation, since they largely overlap: 
susceptibility to sunburn, high oc-
cupational or recreational sun expo-
sure, and family history of melanoma 
[1]. Arguments against sunscreen as 
a melanoma preventive were also 
put forward, such as the example of 
dedicated sunbathers who misused 
sunscreen to prolong rather than 
minimize their sun exposure.
Evidence from a community-
based trial has gone a long way 
towards resolving this debate. The 
Nambour Skin Cancer Prevention 
Trial was a randomized controlled 
trial involving 1621 adults aged 25–
75 years who had been randomly 
selected from all adult residents of 
Nambour, a subtropical Australian 
township. In 1992 they were ran-
domized either to apply a freely 
supplied broad-spectrum sunscreen 
with a sun protection factor (SPF) 
of 15+ to the head and arms daily 
until 1996, or to continue their usual 
level of sunscreen use or non-use. 
Trial participants were then followed 
up for a decade after cessation of 
the sunscreen intervention, with 
monitoring of all new melanomas, 
through pathology laboratories and 
the Queensland Cancer Registry, 
and of their ongoing sun behav-
iour. Ten years after cessation of 
the sunscreen intervention, the 812 
people randomized to daily sun-
screen use had half as many new 
melanomas (11) as the control group 
of 809 people (22) [2], a difference 
of borderline statistical significance 
(P = 0.051). The decrease after 
regular sunscreen use was greater 
in invasive melanomas than in situ 
melanomas. During the trial, 75% of 
the intervention group applied sun-
screen at least 3 or 4 days per week, 
compared with 25% of the control 
group; the sunscreen group also 
applied sunscreen more often to 
the trunk and legs than did the con-
trols. Otherwise, background sun 
exposure and protection patterns 
were the same in the intervention 
and control groups throughout the 
study period [2].
Use of a sunscreen with a 
higher SPF or greater ultraviolet 
A protection may have shown a 
stronger preventive effect, but in-
creasing the participants’ average 
thickness of sunscreen application 
would more likely have had an even 
greater beneficial effect [3]. While 
this trial showed that regular use of 
sunscreen could halve people’s risk 
of developing melanoma, replication 
of the findings in another popula-
tion would give further weight to the 
evidence.
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with localized disease and primary 
tumours less than 1.0 mm in thick-
ness. As recommended in the lat-
est American Joint Committee on 
Cancer staging manual, melanoma 
patients are categorized into three 
groups: localized disease with no 
evidence of metastases (stage I–
II), regional disease (stage III), and 
distant metastatic disease (stage 
IV). For localized disease (stage I 
and II), Breslow tumour thickness, 
ulceration, and mitotic rate are the 
three most important characteristics 
of the primary tumour for predicting 
outcome [6].
Genetics
Heritable susceptibility is very im-
portant in melanoma tumorigenesis. 
Germline mutations of two genes 
have been discovered in melanoma-
prone families: CDKN2A (on chromo-
some 9p21), which encodes p16INK4A, 
and CDK4 (on chromosome 12), 
which encodes cyclin-dependent ki-
nase 4. A CDKN2A mutation causing 
functional inactivity of p16 has been 
found in up to 25% of melanoma-
prone families worldwide, whereas 
a CDK4 mutation causing overex-
pression of CDK4 protein, which is 
inhibited by p16, resulting in dysreg-
ulation of the cell cycle, has been 
observed in only a few rare families 
[7]. In addition, loss-of-function 
mutations in the human melanocor-
tin 1 receptor (MC1R) gene have 
been associated with red hair, fair 
skin, freckles, and decreased ability 
to tan. However, susceptibility genes 
identified in melanoma-prone fami-
lies are rarely mutated in sporadic 
melanomas. Numerous somatic mu-
tations in melanoma vary between 
individuals and are different from 
those in other malignancies. Only 
20% of melanomas harbour common 
TP53 mutations and inactivation of 
p16INK4A, associated with a poorer 
prognosis in melanoma.
Genes identified as playing a 
role in development of sporadic 
melanoma include CDKN2A, PTEN, 
and BRAF, and genes located on 
chromosomes 1p, 6q, 7p, 9p, and 
11q. Mutations in BRAF (on chromo-
some 7q) occur at a high frequency 
(45%) in melanomas [8], while so-
matic mutations in BRAF have also 
been detected in 50% of patients with 
dysplastic naevi. The BRAF, NRAS, 
and KIT genes, involved in cell-cycle 
activating pathways, are commonly 
mutated in melanomas. The cur-
rent data support a model in which 
melanoma tumorigenesis requires 
changes that initiate clonal expan-
sion, overcome cell senescence, and 
reduce apoptosis. Thus, combination 
drug therapies with tyrosine kinase 
inhibitors of multiple components in 
the mitogen-activated protein kinase 
pathway, including MEK and ERK, 
are in clinical trials. Melanoma also 
is characterized by chromosomal 
gains, for example at 1q, 3p, 6p, 7, 
8q, 11q, 12q14, 17q, and 20q, which 
encompass the melanoma onco-
genes CDK4, cyclin D1 (CCND1), 
MYC, MDM2, and MITF, as well as 
chromosomal losses, for example at 
1p, 6q, 9p, 10q, 11q, 17p, and 21q, 
which harbour the tumour suppres-
sors p15 INK4B, p16 INK4A, p14ARF, and 
PTEN.
Whole-genome sequence data 
from 25 metastatic tumours identi-
fied PREX2 – a PTEN-interacting 
protein and a negative regulator of 
PTEN in breast cancer – as a signifi-
cantly mutated gene, with a mutation 
frequency of approximately 14% in 
an independent extension cohort of 
107 human melanomas [9]. Other ge-
netic changes include microsatellite 
instability, loss of heterozygosity, and 
increased activity of the telomerase 
enzyme.
Changes in gene expression con-
tribute to progression from early be-
nign melanocytic lesions to dysplas-
tic naevi, to primary melanoma with 
a radial and then a vertical growth 
pattern, and to the acquisition of 
metastatic capacities. However, this 
sequence is challenged by the identi-
fication of malignant melanoma stem 
cells [10]. Stem-like melanoma cells 
with expression of CD133, ABCB5, 
CD271, and CD166 are involved in 
the processes of progression and 
metastasis and are highly resistant 
to drugs and toxins [11].
Melanoma development not only 
requires genetic changes but is also 
driven by epigenetic alterations. 
5-Hydroxymethylcytosine, a further 
indicator of modified DNA methyla-
tion, is lost in melanoma genome-
wide [12]. Rebuilding the 5-hydroxy- 
methylcytosine landscape in mela-
noma cells by reintroducing active 
TET2 or IDH2 suppresses melanoma 
growth and increases tumour-free 
survival in animal models. Tumour 
suppressor small, non-coding RNAs, 
including miR-9, miR-34, miR-148a, 
and miR-375, are silenced by promot-
er hypermethylation [13]. Expression 
of the histone H3K9 methyltrans-
ferase SETDB1 accelerates mela-
noma formation in zebrafish [14]. 
In addition, the H3K4 demethylase 
KDM5B (also called JARID1B) is con-
sidered a melanoma stem cell marker 
[15]. The ability to understand and 
Fig. 5.14.2. Malignant melanoma. Micro- 
graph showing a lesion just beneath 
the epidermis with pigmented and non- 
pigmented cells.
Fig. 5.14.1. Gross appearance of a cuta-
neous pigmented lesion, which had been 
diagnosed as nodular melanoma. Note the 
dark reddish brown to black coloration of 
this lesion, as well as its raised nodular 
texture and amorphous, irregular borders, 
which should evoke suspicions about its 
classification.
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control reversible epigenetic changes 
before irreversible mutations ensue 
may play an increasingly important 
role in further cancer prevention and 
treatment.
Prospects
Prevention
Prevention of melanoma is based on 
limiting exposure to ultraviolet radia-
tion, particularly in the first 20 years 
of life. Sun avoidance behaviour and 
protection through increased shaded 
areas and appropriate clothing have 
been widely adopted as protective 
measures. Exposure can also be re-
duced by avoiding artificial sources 
of ultraviolet radiation like sunbeds. 
Unequivocal evidence of the melano-
ma-preventive effects of sunscreen 
use is lacking (see “Evaluating sun-
screen as a measure to reduce the 
risk of melanoma”). Notwithstanding 
the inherent uncertainties and as-
sumptions, the available evidence 
suggests that significant numbers 
of melanomas might be avoided 
by regular sunscreen use during 
recreational summer sun exposure 
[16]. The matter is of high priority to 
countries with a large fair-skinned 
community and strong lifestyle orien-
tation to sun exposure, such as the 
USA [17] and Australia [18].
Targeted therapy
Ipilimumab, a monoclonal antibody 
against CTLA-4, was the first immu-
nomodulating antibody approved in 
the USA, in March 2011, for meta-
static melanoma. Vemurafenib [19], a 
specific inhibitor of signalling by mu-
tated BRAF, was approved in August 
2011 for patients with stage IV mela-
noma with documented V600E or 
V600K mutation of the BRAF gene. 
These targeted agents have signifi-
cantly changed the treatment regimen 
of metastatic melanoma. However, 
the use of these agents is challenged 
by their side-effects and unique limi-
tations. For example, ipilimumab can 
achieve durable response but has 
a low overall response rate of less 
than 20%; vemurafenib has a higher 
response rate of 40–50% but with a 
median duration of only 5–6 months. 
Recent progress in the understand-
ing of melanoma biology has led to 
the identification of novel pathways 
that could serve as targets for novel 
therapy (Fig. 5.14.4). For example, 
the PI3K pathway [20] and the p16–
cyclin D–CDK4/6–retinoblastoma 
pathway [21] could be exploited. In 
addition, some pilot clinical data sug-
gest potential benefits with targeted 
therapeutic melanoma vaccines, for 
example infusion of lymphocytes 
genetically modified to express 
the MAGE-A3 tumour antigen in 
patients with advanced melanoma. 
A consensus statement on tumour 
immunotherapy for the treatment of 
cutaneous melanoma has recently 
been adopted [22].
Non-melanoma skin cancer
Basal cell carcinomas and squa-
mous cell carcinomas are the two 
malignant epithelial neoplasms and 
the main forms of non-melanoma 
skin cancer, accounting for the large 
majority of all skin cancers.
Etiology
Among several risk factors, sun 
exposure is the most recognized 
environmental cause, especially 
for squamous cell carcinoma. The 
association between sun exposure 
and basal cell carcinoma is more 
complex than that for squamous cell 
carcinoma [23]. Basal cell carcinoma 
seems to be associated more with 
intermittent exposure to high doses 
of solar radiation compared with sim-
ilar doses delivered more continu-
ously [24]. Fair-skinned populations 
who have substantial exposure to 
Fig. 5.14.3. Sunscreen can help prevent 
sunburn and may contribute to a reduced 
risk of both melanoma and non-melanoma 
skin cancer.
Fig. 5.14.4. (A) Key signalling pathways in melanoma. Potentially druggable targets 
are indicated by purple shading. Mitogen-activated protein kinase (MAPK) signalling 
can be constitutively activated through alterations in membrane receptors or through 
mutations of RAS or BRAF. BRAF is frequently mutated in melanomas, almost in-
variably by the V600E mutation, which results in an amino acid substitution at position 
600, from a valine (V) to a glutamic acid (E), causing constitutive kinase activation. 
 (B) Mechanisms of BRAF inhibitor resistance include reactivation of the MAPK pathway 
by CRAF, ARAF, or the p61BRAF(V600E) splice variant, mutational activation of NRAS 
or MEK, loss of the tumour suppressor NF1, and activation of compensatory pathways 
such as the PI3K network via enhanced receptor tyrosine kinase signalling (particularly 
through PDGFRβ, IGF1-R, FGFR, HGFR, and EGFR). Therapies approved or pending 
approval are shown in red. Activating mutations found are indicated by yellow shading, 
and inactivation by pink shading.
Chapter 5.14 • Skin cancer 501
5 
O
R
G
A
N
 S
IT
E
C
H
A
P
TE
R
 5
.1
4
ultraviolet radiation from sun ex-
posure as well as indoor tanning, 
especially at a young age, have an 
increased risk of developing non-
melanoma skin cancers [25,26]. In 
addition, most of these malignancies 
develop on sun-exposed skin sites, 
especially the head and neck area 
(80%). Actinic keratosis is a precur-
sor with the potential to progress to 
invasive squamous cell carcinoma, 
and is considered to be a sun-in-
duced precancerous lesion for these 
tumours. Besides sun exposure, 
therapeutic exposure to “psoralen 
plus ultraviolet A light” therapy for 
cutaneous disorders is associated 
with increased risk of non-melanoma 
skin cancers, particularly squamous 
cell carcinoma. Ionizing radiation 
used to treat childhood cancers in-
creases the risk of subsequent de-
velopment of non-melanoma skin 
cancers, including basal cell carci-
nomas. Arsenic exposure, including 
environmental exposure, has been 
associated with increased risk of 
both tumour types.
Immunocompromised individu-
als – typically organ transplant re-
cipients, patients with a history of 
long-term steroid use, and people 
with HIV/AIDS – are at higher risk 
of non-melanoma skin cancer [27]. 
Non-melanoma skin cancers in organ 
transplant recipients are associated 
with human papillomavirus (HPV) 
infection of skin keratinocytes. In ad-
dition, detection of beta HPV species 
in cutaneous squamous cell carcino-
ma suggests that certain HPV types 
may be involved in the progression 
of squamous cell carcinoma in im-
munocompetent individuals as well. 
Furthermore, epidermodysplasia 
verruciformis-associated HPV infec-
tion of skin keratinocytes seems to 
be associated with increased risk of 
squamous cell but not basal cell car-
cinomas [28]. This association with 
HPV remains confined to squamous 
cell carcinomas arising on chronically 
sun-exposed areas of the skin.
Development of non-melanoma 
skin cancer is associated with a 
range of inherited disorders. Basal 
cell naevus syndrome (also called 
naevoid basal cell carcinoma syn-
drome or Gorlin syndrome) is a rare 
autosomal dominant disorder due 
to germline mutations of the PTCH 
gene. Developmental abnormalities, 
postnatal tumours, and multiple ba-
sal cell carcinomas are observed 
in affected patients. Epidermolysis 
bullosa syndrome is a heteroge-
neous group of inherited blistering 
disorders due to minor trauma. The 
Dowling–Meara form of epidermol-
ysis bullosa simplex is associated 
with an increased risk of basal cell 
carcinoma; squamous cell carcino-
mas arise primarily in autosomal 
recessive dystrophic epidermoly-
sis bullosa and are the most seri-
ous complication for these patients. 
Naevus sebaceous is a rare congen-
ital hamartoma of the skin composed 
of epidermal, follicular, sebaceous, 
and apocrine elements. While 15% 
of patients with naevus sebaceous 
develop some types of appendage 
tumour, 5% are diagnosed with basal 
cell carcinoma.
Pathology and genetics
Squamous cell and basal cell car-
cinomas are the major types of ke-
ratinocytic tumours derived from the 
proliferation of epidermal and adnexal 
keratinocytes. The multiple variants of 
basal cell carcinoma have in common 
lobules, columns, bands, and cords of 
basaloid cells associated with scant 
cytoplasm, and a characteristic outer 
palisade of cells associated with a 
surrounding loose fibromucinous 
stroma. Squamous cell carcinoma is 
a malignant neoplasm of epidermal 
keratinocytes in which the compo-
nent cells show variable squamous 
differentiation.
Besides the risk factors such as 
sun exposure, genetic variations of 
populations also play a role in devel-
opment of non-melanoma skin cancer. 
Basal cell and squamous cell carci-
nomas arise predominantly in sun-
sensitive people with fair skin and a 
history of sunburn [23]. Individuals 
with albinism, with lack of skin pigmen-
tation, and patients with xeroderma 
pigmentosum, which causes an ex-
treme sensitivity to sunlight, have a 
greatly increased risk of developing 
these tumours because they have little 
or no ability to repair skin damaged by 
ultraviolet radiation. In the past dec-
ade, significant advances have been 
made in terms of understanding the 
molecular pathogenesis of non-mela-
noma skin cancer. Ultraviolet-induced 
mutations of the tumour suppressor 
gene TP53 are frequently observed in 
these cancers [29]. The sonic hedge-
hog signalling pathway plays a critical 
role in the pathogenesis of basal cell 
carcinoma. Mutations in the PTCH 
gene, which codes for a receptor of 
sonic hedgehog, are the underlying 
cause of naevoid basal cell carcinoma 
syndrome.
Non-melanoma skin cancers are 
usually indolent, but certain patho-
logical features indicate high risk of 
recurrence and the potential for me-
tastasis. In basal cell carcinoma, the 
histological subtypes of micronodular, 
infiltrative, and morpheaform basal 
cell carcinoma are more likely to recur 
than are the superficial and nodular 
subtypes. Basosquamous carcinoma, 
a “collision”-type tumour, is associated 
with a more aggressive nature, with 
an increased risk of metastasis [30].
Prospects
The primary approach to preventing 
skin cancer is protection from sun ex-
posure with various techniques. See 
the discussion above, at the end of 
the section on cutaneous melanoma.
Fig. 5.14.5. A young woman uses a sun-
bed. Excess exposure to ultraviolet radia-
tion is the most important modifiable risk 
factor for both malignant melanoma and 
non-melanoma skin cancer.
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Summary
• The incidence of thyroid cancer is 
increasing worldwide. This trend 
is attributed predominantly to the 
improved detection and screen-
ing of nodular thyroid disease, 
particularly involving detection 
of papillary microcarcinoma.
• Exposure to ionizing radiation, 
especially during childhood, is a 
cause of thyroid cancer.
• Multiple endocrine neoplasia 
type 2 (MEN2)-associated med-
ullary thyroid carcinoma serves 
as a role model for personal-
ized medicine as RET proto-
oncogene mutation analysis 
enables predictive testing and 
genotype-based, tailored pro-
phylactic treatment.
• Molecular profiling using BRAF 
mutation analysis can allow for 
risk assessment of papillary thy-
roid carcinoma.
• Targeted therapy will provide nov-
el options to treat advanced and 
de-differentiated thyroid cancer.
Thyroid cancer includes a variety 
of malignancies ranging from the 
common differentiated thyroid can-
cers to the very rare but uniformly 
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lethal anaplastic thyroid cancer [1,2]. 
Thyroid cancers develop either from 
the follicular epithelial cells – giving 
rise to papillary thyroid cancer, fol-
licular thyroid cancer, and likely un-
differentiated and anaplastic thyroid 
cancer – or from the parafollicular, 
calcitonin-producing C cells, which 
give rise to medullary thyroid cancer 
(Fig. 5.15.1).
Etiology
Worldwide, thyroid cancer is among 
the less frequent malignancies. 
However, in the past decades the 
incidence has almost doubled – at-
tributed for the most part to the in-
creased diagnosis of papillary thy-
roid cancer [3]. While the reasons 
for the increase in thyroid cancer 
incidence require further elucida-
tion, several lines of evidence indi-
cate that in most circumstances the 
increase is attributable to optimal 
diagnostic scrutiny aided by techni-
cal advances [3,4]. Overall, the eti-
ology of thyroid cancer is not fully 
understood.
A clear gender disparity is evi-
dent for thyroid cancer; it occurs 
more frequently in women than in 
men. In the USA, this tumour type 
accounts for 1.7% of all malignan-
cies, corresponding to 2.6% of 
cancers in women and 0.85% of 
cancers in men, whereas in Japan 
the female-to-male ratio may be 13 
[3]. Reasons for the overall 3-fold 
higher incidence of thyroid cancers 
in women than in men remain un-
clear. A role for female hormonal 
and reproductive factors as drivers 
for thyroid cancer development has 
been shown in vitro but has not been 
unequivocally established in popula-
tion-based analysis [5–7]. Thyroid 
cancer development is strongly as-
sociated with a history of benign 
nodules/adenoma or goitre [7]. 
Solitary, palpable thyroid nodules 
can be identified in about 7% of the 
adult population, and the prevalence 
of nodules increases with age; the 
lifetime risk of developing a thyroid 
Fig. 5.15.1. Surgical specimen showing 
thyroidectomy with en bloc central lymph-
adenectomy for papillary thyroid cancer.
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• With 77% of the cases occur-
ring in women in 2012, thyroid 
cancer is one of the few non-sex-
specific cancers that are more 
frequent in women. There were 
230 000 new cases in women, 
representing the eighth most 
frequent cancer among women, 
compared with 68 000 cases in 
men, representing the 18th most 
frequent cancer among men. 
• The case fatality of thyroid can-
cer is very low, most notably in 
countries with very high levels of 
human development (mortality-
to-incidence ratio, 0.14).
• There were an estimated 40 000 
deaths from thyroid cancer in 
2012 (27 000 of them in wom-
en). Mortality rates are highest in 
Melanesia, in parts of Africa, and 
generally in countries with lower 
levels of human development.
• Although 37% of the estimated 
new cases occurred in Europe 
and North America and 48% in 
Asia, only 21% of the thyroid can-
cer deaths occurred in Europe 
and North America, compared 
with 57% in Asia.
• Elevated incidence rates are 
found in some European coun-
tries and in North America. 
However, the highest incidence 
rates globally are in the Republic 
of Korea, where thyroid cancer is 
the most frequent cancer among 
women. Incidence rates tend to 
be low in many parts of Asia and 
in Africa.
Map 5.15.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for thyroid cancer in women, 2012.
Map 5.15.2. Global distribution of estimated age-standardized (World) mortality 
rates (ASR) per 100 000, for thyroid cancer in women, 2012.
nodule is estimated to be 10%. The 
relative risk of cancer development 
in patients with thyroid nodules 
is 3–6 compared with unaffected 
controls.
Population-based studies sug-
gest that risk of thyroid cancer is 
associated with several conditions. 
For instance, height and body mass 
index are moderately associated 
with thyroid cancer risk in both men 
and women [7]. Acromegaly, a rare 
condition caused by an overpro-
duction of growth hormone, is also 
associated with increased risk of 
thyroid cancer. With regard to di-
etary risk factors for thyroid cancer 
development, iodine deficiency may 
induce benign thyroid conditions 
that predispose for thyroid cancer. 
Furthermore, iodine deficiency is 
associated with the prevalence of 
follicular thyroid cancer [3] because 
in iodine-deficient countries follicular 
thyroid cancer accounts for up to 
40% of all thyroid cancer, whereas 
in regions with high iodine supple-
mentation the same tumour type ac-
counts for less than 20% of cases. 
However, it is uncertain to what ex-
tent dietary iodine intake might serve 
as a risk predictor for thyroid cancer 
development [7]. Published results 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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Chart 5.15.1. Estimated global number of new cases and deaths with proportions by major world regions, for thyroid cancer 
in both sexes combined, 2012.
Chart 5.15.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for thyroid cancer in 
women, circa 1975–2012.
Chart 5.15.3. Age-standardized (World) mortality rates per 
100 000 by year in selected populations, for thyroid cancer in 
women, circa 1975–2012.
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on the contribution of nutritional fac-
tors to thyroid cancer development 
are generally inconsistent and not 
conclusive.
Among the well-established 
high-risk factors for thyroid cancer 
development is exposure to ioniz-
ing radiation, especially when this 
occurs during childhood. Radiation 
exposure accounts for cancer de-
velopment in about 5% of patients. 
Sources of radiation include certain 
medical treatments as well as radia-
tion fallout from nuclear power plant 
accidents or nuclear weapons. The 
Chernobyl nuclear power plant acci-
dent took place in 1986, and during 
the following years an unprecedent-
ed rise in papillary thyroid cancer 
development during childhood was 
observed. Relevant cases indicat-
ed that ionizing radiation leads to 
chromosomal rearrangements such 
as RET/PTC fusion transcripts that 
give rise to papillary thyroid cancer 
development [8,9].
Radiation exposure in the con-
text of medical care has included 
treatment for acne or enlarged ton-
sils during the 1960s. While this in-
tervention is no longer used, previ-
ously exposed individuals are now in 
their fifties, the age group for which 
papillary thyroid cancer occurs most 
commonly. Other reasons for radia-
tion therapy in childhood are tumour 
therapy for cancers such as lympho-
ma, Wilms tumour, or neuroblasto-
ma. Exposure to diagnostic radiation 
(medical diagnostic radiography) has 
increased over the past years and 
currently is the leading source of 
radiation exposure in the USA. It is 
not fully established to what extent 
the repeated exposure to diagnostic 
radiation leads to an increased risk 
of thyroid cancer. However, a re-
cent study showed a 13% increase 
in thyroid cancer risk for every 10 
reported dental radiographs; caution 
should be exercised when requiring 
repeated radiography – especially 
during childhood [10].
Several inherited conditions, 
such as familial adenomatous pol-
yposis syndrome and Cowden syn-
drome, are associated with differ-
ent types of thyroid cancer [11]. For 
non-syndromic familial non-medul-
lary thyroid cancer, epidemiological 
data indicate a very high likelihood 
of familial aggregation and hence a 
strong genetic component. Indeed, 
about 10% of all non-medullary thy-
roid cancers are hereditary, and 
consequently first-degree relatives 
of patients with thyroid cancer have 
an up to 10-fold increased risk com-
pared with the general population. 
The standardized incidence ratio, an 
index for estimating familial risk of 
developing a malignancy, exceeds 
a notable value of 3.8 for thyroid 
cancer. Thus, differentiated epithe-
lial thyroid carcinomas have one of 
the highest familial risks of all cancer 
sites [11].
Pathology
Thyroid cancer primarily involves 
the following entities, in decreasing 
order of frequency: differentiated 
thyroid cancers, which comprise 
papillary and follicular thyroid can-
cer; medullary thyroid cancer; and 
poorly differentiated thyroid cancer, 
which includes undifferentiated and 
anaplastic thyroid cancer [12].
These tumour types are of en-
dodermal origin and arise from the 
thyroid follicles, except for medullary 
thyroid cancer, which develops from 
the parafollicular calcitonin-secret-
ing C cells and is of neuroendocrine 
origin. In addition, the thyroid stroma 
contains lymphoid cells as well as 
connective tissue that might give 
rise to thyroid lymphomas, which are 
nearly always non-Hodgkin lympho-
mas or sarcoma; both, however, are 
rather rare and account for less than 
5% of all thyroid cancers [12].
Differentiated thyroid 
carcinoma
Papillary thyroid carcinomas are ma-
lignant epithelial tumours that show 
evidence of follicular cell differentia-
tion and display characteristic nuclear 
features. These are large nuclei that 
have hypodense chromatin (ground-
glass appearance) and show intranu-
clear inclusions and nuclear grooves. 
The cellular features of papillary thy-
roid cancer are amphophilic, finely 
granular cytoplasm, large pale nuclei, 
nuclear grooves, and psammoma 
bodies. On macroscopic inspection, 
papillary thyroid cancer presents as 
Fig. 5.15.2. More than two years after the accident at Fukushima Daiichi nuclear power 
plant, work continues to ensure that the damaged units remain stable. Here, workers 
in protective clothing and masks are shown outside the Emergency Response Centre, 
the main control hub at the site. Radiation exposure during childhood is the most clearly 
defined environmental factor associated with benign and malignant thyroid tumours.
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an invasive neoplasm of whitish col-
our lacking a tumour capsule [12]. A 
multifocal manifestation is common. 
Approximately 50% of these newly 
detected cancers are papillary micro-
carcinomas, which measure 1 cm or 
less in largest diameter [4]. In autopsy 
studies, these small tumours have 
been detected in as many as 35% of 
cases, and meticulous examination 
of thyroidectomy specimens has re-
vealed micropapillary thyroid cancer 
in as many as 24% of cases. 
There is growing evidence that 
a subset of these overall apparently 
indolent micropapillary thyroid can-
cers are highly aggressive tumours 
that harbour a tendency to recur, me-
tastasize, and cause death. Thus, 
it is of great importance to identify 
prognostic markers. BRAF muta-
tion analysis might identify patients 
at risk. Similarly, histopathological 
characteristics, such as are indicated 
by the sclerosing variant, appear to 
be associated with metastases from 
these small papillary thyroid cancers 
(hazard ratio, 11.8) (Fig. 5.15.5) [13].
Follicular thyroid cancers are 
well-encapsulated lesions that 
display fibrosis, haemorrhage, 
and cystic areas. Three types of 
follicular thyroid cancer may be dis-
tinguished with reference to their 
clinical relevance: (i) minimally in-
vasive tumours without angioinva-
sion, which have the best progno-
sis (disease-free survival, 97%); (ii) 
minimally invasive follicular thyroid 
cancers with angioinvasion (dis-
ease-free survival, 81%); (iii) widely 
invasive follicular thyroid cancers, 
for which distant metastases are 
found in about 50% of patients [14]. 
The WHO classification of thyroid 
cancer defines follicular thyroid 
carcinoma as a lesion showing evi-
dence of follicular cell differentiation 
and lacking the diagnostic nuclear 
features of papillary carcinoma. 
Thus, the diagnosis of follicular thy-
roid cancer is based on the exclu-
sion of the typical nuclear features 
of papillary thyroid cancer [12]. The 
major challenge for pathology rep-
resents those thyroid tumours with a 
follicular growth pattern that include 
an array of neoplastic and malignant 
lesions. In addition, the differentia-
tion of follicular thyroid malignancy 
from follicular adenoma is based on 
the identification of vascular and/or 
capsular invasion [15].
Medullary thyroid carcinoma
On macroscopic examination, 
medullary thyroid carcinomas are 
non-encapsulated but well-circum-
scribed lesions that contain areas 
of calcification. In a hereditary set-
ting, multifocality is rather common. 
The unique feature of this cancer is 
a characteristic deposit of amyloid. 
Furthermore, staining for calcito-
nin and carcinoembryonic antigen 
(CEA) helps to differentiate this 
cancer from other forms [12].
Poorly differentiated thyroid 
carcinoma
Poorly differentiated thyroid can-
cer is a highly aggressive cancer. 
Based on morphological and clini-
cal criteria, these tumours occupy 
an intermediate position between 
differentiated forms (follicular and 
papillary carcinomas) and ana-
plastic carcinomas. Most of these 
cancers develop by de-differenti-
ation from their well-differentiated 
forms, as described above. Thus, 
the biology and histology of poorly 
differentiated thyroid carcinoma 
show characteristics of follicular or 
papillary thyroid cancer. Based on 
the WHO classification of thyroid 
cancer, poorly differentiated thy-
roid carcinomas are neoplasms of 
follicular origin but lack the typical 
structural presentation of follicular 
cell differentiation.
Anaplastic thyroid cancers are 
highly lethal carcinomas derived 
from the thyroid follicular cells that 
lack thyroglobulin expression. Most 
Fig. 5.15.3. Molecular pathways dysregulated, and putative molecular targets for ther-
apy, in differentiated thyroid carcinoma. The highly complex interaction of protein/lipid 
phosphatases and protein/lipid kinases indicates that molecular targeted therapy aimed 
at only one component might not be sufficient to stabilize the dysregulated pathway. 
Furthermore, molecular targeted therapy will have to be adapted to the genomic make-
up of the individual as it interacts with the genome of the tumour. pAKT, phosphory-
lated protein kinase B; PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol 
3,4,5-triphosphate; pMAPK, phosphorylated mitogen-activated protein kinase; PPAR-γ, 
peroxisome proliferator-activated receptor gamma.
Fig. 5.15.4. Cervical computed tomogra-
phy image of anaplastic thyroid cancer.
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of these cancers already show local 
invasion and metastases at the time 
of diagnosis (Fig. 5.15.4).
Genetics
Thyroid cancer oncogenesis is as-
sociated with multiple genetic and 
epigenetic alterations. The activation 
of the MAPK and PI3K/AKT signal-
ling pathways appears to be crucial 
for thyroid cancer initiation and pro-
gression (Fig. 5.15.5) [16].
Point mutations of the BRAF and 
RAS genes are commonly found in 
thyroid cancers, as are alterations in-
volving RET/PTC and PAX8/PPAR-γ 
chromosomal rearrangements [17,18]. 
Several lines of evidence indicate that 
certain etiological factors are asso-
ciated with specific molecular alter-
ations. For instance, exposure to ion-
izing radiation leads to chromosomal 
rearrangements, while exogenous 
chemicals tend to mediate genomic 
damage by causing point mutations. 
The extent to which high iodine intake 
is associated with the development 
of BRAF point mutations requires 
clarification as current data are not 
consistent.
The elucidation of the molecular 
pathology of thyroid carcinoma has 
led to the identification of diagnos-
tic and prognostic markers. Among 
these, a BRAF point mutation may 
be a valuable indicator for the man-
agement of patients with thyroid 
nodules. Growing evidence shows 
that BRAF V600E-positive micro-
papillary thyroid cancer is more ag-
gressive, and surgical management 
should be adopted accordingly [19].
Genetic alterations found in un-
differentiated and anaplastic thyroid 
cancer involve the tumour suppres-
sor gene TP53 and cell-cycle check-
point genes such as p27 or p21. In 
addition, the Wnt pathway genes 
and the PTEN/PI3K/AKT pathway 
appear to play an important role in 
advanced thyroid cancer.
Heritable disease
About 25% of all medullary thyroid 
cancers occur as part of the mul-
tiple endocrine neoplasia type 2 
(MEN2) syndrome [20]. MEN2 is 
an autosomal dominant transmit-
ted tumour syndrome caused by 
germline mutation in the RET pro-
to-oncogene and comprises the key 
endocrine neoplasia components of 
phaeochromocytoma, hyperparathy-
roidism, and, importantly, medullary 
thyroid carcinoma – the life-limiting 
scenario. MEN2-associated medul-
lary thyroid cancer can be consid-
ered the role model for the practice 
of genomic medicine. The presence 
of mutations in the RET medullary 
thyroid cancer susceptibility gene 
has enabled the implementation of 
a powerful molecular diagnostic test 
to identify mutation carriers at a pre-
morbid stage (i.e. predictive testing) 
and the delineation of a genotype–
phenotype correlation that allows 
tailored surgical management based 
on the distinct amino acid altered 
(Fig. 5.15.5).
Heritable non-medullary thyroid 
cancer occurs not as a single entity 
but as part of different tumour syn-
dromes such as Cowden syndrome, 
Carney complex, Gardner syndrome 
(familial adenomatous polyposis 
syndrome), and Werner syndrome, 
all of which are transmitted in an 
autosomal dominant fashion [11]. In 
these tumour syndromes, differen-
tiated thyroid cancer occurs in up 
to 20% of patients. A small portion 
of non-medullary thyroid cancer, 
termed familial non-medullary thy-
roid cancer (mostly papillary thyroid 
cancer), appears to be inherited 
without other associated patholo-
gies. Non-syndromic familial non-
medullary thyroid cancer is charac-
terized by two or more first-degree 
relatives who are affected by thyroid 
carcinomas but lack signs of other 
hereditary syndromes or exposure 
to other risk factors (i.e. radiation). 
Despite extensive research over the 
past 10 years to identify the gene 
or genes associated with non-syn-
dromic familial non-medullary thy-
roid cancer, no susceptibility genes 
have been identified. Nonetheless, at 
least five putative susceptibility loci 
have been identified, at 1q21, 2q21, 
8p23.1-p22, 14q31, and 19p13.2. 
Of these, only 14q31 and 19p13.2, 
which correspond to the location of 
NMTC1 and TCO, respectively, have 
been replicated in independent fam-
ily sets, but the susceptibility genes 
Fig. 5.15.5. Genotype–phenotype correlation in multiple endocrine neoplasia type 2 
(MEN2). Germline RET mutations are specific for subgroups in MEN2. Codons of the 
RET oncogene affected by germline mutations are depicted in correlation to their physi-
cal location within the RET tyrosine kinase (TK) receptor. The horizontal bars indicate 
the frequency of these mutations in the three clinical subtypes MEN2A, MEN2B, and 
familial medullary thyroid carcinoma (FMTC).
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mapped to these loci have not yet 
been identified [21–23].
Prospects
Ionizing radiation causes thyroid 
cancer and, as mentioned above, ex-
posure to such radiation – especially 
in childhood – should be avoided 
whenever possible. Since there are 
no other established causes, one 
challenge is to identify those patients 
with benign nodular thyroid disease 
who have an increased risk of thy-
roid cancer development. Screening 
for thyroid cancer in these patients 
would be optimized by improvement 
in diagnostic modalities such as ul-
trasound elastography of the thyroid 
and molecular classification using 
fine-needle aspirates (Fig. 5.15.6).
Most types of thyroid cancer are 
associated with excellent long-term 
survival: the 10-year overall survival 
exceeds 90% for papillary thyroid 
cancer and declines to 85% for fol-
licular thyroid cancer and 70% for 
medullary thyroid cancer; for ana-
plastic tumours, the long-term out-
come is very poor [1]. Metastasis 
commonly affects the regional lymph 
nodes as well as involving spread to 
the bone, lung, and liver. Tumour re-
currence within the thyroid bed and 
distant recurrence are frequent and 
occur in about 30% of patients within 
10 years after initial diagnosis [2].
Because of the availability of 
RET gene mutation analysis, famil-
ial cases of medullary thyroid carci-
noma as part of the MEN2 tumour 
syndrome can be prevented by early, 
prophylactic resection of the thyroid 
gland. Elucidation of dysregulated 
pathways involved in thyroid onco-
genesis has enabled the identifica-
tion of potential new biomarkers and 
therapeutic targets. Small-molecule 
therapies targeting receptor tyrosine 
kinases, as well as their intracellu-
lar downstream proteins such as 
mTOR, BRAF, AKT, or MEK, are 
being investigated in clinical trials 
and appear to be promising for the 
treatment of advanced thyroid can-
cer [19]. These investigations have 
opened up a new aspect of cancer 
therapy and tumour re-differentiation 
in the setting of advanced tumours 
that are not amenable to treatment 
by surgery or radio-iodine therapy.
Fig. 5.15.6. Ultrasound elastography im-
age of a suspicious thyroid nodule, indicat-
ing a hard nodule (Rago score, 3 or 4).
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Summary
• Tumours of the nervous system 
account for less than 2% of all 
cancers but have a marked im-
pact on cancer morbidity and 
mortality.
• Nervous system tumours oc-
cur throughout life. Diffusely 
infiltrating gliomas manifest pre-
dominantly in adults; embryonal 
malignancies, including medul-
loblastoma and neuroblastoma, 
develop typically in children.
• Therapeutic ionizing radiation is 
the only proven cause of brain 
cancer. The use of mobile phones 
remains under investigation.
• Glioblastomas are the most com-
mon and most malignant central 
nervous system neoplasms. 
Most of them (90%) manifest 
after a short clinical history in 
elderly patients (mean age, 60 
years). Genetic hallmarks in-
clude EGFR amplification and 
PTEN mutations.
• Secondary glioblastomas de-
velop in younger patients (mean 
age, 45 years) through progres-
sion from low-grade or anaplastic 
astrocytoma. Genetic hallmarks 
include IDH1 and TP53 muta-
tions. Distinguishing genetic al-
terations have been identified for 
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other nervous system tumours, 
including oligodendroglioma and 
ependymoma.
• A range of targeted agents have 
been indicated, but establish-
ment of optimal therapy has not 
been achieved. At present, the 
prognosis for most patients with 
brain cancer is poor.
Brain tumours account for less than 
2% of the overall human cancer bur-
den. However, they cause signifi-
cant morbidity, and for gliomas, the 
most common histological type of 
central nervous system neoplasms, 
the prognosis is still poor. This ap-
plies particularly to glioblastomas, 
the most common and most ma-
lignant brain tumours in adults. 
Malignant embryonal tumours typi-
cally manifest in children and oc-
cur in the central nervous system 
in the case of medulloblastoma, and 
in the sympathetic nervous system 
and adrenal glands in the case of 
neuroblastoma. Meningiomas origi-
nate in the meninges, the protective 
coverings of the brain, and are usu-
ally benign and are more common 
in women. The brain is also a com-
mon site of metastases, most often 
due to carcinomas of the breast and 
lung.
Etiology
With the exception of brain tumours 
associated with inherited cancer 
syndromes and causation by thera-
peutic irradiation, which accounts for 
very few cases, no causative envi-
ronmental or lifestyle risk factor has 
been unequivocally identified.
Environmental factors
Therapeutic irradiation of the head 
and neck regions is known to have 
caused brain cancer. In particular, 
Fig. 5.16.1. Protocols for therapeutic 
irradiation of children now recognize the 
inherent risk such radiation presents and 
are designed to minimize any such risk.
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Epidemiology
Nervous system tumours
• Central nervous system tumours 
represent the 17th most common 
cancer worldwide, with an esti-
mated 256 000 new cases an-
nually. Rates tend to be higher 
in more developed countries 
and therefore, combined with 
the rather high case fatality rate, 
these cancers are the 12th most 
frequent cause of cancer-related 
death worldwide.
• Comparisons of rates interna-
tionally are hampered by under-
reporting in many regions, and 
this may largely explain the low 
incidence and mortality rates 
observed in sub-Saharan Africa 
and some Asian countries.
• Incidence rates are highest in 
North America, Europe, and 
Australia, typically 4–8 new cas-
es per 100 000 people annually, 
but are higher in some Nordic 
countries. In multi-ethnic com-
munities, adults and children of 
African or Asian descent have 
an approximately 2-fold lower 
risk than people with European 
ancestry.
• The age distribution of brain tu-
mours is bimodal, with a peak 
incidence in children and a sec-
ond, larger peak in adults aged 
45–70 years. Glioblastomas 
are more frequent in men, while 
benign meningiomas are signifi-
cantly more common in women.
Map 5.16.1. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for tumours of the nervous system in men, 2012.
Map 5.16.2. Global distribution of estimated age-standardized (World) incidence 
rates (ASR) per 100 000, for tumours of the nervous system in women, 2012.
children treated with radiotherapy 
for acute myeloid leukaemia show a 
significantly elevated risk of develop-
ing malignant gliomas, often within 
10 years [1]. Radiation-induced 
meningiomas may follow low-dose 
irradiation for tinea capitis, a fungal 
infection of the scalp, and high-dose 
irradiation for primary brain tumours. 
A recent systematic review of eight 
cohort studies assessing the rela-
tionship between ionizing radiation 
and risk of brain tumours showed 
that the strength of the association 
varied between studies and that ion-
izing radiation was generally more 
strongly associated with risk of me-
ningioma than with risk of glioma [2].
Electromagnetic fields
Exposure to occupational and resi-
dential power-frequency electromag-
netic fields has been a subject of 
public concern. A weak association 
of brain tumours with occupational 
exposure to magnetic fields has 
been observed in some studies [3]; 
others failed to reveal a significantly 
For more details about the maps and charts presented in this chapter, see “A guide to the epidemiology data in World Cancer Report”.
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elevated risk [4]. The available evi-
dence is insufficient to establish that 
electromagnetic fields cause brain 
tumours.
Mobile phones
No consistent association has been 
found between use of mobile (cell) 
phones and brain tumours [5–9]. 
The Interphone study [8] recorded no 
overall elevated odds ratio 10 years 
or less after first mobile phone use. 
In the 10th (highest) decile of re-
called cumulative call time, the odds 
ratio was 1.40 (95% confidence in-
terval [CI], 1.03–1.89) for glioma and 
1.15 (95% CI, 0.81–1.62) for menin-
gioma. The odds ratios for glioma 
were somewhat higher in the tem-
poral lobe. Analysis of United States 
data indicated possible consistency 
with the modest excess risks ob-
served in highly exposed people in 
the Interphone study [9]. In 2011, 
an IARC Monographs evaluation 
determined that the evidence for 
causation of glioma by mobile 
phone use was limited, resulting in 
a classification as Group 2B (pos-
sibly carcinogenic to humans) [10]. 
The evidence for this association 
remains inconclusive because of, 
among other things, lack of data 
about long-term mobile phone use 
[11] (see “An IARC announcement 
that made waves” in Chapter 2.8).
Allergic conditions
Several studies suggest that having 
a personal medical history of specific 
allergic conditions, such as asthma, 
eczema, and hay fever, has a protec-
tive effect against development of 
glioma [12].
Environmental carcinogens
Several occupational exposures and 
environmental carcinogens have been 
reported to be slightly associated 
with gliomagenesis. However, many 
of these reports have not been vali-
dated in independent studies, and 
none of these exposures has been 
unequivocally identified as causative 
[1]. Some studies suggest a causal 
relationship between parental occu-
pational exposure to carcinogens and 
central nervous system tumours in 
their offspring, without identifying any 
specific environmental agent.
Diet
N-nitroso compounds have been 
detected in nitrite-preserved food 
and can be formed in the stomach 
after uptake of their chemical pre-
cursors, nitrate/nitrite and second-
ary amines. Vitamins C and E inhibit 
the formation of nitroso compounds 
from these precursors. Since some 
N-nitroso compounds are potent 
neurocarcinogens in experimental 
animals, several epidemiological 
studies have addressed their role in 
Chart 5.16.1. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for tumours of the 
nervous system in men, circa 1975–2012.
Chart 5.16.2. Age-standardized (World) incidence rates per 
100 000 by year in selected populations, for tumours of the 
nervous system in women, circa 1975–2012.
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the etiology of human brain tumours. 
A meta-analysis of nine published 
studies yielded an elevated risk of 
glioma among adults frequently 
consuming cured meat, bacon, and 
ham, but the data were insufficient 
to establish a dose–response rela-
tionship [13].
Viral infections
JC virus has neuro-oncogenic po-
tential in experimental animals, but 
JC virus sequences are rarely de-
tectable in human brain tumours 
[14]. The polyomavirus SV40 was ia-
trogenically introduced into human 
populations in 1955–1962 through 
SV40-contaminated polio vaccines. 
SV40 sequences have been identi-
fied in a variety of human neoplasms, 
including brain tumours, raising the 
possibility of an etiological role [15]. 
SV40 sequences have been report-
ed to be present at variable frequen-
cies in brain tumour biopsies from 
countries that had used contami-
nated polio vaccine [14]. However, 
assays are easily contaminated 
with plasmids containing SV40 
sequences, and recent studies 
failed to detect SV40 sequences in 
brain tumours [16].
Genetic factors
Central nervous system tumours oc-
cur in the setting of several inherited 
cancer syndromes (Table 5.16.1). 
However, their overall contribution 
amounts to less than 1% of brain 
tumour cases.
Genetic basis of non-syndromic 
familial aggregation
There is a small but significant 
increased risk of primary brain 
tumours among relatives of patients 
with brain tumours. Cohort studies 
showed a standardized incidence 
ratio of approximately 2, i.e. a 2-fold 
increased risk of primary brain tu-
mour or glioma among first-degree 
relatives of glioma probands, com-
pared with population incidence 
data [17]. In a population-based 
study from Sweden and Norway, 
the standardized incidence ratio for 
glioma was 1.8 (95% CI, 1.5–2.0) 
when a parent was a proband, and 
increased to 11.2 (95% CI, 5.7–19.5) 
in multiplex families in which a 
parent and at least two siblings 
were affected by a nervous sys-
tem tumour [18]. A pooled famil-
ial aggregation analysis of glioma 
probands showed an increased risk 
of gliomas, sarcomas, and melano-
mas [19]. Genome-wide associa-
tion studies have identified several 
low-penetrance susceptibility al-
leles for glioma [20,21].
Detection
Signs and symptoms of brain tumours 
largely depend on the location of the 
neoplasm and include paresis, speech 
disturbances, and personality chang-
es. Patients with oligodendroglioma 
often have a long history of epileptic 
seizures. Eventually, malignant brain 
tumours cause life-threatening intra-
cranial pressure that ultimately leads 
to unconsciousness and respiratory 
arrest. Since the brain does not con-
tain pain receptors, headache is typi-
cally present if the tumour infiltrates 
the meninges. The presence of symp-
toms usually leads to a detailed neuro-
logical examination, using techniques 
such as computed tomography and 
magnetic resonance imaging.
Pathology and genetics
The WHO Classification of Tumours 
of the Central Nervous System (4th 
edition) recognizes more than 50 clin-
icopathological entities with a great 
variation in histology, biological be-
haviour, response to therapy, and 
clinical outcome [22]. Clinical and ge-
netic data on the most  common brain 
tumours are detailed in Table 5.16.2.
Astrocytic tumours
Tumours of astrocytic origin con-
stitute the largest proportion of 
gliomas.
Pilocytic astrocytoma
Pilocytic astrocytoma (WHO grade 
I), the most common central ner-
vous system neoplasm in children, 
is predominantly located in the 
cerebellum and midline structures, 
including the optic tract, brain 
stem, and spinal cord. It infiltrates 
adjacent brain structures but grows 
Fig. 5.16.2. Macroscopic features of frequently occurring brain tumours.
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slowly and usually has a favoura-
ble prognosis, with 5-year survival 
rates of more than 85%. Some pi-
locytic astrocytomas occur in the 
setting of neurofibromatosis type 1 
(NF1), particularly those of the optic 
nerve (optic glioma). Pilocytic as-
trocytomas typically show BRAF-
KIAA1549 fusions [23].
Other types of astrocytoma 
(WHO grades II–IV) usually de-
velop in the cerebral hemispheres 
of adults and diffusely infiltrate 
adjacent brain structures (diffuse 
astrocytomas).
Low-grade diffuse astrocytoma
Low-grade diffuse astrocytomas 
(WHO grade II) occur in young adults 
and grow slowly. However, they in-
filtrate adjacent brain structures and 
typically cannot be completely sur-
gically resected. Morphologically, 
tumour cells resemble differentiated 
astrocytes. IDH1 or IDH2 mutations 
(> 80%), TP53 mutations (~65%), 
and ATRX mutations (65%) are early 
and frequent genetic events [24,25].
Anaplastic astrocytoma
Anaplastic astrocytomas (WHO grade 
III) often develop from low-grade 
astrocytomas, grow relatively quickly, 
and typically progress to glioblasto-
ma within 2–3 years, accompanied 
by genetic alterations.
Glioblastoma
Glioblastoma (WHO grade IV) is 
the most frequent and most ma-
lignant nervous system tumour. 
Glioblastomas diffusely infiltrate 
the brain, including the opposite 
hemisphere, and show high cellu-
larity and large areas of necrosis 
despite excessive vascular prolif-
eration (Fig. 5.16.3).
Secondary glioblastomas develop 
by malignant progression from low-
grade and anaplastic astrocytoma 
and are characterized by frequent 
IDH1 or IDH2 mutations, TP53 mu-
tations, ATRX mutations, and loss of 
heterozygosity on chromosome 10q 
and 19p [26]. Primary glioblastomas 
are more frequent, accounting for 
approximately 90% of glioblasto-
mas, and develop rapidly in older 
adults, with a short clinical history 
of usually less than 3 months (Fig. 
5.16.4). Their genetic profile includes 
amplification and overexpression of 
the EGFR gene, PTEN mutations, 
TERT promoter mutations, and loss 
of heterozygosity on chromosome 
10p and 10q [26,27].
Glioblastomas have also been 
classified on the basis of comple-
mentary DNA expression profiles, 
with distinct proneural, neural, clas-
sic, and mesenchymal patterns 
[28]. Secondary glioblastomas with 
Table 5.16.1. Familial cancer syndromes predisposing to the development of tumours of the nervous system
Syndrome Gene (chromosome) Nervous system tumours Other lesions
Neurofibromatosis type 1  
(MIM no. 162200)
NF1 (17q11.2) Neurofibroma, malignant peripheral 
nerve sheath tumour, optic nerve 
glioma, astrocytoma
Café au lait spots, axillary 
freckling, iris hamartomas, 
osseous lesions, 
phaeochromocytoma, 
leukaemia
Neurofibromatosis type 2  
(MIM no. 101000)
NF2 (22q12) Schwannoma, meningioma, 
meningioangiomatosis, spinal 
ependymoma, astrocytoma
Posterior lens opacities, retinal 
hamartoma
Tuberous sclerosis TSC1 and TSC2  
(MIM no. 191100, 191092)
TSC1 (9q34)
TSC2 (16p13.3)
Subependymal giant cell 
astrocytoma
Cutaneous angiofibroma, peau 
chagrin, subungual fibroma, 
cardiac rhabdomyoma, cysts 
of lung and kidney, renal 
angiomyolipoma
Li–Fraumeni syndrome  
(MIM no. 151623, 191170)
TP53 (17p13) Astrocytoma, secondary 
glioblastoma, medulloblastoma
Adrenocortical carcinoma, soft 
tissue and bone sarcomas, 
leukaemia, breast carcinoma
Turcot syndrome type 1  
(MIM no. 276300)
MLH1 (3p21)
PMS2 (7p22)
MSH2 (2p21)
Astrocytoma, glioblastoma Café au lait spots
Colorectal polyps (< 100)
Large polyps (> 3 cm), 
colorectal cancer
Turcot syndrome type 2  
(MIM no. 276300)
APC (5q21) Medulloblastoma Small colorectal polyps (> 100)
Colorectal cancer
Naevoid basal cell carcinoma 
syndrome (NBCCS)/Gorlin 
syndrome (MIM no. 109400)
PTCH (9q22) Medulloblastoma Basal cell carcinomas, palmar 
and plantar pits, jaw cysts, 
ovarian fibroma, skeletal 
abnormalities
Rhabdoid tumour predisposition 
syndrome (RTPS) (MIM no. 609322)
INI1 (22q11.2) Atypical teratoid/rhabdoid tumour 
(AT/RT)
Malignant rhabdoid tumour of 
the kidney
MIM, Mendelian Inheritance in Man (www.omim.org).
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IDH1 mutation have a proneural ex-
pression profile. Additional genetic 
changes typical of the proneural 
type include PDGFR amplification 
or PIK3CA/PIK3R1 mutations and 
loss or mutation of TP53 [29]. The 
neural subtype is related to the clas-
sic expression pattern, which shows 
chromosome 7 amplification, focal 
CDKN2A deletion, chromosome 10 
loss, and EGFR amplification or mu-
tation. The mesenchymal subtype 
has frequent mutation or loss of NF1, 
TP53, and PTEN, and further chro-
mosomal aberrations at CDK6, MET, 
PTEN, CDKN2A, and RB1 loci [29].
New drivers of glioblastoma have 
been identified [30]. LZTR1 and 
CTNND2 mutations and deletions, 
and EGFR-SEPT14 gene fusions are 
proposed to all enhance the self-re-
newal and transformation of glioblas-
toma stem cells, thereby contributing 
to glioblastoma progression.
Key genomic alterations in glio-
blastoma suggest a range of targeted 
agents (Fig. 5.16.5). Particular path-
ways may be identified as a basis for 
therapy (see “Glioma genomics and 
its implications in neuro-oncology”). 
The role of the alkylation-damage 
DNA repair gene MGMT in mediat-
ing response of malignant glioma 
to alkylating agents such as temo-
zolomide has been clarified. Two 
randomized trials demonstrated 
that patients with an epigenetically 
silenced MGMT gene fared better 
when treated with temozolomide, 
whereas patients with an unmethyl-
ated MGMT promoter had a longer 
survival with initial radiotherapy [31].
Oligodendroglial tumours
These neoplasms are assumed to 
develop from myelin-producing oli-
godendroglial cells or their precur-
sors and are typically found in the 
cerebral hemispheres of adults, 
often including the basal ganglia. 
Histologically, they are isomorphic, 
with a typical honeycomb pattern and 
delicate tumour vessels (a “chicken 
wire” pattern). Anaplastic oligoden-
drogliomas show features of ana-
plasia and high mitotic activity and 
have a less favourable prognosis. 
Oligodendrogliomas share with dif-
fuse astrocytomas common and fre-
quent genetic alterations, i.e. IDH1 or 
IDH2 mutations, suggesting that as-
trocytomas and oligodendrogliomas 
arise from the same precursor cells. 
Genetic hallmarks of oligodendro-
gliomas are frequent IDH1 or IDH2 
mutations (> 80%), co-deletion of 
chromosomes 1p and 19q (~70%), 
CIC mutations (~40%), and FUBP1 
mutations (~15%) [26].
Ependymomas
These gliomas develop from the 
ependymal lining of the cerebral 
ventricles and the central canal 
of the spinal cord. They manifest 
preferentially in children and young 
adults. Histologically, they are cel-
lular, with typical perivascular ro-
settes. Spinal ependymomas show 
a high frequency of mutations in the 
neurofibromatosis gene NF2 [22].
Glioneuronal tumours
This group of brain tumours is less 
frequent and generally has a favour-
able prognosis. Some manifest pref-
erentially in children (desmoplastic 
infantile astrocytoma/ganglioglioma, 
dysembryoplastic neuroepithelial tu-
mour), others preferentially in ado-
lescents and adults (gangliocytoma, 
central neurocytoma). They often 
cause a long-term history of epilep-
tic seizures [22].
Embryonal tumours
These neoplasms are derived from 
embryonal or fetal precursor cells, 
Table 5.16.2. Clinical and genetic data on the most common tumours of the nervous system
Tumour Age (years)a 5-Year survival Genetic alterations
Pilocytic astrocytoma
(WHO grade I)
< 20 > 85% BRAF-KIAA1549 fusion, NF1 mutation 
(neurofibromatosis cases)
Diffuse astrocytoma
(WHO grade II)
20–45 > 60% IDH mutation, TP53 mutation, ATRX mutation
Secondary glioblastoma
(WHO grade IV)
~45 ~10% IDH mutation, TP53 mutation, ATRX mutation, 
LOH 10q, LOH 19q
Primary glioblastoma
(WHO grade IV) 
~60 < 3% EGFR amplification, PTEN mutation, LOH 10p, 
LOH 10q
Oligodendroglioma
(WHO grade II/III)
> 20 > 50% IDH mutation, 1p and 19q co-deletion, CIC 
mutation, FUBP1 mutation
Ependymoma
(WHO grade II)
< 45 < 30% Chromosome 22 alteration, NF2 mutation 
Medulloblastoma
(WHO grade IV)
< 20 > 50% Isochromosome 17, TP53 mutation, PTCH 
mutation, b-catenin mutation, DDX3X mutation, 
SMARCA4 mutation 
Neuroblastoma
(WHO grade IV)
< 10 > 90%; 
20–50%b
LOH 1p, LOH 11q, MYCN amplification, trisomy 
17q, ALK mutation
LOH, loss of heterozygosity.
a Age range in which 60% or more of the respective tumour types are clinically manifested.
b Patients < 1 year old; patients > 1 year old.
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typically manifest in children, and 
are highly malignant but often re-
spond to radiotherapy or chemo-
therapy. In the central nervous sys-
tem, cerebellar medulloblastomas 
are the most common. The peak 
incidence age is 3–6 years; these 
tumours are uncommon in adults. 
Expression array analysis and DNA 
sequencing have led to the identi-
fication of four distinct subgroups, 
which differ greatly in clinical out-
come [32,33]. The most benign 
course is seen in medulloblastomas 
with activation of the WNT pathway, 
as determined by nuclear β-catenin 
accumulation, and the presence of 
CTNNB1 mutations in most cases 
[34]. The WNT subtype shows clas-
sic medulloblastoma histology and 
cannot be identified morphologi-
cally. The SHH type is biologically 
characterized by activation of the 
sonic hedgehog (SHH) signalling 
pathway, which in about one third 
of cases is caused by a muta-
tion in the PTCH gene [35]. This 
subtype tends to be associated 
with the desmoplastic phenotype 
[36]. Type 3 medulloblastomas are 
not associated with a distinct sig-
nalling pathway, but they typically 
show NPR3 expression and MYC 
amplification. Type 4 medulloblas-
tomas comprise about one third of 
all medulloblastomas and have a 
less favourable clinical outcome. 
Type 3 and 4 medulloblastomas are 
characterized by a strong male pre-
dominance and a greater tendency 
to metastasize via cerebrospinal 
fluid pathways.
Tumours of peripheral nerves
Most of these tumours develop from 
myelin-producing Schwann cells and 
are termed neurinomas or schwanno-
mas. Bilateral acoustic schwannomas 
are diagnostic of inherited neurofi-
bromatosis type 2 (NF2). Acoustic 
schwannomas are benign (WHO 
grade I) and rarely recur after surgical 
resection. Neurofibromas and malig-
nant peripheral nerve sheath tumours 
represent typical manifestations of 
the NF1 syndrome [22].
Meningiomas
These are generally benign, slowly 
growing intracranial tumours at-
tached to the dura mater. They are 
composed of neoplastic menin-
gothelial (arachnoidal) cells and 
typically occur in adults, with a 
marked female predominance, 
particularly for those located in 
the spine. Meningiomas do not 
infiltrate the brain but may cause 
symptoms of intracranial pressure 
due to compression of adjacent 
brain structures. Preferential sites 
Fig. 5.16.3. Typical histological features 
of glioblastoma, with necrosis (NE) and 
vascular proliferation (VP).
Fig. 5.16.4. (A) Rapid evolution of a primary glioblastoma. Magnetic resonance image 
shows a small cortical lesion that within 68 days developed into a full-blown glioblastoma 
with perifocal oedema and central necrosis. This is in contrast to (B) the development 
of a secondary glioblastoma through progression from low-grade astrocytoma.
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Glioma genomics and its implications in neuro-oncology
Hai Yan
Mutations in the critical chromatin 
modifier ATRX and mutations in 
CIC and FUBP1, which are potent 
regulators of cell growth, have been 
discovered in specific subtypes of 
gliomas, the most common type 
of primary malignant brain tumour. 
However, the frequency of these 
mutations in many subtypes of glio-
mas, and their association with the 
clinical features of patients, is poorly 
understood. These loci were ana-
lysed in 363 brain tumours. ATRX 
is frequently mutated in grade II/III 
astrocytomas (71%), oligoastrocyto-
mas (68%), and secondary glioblas-
tomas (57%), and ATRX mutations 
are associated with IDH1 mutations 
and with the alternative lengthening 
of telomeres phenotype. CIC and 
FUBP1 mutations occurred fre-
quently in oligodendrogliomas (46% 
and 24%, respectively) but rarely in 
astrocytomas or oligoastrocytomas 
(< 10%). This analysis enabled the 
identification of two highly recurrent 
genetic signatures in gliomas: IDH1/
ATRX (I-A) and IDH1/CIC/FUBP1 
(I-CF).
Patients with I-CF gliomas 
had a significantly longer median 
overall survival (96 months) com-
pared with patients with I-A glio-
mas (51 months) and patients with 
gliomas that did not harbour either 
signature (13 months). The genetic 
signatures distinguished clinically 
distinct groups of oligoastrocytoma 
patients, who usually present a diag-
nostic challenge, and were associ-
ated with differences in clinical out-
come even among individual tumour 
types. In addition to providing new 
clues about the genetic alterations 
underlying gliomas, the results have 
immediate clinical implications, pro-
viding a tripartite genetic signature 
that can serve as a useful adjunct 
to conventional glioma classification 
and that may aid in prognosis, treat-
ment selection, and therapeutic trial 
design.
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are the cerebral hemispheres [22]. 
Meningiomas can often be cured 
by surgical resection. Atypical or 
malignant meningiomas are less 
frequent (~5% of all meningiomas) 
(http://www.cbtrus.org) and may 
infiltrate the brain and often recur 
locally.
Neuroblastomas
This tumour develops from the 
primitive neural crest and is the 
most frequent neoplasm in chil-
dren younger than 1 year, with an 
incidence of approximately 1 per 
100 000. It is typically located in 
the adrenal gland and sympathetic 
nervous system and is responsible 
for up to 15% of all cancer deaths 
in children. Neuroblastomas are 
heterogeneous with respect to the 
degree of maturation, ranging from 
highly malignant examples to be-
nign ganglioneuroma.
More than 60% of neuroblas-
tomas are metastatic, often carry-
ing MYCN amplification or ATRX 
mutation, and/or ALK mutation. 
Neuroblastoma can evade T cells 
and natural killer cells. Anti-GD2 
antibodies, when combined with 
granulocyte-macrophage colony-
stimulating factor with or without 
interleukin-2, offer strategies for 
a curative approach to therapy. 
Neuroblastomas with single copy 
MYCN or similar indicators are 
RAS 
PI3K 
AKT 
mTOR 
MAPK 
pathway 
S-phase 
genes 
RB INK4A 
Proliferation 
Cell-cycle 
arrest 
ARF/MDM2/p53 
Apoptosis 
MET, EGFR, PDGFR 
NF1 
PTEN 
Fig. 5.16.5. Cell-cycle dysregulation in glioblastoma is in part a result of abnormal sig-
nalling by several different receptor tyrosine kinases (RTKs), including EGFR, PDGFR, 
and MET. Genes shown in red may be targeted by agents, including RTK inhibitors. 
(For details, see [29].)
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highly curable with surgery alone or 
with surgery and low-dose chemo-
therapy [37].
Prospects
Although brain tumours do not oc-
cur very frequently, they contribute 
significantly to morbidity, often affect 
children, and have an overall poor 
prognosis. Due to marked resistance 
to radiation and chemotherapy, the 
prognosis for patients with glioblas-
tomas, the most common type of 
malignant brain tumour in adults, is 
still very poor. Unfortunately no en-
vironmental, lifestyle, or genetic risk 
factor has been discovered that ac-
counts for a significant proportion 
of newly diagnosed brain tumours. 
Many genetic alterations involved in 
the development of nervous system 
tumours have been identified and 
may lead to novel targeted therapeu-
tic approaches.
Glial progenitor cells Glial progenitor cells Glial progenitor cells 
Common precursor cells with IDH1/2 mutation 
TP53 mutation (>65%) 
ATRX mutation (>65%) 
Loss 1p/19q (>75%) 
CIC mutation (  ̴40%) 
FUBP1 mutation (  ̴15%) 
Diffuse astrocytoma Oligodendroglioma 
Anaplastic 
astrocytoma 
Anaplastic 
oligodendroglioma 
  ̴5 years 
Primary 
glioblastoma 
Secondary  
glioblastoma 
LOH 19q (  5̴0%) 
LOH 10q (>60%) 
 
  ̴2 years 
EGFR amp (  ̴35%) 
TP53 mutation (  ̴30%) 
PTEN mutation (  ̴25%) 
LOH 10p (  ̴50%) 
LOH 10q (  ̴70%) 
3-6 months 
Pilocytic  
astrocytoma 
BRAF-KIAA1549 
fusion (>60%) WHO 
grade 
I 
II 
III 
IV 
Fig. 5.16.6. Current concept of genetic pathways giving rise to primary and secondary gliomas.
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Summary
Cancer screening controversies 
have raged for a long time. However, 
there are paths forward that could 
modulate the content and tone of 
the discussions. They involve use 
of emerging molecular techniques 
to help us refine our assessment of 
screen-detected cancers, profes-
sional education, and more nuanced 
information for the public. Time will 
tell if such strategies provide resolu-
tions to the controversies.
Cancer screening is one of the 
most contentious areas in medicine. 
Debates over the balance of benefits 
and harms of screening tests play 
out at national conferences, in the 
medical literature, in the media, and 
occasionally in Congress. The intui-
tive sense that detection of asymp-
tomatic cancers must necessarily 
be of benefit is strong, sometimes 
triggering arguments when the ben-
efits of screening are questioned or 
harms are reported.
The concept that early detection 
of cancer before clinically evident 
symptomatic presentation would 
lead to cure in the majority of cases 
has its origins more than a century 
ago. In 1907 Dr Charles Childe, in 
his book The Control of a Scourge, 
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or How Cancer is Curable, asserted 
that if people were to only heed the 
earliest, apparently trivial, symp-
toms or signs of cancer, “it requires 
no stretch of the imagination… 
to say that the majority… would 
be cured” [1]. In 1924, Dr Joseph 
Colt Bloodgood of Johns Hopkins 
Hospital was quoted in the New 
York Times as stating that “deaths 
from cancer would be practically 
eliminated” by a careful search for 
“growths in any part of the body” [2]. 
(In retrospect, we now know how far 
off the mark these assertions were.) 
Nevertheless, the allure of the logic 
remains strong, and often inde-
pendent of the actual evidence for 
several screening tests in common 
use. But the concept is easy to grasp 
by health professionals and the 
public alike. Public health messages 
have frequently been unequivocal, 
often at the expense of appropriate 
nuance [3]. Some cancer advocacy 
groups have focused on screening as 
the most important tool in the “war on 
cancer”, sometimes spawning health 
fairs dedicated to screening as many 
people as possible [4,5].
The screening message has 
taken hold, at least in the USA. Data 
from the United States National 
Health Interview Survey (NHIS) from 
2005 and 2008 indicate that high 
rates of cancer screening persist 
even among people aged 80 years 
Barnett S. Kramer
522
and older – a population unlikely 
to derive substantial benefit from 
screening but nevertheless at risk 
for all of the harms. More than 50% 
of the respondents aged 75 years 
and older reported that their physi-
cian continued to actively recom-
mend screening [6]. Perhaps even 
more strikingly, an analysis of the 
Surveillance, Epidemiology and End 
Results (SEER)-Medicare database 
showed that a sizeable proportion 
of patients aged 65 years and older 
already diagnosed with advanced 
incurable lung, colorectal, pancre-
atic, gastrointestinal, or breast can-
cers (with a median survival time 
of 4.3–16.2 months) were still be-
ing screened with mammography, 
Pap tests, prostate-specific antigen 
(PSA) tests, and lower gastrointesti-
nal endoscopy [7]. The assumption of 
benefit is so strong that the motives 
of anyone who raises the possibility 
of screening-associated harms are 
sometimes attacked. For example, a 
mammographer recently dismissed 
a study suggesting that the harms 
of breast cancer screening due to 
overdetection of non-life-threatening 
lesions (“overdiagnosis”) have been 
underestimated [8] as “malicious 
nonsense” driven simply by a desire 
to reduce health-care costs [9]. But 
the genesis of the disagreements 
goes beyond financial incentives on 
either side of the argument.
The numerator/denominator 
problem
Public health is in some sense a sci-
ence of the denominator (the general 
population), while clinical medicine 
is a science of the numerator (peo-
ple plucked out of the denominator 
to become patients). Each of the 
two disciplines has separate train-
ing programmes, and the respective 
trainees acquire distinctly differ-
ent heuristics and mental shortcuts 
when interpreting and applying evi-
dence [10]. The target population is 
usually the relatively healthy general 
population, but the testing gener-
ally takes place in a clinical setting. 
Cancer screening therefore sits at 
the interface between these two 
worlds, inviting a clash of philoso-
phies that are anchored in totally dif-
ferent worlds.
Health-care professionals are 
strongly influenced by personal ex-
perience, and that is as it should 
be. Cumulative experience is a core 
element in the evolution of clinical 
judgement. However, it has been 
shown empirically that personal ex-
perience can also distort diagnostic 
reasoning, termed “availability bias” 
[11]. Cancer specialists, who treat 
the numerator of cancer patients, 
witness the suffering of their patients 
on a daily basis and naturally em-
brace strategies that could prevent 
that suffering, even if not based on 
the strongest achievable evidence. 
In fact, they may be impatient with 
public health-oriented professionals, 
who demand high-quality evidence 
before making recommendations 
that affect hundreds of thousands 
or even millions of healthy people. 
One of the core principles of cancer 
screening and prevention is that it is 
difficult to make healthy people bet-
ter off than they already are – but not 
difficult to make them worse off. This 
numerator/denominator issue also 
probably accounts for the fact that 
clinical specialty societies frequently 
have more aggressive screening 
recommendations than do general 
practice specialties [12].
A similar phenomenon occurs 
in the public. Healthy people in-
habit the denominator, not generally 
knowing which numerator(s) they 
will ultimately enter. However, the di-
agnosis of cancer suddenly changes 
that perspective. Here, availability 
bias is particularly personal, bring-
ing a desire to benefit others with the 
newly acquired perspective. Cancer 
advocacy groups often have more 
aggressive approaches to screen-
ing for cancer than do broad-based 
health advocacy groups.
Direct experience may distort 
perceived outcomes of 
screening
However, there is more than avail-
ability bias at work in the clinical 
setting. Personal experience may 
more directly affect a clinician’s 
perceptions of the value of screen-
ing, both increasing the magni-
tude of perceived benefits and de-
creasing perceived harms [13,14]. 
Several well-known biases artefac-
tually amplify the apparent benefit 
of a cancer screening test, and may 
even make a completely ineffective 
test appear highly effective in the 
eyes of an individual clinician. The 
ultimate benefit of a screening test 
is determined by its effect on over-
all or disease-specific mortality, but 
individual clinicians cannot observe 
mortality changes in practice. They 
do, however, directly observe the 
survival of their patients after diag-
nosis, and these observations can 
seriously mislead.
People self-select for screen-
ing, introducing confounding fac-
tors that are associated both with 
the propensity to be screened and 
with favourable health outcomes 
independent of the actual screen-
ing – an effect known as healthy 
volunteer bias or healthy screenee 
bias. For example, the number of 
observed deaths from a variety of 
causes unrelated to the target can-
cers was substantially less than 
expected in participants in a large 
randomized screening trial for pros-
tate, lung, colorectal, and ovarian 
cancers [15]. This reduction even 
extended to deaths from accidents 
or poisoning, highly unlikely to be 
affected by the actual screening 
tests.
Lead-time bias occurs with every 
screening test because the date 
of diagnosis of screen-detected 
cancers is moved up, lengthening 
the apparent survival time even if 
the date and cause of death are 
unaltered. For example, if a can-
cer killed all of its victims on the 
fourth anniversary of diagnosis, the 
5-year survival would be zero. If a 
new (but ineffective) screening test 
advanced the date of diagnosis by 
3 years without changing the risk 
of death, the 5-year survival rate 
would be 100%. Such a dramatic in-
crease in survival time would make 
most clinicians true believers in the 
test.
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Most, if not all, cancer screen-
ing tests are also associated with 
length-biased sampling. This occurs 
because they are better at detecting 
slow-growing asymptomatic cancers 
than they are at picking up the most 
rapidly growing tumours that come to 
clinical attention between scheduled 
screenings, even when adjusted for 
clinical stage and histopathological 
phenotypic features [16]. An extreme 
form of length-biased sampling, over-
diagnosis, is the detection of tumours 
that are so slow-growing that they 
would not have caused any harm 
during the lifespan of the patient. 
Without screening, the patient would 
have gone on to die of a competing 
cause of death without ever being la-
belled as a cancer patient. Empirical 
evidence for detection-related over-
diagnosis has been shown for a wide 
variety of cancers, including mela-
noma and cancers of the thyroid, 
prostate, kidney, and breast [8,17]. 
Since cancer is primarily a disease 
of ageing, during a period of life in 
which competing causes of death in-
crease in incidence, cancer screen-
ing is particularly prone to overdiag-
nosis. However, screening has even 
been shown to produce overdiagno-
sis in the case of neuroblastoma, a 
disease of infancy (reviewed in [18]). 
The effect is not only to increase the 
survival rate but also to increase the 
cure rate. After all, it is easiest to 
“cure” patients who did not need to 
be treated in the first place.
All of these biases inflate surviv-
al rates in association with screen-
ing independent of the actual effect 
of a screening test on mortality. In 
fact, it has been shown empirically 
that increasing 5-year survival rates 
in the USA from 1950 to 1995 and 
changes in mortality rates for the 
same cancers had little or no rela-
tionship (Pearson r = 0.00) [19]. In 
other words, survival is an unreli-
able measure of success, whether 
judged at the individual or popula-
tion level, when a screening test is 
involved.
Since survival time after diagno-
sis, rather than mortality, is the only 
observation that a physician can di-
rectly make, even astute clinicians 
such as Drs Childe and Bloodgood 
may be misled by their own care-
ful observations and experience. In 
fact, surveys show that most primary 
care physicians erroneously inter-
pret improved survival in associa-
tion with screening as evidence that 
screening saves lives [20].
Likewise, patients who undergo 
screening may interpret observa-
tions from their own experience as 
evidence of benefit, whether or not 
the screening test is effective. A 
negative test provides reassurance. 
A false-positive test brings immense 
relief when cancer is ruled out. A 
true-positive test triggers gratitude 
towards the physician for order-
ing the test and detecting the can-
cer early (even if it is nothing more 
than a case of overdiagnosis). Even 
severe side-effects of therapy are 
judged to be worthwhile by both pa-
tient and physician. If the patient still 
goes on to die of cancer, the physi-
cian and family alike can feel reas-
sured that everything possible was 
done. In essence, there is little or no 
negative feedback [21].
Little wonder that so much scep-
ticism and vitriol is aimed at authors 
of research papers or media reports 
that question the net benefits of 
some screening tests. The reports 
seem to run counter to personal 
experience on the part of both the 
public and physicians. The result is 
cognitive dissonance, which breeds 
anxiety, a progenitor of anger.
Are there resolutions to the 
controversy?
Potential resolutions map to the 
genesis of the controversies de-
scribed above: (1) imprecise un-
derstanding of the biology of many 
screen-detected cancers, (2) in-
sufficient training to recognize the 
powerful biases that affect interpre-
tation of personal experience, and 
(3) inadequate nuance and framing 
of messages about screening.
Towards a better 
understanding of biology
Traditional staging and prognostic 
systems such as tumour–node–
metastasis (TNM) classification 
and histological grading are crude, 
providing insufficient guidance in 
discerning overdiagnosis at the 
individual level. Therefore, the pa-
tient and physician may feel driven 
to treat all or most screen-detected 
cancers, even if that means unnec-
essary treatment or overtreatment 
in many cases. Some of the con-
troversies would be calmed if there 
were more reliable ways to dis-
tinguish screen-detected cancers 
that are aggressive from those that 
would not cause harm, reserving 
treatment for the former. This ap-
proach is implicit in the use of active 
surveillance for screen-detected 
prostate cancer and neuroblastoma 
[22–24]. However, prediction at the 
individual level for most cancers is 
too crude for comfort.
One strategy would be to use 
emerging molecular techniques to 
characterize screen-detected le-
sions. This research strategy is un-
der way within the Early Detection 
Research Network of the United 
States National Cancer Institute 
(http://edrn.nci.nih.gov/). An exam-
ple of a prospective design would 
be to characterize tumours from 
patients with screen-detected pros-
tate cancer who are undergoing se-
rial biopsies as part of active sur-
veillance. Cross-sectional designs 
may also provide initial insights if 
tumour specimens are accurately 
annotated with respect to method 
of diagnosis: screen-detected ver-
sus symptomatic interval cancers 
in people being actively screened. 
Screen-detected cancers are, on 
average, less aggressive tumours 
compared with symptomatic inter-
val cancers, and their molecular 
patterns can be compared. Finally, 
rapid autopsy studies to find sub-
clinical cancers in people who died 
of causes unrelated to cancer could 
be used to characterize the reser-
voir of cancers that could be overdi-
agnosed by screening. With better 
molecular characterization of over-
diagnosed cancers, any benefits of 
screening could be preserved while 
harms would be minimized.
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Improvements in professional 
training
Formal training that covers the 
strong screening-related biases 
that distort clinical observation (and 
non-randomized screening studies) 
could better prepare health profes-
sionals to judge the value of screen-
ing tests and to evaluate published 
studies, damping down the cogni-
tive dissonance created by personal 
experience. Such training is best 
begun early in medical training, be-
fore specialty-associated heuristics 
become imprinted. Additional pub-
lic health and epidemiology training 
during medical school could alleviate 
some of the “numerator/denomina-
tor” tension.
Better framing of screening 
messages
The strength of screening mes-
sages should match the strength 
of evidence. We need to get be-
yond cancer screening campaigns 
that oversimplify the complexities of 
screening [3]. Cancer screening is 
often a closer call than can be de-
scribed in sound bites. Informed de-
cision-making, rather than persua-
sion, should be the goal. Likewise, 
the benefits of screening are most 
frequently described in relative 
terms. Empirical evidence, includ-
ing randomized trials, has shown 
that the public develops a better 
grasp of the efficacy and harms of 
an intervention when they are pre-
sented in terms of absolute rates or 
frequencies [25,26]. The statement 
that a screening test for lung cancer 
has been shown to decrease lung 
cancer mortality by 20% is roughly 
equivalent to the statement that if 
1000 heavy smokers and former 
smokers were to be screened annu-
ally for three screens, about 4 lung 
cancer deaths would be avoided 
over the next 6–7 years (the results 
of the National Lung Screening 
Trial comparing low-dose helical 
computed tomography [CT] with 
chest radiograph) [27]. However, 
the “feel” of the two methods of ex-
pressing the results is different, and 
the latter method is generally bet-
ter incorporated into individual de-
cision-making. An example of this 
method of presenting the results of 
the trial can be found at http://www.
cancer.gov/newscenter/qa/2002/
NLSTstudyGuidePatientsPhysicians.
Opinions expressed in this manuscript 
are those of the author and do not neces-
sarily represent official positions of the 
United States federal government or of the 
Department of Health and Human Services.
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Cancer 
control
6
Earlier sections of this Report have addressed the 
worldwide burden of cancer, its causation and preven-
tion, and current understanding of cancer biology as un-
derpinning new approaches to both therapy and preven-
tion, with these various parameters explored in relation 
to each of the most frequent tumour types. Knowledge 
about all of these matters, specifically including inter-
ventions to reduce cancer incidence and mortality, is 
primarily dependent on research; research findings have 
determined the content of all previous chapters. Section 
6 is not primarily a specification of research findings but 
more a description of the manner and extent to which 
knowledge of cancer control may be applied at the na-
tional level and a consideration of the resources relevant 
to achieving this end. The focus shifts from the prospect 
of increased understanding to presently coordinated 
action predicated on methodologies already known to 
reduce the burden of cancer. Differences between coun-
tries are evident, sometimes usefully expressed in rela-
tion to national prosperity, but often extending to other 
parameters. Development and implementation of an ad-
equately resourced national cancer control plan is now 
recognized as a fundamental element within the broad 
scope of population health and clinical services activ-
ity. International collaboration provides an opportunity 
to minimize unnecessary evaluation and to optimize im-
plementation for the benefit of national, or sometimes 
local, populations. In parallel with the implementation of 
cancer control measures, infrastructure for continued, 
locally relevant, implementation research may be adopt-
ed and managed, thereby laying the foundation for even 
more effective cancer control measures consequent to 
such investigations.
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Cancer control in Africa: options for a 
vulnerable continent
Isaac F. Adewole 
Cancer remains a leading noncom-
municable disease in Africa, and it 
is also emerging as a great burden 
when compared with infections that 
are ravaging the continent. The tri-
ad of ignorance, poverty, and poor 
health-seeking behaviour makes 
Africa vulnerable to the cancer bur-
den in both male and female, and 
young and adult populations [1]. Of 
the 7.6 million cancer deaths that 
occur worldwide, 4.8 million occur 
in developing countries, translating 
to about 21 000 cancer deaths per 
day, and Africa shares the highest 
proportion globally. The rapidly in-
creasing cancer burden is attribut-
able to the transitional demographic 
profile of several countries in Africa, 
with increasing proportions of older 
people in the population and a shift 
towards lifestyles typical of indus-
trialized countries. Only 17 African 
countries had operational cancer 
control policies in 2010, and virtually 
no African country presently imple-
ments a well-funded national cancer 
control plan. This clearly suggests a 
lack of political will and commitment 
across the continent [2]. Addressing 
this is a continental imperative.
First, each country should pro-
duce a blueprint for national cancer 
control using a framework that is 
socially and culturally sensitive. 
Second, creating awareness about 
cancer as a complex group of diseas-
es that often have identifiable triggers 
should be pursued in a systematic 
manner. This will involve population-
wide health promotion strategies fo-
cused on diet and exercise, lifestyle 
modifications, sexuality/family life 
education programmes, campaigns 
against cultural norms/practices, and 
other behavioural change commu-
nication strategies that are linkable 
to cancer risk. In addition, legislative 
support that promotes healthy living 
within the household and in commu-
nities is imperative. These initiatives 
are expected to foster a strong pri-
mary prevention strategy in a con-
tinent where about 33% of cancers 
are infection-related [3].
Credible evidence abounds that 
some cancers are preventable with 
vaccination, and African countries 
should actively participate in cur-
rent global efforts using practical 
approaches that are feasible in 
their countries, without an over-
dependence on donor support. 
Institutionalization of these vac-
cines into the already existing and 
successful national immunization 
programmes provides a true oppor-
tunity in the continent [4].
Screening for premalignant and 
early diseases is another control 
strategy that has yet to be entrenched 
in Africa. Priorities should be the es-
tablishment of cancer registries as 
well as centres of excellence, and the 
training of a critical mass of experts 
to offer multidisciplinary team care 
for cancer patients in Africa, through 
collaboration with cancer centres 
offering cutting-edge services, pro-
fessional organizations, and pharma-
ceutical companies. Tax incentives 
could be offered for interested foun-
dations, multinational companies, 
and individuals that are ready to in-
vest in cancer control in Africa.
Cancer control in Africa is fea-
sible, but the focus should be on a 
control plan that is realistic, sustain-
able, equitable, and part of a strong 
health-care system.
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Summary
• National cancer control plans 
detail the strategy to address 
the population burden of cancer 
through interventions to reduce 
incidence, mortality, and mor-
bidity and enhance the quality 
of life of those at risk of, or ex-
periencing, cancer.
• The integrity of these plans is 
based on current and accurate 
determination of burden, real-
istic targets for improvement, 
and continuous surveillance 
to document performance and 
outcomes.
• National cancer control plans 
define: the purpose of planned 
activity, the content of interven-
tions to reduce the cancer bur-
den, the context within which ac-
tivities are adapted to prevailing 
circumstances, the relationships 
required between stakeholders, 
and the resources (internal and 
external) to execute the plan.
• Adoption and implementation 
of national cancer control plans 
has been particular to high-
income countries, but progress 
is now occurring in middle- and 
low-income countries as strate-
gies appropriate to circumstanc-
es and resources are identified.
6.1
6 CONTROL
National cancer control plans
Simon B. Sutcliffe Raul Hernando Murillo Moreno 
(reviewer)
Edward L. Trimble (reviewer)
• Resistance, barriers to imple-
mentation, and susceptibil-
ity to unplanned modification 
or revised priorities are an im-
mediate and ever-present real-
ity. Determination, commitment, 
resolve, and collaboration are 
mandatory requirements to real-
ize the future gains of population-
based interventions to control 
cancer and other noncommuni-
cable diseases.
A national cancer control plan is a 
public health programme designed 
to reduce the number of new cancer 
cases and cancer-related deaths 
and to improve the quality of life of 
cancer patients, through systematic 
and equitable implementation of 
evidence-based strategies for pre-
vention, early detection, diagnosis, 
treatment, and palliation, making the 
best use of available resources [1].
The population burden of cancer 
is considerable, with 32.5 million 
people globally living with cancer [2] 
and 169.3 million years of healthy 
life (disability-adjusted life years) lost 
per year due to cancer [3]. The global 
burden will only continue to increase 
in the coming decades due to popu-
lation growth and ageing. In 2012, 
there were an estimated 14.1 million 
new cases of cancer and 8.2 million 
cancer-related deaths worldwide [2]. 
Deaths due to cancer are projected 
to increase to 13 million in 2030. 
Although incidence rates are lower in 
lower-resource countries, mortality 
rates are higher; patterns of disease 
distribution and survival reflect vary-
ing levels of socioeconomic develop-
ment [2,4,5]. Mortality-to-incidence 
ratios for cancer vary from less 
than 0.50 to more than 0.90 across 
world regions (see Chapter 1.1). 
This variation reflects less a lack of 
knowledge of what should be done 
to control cancer than the level of 
commitment to implementing ef-
fective cancer control interventions 
population-wide.
The cost of cancer is substantial. 
In 2009, new cancer cases globally 
were estimated to cost US$ 286 bil-
lion, both in direct – i.e. medical – 
costs and in indirect costs, prin-
cipally including lost productivity. 
Approximately 94% of these costs 
were incurred in high-resource 
countries; only 6% were incurred 
in upper-middle, lower-middle, and 
low-income countries [6]. Other 
estimates of the economic cost of 
cancer are far higher (US$ 1.16 tril-
lion) when taking account of costs 
of prevention and treatment, and the 
annual economic cost of disability-
adjusted life years (see Chapter 6.7). 
As the burden of cancer grows, it 
will unequally and inequitably affect 
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those with the least ability and capa-
bility to respond.
To address this growing burden 
of cancer, population-based cancer 
control must be recognized as far 
more than a medical response to 
cancer. The cancer burden is driven 
by a complex interaction of changing 
factors, including social determi-
nants such as poverty, education, 
the built environment, gender equity, 
and so on, and population health, in-
cluding primary prevention/risk fac-
tor control and early detection and 
management of disease and illness. 
Accordingly, improving cancer con-
trol at a population level is a social 
imperative, which requires a societal 
response that may be challenging 
to prevailing social, business, and 
economic interests.
Addressing the increasing bur-
den of cancer requires a country or 
population cancer control plan. The 
WHO strategic definition of a na-
tional cancer control plan (NCCP), 
as specified above, is predicated 
on evidence-based interventions 
that need to be implemented for 
prevention, early detection, diagno-
sis, treatment, and palliation. This 
definition emphasizes the scientific 
and medical content of a plan, which 
is the focus of much of the discourse 
around NCCPs. The success of the 
plan, however, is dependent not 
only on its content – what needs to 
be done – but also on its context, 
which includes: cultural and circum-
stance-specific factors influencing 
implementation; the key actors and 
stakeholders, and their responsibili-
ties and accountabilities; available 
resources, including human, tech-
nology, facilities, and financing per-
spectives that influence how the plan 
will be operationalized; and evalu-
ation of the plan and its impact on 
cancer control outcomes and the 
achievement of defined targets. If 
these elements are not addressed in 
the NCCP, implementation and sus-
tainability will be difficult to achieve 
and the impact of the plan on cancer 
control and the health of the popula-
tion will be jeopardized regardless of 
the effectiveness of the interventions 
outlined within it.
The fundamental role of data
The first step in establishing an 
NCCP is to understand the scope 
of the region-specific cancer burden, 
as patterns of cancer vary by geog-
raphy. This variation can arise for 
many reasons, including heteroge-
neities in etiological risk factors such 
as tobacco use and chronic infec-
tion; geography, as exemplified by 
climate; social determinants, such as 
poverty; and health systems, specifi-
cally including access to diagnostic, 
treatment, and care services. These 
heterogeneities can contribute to 
variation in pathology and stage, 
survival, functionality, and quality of 
life [7]. Given this wide variation, no 
single NCCP will satisfy the needs of 
every country or population. Instead, 
NCCPs must be adapted to national 
and regional needs and capabilities.
Population data are the founda-
tion for understanding the burden 
and pattern of cancer. These data 
can also be used to synthesize and 
prioritize planned interventions, 
establish system capacity require-
ments for care, evaluate population-
based cancer control activities, and 
justify continued investment of re-
sources according to performance 
and outcomes of plans. Projection 
CANCER 
CONTROL 
PROGRAMME 
Early 
detection Treatment 
Prevention Palliative care 
Fig. 6.1.1. National cancer control programme: a systemic and comprehensive approach.
Fig. 6.1.2. A WHO poster for World No 
Tobacco Day 2010 focuses on the mar-
keting of tobacco to women.
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of data can also define future bur-
den, needs, capacity, impact, and 
required investment.
Cancer registries are the primary 
source of data for NCCPs. Registries 
present the population burden of 
cancer and can do so by time, key 
population attributes (including age, 
gender, and recognition of paedi-
atric and adolescent/young adult 
cases), cancer site/type, impact of 
interventions as affecting stage dis-
tribution, 5-year survival, disability, 
the presence or absence of health 
insurance [8], and peer comparison 
with reference, for example, to geo-
graphical, political, economic, eth-
nic, and heritage status [2,7,9]. In the 
United Kingdom and the European 
Union, comparative presentation of 
data has provided the stimulus for 
NCCP development, renewal, and 
implementation. Indeed, increasing 
recognition of the global variation 
in incidence, mortality, and 5-year 
survival, and reasons for this varia-
tion – which include access to care, 
diagnostic and treatment services, 
and investment in health resources – 
have provided an important stimulus 
for viewing NCCPs as a means of 
improving cancer burden, mitigating 
variation, and addressing disparities.
However, as fundamental as 
cancer registries are for cancer con-
trol planning, many lower-resource 
countries are challenged by having 
neither registries nor a systematic 
ability to collect data. These chal-
lenges result from a lack of medi-
cal facilities, low cancer awareness, 
poor follow-up, poorly maintained 
records, lack of trained staff, and/
or lack of fiscal, medical, and po-
litical resolve. Potential solutions 
include establishing the culture of 
evidence, supported by data, be-
tween clinicians and data registrars; 
educational meetings to raise aware-
ness; household visits; collection of 
data on admissions, procedures, 
and mortality from urban reference 
centres; and a focus on good data 
collection from a few, more estab-
lished centres rather than an entire 
population survey. Ultimately, ef-
forts to establish reliable population 
data for programme planning need 
to consider comprehensiveness 
across the disease control spectrum, 
completeness, accuracy, timeliness, 
and coverage. Notable examples 
of approaches by lower-resource 
countries exist in South and Central 
America and India.
Once established, registries 
should not be viewed as static re-
positories of data. They should be 
enhanced over time to incorporate 
more detailed data on diagnosis 
and treatment. Along with projec-
tion and modelling methodologies, 
these continually updated data will 
help refine needs, capacity, resourc-
es, programme evaluation, and in-
vestments, thereby allowing health 
systems to maintain optimal cancer 
control outcomes.
The coverage and quality of 
registry data can vary considerably 
worldwide. Estimates of the propor-
tion of the population covered by 
cancer registries range from more 
than 80% in North America, Europe, 
and Australia to approximately 30% 
in the Russian Federation, less than 
10% in South America and South-
East Asia, and only a few percent 
in Africa. Regional registries also 
vary in their comprehensiveness, 
completeness of information cap-
ture, timeliness, accuracy and con-
sistency of terminology, and use 
of international classifications and 
recording standards. Irrespective of 
their coverage and quality, registries 
are nevertheless useful for informing 
and refining NCCPs. Thus, even in 
regions without functioning regis-
tries, at least minimal cancer-rele-
vant health surveillance should be 
developed concurrent with NCCPs 
to rationalize activities, investments, 
and performance of cancer control 
plans [10].
The content of NCCPs
An NCCP is a strategic plan en-
compassing the spectrum of cancer 
control measures and is evidence-
based, scientifically accurate, and 
current. Establishing the content of 
this plan is relatively straightforward 
as it is based on best practices, the 
scientific and clinical literature, and 
Box 6.1.1. Guiding principles for 
developing a national cancer control 
plan.
1. Comprehensiveness: The plan 
should address all members of 
the population, with attention 
to addressing inequities and 
disparities.
2. Scope: The plan should address 
cancer control from the perspec-
tives of human development, risk 
factor control, and health and dis-
ease management.
3. Evidence base: The plan should 
be based on evidence or best 
practices and should incorporate 
indicators and metrics of perfor-
mance, output, and outcomes.
4. Standards of practice: The 
cancer control plan should take 
into account measures to define 
standards and ensure consis-
tent application, such as access, 
timeliness, quality of care, and 
safety.
5. Minimization of inappropriate 
variation of practice and fac-
tors influencing compliance 
with therapy: The plan should 
use guidelines or best practices 
and measures to support adher-
ence and compliance.
6. Integration and continuity: 
The plan should strive for conti-
nuity across states of health and 
illness, and across home, com-
munity, and tertiary or specialist 
environments.
7. Inclusiveness: The cancer con-
trol plan should be developed 
with input and support from the 
public, patients, providers, poli-
cy-makers, and payers.
8. Governance: The plan should 
align with population health 
priorities and outline respon-
sibilities, accountabilities, and 
reporting.
9. Sustainability: The plan should 
be developed with the inten-
tion of being self-sufficient and 
sustainable.
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training and planning manuals [11–
13]. Published plans are accessible 
[14–16]. As NCCPs are about con-
trol of disease within the context of a 
country and the health of its popula-
tion, each country must adapt the 
content of its plan to its population 
and circumstances. A set of core 
principles have been recognized 
as guiding acceptance and imple-
mentation (Box 6.1.1). The plan must 
describe how beneficial change in 
cancer control will occur; address 
purpose, content, context, relation-
ships, and resources; present a busi-
ness plan to determine how resource 
inputs will be acquired, deployed, 
and accounted for; and include an 
operational plan to determine how 
implementation is going to roll out 
over time in a coordinated, inte-
grated manner that leads to perfor-
mance and achievement of results 
(Box 6.1.2).
Surveys of WHO Member 
States indicate that elements of 
functional cancer control plans 
are present in 35% of low-income 
countries, 35–60% of countries in 
the lower-middle and upper-middle 
income groups, and 75% of high-
income countries. However, sub-
stantial variation exists within re-
source settings with respect to the 
specific components of the plans 
(see Chapter 6.2).
The context of NCCPs
Critical to the success of the NCCP 
is its adaptation to its country or 
population context. Contextual fac-
tors include resources and priorities.
For any country, the level of 
resources available in the health 
system is the major determinant 
for decision-making in health plan-
ning and its limitations. Resources 
include human resources, and 
specifically qualified personnel; 
technology, which includes infor-
mation technology; drugs, and diag-
nostic and therapeutic equipment; 
facilities, with reference, for exam-
ple, to access to transportation and 
affordable in-patient and ambula-
tory accommodation; and financial 
resources, including current and pro-
jected annual growth. As interven-
tions move from a population level to 
a person, tissue, cell, and genome, 
Box 6.1.2. Elements to be included in a national cancer control plan.
1. Why a national cancer control plan is necessary:
• What is the burden of cancer?
• What is the capability and capacity for control?
• What is the imperative for change?
• How important is cancer relative to other health challenges?
2. What interventions are required:
• What interventions for cancer are most important: risk factor control, early detection, diagnosis, treatment, 
and care?
• How will these interventions be prioritized in relation to other elements of cancer and noncommunicable 
disease control?
3. How interventions will be implemented, and how the process of implementation will be monitored and 
evaluated:
• How will human, technology, facilities, and organizational resources be aligned to the implementation?
4. Who will be involved:
• How will collaboration be fostered and managed?
• How will roles and resources be shared?
• How will responsibility and accountability be established?
• How will “buy-in”, progress, and performance be communicated and reported?
5. When activities will be undertaken according to priority, what is the capability and the resource avail-
ability (the operational plan).
6. How the national cancer control plan and its implementation will be financed (the business plan):
• What are the contributions of foreign aid, in-kind services, and local financing?
• How are self-sufficiency and sustainability being addressed?
7. How the plan will be evaluated:
• How will outputs and outcomes be measured (system performance), linked to a changing burden of cancer, 
and aligned with resource allocation to determine value?
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the requirements for level of qualifi-
cations of personnel, technology, in-
frastructure, time, and cost increase, 
while population access commonly 
decreases. Interventions directed at 
behaviour change at a community 
or individual level, while sometimes 
difficult to achieve, require modest 
technical support, whereas interven-
tions involving clinical care – such 
as surgery and provision of radiation 
and drug-based therapy – require a 
proficient level of specialist skill and 
technological capacity.
Recognizing the resource chal-
lenges of lower-resource countries, 
WHO has presented a core set of 
“best buy” lower-cost intervention 
strategies for four noncommunica-
ble diseases: cardiovascular dis-
ease, chronic respiratory diseases, 
diabetes, and cancer [17]. These 
strategies address factors common 
to more than one such disease, 
such as tobacco use, alcohol con-
sumption, unhealthy diet, and lack 
of physical activity. Interventions in-
clude tax increases and legislation, 
as illustrated by measures relating 
to smoke-free environments, limited 
retail access, and advertising bans; 
hepatitis B vaccination and cervi-
cal cancer screening programmes; 
and recommendations for reducing 
salt intake, substituting trans fats, 
and using aspirin for myocardial 
ischaemia.
The annual cost of implement-
ing these interventions for all people 
in lower-middle-income countries is 
estimated to be US$ 11.4 billion – 
an investment of US$ 1 per person 
in low-income countries to US$ 3 
per person in upper-middle-income 
countries. This contrasts with a cur-
rent “business as usual” scenario 
whereby economic losses of US$ 500 
billion per year are incurred for the 
four noncommunicable diseases – 
a loss equivalent to 4% of annual 
output of low-income countries and 
lower-middle-income countries, or 
US$ 25–50 per person per year. 
Initial investments, which may be 
quite modest for many aspects of 
population health, have a personal, 
family, community, and economic 
return on investment based on in-
creased longevity, productivity, so-
cietal contribution, and avoidance of 
health-care costs.
Most of the above-mentioned 
“best buy” interventions relate to 
prevention, intuitively considered to 
be more cost-effective than interven-
tions for early or established dis-
ease. A further distinction of disease 
prevention interventions relates to 
whether they are environmental 
(involving measures that affect the 
whole population) or personal (di-
rected towards changing individual 
behaviour) and whether they are 
clinical (delivered in a health-care 
facility) or non-clinical (delivered 
outside of the health-care setting). 
Environmental interventions are 
generally the most cost-effective as 
they affect a large proportion of the 
population. Typically such measures 
are achieved through policy and reg-
ulation – examples are smoke-free 
laws or food regulations addressing 
fortification or control of unhealthy 
food components such as trans fats. 
In contrast, interventions directed 
at lifestyle or individual choice, or 
delivered in clinical settings, are less 
cost-effective, although not mutually 
exclusive of environmental interven-
tions [18].
Even though “best buy” inter-
ventions are clearly cost-effective, 
economics is not the sole criterion 
for NCCP development within limited 
resources. Other factors, including 
societal and circumstance-specific 
factors [19], alternative models of 
service delivery [20], and priorities 
within the disease, health, and other 
sectors will determine ultimate de-
cisions. In low-resource settings, 
NCCPs may not be feasible as 
stand-alone plans. The principles 
underlying NCCPs, however, are 
also broadly applicable to other non-
communicable diseases, as noted 
above, even though treatment op-
tions may be disease-specific [21].
Enhancing NCCPs
NCCPs commonly define strategies 
to control cancer. Cancer control 
measures, however, will be achieved 
only if the NCCP is implemented 
within the health system through the 
Fig. 6.1.3. Poster from the National 
Research and Safety Institute (INRS), 
France, advocating the wearing of protec-
tive masks by workers exposed to asbes-
tos: “When working on construction sites, 
I never wore a protective mask against 
asbestos. Now, I wear a mask every day. 
With asbestos, don’t take chances. Protect 
yourself!”
Fig. 6.1.4. Poster from the Iowa De- 
partment of Public Health, USA, advo-
cating colorectal cancer screening for 
Vietnamese Americans: “Life is good, and 
I’m not letting anything take me away from 
my family. Asian Americans are at higher 
risk of colorectal cancer. Treatment is easy 
if it is detected early through testing. If you 
are 50 or older, get tested today! ”
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“push” of science and medicine and 
the “pull” of patients and the public 
(sociopolitical imperative) [22].
Such an approach involves social 
mobilization, causing the challenge 
to be embraced and championed by 
key constituencies influencing so-
cial and political change. There are 
roles for advocate and stakeholder 
participation, together with the en-
gagement of relevant networks and 
coalitions.
Collaboration across networks 
and coalitions will increase their 
impact and may extend from infor-
mation exchange to agreed coor-
dination and cooperation. The lat-
ter requires trust, mutual respect, 
a sensitivity to issues of authority, 
and understandings about roles, 
responsibilities, and accountabili-
ties. Examples of such networks 
include national organizations, 
such as the Canadian Partnership 
Against Cancer; regional entities 
for cancer control, such as the 
African Organisation for Research 
and Training in Cancer and the 
Latin American Network of National 
Cancer Institutes; and international 
entities, such as the International 
Network for Cancer Treatment and 
Research and the International 
Cancer Control Congresses. Also 
key to effective collaboration are 
well-defined and secure financial 
commitments through, for example, 
a business plan, a detailed imple-
mentation plan, and an understand-
ing that the NCCP is an integral 
component of the population health 
system.
The value of NCCPs
Proof of effectiveness of cancer 
control measures is hindered by the 
long time gap between implemen-
tation of interventions and changes 
in incidence and mortality. Other 
limitations stem from the paucity of 
data linking intervention and effect 
directly, the continuous introduc-
tion of new technologies and thera-
peutic advances, and the inability 
to undertake a controlled study of 
NCCP versus no-NCCP within a 
single population over a given time. 
Thus, causality can be approximated 
and can be discussed; it cannot be 
assumed [23]. For NCCPs to dem-
onstrate value, they must be imple-
mented and audited.
Although direct evidence of ef-
fectiveness is not available, sup-
portive evidence for the benefit of 
NCCPs exists. This evidence de-
rives from several sources.
The first is programmes address-
ing specific elements of cancer con-
trol. Changes in mortality are evident 
after the implementation of tobacco 
control programmes (in Australia, 
Canada, and Brazil), organized pre-
vention through vaccination (against 
human papillomavirus in Costa 
Rica and against hepatitis B virus in 
Taiwan, China), sun protection cam-
paigns and screening for melanoma 
(in Australia), and organized early 
detection programmes for cervical 
cancer (in Colombia, Ecuador, Chile, 
the United Kingdom, and Canada).
The second is control of multi-
ple risk factors for noncommunicable 
diseases, including cancer. In North 
Karelia, Finland, substantial reduc-
tions in cardiovascular disease and 
cancer – and particularly lung can-
cer – mortality have been achieved 
through control of targeted risk 
factors [24]. In the USA, decreases 
in coronary heart disease mortal-
ity over the past four decades have 
been achieved through improve-
ments in risk factor control, exem-
plified by smoking, hypercholesterol-
aemia, and hypertension, and, more 
recently, through the introduction 
and adoption of treatment innova-
tions [25].
The third is treatment improve-
ments. Increased clinical trial en-
rolment and rigorous definition of 
benefit and measures to encour-
age adoption of evidence-based 
care have led to reduced paediat-
ric cancer mortality in high-income 
countries and in lower-resource 
countries such as Argentina. The 
adoption of professional practice 
standards to reduce inconsisten-
cies, deficiencies, and variability in 
clinical practice – including, for ex-
ample, surgery, pathology assess-
ment, and therapy allocation – has 
led to decreased mortality for resect-
able colorectal cancer. Compliance 
with evidence-based/informed clini-
cal practice guidelines has led to 
increased breast cancer survival, 
and implementation and application 
of evidence-based new therapies 
have led to reduced mortality for 
Fig. 6.1.5. The “Nobody’s Immune to Breast Cancer” campaign of Associação da Luta 
Contra o Cancro (Association for the Fight Against Cancer), Mozambique: “When we 
talk about breast cancer, there are no women or superwomen. Everybody has to do 
a monthly self-examination. Fight with us against this enemy and, when in doubt, talk 
with your doctor.”
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B-cell non-Hodgkin lymphoma. The 
achievement of surrogate targets of 
improved health outcomes is illus-
trated by access to care and treat-
ment, screening rates, and quality 
and timeliness of diagnostic services 
[26].
Finally, comparisons have been 
made of trends in mortality rates in 
comparable populations with and 
without NCCPs, as indicated, for ex-
ample, by survival trends in England 
versus Wales up to 2007 [27].
Conclusions
Cancer is a major and increasing 
public health problem and popula-
tion burden for all countries. An 
NCCP presents an opportunity to 
implement effective change at a 
population level on an ongoing, 
adaptable basis, using a variety of 
interventional methods that can be 
accommodated within the contex-
tual, social, and financial means of 
even the poorest nations.
The challenge for NCCPs is 
less the derivation of content than 
the ability to apply and achieve 
sustainable change at a population 
level. If conditions are favourable 
(Box 6.1.3), with the support and 
engagement of all key actors and a 
clear and common vision for cancer 
control, the plan is more likely to suc-
ceed in improving the health of the 
population.
NCCPs identify why action is nec-
essary and what action is required. 
To change the population impact of 
cancer, however, it must be clear 
how NCCPs will be implemented, 
adopted, evaluated, and sustained. 
An NCCP, as defined by WHO, has 
the potential to change population 
incidence, suffering, and mortality 
from cancer through implementa-
tion in a contextually aligned man-
ner when supported by all relevant 
stakeholders in an inclusive and inter-
disciplinary partnership, and financed 
and governed to achieve long-term, 
sustainable improvements in cancer 
control.
Box 6.1.3. Conditions underlying the probability of a successful national cancer control plan.
1. Political and professional consistency and resolve to address the population cancer burden.
2. Use of data and a commitment to support and maintain cancer registration and surveillance.
3. Clearly defined vision for cancer control, commonly agreed and supported.
4. Contextual relevance, defined priorities, achievable implementation, and an appropriate time frame to 
achieve goals.
5. Defined, secure funding commitment.
6. Trust, mutual respect, and willingness to achieve commonly defined goals through collaboration by all key 
actors.
7. Scalability, incorporation into the health system, self-sufficiency, and sustainability.
8. Applicability to, and coordination and cooperation with, other population disease control plans.
9. Sound governance, evaluation, communication, and ongoing adaptation to meet future needs.
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Cancer control in Canada: challenges and 
strategies in a high-income country
Heather Bryant and Lee Fairclough 
In 2006, the federal government 
of Canada created the Canadian 
Partnership Against Cancer, a fed- 
erally funded nongovernmental 
organization charged with the im-
plementation of the national cancer 
control strategy [1,2]. While the de-
velopment of the strategy was built 
on many years of collaborative 
work, there were challenges that 
needed to be met and lessons to 
be learned in its implementation.
Many of the initial challenges 
concerned creating the appropriate 
measures needed to stimulate and 
assess the impact of such a strat-
egy. Canada had the same excellent 
starting point that many high-income 
countries have: the presence of pop-
ulation-based cancer registries with 
high-quality data throughout most 
of the country. However, there were 
gaps that had not been addressed. 
The first related to high-quality 
staging data, which was absent at 
a pan-Canadian level. Thus, one of 
the first initiatives of the Canadian 
Partnership Against Cancer was to 
work with the provincial registries 
and clinicians (particularly patholo-
gists) to identify an approach to 
address this issue. The result was 
the National Staging Initiative, a 
large-scale programme designed 
to catalyse coordinated efforts in 
all jurisdictions with investments in 
infrastructure and implementation 
of standards. The National Staging 
Initiative has successfully achieved 
the goal of making collaborative 
stage information available in a sus-
tainable way for more than 90% of 
the four major cancers (lung, colo-
rectal, breast, and prostate) starting 
in the 2010 coding year.
For many years, routine inter-
provincial comparisons had been 
done on incidence, mortality, and, 
to a lesser extent, prevalence and 
survival. However, none of these 
measures were able to shine a 
light on what occurred between the 
two key time points: diagnosis and 
death. Some provinces had initiated 
reporting in this area where limited 
data existed, but the comparison 
of this across the country had not 
occurred. Thus, provincial cancer 
agencies and health departments 
were engaged to come to consen-
sus on indicators that would be most 
useful as initial assessments of con-
cordance of treatment with high-lev-
el recommendations. Initially, only 
a few provinces were able to pro-
duce the necessary data. However, 
over the past few years, the Cancer 
System Performance Report [3] has 
evolved from having “proxy” indica-
tors for many variables to a report 
with an ever-increasing insight into 
possible areas for improvement in 
each jurisdiction. These measures 
are placed with others to provide 
a view across the cancer control 
continuum, including population 
measures of risk factors, of screen-
ing, and of patient experience. The 
report continues to develop, with the 
joint leadership of senior representa-
tives of each provincial cancer agen-
cy and the Canadian Partnership 
Against Cancer, and has been used 
by several provinces to target quality 
initiatives in their own jurisdictions.
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Summary
• The national capacity of a 
country for cancer prevention 
and control may be assessed 
based on the WHO 2013 
Noncommunicable Disease 
Country Capacity Survey by 
analysing cancer-specific data. 
Information is available from 176 
countries.
• Although 85% of the participat-
ing countries have cancer plans 
or policies, many of those plans 
are not operational. Only 38% 
of countries in Africa and 45% 
of low-income countries have 
operational plans with a budget 
to support implementation.
• Population-based cancer reg-
istries were reported to exist in 
72% of countries.
• From survey information re-
ceived by WHO, major gaps in 
health care for cancer control 
were identified. Many countries, 
especially low-income coun-
tries, lack a national cancer con-
trol policy or plan. Where cancer 
policies have been developed, 
such policies are not always 
comprehensive.
• Because the cancer burden is 
high and is increasing globally, 
adoption and implementation, 
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by each country, of a national 
cancer policy and plan is an im-
perative. Political, financial, and 
technical support is required. 
Progress could be furthered by 
making existing cancer plans 
operational and, in particular, 
by increasing resources for 
early detection and treatment 
capacity.
With increasing awareness by pol-
icy-makers of the burden that non-
communicable diseases (NCDs) – 
including cardiovascular disease, 
diabetes, and cancer – impose on 
national health systems and econo-
mies, WHO has been asked to pro-
vide data indicating the prepared-
ness of national health systems to 
prevent and control NCDs. Together 
with monitoring of the cancer burden 
by cancer registries, cancer capac-
ity assessment is a fundamental re-
quirement for rational cancer control 
planning. The WHO Global Action 
Plan for the Prevention and Control 
of NCDs 2013–2020, endorsed by 
the 66th World Health Assembly 
(resolution WHA66.10) in 2013, ad-
dresses an urgent requirement to 
provide the information relevant to 
national NCD planning. National 
capacity data from the WHO 2013 
Noncommunicable Disease Country 
Capacity Survey [1] indicate the 
current preparedness of countries to 
undertake cancer control.
A WHO survey of Member 
States
The WHO 2013 Noncommunicable 
Disease Country Capacity Survey 
was a further development of a 
regular survey conducted periodi-
cally to assess responses by indi-
vidual countries to NCD challenges. 
Cancer-control-specific items are an 
integral part of the survey. Those re-
sults that are common to all NCDs 
are published in country profiles [2], 
which provide an overview of nation-
al priority setting for NCDs and the 
availability of corresponding inter-
ventions. The NCD country profiles 
complement the WHO global report 
on the burden of these diseases and 
respective recommended interven-
tions [3].
National NCD capacity is as-
sessed by the dimensions of public 
health infrastructure and partner-
ships focused on NCDs, taking 
account of relevant strategies, pro-
grammes, and action plans, health 
information systems, and health-
care capacity. The questionnaire 
used in the 2013 Noncommunicable 
Disease Country Capacity Survey 
included these dimensions in four 
modules that captured information 
on cancer. Cancer control capacity 
is defined as the availability of plans, 
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programmes, and services covering 
the essential components of a na-
tional cancer control programme [4], 
including prevention, early detection, 
treatment, and palliative care.
Information to assess the na-
tional capacity for prevention and 
control of cancer was extracted from 
the 2013 Noncommunicable Disease 
Country Capacity Survey by using 
methods that have been previously 
used and described in detail [1]. The 
relevant questionnaire was sent in 
2012 to appropriate authorities 
within the ministries of health of all 
193 WHO Member States. Detailed 
information about the situation with 
respect to NCD control was received 
from 176 countries.
National cancer plans and 
their implementation
Ministries of health in the majority of 
participating countries, specifically 
149 of 176, reported having a national 
cancer policy, strategy, or action plan, 
hereafter referred to as a “cancer 
plan”. There are, however, regional 
differences. The European Region 
has the highest coverage of national 
plans, with 49 of the 50 countries hav-
ing plans, while the South-East Asia 
Region has the lowest proportion of 
national cancer plans, with 7 of the 10 
countries so identified. In the African 
Region, 27 of 37 countries reported 
having a cancer plan. Overall, cancer 
control is formally included in nation-
al health planning in the majority of 
countries.
To gain more detailed insight 
into national cancer control planning 
processes, several criteria were as-
sessed. These included whether 
the plan was operational as well as 
the availability of dedicated funding 
for the plan. The inclusion of these 
additional criteria enabled a more 
differentiated assessment of the 
status of national cancer plans and 
policies. In the African and Eastern 
Mediterranean Regions, in contrast 
to the high percentage of countries 
that reported having a formal can-
cer plan, only 36% of the countries 
Fig. 6.2.1. Mothers and children at a health-care clinic in Sarlahi District, Nepal. In low-
income countries generally, the burden associated with cervical cancer may be mark-
edly reduced by the incorporation of appropriate screening into routine health services.
Table 6.2.1. Results from the WHO 2013 Noncommunicable Disease Country 
Capacity Survey: percentage of countries with cancer policies, strategies, or action 
plans and their functionality
WHO regiona Number of countries
Percentage of countries with cancer 
policies, strategies, or plans
Existing 
policy
Operational policy 
with funding
African 37 73% 38%
Americas 31 90% 65%
Eastern Mediterranean 21 76% 43%
European 50 98% 84%
South-East Asia 10 70% 70%
Western Pacific 27 85% 78%
World Bank income groupb
Low 29 79% 45%
Lower-middle 43 84% 58%
Upper-middle 49 84% 65%
High 55 91% 78%
Total 176 85% 64%
a  For a list of countries corresponding to each WHO region, see http://www.who.int/about/regions/en/
index.html.
b  For definitions of World Bank income groups, see http://data.worldbank.org/about/country- 
classifications.
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reported that the plan was operation-
al and only 43% had dedicated fund-
ing available for the implementation 
of the plan. Similar, but less marked, 
differences were evident in the other 
WHO regions, where allocation of re-
sources for implementation of many 
national plans is lacking. In addition, 
the specification of a plan does not 
guarantee that its implementation 
is monitored or that there is a clear 
definition of measurable anticipated 
outcomes.
Approximately 15% of all partici-
pating countries did not have a cancer 
plan. Overall, only 64% of countries 
reported having cancer control plans 
that were operational and funded. 
Analysis of the available findings by 
World Bank income group revealed a 
consistent gradient from low-income 
countries to high-income countries 
with respect to the specification and 
completeness of national cancer 
plans. High-income countries are 
more likely to have plans that are also 
funded and monitored with regard to 
their defined outcomes (Table 6.2.1). 
However, even within countries in the 
highest income group, characterized 
by 90% of countries having a national 
cancer plan, only a proportion (78%), 
rather than all countries, confirmed 
that these plans were operational and 
funded.
Monitoring the cancer burden
The availability of data establishing 
the national cancer burden is the ba-
sis for any rational cancer planning 
and the ordering of priorities. Cancer 
registries therefore play a key role in 
national cancer planning. In the ma-
jority of countries, i.e. in 80% of the 
176 countries responding, a registry 
for cancer was reported, regardless 
of the type of the registration under-
taken (Table 6.2.2). The European 
Region exhibited the highest propor-
tion of countries with cancer regis-
tries (94%), and the South-East Asia 
Region had the lowest proportion of 
countries (60%). In 25 of 37 coun-
tries in the African Region and in 
24 of 27 countries in the Western 
Pacific Region, there was a moni-
toring system for cancer. 
The various cancer registries 
were further differentiated from 
each other by type of registry – 
some of the key differences are 
whether the registry is popula-
tion-based or hospital-based, and 
whether the population covered is 
national or is identified at a less 
comprehensive level. In almost 
all regions, population-based reg-
istries are the predominant type, 
accounting for 69% in the Eastern 
Mediterranean Region and 81% in 
the European Region. The region 
in which population-based cancer 
registries are the least common is 
the South-East Asia Region (50%). 
There is a consistent link between 
cancer registration and national 
Fig. 6.2.2. The Children’s Vaccine Pro- 
gram is working with the Cambodian 
government and other partners to make 
hepatitis B vaccines available to all chil-
dren in the country. Here, health-related 
brochures are distributed to villagers by 
the mobile health team in the village of 
Choumpou in Kampong Cham Province.
Table 6.2.2. Results from the WHO 2013 Noncommunicable Disease Country Capacity Survey: percentage of countries with 
cancer registries and type of registry
WHO regiona Number of countries
Percentage (number) of countries with cancer registries
Existing cancer 
registriesb
National 
registriesc,d
Subnational 
registriesc,d
Population-based 
registriesd
Hospital-based 
registriesd
African 37 68% (25) 32% (8) 68% (17) 64% (16) 36% (9)
Americas 31 71% (22) 64% 36% 77% (17) 18% (4) (missing 1)
Eastern Mediterranean 21 76% (16) 69% 31% 69% (11) 25% (4) (missing 1)
European 50 94% (47) 81% 19% 81% (38) 15% (7) (missing 2)
South-East Asia 10 60% (6) 17% 83% 50% (3) 50% (3)
Western Pacific 27 89% (24) 75% 25% 58% (14) 42% (10)
World Bank income groupe
Low 29 59% (17) 35% 65% 47% (8) 47%
Lower-middle 43 72% (31) 35% 65% 48% (15) 52%
Upper-middle 49 84% (41) 68% 32% 71% (29) 22%
High 55 93% (51) 88% 12% 92% (47) 8%
Total 176 80% (140) 64% 36% 71% (99) 26%
a For a list of countries corresponding to each WHO region, see http://www.who.int/about/regions/en/index.html.
b Data reporting on the answer “yes” to the overall question “Does your country have a cancer registry (of any kind)?”
c  Data reporting on the answer to the question “Does your country have a national cancer registry vs a regional registry?” The positive response to this 
question does not imply that there is national coverage.
d Percentage of countries out of the total responding “yes” to the overall question “Does your country have a cancer registry (of any kind)?”
e For definitions of World Bank income groups, see http://data.worldbank.org/about/country-classifications.
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Cervical cancer prevention in six African countries
Nathalie Broutet
A WHO demonstration programme 
for cervical cancer prevention began 
in September 2005 and was com-
pleted in May 2009. Training of proj- 
ect coordinators was organized at 
the University of Zimbabwe, Harare. 
Training in data management was 
undertaken at all project sites, with 
the African Population and Health 
Research Center (APHRC) and 
IARC. The project created aware-
ness in communities about cervi-
cal cancer and its prevention in 
six African countries: Madagascar, 
Malawi, Nigeria, Uganda, the United 
Republic of Tanzania, and Zambia.
Women were counselled and 
offered screening using visual in-
spection with acetic acid (VIA), and 
patients with a positive screening 
test were treated using cryothera-
py. Patients who were not eligible 
for cryotherapy were referred to a 
higher level of health care for fur-
ther evaluation and treatment (Fig. 
B6.2.1). Continuous monitoring and 
evaluation of the project was carried 
out by IARC and APHRC, to gener-
ate evidence about the acceptability 
and feasibility in a primary health-
care setting, referral site, or district 
hospital. The project targeted all 
women resident in the catchment 
area and aged between 30 and 
50 years.
Between September 2005 and 
May 2009, a total of 19 579 wom-
en were screened in the six coun-
tries. Overall, 10.1% of screening 
with VIA results were positive, and 
1.7% of women had lesions suspi-
cious of cancer on inspection. A 
total of 87.7% of all VIA-positive 
cases were eligible for cryotherapy. 
The majority of women (63.4%) 
received cryotherapy within one 
week of initial screening. The sin-
gle-visit approach enabled 39.1% of 
women to be screened and treated 
on the same day. However, more 
than 39.1% of all women eligible 
for cryotherapy did not receive 
treatment, for various reasons, 
including equipment failure and 
women needing to obtain consent 
from their spouses before cryo-
therapy could be done. The VIA 
and cryotherapy procedures were 
well tolerated by the women, and 
almost all of those who underwent 
these procedures said they would 
recommend them to other women.
This programme has shown that 
the “screen and treat” approach can 
be introduced into existing reproduc-
tive health services in low-resource 
countries. Screening for precancer-
ous lesions using VIA and treatment 
with cryotherapy is acceptable and 
feasible at low-level health facili-
ties. VIA is an attractive alternative 
to cytology-based screening in low-
resource settings. The alternative 
simple and safe cervical cancer 
prevention techniques simplify the 
process and render it feasible and 
acceptable to women and service 
providers in low-resource settings.
At the final meeting of the proj- 
ect, country teams presented plans 
on how best to scale up cervical 
cancer prevention services using 
the “screen and treat” approach. 
Training of an adequate number 
of providers, sustainable supervi-
sion, and supply and maintenance 
of equipment and consumables are 
key elements of the programme. 
The country teams noted that fund-
ing shortages and limited human re-
sources are some of the factors that 
may prevent the ministries of health 
in the six countries from sustain-
ing and scaling up the programme. 
However, at least four of these six 
countries now have national cervi-
cal cancer prevention programmes.
Fig. B6.2.1. Programme for strengthening cervical cancer prevention: operational 
framework. VIA, visual inspection with acetic acid.
income. In the highest income cate-
gory, 93% of countries have a moni-
toring system for cancer, and this 
proportion falls to 59% for countries 
in the lowest income group. This 
gradient in cancer monitoring with 
the level of prosperity is particularly 
dramatic for population-based reg-
istries, which are available in only 8 
of the 29 countries in the lowest in-
come group compared with 47 of the 
55 countries in the highest. Overall, 
36 countries reported that they have 
no cancer-specific registration.
Prevention and early 
detection policies
Prevention
Certain declared policies to prevent 
cancer are also amenable to com-
parison and evaluation. Interventions 
based on exposure to relevant 
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infectious agents and environmental 
carcinogens, apart from those en-
countered through lifestyle choice, 
were not addressed by the survey. 
Of the 176 responding countries, 
92% report having a national policy 
for tobacco control, 77% have 
policies on harmful use of alcohol, 
84% address unhealthy diet, 77% act 
on overweight or obesity, and 81% 
have a policy that focuses on improv-
ing physical activity. Although more 
countries have a policy for tobacco 
use than have policies in relation to 
any other NCD-based prevention 
strategy, only 69% of the responding 
countries have a tobacco policy that 
was reported as operational and as 
having a dedicated budget.
Early detection
Several cancer types of major public 
health relevance have a high prob-
ability of being cured if they are 
detected early in their clinical course 
and relevant cases are then referred, 
in a timely fashion, for definitive diag-
nosis and treatment at secondary or 
tertiary levels of care.
Population-based screening for 
certain cancers is established (see 
Chapter 4.7) and subject to national 
survey. Cytology (Pap smear) testing 
for cervical cancer is the most widely 
applied detection procedure but re-
quires specialized laboratories and a 
recall system for test-positive cases. 
Visual methods, such as inspection 
of the cervix after acetic acid staining, 
are options for low-income settings 
because no sophisticated technol-
ogy is required (see “Cervical cancer 
Fig. 6.2.3. The World Health Assembly in Geneva, 2011. WHO initiatives, in relation to 
the global burden of noncommunicable diseases generally, have permitted assessment 
of national policies for cancer control and their implementation. The data indicate that 
low-income countries face challenges in implementing proven means to reduce cancer 
incidence and mortality.
Table 6.2.3. Results from the WHO 2013 Noncommunicable Disease Country Capacity Survey: percentage of countries where 
tests and procedures for the early detection of cancer are available
WHO regiona Number of countries
Percentage of countries where available
Pap smear 
cervical 
cytology
VIA FOBT DRE Breast palpation Mammography
African 37 38% 24% 14% 16% 57% 30%
Americas 31 97% 45% 81% 65% 94% 61%
Eastern Mediterranean 21 38% 24% 38% 24% 81% 43%
European 50 80% 56% 80% 68% 86% 70%
South-East Asia 10 20% 10% 0% 10% 60% 0%
Western Pacific 27 67% 30% 63% 56% 89% 56%
World Bank income groupb
Low 29 21% 14% 3% 7% 52% 17%
Lower-middle 43 42% 28% 26% 23% 72% 23%
Upper-middle 49 78% 31% 65% 51% 90% 55%
High 55 91% 62% 93% 80% 91% 85%
Total 176 64% 37% 54% 46% 80% 51%
DRE, digital rectal examination; FOBT, faecal occult blood testing; VIA, visual inspection with acetic acid.
a For a list of countries corresponding to each WHO region, see http://www.who.int/about/regions/en/index.html.
b For definitions of World Bank income groups, see http://data.worldbank.org/about/country-classifications.
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prevention in six African countries”). 
Mammography is used to detect ear-
ly-stage breast cancer. Clinical breast 
examination by palpation performed 
by health professionals is a low-cost 
approach to detect early breast can-
cer. Rectal cancer can be detected at 
an early stage by clinical examination 
(digital rectal examination). Faecal 
occult blood testing is in use for early 
detection of colorectal cancer.
Ministry of health officials were 
asked whether tests for early detec-
tion of cervical, breast, and colorectal 
cancers were available in the national 
public system at primary health-care 
level. Responses received are sum-
marized in Table 6.2.3. A more de-
tailed assessment of the presence 
of a specific detection programme 
(screening programme) was not in-
cluded in the survey.
Concerning detection of cervical 
cancer and precancer, 64% of the 
Traditional household cooking: risks and prevention
Majid Ezzati
More than 2 billion people world-
wide use biomass fuels (firewood, 
charcoal, animal dung, and crop 
residues) and coal for cooking and 
heating. Biomass use is currently 
most common in sub-Saharan Africa 
[1], followed by South Asia. In devel-
oping countries, these fuels, which 
together are called solid fuels, are 
often burned in open fires or tradi-
tional stoves with poor combustion 
efficiency. Solid-fuel smoke contains 
many solid (particle) and gaseous 
pollutants, including known human 
carcinogens. As a result, people liv-
ing in homes that use solid fuels, es-
pecially women and young children 
who may spend hours near cooking 
fires, have high exposures to parti-
cles and other pollutants.
There is increasing epidemiolog-
ical evidence that exposure to bio-
mass and coal smoke is a risk factor 
for childhood pneumonia, chronic 
obstructive pulmonary disease, lung 
cancer, and cataracts, with some 
evidence of a dose–response rela-
tionship. Evidence is also emerging 
for effects on tuberculosis, low birth 
weight, and cardiovascular out-
comes. Exposure to air pollution 
from solid fuels is responsible for 
an estimated 3.5 million deaths per 
year and more than 4% of the global 
disease burden. Importantly, the ma-
jority of the burden is now from non-
communicable diseases. The health 
effects of household air pollution are 
largest in low-income regions and in 
poor households.
The large disease burden in 
poor communities and households 
has helped make solid fuel use a 
major global health concern. For ex-
ample, solid fuel use is an indicator 
for Goal 7 (ensuring environmental 
sustainability) of the United Nations 
Millennium Development Goals. 
Yet there are several challenges in 
implementing interventions that re-
duce exposure by a large amount. 
Alternative stove technologies, de-
spite having gained support among 
activists in developed countries, 
have proven not to be a viable option 
for intervention in most places be-
cause user behaviours modify their 
performance and because they re-
quire regular maintenance. Clean 
fuels such as electricity and natural 
gas will certainly reduce exposure 
substantially and provide substantial 
health gains [1,2]. However, wide-
spread use of these clean fuels is 
restricted by their cost, uncertainty 
about prices, and the absence of 
an energy infrastructure that allows 
households to buy fuels when they 
need them and without having to 
travel long distances [3]. In addition 
to clean fuels, it may be possible to 
“pre-process” biomass and coal to 
burn more cleanly, by converting it 
to gaseous or liquid fuels, charcoal, 
or briquettes.
In summary, research over the 
past two decades has helped to 
establish air pollution from house-
hold solid fuel use as an important 
global health risk, especially among 
the poor [4]. The increased visibility 
must be sustained but needs to be 
accompanied with efforts to reduce 
the burden of disease, including 
cancers, caused by emissions from 
indoor combustion.
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Fig. B6.2.2. A traditional three-stone 
open fire, as used in many households 
in developing countries.
Fig. B6.2.3. The traditional open fire 
used in many developing counties is 
associated with high concentrations 
of pollutants, as seen from the smoke 
rising from the roof of a house in central 
Kenya.
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176 countries reported the availability 
of a cytology-based screening test at 
primary care level, a major increase 
over the corresponding data reported 
in 2010 (26%) (Box 6.2.1). The pres-
ence of cytology services was still 
low in the African Region (38%) and 
the South-East Asia Region (20%), 
as was the availability of visual in-
spection after acetic acid staining, 
with 24% of countries in the African 
Region and 10% in the South-East 
Asia Region reporting positively. 
Compared with cytology tests, visual 
inspection was generally less avail-
able in all regions. The availabil-
ity of breast palpation by a health 
worker as routine in primary health 
care was low in the African Region, 
where 57% of countries reported 
availability, and in the South-East 
Asia Region, where the procedure 
was available in 60% of countries. In 
Europe, the Eastern Mediterranean, 
and the Americas, breast examina-
tion was reported as generally avail-
able in primary health-care facilities 
in 86%, 81%, and 94% of countries, 
respectively.
The situations concerning avail-
ability of radiotherapy and chemo-
therapy for cancer treatment in the 
public health sector, as well as the 
availability of palliative care servic-
es, were also subject to report in the 
survey but are outside the scope of 
the present Report.
Imperatives for improvement 
of cancer control
Analysis of the data collected by the 
Noncommunicable Disease Country 
Capacity Survey provides an over-
view of the extent of national capac-
ity to address the cancer burden in 
almost all WHO Member States. 
Although the survey was designed 
to assess national capacity for NCD 
control from the perspective of an 
integrated approach, it is practica-
ble to develop a comparable global 
picture specifically for cancer control 
along the continuum from prevention 
to palliative care. The summation in 
this chapter has addressed cancer 
control apart from clinical care.
The recognized limitations of such 
an analysis arise from the fact that the 
sources of information were NCD ref-
erence points in ministries of health 
not necessarily closely connected 
with the cancer control situation. 
The design of the survey allowed the 
assessment of key areas of cancer 
control to inform a global rating, 
but without any details about, for 
example, the proportion of the popu-
lation covered by defined interven-
tions (see “Traditional household 
cooking: risks and prevention”). The 
question and response structure of 
the survey may not have allowed re-
spondents to reflect in detail the na-
Box 6.2.1. Trends in national cancer control capacity.
Of the 176 countries that participated 
in the WHO 2013 Noncommunicable 
Disease Country Capacity Survey, 
responses from those with prior data 
from a 2010 study were assessed 
for trends.
Overall, the percentage of countries 
with a cancer plan increased, from 
81% in 2010 to 86% in 2013, as did 
the percentage with an operational 
cancer plan (from 61% to 65%). The 
largest gain in national cancer plans 
was in low-income countries (from 
54% to 79%). However, increases in 
an operational cancer plan followed 
an income gradient: high-income 
countries had the most advance-
ment from 2010 to 2013 (from 74% 
to 81%), whereas there was little or 
no gain in lower-middle and low- 
income countries (remaining at 
about 56% and 43%, respectively).
The percentage of countries with 
cancer registries, regardless of 
their type, remained largely un-
changed (80%). Further differen-
tiation found an increase in popu-
lation-based registries rather than 
hospital-based registries, from 46% 
in 2010 to 59% in 2013. While na-
tional-level registries among high-
income countries remained at a 
steady 85%, overall this percentage 
decreased from 64% to 49%, a drop 
distributed across all other income 
groups and regions.
The availability of cervical cancer 
screening by visual inspection af-
ter acetic acid staining increased 
in European countries (from 27% 
to 56%) and in African countries 
(from 14% to 24%). The availabil-
ity of cervical cytology and breast 
cancer screening by palpation 
was steady across all countries. 
Only regional differences were 
seen: cervical cytology access 
increased in Africa (from 27% to 
38%) and in the Western Pacific 
Region (from 56% to 67%) while 
decreasing significantly in Eastern 
Mediterranean countries (from 57% 
to 38%). Notably, the South-East 
Asia Region showed a consistent 
20% drop in all survey indicators, 
including the presence of a cancer 
plan, an operational cancer plan, 
cancer registries, and access to 
cervical cytology and breast cancer 
screening by palpation.
Fig. 6.2.4. Cover of WHO Guide for Effec- 
tive Programmes on cancer control. This 
publication is a series of six modules on 
cancer control: Planning, Prevention, 
Early detection, Diagnosis and treatment, 
Palliative care, and Policy and advocacy.
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tional particularities of health-care 
systems and their organizational 
structures. Finally, although the ques-
tionnaire and its instructions were 
available in almost all WHO official 
languages (English, French, Spanish, 
and Russian), there may have been 
language barriers with regard to the 
definitions of technical terms and 
their meaning.
Despite such limitations, the key 
results available provide evidence of 
major gaps between what is known 
about effective cancer control and 
the implementation of measures to 
reduce the cancer burden.
• The formal specification of a na-
tional cancer control policy or plan 
does not guarantee implementa-
tion. Government officials were 
very clear in reporting major dis-
crepancies between the endorse-
ment of a formal government policy 
or plan and its operational status. 
In only two thirds of all respond-
ing countries did a cancer plan or 
policy have a specific budget that 
would allow the necessary organi-
zational arrangements as recom-
mended by WHO (see Chapter 6.1).
• Established cancer prevention 
policies were far from being im-
plemented universally. Although 
there is definitive knowledge about 
the behavioural aspects of cancer 
causation, such as tobacco use, 
and there are effective strategies 
to reduce such use, as outlined in 
this Report (see Chapter 4.1), na-
tional implementation capacity to 
prevent cancer caused by tobacco 
and alcohol use, unhealthy diet, 
obesity, and lack of physical activ-
ity is markedly limited.
• Early detection of cancer was gen-
erally absent from the public care 
delivery systems in most countries 
in the low and lower-middle income 
groups. Because cervical cancer is 
of major public health relevance in 
most of these countries, increasing 
access to early detection through 
organized cervical cancer screen-
ing will have a major impact on the 
cancer burden.
The survey identified major gaps 
and challenges for national health-
care systems to achieve better can-
cer control. The majority of countries 
reported the existence of a national 
policy, strategy, or action plan to ad-
dress cancer. Even among countries 
in the lowest income group, where 
communicable diseases such as HIV/
AIDS, tuberculosis, and malaria are 
the major focus of national health 
planning and international health 
aid, national cancer plans are at 
least formally specified in more than 
half. However, to be effective, these 
policies and plans must be further 
developed and funded. Every country 
will have to determine national priori-
ties for cancer control in the context 
of other NCDs and the opportunities 
that health system reforms will offer.
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Cancer control in China: preventive 
policies and accessible health care
Guiqi Wang 
In 2010, cancer accounted for 
23.82% of overall deaths and be-
came one of the leading causes of 
death in China [1]. Most of the cases 
were diagnosed at a medium or late 
stage, so the efficacy of treatment 
was unsatisfactory. The health-care 
cost of these diseases created a 
severe economic burden on many 
individuals and on society, and be-
came a major cause of poverty or 
returning to poverty for the patients 
and their families. The Chinese gov-
ernment places great importance on 
cancer control and carries out ac-
tive preventive strategies and cancer 
control projects in collaboration with 
all sectors of society.
In 2005, China initiated a nation-
al programme of early detection and 
treatment for oesophageal cancer, 
gastric cancer, colorectal cancer, liv-
er cancer, nasopharyngeal cancer, 
and lung cancer in high-incidence 
areas, and in 2009, China started a 
national screening programme for 
cervical cancer and breast cancer 
in rural areas. In both programmes, 
early detection and treatment has be-
come an effective strategy for cancer 
control. For example, in some local 
areas of China, people have had very 
high rates of oesophageal cancer 
for a long time. The early detection 
and treatment programme screens 
residents in those areas aged 40–
69 years by endoscopy with iodine 
staining and biopsy of early lesions. 
Patients with early-stage neoplasia, 
including severe squamous dyspla-
sia, carcinoma in situ, and intramu-
cosal carcinoma, can receive early 
treatments in a timely manner.
To accumulate experience and 
optimize techniques for this plan, the 
national programme first chose eight 
high-incidence areas as demon-
stration sites and screened about 
13 000 high-risk adults each year. 
Now, after a step-by-step expansion, 
88 high-incidence areas in 26 prov-
inces are participating in this early 
detection and treatment programme 
for oesophageal cancer [2]. From 
2006 to 2012, 412 641 adults from 
high-risk areas were screened by 
endoscopy, and 4011 patients were 
diagnosed with severe precancer-
ous lesions or early-stage cancer 
[2]. Most of these patients received 
timely treatment, with great benefit 
to health, and an economic analysis 
of this programme has shown that it 
is cost-effective [3].
In addition to such early detec-
tion and treatment programmes, 
the Chinese government promotes 
widespread public education about 
cancer prevention and treatment, 
and has conducted interventions to 
control cancer occurrence, including 
neonatal vaccination against hepa-
titis B virus, programmes promoting 
better nutrition, and targeted pro-
grammes to improve occupational 
safety.
The China National Central 
Cancer Registry has also improved 
the national cancer registry sys-
tem, and since 2008 has reported 
national cancer registry data annu-
ally. In 2012, there were 222 cancer 
registry sites, covering 200 million 
people nationwide.
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Summary
• Developing countries need 
stronger health systems to sup-
port essential cancer control 
efforts. The experience in high-
income countries has dem-
onstrated that cancer control 
cannot succeed without well-
functioning and flexible health 
systems.
• In most developing countries, 
health-related infrastructure and 
trained human resources are 
lacking or poorly developed. 
However, when an infrastructure 
is established, the availability of 
treatment services indicates the 
likelihood of further positive de-
velopments within the context of 
a national cancer control plan.
• Since 2005, WHO and the 
International Atomic Energy 
Agency have engaged in dem-
onstration projects using exist-
ing radiation medicine capacity 
in developing countries to initiate 
multidisciplinary cancer capac-
ity building programmes. These 
programmes complement and 
enhance the clinical and public 
health impact of treatments by 
concurrently building capacity 
for all aspects of cancer control, 
including advocacy, epidemiol-
ogy, prevention, early detection, 
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diagnosis and treatment, pallia-
tive care, and society building.
• Basic strength in the health 
system, exemplified by a radio-
therapy service with adequate 
personnel and diagnostic facili-
ties, has led to the initiation of a 
more robust cancer control plan, 
which in turn tends to further 
strengthen the health system.
With 8.2 million deaths due to cancer 
in 2012, cancer remains a leading 
cause of death and disability world-
wide [1]. As highlighted throughout 
this Report, the pattern of disease 
has shifted so that an increasing 
burden now falls on low- and mid-
dle-income countries, where health-
care systems are not designed, or 
prepared, to tackle chronic noncom-
municable diseases in general. As 
population age distributions trend 
higher [2] and unhealthy lifestyles 
are increasingly adopted, popula-
tions in low- and middle-income 
countries face an expected rise in 
annual cancer incidence of nearly 
70% by 2030 relative to the 2010 
rates [3]. In 2010, there were more 
than 7.5 million new cases of cancer 
in low- and middle-income countries, 
and less than 30% of those patients 
had access to any reasonable treat-
ment services [4].
For particular malignancies, 
specific modes of therapy, health 
technologies, and relevant skills 
and experience are recognized as 
the basis for treatment and, in some 
cases, cure.
All people, including those in 
low- and middle-income countries, 
are entitled to means of cancer 
prevention and appropriate care 
if they are diagnosed with cancer. 
Fig. 6.3.1. In Sri Lanka, a patient with 
brain cancer looks at his scan. Sri Lanka 
is one of the WHO-IAEA Programme of 
Action for Cancer Therapy (PACT) Model 
Demonstration Sites. The country has im-
plemented a successful comprehensive 
cancer control plan.
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Strengthening national health sys-
tems, by providing equitable and 
affordable access to cancer care 
for all who require it and making the 
essential clinical services, such as 
diagnostic imaging and radiother-
apy, available, is an increasingly 
high priority for most governments 
in low- and middle-income coun-
tries. This is also a priority for WHO 
and other United Nations agencies, 
such as IARC and the International 
Atomic Energy Agency (IAEA), 
and active nongovernmental or-
ganizations such as the Union for 
International Cancer Control [5] and 
the International Network for Cancer 
Treatment and Research [2]. This 
imperative has been given new em-
phasis after the resolution approved 
by all United Nations Member States 
in September 2011 on the preven-
tion and control of noncommunica-
ble diseases.
In 2012, the World Health As- 
sembly set a global target of a 25% 
reduction in premature mortality 
from noncommunicable diseases 
by 2025, among eight other volun-
tary targets [6]. As highlighted in the 
discussion of national cancer control 
plans (Chapter 6.1), the prevention 
and control of cancer should be in-
tegrated into all major actions for 
other noncommunicable diseases. 
Various aspects of cancer control 
plans – from prevention to manage-
ment of cancer and related research 
priorities – should be part of the na-
tional initiatives for strengthening 
each country’s health system [7].
Treatment: an essential 
element of cancer control
As a growing number of cancer pa-
tients seek relief from pain and suf-
fering in most developing countries, 
the traditional focus of attention by 
health authorities on treatment as 
the first priority is understandable. 
Indeed, even with the optimal appli-
cation of cancer prevention strate-
gies, benefits are evident only after 
the passage of about 20–30 years, 
and are not relevant to millions of 
new cancer patients diagnosed in 
the interim, specifically in developing 
countries. However, early diagnosis 
and/or screening combined with ad-
equate treatment – often designated 
as secondary prevention – of certain 
common cancers has the potential 
to improve cure rates and to reduce 
mortality from these cancers in a time 
frame of 5–10 years. If there is a pros-
pect of effective treatment, people 
will be motivated to seek screening 
[8]. Moreover, availability of treatment 
involves families and different sec-
tors of the community in a common 
effort to promote health care. The 
availability of effective treatment also 
builds public support and motivates a 
core of professionals who may then 
campaign for a higher national prior-
ity to be accorded to comprehensive 
cancer control.
Over the past 30 years, a com-
bination of early detection and new 
treatment modalities has contributed 
to a modest, but constant, decline in 
cancer mortality rates in high-income 
countries [9]. This decline is not only 
due to the availability of more effec-
tive curative drugs, but is also the 
result of effective national cancer 
control plans, which have led to bet-
ter public education and community 
access to prompt diagnosis and treat-
ment. Such programmes now result 
in increased health awareness and 
prevention, improved cure rates, and 
improved quality of life for cancer pa-
tients in high-income countries [10].
The experience in high-income 
countries has demonstrated that 
cancer control cannot succeed with-
out well-functioning, robust, and flex-
ible health systems. More specifically, 
strengthening health systems to de-
liver life-saving treatments requires 
well-developed technical infrastruc-
ture and a sufficient number of clini-
cians trained in treatment delivery. 
Among other services, pathology 
services to provide accurate diag-
nosis and staging of cancers and 
laboratory facilities, equipment, and 
technicians to run screening tests 
and deliver radiotherapy treatments 
must also be available.
Unfortunately, in most low-income 
countries and some other countries, 
such infrastructure and trained hu-
man resources are not available 
or are poorly developed. However, 
emerging evidence from many de-
veloping countries establishes that 
availability of treatment services can 
Fig. 6.3.2. The children’s cancer ward at Ocean Road Cancer Institute in Dar es Salaam, 
Tanzania. Despite the crowded conditions, these children are among those fortunate 
enough to receive treatment.
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create a high probability for further 
positive developments within the con-
text of a national cancer control plan 
[11–13]. With proper planning and ap-
propriate strategies, and availability 
of trained professionals, developing 
countries can achieve much higher 
survival rates, in addition to pre-
venting and otherwise controlling 
cancers. In a comparative study of 
cancer outcomes across 12 countries 
in Africa, Asia, and Central America, 
cancer outcomes correlated with the 
level of development of health ser-
vices [14].
The question is to what extent the 
models from high-income countries 
can be replicated in low-income set-
tings, and what options are economi-
cal and cost-effective in particular 
situations. For example, which di-
agnostic and treatment modalities 
should be developed? The dilemma 
for policy-makers and health authori-
ties in developing countries is often to 
determine what comes first. Options 
may include providing affordable 
means of treating a portion of the 
growing number of patients, particu-
larly in terms of medicine and health 
technology such as diagnostic imag-
ing and radiotherapy, or adapting the 
most feasible strategies for cancer 
prevention and screening services.
The development of radiotherapy 
capacity is evidentially a cost-effective 
and resource-level-appropriate strat-
egy in developing countries to initiate 
capacity building in treatment [15]. As 
demonstrated in several countries, 
radiotherapy can serve as an anchor 
to develop self-sustaining national 
cancer control programmes, which in 
turn could help improve and expand 
other cancer services and infrastruc-
ture. Radiotherapy is fundamental to 
the optimum management of cancer 
patients, and provision of radiotherapy 
services is central to national cancer 
control strategies (Box 6.3.1) [16–20]. 
Although it requires long-term plan-
ning and appropriate assessment 
of health-care resources, effective 
radiotherapy for many cancers can 
be comprehensively provided at 
moderate cost, without recourse to 
sophisticated technologies [21]. Most 
countries have later expanded their 
initial radiotherapy capacity to add 
chemotherapy and other essential 
capacity, including imaging, pathol-
ogy, and surgery. Such expanded 
capacity has often become the focus 
around which a national cancer centre 
is established [11].
Health systems strengthened 
through radiotherapy 
planning
Experience in many developing 
countries indicates that cancer 
control cannot achieve its potential 
unless the existing health system 
can sustain and support some 
key requirements. These include 
the technical capacity to initiate or 
manage the national cancer control 
plan and to deliver certain services. 
The initiation of a national cancer 
control plan requires establishing a 
cancer policy and additional legisla-
tive steps, setting or defining some 
key targets, and/or allocating funds 
for cancer control activities; this 
represents a top-down approach. 
However, quite often, where the 
leadership of existing cancer clinics 
or radiotherapy centres is supported 
by nongovernmental organizations, 
some members of the community 
may be particularly active in de-
veloping cancer control proposals: 
a bottom-up approach. For most 
low- and middle-income countries, 
a combination of these two ap-
proaches is more likely to succeed 
in initiating cancer control activities 
[22]. In countries that have been as-
sessed, the initiation of cancer con-
trol activities and plans has been 
prompted by the leadership of an 
existing radiotherapy centre (often 
the only one in the country) because 
such centres are the places that im-
mediately appreciate the severity 
of the cancer burden. The tragedy 
in developing countries is that 80% 
Box 6.3.1. Radiation medicine: a vital component of cancer diagnosis and treatment.
The first cure of cancer by radio-
therapy was reported in 1899, a few 
years after Röntgen’s description of 
X-rays in 1895 and the discovery 
of radium in 1898 [16]. The tech-
nology has evolved radically since 
the 1950s, and today knowledge of 
radiation medicine and the avail-
ability of relevant technology are 
indispensable for cancer diagnosis, 
cure, and care, where radiation and 
radioactivity play fundamental roles. 
Depending on the stage and type of 
cancer, typically some 50–65% of 
all cancer patients require radio-
therapy during the course of their 
disease, either as a single modal-
ity or in combination with surgery, 
chemotherapy, hormone therapy, 
and/or immunotherapy [17].
Worldwide, radiotherapy is a major 
aspect of investment in health-care 
systems to treat cancer. Low- and 
middle-income countries have far 
to advance if their patients are to 
have reasonable access to such 
treatment. Although these countries 
account for 85% of the world’s pop-
ulation, there are only about 4400 
megavoltage machines in low- and 
middle-income countries, less than 
35% of the world’s radiotherapy 
facilities, leaving most cancer pa-
tients in these countries without any 
access to potentially life-saving ra-
diotherapy treatment [18].
The International Atomic Energy 
Agency (IAEA) emphasizes that 
radiotherapy treatment is most ef-
fective when it is linked to a com-
prehensive national cancer control 
programme. For this reason, in 2004 
IAEA established its Programme 
of Action for Cancer Therapy to 
help expand radiotherapy capacity 
in developing countries and build 
partnerships with WHO and others 
to address the huge disparities that 
exist in cancer control and services 
[19,20].
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of cancer cases are diagnosed at a 
very advanced stage of disease.
The burden of late-stage diagno-
sis of cancer in developing countries 
provides strong motivation to move 
such a country towards cancer con-
trol planning rather than attempting 
to expand clinical facilities to treat the 
large number of patients. Countries 
that have committed to this option, 
and initiated some cancer control ac-
tivities, have been more successful 
in seeking new funding to acquire 
additional treatment facilities and re-
sources. Accordingly, basic strength 
in the health system, exemplified by 
a radiotherapy centre, can lead to 
the initiation of a more robust cancer 
control plan, which in turn can result 
in further health systems strengthen-
ing through improvements in other 
essential treatment modalities, and 
most often the establishment of a na-
tional cancer centre [11]. The direc-
tors of such national cancer centres 
in more than 40 low- and middle-
income countries have prompted 
the launch of cancer control plans 
[23]. Arguably, a minimum level of 
national capacity and infrastructure 
must be present within the health 
system of any country before any 
cancer control activities can be initi-
ated or launched successfully [13].
WHO-IAEA cooperation on 
cancer control
To build on the premises already 
described, and after the establish-
ment of the Programme of Action 
for Cancer Therapy (PACT), WHO 
and IAEA signed an agreement in 
March 2009 to launch a cooperation 
on cancer control, aimed at strength-
ening and accelerating cancer con-
trol in developing countries [24,25]. 
The formation of a WHO-IAEA 
cooperation began in May 2005 
when the World Health Assembly 
adopted a far-reaching resolution in 
response to the marked increase in 
cancer incidence worldwide. Since 
then, PACT, WHO, IARC, and other 
key international cancer organiza-
tions have undertaken increasingly 
productive collaboration. Particular 
emphasis is placed on providing 
assistance within a broad, multidis-
ciplinary cancer capacity building 
programme that complements and 
enhances the clinical and public 
health impact of treatment.
The WHO-IAEA cooperation 
provides the framework for the two 
organizations to integrate their work, 
building on their areas of expertise 
to create a more coordinated and ro-
bust approach to combating cancer 
in low- and middle-income countries. 
The focus of WHO support within the 
cooperation is on public awareness, 
prevention, early detection, and 
overall care for patients. In particular, 
WHO emphasizes population-based 
interventions and the strengthening 
of public health approaches to pre-
vention and control of cancer, with 
special attention to primary health 
care. National cancer control pro-
grammes fit into the broader WHO 
framework to strengthen health sys-
tems with a major focus on primary 
health care, and are part of the im-
plementation of the Action Plan of the 
Global Strategy for the Preventions 
and Control of Noncommunicable 
Diseases, which was endorsed by 
the World Health Assembly in May 
2008 and has been updated to cover 
the 2013–2020 period [26,27]. Since 
the launch of PACT, IAEA requires 
that all of its assistance related to 
radiation medicine be channelled 
through ministries of health to en-
sure an integrated and balanced ap-
proach. IAEA recommends that low- 
and middle-income countries should 
prepare their national cancer control 
plans and then specifically examine 
the need for expansion of diagnostic 
and treatment services based on lo-
cal resources, types of cancer, and 
other relevant conditions.
Cancer control through 
demonstration projects
Efforts in the WHO-IAEA coopera-
tion on cancer control have been 
focusing on eight PACT Model 
Demonstration Sites (PMDS), in Al- 
bania, Ghana, Mongolia, Nicaragua, 
Sri Lanka, the United Republic of 
Tanzania, Viet Nam, and Yemen [28], 
most of which have been successful 
in using their existing radiotherapy 
programmes to embark on develop-
ing cancer control strategies. WHO 
and IAEA have assisted these coun-
tries in needs assessment, evalua-
tion of possible strategies, setting of 
priorities, and selection of resource-
level-appropriate interventions.
Fig. 6.3.3. Ghana’s first cancer hospital was established in 1997 with IAEA support. The 
operation of this cancer centre is helping Ghana to expand its cancer infrastructure and 
capacity in three regions of the country within the scope of its national cancer control plan.
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Through the cooperation on 
cancer control, WHO and IAEA 
have also responded to requests 
for cancer control assessment and 
programme development assistance 
in more than 45 countries since 2005 
[29,30]. Each country has particu-
lar features in terms of the cancer 
burden, cancer risk factors, culture, 
health system, available financial 
and human resources, and infra-
structure. Careful assessment of 
these elements helps to establish 
realistic and achievable priorities 
for action in a specific context [31]. 
WHO, IAEA, IARC, and partners 
assist national authorities in their 
cancer control endeavours, shar-
ing the experiences of developing 
countries that have already achieved 
successes in cancer control. Once 
a country’s most pressing needs 
are identified and prioritized, part-
ners and donors are approached 
for adequate response strategies, 
which may be on the technical and/
or financial side. Follow-up missions 
for monitoring progress are also con-
ducted regularly.
Early evaluation of PMDS
PMDS projects are at different stag-
es of implementation, having started 
at different baselines. However, they 
all share very high motivation at the 
professional and political level. Each 
of the PMDS projects has worked 
diligently on developing a national 
cancer control plan and establish-
ing a national steering committee to 
oversee the implementation of the 
plan. With support from partners, 
PACT has mobilized funds to support 
countries with expert advice, human 
resource development, acquisition of 
radiation medicine equipment, and 
cancer control capacity building [19].
As reported by a recent evalu-
ation of PMDS [12], it is clear that 
in each PMDS project, availability 
of radiation medicine capacity, al-
though still limited, has played a 
pivotal role as an initial driver of the 
country’s cancer control plan, and 
in the implementation of elements of 
each country’s national cancer con-
trol programme. There are already 
signs and actions in PMDS projects 
demonstrating that health authori-
ties have appreciated that health 
systems strengthening for cancer 
care and control cannot be achieved 
without balanced investments in pre-
vention, early detection, diagnosis, 
treatment, and palliative care.
Hence, the success of national 
cancer control plans is dependent 
to a large extent on broader reform 
measures within the health system of 
each country to address the inequal-
ities in health care and services. 
Equally important is the capacity of 
ministries of health, and their longer-
term commitment to implementation 
and evaluation of the policies and 
strategies developed. In particular, 
if there is no commitment towards 
efforts aimed at prevention, coordi-
nation of services, and affordability 
of, and access to, health services, 
then there is unlikely to be an im-
provement in health systems.
To ensure further progress and 
sustainability of cancer control 
programmes already initiated, all 
developing countries should con-
sider establishing at least one gov-
ernment-supported cancer centre of 
excellence based on existing can-
cer centres to provide high-quality 
services and act as a driving force 
for national cancer control [11,23]. 
Furthermore, in view of prevailing 
limitations in workforce capability, 
for the long-term strengthening and 
success of cancer control, each 
country should have a 10–15-year 
training programme [13]. Cancer 
registries, health data collection, 
and health services research in all 
countries require support [32]. In this 
context, the IARC Global Initiative 
for Cancer Registry Development in 
Low- and Middle-Income Countries 
and the International Cancer Control 
Partnership, jointly coordinated by 
the UICC and the United States 
National Cancer Institute and involv-
ing WHO, IAEA-PACT, IARC, and 
several key cancer organizations 
and individual experts, are immedi-
ately relevant.
Fig. 6.3.4. Mongolia’s National Cancer 
Centre, established with WHO-IAEA sup-
port. As part of implementation of the 
national cancer control plan, with funding 
provided by the United Nations Women’s 
Guild, the National Cancer Centre con-
structed this playground on the premises 
to provide young cancer patients with a 
diversion from their treatment.
Fig. 6.3.5. The number of cancer patients 
threatens to overwhelm this children’s 
cancer ward in Hanoi, Viet Nam, where 
children sleep on floors with their family 
members nearby.
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Cancer control in France: towards patient-
centred precision medicine
Agnès Buzyn 
The two successive cancer control 
plans endorsed by the president of 
France have helped shape a new era 
of coordinated and integrated cancer 
care, centred on the patients’ needs 
and grounded on evidence-based 
measures. They have helped to 
build the components of the current 
organizational cancer care frame-
work in France, which is designed 
to deliver high-quality services and 
facilitate the evolution of stratified 
medicine. This organizational frame-
work bridges both patient-centred 
and tumour-centred approaches, 
and encompasses the personal-
ized care programme, specialized 
structures or organizations (for rare 
cancers, oncogeriatrics, oncopaedi-
atrics, etc.), and molecular profiling 
of tumours. The ultimate goal, yet to 
be attained, is to bring high value to 
patients and survivors while fighting 
the roots of health inequities through 
fair access to innovation.
The personalized care pro-
gramme offers patients their road 
map towards completion of their 
treatment, and helps them to navi-
gate through referral from one point 
in the process to the next with ease. 
The personalized care programme 
has helped address the fragmenta-
tion of the cancer care pathway. As 
the number of cancer survivors in-
creases in most high-income coun-
tries, the next challenge is to further 
develop a survivorship plan that is 
fully integrated into the continuum 
of the person’s care, from the onset 
of the disease.
To strengthen the cancer care 
framework, specialized networks for 
rare cancers, and specific organi-
zational frameworks for oncogeriat-
rics and oncopaediatrics, have been 
developed based on scientific and 
clinical excellence, with integrated 
facilities and dedicated staff. They 
usually function as a network with a 
wide geographical coverage. They 
have close links with biobank re-
sources and molecular genetics in-
frastructures. The implementation of 
a quality assurance programme and 
a collaborative approach warrants 
that all network centres meet re-
quired standards and deliver state-
of-the-art cancer care.
Advances in the molecular profil-
ing of tumour tissues have opened 
up an era of personalized cancer 
treatment where therapies are 
matched to the individual tumour. 
Pivotal to this personalized ap-
proach are drugs that have been 
designed to target a particular mo-
lecular pathway affected in a cer-
tain cancer type. Targeted therapies 
have been successfully introduced 
into clinical practice for breast and 
stomach cancers (HER2 overex-
pression), lung cancer (EGFR muta-
tions), and colorectal cancer (KRAS 
mutations). Molecular characteriza-
tion of tumours has become a de-
cisive factor in the choice of thera-
peutic strategies for cancer patients. 
To meet this challenge, a network of 
molecular genetics centres with na-
tionwide reach was developed. This 
organizational framework has now 
been operational for 4 years and 
is successful in delivering state-of-
the-art targeted cancer treatments. 
Access time to novel therapies has 
been reduced. The latest genomic 
knowledge and technologies (next-
generation sequencing) should ac-
celerate progress towards precision 
medicine.
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Summary
• The development and evalua-
tion of effective health services 
for cancer control is dependent 
on high-quality prevention and 
related research, which in turn 
is reliant on the efficient op-
eration of functional research 
infrastructures.
• Cohorts, biobanking facilities, 
and cancer registries play a key 
role in research and the devel-
opment and evaluation of cancer 
control measures.
• From a global perspective, there 
is an increasing rate of initiation 
of large population-based co-
horts and advanced biobank-
ing facilities. International or-
ganizations, including IARC, as 
well as national and other au-
thorities operate multiple, often 
large, biobanks. The necessary 
resources on which cancer re-
search is based are termed the 
study bases and are formed by 
longitudinal follow-up of cohorts 
and biobanks using cancer reg-
istry linkages.
• International standardization and  
networking of infrastructures 
is required to enable compre-
hensive investigations and to 
ensure the standardization and 
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comparability of research data 
and results.
Research infrastructure: 
essential resources for 
cancer research
Research infrastructure refers to fa-
cilities, databases, and collections 
together with related services used 
by the scientific community to con-
duct research [1]. When operated 
on an international scale, research 
infrastructure offers unique research 
services to users from different 
countries. In addition, a tangential 
function of research infrastructure 
is to engage young investigators 
seeking to establish careers in sci-
ence and so contribute to the growth 
of scientific communities. This goal 
can be achieved when research 
infrastructure serves as a hub for 
providing services in essential el-
ements of research such as (i) ac-
cess to high-quality and standard-
ized data; (ii) access to high-quality, 
well-documented, and standardized 
biospecimens; (iii) access to high-
performance molecular analysis 
platforms and/or molecular data 
generated on demand; (iv) develop-
ment, implementation, and monitor-
ing of best practices; and (v) educa-
tion, expertise, and advice.
The concept of the knowledge tri-
angle involves research, education, 
and innovation [2]. A high-quality 
research infrastructure should be at 
the centre of the knowledge triangle. 
A successful research infrastructure 
does not merely serve to provide 
materials. Research infrastructure 
should also contribute by having a 
role in the production of knowledge 
through research, the diffusion of 
knowledge through education, and 
the application of knowledge through 
innovation.
To enable comparison of health 
outcomes and research results from 
different parts of the world [3], col-
laboration between research infra-
structure hubs on an international 
scale is imperative, specifically in 
Fig. 6.4.1. Blood samples are taken from a 
newborn baby in Sweden for the national 
phenylketonuria (PKU) registry biobank. 
In Sweden, such blood samples for the 
screening of metabolic diseases, including 
PKU, have been stored since 1974 and 
comprise about 2.7 million samples.
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particular areas such as standardi-
zation, quality control, and coordi-
nated development. An international 
infrastructure for cancer research 
will be required for progress in in-
ternational cancer control.
There is a growing realization 
that research is an essential compo-
nent for delivery of effective health-
care and preventive services in any 
setting, and is not only relevant to 
high-income countries. Studies that 
have affected the development of 
this concept include the Dartmouth 
Atlas, a systematic inventory of the 
different health services delivered 
in various parts of the USA, their 
cost, and their effectiveness (www.
dartmouthatlas.org). These studies 
have estimated that if the most cost-
effective health services were used 
throughout, the quality of health care 
would increase, while provision of 
health care would be up to 30% less 
expensive [4].
In health services research, the 
medical practice under study is in 
place irrespective of whether there 
is ongoing research. The purpose 
of such research is simply to study 
whether the health services deliv-
ered actually work, based on imme-
diate experience. Although there is 
current political interest in research 
on the comparative effectiveness of 
health services, research on the ef-
fectiveness of health services has 
a long tradition in many countries. 
One of the best known and estab-
lished traditions of health services 
research is the activities of cancer 
registries to evaluate the effective-
ness of screening and other cancer 
control policies. When new policies 
are implemented, they are frequently 
evaluated using randomized study 
designs, in so-called randomized 
health services studies [5].
Cohorts: studies of health 
outcomes and disease 
etiology
Cohort studies aim to provide a 
reliable database for investigation 
of risk factors for the diseases that 
affect a population. Basic informa-
tion about the diseases affecting 
the population and the risk factors 
that cause these diseases is the 
foundation for planning of preven-
tive services. A large number of 
healthy volunteers in the population 
provide data about living conditions 
and lifestyle (such as diet, exercise, 
smoking, and other habits), donate a 
series of biospecimens, and are fol-
lowed up longitudinally, specifically 
in relation to disease development. 
While it may be inferred that most 
cancer is attributable to the impact 
of environmental factors rather than, 
for example, heritable risk, many 
causal factors remain to be specifi-
cally identified. Cohort studies with 
comprehensive collection of data 
and molecular analysis of biospeci-
mens may clarify – and, in some in-
stances, identify – these factors and 
the inherent possibility of prevention. 
This approach was proposed by Doll 
and Peto more than 30 years ago [6] 
and has received renewed attention 
with the emergence of effective and 
comprehensive resources for mo-
lecular analysis of both genetic and 
environmental risk factors [7].
The Public Population Project in 
Genomics and Society (www.p3g.
org) has a global cohort observa-
tory that lists 15 international cohort 
networks and 79 individual cohorts. 
Many of these cohorts are extremely 
well funded. The best known exam-
ple is the National Children’s Study 
in the USA, a US$ 200 million/year 
cohort study that monitors pregnant 
women and their children to iden-
tify factors contributing to healthy 
childbearing and child development 
(www.nationalchildrensstudy.gov).
The largest among the compre-
hensive cohorts is the European 
Prospective Investigation into Cancer 
and Nutrition (EPIC), designed to in-
vestigate the relationships between 
diet, nutritional status, lifestyle, and 
other environmental factors and the 
incidence of cancer and other chronic 
Fig. 6.4.2. Liquid nitrogen containers in the 
biobank of the Coriell Institute for Medical 
Research in Camden, New Jersey, USA.
Fig. 6.4.3. Analysis of biological samples, in this case by quantitative micrographic 
determination, may be undertaken in collaboration with remote investigators where 
tissues are stored, rather than basing collaboration on the transportation of samples 
to remote locations.
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diseases. EPIC recruited more than 
520 000 people in 10 European coun-
tries: Denmark, France, Germany, 
Greece, Italy, the Netherlands, Nor- 
way, Spain, Sweden, and the United 
Kingdom [8]. The EPIC cohort has 
multiple associated working groups, 
concerned not only with most major 
cancer types but also with cardiovas-
cular diseases, ageing, and diabetes.
Why are biobanks needed?
Collections of human biological spec-
imens are essential, both for cancer 
research and for improved clinical di-
agnosis. The revolutionary develop-
ment of high-performance molecular 
analysis platforms in recent years 
has meant that the rate-limiting step 
in translating the advances in basic 
research to cancer control is no 
longer the molecular analysis, but 
access to well-characterized speci-
mens with associated follow-up data. 
Because of biobanking, scientists no 
longer need to initiate sample collec-
tion either individually or within their 
research groups – relevant samples 
are already available.
The main advantage of biobank-
ing is that a long follow-up on health 
outcomes for particular specimens is 
immediately available without a fur-
ther requirement for the passage of 
time. A translational research project 
need not be restricted to testing new 
specimens and allowing the passage 
of a decade or more to determine 
relevant health outcomes. Rather, 
the project design may be based on 
locating specimens that have been 
stored for decades under circum-
stances where the health outcomes 
after specimen donation have been 
determined by registry linkages [9]. 
Prevention research may involve the 
search for novel biomarkers that can 
be used for early diagnosis and/or 
as new screening tests. This goal 
requires specimens taken before 
diagnosis, and a situation where 
diagnoses made at a later time are 
known. Explanations for differenc-
es in cancer occurrence worldwide 
are central to an understanding of 
cancer etiology. Such research also 
requires specimens taken before 
diagnosis, but with data about the 
later diagnosis of cancer in particular 
individuals.
The study base and the role 
of cancer registry linkages
The study base is a term that refers 
to the specimens and data on which 
scientific studies are based, i.e. the 
stored specimens and accessory 
Fig. 6.4.4. Map of the Nordic region depicting the enrolment regions for the biobank cohorts that participated in a joint cancer registry 
linkage that identified more than 2 million sample donors and more than 100 000 prospectively occurring cancer cases.
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data plus the results of longitudinal 
follow-up for health outcomes.
A major limitation of biobank-
based research is that many 
biobanks are not regularly linked to 
the relevant cancer registries and 
thus the study bases for scientific 
studies are unknown. Even if the 
biobanks are regularly followed up, 
there may be a lack of comprehen-
sive and updated overviews for in-
vestigators about which study bases 
are available. The most advanced 
presentation of such study bases 
is currently the Danish National 
Biobank Register (www.biobanks.
dk), which has an online, automat-
ed service to determine the study 
bases by on-demand linkages of 
the major biobanks in Denmark 
with the cancer registry and other 
health data registries. Large-scale 
and standardized cancer registry 
linkages for many biobanks in the 
Nordic countries have also been 
performed by the Finnish Cancer 
Registry under the auspices of 
European Union biobanking proj- 
ects (Fig. 6.4.4) [10], most recently 
the FP7 project Eurocourse (Europe 
against Cancer: Optimisation of 
the Use of Registries for Scientific 
Excellence in Research; www.eu 
rocourse.org). Together with the 
European Union biobanking plat-
form BBMRI (Biobanking and 
Biomolecular Resources Research 
Infrastructure; www.bbmri.eu), Euro- 
course has also developed a for-
mat for standardized description of 
available study bases.
The requirement for follow-up to 
exploit the potential of biobank spec-
imens has important implications. In 
particular, this has implications for 
anonymity in respect of specimens. 
Although scientists who use biobank 
specimens have access only to cod-
ed specimens, the identity of the do-
nors must be known to the agency 
responsible for the follow-up [11].
In many respects, biobanks are 
similar to cancer registries. Biobanks 
constitute research infrastructure 
responsible for collection and stor-
age of information about patients. 
Stringent and similar standards are 
required of biobanks and registries 
for strict handling of personal data 
to protect the integrity of individuals. 
As linkage to cancer registries is 
essential for the follow-up of biobank 
specimens to define the study base, 
the standardized overview and de-
scription of biobanks and biobank-
based study bases can be han-
dled by cancer registries. Because 
cancer registries are the disease 
registers with the longest follow-up 
and experience of data handling as 
well as international networking and 
standardization of data, it is conceiv-
able that they could drive the excel-
lence in realizing the potential of 
biobanks for health. A role model for 
this concept is the Janus Biobank, 
a population-based biobank with 
samples from 350 000 donors that 
is operated entirely by the Cancer 
Registry of Norway [12].
Biological resource centres
Historically, every research study 
or diagnostic laboratory developed 
its own separate system for storing 
biospecimens. However, this frag-
mentation resulted in expensive 
duplication and severely limited the 
cumulative use of specimens, which 
had been handled and stored by 
Fig. 6.4.5. Geographical origin of the samples stored at the IARC Biobank (excluding EPIC samples).
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differing procedures. International 
studies based on samples from sev-
eral sources were not necessarily 
valid. With the growing operational 
complexity of biobanks, investigators 
are increasingly reliant on special-
ized service facilities that handle 
the acquisition, quality control, stor-
age, processing, and distribution of 
biospecimens [13]. These biobank-
ing facilities are termed biological 
resource centres. A biological re-
source centre will provide services 
for all steps in the scientific study, 
from contacting study participants 
to archiving research results.
Most biological resource centres 
collaborate in international biobank-
ing networks committed to common 
international standards for collec-
tion, labelling, annotation, process-
ing, storage, retrieval, and analysis 
of the biospecimens, while ensuring 
biological safety and protection of 
personal data. Under the auspices 
of the United States National Cancer 
Institute, the Cancer Human Biobank 
(caHUB) is a national biorepository 
of human tissue, blood, and other bi-
ological materials (http://cahub.can-
cer.gov). In Europe, major networks 
of biobanks are the above-men-
tioned Biobanking and Biomolecular 
Resources Research Infrastructure 
and the International Society 
for Biological and Environmental 
Repositories (www.isber.org). There 
is increasing emphasis on the view 
from funding agencies and other 
stakeholders that publicly funded 
research materials should be open-
ly accessible.
The IARC Biobank is an inter-
national biological resource centre 
serving more than 50 studies from 
30 countries worldwide. As is typical 
for such centres, study designs in-
clude cohorts, case series, preva-
lence studies, and case–control 
studies (Fig. 6.4.5). A total of about 
5.0 million samples from 1.5 mil-
lion subjects are stored. Most of the 
samples are body fluids, including 
plasma, serum, and urine, as well as 
extracted DNA samples (Fig. 6.4.6). 
The IARC Biobank has an access 
policy to encourage proposals for 
new collaborative studies on exist-
ing biospecimen collections (http://
ibb.iarc.fr/).
Cohort and biobanking 
networks
The Low- and Middle-Income Coun- 
tries Biobank and Cohort Network 
(BCNet) is an IARC initiative in-
tended to support the development 
of cancer control in low- and middle-
income countries. Currently, invest-
ments in research infrastructure 
calculated to assist the development 
of high-quality science, which will 
underpin effective cancer control 
measures, are receiving increased 
attention. Population cohorts can as-
sist countries in providing scientific 
education, stimulating translational 
research, and identifying, launching, 
and evaluating interventions for im-
proving health.
Fig. 6.4.6. An indication of the amount and nature of biological materials that may be 
subject to collection and storage in a biobank. In this instance, the data refer to samples 
stored at the IARC Biobank.
Fig. 6.4.7. Sharing of sample analysis results rather than samples may accelerate 
research: the concept of the biological expert centre.
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The tools and methodologies used 
to develop a biobank infrastructure 
and population cohorts are basically 
similar. Thus, by comparison with 
earlier endeavours, lower cost and 
improved effectiveness in the con-
text of establishing cohorts may be 
achieved by the operation of interna-
tional networks. Such networks pro-
vide initiating countries with guidance 
for establishing sustainable infra-
structure, often involving procedures 
that have been tested and optimized 
in a variety of different settings. 
Because population cohorts and 
biobanking facilities are not prevalent 
in low- and middle-income countries, 
the development of health sciences 
and evidence-based cancer control 
may be affected. BCNet provides an 
opportunity for these countries to co-
operate in a coordinated and effective 
manner to address local shortfalls in 
biobanking infrastructure.
A successful biobank is one that 
fosters successful science. Many 
current cohort studies are designed 
to investigate several diseases, with 
associated disease-specific working 
groups, as noted above in relation 
to EPIC. Compared with fragmented 
studies on a single risk determinant 
or a single predictive factor, the co-
ordinated approach is necessary 
to evaluate whether different risk 
determinants studied represent pri-
mary risk factors or are the result of 
confounding. In the future, many dis-
ease working groups will formalize 
their coordination by publishing open 
calls for proposals that describe the 
available study bases, with samples 
and data relating to different diseas-
es, and invite scientists to apply for 
access.
Within the Biobanking and Bio- 
molecular Resources Research 
Infrastructure in the European 
Union, the concept of the biological 
expert centre has been developed. 
This centre offers an alternative to 
time-consuming and costly sam-
ple shipments by providing sample 
analysis results rather than send-
ing the samples to the investigator 
(Fig. 6.4.7). This initiative involves 
the availability of medical and 
scientific expertise in biobank-based 
research on issues such as proper 
sample selection, study design, and 
data interpretation [14]. At best, such 
an approach is optimally supported 
by in-house state-of-the-art analy-
sis platforms that are so standard-
ized and quality-assured that the 
results of analyses can be shared 
between centres and used for appli-
cations that require stringent quality 
and documentation of results. It is 
envisaged that a more rapid, more 
quality-assured, and less costly de-
livery of the final data that the cus-
tomer needs could further advance 
the central usefulness of biobanks 
for cancer research.
Conclusion
The continuing quest to understand 
the causes of cancer and to develop 
global cancer control requires com-
parisons between disease patterns 
in different parts of the world [15]. 
These research goals may be bet-
ter achieved through different insti-
tutions and countries endorsing the 
concept that samples and data for 
research should be openly acces-
sible and that international – rather 
than national (or even subnational) – 
standards, rules, and procedures are 
to be preferred [16,17]. Promoting 
the adoption of common standards is 
desirable in high-resource countries 
as well as in low-resource countries. 
International collaboration to estab-
lish essential research infrastruc-
ture, including cohorts, biobanking 
facilities, and registry linkage sys-
tems, is key to promote international 
cancer research, and is particularly 
relevant for cancer research in low- 
and middle-income countries.
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Cancer control in India: cancer care 
through a four-tier system
G.K. Rath 
In 2012, there were an estimated 
1.01 million new cancer cases in 
India (age-standardized incidence, 
94.0 per 100 000) and 980 000 can-
cer-related deaths (age-standard-
ized mortality, 64.5 per 100 000), 
and the 5-year prevalence was 
1.79 million (proportion, 202.9 per 
100 000) [1]. The cancer pattern is 
varied in different parts of the coun-
try because of diverse lifestyles. 
The data from 27 population-based 
cancer registries in India show that 
the highest incidence of cancer is 
in Mizoram state, which is in the 
north-eastern part of India, com-
pared with the lowest incidence 
from a rural registry in Barshi, in the 
western part of the country. There 
is an increasing trend of incidence 
rates for all malignancies except for 
cervical cancer, which has a down-
ward trend.
The government has estab-
lished the National Centre for 
Disease Informatics and Research 
to develop a national research da-
tabase on cancer, diabetes, cardio-
vascular diseases, and stroke [2]. 
India is one of the first countries to 
initiate a comprehensive national 
cancer control programme. There 
are 27 Regional Cancer Centres, 
including 339 radiotherapy facili-
ties equipped with 481 teletherapy 
machines. Most Regional Cancer 
Centres also have medical, surgi-
cal, palliative care, imaging, and 
laboratory facilities. They are ac-
tively involved in teaching and re-
search as well.
The government has started a 
National Programme for Prevention 
and Control of Cancer, Diabe- 
tes, Cardiovascular Diseases, and 
Stroke. This has been done with 
the aim of combating the common 
risk factors for these diseases. The 
strategies under this programme 
include prevention through behav-
iour change, early diagnosis, treat-
ment, capacity building of human 
resources, surveillance, monitoring, 
and evaluation.
The cancer care network is en-
visaged to be a four-tier system. 
Initially, the programme is being 
implemented in 100 districts across 
21 states. Subsequently, this will be 
expanded to all 640 districts in the 
country. District hospitals are being 
strengthened for prevention, early 
detection, and management of com-
mon cancers, especially oral, breast, 
and cervical cancers. Tertiary care 
centres will be the referral for the 
district hospitals and provide com-
prehensive cancer care services. 
Training will be provided at tertiary 
care centres/State Cancer Institutes 
for health-care professionals. State 
Cancer Institutes will be referral cen-
tres for the tertiary care centres and 
district hospitals, and provide spe-
cialized cancer care services. Three 
apex centres (National Cancer 
Institutes) will conduct research on 
the various malignancies that are 
common and pertinent to our part 
of the world, i.e. tobacco-related 
cancers, and cancers of the cervix, 
gall bladder, and liver. Besides work-
ing as referral centres, the National 
Cancer Institutes will also provide 
training to generate high-quality hu-
man resources. They will help the 
government in formulating national 
cancer control policies. State and 
district noncommunicable disease 
cells will be established in the se-
lected states/districts for monitoring 
of the programme’s implementation.
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Summary
• The 2011 United Nations 
General Assembly High-Level 
Meeting on the Prevention and 
Control of Noncommunicable 
Diseases presented the cancer 
community with an unprec-
edented advocacy opportunity 
to position cancer as a global 
health and development issue 
and to use the momentum gen-
erated at the meeting to press 
for increased efforts to reduce 
the global cancer burden, par-
ticularly in low- and middle-in-
come countries.
• In high-income countries, the 
role of advocacy in ensuring 
the provision of optimal clini-
cal care and other benefits is 
established; advocacy in wider 
aspects of cancer control is be-
ing increasingly specified as a 
key consideration.
• Comprehensive national cancer 
control plans, based on knowl-
edge about the cancer burden 
provided by population-based 
cancer registries, are funda-
mental to cancer prevention and 
control and should be the focus 
of cancer advocacy efforts.
• Advocacy is about achieving a 
change that delivers a desired 
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outcome. Advocacy requires 
a strategic plan, supported by 
a strong evidence base, emo-
tional appeal, and a convincing 
financial case, and is most ef-
fectively implemented in collab-
oration with other like-minded 
organizations.
• Particular roles for advocacy for 
cancer control are being iden-
tified both as contributing to 
progress in high-income coun-
tries and as being developed 
in the context of local experi-
ence in low- and middle-income 
countries.
Using advocacy to accelerate 
the fight against cancer
Advocacy is about achieving a 
change that delivers a desired out-
come. Health advocacy aims to raise 
political awareness and influence 
public policy decisions in support 
of an organization’s mission. In the 
context of cancer control, effective 
advocacy is required to create an 
engaged political environment con-
ducive to improving the way cancer 
control knowledge influences policy 
and practice [1].
In high-income countries par-
ticularly, the key role of advocacy 
in ensuring optimal clinical care is 
well recognized. Beyond contributing 
to improving the circumstances of 
individual patients, such advocacy 
may serve, for example, to facilitate 
and encourage participation in clini-
cal trials [2]. Indeed, a role in cancer 
research is recognized: cancer pa-
tient advocates may contribute by 
offering perspectives different from 
those derived through government, 
academic, medical, and scientific 
approaches [3].
Complementing such perspec-
tives, a role of cancer advocacy in 
cancer control in its broadest con-
text, including all aspects of preven-
tion, may be recognized. In this con-
text, advocacy has a singular role. 
Thus, for example, in the prevention 
of human papillomavirus-related ma-
lignancies, a field readily identified 
with major achievements, more con-
certed advocacy is encouraged as 
complementing research and policy 
initiatives, if progress is to be opti-
mal [4].
In September 2011, the United 
Nations General Assembly held 
a historic High-Level Meeting on 
the Prevention and Control of 
Noncommunicable Diseases. Only 
the second such health summit in 
the history of the United Nations, 
this meeting represented global rec-
ognition of the growing burden of 
cancer and other noncommunicable 
diseases, including diabetes and car-
diovascular and respiratory diseases, 
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and positioned cancer control as a 
global health and development im-
perative. This provided the cancer 
community with an unprecedented 
advocacy opportunity to build on the 
momentum generated at the meeting 
and by the United Nations Political 
Declaration on noncommunicable 
diseases that was adopted [5], to 
press for increased efforts to reduce 
the cancer burden, particularly in low- 
and middle- income countries, where 
the cancer burden is set to rise by 
81% by 2030 [6].
Advocacy for cancer control: 
what is wanted?
Calling for national cancer 
control plans
The ultimate goal of advocacy efforts 
in cancer control is threefold: (i) to 
ensure that governments develop 
comprehensive national cancer 
control plans that span the entire 
continuum of care; (ii) to ensure that 
such national plans are informed by 
population-based cancer registries 
that provide the necessary knowl-
edge about cancer burden, as well 
as a means to evaluate the impact 
of implemented activities; and (iii) 
to ensure that governments finance 
and implement interventions known 
to be cost-effective and productive.
Even in countries with an exist-
ing cancer policy, plan, or strategy, 
these plans are not always sup-
ported by the necessary funds, per-
sonnel power, or infrastructure. In 
a recent survey, only 43% of low-
income countries reported having 
operational national cancer control 
plans (see Chapter 6.2). Similarly, 
there are stark disparities in cancer 
registration between high-income 
and low- and middle-income coun-
tries: the percentage of the popu-
lation covered by cancer registries 
in the reference publication Cancer 
Incidence in Five Continents, Vol. 
X (2013) is 95% in North America 
and 42% in Europe but only 8% in 
Latin America, 6% in Asia, and 2% 
in Africa [7].
Granted circumstances in sub-
Saharan Africa, approaches to mini-
mize the cancer burden in the recent 
past have had little success, among 
other things because of a poor 
understanding of the potential for 
cancer prevention [8]. The situation 
may be addressed by initiatives in 
advocacy, research, workforce, 
care, and funding. Cancer advocates 
in Africa, for example, may look to 
North America and Europe for guid-
ance. However, lessons learned 
from high-income countries are not 
necessarily applicable, and relevant 
resources based on Africa are be-
coming increasingly available [9].
Population-based cancer reg-
istries and national cancer control 
plans are a vital investment in un-
derstanding and responding to the 
cancer burden in all countries. A 
well-conceived plan that is based 
on cancer incidence, prevalence, 
and survival rate data provided by 
cancer registries and that outlines 
evidence-based strategies for pre-
vention, early detection, diagnosis, 
treatment, and palliation can signifi-
cantly lower the number of cancer 
cases and improve the quality of life 
of cancer patients. In the absence of 
population-based cancer registries, 
cancer planners can nevertheless 
use available data to outline strate-
gies for implementing proven cost-
effective interventions for reducing 
the cancer burden. Given the cur-
rent economic climate, it is crucial 
to maximize the population impact of 
money spent. Investing in the collec-
tion of basic cancer information and 
the development of comprehensive 
national cancer control plans needs 
Supporting national cancer  
control planning: 
a toolkit for Civil SoCiety 
organiSationS (CSoS)
geneva, 2012
CollaBoration
aCtion
Content
evalUation
BUrDen
Fig. 6.5.2. Cover of an advocacy toolkit. 
This publication from the Union for Inter- 
national Cancer Control provides support 
to civil society organizations.
Fig. 6.5.1. The United Nations General Assembly High-Level Meeting on the Prevention 
and Control of Noncommunicable Diseases, held in September 2011, was only the second 
such health summit in the history of the United Nations.
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to be clearly specified to ensure that 
the greatest impact is achieved for 
the funds allocated.
There are cost-effective evi-
dence-based interventions that can 
significantly reduce the cancer bur-
den. These include screening for 
cervical cancer and breast cancer, 
and vaccination against hepatitis B 
virus and human papillomavirus to 
protect against infection-related liver 
cancer and cervical cancer, respec-
tively. Cervical cancer screening and 
hepatitis B virus immunization were 
underscored as priority interventions 
in the 2011 United Nations Political 
Declaration on noncommunicable 
diseases [5] and have also been 
highlighted by WHO as not only high-
ly cost-effective but also feasible and 
appropriate to implement within the 
constraints of health systems in low- 
and middle-income countries [10].
What does success look like?
Advocacy at a global level was key 
to adoption of the WHO Framework 
Convention on Tobacco Control, the 
first treaty negotiated under the aus-
pices of WHO. The Convention pro-
vides a robust framework to confront 
the efforts of the tobacco industry, 
which employs lawyers and market-
ing and communications experts to 
counter health advocates around the 
globe. The recent major achievement 
involving Australia’s adoption of legis-
lation for plain packaging of tobacco 
products highlights the impact that 
a persistent, united, and vocal civil 
society may have.
Similarly, the NCD Alliance (www.
ncdalliance.org), a global network of 
more than 2000 civil society organi-
zations from 170 countries address-
ing the four main noncommunicable 
diseases (cardiovascular disease, 
diabetes, cancer, and chronic re-
spiratory disease), played a pivotal 
role in the lead-up to the United 
Nations General Assembly High-
Level Meeting on the Prevention 
and Control of Noncommunicable 
Diseases, pressing governments to 
recognize that noncommunicable 
diseases are a global development 
priority requiring an urgent response. 
Since then, the NCD Alliance has 
sustained global action on noncom-
municable diseases and spearhead-
ed remarkable progress, culminating 
in the adoption of an omnibus resolu-
tion on noncommunicable diseases 
at the 66th World Health Assembly, 
which will benefit the millions of peo-
ple worldwide who are at risk of, or liv-
ing with, noncommunicable diseases.
Advocacy for cancer control: 
how do we do it?
Effective advocacy for cancer con-
trol requires a carefully constructed 
strategic plan identifying the prob-
lem, advocacy goal, key messages 
and target audiences, activity plan, 
and evaluation process [1], and is 
optimally supported by three core 
components: a comprehensive evi-
dence base, emotional appeal, and 
a strong financial case. Neglecting 
both the views of patients and their 
loved ones and the compelling 
case for investing in cancer preven-
tion and control now will inevitably 
result in a rise in the cancer burden 
and require a significantly greater in-
vestment later. In addition to these 
three core components, effective ad-
vocacy for cancer control needs to 
occur at the local, national, regional, 
and global levels. These efforts can 
be enhanced through strong part-
nerships between local and global 
advocates, as well as across groups 
concerned with related diseases, 
specifically including other noncom-
municable diseases, and involv-
ing multiple sectors, including the 
private sector. Thus, in identifying 
breast cancer control strategies in 
Asia, Latin America, and the Middle 
East, a specific role for advocacy was 
identified [11]. The development of ef-
fective strategies may be grounded 
in the experience of local practition-
ers, policy-makers, and advocacy 
leaders.
Evidence-based advocacy
Evidence is critical for influencing 
public policy decisions; it provides 
the necessary information for ad-
vocates to raise awareness of the 
nature and extent of a problem and 
make realistic projections of possible 
policy outcomes. Screening for cervi-
cal cancer is a good example of the 
links between research, policy, and 
practice. Over the previous decades, 
advocacy has helped to drive the re-
search agenda, culminating in large-
scale randomized clinical trials to 
test the “screen and treat” approach 
using visual inspection with acetic 
acid. The evidence base generated 
through these trials, particularly in 
low-income settings, has resulted 
in widespread recognition of cervi-
cal cancer screening as a proven 
Fig. 6.5.3. This model of a cigarette, an 
inflated balloon, was displayed in Hyder- 
abad, India, during World No Tobacco Day 
2012. World No Tobacco Day is marked on 
31 May each year, to create awareness 
about the harmful effects of tobacco and 
smoking.
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cost-effective intervention for reduc-
ing the global cancer burden, and has 
enabled the rapid integration of an in-
dicator for cervical cancer screening 
into the Global Monitoring Framework 
for the Prevention and Control of 
Noncommunicable Diseases [12] fi-
nalized by United Nations Member 
States in November 2012. Cervical 
Cancer Action, a global coalition of 
organizations including the American 
Cancer Society, PATH (an interna-
tional non-profit organization), the 
Pan American Health Organization, 
and the Union for International 
Cancer Control, has been a driving 
force behind these successful advo-
cacy efforts [13].
The power of the patient voice
Cancer patients, survivors, and their 
families are not only key to docu-
menting the impact of policies on 
individuals; these same individuals 
can also be highly effective and pow-
erful advocates for the adoption of 
cancer prevention and control poli-
cies. Patient participation in cancer 
advocacy is often hindered by the 
lack of long-term survivors among 
those diagnosed with particular ma-
lignancies, but as medical advances 
result in increasing survival rates 
such situations may change, as high-
lighted by the rising cohesive body 
of lung cancer advocacy groups. A 
good example of this is the Global 
Lung Cancer Coalition, established 
in 2001, which now comprises 28 
nongovernmental patient organiza-
tions from more than 20 countries, 
and works to improve disease out-
comes for lung cancer patients glob-
ally [14].
Case study: access to opioids 
for cancer pain relief
Bringing the patient voice to policy 
discussions, and emphasizing the 
need for a rights-based approach 
to address the global inequities 
in access to pain relief, has been 
instrumental in effecting policy 
changes at the highest level. Since 
2009, the Union for International 
Cancer Control has worked with its 
members to add the cancer voice 
to the human rights and palliative 
care communities’ efforts towards 
increased access to opioid analge-
sics. During this period, the United 
Nations’s drug policy-making organ, 
the Commission on Narcotic Drugs, 
has adopted two resolutions [15,16], 
emphasizing that more needs to be 
done to enhance availability of con-
trolled medications while prevent-
ing their diversion and abuse. The 
2011 Commission on Narcotic Drugs 
resolution specifically requested 
the United Nations Office on Drugs 
and Crime, in consultation with 
the International Narcotics Control 
Board and WHO, to update its model 
laws to ensure that they reflect an 
appropriate balance between ensur-
ing adequate access to internation-
ally controlled drugs and preventing 
diversion and abuse.
In 2012, commendable advoca-
cy efforts led by the palliative care 
community resulted in the inclusion 
of an indicator on access to pal-
liative care, assessed by morphine-
equivalent consumption of strong 
opioid analgesics per cancer death, 
in the Global Monitoring Framework 
for the Prevention and Control of 
Noncommunicable Diseases [12].
Building the financial case
The World Economic Forum has 
identified noncommunicable dis-
eases, including cancer, as the sec-
ond greatest risk to global economic 
growth [17]. One half of those who 
die from noncommunicable diseases 
are in their most productive years, 
meaning that the social costs and 
economic consequences in terms 
of lost productivity are consider-
able. The cost of cancer alone is 
estimated to reach US$ 458 billion 
in 2030 [10], yet WHO estimates that 
a basic package of cost-effective 
strategies to address the common 
cancer risk factors (tobacco use, 
alcohol consumption, unhealthy 
diet, and physical inactivity) would 
cost only US$ 2 billion a year [18]. 
Even so, less than 3% (US$ 503 mil-
lion out of US$ 22 billion) of overall 
development assistance for health 
was allocated to noncommunicable 
diseases in 2007 [19], and only 5% 
of global spending on cancer is in 
developing countries. This is despite 
the fact that nearly 80% of the pre-
ventable deaths from these diseases 
occur in developing countries, with 
this percentage set to rise [20]. The 
financial case for investing in cancer 
is strong, and is one that can and 
must be used by cancer advocates 
at all levels to support adequate and 
sustained resourcing of national 
cancer control plans.
Multisectoral partnerships
The United Nations Political Decla- 
ration on noncommunicable diseas-
es clearly articulated the need for 
multisectoral partnerships, engaging 
Fig. 6.5.4. A nurse provides pain relief to a cancer patient in Uganda.
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both health and non-health actors, 
including civil society and the private 
sector, to promote and support the 
provision of services for noncommu-
nicable disease prevention and con-
trol. In addition to bolstering global 
and national advocacy efforts, such 
partnerships are essential for the im-
plementation of cancer interventions 
at the country level. Given today’s fi-
nancial climate, engagement of parts 
of the private sector, with appropriate 
safeguards to manage potential con-
flicts of interest, is more critical than 
ever. There is a clear willingness in 
the private sector to engage at this 
level; according to a recent survey 
conducted by Business for Social 
Responsibility, 40% of companies 
expect to increase their commit-
ment to global health partnerships 
focused on noncommunicable dis-
eases in the next 5 years [21]. Global 
health partnerships could play an 
important role in improving primary 
health-care systems, which are the 
front lines – particularly in low- and 
middle-income countries – for en-
gaging communities with prevention, 
diagnosis, and treatment across a 
range of diseases, including cancer.
Advocacy for cancer control: 
the road ahead
In May 2013, Member States at the 
66th World Health Assembly adopted 
an omnibus resolution on noncom-
municable diseases that combined 
major decisions and recommen-
dations in a single comprehensive 
resolution, including (i) adopting 
a Global Monitoring Framework 
for the Prevention and Control of 
Noncommunicable Diseases; (ii) 
endorsing a Global Action Plan for 
Noncommunicable Diseases 2013–
2020; and (iii) agreeing to establish a 
Global Coordination Mechanism for 
Noncommunicable Diseases [22]. 
This emerging framework for non-
communicable diseases will carve 
out a new global advocacy space 
for the cancer community, and an 
opportunity to ensure that noncom-
municable diseases, including can-
cer, continue to occupy a place on 
the global health and development 
agenda. Ensuring that cancer is part 
of the 2013 Millennium Development 
Goal review and the emerging de-
bate on universal health coverage, 
the sustainable development goals, 
and other development issues will 
also be vital to ensuring that cancer 
control remains central to future 
thinking. Cancer advocates face 
both new opportunities and chal-
lenges as “latecomers” to the devel-
opment discourse. Now more than 
ever, innovative partnerships that go 
beyond traditional health groups and 
embrace partners in the develop-
ment sphere, including reproductive, 
maternal, and child health organiza-
tions as well as the AIDS community, 
are critical if the currently predicted 
cancer burden for future generations 
is to be reduced.
Fig. 6.5.5. Cancer Council Australia provides a range of resources related to evidence-
based cancer control policy and advocacy on its website.
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Cancer control in Jordan: goals for low- 
and middle-income countries
Omar Nimri 
In Jordan, a country with about 
6.5 million people, cancer is the 
second most frequent cause of 
death, after heart disease. A total 
of 6820 new cancer cases were 
registered by the national Jordan 
Cancer Registry in 2010. Of these, 
72% were among Jordanians and 
28% were among non-Jordanians.
The rank order of the five 
most common cancers affecting 
Jordanians is: breast cancer (19.6% 
of all cases), colorectal cancer 
(11.5%), lymphoma (7.9%), lung 
cancer (7.8%), and prostate cancer 
(4.5%). The crude annual incidence 
rate of all cancers among Jordanians 
is 79.4 per 100 000 (male, 74.0; 
female, 85.1). The most frequent 
paediatric cancers (0–14 years) are 
leukaemias (38%), brain and central 
nervous system tumours (27%), lym-
phomas (20%), renal tumours (8%), 
and soft tissue cancers (7%) [1].
Growing and ageing populations 
are projected to experience dramatic 
increases in the number of cancer 
cases and cancer deaths, particular-
ly in low- and middle-income coun-
tries like Jordan. It is imperative that 
planning begins now to deal not only 
with those cancers already occur-
ring but also with the larger numbers 
expected in the future.
A national cancer control plan 
(NCCP) for Jordan is in the process 
of being finalized. A simple NCCP 
existed previously, but the idea of a 
full, up-to-date NCCP really started 
in October 2008 at a meeting at-
tended by many parties, including 
the Jordanian Ministry of Health, 
the WHO office in Amman, the King 
Hussein Cancer Center, some non-
governmental organizations, and the 
King Hussein Institute for Cancer 
Research and Biotechnology). A 
draft NCCP was prepared and pre-
sented to the minister of health, but 
unfortunately the draft was not en-
dorsed and the NCCP was shelved.
In January 2012, the International 
Atomic Energy Agency, upon offi-
cial request of the Ministry of Health, 
conducted a mission in close col-
laboration with the ministry. Based 
on the findings and recommenda-
tions of that mission, a new NCCP 
is now in preparation. The major 
partners are the Ministry of Health, 
the King Hussein Cancer Center, 
the Jordanian Royal Medical 
Services, the private medical sec-
tor, WHO, nongovernmental or-
ganizations such as the Jordan 
Medical Association and the Jordan 
Oncology Society, academia and 
research institutes, smoking cessa-
tion programmes, and others. It is 
hoped that the new, updated NCCP 
will cover all aspects of cancer, in-
cluding prevention, early detection, 
screening, diagnosis and treatment, 
palliative care, and rehabilitation.
Most people pick up their bad 
habits at a younger age, leading 
to unhealthy diet, smoking, poor 
hygiene, and many other risk fac-
tors. The majority of cancers are 
preventable, by reducing exposure 
to factors that are known to cause 
the disease. Hence, education of 
the youth should be a priority to 
decrease these risks in the context 
of cancer control.
In 2001, a national tobacco 
control programme was started. In 
2004, Jordan was the second coun-
try in the local region and the 29th 
in the world to endorse the WHO 
Framework Convention on Tobacco 
Control. The prevalence of smoking 
among adults (18 years and older) 
was 29% (male, 51%; female, 7%) in 
2007. The prevalence among youth 
(13–15 years) was 11.5% (male, 
17.4%; female, 8.3%) in 2009 [2]. 
In 2008, a law was passed banning 
smoking in public places; enforce-
ment of this smoke-free legislation is 
still needed. Also, a repulsive picture 
of lungs and smoking is required on 
all cigarette packaging, along with 
warning statements.
Given that breast cancer is the 
most common cancer in Jordan, 
a national programme for breast 
cancer awareness, early detection, 
and screening was initiated in 2006, 
led by the King Hussein Cancer 
Foundation and Center.
The whole spectrum of cancer 
treatment is available in Jordan, but 
the inequality of access is the major 
obstacle faced.
Palliative care services remain 
grossly inadequate and represent a 
further area of priority.
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Summary
• The effective application of law 
is essential to cancer control 
and requires engagement across 
such diverse areas as trade law, 
intellectual property law, invest-
ment law, human rights law, drug 
control law, constitutional law, 
consumer protection law, neg-
ligence law, medical law, and 
criminal law.
• Current challenges to Australia’s 
world-first plain tobacco pack-
aging legislation have become 
seminal cases on the inter-
section between global public 
health and trade and investment 
laws and norms, with profound 
implications for cancer control.
• Overly restrictive laws continue 
to operate as barriers to the 
availability of opioid analgesics 
for the relief of cancer-associ-
ated pain. Significant norma-
tive progress has recently been 
made at the international level.
• Efforts to address the unavoid-
able tensions between the pub-
lic interests in privacy protection 
and cancer research should ac-
knowledge the role of the right 
to health, understood as a col-
lective right of populations, the 
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fulfilment of which depends on 
high-quality research.
Law is everywhere in cancer control. 
Some examples of areas are:
• the regulation of the behaviour of 
the tobacco, alcohol, food, asbes-
tos, and sunbed industries;
• the regulation of where people can 
use products that cause harm to 
third parties, such as laws prohibit-
ing smoking in workplaces, public 
places, residential facilities, and 
cars carrying children;
• court challenges to cancer preven-
tion measures such as tobacco 
product display bans (Norway), 
graphic health warnings (Uruguay 
and the USA), and plain packaging 
(Australia);
• litigation against industries whose 
products and practices cause 
cancer;
• the application of occupational 
health and safety laws to exposure 
to carcinogens in the workplace;
• the relationship between patent 
law and pharmaceutical research 
and the affordability of medicines;
• the effect of laws regulating the 
trade, prescription, and supply of 
opioid analgesics on their avail-
ability for the treatment of cancer-
associated pain;
• the regulation of health profes-
sionals, including the protection 
of patients from inappropriate or 
dangerous “treatments”;
• the regulation of decision-making 
in treatment and care, including 
the end-of-life period;
• the conduct of clinical trials and 
the relationship between epide-
miological research and health 
information privacy;
• the access of family members to 
genetic information; and
• intellectual property rights over 
genetic material and scientific 
discovery. 
In these and a host of other areas, 
the effective application of law is es-
sential to cancer control.
For each of these areas, law 
has both domestic and interna-
tional elements. Domestically, law 
is constituted by a combination of 
constitutional arrangements, legis-
lation, regulations, court decisions, 
regulatory practices and policies, 
and professional and community un-
derstandings of what the law is and 
how it operates in practice. At the 
international level, law includes trea-
ties – notably the WHO Framework 
Convention on Tobacco Control 
(FCTC); the United Nations Single 
Convention on Narcotic Drugs; the 
International Covenant on Economic, 
Social, and Cultural Rights, which 
enshrines the right to the highest 
attainable standard of health; other 
international human rights treaties; 
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the World Trade Organization (WTO) 
agreements; and a raft of regional, 
plurilateral, and bilateral trade and 
investment treaties – as well as a 
wide range of “softer” normative 
instruments, such as declarations, 
guidelines, and strategies.
Health law and governance – 
at both domestic and international 
levels – is an increasingly crowded 
and fragmented space. The United 
Nations Political Declaration on 
the Prevention and Control of Non- 
communicable Diseases [1] under-
lines that prevention and control of 
these diseases require multisectoral 
approaches, including across such 
sectors as health, education, energy, 
agriculture, sports, transport, com-
munication, urban planning, environ-
ment, labour, employment, industry 
and trade, finance, and social and 
economic development.
Internationally, WHO is the 
United Nations’s specialized agen-
cy for health, but it is only one of 
a large number of international 
agencies whose work directly or 
indirectly affects health, includ-
ing cancer, such as the United 
Nations Children’s Fund, the Food 
and Agriculture Organization of the 
United Nations, the United Nations 
Environment Programme, the United 
Nations Development Programme, 
the United Nations Population Fund, 
the World Bank, the United Nations 
Human Rights Council, the WTO, 
the United Nations Office on Drugs 
and Crime, the International Atomic 
Energy Agency, and the International 
Labour Organization. These agen-
cies have very different mandates, 
priorities, instruments, and values, 
meaning that policy and operational 
coherence in the interests of health 
is often elusive.
Against this broader backdrop, 
this chapter focuses on three topi-
cal and important areas, relating to 
prevention, treatment, and research, 
respectively.
Trade and investment 
challenges to tobacco control
The foreword to the WHO FCTC [2] 
describes the treaty as having been 
“developed in response to the glob-
alization of the tobacco epidemic”, 
the spread of which “is facilitated 
through a variety of complex factors 
with cross-border effects, including 
trade liberalization and direct foreign 
investment”. The WHO FCTC was 
conceived, in part, as a global re-
sponse to these dynamics.
Increasingly, the relationship 
between the WHO FCTC, as an in-
ternational legal instrument, and the 
international legal instruments that 
govern trade, intellectual property, 
and investment is being played out 
in the form of legal challenges [3]. 
As this Report goes to press, chal-
lenges to Australia’s world-first “plain 
packaging” laws are the most promi-
nent example.
In November 2011, the Australian 
Parliament enacted the Tobacco 
Plain Packaging Act 2011 [4]. As of 
1 December 2012, all tobacco prod-
ucts sold in Australia were required 
to comply with the legislation. The 
legislation bans the use of logos, 
brand imagery, symbols, other im-
ages, colours, and promotional text 
on tobacco products and tobacco 
product packaging, and requires 
packaging to be a standard drab 
dark-brown colour in matte finish. 
Products are differentiated by the 
brand and product name, displayed 
in a standard colour, position, font 
size, and style. Graphic health warn-
ings are required on 75% of the front 
surface and 90% of the back surface 
of tobacco packaging. Indeed, the 
“plain” in “plain packaging” is some-
what of a misnomer.
Plain packaging is supported by 
two sets of guidelines adopted by the 
governing body of the WHO FCTC – 
its Conference of the Parties – in 
November 2008: one on packaging 
and labelling (Article 11) [5] and the 
other on tobacco advertising, pro-
motion, and sponsorship (Article 13) 
[6]. The guidelines for the implemen-
tation of Article 11 state that plain 
packaging “may increase the notice-
ability and effectiveness of health 
warnings and messages, prevent 
the package from detracting atten-
tion from them, and address industry 
design techniques that may suggest 
that some products are less harmful 
than others”. The Article 13 guide-
lines acknowledge that packaging “is 
an important element of advertising 
and promotion”. The Australian leg-
islation includes as one of its objects 
“to give effect to certain obligations 
that Australia has as a party to the 
Convention on Tobacco Control”.
Plain packaging has been chal-
lenged both in the WTO and under a 
bilateral investment treaty between 
Australia and Hong Kong Special 
Administrative Region. In the WTO, 
in which dispute settlement is state–
state rather than investor–state, 
Fig. 6.6.1. Health warning images and plain packaging designs used in Australia. All 
brand names are specified in a standard colour, position, font size, and style.
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Ukraine, Honduras, the Dominican 
Republic, Cuba, and Indonesia 
have claimed that plain packaging 
breaches Australia’s obligations 
under the General Agreement on 
Tariffs and Trade, the Agreement 
on Technical Barriers to Trade, and 
the Agreement on Trade-Related 
Aspects of Intellectual Property 
Rights. It has been reported that 
the two multinational tobacco com-
panies, Philip Morris and British 
American Tobacco, have been pro-
viding support to countries to chal-
lenge plain packaging [7].
Unlike in the WTO, the bilat-
eral investment treaty between 
Australia and Hong Kong Special 
Administrative Region – like many 
other investment treaties – enables 
a foreign investor to sue a govern-
ment directly. Philip Morris Asia – 
which acquired its interest in Philip 
Morris Australia on 23 February 
2011, i.e. after plain packaging had 
been announced by the Australian 
Government, in April 2010 – has 
brought proceedings against the 
Australian Government claiming “ex-
propriation” of its investment and de-
nial of “fair and equitable treatment”.
The Australian Government is 
vigorously defending both the WTO 
and bilateral investment treaty pro-
ceedings. These challenges to plain 
packaging have become seminal 
cases on the intersection between 
global public health and trade and 
investment laws and norms, touch-
ing on broader issues relating to the 
power of governments to regulate in 
the public interest, the relationship 
between private intellectual prop-
erty rights and public health, and 
the nature and role of evidence in 
policy-making.
Achieving balance in the 
regulation of opioids
Opioid analgesics are regulated inter-
nationally under the United Nations 
Single Convention on Narcotic Drugs, 
1961, as amended by its 1972 Protocol 
[8]. The Single Convention seeks to 
strike a balance between the two aims 
of ensuring the availability of opioids 
for medical use for the relief of pain 
and suffering – which it describes 
as “indispensable” – and preventing 
their diversion and abuse. In practice, 
this balance has not been achieved, 
with poor availability in much of the 
world and great global disparities. 
In 2011, Australia, Canada, Japan, 
New Zealand, the USA, and some 
European countries accounted for 
more than 93% of total global mor-
phine consumption [9].
The major barriers to the avail-
ability of opioid analgesics are well 
known. They include insufficient 
training of health-care profession-
als in the prescription and admin-
istration of opioids; misperceptions 
among health-care professionals, 
policy-makers, and patients and 
their families about the safety of 
opioids; exaggerated fears about 
the development of dependence; 
overly restrictive laws and regula-
tions that exceed the requirements 
of the Single Convention; and unduly 
harsh sanctions for the unintention-
al mishandling of opioids by health 
workers [10].
The Single Convention estab-
lishes a regulatory system that 
includes requirements for: govern-
ment authorization for participa-
tion in the trade and distribution 
of narcotics; provision by states to 
the International Narcotics Control 
Board of estimates of need, and 
statistical returns covering produc-
tion, manufacture, consumption, im-
port, and export; export and import 
licences for international transac-
tions; licensing and record-keeping 
for trade or distribution; and medical 
prescriptions for dispensation.
Many states have adopted overly 
restrictive laws and regulations that 
exceed the requirements of the 
Single Convention and that operate 
as barriers to availability. Examples 
include limitations on who can pre-
scribe, special prescription proce-
dures, restrictions on doses that may 
be prescribed or on the number of 
days’ supply that may be provided 
in a single prescription, arbitrary 
restrictions on the number of phar-
macies that are allowed to dispense 
opioid medications, and overly bur-
densome administrative and bureau-
cratic procedures.
The lack of balance in legal and 
regulatory approaches to opioid 
analgesics is increasingly being ad-
dressed at the international level. 
Several important documents have 
been developed and adopted over 
the past few years:
• two resolutions of the United 
Nations’s main drug policy-mak-
ing organ, the Commission on 
Narcotic Drugs, in 2010 [11] and 
2011 [12], with co-sponsorship by 
countries from different regions 
and with different levels of income, 
which have emphasized that more 
needs to be done to enhance the 
availability of controlled medica-
tions while preventing their diver-
sion and abuse;
• new WHO policy guidelines (2011) 
[13], which provide guidance on 
policies and legislation with re-
spect to availability, accessibility, 
affordability, and control of con-
trolled medicines;
• a special supplement to the 2010 
International Narcotics Control 
Fig. 6.6.2. Disparity in morphine consumption in high-income countries (High) versus 
low- and middle-income countries (LMIC). (A) Morphine consumption (as a percentage 
of the total number of kilograms consumed) in 2010. (B) Total population of countries 
reporting opioid consumption to the International Narcotics Control Board in 2010.
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Board Annual Report [14], which 
includes recommendations on 
availability of controlled medicines 
and their appropriate use, national 
control systems, and prevention of 
diversion and abuse;
• a 2011 United Nations Office on 
Drugs and Crime discussion paper 
[15], which includes recommen-
dations relating to data collec-
tion, laws and policies, and public 
awareness.
The 2011 Commission on 
Narcotic Drugs resolution requested 
the United Nations Office on Drugs 
and Crime, in consultation with 
the International Narcotics Control 
Board and WHO, to update its model 
laws to ensure that they reflect an 
appropriate balance between en-
suring adequate access to interna-
tionally controlled drugs and pre-
venting diversion and abuse. At the 
2013 session of the Commission on 
Narcotic Drugs, the United Nations 
Office on Drugs and Crime released 
proposed amendments to its model 
drug laws [16], including:
• the introduction of substantive 
objects into the model law (rather 
than simply compliance with the 
relevant conventions): “ensuring 
the availability of narcotic drugs 
and psychotropic substances for 
medical and scientific use, and 
preventing the non-medical and 
non-scientific use of narcotic drugs 
and psychotropic substances”.
• the use of neutral terminology to 
describe drugs that have medical 
or scientific uses but can cause 
harm when misused. For exam-
ple, the proposals describe the 
Schedule in which morphine is 
listed as including “drugs and 
substances having a medical and/
or scientific use which should be 
subject to control in view of the 
harms that their non-medical and/
or non-scientific use can cause”. 
This contrasts with the previous 
wording, which referred to “strict-
ly controlled substances and 
plants having a medical use” and 
“substances with a high potential 
risk to public health but having a 
medical use” (emphasis added). 
Under the previous formulation, 
concern about the risk of mis-
use predominated over the need 
to ensure appropriate medical 
treatment.
• an explicit recognition that, as rec-
ommended by WHO, the capacity 
to prescribe controlled medicines 
should not be restricted to a small 
number of medical specialties 
(such as oncologists); controlled 
medicines should be available 
at all appropriate levels of care, 
and the amount of medicine pre-
scribed, the appropriate formula-
tion, and the duration of treatment 
should be for the health practition-
er to decide, based on individual 
patient needs and sound scientific 
medical guidance.
Privacy and cancer research
High-quality research – clinical, 
behavioural, and epidemiological – 
is key to effective cancer control. 
Epidemiological research provides 
a wealth of information that is es-
sential for planning, resource alloca-
tion, programme development and 
delivery, legal and regulatory inter-
ventions, therapy development, and 
care improvement.
In practice, such research can-
not be effectively conducted with-
out access to sometimes sensitive 
Fig. 6.6.3. Marked differences between countries in relation to medicinal opioid consumption (2010), assessed by morphine-equivalent 
consumption (in milligrams) of strong opioid analgesics per cancer death.
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personal health information, the dis-
closure of which can have a range of 
consequences for individuals. Public 
health research and surveillance 
cannot be effectively performed on 
the basis of fully de-identified data. 
De-identified data are not sufficient 
for the individual–data linkages re-
quired for epidemiological research 
designed to investigate more intri-
cate interactions between exposure, 
lifestyle, preventive interventions, 
treatment, and outcomes [17]. Even 
after research has been conduct-
ed, data may need to remain re- 
identifiable to allow for the correc-
tion of errors or updating of new 
data, and for the review of scientific 
work, thereby guarding against sci-
entific fraud [18].
It is not feasible to condition the 
use of personal health information in 
public health research on individual 
consent in all cases. When informa-
tion is collected, it is seldom possi-
ble to identify all its future valuable 
uses. When dealing with large data 
sets, it may not be feasible to obtain 
consent from each individual whose 
data is proposed to be used [19]. 
Further, relying on individual consent 
can lead to compromised or invalid 
results because of significant differ-
ences between individuals who do 
and do not grant consent, meaning 
that research might be conducted on 
the basis of unrepresentative data 
[20].
The effect of these research re-
alities is an unavoidable tension be-
tween the public interests in privacy 
protection and cancer research. 
Many cancer (and other public 
health) researchers believe that 
regulation is increasingly privileging 
privacy protection to the detriment of 
the conduct of research. One of the 
striking features of the literature on 
the relationship between information 
privacy and public health research – 
both academic articles and legal and 
policy documents – is that only one 
species of right, the right to privacy, 
seems to feature. There is invariably 
an “interest” against which the right 
should be balanced, often expressed 
as public health. While the point is 
often made that the “public” consists 
of individuals, who are the ultimate 
beneficiaries of public health re-
search [21], it is curious that the right 
to health seems never to be raised.
This is the case notwithstanding 
the recognition that fulfilment of the 
right to health depends on the con-
duct of research. The International 
Covenant on Economic, Social, and 
Cultural Rights is the primary inter-
national legal instrument on eco-
nomic, social, and cultural rights. 
The United Nations Committee 
on Economic, Social, and Cultural 
Rights’s General Comment on Article 
12 (the right of everyone to the enjoy-
ment of the highest attainable stan-
dard of physical and mental health) 
states that one of the “core obliga-
tions” of the article is “to adopt and 
implement a national public health 
strategy and plan of action, on the 
basis of epidemiological evidence, 
addressing the health concerns of the 
whole population” (emphasis added) 
[22]. The control of diseases required 
by Article 12.2(c) necessitates “us-
ing and improving epidemiological 
surveillance and data collection on 
a disaggregated basis”.
Bringing the right to health to bear 
on matters relating to health informa-
tion privacy need not entail a disre-
gard, or a downgrading, of the right 
to privacy or the values it promotes. 
Rather, it would situate debates in 
their proper legal context, and should 
ultimately influence the way in which 
public health research is regulated. 
Too often, public health research ap-
pears as an afterthought exception 
in regimes aimed at strengthening 
privacy protection, often driven by 
concerns about such matters as pub-
lication of information about celebri-
ties, online security, and identity theft. 
Acknowledging the role that the right 
to health has to play here touches on 
broader debates about the nature of 
the right to health and the need to 
conceive of it as not just an individual 
right but a collective right of popula-
tions [23].
Conclusion
Cancer control requires expertise 
and capacity in law. But there is no 
single discipline of “cancer control 
law”. Cancer control law requires en-
gagement at both domestic and in-
ternational levels and across such di-
verse areas as trade law, intellectual 
property law, investment law, human 
rights law, drug control law, constitu-
tional law, consumer protection law, 
negligence law, medical law, and 
criminal law. The need for capac-
ity in cancer control law continues 
to grow. The global cancer control 
community has begun to recognize 
and respond to this challenge.
Fig. 6.6.4. An opium poppy field in Tasmania, Australia, where opium is grown for me-
dicinal morphine. The opium poppies are usually genetically modified so that extraction 
of opiate can be undertaken only in a laboratory.
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Cancer control in Morocco: action in 
harmony with the socioeconomic and 
cultural context
Rachid Bekkali
Cancer control in Morocco is a na-
tional priority. Created in November 
2005, the Lalla Salma Foundation for 
Cancer Prevention and Treatment 
has conducted, in collaboration with 
the Moroccan Ministry of Health, 15 
studies to analyse the situation re-
garding all aspects related to cancer. 
The findings were the basis for the 
development of the National Cancer 
Prevention and Control Plan 2010–
2019 (NCPCP), ratified by the gov-
ernment in March 2010. The vision 
of the NCPCP is to control cancers 
nationwide through a multisectoral 
approach, proposing concrete and 
sustainable actions and making the 
best use of available resources, 
while being in harmony with the 
socioeconomic and cultural con-
text. The values of the NCPCP are 
equity, solidarity, quality, and excel-
lence. The objective of the NCPCP 
is to reduce cancer morbidity and 
mortality, and to improve the quality 
of life of patients and their relatives.
The NCPCP action strategy con-
sists of 78 operational measures 
to be undertaken in four strategic 
fields: prevention, early detection, di-
agnosis and treatment, and palliative 
care. These strategic components 
are supported by the activities of 
communication, social mobilization, 
regulation, training, and research. 
All these components are being 
integrated around a national and 
international mobilization and thus 
constitute the conceptual framework 
of the NCPCP. Since the creation of 
the Lalla Salma Foundation, several 
projects have been accomplished 
in partnership with the Ministry of 
Health, national and internation- 
al nongovernmental organizations, 
governmental and private agencies, 
and benefactors. As of the end of 
2012, of the 78 measures of the 
NCPCP, 72 measures had been 
initiated, among which 51 were well 
advanced.
In the area of prevention, public 
awareness campaigns are organized 
every year, a programme of smoke-
free schools and businesses has 
been implemented, a human papil-
lomavirus vaccination programme is 
planned to be generalized in 2014, 
and the strengthening of regulations 
is ongoing. In the field of health care, 
several oncology centres were built 
and equipped, as well as “Houses of 
Life” to accommodate patients and 
their families during the treatment 
period. A programme of access to 
medication for low-income patients 
has been established. Human skills 
have been developed. Therefore, 
between 2006 and the end of 2012, 
for example, Morocco improved from 
two oncology centres to nine, from 
two accelerators to 22, from one 
“House of Life” to nine, from 50 on-
cologists to more than 150, and from 
11 500 patients treated to 23 000. 
In addition, a detection programme 
for breast and cervical cancers has 
been implemented, a palliative care 
network project was initiated, and 
an ambitious plan to structure can-
cer research in Morocco has been 
started.
The situation analysis reports, 
the NCPCP, and more details about 
cancer control activities in Morocco 
can be found at http://www.contrele 
cancer.ma/en/documents/.
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Summary
• The 14 million estimated new 
cases of cancer worldwide an-
nually inflict a crushing burden 
of economic costs and human 
suffering. A significant part of 
this burden could be avoided by 
expanding coverage of preven-
tion, early detection, and treat-
ment for specific cancers.
• The estimated total annual eco-
nomic cost of cancer was ap-
proximately US$ 1.16 trillion in 
2010 – the equivalent of more 
than 2% of total global gross 
domestic product. Even this im-
pressively high figure is a lower 
bound, as it does not include the 
substantial longer-term costs to 
families and caregivers.
• Between one third and one 
half of cancer deaths could be 
avoided with prevention, early 
detection, and treatment – be-
tween 2.4 million and 3.7 mil-
lion avoidable deaths per year, 
80% of which occur in low- and 
middle-income countries.
• Investing strategically in cancer 
care and control more than pays 
for itself. A reasonable estimate 
shows that the world could have 
saved between US$ 100 billion 
and US$ 200 billion in 2010 by 
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investing in prevention, early de-
tection, and effective treatment 
of cancer.
• The ability to prevent, detect, 
and treat many cancers has 
improved over time, and many 
of these advances have led to 
reductions in costs. Harnessing 
markets and increasing access 
can also bring down prices.
Human life and well-being have an 
intrinsic and immeasurable value. 
They also have economic value. 
Viewing health as an investment, 
rather than a cost, is the philosophy 
that today inspires human, econom-
ic, and environmental global devel-
opment agendas.
Yet this investment philosophy 
remains largely ignored in formulat-
ing global and national policies to 
deal with cancer and other chronic 
illnesses, leaving wide open the 
agenda for research into the eco-
nomics of cancer. Impressive oppor-
tunities exist to develop and expand 
the knowledge needed to better 
understand how to reduce the eco-
nomic burden of this set of diseases.
This chapter highlights compel-
ling economic arguments for invest-
ments to increase global access to 
cancer care and control, drawing 
heavily on published research and 
analysis of the Global Task Force on 
Expanded Access to Cancer Care 
and Control [1]. Estimates of the eco-
nomic value of the avoidable cancer 
burden are provided, and these are 
compared with potential savings 
based on the current costs of cancer 
care and control. These estimates 
are illustrative of how economics can 
contribute to a deeper understanding 
of the global cancer burden and to 
more effective strategies for reduc-
ing it.
The economics of investing in 
cancer care and control
The estimated 14 million new cases 
of cancer worldwide annually lead 
to enormous economic cost as well 
as incalculable human suffering 
[2,3]. The economic consequences 
of each cancer case include the di-
rect and indirect costs of treatment, 
the income forgone by patients and 
their families unable to work during 
periods of treatment and illness, 
and, most importantly in economic 
terms, the productivity lost due to 
premature death, disability, and suf-
fering. Further, catastrophic health 
spending undermines the economic 
stability of families, often generating 
dynamic losses and forcing families 
into impoverishment and economic 
ruin that may extend far beyond the 
course of the disease. Broader es-
timates of economic consequences 
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also, and appropriately, take into ac-
count the perceived costs of human 
suffering. While a full estimate of the 
economic burden of cancer would 
take into account each of these cost 
components, several of them are dif-
ficult to calculate with available data.
A significant part of the economic 
and health burden of cancer could 
be avoided by expanding cover-
age of prevention, early detection, 
and treatment for specific cancers. 
Indeed, it is reasonable to consider 
that the additional financial invest-
ments in cancer care and control 
would be more than counterbal-
anced by reductions in the economic 
toll caused by the disease. This hy-
pothesis is analysed below.
The economic cost of cancer
A first approximation of the total 
annual economic cost of cancer is 
US$ 1.16 trillion, which is more than 
2% of total global gross domestic 
product. This figure is the sum of the 
costs of prevention and treatment, 
plus the annual economic value of 
disability-adjusted life years (DALYs) 
lost (a measure that combines years 
of life lost due to premature mortality 
and years of healthy life lost due to 
disability) as a result of cancer.
The estimate is derived as fol-
lows: First, the value of lost produc-
tivity due to premature death and 
disability is taken from a study of 
DALYs for 17 categories of cancer 
covering all cancer sites, which pro-
duced an estimate of US$ 921 billion 
for 2010 [3,4]. Second, based on an-
other recent study, the annual global 
economic cost of treating new (inci-
dent) cancer cases was assumed to 
be US$ 310 billion for 2010 [2,5,6]. 
Of this, 53% (US$ 163 billion) is 
due to medical costs, and 23% to 
the time of caregivers and the cost 
of transportation to treatment facili-
ties. The remaining 24% is attributed 
to productivity losses from time in 
treatment and associated disability; 
since this portion is also covered in 
the estimate of DALYs, it was not in-
cluded in the summation. Finally, the 
cost of prevention is assumed to be 
7% of the cost of treatment. This is 
a rough estimate that corresponds 
to the ratio of prevention to health 
spending in Canada [5,7]. Applied 
to the global treatment estimate of 
US$ 163 billion, the cost of preven-
tion of cancer is assumed to be just 
more than US$ 11.4 billion.
Although impressively high, the 
figure of US$ 1.16 trillion underes-
timates the total annual economic 
cost of cancer, for several reasons. 
The most important factor is lack of 
data on the substantial longer-term 
costs to families and caregivers, 
which often extend well beyond the 
first year of treatment. The figure 
also fails to account for the value 
that patients and families place on 
human suffering, which may be far 
higher than the productivity losses 
measured by DALYs.
An alternative method for esti-
mating the cost of cancer is to use 
a value of a statistical life (VSL) ap-
proach. This methodology, which 
includes substantially more of the 
variety of costs that are incurred by 
patients and their families, attempts 
to account for the value individuals 
themselves place on lost income, 
out-of-pocket spending on health, 
and pain and suffering. Based on an-
other recent study, the total 2010 VSL 
estimate of the global cost of cancer 
is US$ 2.5 trillion. Of this, close to 
US$ 1.7 trillion is attributed to high-
income countries and the remaining 
US$ 800 billion to low- and middle-
income countries (LMICs) [8].
Working from these estimates 
of the economic costs of cancer, it 
is possible to calculate the potential 
return on investments in expanding 
cancer care and control by determin-
ing values for two other key factors: 
the economic value of lives that 
could be saved by expanding ac-
cess to prevention, early detection, 
and treatment; and the costs of the 
expansion of cancer care and con-
trol that would be required to achieve 
these gains.
The “avoidable” cancer 
burden
A significant proportion of the cancer 
burden could be avoided through 
prevention, early detection, and 
treatment. Calculating the propor-
tion of years of healthy, productive 
life that could be saved and their 
value to both the economy and the 
individual is the key to estimating 
the economic benefit of investing in 
cancer care and control.
Fig. 6.7.1. A nurse delivers chemotherapy to a patient with Kaposi sarcoma at Neno 
District Hospital in Malawi. Kaposi sarcoma is among the most common cancers in 
Malawi, but it is highly treatable – chemotherapy can control Kaposi sarcoma cancer 
growth and help patients return to normal lives.
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These calculations require an 
assumption about the proportion 
of deaths that can be avoided. The 
literature on avoidable deaths has 
typically established premature death 
using an empirical approach to set an 
upper limit – for example, 64 years. 
Under this scenario, a death that oc-
curred before the age of 65 years (or 
any other upper limit) is considered 
avoidable. The selection of cancers 
that are considered either prevent-
able or treatable or both preventable 
and treatable (with or without earlier 
detection that might have resulted in 
either a cure or a significant increase 
in healthy life expectancy) is based 
on earlier research [9–15].
Each life expectancy scenario is 
applied to countries’ income-group-
specific GLOBOCAN estimates of 
mortality and age at death by can-
cer type [16,17]. Using a minimum 
standard of 65 years of life expec-
tancy, an estimated 32% of deaths 
can be avoided. Setting the standard 
for life expectancy at the level of the 
best-performing countries in each 
income region, 36% of deaths could 
be avoided. Finally, using life expec-
tancy of 75 years as the standard, 
an estimated 49% of cancer deaths 
are considered avoidable with pre-
vention, early detection, and/or 
treatment.
These estimates suggest, re-
spectively for each scenario, that 
there are 2.4, 2.7, and 3.7 million 
avoidable deaths from cancer per 
year. LMICs account for approxi-
mately 80% of this avoidable mortal-
ity in each life expectancy scenario.
Costs of treatment and 
prevention
Another factor that affects the cal-
culations of returns on investments 
is the dynamic nature of the costs 
of treatment and prevention. The 
estimate of the costs of treatment 
presented above and used as the 
baseline here – US$ 310 billion – 
does not account for the possibil-
ity of more effective primary and 
secondary prevention becoming 
available.
Several of the cancers that gen-
erate significant global investment 
in treatment are preventable, either 
by reducing exposure to risk factors, 
such as tobacco, or by vaccination, 
as for cervical cancer. Preventing 
the majority of these cancers means 
avoiding a considerable proportion 
of treatment costs. For several can-
cers with a high burden in LMICs – 
including Kaposi sarcoma and can-
cers of the cervix, liver, and (most 
importantly in terms of burden) lung – 
a considerable proportion of cases 
could be prevented or detected 
in precancerous stages, avoiding 
the far higher costs of treatment. 
A 90% reduction in cases (through 
prevention) for Kaposi sarcoma and 
cancers of the cervix, liver, and 
lung implies a reduction of at least 
20% in the total estimated costs 
of treating cancer – or approxi-
mately US$ 65 billion per year [18]. 
Prevention can also extend to other 
cancers with a lower overall burden, 
such as head and neck cancers, as 
well as stomach cancers (by treat-
ing Helicobacter pylori) [5].
Hence, with more effective pre-
vention, the global cost of treatment 
for cancer would be significantly 
less than what is currently being 
spent: rather than the estimated 
US$ 310 billion, it would be ap-
proximately US$ 246 billion. Adding 
the estimated cost of prevention 
(US$ 11.4 billion) produces an over-
all figure of about US$ 257 billion 
[19].
Fig. 6.7.2. Cancer patients participate in an art activity at the Advanced Paediatric Centre 
of the Post Graduate Institute of Medical Education and Research in Chandigarh, India. 
The activity was part of events to mark International Childhood Cancer Day.
Fig. 6.7.3. In China, participants in a clini-
cal trial for liver cancer prevention wait to 
have their blood drawn.
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Estimating the return on 
investments in expanding 
cancer care and control
The estimates in Table 6.7.1 com-
pare the economic value of lives 
saved in DALYs and VSL to the total 
costs of treatment and prevention. 
These estimates provide approxi-
mations of what the world could 
have saved in 2010 by investing 
in cancer care and control. They 
range from the most optimistic re-
turns of US$ 230 billion and almost 
US$ 1 trillion (US$ 940 billion) in 
terms of DALYs and VSL [18], re-
spectively, to the lower bounds of 
US$ 10 billion and US$ 531 billion 
[20], respectively.
A longer-term view
Taking a longer-term, dynamic view 
of costs and benefits of treatment 
for cancer provides a more complete 
vision of the costs and benefits of 
investing in expanded access to 
cancer care and control. Existing 
studies are scarce; this section is 
restricted to a discussion of issues, 
and further research in this area is 
recommended.
Estimates of the total value of 
lost output from cancer, based on 
macroeconomic modelling for 2011 
to 2030 – an approach that differs 
from the ones presented above by 
taking into account accumulated 
losses over time – suggest substan-
tially higher cumulative economic 
losses of US$ 2.9 trillion for LMICs 
and US$ 5.4 trillion for high-income 
countries [8]. These macroeconomic 
models show that between 2011 and 
2030, noncommunicable diseases – 
including cancer, cardiovascular dis-
ease, chronic respiratory disease, 
diabetes, and mental health – repre-
sent a global cumulative output loss 
of up to US$ 47 trillion [8].
A further, and significant, con-
sideration in modelling the costs 
and benefits of investing in cancer 
care and control is that the dimen-
sions and boundaries of prevention 
and treatment change over time. 
Cancers that are considered largely 
untreatable (liver cancer), or costly 
to treat (cervical cancer), can now be 
prevented by applying relatively new 
medical technologies and vaccines. 
As science develops, cancers of in-
fectious origin that tend to be more 
common in LMICs will become in-
creasingly susceptible to prevention, 
and the global costs of treatment can 
be expected to decline [1]. Hence, 
estimates of future global costs of 
cancer treatment may be overstated 
as science progresses and identifies 
new options for prevention that are 
less costly than treating the cancers 
that primarily affect people in LMICs.
The cost of producing and de-
livering drugs and vaccines can 
fall over time, especially as innova-
tive global financing platforms are 
developed and implemented [21]. 
This has been amply demonstrated 
by the experience with antiretroviral 
drugs for HIV/AIDS and by huge re-
ductions in the cost of the hepatitis 
B virus vaccine, achieved in part 
through the GAVI Alliance, a pub-
lic–private partnership committed to 
increasing access to immunization 
in LMICs. A notable example is the 
recent GAVI-spurred drop of more 
than 95% in the price of the human 
papillomavirus vaccine, from the 
US$ 130 per dose that prevails in 
high-income countries to less than 
US$ 5 per dose in the lowest-income 
countries. Earlier, the Pan American 
Health Organization Revolving Fund 
had garnered an almost 90% reduc-
tion, to US$ 14 per dose. Although 
the vaccine is still unaffordable for 
Table 6.7.1. Sensitivity analysis of economic returns to investing in cancer care and control
Cost of care and controla Economic cost of cancer
(billions of US dollars)
DALYs:
valued at US$ 921 billion
VSL less OOP:
valued at US$ 2.37 trillion
Avoidable deaths Avoidable deaths
49%b 36%c 49%b 36%c
Scenario 1. Assuming full cost of treatment based on Bloom et al. 
(2011) [8] + cost of prevention: 310 + 11 = US$ 321 billion
130 10 839 531
Scenario 2. Scenario 1 with reduced costs of treatment based on 
preventing 90% of Kaposi sarcoma and cancers of the cervix, liver, 
and lung: (310 – 64) + 11 = US$ 257 billion
194 75 904 596
Scenario 3. Scenario 1 with reduced costs of treatment based on 
preventing 90% of all potentially preventable cancers: (310 – 100) 
+ 11 = US$ 221 billiond
230 110 940 632
DALYs, disability-adjusted life-years; OOP, out-of-pocket health spending by families; VSL, value of a statistical life.
a Each cell equals: [(economic cost of cancer) * (% mortality avoided with treatment or prevention)] – (medical and non-medical costs of treating new cancer 
cases + costs of prevention).
b 49% of cancer mortality is assumed avoidable using a scenario of achieving the levels of the best-performing countries – the social justice approach.
c 36% of cancer mortality is assumed avoidable using a scenario of achieving the levels of the best-performing country in each income region.
d 90% reduction in incidence and hence treatment costs for Kaposi sarcoma and cancers of the cervix, larynx, liver, lung, nasopharynx, other pharynx, and 
stomach.
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Towards understanding the economics of cancer: priority areas for research
Felicia Marie Knaul
Research in health economics – 
especially towards a better under-
standing of the global distribution of 
costs and the most effective oppor-
tunities to achieve impacts – could 
greatly contribute to reducing both 
the economic and the health burden 
of cancer. Yet, economic analysis 
of cancer is a nascent area of re-
search that to date has focused on 
high-income countries.
Based on an initial review of the 
literature, there has never been a 
comprehensive body of work on the 
economics of the global cancer bur-
den. Core analysis is, however, be-
ing undertaken for an upcoming vol-
ume as part of the third round of the 
Disease Control Priorities project. 
This is a follow-up volume to the 
second edition of Disease Control 
Priorities in Developing Countries 
(published in 2006), which includes 
several chapters applying econom-
ics to cancer care and control [1–3].
Although overall work on the 
economics of cancer is sparse, a 
noteworthy exception is the litera-
ture on risk factors (or risky be-
haviour), and especially tobacco 
consumption and its control [4–8]. 
Indeed, the existing literature about 
risky behaviour speaks to the rich 
array of techniques that econom-
ics, and especially health econom-
ics, can contribute to reducing the 
global burden of cancer and closing 
the cancer divide between rich and 
poor.
To fully understand the econom-
ics of cancer, it will be necessary 
to analyse each component of the 
cancer care and control continuum: 
primary prevention, secondary 
prevention, diagnostics, treatment, 
survivorship care, pain control, and 
palliative care [9]. This is particu-
larly important because cancer 
covers a complex set of diseases: 
some are associated with infection 
or behaviour; others are largely de-
termined by stage at detection; and 
yet another, overlapping, subset is 
susceptible to treatment.
There are a host of opportuni-
ties for research on the econom-
ics of cancer, based on the field of 
health economics – an area that 
has blossomed over the past two 
to three decades [10]. The research 
should consider both economics 
of health (determinants of cancer 
outcomes) and economics of health 
care (the market for the provision of 
cancer care, including global health 
and health systems), including:
• the economics of global cancer 
and the relationship between the 
disease and economic develop-
ment, using dynamic analysis of 
the impact on economic growth 
and the spillover effects on hu-
man and social development and 
the “costs of inaction” [2];
• the analysis of current and fu-
ture demand for cancer care and 
control globally, to project global 
cancer care spending growth un-
der different scenarios for prices 
and investment in prevention and 
treatment;
• determinants of cancer incidence 
and outcomes, the effect of pov-
erty and socioeconomic status, 
and the social and economic de-
terminants of access to and use 
of health services;
• spending patterns by families 
over time on cancer care and 
control and under different incen-
tive and insurance scenarios, and 
over time on long-term care;
• analysis of the supply of cancer 
care and control services glob-
ally, and the role of incentives for 
expanding access, with quality, at 
the least possible cost and with 
greatest equity, considering all 
aspects of service provision and 
delivery: pharmaceuticals, pri-
mary care-based services, hos-
pital-based services, the health- 
care workforce, technologies, and 
so on;
• intellectual property and patent 
markets for drugs and vaccines, 
and the role of innovative financ-
ing platforms such as the GAVI 
Alliance [11];
• the economics of pain control and 
palliation, which spans the global 
regulatory environment and eco-
nomics of access;
• the medical workforce and the 
optimal supply of human re-
sources to respond to current 
and future needs for cancer care 
and control;
• health system financing, covering 
innovations that would optimize 
the incentive structure for cancer 
care and control in different re-
source settings;
• health system reform analysis, 
including the design, evalua-
tion, and implementation of pro-
grammes and policies; and
• other research that could both 
benefit from and contribute to 
some of the more novel areas 
of current health systems work – 
such as the diagonal approach 
[9,12,13] and delivery science – 
and avoid single-intervention 
analysis by considering value 
chains to analyse complex pro-
cesses and diseases and by 
using the diagonal approach to 
merge horizontal and vertical 
interventions to facilitate syner-
gistic investments that generate 
system-wide improvements [14].
Applying techniques of health 
economics, and integrating them 
with novel frameworks in health 
systems research, would generate 
new knowledge especially applica-
ble to improving the capacity to re-
spond to the global cancer burden 
with more appropriate strategies for 
lower-income settings. Yet to truly 
improve our understanding of the 
economic burden of cancer globally 
and identify the most appropriate 
ways to face this burden, a multi-
disciplinary approach is required 
that links economists to a myriad of 
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many countries, this price reduction 
marks a huge step forward and was 
accomplished in only half a decade 
[22].
Further, the costs of care – and 
hopes for cure – for several preva-
lent cancers like breast, colorectal, 
and cervical cancers depend on the 
stage at which they are diagnosed. 
Thus, investing in earlier detection, 
much of which depends on devel-
oping and implementing innovative 
delivery models, can greatly reduce 
the cost per year of life saved. At the 
same time, population-wide screen-
ing for cancer can be very costly, 
making it a priority to develop inno-
vations for earlier detection, many of 
which will be especially important in 
LMIC settings.
Many of the dynamic aspects of 
improving cancer care and control – 
such as global innovations in financ-
ing platforms and country-level inno-
vations in early detection – are part 
of developing a science of delivery 
around cancer [23].
Research in health economics, 
largely unexplored to date, could 
inform policy and provide recom-
mendations that would help reduce 
the financial and human burden of 
cancer. Establishing economic in-
centives that help change behaviour 
and increasing the efficacy of ser-
vices are two avenues (see “Towards 
understanding the economics of 
cancer: priority areas for research”).
Conclusions
Health is an investment, rather than 
a cost. Yet this idea has not suffi-
ciently permeated the discussions 
on cancer care and control. Planning 
for cancer prevention and manage-
ment must be integrated in a for-
ward-looking manner into all policy 
agendas to achieve the most effec-
tive investment of health spending. 
Adopting an investment approach to 
health reshapes human, economic, 
social, and sustainable development 
agendas.
Chronic disease, including can-
cer, is a leading global economic 
risk. The drain of tobacco alone on 
the global economy exceeds the to-
tal annual expenditure on health of 
all LMICs. This makes investment 
in both prevention and treatment a 
priority for health and for economic 
development.
Between one third and one half 
of cancer deaths can be avoided 
with prevention, early detection, and 
treatment. Thus, between 2.4 mil-
lion and 3.7 million deaths are 
avoidable per year, 80% of which 
occur in LMICs.
Given the huge and avoidable 
suffering caused by cancer, meet-
ing the unmet need for cancer care 
and control in LMICs is a moral im-
perative. In addition, and from an 
economic standpoint, expanding 
prevention, detection, and treat-
ment of cancer yields benefits that 
exceed the costs.
The total annual economic 
cost of cancer – not including 
longer-term costs to families and 
caregivers – was approximately 
US$ 1.16 trillion in 2010, which 
amounts to more than 2% of total 
global gross domestic product. 
By contrast, investing in cancer 
care and control yields a positive 
annual return on prevention and 
treatment because of the number 
of deaths that are potentially avoid-
able. Global economic savings of at 
least US$ 100–200 billion could be 
achieved by avoiding deaths, and 
other disciplines in health and even 
in other sectors. The challenge 
ahead is to both increase econom-
ics research and integrate it into 
efforts to better understand cancer 
globally.
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hence lost healthy years of pro-
ductive life, through treatment and 
prevention. Taking into account the 
human cost of suffering – the value 
that individuals place on reduced 
suffering and illness – the savings 
are at least US$ 500 billion and 
could reach almost US$ 950 billion.
Yet, economic analysis of the 
global cancer burden is a nascent 
field, and most research to date has 
focused on high-income countries. 
Research in this area could great-
ly contribute to reducing both the 
economic and health burden. The 
agenda for this research is ample, 
and one of the main limiting factors 
is the lack of adequate data. Indeed, 
better data are required to promote a 
better understanding of the econom-
ics of cancer, and any initiative to 
collect these data could and should 
be linked to existing initiatives to im-
prove global cancer registries [24].
To truly improve our understand-
ing of the economic burden of cancer 
globally, a multidisciplinary approach 
is required that links economists to 
a myriad of other disciplines. Future 
efforts should seek to increase 
economics research and also to in-
tegrate it into efforts to better under-
stand cancer globally.
Planning for the future requires 
harnessing markets in ways that 
can stimulate innovation, encourage 
savings that reduce prices, promote 
investments that generate system-
wide improvements that reduce the 
impact of cancer and also accrue 
to other diseases, spread benefits, 
and reduce costs. These economic 
benefits could be much greater if the 
potential cost savings from innova-
tive delivery and financing, com-
bined with more equitable pricing 
of drugs and other therapies, could 
be achieved. Adopting a diagonal 
approach using care delivery value 
chains can ensure that the potential 
synergies and shared benefits of in-
terventions are maximized and fully 
taken into account.
A future where prevention, early 
detection, and treatment become 
more accessible to patients and 
health systems in LMICs is one that 
builds on the “economics of hope”. 
Neither the costs of prevention nor 
the potential benefits of extending 
cancer care and control should be 
taken as fixed, given the many op-
portunities that exist to increase ac-
cess and reduce the global burden 
of cancer.
This chapter is adapted from Chapter 3 in 
Knaul FM, Gralow JR, Atun R, Bhadelia A, eds 
(2012). Closing the Cancer Divide: An Equity 
Imperative. Based on the work of the Global 
Task Force on Expanded Access to Cancer 
Care and Control in Developing Countries. 
Cambridge, MA: Harvard Global Equity 
Initiative. Distributed by Harvard University 
Press. © 2012 by President and Fellows of 
Harvard College acting through the Harvard 
Global Equity Initiative. Reprinted by permis-
sion of the Harvard Global Equity Initiative.
Fig. 6.7.4. A female adolescent receives an intramuscular immunization from a nurse. 
The availability of vaccines to prevent cervical cancer represents one of the most im-
mediate advances in cancer prevention achieved in the past decade.
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Cancer control in Peru: “El Plan 
Esperanza” – the Hope Plan
Carlos Vallejos 
Peru has a population of about 
30 million people, and the region 
of Lima (the capital city) is home 
to about one third of the national 
population. Peru allocates 5.1% of 
its gross domestic product to ex-
penditure on health. The growth of 
the Peruvian economy in the past 
two decades has led to an increase 
in life expectancy, from 66.7 years in 
1995 to 74.1 years in 2010. Prostate 
cancer (25.1% of all cases), stom-
ach cancer (15.7%), non-Hodgkin 
lymphoma (5.8%), and lung cancer 
(5.4%) are the most frequent ma-
lignant tumours in men, and cervi-
cal cancer (19.5%), breast cancer 
(18.9%), stomach cancer (11.5%), 
and colorectal cancer (5.1%) are 
the most common in women. Peru’s 
first institution for specialized cancer 
treatment was the Instituto Nacional 
de Enfermedades Neoplásicas 
(INEN), which was founded in 1939 
and is supported by government 
funds. INEN was designated as an 
autonomous institution in 1985 and 
is required to formulate, regulate, 
and advise on the development of 
health policies in the field of cancer.
Problems frequently faced by 
oncologists in Peru have been: 
(i) tumours in advanced stages, 
mainly because there is a long pe-
riod between the first signs of cancer 
and seeking specialist attention; 
(ii) lack of adherence to treatment, or 
delay in the treatment, due to costs 
and because sometimes patients 
have to travel long distances to re-
ceive treatment; and (iii) inadequate 
follow-up. These three problems are 
certainly related to the geographical 
distance between a patient’s home 
and a treatment facility. Until 2000, 
INEN was the only public centre for 
cancer care in Peru. The develop-
ment of new policies for the decen-
tralization of cancer care led to the 
inauguration of a new specialized 
centre covering a major population.
In 2007, Peru implemented the 
first national cancer control plan in 
Latin America. Priority was accorded 
to the most relevant cancers in 
Peru – cancers of the breast, cervix, 
stomach, lung, and prostate – and 
beneficial results were obtained. 
In addition, new policies and strat-
egies were developed to provide 
access to medical attention for the 
poorest people under a universal 
insurance coverage. In 2011, a 
newly fledged budgetary strategic 
programme (budget by results) for 
cancer control was released, which 
provided US$ 10.3 million, with the 
benefits being directed mainly to 10 
regions (selected according to pri-
orities in terms of population size 
and cancer incidence). Meeting 
strategic goals has led to an in-
crease in the budget for nationwide 
activity to US$ 29.8 million for 2012. 
These state policies established in 
the past 10 years have established 
the foundation for the current “Plan 
Esperanza” (Hope Plan).
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Cancer control in Turkey: an encouraging 
national cancer control plan for the future
Ezgi Hacikamiloglu, Guledal Boztas, Murat Gultekin, and Murat Tuncer 
Turkey’s national cancer control 
programme, which was prepared 
and initiated in cooperation with 
national and international organi-
zations to decrease the number of 
cancer-related deaths, consists of 
four main pillars: cancer registry 
activities, cancer prevention, can-
cer screening and early diagnosis, 
and cancer treatment and palliative 
care.
Cancer registry activities
Since 2002, in conjunction with 
passive registration, active cancer 
registration has also been imple-
mented. There are 16 active cancer 
registration centres in 15 cities in 
Turkey (50% population cover-
age). Currently, four of the active 
registration centres are accredited 
by IARC. The cancer registration 
centre in the city of İzmir is desig-
nated an international training cen-
tre (hub) by IARC. The implementa-
tion of active registration centres in 
all 81 cities, with a 100% coverage 
rate, is planned to be completed by 
the end of 2015.
Cancer prevention
Cancer prevention in Turkey is man-
aged under certain programmes. 
The nationwide programmes are 
the Alcohol Control Programme; 
the Healthy Nutrition, Obesity Con- 
trol, and Promotion of Physical 
Activity Programmes; the Reduction 
of Excessive Salt Consumption 
Programme; the Strategic Asbes- 
tos Control Programme; the Ra- 
don Mapping Programme; and 
the National Tobacco Control 
Programme. The National Tobacco 
Control Programme, which was start-
ed in 2008, is extremely successful 
with excellent outcomes. Tobacco 
consumption rates decreased from 
33.6% to 27.5%, and Turkey be-
came the first country in the world 
to implement all the tobacco control 
measures of MPOWER [1–3].
Cancer screening and early 
diagnosis
A Cancer Early Diagnosis, Screen- 
ing, and Training Centre has been 
opened in each city in Turkey. 
Population-based screening and 
public training programmes about 
breast, cervical, and colorectal 
cancers are being organized within 
these centres totally free of charge. 
In 2012, the national cancer screen-
ing standards were revised as fol-
lows: breast cancer screening every 
2 years from the age of 40 years; 
colorectal cancer screening, by 
using immunological faecal occult 
blood testing in conjunction with 
colonoscopy, for all people aged 
51 years and 61 years; and cervi-
cal cancer screening implementing 
human papillomavirus (HPV) DNA 
testing. Nationwide software pack-
ages have been produced to follow 
European Union quality criteria on 
screening. By means of 130 new 
mobile screening units, digitiza-
tion of mammography, and central 
mammography reporting units, and 
by evoking the potential help of 
family physicians and screening via 
HPV tests, Turkey aims to raise the 
population screening rates to 70% 
by 2015.
Cancer treatment and palliative 
care
Cancer treatment is free of charge 
for all citizens in Turkey, and all 
standard treatments are available 
in the country. Treatment facilities 
are implemented according to the 
2023 strategic investment plans, 
according to the disease burden, 
geographical transportation, and 
population dynamics. Also, domes-
tic production of some chemother-
apeutics and opioids has already 
started. One of the basic essentials 
for palliative care, which was start-
ed in 2010, is providing health care 
at home. This service is also being 
provided for terminal-stage cancer 
patients. Palliative care legislation 
has been prepared and is planned 
to be launched by the end of 2013. 
In addition, opioid legislation is be-
ing evaluated to increase acces-
sibility. Turkey aims to implement 
a population-based palliative care 
system based on family physicians 
and home care teams supported by 
more than 200 palliative care units 
within the next 5 years.
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Summary
Recent studies of the hazards of 
people in the United Kingdom, 
USA, or Japan who began smok-
ing in adolescence or early adult 
life show loss of about 10 years of 
life expectancy if they continue, and 
avoidance of more than 90% of the 
excess risk if they stop before age 40 
(and preferably well before age 40). 
Smokers who did not start in early 
adult life have much smaller hazards 
in middle and old age. Hence, when 
smoking becomes common among 
a population of young adults, the full 
eventual effects of tobacco on mor-
tality rates in middle and old age take 
more than half a century to emerge 
in that population. For women in 
many developed countries and men 
in many other countries, there will 
be a large increase in tobacco- 
attributed mortality over the next 
few decades as a result of increas-
es in smoking that have already 
happened, unless there is wide-
spread cessation.
Cancer mortality and overall 
mortality
Taking all countries in the world to-
gether, smoking is by far the most 
important cause of cancer, and al-
though tobacco-attributed cancer 
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mortality is now falling in some 
populations in developed countries, 
worldwide it is increasing. Smoking 
can cause death not only from lung 
cancer (the main neoplastic hazard) 
but also from cancer of the mouth, 
pharynx, larynx, oesophagus, stom-
ach, pancreas, liver, kidney, bladder, 
or cervix [1]. It also causes more 
deaths from other diseases (e.g. 
heart disease, stroke, chronic ob-
structive lung disease, tuberculosis, 
and pneumonia) than from cancer.
This Perspective summarizes 
the full eventual effects on lung 
cancer mortality, overall cancer 
mortality, and all-cause mortality 
of starting to smoke in early adult 
life and continuing to do so and, 
conversely, the full eventual effects 
among smokers who did start when 
young of cessation at various ages, 
in comparison with the hazards 
they would have faced if they had 
continued smoking.
In general, among cigarette 
smokers who started in early adult 
life, those who stop before middle 
age (here defined as ages 35–69) 
gain about 10 years of life expec-
tancy. This is now known to be true 
for both men and women [2–5]. It 
is likely to be true in any popula-
tion where the smokers who have 
not yet reached middle age started 
smoking cigarettes in early adult 
life, even if in that population the 
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effects of smoking on mortality in 
middle and old age (i.e. in previous 
generations) are not yet substantial, 
because those who started in early 
adult life will, if they continue smok-
ing, eventually experience substan-
tial hazards in middle and old age.
Effects of smoking cigarettes 
throughout adult life
Cigarette smokers who start in ear-
ly adult life are at far greater risk in 
later adult life than otherwise similar 
smokers who start somewhat later 
[6]. This implies a remarkably long 
delay of half a century or more be-
tween cause and full effect. As long 
as due allowance is made for this 
delay, reliable quantitative predic-
tions can be made of the substantial 
hazards that will eventually be faced 
by those who have been cigarette 
smokers since early adult life but are 
still only in their twenties, thirties, or 
forties if they continue to smoke, and 
of the substantial benefits for such 
smokers of stopping at various ages.
Cigarette smoking is extraor-
dinarily destructive (Box P7.1; 
Figs P7.1, P7.2). It is common in 
many populations, and where it has 
been widespread among young 
adults for many decades, at least half 
of all persistent cigarette smokers 
are eventually killed by it, unless 
they stop. Bidi smoking (bidis con-
sist of a small amount of tobacco 
wrapped in the leaf of another 
plant), which is common in parts of 
South Asia, can cause similar risks 
[7–8].
Cigarette smoking causes rel-
atively few deaths before about 
35 years of age but causes many 
deaths in middle and old age. 
Although some of those killed by 
tobacco in middle age might have 
died soon anyway, many would 
have lived on for another 10, 20, 30, 
or more years (Box P7.1).
British men, the first severely 
affected population to be 
studied
Studies of British men born in the 
first few decades of the 20th century 
were particularly informative about 
the full lifelong hazards of smoking 
and the benefits of stopping because 
this was the first large population in 
which many had begun to smoke 
cigarettes in early adult life and con-
tinued to do so. By 1970, Britain had 
the worst tobacco-attributed mortal-
ity rates in the world [9–11]. The life-
long effects of persistent cigarette 
smoking, and the corresponding 
benefits of stopping, can therefore 
be illustrated by Doll’s study of male 
British doctors born during the first 
few decades of the 20th century 
and followed prospectively through-
out the second half of the century 
(Fig. P7.1) [2].
The doctors who smoked (and 
those who later stopped smoking) 
had on average begun at 18 years 
of age. There were no big differ-
ences between smokers, former 
smokers, and never-smokers in 
occupation, obesity, or alcohol 
consumption [12]. As all were 
doctors, they were easily traced 
even if they emigrated, and the 
underlying causes of most deaths 
were recorded reliably.
Fig. P7.1A compares the ciga-
rette smokers with the never-smok-
ers, showing a 10-year difference in 
life expectancy. During middle age 
(35–69), 19% of the never-smokers 
and 42% of the cigarette smokers 
died (i.e. the respective probabili-
ties of survival from age 35 to age 
70 were 81% and 58%). Much of 
this absolute difference of 23% in 
mortality was actually caused by 
smoking, because it mainly involved 
differences in the numbers dying 
from diseases that can be caused 
by smoking (lung cancer, heart dis-
ease, chronic lung disease, etc.).
The risk is big, if they continue 
smoking
• At least half are eventually killed 
by smoking, if they continue. 
(Among persistent cigarette 
smokers, male or female, the 
overall relative risk of death is 
greater than 2 throughout mid-
dle age and well into old age. 
Thus, among smokers of a giv-
en age, more than half of those 
who die in the near future would 
not have done so at never-
smoker death rates.)
• On average, smokers lose at 
least 10 years of life. (This av-
erage combines a zero loss 
for those not killed by tobacco 
with a loss of much more than 
10 years for those who are 
killed by it.)
Those killed in middle age 
(35–69 years of age) lose many 
years of life
• Some of those killed in middle 
age might have died soon any-
way, but others might have lived 
on for another 10, 20, 30, or 
more years.
• On average, those killed in mid-
dle age lose about 20 years of 
never-smoker life expectancy.
Stopping smoking works
• Those who stop before age 40 
(and preferably well before age 
40) avoid more than 90% of the 
excess risk among those who 
continue to smoke. Those who 
stop before age 30 avoid more 
than 97% of the smokers’ ex-
cess risk.
• Those who have smoked ciga-
rettes since early adult life but 
stop at 60, 50, 40, or 30 years of 
age gain, respectively, about 3, 
6, 9, or almost the full 10 years of 
life expectancy, compared with 
those who continue smoking.
Box P7.1. Main findings for the individual who becomes a cigarette smoker in adolescence or early adult life.
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Twenty-first century hazards 
in women born around 1940 
in the United Kingdom and 
the USA
Among British women, few born 
early in the 20th century smoked 
from early adult life, but many born 
around 1940 did so and were there-
fore at high risk in later adult life if 
they continued to smoke. A recent 
prospective study of 1.3 million such 
women found hazards comparable 
to those in men [3].
Fig. P7.2A shows the relation-
ship between daily cigarette con-
sumption and all-cause mortal-
ity among these women during 
the 2000s, when they were in their 
sixties. On average, smokers had 
3 times the overall mortality rate 
of otherwise comparable never-
smokers. This 3-fold relative risk is 
standardized for age and for many 
other factors. It therefore means 
that about two thirds of the deaths 
of smokers would not have oc-
curred when they did if the smok-
ers had had the same death rates 
as otherwise similar nonsmokers. 
Smoking even just a few cigarettes 
a day was sufficient to double the 
overall mortality rate.
Similarly extreme smoker ver-
sus nonsmoker mortality ratios dur-
ing the 2000s, and a similar 10-year 
difference in survival, have recently 
been reported for men and women 
in the USA and in Japan [4,5,13].
Cessation, lung cancer 
mortality, and all-cause 
mortality in the United 
Kingdom and the USA
Smokers who stop before age 40 
(preferably well before age 40) avoid 
more than 90% of their risk of being 
killed by tobacco, gaining on aver-
age more than 9 extra years of life 
expectancy. Fig. P7.1B shows that in 
Doll’s study of British doctors, men 
who stopped at about 40 (35–44) 
years of age avoided about 90% of 
the excess risk they would have suf-
fered if they had continued smok-
ing. Those who stopped at about 60, 
50, 40, or 30 years of age gained, 
Fig. P7.1. The full eventual effects of smoking from early adult life in men in the United Kingdom (born 1900–1930), showing the 
lifelong hazards of smoking and the benefits of stopping at age 40 among male British doctors followed up until old age. (A) Survival 
from age 35 in continuing smokers and never-smokers, showing 10-year loss. (B) Survival from age 40 in smokers, never-smokers, 
and those who stopped at age 35–44. Follow-up was from 1951 until 2001, with smoking recorded in 1951 and again every few 
years until 2001. The smokers and the former smokers had both started at mean age 18 years.
Fig. P7.2. The full eventual effects of smoking from early adult life in women (from 
the Million Women Study during the 2000s of British women born around 1940): 
multivariable-adjusted relative risks in never-smokers and in continuing smokers, by 
daily dose, (A) for all-cause mortality and (B) for lung cancer mortality. The smokers had 
started at mean age 19 years. For each category, the area of the square is inversely 
proportional to the variance of the category-specific log risk, which also determines the 
confidence interval.
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respectively, about 3, 6, 9, or almost 
the full 10 years [2].
Fig. P7.3A shows, based on the 
much larger Million Women Study, 
more precise evidence that stop-
ping at age 40 avoids about 90% of 
the excess mortality among those 
who continue smoking [3]. Similarly 
extreme benefits of having stopped 
at 30 or 40 years of age have been 
reported from studies of mortality in 
the USA during the 2000s [4,5].
Lung cancer is one of the main 
diseases caused by smoking. Even 
though it accounts for less than half 
of all smoking-attributed mortality, 
when the lung cancer death rates 
among persistent cigarette smok-
ers, former smokers, and never-
smokers are compared, the relative 
risks are so extreme that the long-
term hazards of smoking and the 
benefits of stopping can be seen 
particularly clearly [3,14,15].
Fig. P7.3B shows the lung can-
cer findings for smokers by age at 
cessation in the Million Women 
Study [3]. Although the former 
smokers who stopped at about age 
30, 40, or 50 still had a highly signif-
icant excess lung cancer risk some 
decades after stopping, there is a 
large absolute difference between 
the risks in those who stopped at 
these ages and in those who con-
tinued smoking.
Those who stopped at 30 avoid-
ed 97% of the excess lung cancer 
risk a few decades later in those 
who continued (i.e. they had only 
3% of the excess risk, with confi-
dence interval 2–4%), and those 
who stopped at 40 avoided 90% of 
the excess lung cancer risk in those 
who continued (i.e. they had only 
10% of the smokers’ excess risk).
Comparable findings have re-
cently been reported for men and 
women in the USA [4,5].
Evolution of the epidemic in 
male and female smokers in 
the USA
The report by Thun et al. [5] is partic-
ularly illuminating because it spans a 
50-year period (1960–2010) during 
which there was a more than 10-fold 
increase in the excess lung cancer 
mortality among female smokers as 
the epidemic matured. It describes 
three separate large studies – one in 
the 1960s, one in the 1980s, and one 
in the 2000s – that recorded each 
woman’s smoking and then moni-
tored lung cancer rates over the next 
few years among women who were 
older than 55 years. The age-stand-
ardized death rate from lung cancer 
in women who had never smoked 
was about the same in all three stud-
ies because there has been no big 
change in nonsmoker lung cancer 
rates in the USA.
The lung cancer risk ratio com-
paring current smokers with other-
wise similar never-smokers was, 
however, very different in the three 
studies (Table P7.1): only 3-fold in 
the 1960s, 13-fold in the 1980s, 
and 26-fold in the 2000s (similar to 
the 24-fold risk ratio in the Million 
Women Study in the 2000s in the 
United Kingdom). This is because 
in the USA women older than 55 
who were smokers in the 1960s had 
not been smoking ever since early 
adult life, whereas most who were 
smokers in the 2000s had been do-
ing so.
Note that in the USA many 
women who were young smokers 
in the 1960s (when their mothers 
and grandmothers were enjoying 
Fig. P7.3. The benefits of stopping at about 30, 40, or 50 years of age in a population where substantial effects of smoking are 
already apparent (from the Million Women Study during the 2000s of British women born around 1940): multivariable-adjusted 
relative risks (1.0 for never-smokers) in ex-smokers and in current smokers, (A) for all-cause mortality and (B) for lung cancer 
mortality. The group of continuing cigarette smokers and the groups who stopped at ages 25–34, 35–44, or 45–54 had all started 
at mean age about 19 years and all smoked about 15 cigarettes per day. The area of each square is inversely proportional to the 
variance of the log relative risk (vs never-smokers), which also determines the confidence interval.
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relatively low lung cancer rates 
in middle and old age) had been 
smoking all their young adult lives, 
so those of them who kept on smok-
ing for the next 40 years went on to 
become the older smokers in the 
2000s with high lung cancer rates 
(much higher than those in previous 
generations of women).
Underestimation of eventual 
hazards in studies of other 
populations
Cigarette consumption was low 
throughout the world in 1900, but 
among men in many developed 
countries, such as the United 
Kingdom and the USA, it increased 
substantially during the first few 
decades of the 20th century [1]. In 
recent decades it has also increased 
substantially among women in many 
developed countries and among 
men in many developing countries, 
including China [16].
When in a particular popula-
tion there is an upsurge of cigarette 
smoking among young adults, it 
will be 40 or more years before the 
main upsurge of tobacco-related 
deaths in middle age is seen, and 
then another 20 years before the 
main upsurge of tobacco-related 
deaths in old age. Thus, even in 
populations where there is not yet 
a high death rate from smoking (be-
cause relatively few people who are 
now in middle or old age have been 
cigarette smokers throughout adult 
life), many of the young adults who 
smoke began to do so in adoles-
cence or early adult life, so decades 
hence they will face substantial 
risks in middle and old age if they 
continue, and they have much to 
gain from prompt cessation.
Many previous studies of smok-
ing and disease were in populations 
where the middle-aged or, particu-
larly, older smokers had not been 
smoking cigarettes throughout adult 
life. The risks found by comparing 
smokers and never-smokers (or for-
mer smokers) in those studies may 
therefore greatly underestimate 
the risks that the younger ciga-
rette smokers of today will eventu-
ally face if they continue. Hence, in 
those previous studies the benefits 
of cessation appear to be substan-
tially less than the benefits that the 
younger cigarette smokers of today 
would gain from cessation (in com-
parison with the risks they would 
face if they were to continue). Thus, 
for example, earlier studies that 
suggested relatively small excess 
risks among smokers in Japan have 
been succeeded by a recent study 
that shows there are now large risks 
among those in Japan who contin-
ue to smoke [13].
In many past studies the pro-
portional excess mortality in mid-
dle and old age from smoking was 
greater among male than among 
female smokers, but this was 
chiefly because male smokers had 
smoked cigarettes more intensively 
when young than had female smok-
ers. Recent studies of women in the 
United Kingdom and the USA show, 
however, that smoking cigarettes 
throughout adult life eventually pro-
duces about as great a proportional 
increase in female as in male over-
all death rates, so in terms of years 
of life expectancy lost, the even-
tual hazards of persistent cigarette 
smoking (and the corresponding 
benefits of cessation) will be about 
as great for women as for men.
Likewise in China, the hazards 
that younger cigarette smokers will 
face in middle and old age may 
well be substantially greater than 
the risks now seen among Chinese 
smokers in middle and old age [17]. 
Indeed, for any cigarette smoker, 
male or female, in any part of the 
world who started smoking sub-
stantial numbers of cigarettes when 
young and has continued, the even-
tual hazards may well be similar: 
about half will be killed by smoking 
unless they stop, and cessation be-
fore age 40 (preferably well before 
40) would avoid more than 90% of 
that risk.
In any population in the world, 
therefore, the prevalence of ciga-
rette (or bidi) smoking among 
young adults can be used as a 
proxy to predict reasonably reliably 
the eventual future impact of smok-
ing on mortality in that population 
several decades hence if those 
who now smoke continue to do so, 
and to predict the importance for 
those who now smoke of prompt 
cessation.
Contrasting national trends in 
tobacco-attributed mortality 
at ages 35–69
In many countries the trends in over-
all cancer mortality in the past few 
decades have been dominated by 
the delayed effects of long-past in-
creases in cigarette smoking among 
young adults and, more recently, by 
the more rapid effects of widespread 
cessation. The United Kingdom, the 
USA, and Poland offer contrasting 
examples of this (Figs P7.4–P7.9).
By 1970, male tobacco-attrib-
uted mortality rates in the United 
Kingdom were the worst in the 
Table P7.1. Maturing of the lung cancer epidemic in male and female smokers in the USA from the 1960s to the 2000s: ratio of 
lung cancer death rates, current smoker versus never-smoker, in three large prospective studies
Sex
Ratio (95% confidence interval)a
1959–1965 1982–1988 2000–2010
Male 12 (10–16) 24 (21–28) 25 (22–28)
Female 3 (2–4) 13 (11–14) 26 (23–28)
a Multivariable-adjusted lung cancer mortality ratio, current smoker versus never-smoker (age > 55 years), and 95% confidence interval. Age-standardized 
never-smoker lung cancer rates were similar in different time periods (showing no significant trend) and in men and women.
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world, with smoking causing well 
over half of all cancer mortality and 
almost half of all mortality at ages 
35–69, and female tobacco-attrib-
uted mortality was rising (Figs P7.4, 
P7.5). Over the past few decades 
in the United Kingdom, however, 
there has been widespread ces-
sation, a substantial decrease in 
male tobacco-attributed mortality 
and, more recently, some decrease 
in female tobacco-attributed mor-
tality. Had female smokers in the 
United Kingdom continued smok-
ing, there would have been a major 
increase in female tobacco-attribut-
ed mortality in the United Kingdom 
throughout the past few decades 
instead of the moderate decrease 
actually seen.
In the USA (Figs P7.6, P7.7), 
a rapid increase in male tobacco-
attributed mortality was still in 
progress when it was halted (well 
before the cancer or overall death 
rates from smoking had become 
as high as they were in the United 
Kingdom) by a substantial decrease 
in cigarette consumption over the 
past few decades. In the USA, male 
Fig. P7.4. United Kingdom, 1950–2010. Total cancer mortality rates at ages 0–34 and 35–69, with the rates at 35–69 subdivided 
into parts attributed, and not attributed, to smoking. Rates are calculated from WHO mortality data and UN population estimates. 
Notes: The rate for a 35-year age range is the mean of the 7 annual death rates in the component 5-year age ranges. (Hence, 
without other causes of death, a rate of R per 100 000 would imply a 35-year risk of 1 – exp[–35R/100 000].) The mortality attributed 
to smoking is estimated indirectly from the national mortality statistics, using the absolute lung cancer rate as a guide to the fraction 
of the deaths from other causes, or groups of causes, attributable to smoking.
Fig. P7.5. United Kingdom, 1950–2010. Probabilities of death at ages 0–34 and 35–69, with probabilities of death from smoking at 
ages 35–69 shaded. Rates are calculated from WHO mortality data and UN population estimates. Notes: Most of those killed by 
smoking would otherwise have survived beyond age 70, but a minority (shaded area to right of dotted line) would have died by 70 
anyway. The mortality attributed to smoking is estimated indirectly from the national mortality statistics.
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lung cancer mortality in early mid-
dle age (35–44; data not shown) 
has fallen substantially since 1970, 
and male lung cancer mortality later 
in middle age is now falling. In the 
USA, the death rate from smoking 
among women was still low in 1950, 
but it rose rapidly and by the 1990s 
female tobacco-attributed mortal-
ity rates in the USA were among 
the worst in the world, although (as 
in men in the USA) the rise was 
eventually halted by a decrease in 
cigarette consumption. Again, had 
female smokers in the USA contin-
ued smoking, the steep rise in fe-
male death rates from smoking in 
the USA would still be continuing.
In Poland (Figs P7.8, P7.9), the 
main increase in cigarette smok-
ing among men took place around 
the middle of the century and was 
followed by a large increase in male 
tobacco-attributed mortality during 
the second half of the century (to 
levels comparable with those seen 
20 years earlier in the United 
Kingdom). However, a decrease in 
smoking since 1990 and changes 
in the nature of the cigarette have 
decreased this mortality. In Poland 
women have thus far been less se-
verely affected than men, but fe-
male tobacco-attributed mortality 
is rising steadily, and young Polish 
women who now smoke will face 
substantial hazards if they continue.
The methods used in these three 
populations to estimate smoking- 
Fig. P7.6. USA, 1950–2010. Total cancer mortality rates at ages 0–34 and 35–69, with the rates at 35–69 subdivided into parts 
attributed, and not attributed, to smoking. Rates are calculated from WHO (and 2009–2010 United States National Center for Health 
Statistics) mortality data and UN population estimates. For notes, see Fig. P7.4.
Fig. P7.7. USA, 1950–2010. Probabilities of death at ages 0–34 and 35–69, with probabilities of death from smoking at ages 35–69 
shaded. Rates are calculated from WHO (and 2009–2010 United States National Center for Health Statistics) mortality data and UN 
population estimates. For notes, see Fig. P7.5.
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attributed mortality, past and pre-
sent, are indirect [9,10], but the over-
all patterns should be reasonably 
trustworthy, particularly for cancer. 
The findings demonstrate the enor-
mous potential relevance of smoking 
cessation to cancer mortality and to 
overall mortality rates in such coun-
tries, and the practicability of sub-
stantial changes in tobacco-attrib-
uted mortality accumulating over a 
period of decades. This is true both 
in populations where smoking is al-
ready a major cause of death and in 
populations where it is not but where 
it will become so if current smoking 
patterns persist.
Worldwide trends
Worldwide, about 100 million peo-
ple a year reach adult life. Based 
on present smoking patterns, about 
30 million (50% of the young men 
and 10% of the young women) will 
start to smoke, and more than two 
thirds will continue because in low- 
and middle-income countries cessa-
tion is uncommon [16]. Of those who 
continue to smoke cigarettes or bi-
dis, whether in Asia, America, Africa, 
or Europe, about half will eventually 
be killed by their habit (unless they 
die of something else before middle 
age). Hence, if more than 20 million 
of these 30 million new smokers a 
year continue smoking, and do not 
Fig. P7.9. Poland, 1955–2010. Probabilities of death at ages 0–34 and 35–69, with probabilities of death from smoking at ages 
35–69 shaded. Rates are calculated from WHO mortality data and UN population estimates. For notes, see Fig. P7.5.
Fig. P7.8. Poland, 1965–2010. Total cancer mortality rates at ages 0–34 and 35–69, with the rates at 35–69 subdivided into parts 
attributed, and not attributed, to smoking. Rates are calculated from WHO mortality data and UN population estimates. For notes, 
see Fig. P7.4.
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stop, and half of those who do so are 
killed by their habit, eventually more 
than 10 million people per year will 
be killed by tobacco [18].
Based on current smoking pat-
terns, where 30% start and most 
who start will not stop, worldwide 
annual mortality from tobacco 
is likely to reach 10 million per 
year (i.e. 100 million per decade) 
before the middle of this century 
[10,18,19], and will rise somewhat 
further in later decades. Tobacco is 
therefore expected to cause about 
150 million deaths in the first quar-
ter of this century (many of which 
have already happened, as smok-
ing is already causing about 6 mil-
lion deaths a year worldwide [20]) 
and 250–300 million in the second 
quarter. Predictions for the third 
and, particularly, the fourth quarter 
of the century are inevitably more 
speculative. However, due partly 
to population growth and partly to 
the maturing of the epidemic, if cur-
rent smoking patterns persist then 
the number of tobacco-attributed 
deaths is likely to exceed 100 mil-
lion per decade throughout the sec-
ond half of the century (Table P7.2).
Cessation and not starting
The number of tobacco-related 
deaths predicted to occur before 
2050 cannot be greatly reduced un-
less a substantial proportion of the 
adults who have already been smok-
ing for some time give up the habit. 
A decrease over the next decade or 
two in the proportion of young peo-
ple who become smokers will not 
have its main effects on mortality 
until the second half of the century. 
The effects of adult smokers quit-
ting on deaths before 2050 and of 
young people not starting to smoke 
on deaths after 2050 will probably be 
approximately as follows.
Cessation
If many of the adults who now smoke 
were to give up over the next decade 
or two, thus halving global cigarette 
consumption per adult by the 2020s, 
this would prevent about one third 
of tobacco-related deaths in the 
2020s and almost halve tobacco-
related deaths thereafter. Within a 
decade of their occurrence, such 
changes could avoid 10 or 20 million 
tobacco-related deaths per decade, 
and could avoid 100 million tobacco-
related deaths in the second quarter 
of the century.
Not starting
If, by reduction over the next decade 
or two in the global uptake rate of 
smoking by young people, the pro-
portion of young adults who become 
smokers were to be halved by the 
2030s, this would avoid hundreds 
of millions of deaths from tobacco 
in the second half of the century. It 
would, however, avoid almost none 
of the 150 million deaths from tobac-
co in the first quarter of the century, 
and would probably avoid “only” a 
few million deaths from tobacco in 
the second quarter of the century.
Thus, using widely practicable 
ways of helping large numbers of 
young people not to start smoking 
could avoid hundreds of millions 
of tobacco-related deaths in the 
second half of the century, but not 
before. In contrast, widely practica-
ble ways of helping large numbers 
of adult smokers to quit (prefer-
ably before middle age, but also in 
middle age) could well avoid more 
than 100 million tobacco-related 
deaths in the first half of this cen-
tury. Large numbers of deaths dur-
ing the second half of the century 
would also be avoided if many of 
those who, despite everything, still 
start to smoke in future years could 
be helped to stop before they are 
killed by tobacco. Such calculations 
suggest that the effect of quitting 
could be more rapidly apparent on 
a population scale than the effects 
of not starting to smoke. Both, how-
ever, are of great importance.
This Perspective is adapted from IARC (2007) 
[21]. We are grateful to Jillian Boreham and 
Kirstin Pirie for help with the figures.
Table P7.2. Projected numbers of deaths from tobacco during the 21st century, if current smoking patterns persista
Period (years) Deaths from tobacco (millions)
2000–2024 ~150
2025–2049 ~250–300
2050–2099 > 500
Total, entire 21st century ~1000
Total, entire 20th century ~100
a Worldwide, about 30% of young adults become smokers, and with the current low cessation rates among smokers in low- and middle-income countries, 
most who start will not stop.
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